AU2015203814A1 - Methods and compositions for diagnosis and prognosis of renal injury and renal failure - Google Patents

Abstract

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Beta-nerve growth factor, Interleukin-17A, Follitropin subunit beta, Collagenase 3, Follistatin, Vitamin D Binding Protein, Islet amyloid polypeptide, Insulin C-peptide, Complement Factor H, Gastric inhibitory polypeptide, Glucagon-like peptide 1, Glucagon, Involucrin, Type II cytoskeletal Keratin-1/Keratin-10, Type II cytoskeletal Keratin-6A/6B/6C, Osteocalcin, Lipopolysaccharide, Pancreatic prohormone, Peptide YY, Agouti-related protein, Ciliary neurotrophic factor, Appetite-regulating hormone, Transthyretin, Insulin receptor substrate 1, and NF-kappa-B inhibitor alpha as diagnostic and prognostic biomarker assays in renal injuries.

Description

METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE [0001] The present application is a divisional application of Australian Patent Application No. 2011311997. The present application claims priority to U.S. Provisional Patent Application No. 61/308,861 filed February 26, 2010 and U.S. Provisional Patent Application 61/390,999 filed October 7, 2010, which is hereby incorporated in its entirety including all tables, figures, and claims. BACKGROUND OF THE INVENTION [0002] The following discussion of the background of the invention is merely provided to aid the reader in understanding the invention and is not admitted to describe or constitute prior art to the present invention. [0003] The kidney is responsible for water and solute excretion from the body. Its functions include maintenance of acid-base balance, regulation of electrolyte concentrations, control of blood volume, and regulation of blood pressure. As such, loss of kidney function through injury and/or disease results in substantial morbidity and mortality. A detailed discussion of renal injuries is provided in Harrison's Principles of Internal Medicine, 17" Ed., McGraw Hill, New York, pages 1741-1830, which are hereby incorporated by reference in their entirety. Renal disease and/or injury may be acute or chronic. Acute and chronic kidney disease are described as follows (from Current Medical Diagnosis & Treatment 2008, 47" Ed, McGraw Hill, New York, pages 785-815, which are hereby incorporated by reference in their entirety): "Acute renal failure is worsening of renal function over hours to days, resulting in the retention of nitrogenous wastes (such as urea nitrogen) and creatinine in the blood. Retention of these substances is called azotemia. Chronic renal failure (chronic kidney disease) results from an abnormal loss of renal function over months to years". [0004] Acute renal failure (ARF, also known as acute kidney injury, or AKI) is an abrupt (typically detected within about 48 hours to 1 week)reduction in glomerular filtration. This loss of filtration capacity results in retention of nitrogenous (urea and creatinine) and non-nitrogenous waste products that are normally excreted by the kidney, a reduction in urine output, or both. It is reported that ARF complicates about 5% of hospital admissions, 4-15% of cardiopulmonary bypass surgeries, and up to 30% of intensive care admissions. ARF may be categorized as prerenal, intrinsic renal, or postrenal in causation. Intrinsic renal disease can be further divided into glomerular, 1 tubular, interstitial, and vascular abnormalities. Major causes of ARF are described in the following table, which is adapted from the Merck Manual, 17 th ed., Chapter 222, and which is hereby incorporated by reference in their entirety: Type Risk Factors Prerenal ECF volume depletion Excessive diuresis, hemorrhage, GI losses, loss of intravascular fluid into the extravascular space (due to ascites, peritonitis, pancreatitis, or bums), loss of skin and mucus membranes, renal salt- and water-wasting states Low cardiac output Cardiomyopathy, MI, cardiac tamponade, pulmonary embolism, pulmonary hypertension, positive-pressure mechanical ventilation Low systemic vascular Septic shock, liver failure, antihypertensive drugs resistance Increased renal vascular NSAIDs, cyclosporines, tacrolimus, hypercalcemia, resistance anaphylaxis, anesthetics, renal artery obstruction, renal vein thrombosis, sepsis, hepatorenal syndrome Decreased efferent ACE inhibitors or angiotensin II receptor blockers arteriolar tone (leading to decreased GFR from reduced glomerular transcapillary pressure, especially in patients with bilateral renal artery stenosis) Intrinsic Renal Acute tubular injury Ischemia (prolonged or severe prerenal state): surgery, hemorrhage, arterial or venous obstruction; Toxins: NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, streptozotocin Acute glomerulonephritis ANCA-associated: Crescentic glomerulonephritis, polyarteritis nodosa, Wegener's granulomatosis; Anti GBM glomerulonephritis: Goodpasture's syndrome; Immune-complex: Lupus glomerulonephritis, postinfectious glomerulonephritis, cryoglobulinemic glomerulonephritis Acute tubulointerstitial Drug reaction (eg, j-lactams, NSAIDs, sulfonamides, nephritis ciprofloxacin, thiazide diuretics, furosemide, phenytoin, allopurinol, pyelonephritis, papillary necrosis Acute vascular Vasculitis, malignant hypertension, thrombotic nephropathy microangiopathies, scleroderma, atheroembolism Infiltrative diseases Lymphoma, sarcoidosis, leukemia Postrenal Tubular precipitation Uric acid (tumor lysis), sulfonamides, triamterene, acyclovir, indinavir, methotrexate, ethylene glycol 2 Type Risk Factors ingestion, myeloma protein, myoglobin Ureteral obstruction Intrinsic: Calculi, clots, sloughed renal tissue, fungus ball, edema, malignancy, congenital defects; Extrinsic: Malignancy, retroperitoneal fibrosis, ureteral trauma during surgery or high impact injury Bladder obstruction Mechanical: Benign prostatic hyperplasia, prostate cancer, bladder cancer, urethral strictures, phimosis, paraphimosis, urethral valves, obstructed indwelling urinary catheter; Neurogenic: Anticholinergic drugs, upper or lower motor neuron lesion [0005] In the case of ischemic ARF, the course of the disease may be divided into four phases. During an initiation phase, which lasts hours to days, reduced perfusion of the kidney is evolving into injury. Glomerular ultrafiltration reduces, the flow of filtrate is reduced due to debris within the tubules, and back leakage of filtrate through injured epithelium occurs. Renal injury can be mediated during this phase by reperfusion of the kidney. Initiation is followed by an extension phase which is characterized by continued ischemic injury and inflammation and may involve endothelial damage and vascular congestion. During the maintenance phase, lasting from 1 to 2 weeks, renal cell injury occurs, and glomerular filtration and urine output reaches a minimum. A recovery phase can follow in which the renal epithelium is repaired and GFR gradually recovers. Despite this, the survival rate of subjects with ARF may be as low as about 60%. [0006] Acute kidney injury caused by radiocontrast agents (also called contrast media) and other nephrotoxins such as cyclosporine, antibiotics including aminoglycosides and anticancer drugs such as cisplatin manifests over a period of days to about a week. Contrast induced nephropathy (CIN, which is AKI caused by radiocontrast agents) is thought to be caused by intrarenal vasoconstriction (leading to ischemic injury) and from the generation of reactive oxygen species that are directly toxic to renal tubular epithelial cells. CIN classically presents as an acute (onset within 24-48h) but reversible (peak 3-5 days, resolution within 1 week) rise in blood urea nitrogen and serum creatinine. [0007] A commonly reported criteria for defining and detecting AKI is an abrupt (typically within about 2-7 days or within a period of hospitalization) elevation of serum creatinine. Although the use of serum creatinine elevation to define and detect AKI is well established, the magnitude of the serum creatinine elevation and the time over which 3 it is measured to define AKI varies considerably among publications. Traditionally, relatively large increases in serum creatinine such as 100%, 200%, an increase of at least 100% to a value over 2 mg/dL and other definitions were used to define AKI. However, the recent trend has been towards using smaller serum creatinine rises to define AKI. The relationship between serum creatinine rise, AKI and the associated health risks are reviewed in Praught and Shlipak, Curr Opin Nephrol Hypertens 14:265-270, 2005 and Chertow et al, JAm Soc Nephrol 16: 3365-3370, 2005, which, with the references listed therein, are hereby incorporated by reference in their entirety. As described in these publications, acute worsening renal function (AKI) and increased risk of death and other detrimental outcomes are now known to be associated with very small increases in serum creatinine. These increases may be determined as a relative (percent) value or a nominal value. Relative increases in serum creatinine as small as 20% from the pre-injury value have been reported to indicate acutely worsening renal function (AKI) and increased health risk, but the more commonly reported value to define AKI and increased health risk is a relative increase of at least 25%. Nominal increases as small as 0.3 mg/dL, 0.2 mg/dL or even 0.1 mg/dL have been reported to indicate worsening renal function and increased risk of death. Various time periods for the serum creatinine to rise to these threshold values have been used to define AKI, for example, ranging from 2 days, 3 days, 7 days, or a variable period defined as the time the patient is in the hospital or intensive care unit. These studies indicate there is not a particular threshold serum creatinine rise (or time period for the rise) for worsening renal function or AKI, but rather a continuous increase in risk with increasing magnitude of serum creatinine rise. [0008] One study (Lassnigg et all, J Am Soc Nephrol 15:1597-1605, 2004, hereby incorporated by reference in its entirety) investigated both increases and decreases in serum creatinine. Patients with a mild fall in serum creatinine of -0.1 to -0.3 mg/dL following heart surgery had the lowest mortality rate. Patients with a larger fall in serum creatinine (more than or equal to -0.4 mg/dL) or any increase in serum creatinine had a larger mortality rate. These findings caused the authors to conclude that even very subtle changes in renal function (as detected by small creatinine changes within 48 hours of surgery) seriously effect patient's outcomes. In an effort to reach consensus on a unified classification system for using serum creatinine to define AKI in clinical trials and in clinical practice, Bellomo et al., Crit Care. 8(4):R204-12, 2004, which is hereby 4 incorporated by reference in its entirety, proposes the following classifications for stratifying AKI patients: "Risk": serum creatinine increased 1.5 fold from baseline OR urine production of <0.5 ml/kg body weight/hr for 6 hours; "Injury": serum creatinine increased 2.0 fold from baseline OR urine production <0.5 ml/kg/hr for 12 h; "Failure": serum creatinine increased 3.0 fold from baseline OR creatinine >355 tmol/1 (with a rise of >44) or urine output below 0.3 ml/kg/hr for 24 h or anuria for at least 12 hours; And included two clinical outcomes: "Loss": persistent need for renal replacement therapy for more than four weeks. "ESRD": end stage renal disease-the need for dialysis for more than 3 months. [0009] These criteria are called the RIFLE criteria, which provide a useful clinical tool to classify renal status. As discussed in Kellum, Crit. Care Med. 36: S 141-45, 2008 and Ricci et al., Kidney Int. 73, 538-546, 2008, each hereby incorporated by reference in its entirety, the RIFLE criteria provide a uniform definition of AKI which has been validated in numerous studies. [0010] More recently, Mehta et al., Crit. Care 11:R31 (doi:10.1186.cc5713), 2007, hereby incorporated by reference in its entirety, proposes the following similar classifications for stratifying AKI patients, which have been modified from RIFLE: "Stage I": increase in serum creatinine of more than or equal to 0.3 mg/dL (> 26.4 [tmol/L) or increase to more than or equal to 150% (1.5-fold) from baseline OR urine output less than 0.5 mL/kg per hour for more than 6 hours; "Stage II": increase in serum creatinine to more than 200% (> 2-fold) from baseline OR urine output less than 0.5 mL/kg per hour for more than 12 hours; "Stage III": increase in serum creatinine to more than 300% (> 3-fold) from baseline OR serum creatinine > 354 [tmol/L accompanied by an acute increase of at least 44 [tmol/L OR urine output less than 0.3 mL/kg per hour for 24 hours or anuria for 12 hours. [0011] The CIN Consensus Working Panel (McCollough et al, Rev Cardiovasc Med. 2006;7(4):177-197, hereby incorporated by reference in its entirety) uses a serum 5 creatinine rise of 25% to define Contrast induced nephropathy (which is a type of AKI).Although various groups propose slightly different criteria for using serum creatinine to detect AKI, the consensus is that small changes in serum creatinine, such as 0.3 mg/dL or 25%, are sufficient to detect AKI (worsening renal function) and that the magnitude of the serum creatinine change is an indicator of the severity of the AKI and mortality risk. [0012] Although serial measurement of serum creatinine over a period of days is an accepted method of detecting and diagnosing AKI and is considered one of the most important tools to evaluate AKI patients, serum creatinine is generally regarded to have several limitations in the diagnosis, assessment and monitoring of AKI patients. The time period for serum creatinine to rise to values (e.g., a 0.3 mg/dL or 25% rise) considered diagnostic for AKI can be 48 hours or longer depending on the definition used. Since cellular injury in AKI can occur over a period of hours, serum creatinine elevations detected at 48 hours or longer can be a late indicator of injury, and relying on serum creatinine can thus delay diagnosis of AKI. Furthermore, serum creatinine is not a good indicator of the exact kidney status and treatment needs during the most acute phases of AKI when kidney function is changing rapidly. Some patients with AKI will recover fully, some will need dialysis (either short term or long term) and some will have other detrimental outcomes including death, major adverse cardiac events and chronic kidney disease. Because serum creatinine is a marker of filtration rate, it does not differentiate between the causes of AKI (pre-renal, intrinsic renal, post-renal obstruction, atheroembolic, etc) or the category or location of injury in intrinsic renal disease (for example, tubular, glomerular or interstitial in origin). Urine output is similarly limited, Knowing these things can be of vital importance in managing and treating patients with AKI. [0013] These limitations underscore the need for better methods to detect and assess AKI, particularly in the early and subclinical stages, but also in later stages when recovery and repair of the kidney can occur. Furthermore, there is a need to better identify patients who are at risk of having an AKI. BRIEF SUMMARY OF THE INVENTION [0014] It is an object of the invention to provide methods and compositions for evaluating renal function in a subject. As described herein, measurement of one or more 6 biomarkers selected from the group consisting of Beta-nerve growth factor, Interleukin 17A, Follitropin subunit beta, Collagenase 3, Follistatin, Vitamin D Binding Protein, Islet amyloid polypeptide, Insulin C-peptide, Complement Factor H, Gastric inhibitory polypeptide, Glucagon-like peptide 1, Glucagon, Involucrin, Type II cytoskeletal Keratin 1/Keratin-10, Type II cytoskeletal Keratin-6A/6B/6C, Osteocalcin, Lipopolysaccharide, Pancreatic prohormone, Peptide YY, Agouti-related protein, Ciliary neurotrophic factor, Appetite-regulating hormone, Transthyretin, Insulin receptor substrate 1, and NF-kappa-B inhibitor alpha (referred to herein as a "kidney injury marker") can be used for diagnosis, prognosis, risk stratification, staging, monitoring, categorizing and determination of further diagnosis and treatment regimens in subjects suffering or at risk of suffering from an injury to renal function, reduced renal function, and/or acute renal failure (also called acute kidney injury). [0015] The kidney injury markers of the present invention may be used, individually or in panels comprising a plurality of kidney injury markers, for risk stratification (that is, to identify subjects at risk for a future injury to renal function, for future progression to reduced renal function, for future progression to ARF, for future improvement in renal function, etc.); for diagnosis of existing disease (that is, to identify subjects who have suffered an injury to renal function, who have progressed to reduced renal function, who have progressed to ARF, etc.); for monitoring for deterioration or improvement of renal function; and for predicting a future medical outcome, such as improved or worsening renal function, a decreased or increased mortality risk, a decreased or increased risk that a subject will require renal replacement therapy (i.e., hemodialysis, peritoneal dialysis, hemofiltration, and/or renal transplantation, a decreased or increased risk that a subject will recover from an injury to renal function, a decreased or increased risk that a subject will recover from ARF, a decreased or increased risk that a subject will progress to end stage renal disease, a decreased or increased risk that a subject will progress to chronic renal failure, a decreased or increased risk that a subject will suffer rejection of a transplanted kidney, etc. [0016] In a first aspect, the present invention relates to methods for evaluating renal status in a subject. These methods comprise performing an assay method that is configured to detect one or more biomarkers selected from the group consisting of Beta nerve growth factor, Interleukin- 17A, Follitropin subunit beta, Collagenase 3, Follistatin, Vitamin D Binding Protein, Islet amyloid polypeptide, Insulin C-peptide, Complement 7 Factor H, Gastric inhibitory polypeptide, Glucagon-like peptide 1, Glucagon, Involucrin, Type II cytoskeletal Keratin-1/Keratin-10, Type II cytoskeletal Keratin-6A/6B/6C, Osteocalcin, Lipopolysaccharide, Pancreatic prohormone, Peptide YY, Agouti-related protein, Ciliary neurotrophic factor, Appetite-regulating hormone, Transthyretin, Insulin receptor substrate 1, and NF-kappa-B inhibitor alpha in a body fluid sample obtained from the subject. The assay result(s), for example measured concentration(s) of one or more biomarkers selected from the group consisting of Beta-nerve growth factor, Interleukin-17A, Follitropin subunit beta, Collagenase 3, Follistatin, Vitamin D Binding Protein, Islet amyloid polypeptide, Insulin C-peptide, Complement Factor H, Gastric inhibitory polypeptide, Glucagon-like peptide 1, Glucagon, Involucrin, Type II cytoskeletal Keratin-1/Keratin-10, Type II cytoskeletal Keratin-6A/6B/6C, Osteocalcin, Lipopolysaccharide, Pancreatic prohormone, Peptide YY, Agouti-related protein, Ciliary neurotrophic factor, Appetite-regulating hormone, Transthyretin, Insulin receptor substrate 1, and NF-kappa-B inhibitor alpha is/are then correlated to the renal status of the subject. This correlation to renal status may include correlating the assay result(s) to one or more of risk stratification, diagnosis, prognosis, staging, classifying and monitoring of the subject as described herein. Thus, the present invention utilizes one or more kidney injury markers of the present invention for the evaluation of renal injury. [0017] In certain embodiments, the methods for evaluating renal status described herein are methods for risk stratification of the subject; that is, assigning a likelihood of one or more future changes in renal status to the subject. In these embodiments, the assay result(s) is/are correlated to one or more such future changes. The following are preferred risk stratification embodiments. [0018] In preferred risk stratification embodiments, these methods comprise determining a subject's risk for a future injury to renal function, and the assay result(s) is/are correlated to a likelihood of such a future injury to renal function. For example, the measured concentration(s) may each be compared to a threshold value. For a "positive going" kidney injury marker, an increased likelihood of suffering a future injury to renal function is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold. For a "negative going" kidney injury marker, an increased likelihood of suffering a future injury to renal function is assigned to the subject when the measured 8 concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold. [0019] In other preferred risk stratification embodiments, these methods comprise determining a subject's risk for future reduced renal function, and the assay result(s) is/are correlated to a likelihood of such reduced renal function. For example, the measured concentrations may each be compared to a threshold value. For a "positive going" kidney injury marker, an increased likelihood of suffering a future reduced renal function is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold. For a "negative going" kidney injury marker, an increased likelihood of future reduced renal function is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold. [0020] In still other preferred risk stratification embodiments, these methods comprise determining a subject's likelihood for a future improvement in renal function, and the assay result(s) is/are correlated to a likelihood of such a future improvement in renal function. For example, the measured concentration(s) may each be compared to a threshold value. For a "positive going" kidney injury marker, an increased likelihood of a future improvement in renal function is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold. For a "negative going" kidney injury marker, an increased likelihood of a future improvement in renal function is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold. [0021] In yet other preferred risk stratification embodiments, these methods comprise determining a subject's risk for progression to ARF, and the result(s) is/are correlated to a likelihood of such progression to ARF. For example, the measured concentration(s) may each be compared to a threshold value. For a "positive going" kidney injury marker, an increased likelihood of progression to ARF is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold. For a "negative going" kidney injury marker, an increased likelihood of progression to ARF is assigned to the subject when the measured 9 concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold. [0022] And in other preferred risk stratification embodiments, these methods comprise determining a subject's outcome risk, and the assay result(s) is/are correlated to a likelihood of the occurrence of a clinical outcome related to a renal injury suffered by the subject. For example, the measured concentration(s) may each be compared to a threshold value. For a "positive going" kidney injury marker, an increased likelihood of one or more of: acute kidney injury, progression to a worsening stage of AKI, mortality, a requirement for renal replacement therapy, a requirement for withdrawal of renal toxins, end stage renal disease, heart failure, stroke, myocardial infarction, progression to chronic kidney disease, etc., is assigned to the subject when the measured concentration is above the threshold, relative to a likelihood assigned when the measured concentration is below the threshold. For a "negative going" kidney injury marker, an increased likelihood of one or more of: acute kidney injury, progression to a worsening stage of AKI, mortality, a requirement for renal replacement therapy, a requirement for withdrawal of renal toxins, end stage renal disease, heart failure, stroke, myocardial infarction, progression to chronic kidney disease, etc., is assigned to the subject when the measured concentration is below the threshold, relative to a likelihood assigned when the measured concentration is above the threshold. [0023] In such risk stratification embodiments, preferably the likelihood or risk assigned is that an event of interest is more or less likely to occur within 180 days of the time at which the body fluid sample is obtained from the subject. In particularly preferred embodiments, the likelihood or risk assigned relates to an event of interest occurring within a shorter time period such as 18 months, 120 days, 90 days, 60 days, 45 days, 30 days, 21 days, 14 days, 7 days, 5 days, 96 hours, 72 hours, 48 hours, 36 hours, 24 hours, 12 hours, or less. A risk at 0 hours of the time at which the body fluid sample is obtained from the subject is equivalent to diagnosis of a current condition. [0024] In preferred risk stratification embodiments, the subject is selected for risk stratification based on the pre-existence in the subject of one or more known risk factors for prerenal, intrinsic renal, or postrenal ARF. For example, a subject undergoing or having undergone major vascular surgery, coronary artery bypass, or other cardiac surgery; a subject having pre-existing congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, 10 glomerular filtration below the normal range, cirrhosis, serum creatinine above the normal range, or sepsis; or a subject exposed to NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin are all preferred subjects for monitoring risks according to the methods described herein. This list is not meant to be limiting. By "pre-existence" in this context is meant that the risk factor exists at the time the body fluid sample is obtained from the subject. In particularly preferred embodiments, a subject is chosen for risk stratification based on an existing diagnosis of injury to renal function, reduced renal function, or ARF. [0025] In other embodiments, the methods for evaluating renal status described herein are methods for diagnosing a renal injury in the subject; that is, assessing whether or not a subject has suffered from an injury to renal function, reduced renal function, or ARF. In these embodiments, the assay result(s), for example measured concentration(s) of one or more biomarkers selected from the group consisting of Beta-nerve growth factor, Interleukin-17A, Follitropin subunit beta, Collagenase 3, Follistatin, Vitamin D Binding Protein, Islet amyloid polypeptide, Insulin C-peptide, Complement Factor H, Gastric inhibitory polypeptide, Glucagon-like peptide 1, Glucagon, Involucrin, Type II cytoskeletal Keratin-1/Keratin-10, Type II cytoskeletal Keratin-6A/6B/6C, Osteocalcin, Lipopolysaccharide, Pancreatic prohormone, Peptide YY, Agouti-related protein, Ciliary neurotrophic factor, Appetite-regulating hormone, Transthyretin, Insulin receptor substrate 1, and NF-kappa-B inhibitor alpha is/are correlated to the occurrence or nonoccurrence of a change in renal status. The following are preferred diagnostic embodiments. [0026] In preferred diagnostic embodiments, these methods comprise diagnosing the occurrence or nonoccurrence of an injury to renal function, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of such an injury. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of an injury to renal function is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of an injury to renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the 11 threshold). For a negative going marker, an increased likelihood of the occurrence of an injury to renal function is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury to renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold). [0027] In other preferred diagnostic embodiments, these methods comprise diagnosing the occurrence or nonoccurrence of reduced renal function, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of an injury causing reduced renal function. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of an injury causing reduced renal function is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of an injury causing reduced renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of an injury causing reduced renal function is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury causing reduced renal function may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold). [0028] In yet other preferred diagnostic embodiments, these methods comprise diagnosing the occurrence or nonoccurrence of ARF, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of an injury causing ARF. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of ARF is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased 12 likelihood of the nonoccurrence of ARF may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of ARF is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of ARF may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold). [0029] In still other preferred diagnostic embodiments, these methods comprise diagnosing a subject as being in need of renal replacement therapy, and the assay result(s) is/are correlated to a need for renal replacement therapy. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of an injury creating a need for renal replacement therapy is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal replacement therapy may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of an injury creating a need for renal replacement therapy is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal replacement therapy may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold). [0030] In still other preferred diagnostic embodiments, these methods comprise diagnosing a subject as being in need of renal transplantation, and the assay result(sO is/are correlated to a need for renal transplantation. For example, each of the measured concentration(s) may be compared to a threshold value. For a positive going marker, an increased likelihood of the occurrence of an injury creating a need for renal transplantation is assigned to the subject when the measured concentration is above the threshold (relative to the likelihood assigned when the measured concentration is below 13 the threshold); alternatively, when the measured concentration is below the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal transplantation may be assigned to the subject (relative to the likelihood assigned when the measured concentration is above the threshold). For a negative going marker, an increased likelihood of the occurrence of an injury creating a need for renal transplantation is assigned to the subject when the measured concentration is below the threshold (relative to the likelihood assigned when the measured concentration is above the threshold); alternatively, when the measured concentration is above the threshold, an increased likelihood of the nonoccurrence of an injury creating a need for renal transplantation may be assigned to the subject (relative to the likelihood assigned when the measured concentration is below the threshold). [0031] In still other embodiments, the methods for evaluating renal status described herein are methods for monitoring a renal injury in the subject; that is, assessing whether or not renal function is improving or worsening in a subject who has suffered from an injury to renal function, reduced renal function, or ARF. In these embodiments, the assay result(s), for example measured concentration(s) of one or more biomarkers selected from the group consisting of Beta-nerve growth factor, Interleukin-17A, Follitropin subunit beta, Collagenase 3, Follistatin, Vitamin D Binding Protein, Islet amyloid polypeptide, Insulin C-peptide, Complement Factor H, Gastric inhibitory polypeptide, Glucagon-like peptide 1, Glucagon, Involucrin, Type II cytoskeletal Keratin-1/Keratin-10, Type II cytoskeletal Keratin-6A/6B/6C, Osteocalcin, Lipopolysaccharide, Pancreatic prohormone, Peptide YY, Agouti-related protein, Ciliary neurotrophic factor, Appetite regulating hormone, Transthyretin, Insulin receptor substrate 1, and NF-kappa-B inhibitor alpha is/are correlated to the occurrence or nonoccurrence of a change in renal status. The following are preferred monitoring embodiments. [0032] In preferred monitoring embodiments, these methods comprise monitoring renal status in a subject suffering from an injury to renal function, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of a change in renal status in the subject. For example, the measured concentration(s) may be compared to a threshold value. For a positive going marker, when the measured concentration is above the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is below the threshold, an improvement of renal function may be assigned to the subject. For a negative going marker, when the measured 14 concentration is below the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject. [0033] In other preferred monitoring embodiments, these methods comprise monitoring renal status in a subject suffering from reduced renal function, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of a change in renal status in the subject. For example, the measured concentration(s) may be compared to a threshold value. For a positive going marker, when the measured concentration is above the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is below the threshold, an improvement of renal function may be assigned to the subject. For a negative going marker, when the measured concentration is below the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject. [0034] In yet other preferred monitoring embodiments, these methods comprise monitoring renal status in a subject suffering from acute renal failure, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of a change in renal status in the subject. For example, the measured concentration(s) may be compared to a threshold value. For a positive going marker, when the measured concentration is above the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is below the threshold, an improvement of renal function may be assigned to the subject. For a negative going marker, when the measured concentration is below the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject. [0035] In other additional preferred monitoring embodiments, these methods comprise monitoring renal status in a subject at risk of an injury to renal function due to the pre-existence of one or more known risk factors for prerenal, intrinsic renal, or postrenal ARF, and the assay result(s) is/are correlated to the occurrence or nonoccurrence of a change in renal status in the subject. For example, the measured concentration(s) may be compared to a threshold value. For a positive going marker, when the measured concentration is above the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is below 15 the threshold, an improvement of renal function may be assigned to the subject. For a negative going marker, when the measured concentration is below the threshold, a worsening of renal function may be assigned to the subject; alternatively, when the measured concentration is above the threshold, an improvement of renal function may be assigned to the subject. [0036] In still other embodiments, the methods for evaluating renal status described herein are methods for classifying a renal injury in the subject; that is, determining whether a renal injury in a subject is prerenal, intrinsic renal, or postrenal; and/or further subdividing these classes into subclasses such as acute tubular injury, acute glomerulonephritis acute tubulointerstitial nephritis, acute vascular nephropathy, or infiltrative disease; and/or assigning a likelihood that a subject will progress to a particular RIFLE stage. In these embodiments, the assay result(s), for example measured concentration(s) of one or more biomarkers selected from the group consisting of Beta nerve growth factor, Interleukin- 17A, Follitropin subunit beta, Collagenase 3, Follistatin, Vitamin D Binding Protein, Islet amyloid polypeptide, Insulin C-peptide, Complement Factor H, Gastric inhibitory polypeptide, Glucagon-like peptide 1, Glucagon, Involucrin, Type II cytoskeletal Keratin-1/Keratin-10, Type II cytoskeletal Keratin-6A/6B/6C, Osteocalcin, Lipopolysaccharide, Pancreatic prohormone, Peptide YY, Agouti-related protein, Ciliary neurotrophic factor, Appetite-regulating hormone, Transthyretin, Insulin receptor substrate 1, and NF-kappa-B inhibitor alpha is/are correlated to a particular class and/or subclass. The following are preferred classification embodiments. [0037] In preferred classification embodiments, these methods comprise determining whether a renal injury in a subject is prerenal, intrinsic renal, or postrenal; and/or further subdividing these classes into subclasses such as acute tubular injury, acute glomerulonephritis acute tubulointerstitial nephritis, acute vascular nephropathy, or infiltrative disease; and/or assigning a likelihood that a subject will progress to a particular RIFLE stage, and the assay result(s) is/are correlated to the injury classification for the subject. For example, the measured concentration may be compared to a threshold value, and when the measured concentration is above the threshold, a particular classification is assigned; alternatively, when the measured concentration is below the threshold, a different classification may be assigned to the subject. [0038] A variety of methods may be used by the skilled artisan to arrive at a desired threshold value for use in these methods. For example, the threshold value may be 16 determined from a population of normal subjects by selecting a concentration representing the 75', 85', 90', 95', or 99t percentile of a kidney injury marker measured in such normal subjects. Alternatively, the threshold value may be determined from a "diseased" population of subjects, e.g., those suffering from an injury or having a predisposition for an injury (e.g., progression to ARF or some other clinical outcome such as death, dialysis, renal transplantation, etc.), by selecting a concentration representing the 75', 85', 90', 95', or 99' percentile of a kidney injury marker measured in such subjects. In another alternative, the threshold value may be determined from a prior measurement of a kidney injury marker in the same subject; that is, a temporal change in the level of a kidney injury marker in the subject may be used to assign risk to the subject. [0039] The foregoing discussion is not meant to imply, however, that the kidney injury markers of the present invention must be compared to corresponding individual thresholds. Methods for combining assay results can comprise the use of multivariate logistical regression, loglinear modeling, neural network analysis, n-of-m analysis, decision tree analysis, calculating ratios of markers, etc. This list is not meant to be limiting. In these methods, a composite result which is determined by combining individual markers may be treated as if it is itself a marker; that is, a threshold may be determined for the composite result as described herein for individual markers, and the composite result for an individual patient compared to this threshold. [0040] The ability of a particular test to distinguish two populations can be established using ROC analysis. For example, ROC curves established from a "first" subpopulation which is predisposed to one or more future changes in renal status, and a "second" subpopulation which is not so predisposed can be used to calculate a ROC curve, and the area under the curve provides a measure of the quality of the test. Preferably, the tests described herein provide a ROC curve area greater than 0.5, preferably at least 0.6, more preferably 0.7, still more preferably at least 0.8, even more preferably at least 0.9, and most preferably at least 0.95. [0041] In certain aspects, the measured concentration of one or more kidney injury markers, or a composite of such markers, may be treated as continuous variables. For example, any particular concentration can be converted into a corresponding probability of a future reduction in renal function for the subject, the occurrence of an injury, a classification, etc. In yet another alternative, a threshold that can provide an acceptable level of specificity and sensitivity in separating a population of subjects into "bins" such 17 as a "first" subpopulation (e.g., which is predisposed to one or more future changes in renal status, the occurrence of an injury, a classification, etc.) and a "second" subpopulation which is not so predisposed. A threshold value is selected to separate this first and second population by one or more of the following measures of test accuracy: an odds ratio greater than 1, preferably at least about 2 or more or about 0.5 or less, more preferably at least about 3 or more or about 0.33 or less, still more preferably at least about 4 or more or about 0.25 or less, even more preferably at least about 5 or more or about 0.2 or less, and most preferably at least about 10 or more or about 0.1 or less; a specificity of greater than 0.5, preferably at least about 0.6, more preferably at least about 0.7, still more preferably at least about 0.8, even more preferably at least about 0.9 and most preferably at least about 0.95, with a corresponding sensitivity greater than 0.2, preferably greater than about 0.3, more preferably greater than about 0.4, still more preferably at least about 0.5, even more preferably about 0.6, yet more preferably greater than about 0.7, still more preferably greater than about 0.8, more preferably greater than about 0.9, and most preferably greater than about 0.95; a sensitivity of greater than 0.5, preferably at least about 0.6, more preferably at least about 0.7, still more preferably at least about 0.8, even more preferably at least about 0.9 and most preferably at least about 0.95, with a corresponding specificity greater than 0.2, preferably greater than about 0.3, more preferably greater than about 0.4, still more preferably at least about 0.5, even more preferably about 0.6, yet more preferably greater than about 0.7, still more preferably greater than about 0.8, more preferably greater than about 0.9, and most preferably greater than about 0.95; at least about 75% sensitivity, combined with at least about 75% specificity; a positive likelihood ratio (calculated as sensitivity/(1-specificity)) of greater than 1, at least about 2, more preferably at least about 3, still more preferably at least about 5, and most preferably at least about 10; or a negative likelihood ratio (calculated as (1-sensitivity)/specificity) of less than 1, less than or equal to about 0.5, more preferably less than or equal to about 0.3, and most preferably less than or equal to about 0.1. [0042] The term "about" in the context of any of the above measurements refers to +/ 5% of a given measurement. 18 [0043] Multiple thresholds may also be used to assess renal status in a subject. For example, a "first" subpopulation which is predisposed to one or more future changes in renal status, the occurrence of an injury, a classification, etc., and a "second" subpopulation which is not so predisposed can be combined into a single group. This group is then subdivided into three or more equal parts (known as tertiles, quartiles, quintiles, etc., depending on the number of subdivisions). An odds ratio is assigned to subjects based on which subdivision they fall into. If one considers a tertile, the lowest or highest tertile can be used as a reference for comparison of the other subdivisions. This reference subdivision is assigned an odds ratio of 1. The second tertile is assigned an odds ratio that is relative to that first tertile. That is, someone in the second tertile might be 3 times more likely to suffer one or more future changes in renal status in comparison to someone in the first tertile. The third tertile is also assigned an odds ratio that is relative to that first tertile. [0044] In certain embodiments, the assay method is an immunoassay. Antibodies for use in such assays will specifically bind a full length kidney injury marker of interest, and may also bind one or more polypeptides that are "related" thereto, as that term is defined hereinafter. Numerous immunoassay formats are known to those of skill in the art. Preferred body fluid samples are selected from the group consisting of urine, blood, serum, saliva, tears, and plasma. [0045] The foregoing method steps should not be interpreted to mean that the kidney injury marker assay result(s) is/are used in isolation in the methods described herein. Rather, additional variables or other clinical indicia may be included in the methods described herein. For example, a risk stratification, diagnostic, classification, monitoring, etc. method may combine the assay result(s) with one or more variables measured for the subject selected from the group consisting of demographic information (e.g., weight, sex, age, race), medical history (e.g., family history, type of surgery, pre-existing disease such as aneurism, congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, or sepsis, type of toxin exposure such as NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin), clinical variables (e.g., blood pressure, temperature, respiration rate), risk scores (APACHE score, PREDICT score, TIMI Risk Score for UA/NSTEMI, Framingham Risk Score), a glomerular filtration rate, an 19 estimated glomerular filtration rate, a urine production rate, a serum or plasma creatinine concentration, a urine creatinine concentration, a fractional excretion of sodium, a urine sodium concentration, a urine creatinine to serum or plasma creatinine ratio, a urine specific gravity, a urine osmolality, a urine urea nitrogen to plasma urea nitrogen ratio, a plasma BUN to creatnine ratio, a renal failure index calculated as urine sodium / (urine creatinine / plasma creatinine), a serum or plasma neutrophil gelatinase (NGAL) concentration, a urine NGAL concentration, a serum or plasma cystatin C concentration, a serum or plasma cardiac troponin concentration, a serum or plasma BNP concentration, a serum or plasma NTproBNP concentration, and a serum or plasma proBNP concentration. Other measures of renal function which may be combined with one or more kidney injury marker assay result(s) are described hereinafter and in Harrison's Principles of Internal Medicine, 17 th Ed., McGraw Hill, New York, pages 1741-1830, and Current Medical Diagnosis & Treatment 2008, 47 Ed, McGraw Hill, New York, pages 785-815, each of which are hereby incorporated by reference in their entirety. [0046] When more than one marker is measured, the individual markers may be measured in samples obtained at the same time, or may be determined from samples obtained at different (e.g., an earlier or later) times. The individual markers may also be measured on the same or different body fluid samples. For example, one kidney injury marker may be measured in a serum or plasma sample and another kidney injury marker may be measured in a urine sample. In addition, assignment of a likelihood may combine an individual kidney injury marker assay result with temporal changes in one or more additional variables. [0047] In various related aspects, the present invention also relates to devices and kits for performing the methods described herein. Suitable kits comprise reagents sufficient for performing an assay for at least one of the described kidney injury markers, together with instructions for performing the described threshold comparisons. [0048] In certain embodiments, reagents for performing such assays are provided in an assay device, and such assay devices may be included in such a kit. Preferred reagents can comprise one or more solid phase antibodies, the solid phase antibody comprising antibody that detects the intended biomarker target(s) bound to a solid support. In the case of sandwich immunoassays, such reagents can also include one or more detectably labeled antibodies, the detectably labeled antibody comprising antibody that detects the 20 intended biomarker target(s) bound to a detectable label. Additional optional elements that may be provided as part of an assay device are described hereinafter. [0049] Detectable labels may include molecules that are themselves detectable (e.g., fluorescent moieties, electrochemical labels, ecl (electrochemical luminescence) labels, metal chelates, colloidal metal particles, etc.) as well as molecules that may be indirectly detected by production of a detectable reaction product (e.g., enzymes such as horseradish peroxidase, alkaline phosphatase, etc.) or through the use of a specific binding molecule which itself may be detectable (e.g., a labeled antibody that binds to the second antibody, biotin, digoxigenin, maltose, oligohistidine, 2,4-dintrobenzene, phenylarsenate, ssDNA, dsDNA, etc.). [0050] Generation of a signal from the signal development element can be performed using various optical, acoustical, and electrochemical methods well known in the art. Examples of detection modes include fluorescence, radiochemical detection, reflectance, absorbance, amperometry, conductance, impedance, interferometry, ellipsometry, etc. In certain of these methods, the solid phase antibody is coupled to a transducer (e.g., a diffraction grating, electrochemical sensor, etc) for generation of a signal, while in others, a signal is generated by a transducer that is spatially separate from the solid phase antibody (e.g., a fluorometer that employs an excitation light source and an optical detector). This list is not meant to be limiting. Antibody-based biosensors may also be employed to determine the presence or amount of analytes that optionally eliminate the need for a labeled molecule. DETAILED DESCRIPTION OF THE INVENTION [0051] The present invention relates to methods and compositions for diagnosis, differential diagnosis, risk stratification, monitoring, classifying and determination of treatment regimens in subjects suffering or at risk of suffering from injury to renal function, reduced renal function and/or acute renal failure through measurement of one or more kidney injury markers. In various embodiments, a measured concentration of one or more biomarkers selected from the group consisting of Beta-nerve growth factor, Interleukin-17A, Follitropin subunit beta, Collagenase 3, Follistatin, Vitamin D Binding Protein, Islet amyloid polypeptide, Insulin C-peptide, Complement Factor H, Gastric inhibitory polypeptide, Glucagon-like peptide 1, Glucagon, Involucrin, Type II cytoskeletal Keratin-1/Keratin-10, Type II cytoskeletal Keratin-6A/6B/6C, Osteocalcin, 21 Lipopolysaccharide, Pancreatic prohormone, Peptide YY, Agouti-related protein, Ciliary neurotrophic factor, Appetite-regulating hormone, Transthyretin, Insulin receptor substrate 1, and NF-kappa-B inhibitor alpha or one or more markers related thereto, are correlated to the renal status of the subject. [0052] For purposes of this document, the following definitions apply: [0053] As used herein, an "injury to renal function" is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) measurable reduction in a measure of renal function. Such an injury may be identified, for example, by a decrease in glomerular filtration rate or estimated GFR, a reduction in urine output, an increase in serum creatinine, an increase in serum cystatin C, a requirement for renal replacement therapy, etc. "Improvement in Renal Function" is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) measurable increase in a measure of renal function. Preferred methods for measuring and/or estimating GFR are described hereinafter. [0054] As used herein, "reduced renal function" is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) reduction in kidney function identified by an absolute increase in serum creatinine of greater than or equal to 0.1 mg/dL (> 8.8 [tmol/L), a percentage increase in serum creatinine of greater than or equal to 20% (1.2-fold from baseline), or a reduction in urine output (documented oliguria of less than 0. 5 ml/kg per hour). [0055] As used herein, "acute renal failure" or "ARF" is an abrupt (within 14 days, preferably within 7 days, more preferably within 72 hours, and still more preferably within 48 hours) reduction in kidney function identified by an absolute increase in serum creatinine of greater than or equal to 0.3 mg/dl (> 26.4 [tmol/1), a percentage increase in serum creatinine of greater than or equal to 50% (1. 5-fold from baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg per hour for at least 6 hours). This term is synonymous with "acute kidney injury" or"AKI." [0056] As used herein, the term "Beta-nerve growth factor" refers to one or more polypeptides present in a biological sample that are derived from the Beta-nerve growth factor precursor (Swiss-Prot P01138 (SEQ ID NO: 1)). 10 20 30 40 50 60 MSMLFYTLIT AFLIGIQAEP HSESNVPAGH TIPQAHWTKL QHSLDTALRR ARSAPAAAIA 22 70 80 90 100 110 120 ARVAGQTRNI TVDPRLFKKR RLRSPRVLFS TQPPREAADT QDLDFEVGGA APFNRTHRSK 130 140 150 160 170 180 RSSSHPIFHR GEFSVCDSVS VWVGDKTTAT DIKGKEVMVL GEVNINNSVF KQYFFETKCR 190 200 210 220 230 240 DPNPVDSGCR GIDSKHWNSY CTTTHTFVKA LTMDGKQAAW RFIRIDTACV CVLSRKAVRR 241 A [0057] The following domains have been identified in Beta-nerve growth factor: Residues Length Domain ID 1-18 18 signal sequence 19-121 103 propeptide 122-241 120 mature Beta-nerve growth factor [0058] As used herein, the term "Interleukin-17A" refers to one or more polypeptides present in a biological sample that are derived from the Interleukin- 17A precursor (Swiss Prot Q16552 (SEQ ID NO: 2)). 10 20 30 40 50 60 MTPGKTSLVS LLLLLSLEAI VKAGITIPRN PGCPNSEDKN FPRTVMVNLN IHNRNTNTNP 70 80 90 100 110 120 KRSSDYYNRS TSPWNLHRNE DPERYPSVIW EAKCRHLGCI NADGNVDYHM NSVPIQQEIL 130 140 150 VLRREPPHCP NSFRLEKILV SVGCTCVTPI VHHVA [0059] The following domains have been identified in Interleukin- 17A: Residues Length Domain ID 1-23 23 signal sequence 24-155 132 mature Interleukin-17A 23 [0060] As used herein, the term "Follitropin subunit beta" refers to one or more polypeptides present in a biological sample that are derived from the Follitropin subunit beta precursor (Swiss-Prot P01225 (SEQ ID NO: 3)). 10 20 30 40 50 60 MKTLQFFFLF CCWKAICCNS CELTNITIAI EKEECRFCIS INTTWCAGYC YTRDLVYKDP 70 80 90 100 110 120 ARPKIQKTCT FKELVYETVR VPGCAHHADS LYTYPVATQC HCGKCDSDST DCTVRGLGPS YCSFGEMKE [0061] The following domains have been identified in Follitropin subunit beta: Residues Length Domain ID 1-18 18 signal sequence 19-129 111 mature Follitropin subunit beta [0062] As used herein, the term "Collagenase 3" refers to one or more polypeptides present in a biological sample that are derived from the Collagenase 3 precursor (Swiss Prot P45452 (SEQ ID NO: 4)). 10 20 30 40 50 60 MHPGVLAAFL FLSWTHCRAL PLPSGGDEDD LSEEDLQFAE RYLRSYYHPT NLAGILKENA 70 80 90 100 110 120 ASSMTERLRE MQSFFGLEVT GKLDDNTLDV MKKPRCGVPD VGEYNVFPRT LKWSKMNLTY 130 140 150 160 170 180 RIVNYTPDMT HSEVEKAFKK AFKVWSDVTP LNFTRLHDGI ADIMISFGIK EHGDFYPFDG 190 200 210 220 230 240 PSGLLAHAFP PGPNYGGDAH FDDDETWTSS SKGYNLFLVA AHEFGHSLGL DHSKDPGALM 250 260 270 280 290 300 FPIYTYTGKS HFMLPDDDVQ GIQSLYGPGD EDPNPKHPKT PDKCDPSLSL DAITSLRGET 310 320 330 340 350 360 MIFKDRFFWR LHPQQVDAEL FLTKSFWPEL PNRIDAAYEH PSHDLIFIFR GRKFWALNGY 370 380 390 400 410 420 DILEGYPKKI SELGLPKEVK KISAAVHFED TGKTLLFSGN QVWRYDDTNH IMDKDYPRLI 430 440 450 460 470 EEDFPGIGDK VDAVYEKNGY IYFFNGPIQF EYSIWSNRIV RVMPANSILW C 24 [0063] The following domains have been identified in Collagenase 3: Residues Length Domain ID 1-19 19 signal sequence 20-103 84 Activation peptide 104-471 368 mature Collagenase 3 [0064] As used herein, the term "Follistatin" refers to one or more polypeptides present in a biological sample that are derived from the Follistatin precursor (Swiss-Prot P19883 (SEQ ID NO: 5)). 10 20 30 40 50 60 MVRARHQPGG LCLLLLLLCQ FMEDRSAQAG NCWLRQAKNG RCQVLYKTEL SKEECCSTGR 70 80 90 100 110 120 LSTSWTEEDV NDNTLFKWMI FNGGAPNCIP CKETCENVDC GPGKKCRMNK KNKPRCVCAP 130 140 150 160 170 180 DCSNITWKGP VCGLDGKTYR NECALLKARC KEQPELEVQY QGRCKKTCRD VFCPGSSTCV 190 200 210 220 230 240 VDQTNNAYCV TCNRICPEPA SSEQYLCGND GVTYSSACHL RKATCLLGRS IGLAYEGKCI 250 260 270 280 290 300 KAKSCEDIQC TGGKKCLWDF KVGRGRCSLC DELCPDSKSD EPVCASDNAT YASECAMKEA 310 320 330 340 ACSSGVLLEV KHSGSCNSIS EDTEEEEEDE DQDYSFPISS ILEW [0065] The following domains have been identified in Follistatin: Residues Length Domain ID 1-29 29 signal sequence 30-344 315 mature Follistatin 318-344 27 missing in isoform 2 318-323 6 missing in isoform 3 [0066] As used herein, the term "Vitamin D Binding Protein" refers to one or more polypeptides present in a biological sample that are derived from the Vitamin D Binding Protein precursor (Swiss-Prot P02774 (SEQ TD NO: 6)). 10 20 30 40 50 60 MKRVLVLLLA VAFGHALERG RDYEKNKVCK EFSHLGKEDF TSLSLVLYSR KFPSGTFEQV 25 70 80 90 100 110 120 SQLVKEVVSL TEACCAEGAD PDCYDTRTSA LSAKSCESNS PFPVHPGTAE CCTKEGLERK 130 140 150 160 170 180 LCMAALKHQP QEFPTYVEPT NDEICEAFRK DPKEYANQFM WEYSTNYGQA PLSLLVSYTK 190 200 210 220 230 240 SYLSMVGSCC TSASPTVCFL KERLQLKHLS LLTTLSNRVC SQYAAYGEKK SRLSNLIKLA 250 260 270 280 290 300 QKVPTADLED VLPLAEDITN ILSKCCESAS EDCMAKELPE HTVKLCDNLS TKNSKFEDCC 310 320 330 340 350 360 QEKTAMDVFV CTYFMPAAQL PELPDVELPT NKDVCDPGNT KVMDKYTFEL SRRTHLPEVF 370 380 390 400 410 420 LSKVLEPTLK SLGECCDVED STTCFNAKGP LLKKELSSFI DKGQELCADY SENTFTEYKK 430 440 450 460 470 KLAERLKAKL PDATPKELAK LVNKRSDFAS NCCSINSPPL YCDSEIDAEL KNIL [0067] The following domains have been identified in Vitamin D Binding Protein: Residues Length Domain ID 1-16 16 signal sequence 17-474 458 mature Vitamin D Binding Protein 1-122 122 missing in isoform 2 [0068] As used herein, the term "Islet amyloid polypeptide" refers to one or more polypeptides present in a biological sample that are derived from the Islet amyloid polypeptide precursor (Swiss-Prot P10997 (SEQ ID NO: 7)). 10 20 30 40 50 60 MGILKLQVFL IVLSVALNHL KATPIESHQV EKRKCNTATC ATQRLANFLV HSSNNFGAIL 70 80 SSTNVGSNTY GKRNAVEVLK REPLNYLPL [0069] The following domains have been identified in Islet amyloid polypeptide: Residues Length Domain ID 1-22 22 signal sequence 23-31 9 propeptide 34-70 37 mature Islet amyloid polypeptide 26 74-89 16 propeptide [0070] As used herein, the term "Insulin C-peptide" refers to one or more polypeptides present in a biological sample that are derived from the insulin precursor (Swiss-Prot P01308 (SEQ ID NO: 8)) and which comprise all or a portion of the C peptide sequence. 10 20 30 40 50 60 MALWMRLLPL LALLALWGPD PAAAFVNQHL CGSHLVEALY LVCGERGFFY TPKTRREAED 70 80 90 100 110 LQVGQVELGG GPGAGSLQPL ALEGSLQKRG IVEQCCTSIC SLYQLENYCN [0071] The following domains have been identified in the Insulin precursor: Residues Length Domain ID 1-24 24 signal sequence 25-54 30 Insulin B chain 57-87 31 Insulin C-peptide 90-110 21 Insulin A chain [0072] As used herein, the term "Complement Factor H" refers to one or more polypeptides present in a biological sample that are derived from the Complement Factor H precursor (Swiss-Prot P08603 (SEQ ID NO: 9)). 10 20 30 40 50 60 MRLLAKIICL MLWAICVAED CNELPPRRNT EILTGSWSDQ TYPEGTQAIY KCRPGYRSLG 70 80 90 100 110 120 NVIMVCRKGE WVALNPLRKC QKRPCGHPGD TPFGTFTLTG GNVFEYGVKA VYTCNEGYQL 130 140 150 160 170 180 LGEINYRECD TDGWTNDIPI CEVVKCLPVT APENGKIVSS AMEPDREYHF GQAVRFVCNS 190 200 210 220 230 240 GYKIEGDEEM HCSDDGFWSK EKPKCVEISC KSPDVINGSP ISQKIIYKEN ERFQYKCNMG 250 260 270 280 290 300 YEYSERGDAV CTESGWRPLP SCEEKSCDNP YIPNGDYSPL RIKHRTGDEI TYQCRNGFYP 310 320 330 340 350 360 ATRGNTAKCT STGWIPAPRC TLKPCDYPDI KHGGLYHENM RRPYFPVAVG KYYSYYCDEH 370 380 390 400 410 420 FETPSGSYWD HIHCTQDGWS PAVPCLRKCY FPYLENGYNQ NYGRKFVQGK SIDVACHPGY 27 430 440 450 460 470 480 ALPKAQTTVT CMENGWSPTP RCIRVKTCSK SSIDIENGFI SESQYTYALK EKAKYQCKLG 490 500 510 520 530 540 YVTADGETSG SITCGKDGWS AQPTCIKSCD IPVFMNARTK NDFTWFKLND TLDYECHDGY 550 560 570 580 590 600 ESNTGSTTGS IVCGYNGWSD LPICYERECE LPKIDVHLVP DRKKDQYKVG EVLKFSCKPG 610 620 630 640 650 660 FTIVGPNSVQ CYHFGLSPDL PICKEQVQSC GPPPELLNGN VKEKTKEEYG HSEVVEYYCN 670 680 690 700 710 720 PRFLMKGPNK IQCVDGEWTT LPVCIVEEST CGDIPELEHG WAQLSSPPYY YGDSVEFNCS 730 740 750 760 770 780 ESFTMIGHRS ITCIHGVWTQ LPQCVAIDKL KKCKSSNLII LEEHLKNKKE FDHNSNIRYR 790 800 810 820 830 840 CRGKEGWIHT VCINGRWDPE VNCSMAQIQL CPPPPQIPNS HNMTTTLNYR DGEKVSVLCQ 850 860 870 880 890 900 ENYLIQEGEE ITCKDGRWQS IPLCVEKIPC SQPPQIEHGT INSSRSSQES YAHGTKLSYT 910 920 930 940 950 960 CEGGFRISEE NETTCYMGKW SSPPQCEGLP CKSPPEISHG VVAHMSDSYQ YGEEVTYKCF 970 980 990 1000 1010 1020 EGFGIDGPAI AKCLGEKWSH PPSCIKTDCL SLPSFENAIP MGEKKDVYKA GEQVTYTCAT 1030 1040 1050 1060 1070 1080 YYKMDGASNV TCINSRWTGR PTCRDTSCVN PPTVQNAYIV SRQMSKYPSG ERVRYQCRSP 1090 1100 1110 1120 1130 1140 YEMFGDEEVM CLNGNWTEPP QCKDSTGKCG PPPPIDNGDI TSFPLSVYAP ASSVEYQCQN 1150 1160 1170 1180 1190 1200 LYQLEGNKRI TCRNGQWSEP PKCLHPCVIS REIMENYNIA LRWTAKQKLY SRTGESVEFV 1210 1220 1230 CKRGYRLSSR SHTLRTTCWD GKLEYPTCAK R [0073] The following domains have been identified in Complement Factor H: Residues Length Domain ID 1-18 18 signal sequence 19-1231 1213 mature Complement Factor H 446-449 KTCS -> SFTL in isoform 2 450-1231 missing in isoform 2 28 [0074] As used herein, the term "Gastric inhibitory polypeptide" refers to one or more polypeptides present in a biological sample that are derived from the Gastric inhibitory polypeptide precursor (Swiss-Prot P09681 (SEQ ID NO: 10)). 10 20 30 40 50 60 MVATKTFALL LLSLFLAVGL GEKKEGHFSA LPSLPVGSHA KVSSPQPRGP RYAEGTFISD 70 80 90 100 110 120 YSIAMDKIHQ QDFVNWLLAQ KGKKNDWKHN ITQREARALE LASQANRKEE EAVEPQSSPA 130 140 150 KNPSDEDLLR DLLIQELLAC LLDQTNLCRL RSR [0075] The following domains have been identified in Gastric inhibitory polypeptide: Residues Length Domain ID 1-21 21 signal sequence 22-50 29 propeptide 52-93 42 mature Gastric inhibitory polypeptide 95-153 59 propeptide [0076] As used herein, the term "Glucagon" refers to one or more polypeptides present in a biological sample that are derived from the Glucagon precursor (Swiss-Prot P01275 (SEQ ID NO: 12)) and which comprises all or a portion of mature Glucagon. Similarly, the term "Glucagon-like peptide 1" refers to one or more polypeptides present in a biological sample that are derived from the Glucagon precursor (Swiss-Prot P01275 (SEQ ID NO: 12)) and which comprises all or a portion of Glucagon-like peptide 1. 10 20 30 40 50 60 MKSIYFVAGL FVMLVQGSWQ RSLQDTEEKS RSFSASQADP LSDPDQMNED KRHSQGTFTS 70 80 90 100 110 120 DYSKYLDSRR AQDFVQWLMN TKRNRNNIAK RHDEFERHAE GTFTSDVSSY LEGQAAKEFI 130 140 150 160 170 180 AWLVKGRGRR DFPEEVAIVE ELGRRHADGS FSDEMNTILD NLAARDFINW LIQTKITDRK [0077] The following domains have been identified in Glucagon: Residues Length Domain ID 1-20 20 signal sequence 29 21-89 69 glicentin 21-50 30 glicentin-related polypeptide 53-89 37 oxyntomodulin 53-81 29 mature Glucagon 84-89 6 propeptide 92-128 37 Glucagon-like peptide 1 98-128 31 Glucagon-like peptide 1(7-37) 98-127 30 Glucagon-like peptide 1(7-36) 131-145 15 propeptide 146-178 33 glucagon-like peptide 2 [0078] As used herein, the term "Involucrin" refers to one or more polypeptides present in a biological sample that are derived from the Involucrin precursor (Swiss-Prot P07476 (SEQ ID NO: 13)). 10 20 30 40 50 60 MSQQHTLPVT LSPALSQELL KTVPPPVNTH QEQMKQPTPL PPPCQKVPVE LPVEVPSKQE 70 80 90 100 110 120 EKHMTAVKGL PEQECEQQQK EPQEQELQQQ HWEQHEEYQK AENPEQQLKQ EKTQRDQQLN 130 140 150 160 170 180 KQLEEEKKLL DQQLDQELVK RDEQLGMKKE QLLELPEQQE GHLKHLEQQE GQLKHPEQQE 190 200 210 220 230 240 GQLELPEQQE GQLELPEQQE GQLELPEQQE GQLELPEQQE GQLELPEQQE GQLELPQQQE 250 260 270 280 290 300 GQLELSEQQE GQLELSEQQE GQLKHLEHQE GQLEVPEEQM GQLKYLEQQE GQLKHLDQQE 310 320 330 340 350 360 KQPELPEQQM GQLKHLEQQE GQPKHLEQQE GQLEQLEEQE GQLKHLEQQE GQLEHLEHQE 370 380 390 400 410 420 GQLGLPEQQV LQLKQLEKQQ GQPKHLEEEE GQLKHLVQQE GQLKHLVQQE GQLEQQERQV 430 440 450 460 470 480 EHLEQQVGQL KHLEEQEGQL KHLEQQQGQL EVPEQQVGQP KNLEQEEKQL ELPEQQEGQV 490 500 510 520 530 540 KHLEKQEAQL ELPEQQVGQP KHLEQQEKHL EHPEQQDGQL KHLEQQEGQL KDLEQQKGQL 550 560 570 580 EQPVFAPAPG QVQDIQPALP TKGEVLLPVE HQQQKQEVQW PPKHK 30 [0079] As used herein, the term "type II cytoskeletal Keratin-1/10" refers to one or more polypeptides present in a biological sample that are derived from the type II cytoskeletal Keratin-1 precursor (Swiss-Prot P04264 (SEQ ID NO: 14)) 10 20 30 40 50 60 MSRQFSSRSG YRSGGGFSSG SAGIINYQRR TTSSSTRRSG GGGGRFSSCG GGGGSFGAGG 70 80 90 100 110 120 GFGSRSLVNL GGSKSISISV ARGGGRGSGF GGGYGGGGFG GGGFGGGGFG GGGIGGGGFG 130 140 150 160 170 180 GFGSGGGGFG GGGFGGGGYG GGYGPVCPPG GIQEVTINQS LLQPLNVEID PEIQKVKSRE 190 200 210 220 230 240 REQIKSLNNQ FASFIDKVRF LEQQNQVLQT KWELLQQVDT STRTHNLEPY FESFINNLRR 250 260 270 280 290 300 RVDQLKSDQS RLDSELKNMQ DMVEDYRNKY EDEINKRTNA ENEFVTIKKD VDGAYMTKVD 310 320 330 340 350 360 LQAKLDNLQQ EIDFLTALYQ AELSQMQTQI SETNVILSMD NNRSLDLDSI IAEVKAQYED 370 380 390 400 410 420 IAQKSKAEAE SLYQSKYEEL QITAGRHGDS VRNSKIEISE LNRVIQRLRS EIDNVKKQIS 430 440 450 460 470 480 NLQQSISDAE QRGENALKDA KNKLNDLEDA LQQAKEDLAR LLRDYQELMN TKLALDLEIA 490 500 510 520 530 540 TYRTLLEGEE SRMSGECAPN VSVSVSTSHT TISGGGSRGG GGGGYGSGGS SYGSGGGSYG 550 560 570 580 590 600 SGGGGGGGRG SYGSGGSSYG SGGGSYGSGG GGGGHGSYGS GSSSGGYRGG SGGGGGGSSG 610 620 630 640 GRGSGGGSSG GSIGGRGSSS GGVKSSGGSS SVKFVSTTYS GVTR or from the type II cytoskeletal Keratin-10 precursor (Swiss-Prot P13645 (SEQ ID NO: 15)). 10 20 30 40 50 60 MSVRYSSSKH YSSSRSGGGG GGGGCGGGGG VSSLRISSSK GSLGGGFSSG GFSGGSFSRG 70 80 90 100 110 120 SSGGGCFGGS SGGYGGLGGF GGGSFRGSYG SSSFGGSYGG IFGGGSFGGG SFGGGSFGGG 130 140 150 160 170 180 GFGGGGFGGG FGGGFGGDGG LLSGNEKVTM QNLNDRLASY LDKVRALEES NYELEGKIKE 190 200 210 220 230 240 WYEKHGNSHQ GEPRDYSKYY KTIDDLKNQI LNLTTDNANI LLQIDNARLA ADDFRLKYEN 31 250 260 270 280 290 300 EVALRQSVEA DINGLRRVLD ELTLTKADLE MQIESLTEEL AYLKKNHEEE MKDLRNVSTG 310 320 330 340 350 360 DVNVEMNAAP GVDLTQLLNN MRSQYEQLAE QNRKDAEAWF NEKSKELTTE IDNNIEQISS 370 380 390 400 410 420 YKSEITELRR NVQALEIELQ SQLALKQSLE ASLAETEGRY CVQLSQIQAQ ISALEEQLQQ 430 440 450 460 470 480 IRAETECQNT EYQQLLDIKI RLENEIQTYR SLLEGEGSSG GGGRGGGSFG GGYGGGSSGG 490 500 510 520 530 540 GSSGGGHGGG HGGSSGGGYG GGSSGGGSSG GGYGGGSSSG GHGGSSSGGY GGGSSGGGGG 550 560 570 580 GYGGGSSGGG SSSGGGYGGG SSSGGHKSSS SGSVGESSSK GPRY [0080] Preferred assays detect both type II cytoskeletal Keratin-1 and type II cytoskeletal Keratin-10 sequences. [0081] As used herein, the term "type II cytoskeletal Keratin-6A/6B/6C" refers to one or more polypeptides present in a biological sample that are derived from the type II cytoskeletal Keratin-6A precursor (Swiss-Prot P02538 (SEQ ID NO: 16)) 10 20 30 40 50 60 MASTSTTIRS HSSSRRGFSA NSARLPGVSR SGFSSVSVSR SRGSGGLGGA CGGAGFGSRS 70 80 90 100 110 120 LYGLGGSKRI SIGGGSCAIS GGYGSRAGGS YGFGGAGSGF GFGGGAGIGF GLGGGAGLAG 130 140 150 160 170 180 GFGGPGFPVC PPGGIQEVTV NQSLLTPLNL QIDPTIQRVR AEEREQIKTL NNKFASFIDK 190 200 210 220 230 240 VRFLEQQNKV LETKWTLLQE QGTKTVRQNL EPLFEQYINN LRRQLDSIVG ERGRLDSELR 250 260 270 280 290 300 GMQDLVEDFK NKYEDEINKR TAAENEFVTL KKDVDAAYMN KVELQAKADT LTDEINFLRA 310 320 330 340 350 360 LYDAELSQMQ THISDTSVVL SMDNNRNLDL DSIIAEVKAQ YEEIAQRSRA EAESWYQTKY 370 380 390 400 410 420 EELQVTAGRH GDDLRNTKQE IAEINRMIQR LRSEIDHVKK QCANLQAAIA DAEQRGEMAL 430 440 450 460 470 480 KDAKNKLEGL EDALQKAKQD LARLLKEYQE LMNVKLALDV EIATYRKLLE GEECRLNGEG 490 500 510 520 530 540 VGQVNISVVQ STVSSGYGGA SGVGSGLGLG GGSSYSYGSG LGVGGGFSSS SGRAIGGGLS 32 550 560 SVGGGSSTIK YTTTSSSSRK SYKH or from the type II cytoskeletal Keratin-6B precursor (Swiss-Prot P04259 (SEQ ID NO: 17)). 10 20 30 40 50 60 MASTSTTIRS HSSSRRGFSA NSARLPGVSR SGFSSISVSR SRGSGGLGGA CGGAGFGSRS 70 80 90 100 110 120 LYGLGGSKRI SIGGGSCAIS GGYGSRAGGS YGFGGAGSGF GFGGGAGIGF GLGGGAGLAG 130 140 150 160 170 180 GFGGPGFPVC PPGGIQEVTV NQSLLTPLNL QIDPAIQRVR AEEREQIKTL NNKFASFIDK 190 200 210 220 230 240 VRFLEQQNKV LDTKWTLLQE QGTKTVRQNL EPLFEQYINN LRRQLDNIVG ERGRLDSELR 250 260 270 280 290 300 NMQDLVEDLK NKYEDEINKR TAAENEFVTL KKDVDAAYMN KVELQAKADT LTDEINFLRA 310 320 330 340 350 360 LYDAELSQMQ THISDTSVVL SMDNNRNLDL DSIIAEVKAQ YEEIAQRSRA EAESWYQTKY 370 380 390 400 410 420 EELQITAGRH GDDLRNTKQE IAEINRMIQR LRSEIDHVKK QCANLQAAIA DAEQRGEMAL 430 440 450 460 470 480 KDAKNKLEGL EDALQKAKQD LARLLKEYQE LMNVKLALDV EIATYRKLLE GEECRLNGEG 490 500 510 520 530 540 VGQVNISVVQ STVSSGYGGA SGVGSGLGLG GGSSYSYGSG LGVGGGFSSS SGRATGGGLS 550 560 SVGGGSSTIK YTTTSSSSRK SYKH or from the type II cytoskeletal Keratin-6C precursor (Swiss-Prot P48668 (SEQ ID NO: 18)). 10 20 30 40 50 60 MASTSTTIRS HSSSRRGFSA NSARLPGVSR SGFSSISVSR SRGSGGLGGA CGGAGFGSRS 70 80 90 100 110 120 LYGLGGSKRI SIGGGSCAIS GGYGSRAGGS YGFGGAGSGF GFGGGAGIGF GLGGGAGLAG 130 140 150 160 170 180 GFGGPGFPVC PPGGIQEVTV NQSLLTPLNL QIDPAIQRVR AEEREQIKTL NNKFASFIDK 190 200 210 220 230 240 VRFLEQQNKV LDTKWTLLQE QGTKTVRQNL EPLFEQYINN LRRQLDSIVG ERGRLDSELR 250 260 270 280 290 300 NMQDLVEDLK NKYEDEINKR TAAENEFVTL KKDVDAAYMN KVELQAKADT LTDEINFLRA 33 310 320 330 340 350 360 LYDAELSQMQ THISDTSVVL SMDNNRNLDL DSIIAEVKAQ YEEIAQRSRA EAESWYQTKY 370 380 390 400 410 420 EELQVTAGRH GDDLRNTKQE IAEINRMIQR LRSEIDHVKK QCASLQAAIA DAEQRGEMAL 430 440 450 460 470 480 KDAKNKLEGL EDALQKAKQD LARLLKEYQE LMNVKLALDV EIATYRKLLE GEECRLNGEG 490 500 510 520 530 540 VGQVNVSVVQ STISSGYGGA SGVGSGLGLG GGSSYSYGSG LGIGGGFSSS SGRAIGGGLS 550 560 SVGGGSSTIK YTTTSSSSRK SYKH [0082] Preferred assays detect each of the type II cytoskeletal Keratin-6A, -6B, and 6C sequences. [0083] As used herein, the term "Osteocalcin" refers to one or more polypeptides present in a biological sample that are derived from the Osteocalcin precursor (Swiss-Prot P02818 (SEQ ID NO: 19)). 10 20 30 40 50 60 MRALTLLALL ALAALCIAGQ AGAKPSGAES SKGAAFVSKQ EGSEVVKRPR RYLYQWLGAP 70 80 90 100 VPYPDPLEPR REVCELNPDC DELADHIGFQ EAYRRFYGPV [0084] The following domains have been identified in Osteocalcin: Residues Length Domain ID 1-23 23 signal sequence 24-51 28 propeptide 52-100 49 mature Osteocalcin [0085] As used herein, the term "Lipopolysaccharide" refers toa cell wall constituent of gram-negative organisms such as Escherichia coli, Klebsiella, Proteus or Pseudomonas. Circulating LPS and, in particular, its constituent lipid A, provokes a wide range of systemic reactions. Activation of circulating monocytes and macrophages leads to release of cytokines such as IL- 6, IL-12, IL-15, IL-18, TNF-a, macrophage migration inhibitory factor (MlF), and cytokine-like molecules such as high mobility group B 1 (HMGB 1), which, in turn activate neutrophils, lymphocytes and vascular endothelium, up-regulate cell adhesion molecules, and induce prostaglandins, nitric oxide synthase and acute- phase proteins. Release of platelet activating factor (PAF), prostaglandins, 34 leukotrienes and thromboxane activates vascular endothelium, regulates vascular tone and activates the extrinsic coagulation cascade. Assays for the measurement of LPS in biological samples, e.g., the Limulus amoebocyte lysate (LAL), are known in the art. [0086] As used herein, the term "Pancreatic prohormone" refers to one or more polypeptides present in a biological sample that are derived from the Pancreatic prohormone precursor (Swiss-Prot P01298 (SEQ ID NO: 20)). 10 20 30 40 50 60 MAAARLCLSL LLLSTCVALL LQPLLGAQGA PLEPVYPGDN ATPEQMAQYA ADLRRYINML 70 80 90 TRPRYGKRHK EDTLAFSEWG SPHAAVPREL SPLDL [0087] The following domains have been identified in Pancreatic prohormone: Residues Length Domain ID 1-29 29 signal sequence 30-65 36 mature Pancreatic prohormone 69-88 20 Pancreatic icosapeptide 89-95 7 propeptide [0088] As used herein, the term "Peptide YY" refers to one or more polypeptides present in a biological sample that are derived from the Peptide YY precursor (Swiss-Prot P10082 (SEQ ID NO: 21)). 10 20 30 40 50 60 MVFVRRPWPA LTTVLLALLV CLGALVDAYP IKPEAPGEDA SPEELNRYYA SLRHYLNLVT 70 80 90 RQRYGKRDGP DTLLSKTFFP DGEDRPVRSR SEGPDLW [0089] The following domains have been identified in Peptide YY: Residues Length Domain ID 1-28 28 signal sequence 29-64 36 mature Peptide YY 31-64 34 Peptide YY(3-36) 68-97 30 propeptide 35 91-97 7 missing in isoform 2 [0090] As used herein, the term "Agouti-related protein" refers to one or more polypeptides present in a biological sample that are derived from the Agouti-related protein precursor (Swiss-Prot 000253 (SEQ ID NO: 22)). 10 20 30 40 50 60 MLTAAVLSCA LLLALPATRG AQMGLAPMEG IRRPDQALLP ELPGLGLRAP LKKTTAEQAE 70 80 90 100 110 120 EDLLQEAQAL AEVLDLQDRE PRSSRRCVRL HESCLGQQVP CCDPCATCYC RFFNAFCYCR 130 KLGTAMNPCS RT [0091] The following domains have been identified in Agouti-related protein: Residues Length Domain ID 1-20 20 signal sequence 21-132 112 mature Agouti-related protein [0092] As used herein, the term "Ciliary neurotrophic factor" refers to one or more polypeptides present in a biological sample that are derived from the Ciliary neurotrophic factor precursor (Swiss-Prot P26441 (SEQ ID NO: 23)). 10 20 30 40 50 60 MAFTEHSPLT PHRRDLCSRS IWLARKIRSD LTALTESYVK HQGLNKNINL DSADGMPVAS 70 80 90 100 110 120 TDQWSELTEA ERLQENLQAY RTFHVLLARL LEDQQVHFTP TEGDFHQAIH TLLLQVAAFA 130 140 150 160 170 180 YQIEELMILL EYKIPRNEAD GMPINVGDGG LFEKKLWGLK VLQELSQWTV RSIHDLRFIS 190 200 SHQTGIPARG SHYIANNKKM [0093] As used herein, the term "Appetite-regulating hormone" refers to one or more polypeptides present in a biological sample that are derived from the Appetite-regulating hormone precursor (Swiss-Prot Q9UBU3 (SEQ ID NO: 24)). 10 20 30 40 50 60 MPSPGTVCSL LLLGMLWLDL AMAGSSFLSP EHQRVQQRKE SKKPPAKLQP RALAGWLRPE 70 80 90 100 110 DGGQAEGAED ELEVRFNAPF DVGIKLSGVQ YQQHSQALGK FLQDILWEEA KEAPADK [0094] The following domains have been identified in Appetite-regulating hormone: 36 Residues Length Domain ID 1-23 23 signal sequence 24-51 28 Ghrelin-28 24-50 27 Ghrelin-27 52-75 24 propeptide 76-98 23 obestatin 99-117 19 propeptide 37 1 missing in isoform 2 [0095] As used herein, the term "Transthyretin" refers to one or more polypeptides present in a biological sample that are derived from the Transthyretin precursor (Swiss Prot P02766 (SEQ ID NO: 25)). 10 20 30 40 50 60 MASHRLLLLC LAGLVFVSEA GPTGTGESKC PLMVKVLDAV RGSPAINVAV HVFRKAADDT 70 80 90 100 110 120 WEPFASGKTS ESGELHGLTT EEEFVEGIYK VEIDTKSYWK ALGISPFHEH AEVVFTANDS 130 140 GPRRYTIAAL LSPYSYSTTA VVTNPKE [0096] The following domains have been identified in Transthyretin: Residues Length Domain ID 1-20 20 signal sequence 21-147 127 mature Transthyretin [0097] As used herein, the term "Insulin receptor substrate 1" refers to one or more polypeptides present in a biological sample that are derived from the Insulin receptor substrate 1 precursor (Swiss-Prot P35568 (SEQ ID NO: 26)). 10 20 30 40 50 60 MASPPESDGF SDVRKVGYLR KPKSMHKRFF VLRAASEAGG PARLEYYENE KKWRHKSSAP 70 80 90 100 110 120 KRSIPLESCF NINKRADSKN KHLVALYTRD EHFAIAADSE AEQDSWYQAL LQLHNRAKGH 130 140 150 160 170 180 HDGAAALGAG GGGGSCSGSS GLGEAGEDLS YGDVPPGPAF KEVWQVILKP KGLGQTKNLI 37 190 200 210 220 230 240 GIYRLCLTSK TISFVKLNSE AAAVVLQLMN IRRCGHSENF FFIEVGRSAV TGPGEFWMQV 250 260 270 280 290 300 DDSVVAQNMH ETILEAMRAM SDEFRPRSKS QSSSNCSNPI SVPLRRHHLN NPPPSQVGLT 310 320 330 340 350 360 RRSRTESITA TSPASMVGGK PGSFRVRASS DGEGTMSRPA SVDGSPVSPS TNRTHAHRHR 370 380 390 400 410 420 GSARLHPPLN HSRSIPMPAS RCSPSATSPV SLSSSSTSGH GSTSDCLFPR RSSASVSGSP 430 440 450 460 470 480 SDGGFISSDE YGSSPCDFRS SFRSVTPDSL GHTPPARGEE ELSNYICMGG KGPSTLTAPN 490 500 510 520 530 540 GHYILSRGGN GHRCTPGTGL GTSPALAGDE AASAADLDNR FRKRTHSAGT SPTITHQKTP 550 560 570 580 590 600 SQSSVASIEE YTEMMPAYPP GGGSGGRLPG HRHSAFVPTR SYPEEGLEMH PLERRGGHHR 610 620 630 640 650 660 PDSSTLHTDD GYMPMSPGVA PVPSGRKGSG DYMPMSPKSV SAPQQIINPI RRHPQRVDPN 670 680 690 700 710 720 GYMMMSPSGG CSPDIGGGPS SSSSSSNAVP SGTSYGKLWT NGVGGHHSHV LPHPKPPVES 730 740 750 760 770 780 SGGKLLPCTG DYMNMSPVGD SNTSSPSDCY YGPEDPQHKP VLSYYSLPRS FKHTQRPGEP 790 800 810 820 830 840 EEGARHQHLR LSTSSGRLLY AATADDSSSS TSSDSLGGGY CGARLEPSLP HPHHQVLQPH 850 860 870 880 890 900 LPRKVDTAAQ TNSRLARPTR LSLGDPKAST LPRAREQQQQ QQPLLHPPEP KSPGEYVNIE 910 920 930 940 950 960 FGSDQSGYLS GPVAFHSSPS VRCPSQLQPA PREEETGTEE YMKMDLGPGR RAAWQESTGV 970 980 990 1000 1010 1020 EMGRLGPAPP GAASICRPTR AVPSSRGDYM TMQMSCPRQS YVDTSPAAPV SYADMRTGIA 1030 1040 1050 1060 1070 1080 AEEVSLPRAT MAAASSSSAA SASPTGPQGA AELAAHSSLL GGPQGPGGMS AFTRVNLSPN 1090 1100 1110 1120 1130 1140 RNQSAKVIRA DPQGCRRRHS SETFSSTPSA TRVGNTVPFG AGAAVGGGGG SSSSSEDVKR 1150 1160 1170 1180 1190 1200 HSSASFENVW LRPGELGGAP KEPAKLCGAA GGLENGLNYI DLDLVKDFKQ CPQECTPEPQ 1210 1220 1230 1240 PPPPPPPHQP LGSGESSSTR RSSEDLSAYA SISFQKQPED RQ 38 [0098] As used herein, the term "and NF-kappa-B inhibitor alpha" refers to one or more polypeptides present in a biological sample that are derived from the precursor (Swiss-Prot P25963 (SEQ ID NO: 27)). 10 20 30 40 50 60 MFQAAERPQE WAMEGPRDGL KKERLLDDRH DSGLDSMKDE EYEQMVKELQ EIRLEPQEVP 70 80 90 100 110 120 RGSEPWKQQL TEDGDSFLHL AIIHEEKALT MEVIRQVKGD LAFLNFQNNL QQTPLHLAVI 130 140 150 160 170 180 TNQPEIAEAL LGAGCDPELR DFRGNTPLHL ACEQGCLASV GVLTQSCTTP HLHSILKATN 190 200 210 220 230 240 YNGHTCLHLA SIHGYLGIVE LLVSLGADVN AQEPCNGRTA LHLAVDLQNP DLVSLLLKCG 250 260 270 280 290 300 ADVNRVTYQG YSPYQLTWGR PSTRIQQQLG QLTLENLQML PESEDEESYD TESEFTEFTE 310 DELPYDDCVF GGQRLTL [0099] As used herein, the term "relating a signal to the presence or amount" of an analyte reflects the following understanding. Assay signals are typically related to the presence or amount of an analyte through the use of a standard curve calculated using known concentrations of the analyte of interest. As the term is used herein, an assay is "configured to detect" an analyte if an assay can generate a detectable signal indicative of the presence or amount of a physiologically relevant concentration of the analyte. Because an antibody epitope is on the order of 8 amino acids, an immunoassay configured to detect a marker of interest will also detect polypeptides related to the marker sequence, so long as those polypeptides contain the epitope(s) necessary to bind to the antibody or antibodies used in the assay. The term "related marker" as used herein with regard to a biomarker such as one of the kidney injury markers described herein refers to one or more fragments, variants, etc., of a particular marker or its biosynthetic parent that may be detected as a surrogate for the marker itself or as independent biomarkers. The term also refers to one or more polypeptides present in a biological sample that are derived from the biomarker precursor complexed to additional species, such as binding proteins, receptors, heparin, lipids, sugars, etc. [0100] In this regard, the skilled artisan will understand that the signals obtained from an immunoassay are a direct result of complexes formed between one or more antibodies and the target biomolecule (i.e., the analyte) and polypeptides containing the necessary 39 epitope(s) to which the antibodies bind. While such assays may detect the full length biomarker and the assay result be expressed as a concentration of a biomarker of interest, the signal from the assay is actually a result of all such "immunoreactive" polypeptides present in the sample. Expression of biomarkers may also be determined by means other than immunoassays, including protein measurements (such as dot blots, western blots, chromatographic methods, mass spectrometry, etc.) and nucleic acid measurements (mRNA quatitation). This list is not meant to be limiting. [0101] The term "positive going" marker as that term is used herein refer to a marker that is determined to be elevated in subjects suffering from a disease or condition, relative to subjects not suffering from that disease or condition. The term "negative going" marker as that term is used herein refer to a marker that is determined to be reduced in subjects suffering from a disease or condition, relative to subjects not suffering from that disease or condition. [0102] The term "subject" as used herein refers to a human or non-human organism. Thus, the methods and compositions described herein are applicable to both human and veterinary disease. Further, while a subject is preferably a living organism, the invention described herein may be used in post-mortem analysis as well. Preferred subjects are humans, and most preferably "patients," which as used herein refers to living humans that are receiving medical care for a disease or condition. This includes persons with no defined illness who are being investigated for signs of pathology. [0103] Preferably, an analyte is measured in a sample. Such a sample may be obtained from a subject, or may be obtained from biological materials intended to be provided to the subject. For example, a sample may be obtained from a kidney being evaluated for possible transplantation into a subject, and an analyte measurement used to evaluate the kidney for preexisting damage. Preferred samples are body fluid samples. [0104] The term "body fluid sample" as used herein refers to a sample of bodily fluid obtained for the purpose of diagnosis, prognosis, classification or evaluation of a subject of interest, such as a patient or transplant donor. In certain embodiments, such a sample may be obtained for the purpose of determining the outcome of an ongoing condition or the effect of a treatment regimen on a condition. Preferred body fluid samples include blood, serum, plasma, cerebrospinal fluid, urine, saliva, sputum, and pleural effusions. In addition, one of skill in the art would realize that certain body fluid samples would be 40 more readily analyzed following a fractionation or purification procedure, for example, separation of whole blood into serum or plasma components. [0105] The term "diagnosis" as used herein refers to methods by which the skilled artisan can estimate and/or determine the probability ("a likelihood") of whether or not a patient is suffering from a given disease or condition. In the case of the present invention, "diagnosis" includes using the results of an assay, most preferably an immunoassay, for a kidney injury marker of the present invention, optionally together with other clinical characteristics, to arrive at a diagnosis (that is, the occurrence or nonoccurrence) of an acute renal injury or ARF for the subject from which a sample was obtained and assayed. That such a diagnosis is "determined" is not meant to imply that the diagnosis is 100% accurate. Many biomarkers are indicative of multiple conditions. The skilled clinician does not use biomarker results in an informational vacuum, but rather test results are used together with other clinical indicia to arrive at a diagnosis. Thus, a measured biomarker level on one side of a predetermined diagnostic threshold indicates a greater likelihood of the occurrence of disease in the subject relative to a measured level on the other side of the predetermined diagnostic threshold. Similarly, a prognostic risk signals a probability ("a likelihood") that a given course or outcome will occur. A level or a change in level of a prognostic indicator, which in turn is associated with an increased probability of morbidity (e.g., worsening renal function, future ARF, or death) is referred to as being "indicative of an increased likelihood" of an adverse outcome in a patient. [0106] Marker Assays [0107] In general, immunoassays involve contacting a sample containing or suspected of containing a biomarker of interest with at least one antibody that specifically binds to the biomarker. A signal is then generated indicative of the presence or amount of complexes formed by the binding of polypeptides in the sample to the antibody. The signal is then related to the presence or amount of the biomarker in the sample. Numerous methods and devices are well known to the skilled artisan for the detection and analysis of biomarkers. See, e.g., U.S. Patents 6,143,576; 6,113,855; 6,019,944; 5,985,579; 5,947,124; 5,939,272; 5,922,615; 5,885,527; 5,851,776; 5,824,799; 5,679,526; 5,525,524; and 5,480,792, and The Immunoassay Handbook, David Wild, ed. Stockton Press, New 41 York, 1994, each of which is hereby incorporated by reference in its entirety, including all tables, figures and claims. [0108] The assay devices and methods known in the art can utilize labeled molecules in various sandwich, competitive, or non-competitive assay formats, to generate a signal that is related to the presence or amount of the biomarker of interest. Suitable assay formats also include chromatographic, mass spectrographic, and protein "blotting" methods. Additionally, certain methods and devices, such as biosensors and optical immunoassays, may be employed to determine the presence or amount of analytes without the need for a labeled molecule. See, e.g., U.S. Patents 5,631,171; and 5,955,377, each of which is hereby incorporated by reference in its entirety, including all tables, figures and claims. One skilled in the art also recognizes that robotic instrumentation including but not limited to Beckman ACCESS@, Abbott AXSYM@, Roche ELECSYS@, Dade Behring STRATUS® systems are among the immunoassay analyzers that are capable of performing immunoassays. But any suitable immunoassay may be utilized, for example, enzyme-linked immunoassays (ELISA), radioimmunoassays (RIAs), competitive binding assays, and the like. [0109] Antibodies or other polypeptides may be immobilized onto a variety of solid supports for use in assays. Solid phases that may be used to immobilize specific binding members include include those developed and/or used as solid phases in solid phase binding assays. Examples of suitable solid phases include membrane filters, cellulose based papers, beads (including polymeric, latex and paramagnetic particles), glass, silicon wafers, microparticles, nanoparticles, TentaGels, AgroGels, PEGA gels, SPOCC gels, and multiple-well plates. An assay strip could be prepared by coating the antibody or a plurality of antibodies in an array on solid support. This strip could then be dipped into the test sample and then processed quickly through washes and detection steps to generate a measurable signal, such as a colored spot. Antibodies or other polypeptides may be bound to specific zones of assay devices either by conjugating directly to an assay device surface, or by indirect binding. In an example of the later case, antibodies or other polypeptides may be immobilized on particles or other solid supports, and that solid support immobilized to the device surface. [0110] Biological assays require methods for detection, and one of the most common methods for quantitation of results is to conjugate a detectable label to a protein or nucleic acid that has affinity for one of the components in the biological system being studied. 42 Detectable labels may include molecules that are themselves detectable (e.g., fluorescent moieties, electrochemical labels, metal chelates, etc.) as well as molecules that may be indirectly detected by production of a detectable reaction product (e.g., enzymes such as horseradish peroxidase, alkaline phosphatase, etc.) or by a specific binding molecule which itself may be detectable (e.g., biotin, digoxigenin, maltose, oligohistidine, 2,4 dintrobenzene, phenylarsenate, ssDNA, dsDNA, etc.). [0111] Preparation of solid phases and detectable label conjugates often comprise the use of chemical cross-linkers. Cross-linking reagents contain at least two reactive groups, and are divided generally into homofunctional cross-linkers (containing identical reactive groups) and heterofunctional cross-linkers (containing non-identical reactive groups). Homobifunctional cross-linkers that couple through amines, sulfhydryls or react non specifically are available from many commercial sources. Maleimides, alkyl and aryl halides, alpha-haloacyls and pyridyl disulfides are thiol reactive groups. Maleimides, alkyl and aryl halides, and alpha-haloacyls react with sulfhydryls to form thiol ether bonds, while pyridyl disulfides react with sulfhydryls to produce mixed disulfides. The pyridyl disulfide product is cleavable. Imidoesters are also very useful for protein-protein cross-links. A variety of heterobifunctional cross-linkers, each combining different attributes for successful conjugation, are commercially available. [0112] In certain aspects, the present invention provides kits for the analysis of the described kidney injury markers. The kit comprises reagents for the analysis of at least one test sample which comprise at least one antibody that a kidney injury marker. The kit can also include devices and instructions for performing one or more of the diagnostic and/or prognostic correlations described herein. Preferred kits will comprise an antibody pair for performing a sandwich assay, or a labeled species for performing a competitive assay, for the analyte. Preferably, an antibody pair comprises a first antibody conjugated to a solid phase and a second antibody conjugated to a detectable label, wherein each of the first and second antibodies that bind a kidney injury marker. Most preferably each of the antibodies are monoclonal antibodies. The instructions for use of the kit and performing the correlations can be in the form of labeling, which refers to any written or recorded material that is attached to, or otherwise accompanies a kit at any time during its manufacture, transport, sale or use. For example, the term labeling encompasses advertising leaflets and brochures, packaging materials, instructions, audio or video cassettes, computer discs, as well as writing imprinted directly on kits. 43 [0113] Antibodies [0114] The term "antibody" as used herein refers to a peptide or polypeptide derived from, modeled after or substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof, capable of specifically binding an antigen or epitope. See, e.g. Fundamental Immunology, 3rd Edition, W.E. Paul, ed., Raven Press, N.Y. (1993); Wilson (1994; J. Immunol. Methods 175:267-273; Yarmush (1992) J. Biochem. Biophys. Methods 25:85-97. The term antibody includes antigen-binding portions, i.e., "antigen binding sites," (e.g., fragments, subsequences, complementarity determining regions (CDRs)) that retain capacity to bind antigen, including (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHl domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CHl domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341:544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR). Single chain antibodies are also included by reference in the term "antibody." [0115] Antibodies used in the immunoassays described herein preferably specifically bind to a kidney injury marker of the present invention. The term "specifically binds" is not intended to indicate that an antibody binds exclusively to its intended target since, as noted above, an antibody binds to any polypeptide displaying the epitope(s) to which the antibody binds. Rather, an antibody "specifically binds" if its affinity for its intended target is about 5-fold greater when compared to its affinity for a non-target molecule which does not display the appropriate epitope(s). Preferably the affinity of the antibody will be at least about 5 fold, preferably 10 fold, more preferably 25-fold, even more preferably 50-fold, and most preferably 100-fold or more, greater for a target molecule than its affinity for a non-target molecule. In preferred embodiments, Preferred antibodies bind with affinities of at least about 107 M- 1 , and preferably between about 108 M- to about 10 9

M-

1 , about 10 9

M-

1 to about 1010 M- 1 , or about 1010 M- 1 to about 10" M- 1 . [0116] Affinity is calculated as Kd = kff/kon (kff is the dissociation rate constant, K,, is the association rate constant and Kd is the equilibrium constant). Affinity can be determined at equilibrium by measuring the fraction bound (r) of labeled ligand at various concentrations (c). The data are graphed using the Scatchard equation: r/c = K(n-r): where r = moles of bound ligand/mole of receptor at equilibrium; c = free ligand concentration 44 at equilibrium; K = equilibrium association constant; and n = number of ligand binding sites per receptor molecule. By graphical analysis, r/c is plotted on the Y-axis versus r on the X-axis, thus producing a Scatchard plot. Antibody affinity measurement by Scatchard analysis is well known in the art. See, e.g., van Erp et al., J. Immunoassay 12: 425-43, 1991; Nelson and Griswold, Comput. Methods Programs Biomed. 27: 65-8, 1988. [0117] The term "epitope" refers to an antigenic determinant capable of specific binding to an antibody. Epitopes usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. Conformational and nonconformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents. [0118] Numerous publications discuss the use of phage display technology to produce and screen libraries of polypeptides for binding to a selected analyte. See, e.g, Cwirla et al., Proc. Natl. Acad. Sci. USA 87, 6378-82, 1990; Devlin et al., Science 249, 404-6, 1990, Scott and Smith, Science 249, 386-88, 1990; and Ladner et al., U.S. Pat. No. 5,571,698. A basic concept of phage display methods is the establishment of a physical association between DNA encoding a polypeptide to be screened and the polypeptide. This physical association is provided by the phage particle, which displays a polypeptide as part of a capsid enclosing the phage genome which encodes the polypeptide. The establishment of a physical association between polypeptides and their genetic material allows simultaneous mass screening of very large numbers of phage bearing different polypeptides. Phage displaying a polypeptide with affinity to a target bind to the target and these phage are enriched by affinity screening to the target. The identity of polypeptides displayed from these phage can be determined from their respective genomes. Using these methods a polypeptide identified as having a binding affinity for a desired target can then be synthesized in bulk by conventional means. See, e.g., U.S. Patent No. 6,057,098, which is hereby incorporated in its entirety, including all tables, figures, and claims. [0119] The antibodies that are generated by these methods may then be selected by first screening for affinity and specificity with the purified polypeptide of interest and, if required, comparing the results to the affinity and specificity of the antibodies with polypeptides that are desired to be excluded from binding. The screening procedure can involve immobilization of the purified polypeptides in separate wells of microtiter plates. 45 The solution containing a potential antibody or groups of antibodies is then placed into the respective microtiter wells and incubated for about 30 min to 2 h. The microtiter wells are then washed and a labeled secondary antibody (for example, an anti-mouse antibody conjugated to alkaline phosphatase if the raised antibodies are mouse antibodies) is added to the wells and incubated for about 30 min and then washed. Substrate is added to the wells and a color reaction will appear where antibody to the immobilized polypeptide(s) are present. [0120] The antibodies so identified may then be further analyzed for affinity and specificity in the assay design selected. In the development of immunoassays for a target protein, the purified target protein acts as a standard with which to judge the sensitivity and specificity of the immunoassay using the antibodies that have been selected. Because the binding affinity of various antibodies may differ; certain antibody pairs (e.g., in sandwich assays) may interfere with one another sterically, etc., assay performance of an antibody may be a more important measure than absolute affinity and specificity of an antibody. [0121] While the present application describes antibody-based binding assays in detail, alternatives to antibodies as binding species in assays are well known in the art. These include receptors for a particular target, aptamers, etc. Aptamers are oligonucleic acid or peptide molecules that bind to a specific target molecule. Aptamers are usually created by selecting them from a large random sequence pool, but natural aptamers also exist. High-affinity aptamers containing modified nucleotides conferring improved characteristics on the ligand, such as improved in vivo stability or improved delivery characteristics. Examples of such modifications include chemical substitutions at the ribose and/or phosphate and/or base positions, and may include amino acid side chain functionalities. [0122] Assay Correlations [0123] The term "correlating" as used herein in reference to the use of biomarkers refers to comparing the presence or amount of the biomarker(s) in a patient to its presence or amount in persons known to suffer from, or known to be at risk of, a given condition; or in persons known to be free of a given condition. Often, this takes the form of comparing an assay result in the form of a biomarker concentration to a predetermined 46 threshold selected to be indicative of the occurrence or nonoccurrence of a disease or the likelihood of some future outcome. [0124] Selecting a diagnostic threshold involves, among other things, consideration of the probability of disease, distribution of true and false diagnoses at different test thresholds, and estimates of the consequences of treatment (or a failure to treat) based on the diagnosis. For example, when considering administering a specific therapy which is highly efficacious and has a low level of risk, few tests are needed because clinicians can accept substantial diagnostic uncertainty. On the other hand, in situations where treatment options are less effective and more risky, clinicians often need a higher degree of diagnostic certainty. Thus, cost/benefit analysis is involved in selecting a diagnostic threshold. [0125] Suitable thresholds may be determined in a variety of ways. For example, one recommended diagnostic threshold for the diagnosis of acute myocardial infarction using cardiac troponin is the 97.5th percentile of the concentration seen in a normal population. Another method may be to look at serial samples from the same patient, where a prior "baseline" result is used to monitor for temporal changes in a biomarker level. [0126] Population studies may also be used to select a decision threshold. Reciever Operating Characteristic ("ROC") arose from the field of signal dectection therory developed during World War II for the analysis of radar images, and ROC analysis is often used to select a threshold able to best distinguish a "diseased" subpopulation from a "nondiseased" subpopulation. A false positive in this case occurs when the person tests positive, but actually does not have the disease. A false negative, on the other hand, occurs when the person tests negative, suggesting they are healthy, when they actually do have the disease. To draw a ROC curve, the true positive rate (TPR) and false positive rate (FPR) are determined as the decision threshold is varied continuously. Since TPR is equivalent with sensitivity and FPR is equal to 1 - specificity, the ROC graph is sometimes called the sensitivity vs (1 - specificity) plot. A perfect test will have an area under the ROC curve of 1.0; a random test will have an area of 0.5. A threshold is selected to provide an acceptable level of specificity and sensitivity. [0127] In this context, "diseased" is meant to refer to a population having one characteristic (the presence of a disease or condition or the occurrence of some outcome) and "nondiseased" is meant to refer to a population lacking the characteristic. While a 47 single decision threshold is the simplest application of such a method, multiple decision thresholds may be used. For example, below a first threshold, the absence of disease may be assigned with relatively high confidence, and above a second threshold the presence of disease may also be assigned with relatively high confidence. Between the two thresholds may be considered indeterminate. This is meant to be exemplary in nature only. [0128] In addition to threshold comparisons, other methods for correlating assay results to a patient classification (occurrence or nonoccurrence of disease, likelihood of an outcome, etc.) include decision trees, rule sets, Bayesian methods, and neural network methods. These methods can produce probability values representing the degree to which a subject belongs to one classification out of a plurality of classifications. Measures of test accuracy may be obtained as described in Fischer et al., Intensive Care Med. 29: 1043-51, 2003, and used to determine the effectiveness of a given biomarker. These measures include sensitivity and specificity, predictive values, likelihood ratios, diagnostic odds ratios, and ROC curve areas. The area under the curve ("AUC") of a ROC plot is equal to the probability that a classifier will rank a randomly chosen positive instance higher than a randomly chosen negative one. The area under the ROC curve may be thought of as equivalent to the Mann-Whitney U test, which tests for the median difference between scores obtained in the two groups considered if the groups are of continuous data, or to the Wilcoxon test of ranks. [0129] As discussed above, suitable tests may exhibit one or more of the following results on these various measures: a specificity of greater than 0.5, preferably at least 0.6, more preferably at least 0.7, still more preferably at least 0.8, even more preferably at least 0.9 and most preferably at least 0.95, with a corresponding sensitivity greater than 0.2, preferably greater than 0.3, more preferably greater than 0.4, still more preferably at least 0.5, even more preferably 0.6, yet more preferably greater than 0.7, still more preferably greater than 0.8, more preferably greater than 0.9, and most preferably greater than 0.95; a sensitivity of greater than 0.5, preferably at least 0.6, more preferably at least 0.7, still more preferably at least 0.8, even more preferably at least 0.9 and most preferably at least 0.95, with a corresponding specificity greater than 0.2, preferably greater than 0.3, more preferably greater than 0.4, still more preferably at least 0.5, even more preferably 0.6, yet more preferably greater than 0.7, still more preferably greater than 0.8, more preferably greater than 0.9, and most preferably greater than 0.95; at least 75% sensitivity, combined with at least 75% specificity; a ROC curve area of greater than 48 0.5, preferably at least 0.6, more preferably 0.7, still more preferably at least 0.8, even more preferably at least 0.9, and most preferably at least 0.95; an odds ratio different from 1, preferably at least about 2 or more or about 0.5 or less, more preferably at least about 3 or more or about 0.33 or less, still more preferably at least about 4 or more or about 0.25 or less, even more preferably at least about 5 or more or about 0.2 or less, and most preferably at least about 10 or more or about 0.1 or less; a positive likelihood ratio (calculated as sensitivity/(1-specificity)) of greater than 1, at least 2, more preferably at least 3, still more preferably at least 5, and most preferably at least 10; and or a negative likelihood ratio (calculated as (1-sensitivity)/specificity) of less than 1, less than or equal to 0.5, more preferably less than or equal to 0.3, and most preferably less than or equal to 0.1 [0130] Additional clinical indicia may be combined with the kidney injury marker assay result(s) of the present invention. These include other biomarkers related to renal status. Examples include the following, which recite the common biomarker name, followed by the Swiss-Prot entry number for that biomarker or its parent: Actin (P68133); Adenosine deaminase binding protein (DPP4, P27487); Alpha-I-acid glycoprotein 1 (P02763); Alpha-1-microglobulin (P02760); Albumin (P02768); Angiotensinogenase (Renin, P00797); Annexin A2 (P07355); Beta-glucuronidase (P08236); B-2 microglobulin (P61679); Beta-galactosidase (P16278); BMP-7 (P18075); Brain natriuretic peptide (proBNP, BNP-32, NTproBNP; P16860); Calcium-binding protein Beta (S100-beta, P04271); Carbonic anhydrase (Q16790); Casein Kinase 2 (P68400); Ceruloplasmin (P00450); Clusterin (P10909); Complement C3 (P01024); Cysteine-rich protein (CYR61, 000622); Cytochrome C (P99999); Epidermal growth factor (EGF, P01133); Endothelin-1 (P05305); Exosomal Fetuin-A (P02765); Fatty acid-binding protein, heart (FABP3, P05413); Fatty acid-binding protein, liver (P07148); Ferritin (light chain, P02793; heavy chain P02794); Fructose-1,6-biphosphatase (P09467); GRO-alpha (CXCLI, (P09341); Growth Hormone (P01241); Hepatocyte growth factor (P14210); Insulin-like growth factor I (P01343); Immunoglobulin G; Immunoglobulin Light Chains (Kappa and Lambda); Interferon gamma (P01308); Lysozyme (P61626); Interleukin lalpha (P01583); Interleukin-2 (P60568); Interleukin-4 (P60568); Interleukin-9 (P15248); Interleukin-12p4O (P29460); Interleukin-13 (P35225); Interleukin-16 (Q14005); LI cell adhesion molecule (P32004); Lactate dehydrogenase (P00338); Leucine Aminopeptidase (P28838); Meprin A-alpha subunit (Q16819); Meprin A-beta subunit (Q16820); Midkine 49 (P21741); MIP2-alpha (CXCL2, P19875); MMP-2 (P08253); MMP-9 (P14780); Netrin-1 (095631); Neutral endopeptidase (P08473); Osteopontin (P10451); Renal papillary antigen 1 (RPA1); Renal papillary antigen 2 (RPA2); Retinol binding protein (P09455); Ribonuclease; S100 calcium-binding protein A6 (P06703); Serum Amyloid P Component (P02743); Sodium/Hydrogen exchanger isoform (NHE3, P48764); Spermidine/spermine NI-acetyltransferase (P21673); TGF-Betal (P01137); Transferrin (P02787); Trefoil factor 3 (TFF3, Q07654); Toll-Like protein 4 (000206); Total protein; Tubulointerstitial nephritis antigen (Q9UJW2); Uromodulin (Tamm-Horsfall protein, P0791 1). [0131] For purposes of risk stratification, Adiponectin (Q15848); Alkaline phosphatase (P05186); Aminopeptidase N (P15144); CalbindinD28k (P05937); Cystatin C (P01034); 8 subunit of FIFO ATPase (P03928); Gamma-glutamyltransferase (P19440); GSTa (alpha-glutathione-S-transferase, P08263); GSTpi (Glutathione-S-transferase P; GST class-pi; P09211); IGFBP-1 (P08833); IGFBP-2 (P18065); IGFBP-6 (P24592); Integral membrane protein 1 (Itml, P46977); Interleukin-6 (P05231); Interleukin-8 (P10145); Interleukin-18 (Q14116); IP-10 (10 kDa interferon-gamma-induced protein, P02778); IRPR (IFRD1, 000458); Isovaleryl-CoA dehydrogenase (IVD, P26440); I TAC/CXCL11 (014625); Keratin 19 (P08727); Kim-I (Hepatitis A virus cellular receptor 1, 043656); L-arginine:glycine amidinotransferase (P50440); Leptin (P41159); Lipocalin2 (NGAL, P80188); MCP-1 (P13500); MIG (Gamma-interferon-induced monokine Q07325); MIP-la (P10147); MIP-3a (P78556); MIP-Ibeta (P13236); MIP-ld (Q16663); NAG (N-acetyl-beta-D-glucosaminidase, P54802); Organic ion transporter (OCT2, 015244); Osteoprotegerin (014788); P8 protein (060356); Plasminogen activator inhibitor 1 (PAI-1, P05121); ProANP(1-98) (P01160); Protein phosphatase 1 beta (PPI-beta, P62140); Rab GDI-beta (P50395); Renal kallikrein (Q86U61 ); RT1.B-1 (alpha) chain of the integral membrane protein (Q5Y7A8); Soluble tumor necrosis factor receptor superfamily member 1A (sTNFR-I, P19438); Soluble tumor necrosis factor receptor superfamily member lB (sTNFR-II, P20333); Tissue inhibitor of metalloproteinases 3 (TIMP-3, P35625); uPAR (Q03405) may be combined with the kidney injury marker assay result(s) of the present invention. [0132] Other clinical indicia which may be combined with the kidney injury marker assay result(s) of the present invention includes demographic information (e.g., weight, sex, age, race), medical history (e.g., family history, type of surgery, pre-existing disease such as aneurism, congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, 50 hypertension, coronary artery disease, proteinuria, renal insufficiency, or sepsis, type of toxin exposure such as NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscamet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin), clinical variables (e.g., blood pressure, temperature, respiration rate), risk scores (APACHE score, PREDICT score, TIMI Risk Score for UA/NSTEMI, Framingham Risk Score), a urine total protein measurement, a glomerular filtration rate, an estimated glomerular filtration rate, a urine production rate, a serum or plasma creatinine concentration, a renal papillary antigen 1 (RPA1) measurement; a renal papillary antigen 2 (RPA2) measurement; a urine creatinine concentration, a fractional excretion of sodium, a urine sodium concentration, a urine creatinine to serum or plasma creatinine ratio, a urine specific gravity, a urine osmolality, a urine urea nitrogen to plasma urea nitrogen ratio, a plasma BUN to creatnine ratio, and/or a renal failure index calculated as urine sodium / (urine creatinine / plasma creatinine). Other measures of renal function which may be combined with the kidney injury marker assay result(s) are described hereinafter and in Harrison's Principles of Internal Medicine, 17 th Ed., McGraw Hill, New York, pages 1741-1830, and Current Medical Diagnosis & Treatment 2008, 4 7 th Ed, McGraw Hill, New York, pages 785-815, each of which are hereby incorporated by reference in their entirety. [0133] Combining assay results/clinical indicia in this manner can comprise the use of multivariate logistical regression, loglinear modeling, neural network analysis, n-of-m analysis, decision tree analysis, etc. This list is not meant to be limiting. [0134] Diagnosis of Acute Renal Failure [0135] As noted above, the terms "acute renal (or kidney) injury" and "acute renal (or kidney) failure" as used herein are defined in part in terms of changes in serum creatinine from a baseline value. Most definitions of ARF have common elements, including the use of serum creatinine and, often, urine output. Patients may present with renal dysfunction without an available baseline measure of renal function for use in this comparison. In such an event, one may estimate a baseline serum creatinine value by assuming the patient initially had a normal GFR. Glomerular filtration rate (GFR) is the volume of fluid filtered from the renal (kidney) glomerular capillaries into the Bowman's capsule per unit time. Glomerular filtration rate (GFR) can be calculated by measuring any chemical that has a steady level in the blood, and is freely filtered but neither reabsorbed nor secreted by the kidneys. GFR is typically expressed in units of ml/min: 51 Urine Concentration x Urine Flow GFR Plsma concentration [0136] By normalizing the GFR to the body surface area, a GFR of approximately 75-100 ml/min per 1.73 m 2 can be assumed. The rate therefore measured is the quantity of the substance in the urine that originated from a calculable volume of blood. [0137] There are several different techniques used to calculate or estimate the glomerular filtration rate (GFR or eGFR). In clinical practice, however, creatinine clearance is used to measure GFR. Creatinine is produced naturally by the body (creatinine is a metabolite of creatine, which is found in muscle). It is freely filtered by the glomerulus, but also actively secreted by the renal tubules in very small amounts such that creatinine clearance overestimates actual GFR by 10-20%. This margin of error is acceptable considering the ease with which creatinine clearance is measured. [0138] Creatinine clearance (CCr) can be calculated if values for creatinine's urine concentration (Ucr), urine flow rate (V), and creatinine's plasma concentration (Pc,) are known. Since the product of urine concentration and urine flow rate yields creatinine's excretion rate, creatinine clearance is also said to be its excretion rate (UcrxV) divided by its plasma concentration. This is commonly represented mathematically as: lb (". :X 1 [0139] Commonly a 24 hour urine collection is undertaken, from empty-bladder one morning to the contents of the bladder the following morning, with a comparative blood test then taken:

-

x 24-hou r volumIe P, x 24 x 60m ins [0140] To allow comparison of results between people of different sizes, the CCr is often corrected for the body surface area (BSA) and expressed compared to the average sized man as ml/min/1.73 m2. While most adults have a BSA that approaches 1.7 (1.6 1.9), extremely obese or slim patients should have their CCr corrected for their actual BSA: 52 (N > .73 B, A [0141] The accuracy of a creatinine clearance measurement (even when collection is complete) is limited because as glomerular filtration rate (GFR) falls creatinine secretion is increased, and thus the rise in serum creatinine is less. Thus, creatinine excretion is much greater than the filtered load, resulting in a potentially large overestimation of the GFR (as much as a twofold difference). However, for clinical purposes it is important to determine whether renal function is stable or getting worse or better. This is often determined by monitoring serum creatinine alone. Like creatinine clearance, the serum creatinine will not be an accurate reflection of GFR in the non-steady-state condition of ARF. Nonetheless, the degree to which serum creatinine changes from baseline will reflect the change in GFR. Serum creatinine is readily and easily measured and it is specific for renal function. [0142] For purposes of determining urine output on a Urine output on a mL/kg/hr basis, hourly urine collection and measurement is adequate. In the case where, for example, only a cumulative 24-h output was available and no patient weights are provided, minor modifications of the RIFLE urine output criteria have been described. For example, Bagshaw et al., Nephrol. Dial. Transplant. 23: 1203-1210, 2008, assumes an average patient weight of 70 kg, and patients are assigned a RIFLE classification based on the following: <35 mL/h (Risk), <21 mL/h (Injury) or <4 mL/h (Failure). [0143] Selecting a Treatment Regimen [0144] Once a diagnosis is obtained, the clinician can readily select a treatment regimen that is compatible with the diagnosis, such as initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, kidney transplantation, delaying or avoiding procedures that are known to be damaging to the kidney, modifying diuretic administration, initiating goal directed therapy, etc. The skilled artisan is aware of appropriate treatments for numerous diseases discussed in relation to the methods of diagnosis described herein. See, e.g., Merck Manual of Diagnosis and Therapy, 17th Ed. Merck Research Laboratories, Whitehouse Station, NJ, 1999. In addition, since the methods and compositions described herein provide prognostic information, the markers of the present invention may be used to 53 monitor a course of treatment. For example, improved or worsened prognostic state may indicate that a particular treatment is or is not efficacious. [0145] One skilled in the art readily appreciates that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The examples provided herein are representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. [0146] Example 1: Contrast-induced nephropathy sample collection [0147] The objective of this sample collection study is to collect samples of plasma and urine and clinical data from patients before and after receiving intravascular contrast media. Approximately 250 adults undergoing radiographic/angiographic procedures involving intravascular administration of iodinated contrast media are enrolled. To be enrolled in the study, each patient must meet all of the following inclusion criteria and none of the following exclusion criteria: Inclusion Criteria males and females 18 years of age or older; undergoing a radiographic / angiographic procedure (such as a CT scan or coronary intervention) involving the intravascular administration of contrast media; expected to be hospitalized for at least 48 hours after contrast administration. able and willing to provide written informed consent for study participation and to comply with all study procedures. Exclusion Criteria renal transplant recipients; acutely worsening renal function prior to the contrast procedure; already receiving dialysis (either acute or chronic) or in imminent need of dialysis at enrollment; expected to undergo a major surgical procedure (such as involving cardiopulmonary bypass) or an additional imaging procedure with contrast media with significant risk for further renal insult within the 48 hrs following contrast administration; 54 participation in an interventional clinical study with an experimental therapy within the previous 30 days; known infection with human immunodeficiency virus (HIV) or a hepatitis virus. [0148] Immediately prior to the first contrast administration (and after any pre procedure hydration), an EDTA anti-coagulated blood sample (10 mL) and a urine sample (10 mL) are collected from each patient. Blood and urine samples are then collected at 4 (±0.5), 8 (±1), 24 (±2) 48 (±2), and 72 (±2) hrs following the last administration of contrast media during the index contrast procedure. Blood is collected via direct venipuncture or via other available venous access, such as an existing femoral sheath, central venous line, peripheral intravenous line or hep-lock. These study blood samples are processed to plasma at the clinical site, frozen and shipped to Astute Medical, Inc., San Diego, CA. The study urine samples are frozen and shipped to Astute Medical, Inc. [0149] Serum creatinine is assessed at the site immediately prior to the first contrast administration (after any pre-procedure hydration) and at 4 (±0.5), 8 (±1), 24 (±2) and 48 (±2) ), and 72 (±2) hours following the last administration of contrast (ideally at the same time as the study samples are obtained). In addition, each patient's status is evaluated through day 30 with regard to additional serum and urine creatinine measurements, a need for dialysis, hospitalization status, and adverse clinical outcomes (including mortality). [0150] Prior to contrast administration, each patient is assigned a risk based on the following assessment: systolic blood pressure <80 mm Hg = 5 points; intra-arterial balloon pump = 5 points; congestive heart failure (Class III-IV or history of pulmonary edema) = 5 points; age >75 yrs = 4 points; hematocrit level <39% for men, <35% for women = 3 points; diabetes = 3 points; contrast media volume = 1 point for each 100 mL; serum creatinine level >1.5 g/dL = 4 points OR estimated GFR 40-60 mL/min/1.73 m 2 2 points, 20-40 mL/min/1.73 m 2 = 4 points, < 20 mL/min/1.73 m 2 = 6 points. The risks assigned are as follows: risk for CIN and dialysis: 5 or less total points = risk of CIN 7.5%, risk of dialysis - 0.04%; 6-10 total points = risk of CIN - 14%, risk of dialysis 0.12%; 11-16 total points = risk of CIN - 26.1%, risk of dialysis - 1.09%; >16 total points = risk of CIN - 57.3%, risk of dialysis - 12.8%. [0151] Example 2: Cardiac surgery sample collection 55 [0152] The objective of this sample collection study is to collect samples of plasma and urine and clinical data from patients before and after undergoing cardiovascular surgery, a procedure known to be potentially damaging to kidney function. Approximately 900 adults undergoing such surgery are enrolled. To be enrolled in the study, each patient must meet all of the following inclusion criteria and none of the following exclusion criteria: Inclusion Criteria males and females 18 years of age or older; undergoing cardiovascular surgery; Toronto/Ottawa Predictive Risk Index for Renal Replacement risk score of at least 2 (Wijeysundera et al., JAMA 297: 1801-9, 2007); and able and willing to provide written informed consent for study participation and to comply with all study procedures. Exclusion Criteria known pregnancy; previous renal transplantation; acutely worsening renal function prior to enrollment (e.g., any category of RIFLE criteria); already receiving dialysis (either acute or chronic) or in imminent need of dialysis at enrollment; currently enrolled in another clinical study or expected to be enrolled in another clinical study within 7 days of cardiac surgery that involves drug infusion or a therapeutic intervention for AKI; known infection with human immunodeficiency virus (HIV) or a hepatitis virus. [0153] Within 3 hours prior to the first incision (and after any pre-procedure hydration), an EDTA anti-coagulated blood sample (10 mL), whole blood (3 mL), and a urine sample (35 mL) are collected from each patient. Blood and urine samples are then collected at 3 (±0.5), 6 (±0.5), 12 (±1), 24 (±2) and 48 (±2) hrs following the procedure and then daily on days 3 through 7 if the subject remains in the hospital. Blood is 56 collected via direct venipuncture or via other available venous access, such as an existing femoral sheath, central venous line, peripheral intravenous line or hep-lock. These study blood samples are frozen and shipped to Astute Medical, Inc., San Diego, CA. The study urine samples are frozen and shipped to Astute Medical, Inc. [0154] Example 3: Acutely ill subject sample collection [0155] The objective of this study is to collect samples from acutely ill patients. Approximately 900 adults expected to be in the ICU for at least 48 hours will be enrolled. To be enrolled in the study, each patient must meet all of the following inclusion criteria and none of the following exclusion criteria: Inclusion Criteria males and females 18 years of age or older; Study population 1: approximately 300 patients that have at least one of: shock (SBP < 90 mmHg and/or need for vasopressor support to maintain MAP > 60 mmHg and/or documented drop in SBP of at least 40 mmHg); and sepsis; Study population 2: approximately 300 patients that have at least one of: IV antibiotics ordered in computerized physician order entry (CPOE) within 24 hours of enrollment; contrast media exposure within 24 hours of enrollment; increased Intra-Abdominal Pressure with acute decompensated heart failure; and severe trauma as the primary reason for ICU admission and likely to be hospitalized in the ICU for 48 hours after enrollment; Study population 3: approximately 300 patients expected to be hospitalized through acute care setting (ICU or ED) with a known risk factor for acute renal injury (e.g. sepsis, hypotension/shock (Shock = systolic BP < 90 mmHg and/or the need for vasopressor support to maintain a MAP > 60 mmHg and/or a documented drop in SBP > 40 mmHg), major trauma, hemorrhage, or major surgery); and/or expected to be hospitalized to the ICU for at least 24 hours after enrollment. Exclusion Criteria 57 known pregnancy; institutionalized individuals; previous renal transplantation; known acutely worsening renal function prior to enrollment (e.g., any category of RIFLE criteria); received dialysis (either acute or chronic) within 5 days prior to enrollment or in imminent need of dialysis at the time of enrollment; known infection with human immunodeficiency virus (HIV) or a hepatitis virus; meets only the SBP < 90 mmHg inclusion criterion set forth above, and does not have shock in the attending physician's or principal investigator's opinion. [0156] After providing informed consent, an EDTA anti-coagulated blood sample (10 mL) and a urine sample (25-30 mL) are collected from each patient. Blood and urine samples are then collected at 4 (± 0.5) and 8 (± 1) hours after contrast administration (if applicable); at 12 (± 1), 24 (± 2), and 48 (± 2) hours after enrollment, and thereafter daily up to day 7 to day 14 while the subject is hospitalized. Blood is collected via direct venipuncture or via other available venous access, such as an existing femoral sheath, central venous line, peripheral intravenous line or hep-lock. These study blood samples are processed to plasma at the clinical site, frozen and shipped to Astute Medical, Inc., San Diego, CA. The study urine samples are frozen and shipped to Astute Medical, Inc. [0157] Example 4. Immunoassay format [0158] Analytes are measured using standard sandwich enzyme immunoassay techniques. A first antibody which binds the analyte is immobilized in wells of a 96 well polystyrene microplate. Analyte standards and test samples are pipetted into the appropriate wells and any analyte present is bound by the immobilized antibody. After washing away any unbound substances, a horseradish peroxidase-conjugated second antibody which binds the analyte is added to the wells, thereby forming sandwich complexes with the analyte (if present) and the first antibody. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution comprising tetramethylbenzidine and hydrogen peroxide is added to the wells. Color develops in proportion to the amount of analyte present in the sample. The color development is stopped and the intensity of the color is measured at 540 nm or 570 nm. An analyte 58 concentration is assigned to the test sample by comparison to a standard curve determined from the analyte standards. [0159] Example 5. Apparently Healthy Donor and Chronic Disease Patient Samples [0160] Human urine samples from donors with no known chronic or acute disease ("Apparently Healthy Donors") were purchased from two vendors (Golden West Biologicals, Inc., 27625 Commerce Center Dr., Temecula, CA 92590 and Virginia Medical Research, Inc., 915 First Colonial Rd., Virginia Beach, VA 23454). The urine samples were shipped and stored frozen at less than -20" C. The vendors supplied demographic information for the individual donors including gender, race (Black /White), smoking status and age. [0161] Human urine samples from donors with various chronic diseases ("Chronic Disease Patients") including congestive heart failure, coronary artery disease, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus and hypertension were purchased from Virginia Medical Research, Inc., 915 First Colonial Rd., Virginia Beach, VA 23454. The urine samples were shipped and stored frozen at less than -20 degrees centigrade. The vendor provided a case report form for each individual donor with age, gender, race (Black/White), smoking status and alcohol use, height, weight, chronic disease(s) diagnosis, current medications and previous surgeries. [0162] Example 6. Use of Kidney Injury Markers for evaluating renal status in patients [0163] Patients from the intensive care unit (ICU) were enrolled in the following study. Each patient was classified by kidney status as non-injury (0), risk of injury (R), injury (I), and failure (F) according to the maximum stage reached within 7 days of enrollment as determined by the RIFLE criteria. EDTA anti-coagulated blood samples (10 mL) and a urine samples (25-30 mL) were collected from each patient at enrollment, 4 (± 0.5) and 8 (± 1) hours after contrast administration (if applicable); at 12 (± 1), 24 (± 2), and 48 (± 2) hours after enrollment, and thereafter daily up to day 7 to day 14 while the subject is hospitalized. Markers were each measured by standard immunoassay methods using commercially available assay reagents in the urine samples and the plasma component of the blood samples collected. 59 [0164] Two cohorts were defined to represent a "diseased" and a "normal" population. While these terms are used for convenience, "diseased" and "normal" simply represent two cohorts for comparison (say RIFLE 0 vs RIFLE R, I and F; RIFLE 0 vs RIFLE R; RIFLE 0 and R vs RIFLE I and F; etc.). The time "prior max stage" represents the time at which a sample is collected, relative to the time a particular patient reaches the lowest disease stage as defined for that cohort, binned into three groups which are +/- 12 hours. For example, "24 hr prior" which uses 0 vs R, I, F as the two cohorts would mean 24 hr (+/- 12 hours) prior to reaching stage R (or I if no sample at R, or F if no sample at R or I). [0165] A receiver operating characteristic (ROC) curve was generated for each biomarker measured and the area under each ROC curve (AUC) is determined. Patients in Cohort 2 were also separated according to the reason for adjudication to cohort 2 as being based on serum creatinine measurements (sCr), being based on urine output (UO), or being based on either serum creatinine measurements or urine output. Using the same example discussed above (0 vs R, I, F), for those patients adjudicated to stage R, I, or F on the basis of serum creatinine measurements alone, the stage 0 cohort may include patients adjudicated to stage R, I, or F on the basis of urine output; for those patients adjudicated to stage R, I, or F on the basis of urine output alone, the stage 0 cohort may include patients adjudicated to stage R, I, or F on the basis of serum creatinine measurements; and for those patients adjudicated to stage R, I, or F on the basis of serum creatinine measurements or urine output, the stage 0 cohort contains only patients in stage 0 for both serum creatinine measurements and urine output. Also, in the data for patients adjudicated on the basis of serum creatinine measurements or urine output, the adjudication method which yielded the most severe RIFLE stage is used. [0166] The ability to distinguish cohort 1 from Cohort 2 was determined using ROC analysis. SE is the standard error of the AUC, n is the number of sample or individual patients ("pts," as indicated). Standard errors are calculated as described in Hanley, J. A., and McNeil, B.J., The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology (1982) 143: 29-36; p values are calculated with a two-tailed Z-test. An AUC < 0.5 is indicative of a negative going marker for the comparison, and an AUC > 0.5 is indicative of a positive going marker for the comparison. 60 [0167] Various threshold (or "cutoff") concentrations were selected, and the associated sensitivity and specificity for distinguishing cohort 1 from cohort 2 are determined. OR is the odds ratio calculated for the particular cutoff concentration, and 95% CI is the confidence interval for the odds ratio. [0168] Table 1: Comparison of marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0) and in urine samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage R, I or F in Cohort 2. Agouti-related protein sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.792 0.977 0.792 0.771 0.792 1.20 Average 1.27 1.71 1.27 1.42 1.27 1.19 Stdev 2.03 2.57 2.03 2.06 2.03 0.736 p(t-test) 0.075 0.56 0.88 Min 0.00318 0.00745 0.00318 0.00952 0.00318 0.141 Max 20.0 20.0 20.0 14.5 20.0 2.41 n (Samp) 237 125 237 82 237 15 n (Patient) 109 125 109 82 109 15 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.935 0.687 0.935 0.816 0.935 1.04 Average 1.52 0.901 1.52 1.11 1.52 1.09 Stdev 2.16 0.772 2.16 1.18 2.16 0.770 p(t-test) 0.077 0.29 0.38 Min 0.00318 0.0333 0.00318 0.00952 0.00318 0.141 Max 20.0 3.30 20.0 6.53 20.0 3.07 n (Samp) 592 38 592 31 592 19 n (Patient) 229 38 229 31 229 19 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.747 1.21 0.747 0.762 0.747 0.736 Average 1.13 1.91 1.13 1.50 1.13 1.00 Stdev 1.81 2.68 1.81 2.09 1.81 0.763 p(t-test) 8.7E-4 0.11 0.78 Min 0.00198 0.00745 0.00198 0.0261 0.00198 0.141 Max 20.0 20.0 20.0 14.5 20.0 2.41 n (Samp) 295 110 295 84 295 16 n (Patient) 124 110 124 84 124 16 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.58 0.42 0.65 0.54 0.46 0.57 0.59 0.49 0.54 SE 0.032 0.050 0.032 0.037 0.054 0.036 0.079 0.068 0.076 p 0.012 0.095 3.7E-6 0.31 0.49 0.043 0.27 0.86 0.56 nCohort 1 237 592 295 237 592 295 237 592 295 nCohort 2 125 38 110 82 31 84 15 19 16 61 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Cutoff 1 0.481 0.379 0.694 0.469 0.599 0.488 0.617 0.420 0.378 Sens 1 70% 71% 70% 71% 71% 70% 73% 74% 75% Spec 1 38% 24% 48% 38% 36% 41% 43% 26% 35% Cutoff 2 0.390 0.228 0.453 0.316 0.399 0.378 0.419 0.300 0.355 Sens 2 80% 82% 80% 80% 81% 81% 80% 84% 81% Spec 2 33% 15% 39% 30% 25% 35% 34% 21% 33% Cutoff 3 0.211 0.159 0.308 0.208 0.175 0.262 0.228 0.173 0.229 Sens 3 90% 92% 90% 90% 90% 90% 93% 95% 94% Spec 3 19% 11% 32% 19% 12% 28% 21% 12% 24% Cutoff 4 1.37 1.59 1.26 1.37 1.59 1.26 1.37 1.59 1.26 Sens 4 38% 13% 47% 32% 26% 35% 47% 21% 31% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 1.77 2.26 1.62 1.77 2.26 1.62 1.77 2.26 1.62 Sens 5 29% 11% 35% 23% 6% 25% 33% 5% 31% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 2.71 3.28 2.52 2.71 3.28 2.52 2.71 3.28 2.52 Sens 6 18% 3% 25% 10% 3% 12% 0% 0% 0% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 2.4 2.1 3.5 2.9 1.4 4.8 1.5 4.7 3.1 p Value 0.0077 0.19 0.0018 0.0056 0.56 1.4E-4 0.65 0.050 0.17 95% CI of 1.3 0.69 1.6 1.4 0.44 2.1 0.25 1.0 0.61 OR Quart2 4.7 6.2 7.7 6.1 4.6 11 9.5 22 16 OR Quart 3 2.1 2.3 4.4 1.3 2.5 1.9 2.6 1.5 1.5 p Value 0.033 0.13 1.7E-4 0.56 0.090 0.14 0.26 0.65 0.66 95% CI of 1.1 0.78 2.0 0.57 0.86 0.80 0.49 0.25 0.24 OR Quart3 4.0 6.8 9.6 2.8 7.3 4.6 14 9.2 9.2 OR Quart 4 2.7 2.5 5.6 2.2 1.4 3.8 2.6 2.6 2.6 p Value 0.0032 0.088 9.6E-6 0.046 0.55 0.0016 0.26 0.26 0.27 95% CI of 1.4 0.87 2.6 1.0 0.44 1.7 0.49 0.49 0.48 OR Quart4 5.2 7.4 12 4.7 4.6 8.5 14 13 14 Osteocalcin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 4920 6940 4920 6040 4920 4990 Average 6250 8840 6250 7730 6250 7600 Stdev 5910 8110 5910 6950 5910 6240 p(t-test) 1.6E-5 0.015 0.15 Min 76.8 473 76.8 103 76.8 520 Max 83000 67900 83000 49400 83000 23400 n (Samp) 385 191 385 144 385 45 n (Patient) 191 191 191 144 191 45 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 6050 6400 6050 5680 6050 4940 Average 7660 9720 7660 9050 7660 7320 Stdev 7660 9080 7660 9090 7660 6010 p(t-test) 0.050 0.20 0.79 Min 76.8 714 76.8 584 76.8 1030 Max 83500 48000 83500 42300 83500 23400 n (Samp) 991 58 991 55 991 35 62 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 n (Patient) 386 58 386 55 386 35 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 5010 7240 5010 6230 5010 6500 Average 6940 8760 6940 7940 6940 8790 Stdev 7020 7510 7020 7160 7020 8580 p(t-test) 0.0044 0.15 0.11 Min 73.4 473 73.4 103 73.4 475 Max 83000 67900 83000 49400 83000 42300 n (Samp) 456 174 456 136 456 42 n (Patient) 202 174 202 136 202 42 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.61 0.55 0.61 0.57 0.51 0.56 0.54 0.47 0.54 SE 0.025 0.040 0.026 0.028 0.040 0.029 0.046 0.050 0.047 p 6.7E-6 0.20 4.3E-5 0.022 0.85 0.035 0.39 0.61 0.43 nCohort 1 385 991 456 385 991 456 385 991 456 nCohort 2 191 58 174 144 55 136 45 35 42 Cutoff 1 4440 4190 4770 3480 3200 4120 3270 3320 3200 Sens 1 70% 71% 70% 70% 71% 71% 71% 71% 71% Spec 1 45% 33% 46% 33% 23% 38% 30% 24% 28% Cutoff 2 3350 3110 3350 2710 2290 2980 3000 3080 2430 Sens 2 80% 81% 80% 81% 80% 80% 80% 80% 81% Spec 2 31% 22% 29% 24% 14% 26% 28% 21% 20% Cutoff 3 2180 1810 2600 1620 1330 1820 1030 2610 1030 Sens 3 90% 91% 90% 90% 91% 90% 91% 91% 90% Spec 3 17% 9% 21% 11% 6% 12% 5% 16% 5% Cutoff 4 7680 8750 7910 7680 8750 7910 7680 8750 7910 Sens 4 44% 40% 44% 40% 38% 42% 38% 26% 43% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 8960 10400 9630 8960 10400 9630 8960 10400 9630 Sens 5 35% 36% 32% 32% 33% 29% 31% 20% 36% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 11300 14300 13600 11300 14300 13600 11300 14300 13600 Sens 6 25% 21% 18% 20% 18% 11% 29% 14% 24% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.3 1.0 1.2 0.96 0.63 1.0 1.5 0.88 0.99 p Value 0.28 1.0 0.60 0.88 0.24 0.88 0.38 0.80 0.99 95% CI of 0.79 0.47 0.67 0.54 0.29 0.59 0.61 0.31 0.40 OR Quart2 2.3 2.1 2.0 1.7 1.4 1.9 3.6 2.4 2.5 OR Quart 3 1.8 0.56 2.0 1.1 0.51 1.2 0.88 1.1 0.58 p Value 0.028 0.20 0.0073 0.67 0.11 0.47 0.80 0.81 0.31 95% CI of 1.1 0.23 1.2 0.65 0.22 0.70 0.33 0.43 0.20 OR Quart3 3.0 1.4 3.4 2.0 1.2 2.2 2.4 3.0 1.6 OR Quart 4 2.9 1.6 2.5 1.9 1.1 1.9 1.8 1.4 1.7 p Value 3.4E-5 0.17 4.OE-4 0.019 0.87 0.017 0.21 0.48 0.23 95% CI of 1.8 0.81 1.5 1.1 0.53 1.1 0.73 0.55 0.73 OR Quart4 4.9 3.2 4.2 3.2 2.1 3.3 4.2 3.5 3.8 Complement factor H 63 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 9.47 8.09 9.47 9.33 9.47 5.77 Average 17.9 16.1 17.9 19.8 17.9 13.7 Stdev 27.2 26.7 27.2 30.4 27.2 17.5 p(t-test) 0.54 0.54 0.36 Min 0.132 0.0818 0.132 0.133 0.132 0.0620 Max 282 223 282 208 282 67.2 n (Samp) 271 140 271 107 271 38 n (Patient) 151 140 151 107 151 38 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 9.31 10.7 9.31 9.05 9.31 10.3 Average 18.1 19.3 18.1 17.7 18.1 15.3 Stdev 28.2 25.3 28.2 23.5 28.2 15.6 p(t-test) 0.79 0.93 0.63 Min 0.0620 1.20 0.0620 1.53 0.0620 0.832 Max 282 142 282 97.5 282 67.2 n (Samp) 667 40 667 39 667 24 n (Patient) 290 40 290 39 290 24 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 10.0 7.77 10.0 9.03 10.0 4.98 Average 20.5 15.0 20.5 18.2 20.5 11.1 Stdev 49.9 26.9 49.9 29.2 49.9 13.9 p(t-test) 0.25 0.67 0.27 Min 0.132 0.0818 0.132 0.133 0.132 0.0620 Max 772 223 772 208 772 59.1 n (Samp) 316 127 316 104 316 35 n (Patient) 155 127 155 104 155 35 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.47 0.55 0.44 0.49 0.49 0.46 0.40 0.51 0.36 SE 0.030 0.048 0.031 0.033 0.048 0.033 0.051 0.060 0.053 p 0.30 0.30 0.048 0.77 0.81 0.24 0.052 0.85 0.0075 nCohort 1 271 667 316 271 667 316 271 667 316 nCohort 2 140 40 127 107 39 104 38 24 35 Cutoff 1 5.87 6.66 5.86 5.67 5.87 4.62 3.03 5.59 3.03 Sens 1 70% 70% 70% 70% 72% 70% 71% 71% 71% Spec 1 28% 36% 26% 25% 29% 20% 13% 27% 12% Cutoff 2 4.41 6.00 4.11 3.61 3.03 3.33 2.30 4.19 2.34 Sens 2 80% 80% 80% 80% 82% 81% 82% 83% 80% Spec 2 20% 30% 17% 15% 13% 13% 11% 20% 10% Cutoff 3 2.81 3.94 2.81 2.52 2.10 2.31 1.69 3.30 1.70 Sens 3 90% 90% 91% 91% 92% 90% 92% 92% 91% Spec 3 12% 18% 11% 11% 9% 10% 8% 14% 7% Cutoff 4 17.2 16.4 18.1 17.2 16.4 18.1 17.2 16.4 18.1 Sens 4 25% 38% 21% 27% 26% 23% 26% 33% 23% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 25.1 23.6 24.8 25.1 23.6 24.8 25.1 23.6 24.8 Sens 5 16% 20% 14% 18% 18% 16% 16% 17% 9% 64 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 38.0 40.5 41.6 38.0 40.5 41.6 38.0 40.5 41.6 Sens 6 9% 10% 4% 14% 13% 11% 13% 8% 6% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 0.91 1.3 1.1 0.87 1.1 1.5 0.53 0.65 1.2 p Value 0.77 0.62 0.75 0.66 0.80 0.25 0.28 0.52 0.76 95% CI of 0.51 0.47 0.60 0.46 0.45 0.76 0.17 0.18 0.36 OR Quart2 1.6 3.6 2.0 1.6 2.8 2.8 1.7 2.4 4.1 OR Quart 3 1.2 1.6 1.6 0.81 1.1 1.1 0.77 1.2 1.2 p Value 0.56 0.34 0.14 0.52 0.81 0.86 0.62 0.79 0.76 95% CI of 0.67 0.61 0.87 0.43 0.44 0.54 0.27 0.38 0.36 OR Quart3 2.1 4.2 2.8 1.5 2.8 2.1 2.2 3.5 4.1 OR Quart 4 1.1 1.9 1.7 1.1 1.1 1.8 2.2 1.2 4.3 p Value 0.73 0.18 0.094 0.72 0.80 0.060 0.084 0.79 0.0058 95% CI of 0.62 0.74 0.92 0.60 0.45 0.98 0.90 0.38 1.5 OR Quart4 2.0 4.9 3.0 2.1 2.8 3.4 5.2 3.5 12 Ciliary neurotrophic factor sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.147 0.0325 0.147 0.0688 0.147 0.0551 Average 0.200 0.196 0.200 0.384 0.200 0.136 Stdev 0.278 0.594 0.278 1.56 0.278 0.166 p(t-test) 0.95 0.081 0.39 Min 0.000103 0.000103 0.000103 0.000103 0.000103 0.000103 Max 2.35 6.11 2.35 14.0 2.35 0.551 n (Samp) 237 125 237 82 237 15 n (Patient) 109 125 109 82 109 15 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0452 0.0765 0.0452 0.0678 0.0452 0.000166 Average 0.221 0.253 0.221 0.226 0.221 0.106 Stdev 0.743 0.502 0.743 0.406 0.743 0.151 p(t-test) 0.79 0.97 0.50 Min 0.000103 0.000103 0.000103 0.000118 0.000103 0.000119 Max 14.0 2.28 14.0 2.11 14.0 0.403 n (Samp) 592 38 592 31 592 19 n (Patient) 229 38 229 31 229 19 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0876 0.0260 0.0876 0.0698 0.0876 0.101 Average 0.209 0.225 0.209 0.392 0.209 0.178 Stdev 0.383 0.660 0.383 1.54 0.383 0.203 p(t-test) 0.77 0.065 0.75 Min 0.000103 0.000103 0.000103 0.000103 0.000103 0.000103 Max 4.30 6.11 4.30 14.0 4.30 0.609 n (Samp) 295 110 295 84 295 16 n (Patient) 124 110 124 84 124 16 65 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.43 0.54 0.44 0.51 0.55 0.53 0.45 0.44 0.53 SE 0.032 0.049 0.033 0.037 0.055 0.036 0.079 0.069 0.075 p 0.027 0.42 0.082 0.89 0.32 0.34 0.53 0.39 0.69 nCohort 1 237 592 295 237 592 295 237 592 295 nCohort 2 125 38 110 82 31 84 15 19 16 Cutoff 1 0.000123 0.00333 0.000123 0.000167 0.000161 0.00333 0.00333 0.000121 0.00333 Sens 1 74% 71% 73% 71% 77% 70% 73% 74% 75% Spec 1 20% 41% 23% 28% 30% 34% 30% 22% 34% Cutoff 2 0.000121 0.000123 0.000119 0.000123 0.000123 0.000123 0.000123 0.000119 0.000167 Sens 2 80% 82% 85% 80% 84% 82% 80% 84% 81% Spec 2 17% 27% 14% 20% 27% 23% 20% 18% 31% Cutoff 3 0.000103 0.000103 0.000103 0.000119 0.000119 0.000118 0.000121 0.000118 0.000121 Sens 3 92% 92% 94% 90% 94% 90% 93% 100% 94% Spec 3 3% 5% 3% 14% 18% 7% 17% 11% 18% Cutoff 4 0.290 0.229 0.245 0.290 0.229 0.245 0.290 0.229 0.245 Sens 4 21% 26% 22% 33% 29% 40% 20% 21% 25% Spec 4 71% 70% 71% 71% 70% 71% 71% 70% 71% Cutoff 5 0.348 0.327 0.348 0.348 0.327 0.348 0.348 0.327 0.348 Sens 5 19% 18% 20% 26% 23% 29% 13% 21% 25% Spec 5 81% 80% 81% 81% 80% 81% 81% 80% 81% Cutoff 6 0.457 0.433 0.459 0.457 0.433 0.459 0.457 0.433 0.459 Sens 6 9% 11% 11% 12% 16% 14% 7% 0% 12% Spec 6 91% 90% 92% 91% 90% 92% 91% 90% 92% OR Quart 2 1.0 1.4 0.96 1.0 2.6 1.1 1.4 0.74 1.7 p Value 0.96 0.46 0.90 0.90 0.12 0.76 0.70 0.70 0.48 95% CI of 0.53 0.54 0.49 0.52 0.79 0.57 0.29 0.16 0.39 OR Quart2 1.9 3.9 1.9 2.1 8.4 2.2 6.3 3.4 7.3 OR Quart 3 1.6 1.8 1.7 0.55 2.0 0.60 1.4 1.0 1.3 p Value 0.16 0.24 0.080 0.12 0.25 0.18 0.70 1.0 0.71 95% CI of 0.84 0.68 0.94 0.26 0.60 0.28 0.29 0.25 0.29 OR Quart3 2.9 4.6 3.2 1.2 6.9 1.3 6.3 4.1 6.2 OR Quart 4 1.8 1.3 1.5 1.0 2.3 1.3 1.4 2.1 1.3 p Value 0.056 0.62 0.19 0.90 0.17 0.42 0.70 0.24 0.71 95% CI of 0.98 0.47 0.81 0.52 0.70 0.68 0.29 0.61 0.29 OR Quart4 3.4 3.6 2.9 2.1 7.7 2.5 6.3 7.0 6.2 Follitropin subunit beta sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 13.7 12.2 13.7 18.7 13.7 5.88 Average 31.7 23.9 31.7 30.9 31.7 33.3 Stdev 41.9 34.4 41.9 40.4 41.9 46.9 p(t-test) 0.073 0.87 0.89 Min 0.0800 0.209 0.0800 0.385 0.0800 0.474 Max 200 256 200 239 200 128 n (Samp) 237 125 237 82 237 15 n (Patient) 109 125 109 82 109 15 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 13.6 7.94 13.6 10.5 13.6 7.46 Average 31.4 18.7 31.4 22.1 31.4 19.4 66 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Stdev 43.1 28.6 43.1 27.3 43.1 28.3 p(t-test) 0.076 0.24 0.23 Min 0.0800 0.209 0.0800 0.838 0.0800 0.474 Max 300 158 300 108 300 108 n (Samp) 592 38 592 31 592 19 n (Patient) 229 38 229 31 229 19 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 11.7 13.4 11.7 18.8 11.7 24.2 Average 28.2 25.1 28.2 32.6 28.2 39.2 Stdev 39.2 34.5 39.2 41.8 39.2 44.2 p(t-test) 0.46 0.37 0.28 Min 0.0800 0.345 0.0800 0.385 0.0800 0.209 Max 200 256 200 239 200 128 n (Samp) 295 110 295 84 295 16 n (Patient) 124 110 124 84 124 16 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.47 0.40 0.53 0.52 0.44 0.58 0.44 0.40 0.57 SE 0.032 0.050 0.033 0.037 0.055 0.036 0.079 0.070 0.076 p 0.29 0.040 0.39 0.54 0.27 0.027 0.41 0.14 0.37 nCohort 1 237 592 295 237 592 295 237 592 295 nCohort 2 125 38 110 82 31 84 15 19 16 Cutoff 1 6.94 4.89 7.15 8.26 5.33 9.43 3.42 3.76 7.66 Sens 1 70% 71% 70% 71% 71% 70% 73% 74% 75% Spec 1 30% 23% 39% 34% 25% 47% 19% 17% 40% Cutoff 2 4.75 3.19 5.43 4.89 2.59 6.22 1.86 1.86 5.45 Sens 2 80% 82% 80% 80% 81% 81% 80% 84% 81% Spec 2 24% 14% 31% 25% 12% 34% 11% 8% 32% Cutoff 3 2.07 0.903 3.09 3.48 1.86 4.42 0.570 0.903 0.329 Sens 3 90% 92% 90% 90% 90% 90% 93% 95% 94% Spec 3 11% 2% 20% 19% 8% 28% 1% 2% 1% Cutoff 4 32.5 31.3 28.3 32.5 31.3 28.3 32.5 31.3 28.3 Sens 4 22% 18% 25% 28% 23% 33% 27% 11% 50% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 51.3 47.1 44.7 51.3 47.1 44.7 51.3 47.1 44.7 Sens 5 10% 11% 15% 17% 16% 19% 20% 11% 25% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 80.6 82.6 74.5 80.6 82.6 74.5 80.6 82.6 74.5 Sens 6 6% 3% 8% 10% 6% 13% 20% 5% 19% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.9 1.4 2.5 1.2 1.2 3.0 0.48 3.6 0.99 p Value 0.037 0.58 0.0067 0.60 0.78 0.0093 0.41 0.11 0.99 95% CI of 1.0 0.46 1.3 0.58 0.39 1.3 0.085 0.74 0.19 OR Quart2 3.7 4.0 4.9 2.5 3.6 6.9 2.7 18 5.0 OR Quart 3 1.7 2.1 2.4 1.7 1.5 4.1 0.74 1.5 1.7 p Value 0.11 0.15 0.010 0.17 0.43 6.1E-4 0.70 0.65 0.48 95% CI of 0.89 0.76 1.2 0.81 0.53 1.8 0.16 0.25 0.39 OR Quart3 3.1 5.7 4.7 3.4 4.4 9.4 3.4 9.2 7.3 OR Quart 4 1.4 2.1 1.7 1.2 1.5 3.0 1.6 3.6 1.7 p Value 0.31 0.15 0.13 0.60 0.42 0.0093 0.51 0.11 0.48 67 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only 95% CI of 0.74 0.77 0.85 0.58 0.54 1.3 0.42 0.74 0.39 OR Quart4 2.6 5.7 3.4 2.5 4.4 16.9 5.8 18 7.3 Follistatin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 6.38 8.68 6.38 8.68 6.38 8.40 Average 44.7 15.3 44.7 28.4 44.7 15.9 Stdev 382 22.7 382 80.0 382 25.4 p(t-test) 0.33 0.62 0.58 Min 0.0191 0.0191 0.0191 0.0191 0.0191 0.0191 Max 8290 217 8290 840 8290 160 n (Samp) 509 162 509 141 509 53 n (Patient) 242 162 242 141 242 53 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 7.02 8.42 7.02 10.5 7.02 6.69 Average 29.2 19.0 29.2 24.7 29.2 27.1 Stdev 256 33.0 256 46.1 256 49.5 p(t-test) 0.78 0.90 0.96 Min 0.000347 0.0425 0.000347 0.0191 0.000347 0.0191 Max 8290 217 8290 310 8290 225 n (Samp) 1153 51 1153 50 1153 33 n (Patient) 423 51 423 50 423 33 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 6.65 9.29 6.65 9.13 6.65 9.05 Average 44.1 29.2 44.1 38.5 44.1 14.0 Stdev 379 166 379 136 379 15.8 p(t-test) 0.64 0.87 0.58 Min 0.00280 0.0191 0.00280 0.0412 0.00280 0.0287 Max 8290 2010 8290 1300 8290 65.1 n (Samp) 517 147 517 136 517 48 n (Patient) 205 147 205 136 205 48 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.54 0.56 0.54 0.55 0.58 0.55 0.52 0.52 0.52 SE 0.026 0.042 0.027 0.028 0.043 0.028 0.042 0.052 0.044 p 0.17 0.16 0.16 0.094 0.072 0.100 0.58 0.69 0.65 nCohort 1 509 1153 517 509 1153 517 509 1153 517 nCohort 2 162 51 147 141 50 136 53 33 48 Cutoff 1 4.89 5.33 5.23 3.57 4.60 3.83 3.21 2.87 3.93 Sens 1 70% 71% 70% 70% 70% 71% 72% 73% 71% Spec 1 40% 41% 40% 31% 36% 31% 28% 25% 32% Cutoff 2 2.37 3.83 2.25 2.49 3.09 2.49 2.12 1.55 2.12 Sens 2 80% 80% 80% 80% 80% 80% 81% 82% 81% Spec 2 22% 31% 18% 23% 26% 21% 20% 14% 17% Cutoff 3 1.15 2.74 1.000 0.386 1.55 0.386 1.000 1.02 1.13 68 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 3 90% 90% 90% 90% 90% 90% 91% 91% 92% Spec 3 10% 24% 8% 7% 14% 6% 9% 10% 9% Cutoff 4 12.5 12.9 13.4 12.5 12.9 13.4 12.5 12.9 13.4 Sens 4 33% 33% 33% 40% 44% 42% 34% 42% 31% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 22.1 21.0 23.7 22.1 21.0 23.7 22.1 21.0 23.7 Sens 5 19% 25% 20% 26% 32% 25% 21% 27% 17% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 47.8 41.3 45.9 47.8 41.3 45.9 47.8 41.3 45.9 Sens 6 9% 12% 11% 13% 20% 15% 8% 15% 6% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 0.80 2.5 0.69 0.84 1.2 0.60 0.47 0.69 0.36 p Value 0.40 0.044 0.20 0.55 0.66 0.084 0.12 0.46 0.060 95% CI of 0.47 1.0 0.39 0.48 0.50 0.34 0.18 0.26 0.13 OR Quart2 1.4 6.2 1.2 1.5 3.0 1.1 1.2 1.8 1.0 OR Quart 3 1.5 1.6 1.5 1.2 1.3 0.96 1.1 0.49 1.3 p Value 0.089 0.34 0.098 0.59 0.51 0.89 0.84 0.20 0.56 95% CI of 0.94 0.61 0.92 0.68 0.56 0.57 0.50 0.17 0.58 OR Quart3 2.5 4.2 2.5 2.0 3.2 1.6 2.3 1.5 2.7 OR Quart 4 1.2 2.4 1.3 1.5 2.1 1.3 1.2 1.1 1.1 p Value 0.46 0.063 0.36 0.097 0.084 0.26 0.58 0.83 0.85 95% CI of 0.73 0.96 0.76 0.92 0.91 0.81 0.58 0.46 0.49 OR Quart4 2.0 5.8 2.1 2.6 4.7 2.2 2.6 2.6 2.4 Vitamin D-binding protein sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 152 258 152 272 152 159 Average 5740 15900 5740 11100 5740 778 Stdev 33600 52300 33600 46600 33600 1650 p(t-test) 0.036 0.28 0.58 Min 1.43 0.430 1.43 5.41 1.43 0.612 Max 352000 379000 352000 365000 352000 5950 n (Samp) 203 113 203 78 203 14 n (Patient) 97 113 97 78 97 14 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 208 306 208 342 208 176 Average 7170 3800 7170 20900 7170 28700 Stdev 33700 10200 33700 77400 33700 92200 p(t-test) 0.58 0.066 0.029 Min 0.892 0.430 0.892 1.50 0.892 0.612 Max 365000 43100 365000 379000 365000 347000 n (Samp) 505 31 505 26 505 14 n (Patient) 210 31 210 26 210 14 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 164 261 164 283 164 276 Average 6350 17800 6350 11800 6350 2380 Stdev 32800 55300 32800 46100 32800 5220 69 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) 0.017 0.25 0.63 Min 0.242 1.50 0.242 10.6 0.242 5.54 Max 352000 379000 352000 365000 352000 20700 n (Samp) 251 100 251 80 251 16 n (Patient) 109 100 109 80 109 16 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.62 0.52 0.63 0.59 0.55 0.58 0.47 0.47 0.56 SE 0.034 0.054 0.034 0.039 0.059 0.038 0.081 0.080 0.077 p 4.7E-4 0.74 2.3E-4 0.017 0.39 0.028 0.72 0.72 0.40 nCohort 1 203 505 251 203 505 251 203 505 251 nCohort 2 113 31 100 78 26 80 14 14 16 Cutoff 1 125 90.2 164 108 105 117 62.7 80.0 104 Sens 1 71% 71% 70% 71% 73% 70% 71% 71% 75% Spec 1 46% 29% 50% 42% 32% 41% 30% 27% 39% Cutoff 2 83.0 71.7 108 78.5 78.7 79.9 7.96 10.1 62.7 Sens 2 81% 81% 80% 81% 81% 80% 86% 86% 81% Spec 2 36% 23% 40% 36% 27% 34% 6% 5% 27% Cutoff 3 31.9 21.7 43.1 40.3 9.08 43.1 3.54 0.892 9.75 Sens 3 90% 90% 90% 91% 92% 90% 93% 93% 94% Spec 3 15% 8% 20% 19% 4% 20% 5% 0% 6% Cutoff 4 346 457 438 346 457 438 346 457 438 Sens 4 43% 32% 43% 40% 46% 34% 29% 36% 38% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 795 1270 944 795 1270 944 795 1270 944 Sens 5 34% 16% 36% 27% 31% 26% 14% 21% 31% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 4700 7480 5930 4700 7480 5930 4700 7480 5930 Sens 6 19% 13% 22% 13% 12% 15% 7% 21% 12% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.6 0.85 2.0 1.4 1.2 1.6 1.4 1.3 0.98 p Value 0.21 0.78 0.076 0.41 0.77 0.26 0.68 0.70 0.98 95% CI of 0.77 0.28 0.93 0.62 0.36 0.72 0.30 0.29 0.19 OR Quart2 3.2 2.6 4.1 3.2 4.0 3.4 6.5 6.1 5.1 OR Quart 3 2.3 1.5 2.1 2.4 0.99 2.4 1.0 1.0 1.3 p Value 0.018 0.45 0.053 0.025 0.99 0.021 0.98 1.0 0.71 95% CI of 1.2 0.54 0.99 1.1 0.28 1.1 0.20 0.20 0.29 OR Quart3 4.6 4.0 4.3 5.3 3.5 5.1 5.3 5.0 6.2 OR Quart 4 3.1 1.2 3.8 2.1 2.1 1.9 1.4 1.4 2.1 p Value 0.0011 0.79 2.5E-4 0.062 0.20 0.097 0.68 0.69 0.32 95% CI of 1.6 0.41 1.9 0.96 0.69 0.89 0.30 0.30 0.49 OR Quart4 6.2 3.3 7.7 4.6 6.2 4.1 6.5 6.2 8.6 Glucagon sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 238 238 238 347 238 347 Average 1510 1480 1510 2220 1510 2980 Stdev 2880 3090 2880 3660 2880 3990 p(t-test) 0.95 0.17 0.030 Min 2.40 1.53 2.40 4.46 2.40 3.67 70 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max 9330 9330 9330 9330 9330 9330 n (Samp) 122 47 122 50 122 26 n (Patient) 98 47 98 50 98 26 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 238 238 238 347 238 2420 Average 1680 2140 1680 3800 1680 4230 Stdev 3080 3900 3080 4400 3080 4290 p(t-test) 0.60 0.0056 0.0047 Min 0.0247 4.37 0.0247 6.86 0.0247 3.67 Max 9330 9330 9330 9330 9330 9330 n(Samp) 261 14 261 19 261 13 n (Patient) 159 14 159 19 159 13 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 238 238 238 238 238 347 Average 1250 1830 1250 1900 1250 2340 Stdev 2480 3370 2480 3500 2480 3790 p(t-test) 0.24 0.19 0.085 Min 2.40 1.53 2.40 4.46 2.40 6.71 Max 9330 9330 9330 9330 9330 9330 n(Samp) 111 44 111 46 111 23 n (Patient) 84 44 84 46 84 23 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.52 0.49 0.56 0.58 0.66 0.56 0.72 0.70 0.68 SE 0.050 0.080 0.052 0.049 0.070 0.051 0.060 0.083 0.066 p 0.73 0.92 0.28 0.086 0.024 0.27 2.1E-4 0.016 0.0057 nCohort1 122 261 111 122 261 111 122 261 111 nCohort 2 47 14 44 50 19 46 26 13 23 Cutoff 1 98.8 166 101 46.8 174 19.3 275 275 238 Sens 1 70% 71% 70% 70% 74% 72% 88% 85% 78% Spec 1 42% 34% 41% 40% 35% 38% 61% 54% 61% Cutoff 2 10.2 10.2 10.8 16.2 75.1 10.8 275 275 168 Sens 2 81% 86% 82% 80% 84% 80% 88% 85% 83% Spec 2 37% 25% 35% 38% 33% 35% 61% 54% 41% Cutoff 3 6.53 8.98 6.52 6.86 11.7 6.71 169 4.46 98.8 Sens 3 91% 93% 93% 90% 95% 91% 92% 92% 91% Spec 3 19% 22% 19% 20% 27% 20% 43% 7% 41% Cutoff 4 347 347 347 347 347 347 347 347 347 Sens 4 19% 21% 25% 30% 47% 24% 42% 62% 30% Spec 4 73% 72% 74% 73% 72% 74% 73% 72% 74% Cutoff 5 2420 2420 2420 2420 2420 2420 2420 2420 2420 Sens 5 13% 21% 16% 20% 37% 17% 27% 38% 22% Spec 5 88% 86% 91% 88% 86% 91% 88% 86% 91% Cutoff 6 9330 9330 2420 9330 9330 2420 9330 9330 2420 Sens 6 0% 0% 16% 0% 0% 17% 0% 0% 22% Spec 6 100% 100% 91% 100% 100% 91% 100% 100% 91% OR Quart 2 2.6 0.32 3.0 2.6 4.2 2.9 2.1 0 4.3 71 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only p Value 0.057 0.33 0.049 0.058 0.21 0.048 0.56 na 0.21 95% CI of 0.97 0.033 1.0 0.97 0.46 1.0 0.18 na 0.45 OR Quart2 7.0 3.2 8.9 6.9 38 8.1 24 na 40 OR Quart 3 2.1 2.9 2.7 2.3 6.5 2.3 22 2.6 18 p Value 0.14 0.13 0.080 0.092 0.088 0.12 0.0039 0.26 0.0070 95% CI of 0.78 0.73 0.89 0.87 0.76 0.80 2.7 0.49 2.2 OR Quart3 5.8 11 8.0 6.3 55 6.6 180 14 150 OR Quart 4 1.1 0.67 2.1 1.5 8.9 1.7 12 3.1 6.9 p Value 0.83 0.66 0.19 0.44 0.042 0.31 0.024 0.17 0.083 95% CI of 0.39 0.11 0.69 0.54 1.1 0.59 1.4 0.61 0.78 OR Quart4 3.3 4.1 6.4 4.2 73 5.1 97 16 60 Glucagon-like peptide 1 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 5.53 3.10 5.53 3.10 5.53 1.20 Average 9.04 5.05 9.04 6.48 9.04 22.4 Stdev 43.4 3.51 43.4 15.1 43.4 101 p(t-test) 0.53 0.68 0.28 Min 0.407 0.407 0.407 0.407 0.407 0.407 Max 482 9.60 482 107 482 519 n (Samp) 122 47 122 50 122 26 n (Patient) 98 47 98 50 98 26 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 3.10 5.53 3.10 3.10 3.10 2.30 Average 9.65 5.97 9.65 4.04 9.65 3.63 Stdev 45.3 3.59 45.3 3.81 45.3 3.70 p(t-test) 0.76 0.59 0.63 Min 0.407 0.407 0.407 0.407 0.407 0.407 Max 519 9.60 519 10.1 519 11.8 n(Samp) 261 14 261 19 261 13 n (Patient) 159 14 159 19 159 13 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 5.53 3.10 5.53 3.10 5.53 0.685 Average 9.53 4.60 9.53 7.43 9.53 25.0 Stdev 45.4 3.51 45.4 16.3 45.4 108 p(t-test) 0.47 0.76 0.27 Min 0.407 0.407 0.407 0.407 0.407 0.407 Max 482 9.60 482 107 482 519 n(Samp) 111 44 111 46 111 23 n (Patient) 84 44 84 46 84 23 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.49 0.60 0.44 0.43 0.45 0.43 0.30 0.42 0.30 SE 0.050 0.082 0.052 0.049 0.070 0.051 0.061 0.085 0.065 p 0.90 0.20 0.24 0.17 0.45 0.15 0.0013 0.36 0.0025 72 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only nCohort1 122 261 111 122 261 111 122 261 111 nCohort 2 47 14 44 50 19 46 26 13 23 Cutoff 1 2.30 2.30 1.71 0.685 0.407 0.685 0 0.407 0 Sens 1 74% 79% 70% 72% 84% 72% 100% 85% 100% Spec 1 28% 36% 23% 12% 15% 10% 0% 15% 0% Cutoff 2 0.685 1.75 0.407 0.407 0.407 0 0 0.407 0 Sens 2 83% 86% 84% 82% 84% 100% 100% 85% 100% Spec 2 12% 33% 9% 10% 15% 0% 0% 15% 0% Cutoff 3 0 0.407 0 0 0 0 0 0 0 Sens 3 100% 93% 100% 100% 100% 100% 100% 100% 100% Spec 3 0% 15% 0% 0% 0% 0% 0% 0% 0% Cutoff 4 5.53 5.53 8.07 5.53 5.53 8.07 5.53 5.53 8.07 Sens 4 34% 43% 27% 26% 26% 22% 15% 15% 9% Spec 4 72% 73% 70% 72% 73% 70% 72% 73% 70% Cutoff 5 9.60 9.60 9.60 9.60 9.60 9.60 9.60 9.60 9.60 Sens 5 0% 0% 0% 10% 11% 11% 8% 15% 4% Spec 5 94% 94% 92% 94% 94% 92% 94% 94% 92% Cutoff 6 9.60 9.60 9.60 9.60 9.60 9.60 9.60 9.60 9.60 Sens 6 0% 0% 0% 10% 11% 11% 8% 15% 4% Spec 6 94% 94% 92% 94% 94% 92% 94% 94% 92% OR Quart 2 0.56 1.5 1.1 0.68 0.38 1.4 1.4 1.5 4.3 p Value 0.25 0.66 0.79 0.45 0.26 0.56 0.69 0.64 0.084 95% CI of 0.21 0.24 0.41 0.25 0.072 0.49 0.29 0.25 0.82 OR Quart2 1.5 9.3 3.2 1.8 2.0 3.7 6.6 9.6 23 OR Quart 3 0.93 1.5 1.5 1.1 0.79 1.2 1.4 2.1 1.0 p Value 0.87 0.66 0.44 0.81 0.73 0.74 0.69 0.41 1.0 95% CI of 0.37 0.24 0.54 0.44 0.20 0.42 0.29 0.36 0.13 OR Quart3 2.3 9.3 4.1 2.8 3.1 3.3 6.6 12 7.5 OR Quart 4 0.74 3.1 1.7 1.5 1.7 2.4 7.7 2.1 9.1 p Value 0.52 0.17 0.28 0.36 0.39 0.080 0.0030 0.40 0.0065 95% CI of 0.29 0.61 0.64 0.62 0.52 0.90 2.0 0.37 1.9 OR Quart4 1.9 16 4.7 3.8 5.4 6.4 30 12 45 Appetite-regulating hormone sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.560 0.232 0.560 0.232 0.560 0.396 Average 0.919 0.539 0.919 2.03 0.919 1.33 Stdev 1.31 0.732 1.31 9.23 1.31 1.61 p(t-test) 0.062 0.19 0.16 Min 0.0793 0.0793 0.0793 0.0793 0.0793 0.0793 Max 8.07 2.40 8.07 65.5 8.07 4.69 n (Samp) 122 47 122 50 122 26 n (Patient) 98 47 98 50 98 26 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.232 0.232 0.232 0.232 0.232 0.560 Average 1.13 0.661 1.13 0.883 1.13 1.17 Stdev 4.19 0.857 4.19 0.994 4.19 1.45 p(t-test) 0.68 0.80 0.97 Min 0.0793 0.0793 0.0793 0.0793 0.0793 0.0793 73 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max 65.5 2.40 65.5 2.92 65.5 4.69 n (Samp) 261 14 261 19 261 13 n(Patient) 159 14 159 19 159 13 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.232 0.232 0.232 0.232 0.232 0.560 Average 0.975 0.527 0.975 2.12 0.975 1.15 Stdev 1.37 0.726 1.37 9.63 1.37 1.49 p(t-test) 0.042 0.22 0.58 Min 0.0793 0.0793 0.0793 0.0793 0.0793 0.0793 Max 8.07 2.40 8.07 65.5 8.07 4.55 n(Samp) 111 44 111 46 111 23 n (Patient) 84 44 84 46 84 23 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.40 0.45 0.38 0.44 0.49 0.42 0.51 0.49 0.49 SE 0.050 0.081 0.051 0.049 0.069 0.051 0.063 0.083 0.067 p 0.048 0.57 0.016 0.19 0.84 0.14 0.94 0.88 0.93 nCohort1 122 261 111 122 261 111 122 261 111 nCohort 2 47 14 44 50 19 46 26 13 23 Cutoff 1 0.0995 0.0995 0.0995 0.108 0 0.0995 0.0995 0 0.108 Sens 1 81% 79% 75% 70% 100% 78% 73% 100% 74% Spec 1 16% 20% 14% 29% 0% 14% 16% 0% 29% Cutoff 2 0.0995 0 0.0793 0.0793 0 0.0793 0 0 0 Sens 2 81% 100% 84% 82% 100% 83% 100% 100% 100% Spec 2 16% 0% 6% 10% 0% 6% 0% 0% 0% Cutoff 3 0 0 0 0 0 0 0 0 0 Sens 3 100% 100% 100% 100% 100% 100% 100% 100% 100% Spec 3 0% 0% 0% 0% 0% 0% 0% 0% 0% Cutoff 4 0.560 0.560 0.560 0.560 0.560 0.560 0.560 0.560 0.560 Sens 4 17% 21% 18% 22% 37% 17% 46% 38% 39% Spec 4 75% 73% 72% 75% 73% 72% 75% 73% 72% Cutoff 5 1.75 1.75 1.75 1.75 1.75 1.75 1.75 1.75 1.75 Sens 5 9% 14% 7% 14% 16% 11% 19% 23% 13% Spec 5 83% 85% 80% 83% 85% 80% 83% 85% 80% Cutoff 6 2.67 2.67 2.67 2.67 2.67 2.67 2.67 2.67 2.67 Sens 6 0% 0% 0% 8% 5% 9% 15% 8% 13% Spec 6 93% 93% 92% 93% 93% 92% 93% 93% 92% OR Quart 2 0.88 1.0 0.57 0.66 1.0 1.4 1.0 0.39 1.6 p Value 0.81 1.0 0.37 0.44 1.0 0.55 1.0 0.27 0.49 95% CI of 0.29 0.19 0.17 0.24 0.31 0.48 0.31 0.073 0.44 OR Quart2 2.7 5.1 1.9 1.9 3.3 4.0 3.2 2.1 5.5 OR Quart 3 4.4 1.7 2.2 2.1 0.15 2.5 0.24 0.19 1.0 p Value 0.0031 0.47 0.14 0.11 0.088 0.075 0.094 0.13 1.0 95% CI of 1.6 0.39 0.79 0.84 0.018 0.91 0.047 0.021 0.26 OR Quart3 12 7.5 6.0 5.2 1.3 6.9 1.3 1.7 3.8 OR Quart 4 1.6 1.0 3.1 1.3 1.0 2.0 1.6 1.0 1.3 p Value 0.40 0.99 0.026 0.63 1.0 0.18 0.41 0.98 0.70 95% CI of 0.55 0.20 1.1 0.49 0.31 0.72 0.53 0.28 0.35 OR Quart4 4.4 5.2 8.6 3.2 3.3 5.6 4.8 3.7 4.7 74 Islet amyloid polypeptide sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.282 0.227 0.282 0.0802 0.282 0.0786 Average 2.08 2.54 2.08 2.95 2.08 0.425 Stdev 9.81 12.3 9.81 10.8 9.81 0.939 p(t-test) 0.80 0.61 0.39 Min 0.00151 0.00151 0.00151 0.00151 0.00151 0.00151 Max 102 84.9 102 57.5 102 4.44 n (Samp) 122 47 122 50 122 26 n (Patient) 98 47 98 50 98 26 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.201 0.901 0.201 0.00945 0.201 0.0527 Average 1.88 7.06 1.88 3.60 1.88 10.9 Stdev 8.86 22.4 8.86 12.0 8.86 36.6 p(t-test) 0.059 0.43 0.0064 Min 0.00151 0.00151 0.00151 0.00151 0.00151 0.00151 Max 102 84.9 102 51.4 102 133 n(Samp) 261 14 261 19 261 13 n (Patient) 159 14 159 19 159 13 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.359 0.261 0.359 0.205 0.359 0.0527 Average 1.32 1.30 1.32 2.39 1.32 4.02 Stdev 3.70 4.10 3.70 9.00 3.70 17.6 p(t-test) 0.98 0.29 0.14 Min 0.00151 0.00151 0.00151 0.00151 0.00151 0.00151 Max 30.4 26.4 30.4 57.5 30.4 84.9 n(Samp) 111 44 111 46 111 23 n (Patient) 84 44 84 46 84 23 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.50 0.62 0.47 0.45 0.37 0.46 0.39 0.43 0.39 SE 0.050 0.082 0.052 0.049 0.071 0.051 0.064 0.085 0.067 p 0.97 0.13 0.53 0.28 0.058 0.38 0.078 0.38 0.11 nCohort1 122 261 111 122 261 111 122 261 111 nCohort 2 47 14 44 50 19 46 26 13 23 Cutoff 1 0.00550 0.0527 0.00571 0.00369 0 0.00369 0.00151 0.00151 0.00187 Sens 1 77% 71% 70% 76% 100% 78% 81% 85% 74% Spec 1 29% 44% 25% 23% 0% 14% 7% 8% 9% Cutoff 2 0.00353 0.00550 0.00353 0.00187 0 0.00353 0.00151 0.00151 0.00151 Sens 2 83% 86% 82% 80% 100% 80% 81% 85% 83% Spec 2 23% 29% 14% 11% 0% 14% 7% 8% 4% Cutoff 3 0.00151 0.00369 0.00151 0.00151 0 0.00151 0 0 0 Sens 3 96% 93% 98% 90% 100% 93% 100% 100% 100% Spec 3 7% 23% 4% 7% 0% 4% 0% 0% 0% Cutoff 4 0.976 0.618 1.06 0.976 0.618 1.06 0.976 0.618 1.06 Sens 4 28% 50% 20% 22% 16% 24% 12% 23% 17% Spec 4 70% 70% 72% 70% 70% 72% 70% 70% 72% Cutoff 5 1.47 1.20 1.47 1.47 1.20 1.47 1.47 1.20 1.47 75 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 5 19% 50% 16% 18% 16% 20% 8% 23% 13% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 2.36 2.21 2.35 2.36 2.21 2.35 2.36 2.21 2.35 Sens 6 11% 29% 11% 12% 16% 11% 4% 23% 4% Spec 6 90% 90% 91% 90% 90% 91% 90% 90% 91% OR Quart 2 1.0 2.0 1.5 1.0 0.32 0.91 2.2 0.67 1.3 p Value 0.95 0.42 0.44 1.0 0.33 0.85 0.29 0.66 0.69 95% CI of 0.39 0.36 0.54 0.37 0.033 0.33 0.50 0.11 0.33 OR Quart2 2.7 11 4.1 2.7 3.2 2.5 9.5 4.1 5.5 OR Quart 3 2.0 0.49 1.3 2.4 2.9 0.79 3.6 0.66 1.9 p Value 0.15 0.56 0.60 0.069 0.13 0.65 0.070 0.65 0.33 95% CI of 0.79 0.043 0.47 0.94 0.73 0.29 0.90 0.11 0.51 OR Quart3 5.0 5.5 3.6 6.0 11 2.2 15 4.1 7.4 OR Quart 4 0.68 3.7 1.5 1.3 2.5 1.8 3.1 2.1 2.0 p Value 0.47 0.11 0.40 0.62 0.20 0.21 0.11 0.30 0.30 95% CI of 0.24 0.75 0.56 0.48 0.61 0.71 0.76 0.51 0.53 OR Quart4 1.9 19 4.2 3.4 10 4.7 13 8.9 7.7 Interleukin-17A sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.00337 0.00303 0.00337 0.00468 0.00337 0.00327 Average 1.11 0.643 1.11 0.788 1.11 0.364 Stdev 8.62 3.07 8.62 3.13 8.62 1.30 p(t-test) 0.44 0.62 0.50 Min 0.000344 0.000344 0.000344 0.000344 0.000344 0.000381 Max 133 29.0 133 25.7 133 9.17 n (Samp) 624 214 624 180 624 60 n (Patient) 282 214 282 180 282 60 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.00337 0.00362 0.00337 0.00362 0.00337 0.00283 Average 1.11 0.299 1.11 0.455 1.11 0.132 Stdev 8.18 1.04 8.18 1.86 8.18 0.320 p(t-test) 0.41 0.52 0.43 Min 0.000344 0.000344 0.000344 0.000344 0.000344 0.000344 Max 157 7.91 157 14.5 157 1.43 n (Samp) 1484 69 1484 66 1484 43 n (Patient) 514 69 514 66 514 43 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.00337 0.00283 0.00337 0.00492 0.00337 0.00360 Average 0.925 1.04 0.925 1.10 0.925 0.343 Stdev 7.93 4.24 7.93 3.73 7.93 1.35 p(t-test) 0.85 0.78 0.59 Min 0.000344 0.000344 0.000344 0.000344 0.000344 0.000381 Max 133 33.1 133 25.7 133 9.17 n (Samp) 659 195 659 170 659 55 n (Patient) 251 195 251 170 251 55 76 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.47 0.50 0.48 0.56 0.50 0.58 0.52 0.45 0.54 SE 0.023 0.036 0.024 0.025 0.036 0.025 0.039 0.046 0.041 p 0.16 0.97 0.36 0.018 0.97 9.5E-4 0.70 0.26 0.31 nCohort 1 624 1484 659 624 1484 659 624 1484 659 nCohort 2 214 69 195 180 66 170 60 43 55 Cutoff 1 0.000662 0.00182 0.000662 0.00275 0.00182 0.00291 0.00263 0.000747 0.00263 Sens 1 72% 71% 70% 72% 74% 70% 70% 77% 73% Spec 1 14% 29% 18% 38% 29% 44% 38% 21% 41% Cutoff 2 0.000597 0.000662 0.000597 0.00182 0.000662 0.00182 0.00174 0.000662 0.00189 Sens 2 83% 81% 83% 81% 80% 81% 83% 84% 82% Spec 2 8% 17% 11% 26% 17% 30% 26% 17% 34% Cutoff 3 0.000381 0.000410 0.000381 0.000410 0.000380 0.000410 0.000734 0.000597 0.000654 Sens 3 92% 93% 91% 91% 92% 93% 90% 91% 91% Spec 3 4% 7% 5% 5% 4% 6% 15% 10% 16% Cutoff 4 0.00875 0.00913 0.00875 0.00875 0.00913 0.00875 0.00875 0.00913 0.00875 Sens 4 32% 32% 32% 37% 35% 37% 32% 30% 27% Spec 4 71% 70% 72% 71% 70% 72% 71% 70% 72% Cutoff 5 0.106 0.150 0.0652 0.106 0.150 0.0652 0.106 0.150 0.0652 Sens 5 21% 20% 23% 29% 26% 31% 22% 19% 18% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 0.608 0.830 0.606 0.608 0.830 0.606 0.608 0.830 0.606 Sens 6 11% 9% 13% 14% 11% 17% 12% 7% 9% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 0.91 0.59 0.80 1.0 0.81 1.2 2.6 0.59 2.5 p Value 0.67 0.15 0.36 0.90 0.58 0.43 0.014 0.32 0.034 95% CI of 0.58 0.28 0.50 0.62 0.40 0.73 1.2 0.21 1.1 OR Quart2 1.4 1.2 1.3 1.7 1.7 2.1 5.7 1.6 5.9 OR Quart 3 0.63 0.95 0.77 1.6 1.0 1.6 0.89 1.3 2.0 p Value 0.058 0.87 0.28 0.070 1.0 0.059 0.81 0.53 0.14 95% CI of 0.40 0.50 0.48 0.96 0.50 0.98 0.35 0.57 0.81 OR Quart3 1.0 1.8 1.2 2.5 2.0 2.7 2.3 3.0 4.7 OR Quart 4 1.7 0.89 1.5 1.8 1.1 2.1 1.8 1.4 1.7 p Value 0.018 0.73 0.076 0.018 0.87 0.0031 0.16 0.41 0.27 95% CI of 1.1 0.46 0.96 1.1 0.54 1.3 0.79 0.62 0.67 OR Quart4 2.5 1.7 2.3 2.8 2.1 3.4 4.0 3.2 4.1 Insulin receptor substrate 1 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.000546 1.04E-5 0.000546 0.00110 0.000546 1.04E-5 Average 0.00176 0.00292 0.00176 0.00630 0.00176 0.00173 Stdev 0.00612 0.0145 0.00612 0.0324 0.00612 0.00415 p(t-test) 0.29 0.040 0.99 Min 1.25E-9 1.25E-9 1.25E-9 1.25E-9 1.25E-9 1.25E-9 Max 0.0712 0.123 0.0712 0.282 0.0712 0.0163 n (Samp) 237 125 237 82 237 15 n (Patient) 108 125 108 82 108 15 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.78E-5 2.78E-5 2.78E-5 0.00110 2.78E-5 0.00137 Average 0.00355 0.00106 0.00355 0.00626 0.00355 0.00210 77 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Stdev 0.0332 0.00146 0.0332 0.0219 0.0332 0.00360 p(t-test) 0.64 0.65 0.85 Min 1.25E-9 1.25E-9 1.25E-9 7.25E-7 1.25E-9 9.90E-7 Max 0.735 0.00563 0.735 0.123 0.735 0.0163 n(Samp) 591 38 591 31 591 19 n (Patient) 229 38 229 31 229 19 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.78E-5 1.04E-5 2.78E-5 0.00110 2.78E-5 3.41E-6 Average 0.00177 0.00317 0.00177 0.00574 0.00177 0.000563 Stdev 0.00574 0.0155 0.00574 0.0320 0.00574 0.000973 p(t-test) 0.19 0.044 0.40 Min 1.25E-9 1.25E-9 1.25E-9 1.25E-9 1.25E-9 1.25E-9 Max 0.0712 0.123 0.0712 0.282 0.0712 0.00243 n(Samp) 294 110 294 84 294 16 n (Patient) 123 110 123 84 123 16 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.43 0.50 0.44 0.57 0.64 0.54 0.43 0.64 0.39 SE 0.032 0.048 0.033 0.037 0.055 0.036 0.079 0.070 0.077 p 0.031 0.93 0.047 0.077 0.014 0.32 0.41 0.038 0.15 nCohort 1 237 591 294 237 591 294 237 591 294 nCohort 2 125 38 110 82 31 84 15 19 16 Cutoff 1 1.78E-6 3.73E-6 1.78E-6 5.14E-6 5.14E-6 2.32E-6 1.50E-6 4.40E-5 1.50E-6 Sens 1 71% 71% 71% 73% 81% 75% 73% 79% 75% Spec 1 24% 35% 24% 36% 40% 32% 17% 53% 17% Cutoff 2 7.25E-7 7.25E-7 7.25E-7 1.78E-6 5.14E-6 1.50E-6 9.90E-7 1.78E-6 9.90E-7 Sens 2 84% 82% 85% 80% 81% 82% 87% 89% 88% Spec 2 8% 12% 8% 24% 40% 17% 13% 28% 13% Cutoff 3 1.25E-9 0 1.25E-9 7.25E-7 7.25E-7 1.25E-9 1.25E-9 7.25E-7 1.25E-9 Sens 3 90% 100% 92% 91% 94% 92% 93% 100% 94% Spec 3 6% 0% 5% 8% 12% 5% 6% 12% 5% Cutoff 4 0.00229 0.00110 0.00163 0.00229 0.00110 0.00163 0.00229 0.00110 0.00163 Sens 4 15% 34% 20% 32% 48% 33% 20% 53% 19% Spec 4 76% 71% 70% 76% 71% 70% 76% 71% 70% Cutoff 5 0.00243 0.00229 0.00243 0.00243 0.00229 0.00243 0.00243 0.00229 0.00243 Sens 5 10% 16% 10% 22% 35% 15% 13% 32% 0% Spec 5 89% 81% 85% 89% 81% 85% 89% 81% 85% Cutoff 6 0.00271 0.00271 0.00281 0.00271 0.00271 0.00281 0.00271 0.00271 0.00281 Sens 6 9% 8% 7% 16% 26% 10% 7% 11% 0% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.6 0.53 2.3 1.1 0.99 1.1 1.0 0.99 1.0 p Value 0.13 0.22 0.015 0.88 0.99 0.74 1.0 0.99 0.99 95% CI of 0.86 0.19 1.2 0.50 0.28 0.55 0.19 0.14 0.20 OR Quart2 3.1 1.5 4.5 2.2 3.5 2.3 5.2 7.1 5.2 OR Quart 3 1.8 1.0 2.1 1.3 1.4 1.4 1.0 3.6 1.4 p Value 0.080 0.99 0.032 0.48 0.56 0.38 1.0 0.11 0.70 95% CI of 0.93 0.42 1.1 0.62 0.44 0.68 0.19 0.74 0.29 OR Quart3 3.3 2.4 4.1 2.7 4.6 2.7 5.2 18 6.2 OR Quart 4 2.0 0.91 2.2 1.8 3.0 1.3 2.1 4.1 2.1 p Value 0.036 0.83 0.022 0.12 0.042 0.40 0.31 0.076 0.30 78 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only 95% CI of 1.0 0.37 1.1 0.86 1.0 0.67 0.50 0.86 0.51 OR Quart4 3.7 2.2 4.3 3.6 8.4 12.7 8.8 20 8.8 Involucrin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.385 0.607 0.385 0.493 0.385 0.414 Average 1.04 1.30 1.04 1.44 1.04 0.846 Stdev 2.89 2.31 2.89 3.36 2.89 1.10 p(t-test) 0.29 0.17 0.63 Min 0.0119 0.0181 0.0119 0.0117 0.0119 0.0176 Max 47.1 19.2 47.1 31.3 47.1 5.04 n (Samp) 475 173 475 139 475 52 n (Patient) 253 173 253 139 253 52 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.499 0.628 0.499 0.502 0.499 0.589 Average 1.38 1.48 1.38 1.60 1.38 0.948 Stdev 4.19 2.75 4.19 3.17 4.19 1.32 p(t-test) 0.86 0.71 0.53 Min 0.0119 0.0214 0.0119 0.0117 0.0119 0.0176 Max 102 19.2 102 15.4 102 7.39 n (Samp) 1031 58 1031 53 1031 37 n (Patient) 424 58 424 53 424 37 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.368 0.647 0.368 0.516 0.368 0.376 Average 1.07 1.37 1.07 1.61 1.07 1.05 Stdev 3.03 2.01 3.03 3.52 3.03 1.43 p(t-test) 0.26 0.078 0.95 Min 0.00244 0.0181 0.00244 0.0378 0.00244 0.0268 Max 47.1 15.5 47.1 31.3 47.1 6.03 n (Samp) 486 156 486 135 486 46 n (Patient) 216 156 216 135 216 46 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.61 0.54 0.64 0.58 0.51 0.61 0.52 0.51 0.54 SE 0.026 0.040 0.026 0.028 0.041 0.028 0.043 0.049 0.045 p 3.7E-5 0.31 8.2E-8 0.0066 0.84 1.1E-4 0.61 0.83 0.38 nCohort 1 475 1031 486 475 1031 486 475 1031 486 nCohort 2 173 58 156 139 53 135 52 37 46 Cutoff 1 0.364 0.308 0.424 0.322 0.276 0.350 0.202 0.393 0.261 Sens 1 71% 71% 71% 71% 72% 70% 71% 70% 72% Spec 1 49% 34% 55% 44% 32% 48% 30% 42% 38% Cutoff 2 0.236 0.230 0.290 0.216 0.212 0.250 0.167 0.204 0.171 Sens 2 80% 81% 80% 81% 81% 80% 81% 81% 80% Spec 2 35% 27% 42% 32% 25% 37% 23% 24% 24% Cutoff 3 0.138 0.126 0.142 0.111 0.0592 0.157 0.0499 0.0373 0.0892 79 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 3 90% 91% 90% 91% 91% 90% 90% 92% 91% Spec 3 17% 12% 19% 14% 3% 21% 4% 2% 10% Cutoff 4 0.701 0.962 0.715 0.701 0.962 0.715 0.701 0.962 0.715 Sens 4 42% 36% 47% 40% 32% 41% 35% 27% 37% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 1.08 1.58 1.11 1.08 1.58 1.11 1.08 1.58 1.11 Sens 5 28% 24% 33% 27% 23% 29% 27% 11% 30% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 2.02 2.84 1.96 2.02 2.84 1.96 2.02 2.84 1.96 Sens 6 17% 16% 20% 17% 13% 19% 10% 8% 13% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.4 1.4 1.6 1.6 1.2 1.9 0.90 1.1 1.3 p Value 0.21 0.42 0.11 0.091 0.69 0.038 0.81 0.81 0.51 95% CI of 0.82 0.62 0.90 0.92 0.53 1.0 0.38 0.43 0.56 OR Quart2 2.5 3.1 3.0 2.9 2.6 3.5 2.1 3.0 3.2 OR Quart 3 2.5 1.4 2.8 1.6 1.1 2.1 1.1 1.8 0.79 p Value 7.1E-4 0.42 3.4E-4 0.11 0.84 0.014 0.85 0.20 0.63 95% CI of 1.5 0.62 1.6 0.90 0.49 1.2 0.47 0.74 0.30 OR Quart3 4.1 3.1 5.0 2.8 2.4 3.8 2.5 4.3 2.1 OR Quart 4 2.3 1.6 3.4 2.1 1.2 2.7 1.4 0.74 1.6 p Value 0.0016 0.25 1.7E-5 0.0072 0.69 0.0011 0.44 0.59 0.30 95% CI of 1.4 0.72 2.0 1.2 0.53 1.5 0.62 0.25 0.68 OR Quart4 3.9 3.4 6.0 3.8 2.6 .8 3.0 2.2 3.6 Keratin, type II cytoskeletal 1; type cytoskeletal 10 (Keratin-1,-10 mix) sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0174 0.0218 0.0174 0.0602 0.0174 0.00541 Average 3.87 1.53 3.87 4.35 3.87 0.704 Stdev 20.3 3.65 20.3 26.4 20.3 2.36 p(t-test) 0.13 0.82 0.26 Min 0.000410 0.000410 0.000410 0.000410 0.000410 0.000410 Max 367 28.7 367 309 367 15.4 n (Samp) 475 173 475 139 475 52 n (Patient) 253 173 253 139 253 52 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0174 0.0174 0.0174 0.0153 0.0174 0.0744 Average 3.28 2.11 3.28 2.20 3.28 1.12 Stdev 18.7 5.58 18.7 5.26 18.7 2.19 p(t-test) 0.64 0.68 0.48 Min 0.000410 0.000410 0.000410 0.000410 0.000410 0.000410 Max 367 28.7 367 27.8 367 11.8 n (Samp) 1031 58 1031 53 1031 37 n (Patient) 424 58 424 53 424 37 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0218 0.0196 0.0218 0.0602 0.0218 0.00896 80 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Average 3.17 1.62 3.17 4.20 3.17 0.804 Stdev 12.1 4.30 12.1 26.7 12.1 2.56 p(t-test) 0.12 0.52 0.19 Min 0.000410 0.000410 0.000410 0.000410 0.000410 0.000410 Max 113 42.0 113 309 113 15.4 n (Samp) 486 156 486 135 486 46 n (Patient) 216 156 216 135 216 46 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.50 0.49 0.48 0.52 0.49 0.51 0.31 0.47 0.33 SE 0.026 0.039 0.027 0.028 0.041 0.028 0.042 0.049 0.045 p 0.94 0.89 0.37 0.39 0.89 0.61 5.5E-6 0.49 2.1E-4 nCohort 1 475 1031 486 475 1031 486 475 1031 486 nCohort 2 173 58 156 139 53 135 52 37 46 Cutoff 1 0.00562 0.00562 0.00521 0.00892 0.00686 0.00892 0 0.00408 0 Sens 1 71% 72% 73% 71% 72% 72% 100% 70% 100% Spec 1 23% 27% 21% 34% 29% 33% 0% 12% 0% Cutoff 2 0.00474 0.00408 0.00474 0.00474 0.000693 0.00508 0 0 0 Sens 2 82% 84% 81% 81% 85% 80% 100% 100% 100% Spec 2 13% 12% 14% 13% 6% 18% 0% 0% 0% Cutoff 3 0.000693 0.000693 0.000693 0 0 0 0 0 0 Sens 3 94% 93% 92% 100% 100% 100% 100% 100% 100% Spec 3 4% 6% 3% 0% 0% 0% 0% 0% 0% Cutoff 4 0.981 1.21 1.21 0.981 1.21 1.21 0.981 1.21 1.21 Sens 4 35% 28% 33% 37% 28% 35% 13% 30% 11% Spec 4 71% 70% 70% 71% 70% 70% 71% 70% 70% Cutoff 5 2.40 2.40 2.41 2.40 2.40 2.41 2.40 2.40 2.41 Sens 5 21% 22% 19% 24% 21% 21% 8% 14% 9% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 6.14 5.06 6.14 6.14 5.06 6.14 6.14 5.06 6.14 Sens 6 3% 10% 4% 11% 11% 9% 2% 5% 2% Spec 6 91% 90% 91% 91% 90% 91% 91% 90% 91% OR Quart 2 1.0 0.93 0.88 0.61 1.0 0.89 1.5 2.1 1.6 p Value 0.90 0.86 0.62 0.084 1.0 0.67 0.43 0.13 0.40 95% CI of 0.64 0.44 0.52 0.34 0.45 0.51 0.53 0.82 0.52 OR Quart2 1.7 2.0 1.5 1.1 2.2 1.5 4.4 5.2 5.1 OR Quart 3 0.53 0.93 0.75 0.96 1.0 1.0 1.9 0.42 2.8 p Value 0.018 0.86 0.29 0.89 1.0 0.89 0.22 0.21 0.060 95% CI of 0.31 0.44 0.44 0.57 0.45 0.60 0.68 0.11 0.96 OR Quart3 0.90 2.0 1.3 1.6 2.2 1.8 5.3 1.6 8.0 OR Quart 4 1.2 1.0 1.3 1.1 1.1 1.2 5.2 1.9 4.5 p Value 0.47 0.99 0.30 0.62 0.84 0.52 4.8E-4 0.18 0.0034 95% CI of 0.74 0.48 0.79 0.68 0.50 0.70 2.1 0.75 1.6 OR Quart4 1.9 2.1 2.1 1.9 2.3 2.0 13 4.8 12 Keratin, type II cytoskeletal 6 (6A, -6B, -6C mix) sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0252 0.111 0.0252 0.0491 0.0252 0.0134 Average 2.82 2.64 2.82 2.58 2.82 2.78 Stdev 8.19 6.71 8.19 6.03 8.19 8.48 81 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) 0.80 0.74 0.97 Min 8.79E-5 8.79E-5 8.79E-5 8.79E-5 8.79E-5 8.79E-5 Max 89.9 48.4 89.9 38.6 89.9 46.7 n (Samp) 475 173 475 139 475 52 n (Patient) 253 173 253 139 253 52 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0252 0.0801 0.0252 0.0462 0.0252 0.129 Average 3.10 3.18 3.10 2.70 3.10 3.66 Stdev 13.8 7.61 13.8 6.98 13.8 8.81 p(t-test) 0.96 0.83 0.80 Min 8.79E-5 8.79E-5 8.79E-5 8.79E-5 8.79E-5 8.79E-5 Max 265 48.4 265 38.6 265 46.7 n (Samp) 1031 58 1031 53 1031 37 n (Patient) 424 58 424 53 424 37 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0252 0.111 0.0252 0.111 0.0252 0.0177 Average 2.34 2.31 2.34 2.39 2.34 1.98 Stdev 6.98 5.78 6.98 5.19 6.98 6.11 p(t-test) 0.96 0.94 0.74 Min 8.79E-5 8.79E-5 8.79E-5 8.79E-5 8.79E-5 8.79E-5 Max 89.9 37.9 89.9 33.8 89.9 34.5 n (Samp) 486 156 486 135 486 46 n (Patient) 216 156 216 135 216 46 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.49 0.52 0.49 0.48 0.50 0.51 0.35 0.50 0.38 SE 0.026 0.039 0.027 0.028 0.041 0.028 0.043 0.048 0.046 p 0.70 0.59 0.76 0.55 0.91 0.85 3.7E-4 0.97 0.0093 nCohort 1 475 1031 486 475 1031 486 475 1031 486 nCohort 2 173 58 156 139 53 135 52 37 46 Cutoff 1 0.0134 0.0134 0.0134 0.0134 0.0134 0.0134 0.000154 0.0127 0.000220 Sens 1 73% 71% 71% 72% 72% 72% 71% 70% 72% Spec 1 25% 29% 28% 25% 29% 28% 3% 23% 7% Cutoff 2 0.0106 0.00903 0.0106 0.00903 0.0106 0.00903 0 0.00821 0 Sens 2 83% 84% 81% 83% 81% 84% 100% 81% 100% Spec 2 16% 15% 16% 12% 18% 13% 0% 12% 0% Cutoff 3 0.000220 0.00533 0.000154 0 0 0.000154 0 0 0 Sens 3 92% 93% 94% 100% 100% 90% 100% 100% 100% Spec 3 6% 9% 3% 0% 0% 3% 0% 0% 0% Cutoff 4 0.758 0.440 0.547 0.758 0.440 0.547 0.758 0.440 0.547 Sens 4 28% 33% 28% 28% 26% 30% 21% 46% 20% Spec 4 70% 70% 71% 70% 70% 71% 70% 70% 71% Cutoff 5 3.08 2.93 2.77 3.08 2.93 2.77 3.08 2.93 2.77 Sens 5 19% 28% 20% 21% 19% 21% 15% 22% 13% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 7.99 8.01 6.75 7.99 8.01 6.75 7.99 8.01 6.75 Sens 6 12% 12% 12% 12% 9% 13% 8% 11% 9% 82 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.4 0.57 1.5 1.2 1.5 0.69 0.79 0.57 1.4 p Value 0.17 0.17 0.15 0.48 0.33 0.20 0.63 0.25 0.48 95% CI of 0.86 0.26 0.87 0.71 0.68 0.39 0.30 0.22 0.55 OR Quart2 2.3 1.3 2.4 2.0 3.3 1.2 2.1 1.5 3.6 OR Quart 3 0.84 0.81 0.96 0.85 1.2 1.1 0.79 0.49 0.74 p Value 0.51 0.58 0.89 0.57 0.68 0.69 0.63 0.16 0.58 95% CI of 0.50 0.39 0.57 0.49 0.52 0.66 0.30 0.18 0.25 OR Quart3 1.4 1.7 1.6 1.5 2.7 1.9 2.1 1.3 2.2 OR Quart 4 1.2 1.00 1.2 1.1 1.2 1.0 3.0 1.0 2.9 p Value 0.38 0.99 0.41 0.76 0.68 0.92 0.0051 1.0 0.014 95% CI of 0.76 0.50 0.74 0.64 0.52 0.61 1.4 0.44 1.2 OR Quart4 2.0 2.0 2.1 1.9 2.7 1.7 6.6 2.3 6.9 NF-kappa-B inhibitor alpha sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.000108 3.20E-5 0.000108 9.81E-5 0.000108 2.25E-5 Average 0.00480 0.00307 0.00480 0.00666 0.00480 0.00602 Stdev 0.0236 0.0194 0.0236 0.0330 0.0236 0.0201 p(t-test) 0.48 0.58 0.85 Min 3.52E-7 3.52E-7 3.52E-7 3.52E-7 3.52E-7 3.80E-7 Max 0.211 0.203 0.211 0.245 0.211 0.0782 n (Samp) 237 125 237 82 237 15 n (Patient) 108 125 108 82 108 15 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 9.81E-5 0.000176 9.81E-5 0.000108 9.81E-5 6.66E-6 Average 0.00443 0.00236 0.00443 0.00796 0.00443 0.00985 Stdev 0.0230 0.0117 0.0230 0.0363 0.0230 0.0396 p(t-test) 0.58 0.42 0.33 Min 3.52E-7 3.52E-7 3.52E-7 3.65E-7 3.52E-7 3.65E-7 Max 0.245 0.0725 0.245 0.203 0.245 0.173 n(Samp) 591 38 591 31 591 19 n (Patient) 229 38 229 31 229 19 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.000190 3.20E-5 0.000190 9.81E-5 0.000190 1.32E-5 Average 0.00460 0.00341 0.00460 0.00638 0.00460 0.00527 Stdev 0.0218 0.0206 0.0218 0.0327 0.0218 0.0195 p(t-test) 0.62 0.56 0.90 Min 3.52E-7 3.52E-7 3.52E-7 3.52E-7 3.52E-7 3.80E-7 Max 0.211 0.203 0.211 0.245 0.211 0.0782 n(Samp) 294 110 294 84 294 16 n (Patient) 123 110 123 84 123 16 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO IsCr only UO only sCr or UO sCr only lUO only sCr or UO sCr only lUO only AUC 0.44 0.51 0.43 0.50 0.55 0.47 0.40 0.45 0.38 83 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only SE 0.032 0.049 0.033 0.037 0.055 0.036 0.079 0.069 0.077 p 0.081 0.90 0.026 0.94 0.34 0.45 0.22 0.46 0.13 nCohort 1 237 591 294 237 591 294 237 591 294 nCohort 2 125 38 110 82 31 84 15 19 16 Cutoff 1 1.03E-6 3.95E-6 1.03E-6 3.95E-6 2.18E-5 1.17E-6 4.18E-7 5.05E-7 4.18E-7 Sens 1 73% 71% 70% 72% 71% 73% 73% 79% 81% Spec 1 22% 33% 21% 28% 36% 26% 13% 19% 13% Cutoff 2 4.18E-7 1.03E-6 4.18E-7 1.03E-6 1.03E-6 5.23E-7 4.17E-7 4.18E-7 4.18E-7 Sens 2 82% 82% 81% 80% 84% 83% 80% 84% 81% Spec 2 13% 28% 13% 22% 28% 18% 9% 19% 13% Cutoff 3 3.80E-7 3.65E-7 3.80E-7 3.80E-7 3.80E-7 3.65E-7 3.52E-7 3.80E-7 3.65E-7 Sens 3 90% 92% 92% 90% 97% 90% 100% 95% 100% Spec 3 5% 5% 4% 5% 8% 3% 3% 8% 3% Cutoff 4 0.000613 0.000532 0.000614 0.000613 0.000532 0.000614 0.000613 0.000532 0.000614 Sens 4 22% 32% 18% 29% 39% 27% 27% 26% 19% Spec 4 71% 70% 72% 71% 70% 72% 71% 70% 72% Cutoff 5 0.00113 0.00109 0.00128 0.00113 0.00109 0.00128 0.00113 0.00109 0.00128 Sens 5 13% 18% 12% 23% 29% 19% 27% 26% 19% Spec 5 81% 80% 80% 81% 80% 80% 81% 80% 80% Cutoff 6 0.00284 0.00274 0.00384 0.00284 0.00274 0.00384 0.00284 0.00274 0.00384 Sens 6 7% 5% 5% 15% 16% 12% 13% 11% 12% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.4 1.3 1.6 0.77 2.6 1.0 0.24 0.60 0.33 p Value 0.32 0.61 0.18 0.47 0.12 0.97 0.20 0.48 0.34 95% CI of 0.74 0.47 0.81 0.37 0.79 0.50 0.026 0.14 0.033 OR Quart2 2.6 3.6 3.1 1.6 8.4 2.1 2.2 2.5 3.2 OR Quart 3 1.0 1.8 1.7 0.94 1.8 1.4 0.74 1.0 1.7 p Value 1.0 0.24 0.10 0.86 0.36 0.30 0.70 1.0 0.47 95% CI of 0.53 0.68 0.90 0.47 0.51 0.72 0.16 0.28 0.39 OR Quart3 1.9 4.6 3.4 1.9 6.2 2.8 3.4 3.5 7.4 OR Quart 4 1.7 1.4 2.3 0.95 2.6 1.2 1.8 1.2 2.5 p Value 0.080 0.46 0.012 0.90 0.12 0.69 0.35 0.75 0.20 95% CI of 0.94 0.54 1.2 0.47 0.79 0.57 0.51 0.36 0.62 OR Quart4 3.2 3.9 4.4 1.9 8.4 2.3 6.6 4.1 10 Beta-nerve growth factor sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.78 1.90 2.78 2.30 2.78 1.12 Average 4.11 3.29 4.11 3.54 4.11 3.40 Stdev 5.11 4.60 5.11 4.26 5.11 7.81 p(t-test) 0.13 0.37 0.61 Min 0.000201 0.000201 0.000201 0.000499 0.000201 0.000201 Max 44.0 35.5 44.0 25.2 44.0 32.2 n (Samp) 238 124 238 82 238 16 n (Patient) 111 124 111 82 111 16 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.40 1.89 2.40 2.83 2.40 1.04 Average 3.90 3.10 3.90 3.12 3.90 4.21 Stdev 5.26 2.83 5.26 2.80 5.26 7.95 84 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) 0.36 0.42 0.80 Min 0.000201 0.000201 0.000201 0.000506 0.000201 0.000201 Max 46.1 10.5 46.1 13.2 46.1 32.2 n (Samp) 593 37 593 31 593 19 n (Patient) 231 37 231 31 231 19 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.59 1.95 2.59 2.30 2.59 1.79 Average 3.80 3.34 3.80 3.68 3.80 3.18 Stdev 4.62 4.77 4.62 4.27 4.62 3.50 p(t-test) 0.38 0.82 0.60 Min 0.000201 0.000201 0.000201 0.000499 0.000201 0.000201 Max 32.2 35.5 32.2 25.2 32.2 11.7 n (Samp) 296 110 296 84 296 16 n (Patient) 126 110 126 84 126 16 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.44 0.49 0.46 0.46 0.50 0.49 0.33 0.38 0.46 SE 0.032 0.049 0.033 0.037 0.053 0.036 0.076 0.070 0.076 p 0.051 0.80 0.19 0.26 0.93 0.80 0.027 0.099 0.56 nCohort 1 238 593 296 238 593 296 238 593 296 nCohort 2 124 37 110 82 31 84 16 19 16 Cutoff 1 0.931 1.43 0.931 1.12 1.33 1.34 0.685 0.397 0.931 Sens 1 71% 70% 71% 71% 71% 70% 75% 74% 75% Spec 1 20% 36% 22% 24% 34% 32% 17% 13% 22% Cutoff 2 0.552 0.365 0.596 0.731 0.834 0.771 0.397 0.000499 0.685 Sens 2 81% 81% 80% 80% 81% 81% 81% 89% 81% Spec 2 15% 12% 17% 17% 22% 19% 12% 3% 18% Cutoff 3 0.0589 0.000506 0.261 0.397 0.111 0.397 0.0368 0.000244 0.0368 Sens 3 90% 95% 90% 90% 90% 90% 94% 95% 94% Spec 3 9% 4% 11% 12% 9% 12% 8% 1% 8% Cutoff 4 4.36 3.90 4.02 4.36 3.90 4.02 4.36 3.90 4.02 Sens 4 23% 32% 25% 22% 26% 27% 12% 21% 31% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 6.12 5.41 5.24 6.12 5.41 5.24 6.12 5.41 5.24 Sens 5 13% 19% 15% 16% 13% 21% 6% 16% 25% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 9.10 9.08 8.06 9.10 9.08 8.06 9.10 9.08 8.06 Sens 6 6% 3% 10% 7% 3% 14% 6% 16% 12% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.3 1.0 0.91 1.2 1.0 0.94 1.0 0.49 0.19 p Value 0.39 0.99 0.78 0.71 1.0 0.86 0.99 0.42 0.13 95% CI of 0.70 0.39 0.49 0.55 0.34 0.46 0.14 0.089 0.022 OR Quart2 2.5 2.6 1.7 2.4 2.9 1.9 7.4 2.7 1.7 OR Quart 3 1.4 1.0 0.85 1.4 1.5 1.3 2.1 1.3 1.0 p Value 0.34 1.0 0.63 0.36 0.46 0.39 0.41 0.74 1.0 95% CI of 0.72 0.39 0.45 0.68 0.54 0.68 0.36 0.33 0.28 OR Quart3 2.6 2.6 1.6 2.9 3.9 2.6 12 4.8 3.6 OR Quart 4 1.9 1.1 1.4 1.6 1.0 1.0 4.5 2.1 1.0 p Value 0.038 0.80 0.26 0.21 1.0 1.0 0.064 0.25 1.0 95% CT of 1.0 0.44 0.77 0.77 0.34 0.50 0.92 0.61 0.28 85 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO IsCr only UO only sCr or UO sCr only lUO only sCr or UO sCr only lUO only OR Quart4 3.6 2.9 2.6 3.3 2.9 2.0 22 7.0 3.6 Pancreatic prohormone sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 1.15 21.0 1.15 18.5 1.15 19.3 Average 87.8 106 87.8 70.5 87.8 53.3 Stdev 190 209 190 134 190 125 p(t-test) 0.59 0.56 0.38 Min 0.117 0.117 0.117 0.117 0.117 0.117 Max 950 1020 950 690 950 613 n (Samp) 122 47 122 50 122 26 n (Patient) 98 47 98 50 98 26 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 5.31 23.4 5.31 17.2 5.31 13.4 Average 87.2 87.5 87.2 109 87.2 79.2 Stdev 190 131 190 183 190 138 p(t-test) 0.99 0.63 0.88 Min 0.117 0.122 0.117 0.117 0.117 0.117 Max 1220 396 1220 728 1220 448 n(Samp) 261 14 261 19 261 13 n (Patient) 159 14 159 19 159 13 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 1.15 24.8 1.15 23.0 1.15 23.3 Average 82.5 109 82.5 87.7 82.5 72.3 Stdev 179 209 179 155 179 149 p(t-test) 0.44 0.86 0.80 Min 0.117 0.117 0.117 0.117 0.117 0.117 Max 950 1020 950 690 950 613 n(Samp) 111 44 111 46 111 23 n (Patient) 84 44 84 46 84 23 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.59 0.56 0.60 0.55 0.52 0.56 0.52 0.50 0.52 SE 0.050 0.081 0.052 0.049 0.069 0.051 0.063 0.082 0.067 p 0.058 0.45 0.050 0.28 0.77 0.23 0.73 0.96 0.72 nCohort1 122 261 111 122 261 111 122 261 111 nCohort 2 47 14 44 50 19 46 26 13 23 Cutoff 1 1.15 1.15 3.15 0.635 0.122 1.15 0.293 0.134 0.293 Sens 1 79% 71% 70% 76% 74% 72% 77% 77% 74% Spec 1 45% 39% 52% 36% 16% 39% 36% 23% 29% Cutoff 2 0.293 0.122 1.15 0.134 0.117 0.134 0.117 0.117 0.117 Sens 2 81% 93% 82% 80% 89% 83% 88% 92% 87% Spec 2 36% 16% 39% 22% 9% 20% 7% 9% 6% Cutoff 3 0.122 0.122 0.122 0.117 0 0.117 0 0.117 0 Sens 3 91% 93% 93% 92% 100% 91% 100% 92% 100% 86 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Spec 3 15% 16% 11% 7% 0% 6% 0% 9% 0% Cutoff 4 35.9 39.2 41.8 35.9 39.2 41.8 35.9 39.2 41.8 Sens 4 43% 36% 36% 36% 42% 39% 27% 31% 26% Spec 4 70% 70% 71% 70% 70% 71% 70% 70% 71% Cutoff 5 96.3 89.0 101 96.3 89.0 101 96.3 89.0 101 Sens 5 21% 29% 23% 20% 37% 22% 12% 31% 13% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 310 310 286 310 310 286 310 310 286 Sens 6 13% 7% 11% 6% 11% 11% 4% 8% 9% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 0.73 0.24 1.1 0.66 0.48 0.53 0.46 0.98 0.28 p Value 0.58 0.20 0.82 0.44 0.31 0.27 0.29 0.99 0.14 95% CI of 0.25 0.026 0.37 0.24 0.11 0.17 0.10 0.19 0.052 OR Quart2 2.2 2.2 3.5 1.9 2.0 1.6 2.0 5.1 1.5 OR Quart 3 2.8 0.98 3.1 2.3 0.31 2.5 2.5 1.0 2.2 p Value 0.038 0.98 0.034 0.073 0.16 0.062 0.11 1.0 0.16 95% CI of 1.1 0.24 1.1 0.93 0.061 0.96 0.82 0.19 0.72 OR Quart3 7.2 4.1 8.7 5.7 1.6 6.5 7.5 5.1 7.1 OR Quart 4 1.6 1.2 2.2 1.1 1.4 1.2 0.81 1.3 0.60 p Value 0.36 0.75 0.14 0.81 0.57 0.67 0.74 0.71 0.46 95% CI of 0.59 0.32 0.77 0.43 0.45 0.46 0.22 0.29 0.15 OR Quart4 4.2 4.9 6.4 2.9 4.2 3.3 2.9 6.2 2.4 Transthyretin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 20.7 29.7 20.7 25.4 20.7 17.9 Average 43.5 55.9 43.5 50.7 43.5 28.3 Stdev 68.4 87.0 68.4 79.2 68.4 30.6 p(t-test) 0.11 0.38 0.18 Min 0.0796 0.486 0.0796 0.773 0.0796 0.000148 Max 668 677 668 551 668 145 n (Samp) 271 140 271 107 271 38 n (Patient) 151 140 151 107 151 38 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 24.3 36.1 24.3 31.4 24.3 23.0 Average 50.7 71.9 50.7 87.9 50.7 48.7 Stdev 126 159 126 144 126 66.6 p(t-test) 0.31 0.076 0.94 Min 0.000148 1.04 0.000148 2.72 0.000148 0.773 Max 2000 997 2000 648 2000 241 n (Samp) 667 40 667 39 667 24 n (Patient) 290 40 290 39 290 24 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 23.0 30.3 23.0 26.9 23.0 20.0 Average 47.3 59.4 47.3 45.7 47.3 31.2 Stdev 72.7 90.9 72.7 59.9 72.7 34.5 p(t-test) 0.14 0.83 0.20 87 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Min 0.0796 0.486 0.0796 0.773 0.0796 0.000148 Max 668 677 668 396 668 182 n (Samp) 316 127 316 104 316 35 n (Patient) 155 127 155 104 155 35 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.57 0.56 0.56 0.55 0.58 0.53 0.46 0.48 0.47 SE 0.030 0.048 0.031 0.033 0.049 0.033 0.051 0.061 0.052 p 0.022 0.20 0.062 0.17 0.089 0.39 0.42 0.75 0.51 nCohort 1 271 667 316 271 667 316 271 667 316 nCohort 2 140 40 127 107 39 104 38 24 35 Cutoff 1 16.1 17.5 16.4 14.1 18.9 14.1 10.3 8.99 13.5 Sens 1 70% 70% 70% 70% 72% 70% 71% 71% 71% Spec 1 40% 39% 37% 37% 42% 33% 27% 20% 32% Cutoff 2 10.2 13.6 10.8 10.7 9.87 11.7 8.81 7.39 9.58 Sens 2 80% 80% 80% 80% 82% 81% 82% 83% 80% Spec 2 27% 30% 26% 28% 22% 28% 25% 16% 24% Cutoff 3 5.50 6.53 5.37 6.06 6.13 7.62 4.25 3.99 8.58 Sens 3 90% 90% 91% 91% 92% 90% 92% 92% 91% Spec 3 16% 15% 14% 18% 14% 20% 13% 9% 22% Cutoff 4 41.3 45.6 47.3 41.3 45.6 47.3 41.3 45.6 47.3 Sens 4 39% 38% 37% 31% 36% 30% 21% 33% 17% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 63.4 63.8 66.2 63.4 63.8 66.2 63.4 63.8 66.2 Sens 5 21% 20% 22% 21% 28% 18% 13% 29% 11% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 92.5 98.6 109 92.5 98.6 109 92.5 98.6 109 Sens 6 14% 15% 12% 14% 23% 10% 5% 12% 3% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.1 1.1 1.0 1.3 0.74 1.6 1.3 0.42 3.3 p Value 0.79 0.81 0.90 0.42 0.58 0.14 0.58 0.21 0.045 95% CI of 0.59 0.42 0.56 0.68 0.25 0.85 0.47 0.11 1.0 OR Quart2 2.0 3.0 1.9 2.5 2.2 3.1 3.8 1.6 11 OR Quart 3 1.8 1.4 1.9 1.8 1.8 1.6 2.1 0.71 3.0 p Value 0.047 0.49 0.033 0.076 0.19 0.14 0.15 0.56 0.069 95% CI of 1.0 0.55 1.1 0.94 0.74 0.85 0.77 0.22 0.92 OR Quart3 3.2 3.5 3.4 3.4 4.4 3.1 5.5 2.3 9.8 OR Quart 4 1.4 1.5 1.4 1.5 1.4 1.4 1.3 1.3 2.1 p Value 0.25 0.37 0.31 0.26 0.49 0.32 0.58 0.60 0.23 95% CI of 0.78 0.61 0.75 0.75 0.55 0.72 0.47 0.48 0.62 OR Quart4 2.5 3.8 2.5 2.8 3.5 2.7 3.8 3.6 7.3 C-peptide Urine sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 25100 20600 25100 14300 25100 19800 Average 36100 27800 36100 27800 36100 30800 Stdev 30900 26000 30900 28800 30900 26800 p(t-test) 0.0067 0.016 0.31 Min 0.00978 83.6 0.00978 53.8 0.00978 1500 Max 102000 100000 102000 103000 102000 93300 88 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 n (Samp) 271 140 271 108 271 38 n (Patient) 151 140 151 108 151 38 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 22200 12200 22200 18000 22200 26300 Average 32800 26900 32800 25600 32800 35700 Stdev 29800 28600 29800 26000 29800 28800 p(t-test) 0.23 0.14 0.63 Min 0.00978 0.0614 0.00978 0.0955 0.00978 53.8 Max 114000 100000 114000 100000 114000 100000 n (Samp) 666 40 666 39 666 25 n (Patient) 290 40 290 39 290 25 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 24400 21400 24400 13400 24400 16400 Average 34800 28500 34800 25700 34800 25300 Stdev 29800 26400 29800 28500 29800 24600 p(t-test) 0.039 0.0067 0.071 Min 0.00978 83.6 0.00978 53.8 0.00978 1500 Max 102000 100000 102000 103000 102000 93300 n (Samp) 316 127 316 105 316 35 n (Patient) 155 127 155 105 155 35 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.42 0.42 0.44 0.41 0.43 0.39 0.45 0.54 0.40 SE 0.030 0.048 0.031 0.033 0.049 0.033 0.051 0.060 0.053 p 0.011 0.11 0.044 0.0073 0.16 7.6E-4 0.32 0.49 0.057 nCohort 1 271 666 316 271 666 316 271 666 316 nCohort 2 140 40 127 108 39 105 38 25 35 Cutoff 1 9360 6880 9360 7850 7340 7820 9280 11700 7780 Sens 1 70% 70% 70% 70% 72% 70% 71% 72% 71% Spec 1 22% 18% 22% 18% 20% 19% 22% 31% 19% Cutoff 2 6520 4890 6490 6490 5860 6440 5690 10400 5700 Sens 2 80% 80% 80% 81% 82% 80% 82% 80% 80% Spec 2 16% 13% 16% 15% 15% 16% 14% 28% 14% Cutoff 3 2730 2000 2160 4320 4980 2670 3080 7180 3080 Sens 3 90% 90% 91% 91% 92% 90% 92% 92% 91% Spec 3 7% 6% 5% 11% 13% 5% 9% 19% 8% Cutoff 4 47300 39400 44200 47300 39400 44200 47300 39400 44200 Sens 4 18% 28% 20% 19% 21% 19% 29% 44% 20% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 64500 59500 60800 64500 59500 60800 64500 59500 60800 Sens 5 12% 15% 13% 13% 10% 14% 11% 20% 14% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 89700 85000 87200 89700 85000 87200 89700 85000 87200 Sens 6 4% 8% 5% 7% 5% 9% 3% 4% 3% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 2.2 1.6 1.7 1.3 1.9 1.2 1.7 2.7 1.2 p Value 0.012 0.33 0.096 0.39 0.22 0.57 0.31 0.14 0.77 89 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only 95% CI of 1.2 0.61 0.91 0.68 0.69 0.61 0.62 0.71 0.38 OR Quart2 4.0 4.3 3.1 2.6 5.3 2.5 4.6 10 3.7 OR Quart 3 1.5 0.85 1.3 1.3 1.2 1.7 1.0 2.0 1.4 p Value 0.21 0.78 0.43 0.39 0.77 0.12 0.98 0.32 0.58 95% CI of 0.80 0.28 0.69 0.68 0.39 0.87 0.34 0.50 0.45 OR Quart3 2.8 2.6 2.4 2.6 3.6 3.3 3.0 8.2 4.1 OR Quart 4 2.4 2.4 2.0 2.5 2.7 2.9 2.1 2.7 2.6 p Value 0.0044 0.057 0.024 0.0044 0.049 0.0012 0.15 0.14 0.061 95% CI of 1.3 0.97 1.1 1.3 1.0 1.5 0.77 0.71 0.96 OR Quart4 4.4 6.1 3.6 4.8 7.0 5.5 5.5 10 7.2 Gastric inhibitory polypeptide Urine sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.372 0.344 0.372 0.411 0.372 0.470 Average 19.8 14.0 19.8 69.4 19.8 81.9 Stdev 236 66.2 236 404 236 373 p(t-test) 0.77 0.14 0.16 Min 0.000104 9.60E-5 0.000104 9.60E-5 0.000104 0.000161 Max 3840 513 3840 3180 3840 2220 n (Samp) 271 140 271 108 271 38 n (Patient) 151 140 151 108 151 38 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.386 0.354 0.386 0.605 0.386 0.612 Average 20.3 19.2 20.3 87.0 20.3 123 Stdev 204 71.0 204 423 204 447 p(t-test) 0.97 0.068 0.020 Min 9.60E-5 9.60E-5 9.60E-5 0.000136 9.60E-5 0.000599 Max 3840 421 3840 2590 3840 2220 n (Samp) 667 40 667 39 667 25 n (Patient) 290 40 290 39 290 25 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.424 0.360 0.424 0.305 0.424 0.427 Average 34.6 10.5 34.6 52.2 34.6 33.9 Stdev 290 57.5 290 329 290 129 p(t-test) 0.35 0.60 0.99 Min 0.000104 9.60E-5 0.000104 9.60E-5 0.000104 9.60E-5 Max 3840 513 3840 3180 3840 647 n (Samp) 316 127 316 105 316 35 n (Patient) 155 127 155 105 155 35 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.48 0.51 0.46 0.49 0.60 0.45 0.53 0.59 0.48 SE 0.030 0.047 0.031 0.033 0.049 0.033 0.051 0.061 0.052 p 0.55 0.76 0.17 0.68 0.034 0.11 0.50 0.13 0.75 nCohort 1 271 667 316 271 667 316 271 667 1316 90 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only nCohort 2 140 40 127 108 39 105 38 25 35 Cutoff 1 0.134 0.186 0.125 0.0726 0.347 0.0484 0.246 0.246 0.164 Sens 1 70% 70% 70% 70% 72% 71% 71% 72% 71% Spec 1 30% 34% 26% 24% 47% 18% 39% 40% 29% Cutoff 2 0.0260 0.119 0.00355 0.00218 0.108 0.00355 0.0384 0.136 0.00982 Sens 2 80% 80% 80% 81% 82% 80% 82% 80% 80% Spec 2 20% 29% 16% 19% 28% 16% 21% 30% 16% Cutoff 3 0.000161 0.000599 0.000104 0.000232 0.00221 0.000232 0.000599 0.00511 0.000520 Sens 3 91% 90% 93% 92% 92% 91% 92% 92% 91% Spec 3 6% 14% 3% 7% 18% 7% 15% 19% 8% Cutoff 4 0.828 0.828 0.969 0.828 0.828 0.969 0.828 0.828 0.969 Sens 4 30% 32% 27% 31% 38% 27% 29% 40% 26% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 1.56 1.64 2.13 1.56 1.64 2.13 1.56 1.64 2.13 Sens 5 20% 18% 17% 20% 31% 18% 24% 24% 20% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 5.24 4.81 7.60 5.24 4.81 7.60 5.24 4.81 7.60 Sens 6 9% 12% 9% 12% 21% 10% 8% 20% 9% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 0.88 2.1 1.0 0.90 1.5 0.91 1.1 1.5 1.3 p Value 0.66 0.13 1.0 0.75 0.44 0.77 0.80 0.52 0.62 95% CI of 0.49 0.82 0.55 0.48 0.53 0.48 0.42 0.42 0.48 OR Quart2 1.6 5.3 1.8 1.7 4.4 1.7 3.1 5.5 3.4 OR Quart 3 1.1 1.6 0.95 0.61 1.7 0.81 1.4 1.8 1.0 p Value 0.77 0.34 0.88 0.14 0.31 0.53 0.46 0.36 1.0 95% CI of 0.61 0.61 0.53 0.31 0.61 0.42 0.54 0.51 0.36 OR Quart3 1.9 4.2 1.7 1.2 4.8 1.6 3.8 6.2 2.8 OR Quart 4 1.1 1.1 1.4 1.2 2.4 1.7 1.3 2.0 1.2 p Value 0.84 0.80 0.23 0.61 0.075 0.088 0.64 0.25 0.78 95% CI of 0.60 0.41 0.80 0.64 0.91 0.93 0.47 0.61 0.42 OR Quart4 1.9 3.2 2.5 2.2 6.5 3.1 3.4 6.9 3.1 Peptide YY Urine sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 4.33 7.08 4.33 10.6 4.33 2.38 Average 36.3 49.5 36.3 64.7 36.3 59.4 Stdev 89.9 123 89.9 181 89.9 173 p(t-test) 0.22 0.043 0.20 Min 0.00976 0.00976 0.00976 0.00976 0.00976 0.00976 Max 936 762 936 1200 936 959 n (Samp) 271 140 271 107 271 38 n (Patient) 151 140 151 107 151 38 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 3.26 10.6 3.26 22.3 3.26 11.4 Average 44.9 53.6 44.9 47.5 44.9 49.4 Stdev 123 114 123 81.6 123 96.5 p(t-test) 0.66 0.90 0.86 Min 0.00976 0.00976 0.00976 0.00976 0.00976 0.0188 Max 1200 502 1200 392 1200 450 91 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 n (Samp) 665 40 665 39 665 25 n (Patient) 290 40 290 39 290 25 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 10.1 7.08 10.1 9.24 10.1 2.92 Average 38.2 48.1 38.2 67.2 38.2 63.9 Stdev 87.3 119 87.3 185 87.3 183 p(t-test) 0.33 0.031 0.15 Min 0.00976 0.00976 0.00976 0.00976 0.00976 0.00976 Max 936 762 936 1200 936 959 n (Samp) 316 127 316 104 316 35 n (Patient) 155 127 155 104 155 35 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.50 0.54 0.48 0.52 0.61 0.50 0.49 0.58 0.47 SE 0.030 0.048 0.030 0.033 0.049 0.033 0.050 0.061 0.052 p 0.94 0.36 0.59 0.46 0.031 0.95 0.86 0.20 0.57 nCohort 1 271 665 316 271 665 316 271 665 316 nCohort 2 140 40 127 107 39 104 38 25 35 Cutoff 1 0.220 0.363 0.220 0.677 0.963 0.220 0.0196 0.817 0.0196 Sens 1 71% 72% 70% 72% 72% 71% 82% 72% 80% Spec 1 25% 32% 26% 32% 44% 26% 22% 41% 24% Cutoff 2 0.0151 0.220 0.0151 0.0188 0.677 0.0151 0.0196 0.677 0.0196 Sens 2 85% 80% 84% 80% 82% 82% 82% 80% 80% Spec 2 15% 30% 15% 18% 36% 15% 22% 36% 24% Cutoff 3 0.0101 0.0128 0.0101 0.0101 0.0151 0.0101 0.0128 0.0151 0.0128 Sens 3 94% 90% 93% 93% 95% 93% 95% 100% 94% Spec 3 5% 11% 5% 5% 18% 5% 8% 18% 8% Cutoff 4 26.8 27.4 35.3 26.8 27.4 35.3 26.8 27.4 35.3 Sens 4 32% 38% 24% 35% 41% 26% 26% 36% 20% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 42.3 42.7 48.2 42.3 42.7 48.2 42.3 42.7 48.2 Sens 5 19% 25% 20% 24% 31% 23% 21% 28% 20% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 86.8 101 97.4 86.8 101 97.4 86.8 101 97.4 Sens 6 12% 12% 10% 15% 10% 16% 11% 16% 11% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.3 1.3 1.3 0.80 2.6 0.81 1.1 1.5 1.2 p Value 0.38 0.63 0.45 0.49 0.11 0.52 0.78 0.53 0.79 95% CI of 0.73 0.49 0.69 0.42 0.80 0.43 0.44 0.42 0.40 OR Quart2 2.3 3.3 2.3 1.5 8.4 1.5 3.0 5.4 3.3 OR Quart 3 0.87 1.1 1.1 0.90 3.1 0.91 0.89 1.8 1.7 p Value 0.65 0.80 0.65 0.75 0.051 0.75 0.82 0.36 0.32 95% CI of 0.48 0.43 0.63 0.48 0.99 0.49 0.32 0.51 0.61 OR Quart3 1.6 3.0 2.1 1.7 10.0 1.7 2.4 6.2 4.5 OR Quart 4 1.3 1.7 1.4 1.0 3.4 0.91 1.3 2.0 1.3 p Value 0.43 0.27 0.28 0.91 0.034 0.75 0.61 0.25 0.58 95% CI of 0.71 0.67 0.77 0.56 1.1 0.49 0.50 0.60 0.47 OR Quart4 2.2 4.1 2.5 1.9 11 1.7 3.3 6.9 3.8 92 [0169] Table 2: Comparison of marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0 or R) and in urine samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage I or F in Cohort 2. Agouti-related protein sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.818 1.47 0.818 0.888 0.818 0.805 Average 1.41 1.95 1.41 1.29 1.41 1.12 Stdev 2.23 1.57 2.23 1.18 2.23 0.811 p(t-test) 0.083 0.65 0.47 Min 0.00318 0.00757 0.00318 0.0343 0.00318 0.00498 Max 20.0 6.53 20.0 6.12 20.0 2.60 n(Samp) 516 55 516 68 516 30 n (Patient) 222 55 222 68 222 30 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.879 0.811 0.879 0.794 0.879 0.892 Average 1.44 1.14 1.44 1.22 1.44 1.13 Stdev 2.00 1.02 2.00 1.46 2.00 0.744 p(t-test) 0.58 0.64 0.59 Min 0.00318 0.0556 0.00318 0.180 0.00318 0.186 Max 20.0 3.30 20.0 6.53 20.0 2.33 n(Samp) 736 14 736 18 736 12 n (Patient) 280 14 280 18 280 12 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.812 1.54 0.812 0.945 0.812 0.735 Average 1.36 2.05 1.36 1.37 1.36 1.06 Stdev 2.14 1.62 2.14 1.21 2.14 0.875 p(t-test) 0.030 0.97 0.49 Min 0.00198 0.00757 0.00198 0.0343 0.00198 0.00498 Max 20.0 6.53 20.0 6.12 20.0 2.60 n (Samp) 559 48 559 63 559 25 n (Patient) 225 48 225 63 225 25 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.65 0.48 0.67 0.54 0.48 0.57 0.52 0.52 0.49 SE 0.042 0.079 0.044 0.038 0.070 0.039 0.055 0.085 0.059 p 3.6E-4 0.78 1.2E-4 0.27 0.77 0.089 0.67 0.82 0.90 nCohort 1 516 736 559 516 736 559 516 736 559 nCohort 2 55 14 48 68 18 63 30 12 25 Cutoff 1 0.867 0.364 0.935 0.574 0.600 0.574 0.579 0.579 0.505 Sens 1 71% 71% 71% 71% 72% 71% 70% 75% 72% Spec 1 52% 24% 55% 38% 37% 38% 39% 36% 35% Cutoff 2 0.562 0.289 0.637 0.364 0.295 0.366 0.465 0.444 0.218 Sens 2 80% 86% 81% 81% 83% 81% 80% 83% 80% Spec 2 38% 20% 41% 27% 20% 27% 32% 28% 17% Cutoff 3 0.235 0.154 0.241 0.211 0.183 0.258 0.173 0.420 0.140 Sens 3 91% 93% 92% 91% 94% 90% 90% 92% 92% Spec 3 18% 11% 18% 16% 13% 20% 14% 27% 10% 93 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Cutoff 4 1.38 1.54 1.37 1.38 1.54 1.37 1.38 1.54 1.37 Sens 4 53% 29% 56% 38% 28% 44% 40% 42% 36% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 1.87 2.15 1.82 1.87 2.15 1.82 1.87 2.15 1.82 Sens 5 42% 21% 46% 21% 6% 29% 20% 17% 28% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 2.99 3.13 2.93 2.99 3.13 2.93 2.99 3.13 2.93 Sens 6 24% 7% 29% 9% 6% 10% 0% 0% 0% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 0.99 1.0 0.99 1.4 1.7 1.1 2.1 5.1 0.10 p Value 0.99 0.99 0.99 0.34 0.47 0.85 0.20 0.14 0.034 95% CI of 0.36 0.20 0.31 0.68 0.40 0.48 0.69 0.59 0.013 OR Quart2 2.7 5.0 3.2 3.1 7.2 2.5 6.2 44 0.84 OR Quart 3 2.0 1.0 2.1 1.3 2.0 1.4 0.79 3.0 1.0 p Value 0.14 1.0 0.16 0.56 0.32 0.43 0.74 0.34 1.0 95% CI of 0.80 0.20 0.76 0.58 0.50 0.63 0.21 0.31 0.39 OR Quart3 4.8 5.0 5.7 2.7 8.3 3.0 3.0 29 2.6 OR Quart 4 3.4 1.7 4.5 1.7 1.3 2.0 2.3 3.0 0.65 p Value 0.0044 0.47 0.0014 0.15 0.70 0.076 0.14 0.34 0.43 95% CI of 1.5 0.40 1.8 0.83 0.30 0.93 0.77 0.31 0.23 OR Quart4 7.8 7.2 11 3.6 6.1 4.1 6.8 29 1.9 Osteocalcin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 5840 6360 5840 7250 5840 6280 Average 7330 8630 7330 8860 7330 8330 Stdev 6430 8820 6430 8710 6430 8630 p(t-test) 0.071 0.032 0.28 Min 76.8 736 76.8 473 76.8 103 Max 83000 67800 83000 49400 83000 42300 n (Samp) 848 98 848 99 848 53 n (Patient) 374 98 374 99 374 53 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 6120 7200 6120 6050 6120 5900 Average 7910 10000 7910 8190 7910 8880 Stdev 7800 6900 7800 5970 7800 8730 p(t-test) 0.19 0.85 0.55 Min 76.8 1450 76.8 1330 76.8 1250 Max 83500 26800 83500 22900 83500 33400 n (Samp) 1223 23 1223 27 1223 24 n (Patient) 472 23 472 27 472 24 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 5920 6040 5920 7100 5920 6280 Average 7580 8220 7580 8560 7580 8280 Stdev 6760 8910 6760 8820 6760 8420 p(t-test) 0.41 0.21 0.50 Min 73.4 736 73.4 473 73.4 103 94 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max 83000 67800 83000 49400 83000 42300 n (Samp) 883 87 883 88 883 45 n(Patient) 361 87 361 88 361 45 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.54 0.62 0.51 0.55 0.54 0.53 0.49 0.51 0.49 SE 0.031 0.063 0.033 0.031 0.057 0.033 0.041 0.060 0.044 p 0.17 0.064 0.70 0.14 0.49 0.44 0.86 0.88 0.85 nCohort 1 848 1223 883 848 1223 883 848 1223 883 nCohort 2 98 23 87 99 27 88 53 24 45 Cutoff 1 4470 4590 4020 4300 4900 3790 3090 4430 3090 Sens 1 70% 74% 70% 71% 70% 70% 72% 71% 71% Spec 1 38% 38% 31% 36% 40% 30% 22% 36% 22% Cutoff 2 3410 4510 2720 3370 4310 3240 2700 3250 2450 Sens 2 81% 83% 80% 81% 81% 81% 81% 83% 80% Spec 2 27% 37% 18% 26% 35% 23% 18% 24% 15% Cutoff 3 2300 3520 2190 1920 1630 1920 1030 2700 584 Sens 3 91% 91% 91% 91% 93% 91% 91% 92% 91% Spec 3 15% 27% 13% 11% 8% 11% 4% 18% 1% Cutoff 4 8640 8880 8700 8640 8880 8700 8640 8880 8700 Sens 4 35% 43% 31% 37% 33% 35% 26% 25% 31% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 10400 11100 10800 10400 11100 10800 10400 11100 10800 Sens 5 27% 39% 23% 23% 22% 18% 26% 21% 27% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 14600 15300 15300 14600 15300 15300 14600 15300 15300 Sens 6 11% 17% 9% 12% 11% 8% 17% 12% 11% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.3 3.5 1.1 1.3 2.5 0.89 1.1 1.4 0.92 p Value 0.35 0.12 0.76 0.43 0.12 0.73 0.84 0.57 0.84 95% CI of 0.72 0.73 0.59 0.68 0.79 0.46 0.51 0.44 0.41 OR Quart2 2.5 17 2.1 2.4 8.2 1.7 2.3 4.5 2.1 OR Quart 3 1.4 2.0 1.1 1.5 1.5 1.4 0.49 1.4 0.37 p Value 0.34 0.42 0.75 0.17 0.53 0.23 0.13 0.57 0.064 95% CI of 0.72 0.37 0.59 0.83 0.42 0.79 0.19 0.44 0.13 OR Quart3 2.5 11 2.1 2.8 5.4 2.6 1.2 4.5 1.1 OR Quart 4 1.6 5.1 1.2 1.5 1.8 1.1 1.2 1.00 1.2 p Value 0.13 0.036 0.64 0.17 0.37 0.76 0.57 1.00 0.70 95% CI of 0.87 1.1 0.62 0.83 0.51 0.59 0.59 0.29 0.54 OR Quart4 2.9 24 2.2 2.8 6.1 2.1 2.6 3.5 2.5 Complement factor H sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 9.31 7.92 9.31 8.75 9.31 8.05 Average 18.9 15.8 18.9 18.5 18.9 14.0 Stdev 41.1 28.0 41.1 29.6 41.1 20.0 p(t-test) 0.54 0.93 0.45 Min 0.0620 0.113 0.0620 0.343 0.0620 0.121 Max 772 193 772 142 772 92.1 n (Samp) 599 70 599 79 599 40 95 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 n (Patient) 281 70 281 79 281 40 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 9.33 7.92 9.33 12.5 9.33 12.3 Average 18.6 16.4 18.6 25.4 18.6 17.0 Stdev 37.7 20.4 37.7 35.9 37.7 14.6 p(t-test) 0.85 0.45 0.86 Min 0.0620 3.87 0.0620 2.72 0.0620 0.832 Max 772 70.6 772 142 772 59.2 n (Samp) 829 10 829 18 829 16 n (Patient) 353 10 353 18 353 16 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 8.90 8.38 8.90 8.03 8.90 7.25 Average 18.6 16.7 18.6 16.1 18.6 12.7 Stdev 40.7 29.7 40.7 25.2 40.7 19.7 p(t-test) 0.71 0.60 0.39 Min 0.0620 0.113 0.0620 0.343 0.0620 0.121 Max 772 193 772 131 772 92.1 n (Samp) 608 66 608 74 608 35 n (Patient) 266 66 266 74 266 35 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.47 0.50 0.48 0.47 0.61 0.46 0.43 0.58 0.40 SE 0.037 0.092 0.038 0.035 0.071 0.036 0.049 0.075 0.052 p 0.41 0.99 0.51 0.45 0.14 0.25 0.14 0.32 0.049 nCohort 1 599 829 608 599 829 608 599 829 608 nCohort 2 70 10 66 79 18 74 40 16 35 Cutoff 1 5.90 6.66 5.27 4.91 9.39 4.95 4.28 8.64 4.04 Sens 1 70% 70% 71% 71% 72% 70% 70% 75% 71% Spec 1 30% 36% 25% 25% 50% 24% 21% 48% 18% Cutoff 2 4.11 6.40 4.11 3.87 6.57 3.87 3.03 6.01 3.03 Sens 2 80% 80% 80% 81% 83% 81% 80% 81% 80% Spec 2 20% 34% 20% 17% 36% 17% 13% 31% 13% Cutoff 3 3.03 3.87 2.60 2.26 4.58 2.26 2.52 2.41 2.54 Sens 3 90% 90% 91% 91% 94% 91% 90% 94% 91% Spec 3 13% 17% 10% 9% 22% 9% 10% 10% 10% Cutoff 4 16.1 15.9 15.6 16.1 15.9 15.6 16.1 15.9 15.6 Sens 4 23% 30% 23% 28% 39% 28% 20% 44% 17% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 24.0 22.8 23.5 24.0 22.8 23.5 24.0 22.8 23.5 Sens 5 13% 20% 14% 14% 22% 16% 15% 31% 11% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 40.5 40.3 40.3 40.5 40.3 40.3 40.5 40.3 40.3 Sens 6 6% 10% 6% 8% 11% 5% 8% 6% 6% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.3 0 1.5 1.1 0.66 1.2 1.7 1.5 2.3 p Value 0.45 na 0.26 0.72 0.65 0.57 0.31 0.65 0.17 95% CI of 0.64 na 0.73 0.58 0.11 0.60 0.61 0.25 0.70 96 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only OR Quart2 2.8 na 3.2 2.2 4.0 2.5 4.8 9.1 7.7 OR Quart 3 1.5 1.7 1.3 1.0 2.0 1.3 1.9 3.1 2.1 p Value 0.27 0.48 0.56 1.0 0.32 0.47 0.22 0.17 0.25 95% CI of 0.73 0.40 0.58 0.50 0.50 0.64 0.68 0.61 0.61 OR Quart3 3.1 7.1 2.7 2.0 8.2 2.7 5.3 15 7.0 OR Quart 4 1.3 0.67 1.4 1.3 2.4 1.5 2.3 2.5 3.8 p Value 0.45 0.66 0.34 0.39 0.22 0.22 0.10 0.27 0.022 95% CI of 0.64 0.11 0.68 0.69 0.60 0.77 0.85 0.48 1.2 OR Quart4 2.8 .0 3.0 2.6 9.3 3.1 6.2 13 12 Ciliary neurotrophic factor sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0787 0.000166 0.0787 0.0325 0.0787 0.0501 Average 0.270 0.130 0.270 0.162 0.270 0.166 Stdev 0.799 0.319 0.799 0.207 0.799 0.287 p(t-test) 0.20 0.27 0.48 Min 0.000103 0.000103 0.000103 0.000103 0.000103 0.000103 Max 14.0 2.14 14.0 0.866 14.0 1.42 n(Samp) 516 55 516 68 516 30 n (Patient) 222 55 222 68 222 30 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0452 0.00883 0.0452 0.0185 0.0452 0.0894 Average 0.233 0.0538 0.233 0.253 0.233 0.120 Stdev 0.709 0.0906 0.709 0.526 0.709 0.133 p(t-test) 0.35 0.90 0.58 Min 0.000103 0.000119 0.000103 0.000119 0.000103 0.000123 Max 14.0 0.290 14.0 2.14 14.0 0.360 n(Samp) 736 14 736 18 736 12 n (Patient) 280 14 280 18 280 12 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0551 0.00951 0.0551 0.0325 0.0551 0.0551 Average 0.249 0.148 0.249 0.158 0.249 0.192 Stdev 0.774 0.338 0.774 0.187 0.774 0.315 p(t-test) 0.37 0.35 0.71 Min 0.000103 0.000103 0.000103 0.000103 0.000103 0.000103 Max 14.0 2.14 14.0 0.778 14.0 1.42 n (Samp) 559 48 559 63 559 25 n (Patient) 225 48 225 63 225 25 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.37 0.41 0.41 0.47 0.51 0.49 0.46 0.52 0.51 SE 0.042 0.081 0.045 0.038 0.069 0.039 0.055 0.085 0.059 p 0.0021 0.24 0.052 0.37 0.91 0.88 0.49 0.85 0.93 nCohort 1 516 736 559 516 736 559 516 736 559 nCohort 2 55 14 48 68 18 63 30 12 25 97 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Cutoff 1 0.000121 0.000161 0.000121 0.000123 0.000161 0.000161 0.000161 0.000161 0.000123 Sens 1 73% 71% 71% 72% 72% 71% 70% 83% 76% Spec 1 18% 29% 19% 21% 29% 28% 25% 29% 24% Cutoff 2 0.000119 0.000121 0.000119 0.000119 0.000121 0.000119 0.000123 0.000161 0.000121 Sens 2 82% 93% 81% 85% 89% 86% 80% 83% 80% Spec 2 15% 22% 15% 15% 22% 15% 21% 29% 19% Cutoff 3 0.000103 0.000121 0 0.000103 0.000119 0.000103 0.000119 0.000123 0.000118 Sens 3 91% 93% 100% 96% 94% 95% 93% 92% 96% Spec 3 5% 22% 0% 5% 18% 4% 15% 26% 10% Cutoff 4 0.290 0.232 0.245 0.290 0.232 0.245 0.290 0.232 0.245 Sens 4 15% 7% 17% 25% 28% 32% 23% 17% 28% Spec 4 71% 71% 71% 71% 71% 71% 71% 71% 71% Cutoff 5 0.360 0.346 0.360 0.360 0.346 0.360 0.360 0.346 0.360 Sens 5 11% 0% 12% 18% 22% 16% 13% 8% 20% Spec 5 81% 80% 82% 81% 80% 82% 81% 80% 82% Cutoff 6 0.467 0.459 0.467 0.467 0.459 0.467 0.467 0.459 0.467 Sens 6 5% 0% 6% 9% 17% 6% 7% 0% 12% Spec 6 90% 90% 91% 90% 90% 91% 90% 90% 91% OR Quart 2 1.3 3.0 1.5 0.86 2.7 0.94 0.71 >6.2 1.0 p Value 0.63 0.34 0.36 0.70 0.14 0.86 0.57 <0.093 1.0 95% CI of 0.49 0.31 0.61 0.40 0.71 0.45 0.22 >0.74 0.31 OR Quart2 3.3 30 3.9 1.8 10 2.0 2.3 na 3.2 OR Quart 3 1.8 9.4 1.4 1.1 0.66 0.93 1.3 >4.1 1.0 p Value 0.19 0.034 0.48 0.85 0.65 0.85 0.61 <0.21 1.0 95% CI of 0.74 1.2 0.55 0.52 0.11 0.44 0.47 >0.45 0.31 OR Quart3 4.5 75 3.6 2.2 4.0 2.0 3.6 na 3.2 OR Quart 4 3.3 1.0 2.3 1.4 1.7 1.1 1.3 >2.0 1.2 p Value 0.0059 1.00 0.064 0.38 0.48 0.84 0.60 <0.57 0.78 95% CI of 1.4 0.062 0.95 0.68 0.39 0.52 0.48 >0.18 0.39 OR Quart4 7.6 16 5.5 2.7 7.1 2.2 3.6 na 3.6 Follitropin subunit beta sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 13.2 11.9 13.2 15.7 13.2 17.4 Average 30.3 22.7 30.3 27.2 30.3 31.0 Stdev 43.2 28.3 43.2 29.8 43.2 40.2 p(t-test) 0.20 0.57 0.93 Min 0.0800 1.24 0.0800 0.345 0.0800 0.474 Max 300 128 300 123 300 158 n(Samp) 516 55 516 68 516 30 n (Patient) 222 55 222 68 222 30 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 13.8 4.96 13.8 6.67 13.8 6.63 Average 29.5 6.97 29.5 16.8 29.5 24.2 Stdev 40.1 6.17 40.1 27.0 40.1 45.3 p(t-test) 0.036 0.18 0.65 Min 0.0800 1.68 0.0800 0.979 0.0800 1.58 Max 300 21.0 300 109 300 158 n(Samp) 736 14 736 18 736 12 98 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 n (Patient) 280 14 280 18 280 12 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 11.9 12.8 11.9 15.5 11.9 21.5 Average 28.4 24.6 28.4 28.2 28.4 36.6 Stdev 42.0 29.7 42.0 30.5 42.0 42.2 p(t-test) 0.55 0.97 0.34 Min 0.0800 1.24 0.0800 0.345 0.0800 0.474 Max 300 128 300 123 300 158 n (Samp) 559 48 559 63 559 25 n (Patient) 225 48 225 63 225 25 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.48 0.26 0.53 0.52 0.35 0.55 0.52 0.38 0.60 SE 0.041 0.077 0.044 0.038 0.071 0.039 0.055 0.087 0.061 p 0.68 0.0022 0.55 0.58 0.035 0.16 0.68 0.16 0.11 nCohort 1 516 736 559 516 736 559 516 736 559 nCohort 2 55 14 48 68 18 63 30 12 25 Cutoff 1 7.02 3.63 7.15 7.07 3.58 7.23 6.91 3.43 10.9 Sens 1 71% 71% 71% 71% 72% 71% 70% 75% 72% Spec 1 33% 16% 38% 34% 15% 38% 32% 15% 48% Cutoff 2 4.50 2.07 4.63 5.45 1.90 5.56 5.33 3.19 6.41 Sens 2 80% 86% 81% 81% 83% 81% 80% 83% 80% Spec 2 22% 9% 26% 27% 9% 30% 26% 13% 35% Cutoff 3 2.63 1.75 3.66 1.57 1.28 1.72 3.42 1.90 4.11 Sens 3 91% 93% 92% 91% 94% 90% 90% 92% 92% Spec 3 14% 8% 21% 8% 4% 10% 17% 9% 23% Cutoff 4 29.2 29.3 26.6 29.2 29.3 26.6 29.2 29.3 26.6 Sens 4 20% 0% 31% 32% 22% 33% 30% 17% 44% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 45.6 44.1 40.9 45.6 44.1 40.9 45.6 44.1 40.9 Sens 5 11% 0% 15% 18% 11% 29% 20% 17% 32% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 76.8 76.0 75.3 76.8 76.0 75.3 76.8 76.0 75.3 Sens 6 7% 0% 8% 12% 6% 13% 13% 8% 16% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 2.0 >2.0 2.0 1.3 1.5 3.1 1.2 1.0 1.0 p Value 0.11 <0.56 0.14 0.44 0.65 0.013 0.79 1.0 1.0 95% CI of 0.86 >0.18 0.80 0.63 0.25 1.3 0.38 0.14 0.25 OR Quart2 4.7 na 4.8 2.9 9.2 7.6 3.6 7.2 4.1 OR Quart 3 1.9 >4.1 2.0 1.5 2.5 2.4 1.5 1.0 2.3 p Value 0.15 <0.21 0.14 0.26 0.27 0.058 0.43 1.0 0.17 95% CI of 0.80 >0.45 0.80 0.73 0.49 0.97 0.53 0.14 0.70 OR Quart3 4.4 na 4.8 3.2 13 6.1 4.4 7.2 7.8 OR Quart 4 1.5 >8.4 1.3 1.5 4.2 3.1 1.3 3.1 2.1 p Value 0.37 <0.046 0.64 0.26 0.074 0.013 0.59 0.17 0.25 95% CI of 0.62 >1.0 0.48 0.73 0.87 1.3 0.45 0.61 0.61 OR Quart4 3.6 na 3.3 3.2 20 7.6 4.0 15 7.0 Follistatin 99 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 7.38 6.85 7.38 9.97 7.38 5.88 Average 31.8 13.6 31.8 29.5 31.8 19.1 Stdev 269 17.1 269 89.8 269 35.4 p(t-test) 0.54 0.93 0.73 Min 0.000347 0.0191 0.000347 0.0191 0.000347 0.0191 Max 8290 98.9 8290 840 8290 225 n (Samp) 1035 84 1035 92 1035 53 n (Patient) 397 84 397 92 397 53 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 7.59 13.9 7.59 9.74 7.59 16.4 Average 28.2 22.2 28.2 13.1 28.2 34.9 Stdev 232 29.4 232 12.7 232 50.1 p(t-test) 0.92 0.75 0.89 Min 0.000347 2.94 0.000347 0.0191 0.000347 0.0191 Max 8290 125 8290 49.9 8290 222 n (Samp) 1406 16 1406 24 1406 22 n (Patient) 496 16 496 24 496 22 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 7.46 6.94 7.46 11.5 7.46 6.64 Average 32.1 38.9 32.1 46.4 32.1 18.7 Stdev 278 225 278 164 278 35.7 p(t-test) 0.83 0.64 0.74 Min 0.000347 0.0191 0.000347 0.0412 0.000347 0.0767 Max 8290 2010 8290 1300 8290 225 n (Samp) 967 79 967 87 967 46 n (Patient) 338 79 338 87 338 46 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.50 0.63 0.50 0.56 0.54 0.58 0.48 0.63 0.48 SE 0.033 0.075 0.034 0.032 0.061 0.033 0.041 0.064 0.044 p 0.92 0.076 0.90 0.057 0.48 0.014 0.57 0.042 0.71 nCohort 1 1035 1406 967 1035 1406 967 1035 1406 967 nCohort 2 84 16 79 92 24 87 53 22 46 Cutoff 1 4.11 5.90 3.64 5.00 6.66 5.46 2.49 5.84 2.49 Sens 1 70% 75% 71% 71% 71% 70% 72% 73% 72% Spec 1 32% 42% 30% 37% 46% 40% 21% 42% 21% Cutoff 2 2.80 5.88 2.31 3.10 3.98 3.10 1.55 4.77 1.64 Sens 2 81% 81% 81% 80% 83% 80% 81% 82% 80% Spec 2 23% 42% 19% 25% 31% 25% 14% 36% 14% Cutoff 3 0.765 4.11 0.541 1.24 0.418 1.26 0.820 3.36 0.820 Sens 3 90% 94% 91% 90% 92% 91% 91% 91% 91% Spec 3 9% 32% 7% 11% 7% 10% 9% 27% 8% Cutoff 4 14.1 14.1 14.1 14.1 14.1 14.1 14.1 14.1 14.1 Sens 4 30% 50% 29% 41% 29% 45% 32% 50% 35% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 23.6 22.6 22.7 23.6 22.6 22.7 23.6 22.6 22.7 Sens 5 14% 31% 18% 26% 17% 32% 23% 45% 20% 100 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 45.8 43.6 43.2 45.8 43.6 43.2 45.8 43.6 43.2 Sens 6 7% 6% 11% 17% 8% 22% 13% 27% 13% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.1 5.0 1.1 1.1 2.0 0.94 0.42 3.0 0.61 p Value 0.74 0.14 0.86 0.75 0.33 0.85 0.062 0.18 0.27 95% CI of 0.58 0.59 0.55 0.58 0.50 0.47 0.17 0.61 0.25 OR Quart2 2.1 43 2.0 2.1 8.1 1.9 1.0 15 1.5 OR Quart 3 1.3 4.0 1.1 1.1 3.4 1.1 0.74 1.5 0.68 p Value 0.35 0.21 0.74 0.75 0.065 0.86 0.44 0.66 0.39 95% CI of 0.72 0.45 0.58 0.58 0.93 0.54 0.34 0.25 0.29 OR Quart3 2.5 36 2.1 2.1 12 2.1 1.6 9.1 1.6 OR Quart 4 1.0 6.1 1.0 1.7 1.7 1.9 1.1 5.6 1.3 p Value 0.99 0.096 0.99 0.080 0.48 0.030 0.72 0.025 0.56 95% CI of 0.52 0.73 0.52 0.94 0.40 1.1 0.57 1.2 0.59 OR Quart4 1.9 51 1.9 3.1 7.0 3.5 2.3 26 2.7 Vitamin D-binding protein sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 200 296 200 391 200 159 Average 7290 14000 7290 14000 7290 17600 Stdev 34200 47100 34200 57800 34200 67900 p(t-test) 0.21 0.19 0.16 Min 0.259 1.50 0.259 1.39 0.259 0.337 Max 365000 283000 365000 379000 365000 347000 n (Samp) 456 49 456 63 456 26 n (Patient) 202 49 202 63 202 26 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 217 291 217 567 217 357 Average 7890 7050 7890 1570 7890 40400 Stdev 35900 13100 35900 3000 35900 115000 p(t-test) 0.95 0.50 0.011 Min 0.259 6.04 0.259 54.6 0.259 0.612 Max 379000 34100 379000 11000 379000 347000 n (Samp) 634 8 634 15 634 9 n (Patient) 259 8 259 15 259 9 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 203 278 203 381 203 173 Average 8460 14000 8460 14600 8460 4310 Stdev 37700 49000 37700 59200 37700 11100 p(t-test) 0.36 0.27 0.60 Min 0.200 1.50 0.200 1.39 0.200 0.337 Max 365000 283000 365000 379000 365000 51700 n (Samp) 482 45 482 60 482 23 n (Patient) 202 45 202 60 202 23 101 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.57 0.51 0.55 0.59 0.61 0.59 0.49 0.53 0.49 SE 0.045 0.10 0.046 0.040 0.078 0.041 0.059 0.099 0.062 p 0.11 0.92 0.25 0.018 0.17 0.031 0.82 0.77 0.92 nCohort 1 456 634 482 456 634 482 456 634 482 nCohort 2 49 8 45 63 15 60 26 9 23 Cutoff 1 158 69.4 143 152 124 156 36.6 80.3 70.1 Sens 1 71% 75% 71% 71% 73% 70% 73% 78% 74% Spec 1 43% 22% 40% 41% 36% 42% 12% 27% 23% Cutoff 2 69.4 15.6 101 94.1 111 98.6 11.7 0.892 33.9 Sens 2 82% 88% 80% 81% 80% 80% 81% 89% 83% Spec 2 23% 7% 32% 31% 33% 31% 6% 1% 11% Cutoff 3 6.72 5.93 6.72 53.2 79.5 52.2 0.892 0.611 9.75 Sens 3 92% 100% 91% 90% 93% 90% 92% 100% 91% Spec 3 4% 4% 5% 20% 26% 18% 1% 0% 5% Cutoff 4 476 498 498 476 498 498 476 498 498 Sens 4 39% 38% 31% 46% 53% 43% 38% 44% 39% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 1080 1530 1490 1080 1530 1490 1080 1530 1490 Sens 5 27% 25% 22% 32% 13% 25% 38% 22% 35% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 9170 10300 13600 9170 10300 13600 9170 10300 13600 Sens 6 16% 25% 11% 13% 7% 12% 15% 22% 9% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 0.48 0 0.65 2.0 4.1 1.8 0.19 0.99 0.36 p Value 0.19 na 0.42 0.14 0.21 0.19 0.034 0.99 0.14 95% CI of 0.16 na 0.22 0.81 0.45 0.74 0.040 0.14 0.094 OR Quart2 1.4 na 1.9 4.8 37 4.5 0.88 7.1 1.4 OR Quart 3 2.2 1.0 2.1 2.4 4.1 2.3 0.48 0.49 0.61 p Value 0.056 1.0 0.076 0.046 0.21 0.064 0.19 0.57 0.41 95% CI of 0.98 0.20 0.92 1.0 0.45 0.95 0.16 0.044 0.20 OR Quart3 4.9 5.0 5.0 5.8 37 5.5 1.4 5.5 1.9 OR Quart 4 1.4 0.66 1.4 3.1 6.2 2.9 0.90 2.0 0.88 p Value 0.40 0.65 0.51 0.0094 0.094 0.014 0.83 0.42 0.80 95% CI of 0.61 0.11 0.55 1.3 0.73 1.2 0.35 0.36 0.31 OR Quart4 3.4 4.0 3.3 7.2 52 6.8 2.3 11 2.5 Glucagon sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 238 347 238 238 238 347 Average 1460 3460 1460 1550 1460 3800 Stdev 2840 4170 2840 3090 2840 4460 p(t-test) 0.0027 0.87 0.0023 Min 1.53 6.86 1.53 0.0247 1.53 6.71 Max 9330 9330 9330 9330 9330 9330 n (Samp) 248 22 248 32 248 16 n (Patient) 160 22 160 32 160 16 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 238 206 238 9330 Average nd nd 1720 536 1720 7060 102 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Stdev nd nd 3110 930 3110 3930 p(t-test) nd nd 0.35 1.1E-5 Min nd nd 0.0247 9.15 0.0247 347 Max nd nd 9330 2420 9330 9330 n (Samp) nd nd 314 6 314 7 n (Patient) nd nd 187 6 187 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 238 347 238 238 238 347 Average 1380 3460 1380 1620 1380 3280 Stdev 2700 4170 2700 3220 2700 4430 p(t-test) 0.0013 0.65 0.013 Min 1.53 6.86 1.53 0.0247 1.53 6.71 Max 9330 9330 9330 9330 9330 9330 n (Samp) 216 22 216 29 216 15 n (Patient) 133 22 133 29 133 15 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.73 nd 0.73 0.47 0.45 0.46 0.71 0.87 0.66 SE 0.063 nd 0.063 0.055 0.12 0.058 0.074 0.087 0.079 p 3.6E-4 nd 3.6E-4 0.55 0.70 0.51 0.0043 2.1E-5 0.040 nCohort 1 248 nd 216 248 314 216 248 314 216 nCohort 2 22 nd 22 32 6 29 16 7 15 Cutoff 1 275 nd 238 8.98 30.4 8.64 275 4790 174 Sens 1 82% nd 82% 72% 83% 72% 75% 71% 87% Spec 1 58% nd 57% 23% 29% 23% 58% 87% 38% Cutoff 2 275 nd 238 7.71 30.4 7.20 174 677 174 Sens 2 82% nd 82% 81% 83% 83% 94% 86% 87% Spec 2 58% nd 57% 20% 29% 17% 39% 73% 38% Cutoff 3 174 nd 174 5.98 8.98 5.82 174 275 30.4 Sens 3 95% nd 95% 91% 100% 93% 94% 100% 93% Spec 3 39% nd 38% 12% 21% 11% 39% 55% 31% Cutoff 4 347 nd 347 347 347 347 347 347 347 Sens 4 45% nd 45% 25% 17% 24% 44% 86% 33% Spec 4 74% nd 74% 74% 72% 74% 74% 72% 74% Cutoff 5 2420 nd 2420 2420 2420 2420 2420 2420 2420 Sens 5 32% nd 32% 12% 0% 14% 38% 71% 33% Spec 5 89% nd 90% 89% 86% 90% 89% 86% 90% Cutoff 6 9330 nd 4790 9330 9330 4790 9330 9330 4790 Sens 6 0% nd 32% 0% 0% 14% 0% 0% 33% Spec 6 100% nd 91% 100% 100% 91% 100% 100% 91% OR Quart 2 3.0 nd 3.1 0.73 1.0 0.70 1.0 >0 4.1 p Value 0.34 nd 0.34 0.57 1.0 0.56 1.0 <na 0.21 95% CI of 0.31 nd 0.31 0.24 0.061 0.21 0.061 >na 0.45 OR Quart2 30 nd 30 2.2 16 2.3 16 na 38 OR Quart 3 10 nd 9.1 0.86 3.1 1.0 7.7 >1.0 5.3 p Value 0.030 nd 0.041 0.78 0.33 0.97 0.060 <0.99 0.13 95% CI of 1.3 nd 1.1 0.29 0.31 0.33 0.92 >0.062 0.60 OR Quart3 83 nd 75 2.5 30 3.1 65 na 47 OR Quart 4 10 nd 12 1.4 1.0 1.5 7.7 >6.4 5.3 p Value 0.031 nd 0.022 0.46 1.0 0.41 0.060 <0.089 0.13 103 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only 95% CI of 1.2 nd 1.4 0.54 0.061 0.55 0.92 >0.75 0.60 OR Quart4 82 nd 94 3.8 16 4. 65 na 47 Glucagon-like peptide 1 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 3.10 2.30 3.10 5.53 3.10 1.20 Average 9.80 3.72 9.80 9.62 9.80 3.20 Stdev 46.0 3.46 46.0 19.0 46.0 3.66 p(t-test) 0.54 0.98 0.57 Min 0.407 0.407 0.407 0.407 0.407 0.407 Max 519 9.60 519 107 519 9.60 n (Samp) 248 22 248 32 248 16 n (Patient) 160 22 160 32 160 16 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 3.10 5.53 3.10 2.30 Average nd nd 9.04 5.71 9.04 3.67 Stdev nd nd 41.4 3.73 41.4 4.10 p(t-test) nd nd 0.84 0.73 Min nd nd 0.407 0.407 0.407 0.407 Max nd nd 519 10.1 519 11.8 n (Samp) nd nd 314 6 314 7 n (Patient) nd nd 187 6 187 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 3.10 2.70 3.10 5.53 3.10 0.685 Average 10.4 4.04 10.4 9.74 10.4 3.36 Stdev 49.3 3.46 49.3 20.0 49.3 3.76 p(t-test) 0.55 0.94 0.58 Min 0.407 0.407 0.407 0.407 0.407 0.407 Max 519 9.60 519 107 519 9.60 n (Samp) 216 22 216 29 216 15 n (Patient) 133 22 133 29 133 15 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.39 nd 0.43 0.56 0.59 0.54 0.34 0.40 0.36 SE 0.066 nd 0.066 0.055 0.12 0.058 0.076 0.11 0.079 p 0.11 nd 0.29 0.30 0.47 0.51 0.038 0.41 0.080 nCohort 1 248 nd 216 248 314 216 248 314 216 nCohort 2 22 nd 22 32 6 29 16 7 15 Cutoff 1 0.407 nd 0.685 2.30 2.30 0.685 0 0.685 0 Sens 1 73% nd 73% 72% 83% 79% 100% 71% 100% Spec 1 13% nd 17% 31% 35% 17% 0% 20% 0% Cutoff 2 0 nd 0 0.685 2.30 0.407 0 0.407 0 Sens 2 100% nd 100% 81% 83% 90% 100% 86% 100% Spec 2 0% nd 0% 17% 35% 14% 0% 14% 0% Cutoff 3 0 nd 0 0.407 0 0 0 0 0 104 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 3 100% nd 100% 91% 100% 100% 100% 100% 100% Spec 3 0% nd 0% 13% 0% 0% 0% 0% 0% Cutoff 4 5.53 nd 5.53 5.53 5.53 5.53 5.53 5.53 5.53 Sens 4 32% nd 36% 34% 33% 31% 25% 29% 27% Spec 4 71% nd 71% 71% 70% 71% 71% 70% 71% Cutoff 5 9.60 nd 9.60 9.60 9.60 9.60 9.60 9.60 9.60 Sens 5 0% nd 0% 16% 17% 14% 0% 14% 0% Spec 5 93% nd 93% 93% 94% 93% 93% 94% 93% Cutoff 6 9.60 nd 9.60 9.60 9.60 9.60 9.60 9.60 9.60 Sens 6 0% nd 0% 16% 17% 14% 0% 14% 0% Spec 6 93% nd 93% 93% 94% 93% 93% 94% 93% OR Quart 2 2.1 nd 2.6 0.41 1.0 0.84 0.66 1.0 0.65 p Value 0.30 nd 0.19 0.16 1.0 0.77 0.65 0.99 0.65 95% CI of 0.51 nd 0.63 0.12 0.061 0.27 0.11 0.062 0.11 OR Quart2 8.9 nd 10 1.4 16 2.7 4.1 16 4.1 OR Quart 3 1.0 nd 1.4 0.87 2.0 1.0 0.66 2.1 0.65 p Value 1.0 nd 0.70 0.80 0.57 1.0 0.65 0.56 0.65 95% CI of 0.19 nd 0.29 0.32 0.18 0.33 0.11 0.18 0.11 OR Quart3 5.1 nd 6.3 2.4 23 3.0 4.1 23 4.1 OR Quart 4 3.8 nd 3.0 1.3 2.0 1.3 3.3 3.1 3.0 p Value 0.051 nd 0.12 0.63 0.57 0.62 0.083 0.33 0.12 95% CI of 1.00 nd 0.75 0.49 0.18 0.45 0.86 0.32 0.75 OR Quart4 14 nd 12 3.3 23 3.8 13 31 12 Appetite-regulating hormone sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.232 0.170 0.232 0.560 0.232 0.108 Average 0.890 0.997 0.890 2.97 0.890 0.599 Stdev 1.25 1.15 1.25 11.5 1.25 0.855 p(t-test) 0.70 0.0061 0.36 Min 0.0793 0.0793 0.0793 0.0793 0.0793 0.0793 Max 8.07 4.38 8.07 65.5 8.07 2.67 n (Samp) 248 22 248 32 248 16 n (Patient) 160 22 160 32 160 16 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 0.232 1.15 0.232 0.0793 Average nd nd 1.07 1.36 1.07 0.688 Stdev nd nd 3.84 1.05 3.84 1.07 p(t-test) nd nd 0.85 0.79 Min nd nd 0.0793 0.232 0.0793 0.0793 Max nd nd 65.5 2.67 65.5 2.67 n (Samp) nd nd 314 6 314 7 n (Patient) nd nd 187 6 187 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.232 0.131 0.232 0.560 0.232 0.108 Average 0.890 1.05 0.890 3.08 0.890 0.471 Stdev 1.28 1.38 1.28 12.1 1.28 0.671 105 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) 0.57 0.0099 0.21 Min 0.0793 0.0793 0.0793 0.0793 0.0793 0.0793 Max 8.07 4.55 8.07 65.5 8.07 1.75 n (Samp) 216 22 216 29 216 15 n (Patient) 133 22 133 29 133 15 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.43 nd 0.42 0.55 0.72 0.53 0.35 0.29 0.34 SE 0.066 nd 0.066 0.055 0.12 0.058 0.076 0.11 0.079 p 0.32 nd 0.23 0.41 0.062 0.65 0.044 0.057 0.040 nCohort 1 248 nd 216 248 314 216 248 314 216 nCohort 2 22 nd 22 32 6 29 16 7 15 Cutoff 1 0 nd 0 0.193 0.398 0.0995 0 0 0 Sens 1 100% nd 100% 72% 83% 79% 100% 100% 100% Spec 1 0% nd 0% 34% 56% 17% 0% 0% 0% Cutoff 2 0 nd 0 0.0995 0.398 0.0793 0 0 0 Sens 2 100% nd 100% 81% 83% 86% 100% 100% 100% Spec 2 0% nd 0% 17% 56% 8% 0% 0% 0% Cutoff 3 0 nd 0 0 0.193 0 0 0 0 Sens 3 100% nd 100% 100% 100% 100% 100% 100% 100% Spec 3 0% nd 0% 0% 38% 0% 0% 0% 0% Cutoff 4 0.560 nd 0.560 0.560 0.560 0.560 0.560 0.560 0.560 Sens 4 45% nd 41% 31% 50% 28% 25% 29% 20% Spec 4 73% nd 74% 73% 73% 74% 73% 73% 74% Cutoff 5 1.75 nd 1.75 1.75 1.75 1.75 1.75 1.75 1.75 Sens 5 9% nd 14% 22% 33% 17% 6% 14% 0% Spec 5 83% nd 83% 83% 84% 83% 83% 84% 83% Cutoff 6 2.67 nd 2.67 2.67 2.67 2.67 2.67 2.67 2.67 Sens 6 5% nd 9% 6% 0% 7% 0% 0% 0% Spec 6 93% nd 93% 93% 94% 93% 93% 94% 93% OR Quart 2 0 nd 0.27 1.2 >1.0 0.84 0.24 0 0.32 p Value na nd 0.11 0.77 <0.99 0.77 0.21 na 0.33 95% CI of na nd 0.053 0.38 >0.062 0.27 0.026 na 0.032 OR Quart2 na nd 1.3 3.7 na 2.7 2.2 na 3.2 OR Quart 3 0.18 nd 0.40 1.6 >2.1 1.2 1.3 0 1.0 p Value 0.029 nd 0.20 0.42 <0.56 0.78 0.73 na 1.0 95% CI of 0.037 nd 0.098 0.53 >0.18 0.39 0.33 na 0.19 OR Quart3 0.84 nd 1.6 4.7 na 3.4 5.0 na 5.2 OR Quart 4 1.0 nd 1.5 1.8 >3.1 1.1 1.6 2.6 3.0 p Value 0.97 nd 0.41 0.29 <0.33 0.81 0.51 0.26 0.12 95% CI of 0.39 nd 0.55 0.61 >0.32 0.39 0.42 0.50 0.75 OR Quart4 2.6 nd 4.4 5.2 na 3.4 5.8 14 12 Islet amyloid polypeptide sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.227 0.0924 0.227 0.336 0.227 0.00270 Average 2.46 0.398 2.46 1.52 2.46 0.129 Stdev 10.5 0.690 10.5 4.16 10.5 0.222 p(t-test) 0.36 0.61 0.38 Min 0.00151 0.00151 0.00151 0.00151 0.00151 0.00151 106 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max 102 2.41 102 23.2 102 0.618 n (Samp) 248 22 248 32 248 16 n (Patient) 160 22 160 32 160 16 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 0.214 1.56 0.214 0.00187 Average nd nd 3.09 5.04 3.09 0.176 Stdev nd nd 14.4 9.05 14.4 0.218 p(t-test) nd nd 0.74 0.59 Min nd nd 0.00151 0.00945 0.00151 0.00151 Max nd nd 136 23.2 136 0.444 n (Samp) nd nd 314 6 314 7 n (Patient) nd nd 187 6 187 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.252 0.0924 0.252 0.227 0.252 0.00571 Average 2.21 0.404 2.21 0.733 2.21 1.66 Stdev 8.89 0.688 8.89 1.23 8.89 5.96 p(t-test) 0.34 0.37 0.81 Min 0.00151 0.00151 0.00151 0.00151 0.00151 0.00151 Max 84.9 2.41 84.9 5.59 84.9 23.2 n (Samp) 216 22 216 29 216 15 n (Patient) 133 22 133 29 133 15 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.42 nd 0.42 0.52 0.66 0.46 0.26 0.28 0.31 SE 0.066 nd 0.066 0.055 0.12 0.058 0.073 0.11 0.078 p 0.23 nd 0.23 0.74 0.18 0.51 8.OE-4 0.047 0.013 nCohort 1 248 nd 216 248 314 216 248 314 216 nCohort 2 22 nd 22 32 6 29 16 7 15 Cutoff 1 0.00571 nd 0.00571 0.00571 0.0290 0.00369 0 0 0.00151 Sens 1 73% nd 77% 75% 83% 76% 100% 100% 73% Spec 1 30% nd 27% 30% 38% 15% 0% 0% 5% Cutoff 2 0.00151 nd 0.00151 0.00369 0.0290 0.00187 0 0 0 Sens 2 91% nd 91% 81% 83% 86% 100% 100% 100% Spec 2 6% nd 5% 19% 38% 11% 0% 0% 0% Cutoff 3 0.00151 nd 0.00151 0.00187 0.00571 0.00151 0 0 0 Sens 3 91% nd 91% 91% 100% 93% 100% 100% 100% Spec 3 6% nd 5% 11% 32% 5% 0% 0% 0% Cutoff 4 0.914 nd 1.04 0.914 0.631 1.04 0.914 0.631 1.04 Sens 4 9% nd 9% 22% 50% 17% 0% 0% 7% Spec 4 70% nd 70% 70% 70% 70% 70% 70% 70% Cutoff 5 1.50 nd 1.50 1.50 1.42 1.50 1.50 1.42 1.50 Sens 5 9% nd 9% 19% 50% 14% 0% 0% 7% Spec 5 80% nd 80% 80% 80% 80% 80% 80% 80% Cutoff 6 2.46 nd 2.35 2.46 2.41 2.35 2.46 2.41 2.35 Sens 6 0% nd 5% 16% 50% 10% 0% 0% 7% Spec 6 90% nd 91% 90% 90% 91% 90% 90% 91% OR Quart 2 3.8 nd 3.3 1.3 >3.1 2.0 >3.1 >3.2 2.0 107 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only p Value 0.10 nd 0.16 0.60 <0.33 0.25 <0.33 <0.32 0.57 95% CI of 0.77 nd 0.63 0.47 >0.32 0.62 >0.32 >0.32 0.18 OR Quart2 19 nd 17 3.8 na 6.3 na na 23 OR Quart 3 3.8 nd 5.1 1.3 >0 1.2 >4.3 >0 5.4 p Value 0.10 nd 0.043 0.60 <na 0.73 <0.20 <na 0.13 95% CI of 0.76 nd 1.1 0.47 >na 0.36 >0.46 >na 0.61 OR Quart3 19 nd 25 3.8 na 4.3 na na 48 OR Quart 4 3.2 nd 2.7 1.0 >3.1 2.0 >10 >4.3 8.0 p Value 0.16 nd 0.25 1.0 <0.33 0.25 <0.028 <0.20 0.056 95% CI of 0.63 nd 0.50 0.33 >0.32 0.62 >1.3 >0.47 0.95 OR Quart4 17 nd 14 3.0 na 6.3 na na 67 Interleukin-17A sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.00360 0.00320 0.00360 0.00444 0.00360 0.00332 Average 1.16 0.678 1.16 0.969 1.16 0.321 Stdev 8.66 2.08 8.66 4.28 8.66 1.27 p(t-test) 0.56 0.82 0.44 Min 0.000344 0.000344 0.000344 0.000344 0.000344 0.000380 Max 157 13.4 157 39.1 157 9.17 n (Samp) 1288 112 1288 113 1288 65 n (Patient) 488 112 488 113 488 65 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.00360 0.00409 0.00360 0.00360 0.00360 0.00233 Average 0.983 0.852 0.983 0.190 0.983 0.938 Stdev 7.46 2.27 7.46 0.458 7.46 2.59 p(t-test) 0.92 0.54 0.97 Min 0.000344 0.000344 0.000344 0.000380 0.000344 0.000380 Max 157 9.48 157 2.17 157 10.2 n (Samp) 1805 29 1805 33 1805 30 n (Patient) 610 29 610 33 610 30 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.00337 0.00320 0.00337 0.00492 0.00337 0.00332 Average 1.10 1.20 1.10 1.45 1.10 0.348 Stdev 8.55 4.21 8.55 4.99 8.55 1.37 p(t-test) 0.91 0.69 0.51 Min 0.000344 0.000344 0.000344 0.000344 0.000344 0.000380 Max 157 33.1 157 39.1 157 9.17 n (Samp) 1247 100 1247 102 1247 55 n (Patient) 430 100 430 102 430 55 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.49 0.55 0.51 0.52 0.46 0.56 0.46 0.46 0.47 SE 0.029 0.055 0.030 0.029 0.052 0.030 0.037 0.054 0.040 p 0.78 0.41 0.66 0.47 0.47 0.063 0.25 0.47 0.41 108 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only nCohort 1 1288 1805 1247 1288 1805 1247 1288 1805 1247 nCohort 2 112 29 100 113 33 102 65 30 55 Cutoff 1 0.000747 0.00172 0.00126 0.00174 0.000734 0.00190 0.000747 0.000734 0.000747 Sens 1 71% 72% 70% 71% 73% 71% 71% 70% 73% Spec 1 19% 26% 25% 26% 19% 33% 19% 19% 23% Cutoff 2 0.000603 0.000662 0.000603 0.000603 0.000410 0.000603 0.000603 0.000662 0.000603 Sens 2 80% 86% 81% 81% 82% 81% 80% 80% 80% Spec 2 13% 17% 15% 13% 6% 15% 13% 17% 15% Cutoff 3 0.000381 0.000380 0.000410 0.000381 0.000380 0.000381 0.000410 0.000410 0.000410 Sens 3 91% 97% 90% 92% 91% 92% 92% 93% 93% Spec 3 4% 3% 7% 4% 3% 5% 5% 6% 7% Cutoff 4 0.00875 0.00875 0.00875 0.00875 0.00875 0.00875 0.00875 0.00875 0.00875 Sens 4 38% 41% 38% 36% 27% 41% 28% 37% 24% Spec 4 71% 70% 71% 71% 70% 71% 71% 70% 71% Cutoff 5 0.111 0.143 0.121 0.111 0.143 0.121 0.111 0.143 0.121 Sens 5 27% 28% 28% 30% 24% 33% 20% 27% 16% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 0.748 0.819 0.791 0.748 0.819 0.791 0.748 0.819 0.791 Sens 6 16% 21% 18% 11% 6% 15% 8% 13% 7% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 0.55 0.62 0.68 0.49 1.0 0.53 0.70 0.22 1.2 p Value 0.037 0.40 0.19 0.021 1.00 0.059 0.35 0.053 0.68 95% CI of 0.31 0.20 0.38 0.27 0.37 0.28 0.33 0.047 0.54 OR Quart2 0.97 1.9 1.2 0.90 2.7 1.0 1.5 1.0 2.6 OR Quart 3 0.57 0.75 0.48 0.84 0.62 0.84 0.82 1.0 1.0 p Value 0.053 0.59 0.023 0.50 0.41 0.56 0.59 1.0 1.0 95% CI of 0.33 0.26 0.25 0.49 0.20 0.47 0.40 0.39 0.44 OR Quart3 1.0 2.2 0.90 1.4 1.9 1.5 1.7 2.5 2.3 OR Quart 4 1.0 1.3 1.1 1.1 1.5 1.4 1.3 1.1 1.4 p Value 0.90 0.64 0.61 0.81 0.37 0.19 0.41 0.81 0.34 95% CI of 0.63 0.49 0.68 0.65 0.61 0.84 0.69 0.45 0.68 OR Quart4 1.7 3.2 1.9 1.8 3.7 2.4 2.5 2.8 3.1 Insulin receptor substrate 1 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.78E-5 4.51E-6 2.78E-5 0.000827 2.78E-5 1.91E-5 Average 0.00323 0.00112 0.00323 0.00901 0.00323 0.000954 Stdev 0.0331 0.00267 0.0331 0.0379 0.0331 0.00137 p(t-test) 0.64 0.18 0.71 Min 1.25E-9 1.25E-9 1.25E-9 1.25E-9 1.25E-9 1.25E-9 Max 0.735 0.0142 0.735 0.282 0.735 0.00563 n (Samp) 515 55 515 68 515 30 n (Patient) 222 55 222 68 222 30 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.78E-5 0.00144 2.78E-5 0.00137 2.78E-5 0.00101 Average 0.00330 0.00249 0.00330 0.00152 0.00330 0.00144 Stdev 0.0301 0.00302 0.0301 0.00169 0.0301 0.00172 p(t-test) 0.92 0.80 0.83 Min 1.25E-9 7.25E-7 1.25E-9 7.25E-7 1.25E-9 9.90E-7 109 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max 0.735 0.00914 0.735 0.00552 0.735 0.00563 n (Samp) 734 14 734 18 734 12 n (Patient) 280 14 280 18 280 12 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 4.40E-5 2.32E-6 4.40E-5 4.40E-5 4.40E-5 4.51E-6 Average 0.00308 0.000702 0.00308 0.00956 0.00308 0.000724 Stdev 0.0318 0.00226 0.0318 0.0393 0.0318 0.00135 p(t-test) 0.61 0.14 0.71 Min 1.25E-9 1.25E-9 1.25E-9 1.25E-9 1.25E-9 1.25E-9 Max 0.735 0.0142 0.735 0.282 0.735 0.00563 n (Samp) 558 48 558 63 558 25 n (Patient) 225 48 225 63 225 25 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.40 0.62 0.34 0.56 0.59 0.55 0.47 0.58 0.41 SE 0.042 0.081 0.044 0.038 0.071 0.039 0.055 0.087 0.061 p 0.013 0.15 4.2E-4 0.13 0.20 0.23 0.54 0.38 0.15 nCohort 1 515 734 558 515 734 558 515 734 558 nCohort 2 55 14 48 68 18 63 30 12 25 Cutoff 1 9.90E-7 1.04E-5 9.90E-7 2.32E-6 3.73E-6 1.78E-6 1.78E-6 3.73E-6 1.50E-6 Sens 1 75% 71% 73% 71% 72% 76% 73% 75% 76% Spec 1 15% 46% 15% 32% 34% 25% 24% 34% 19% Cutoff 2 7.25E-7 9.90E-7 1.25E-9 1.50E-6 1.78E-6 1.50E-6 1.50E-6 1.78E-6 7.25E-7 Sens 2 80% 86% 85% 84% 83% 84% 80% 83% 88% Spec 2 10% 16% 7% 18% 27% 19% 18% 27% 11% Cutoff 3 0 1.25E-9 0 1.25E-9 7.25E-7 1.25E-9 7.25E-7 9.90E-7 1.25E-9 Sens 3 100% 100% 100% 96% 94% 95% 90% 92% 92% Spec 3 0% 8% 0% 7% 12% 7% 10% 16% 7% Cutoff 4 0.00148 0.00110 0.00148 0.00148 0.00110 0.00148 0.00148 0.00110 0.00148 Sens 4 18% 50% 12% 41% 50% 37% 23% 50% 12% Spec 4 72% 72% 72% 72% 72% 72% 72% 72% 72% Cutoff 5 0.00243 0.00229 0.00229 0.00243 0.00229 0.00229 0.00243 0.00229 0.00229 Sens 5 13% 29% 6% 21% 28% 35% 10% 17% 12% Spec 5 88% 81% 80% 88% 81% 80% 88% 81% 80% Cutoff 6 0.00281 0.00281 0.00281 0.00281 0.00281 0.00281 0.00281 0.00281 0.00281 Sens 6 13% 29% 6% 15% 11% 16% 7% 8% 8% Spec 6 92% 91% 91% 92% 91% 91% 92% 91% 91% OR Quart 2 1.1 0.66 1.4 0.86 1.3 0.80 1.0 1.5 2.0 p Value 0.80 0.65 0.58 0.69 0.70 0.56 0.99 0.66 0.32 95% CI of 0.44 0.11 0.46 0.40 0.30 0.37 0.34 0.25 0.50 OR Quart2 2.9 4.0 4.0 1.8 6.1 1.7 3.0 9.1 8.3 OR Quart 3 1.6 1.0 2.3 0.72 1.3 0.73 1.2 1.0 2.8 p Value 0.28 1.0 0.11 0.42 0.70 0.43 0.78 1.0 0.14 95% CI of 0.68 0.20 0.84 0.33 0.30 0.33 0.41 0.14 0.72 OR Quart3 3.9 5.0 6.2 1.6 6.1 1.6 3.3 7.2 11 OR Quart 4 2.7 2.0 3.9 1.7 2.4 1.4 1.2 2.5 2.8 p Value 0.016 0.32 0.0042 0.10 0.21 0.31 0.78 0.27 0.14 95% CI of 1.2 0.50 1.5 0.89 0.61 0.72 0.41 0.48 0.72 OR Quart4 6.2 8.3 10 3.4 9.4 2.8 3.3 13 11 110 Involucrin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.447 0.942 0.447 0.943 0.447 0.422 Average 1.28 1.95 1.28 1.70 1.28 0.802 Stdev 4.30 2.64 4.30 2.50 4.30 1.12 p(t-test) 0.15 0.35 0.41 Min 0.00244 0.0214 0.00244 0.0181 0.00244 0.0268 Max 102 17.3 102 17.0 102 6.07 n (Samp) 938 88 938 97 938 56 n (Patient) 414 88 414 97 414 56 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.506 0.544 0.506 0.473 0.506 0.933 Average 1.35 0.888 1.35 1.86 1.35 2.34 Stdev 3.89 0.881 3.89 3.14 3.89 3.25 p(t-test) 0.61 0.50 0.22 Min 0.00244 0.0214 0.00244 0.0181 0.00244 0.0378 Max 102 3.40 102 14.3 102 14.5 n (Samp) 1263 19 1263 26 1263 24 n (Patient) 496 19 496 26 496 24 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.455 0.963 0.455 0.976 0.455 0.395 Average 1.31 2.07 1.31 1.88 1.31 0.743 Stdev 4.39 2.77 4.39 2.65 4.39 1.15 p(t-test) 0.12 0.23 0.38 Min 0.00244 0.0411 0.00244 0.0508 0.00244 0.0214 Max 102 17.3 102 17.0 102 6.07 n (Samp) 899 81 899 90 899 46 n (Patient) 357 81 357 90 357 46 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.65 0.51 0.65 0.65 0.55 0.66 0.49 0.62 0.44 SE 0.033 0.067 0.034 0.031 0.059 0.032 0.040 0.062 0.045 p 6.OE-6 0.87 2.2E-5 2.7E-6 0.43 6.4E-7 0.71 0.052 0.21 nCohort 1 938 1263 899 938 1263 899 938 1263 899 nCohort 2 88 19 81 97 26 90 56 24 46 Cutoff 1 0.407 0.308 0.407 0.485 0.285 0.513 0.246 0.320 0.193 Sens 1 70% 74% 70% 70% 73% 70% 71% 71% 72% Spec 1 47% 34% 47% 53% 32% 54% 31% 35% 23% Cutoff 2 0.345 0.234 0.345 0.388 0.230 0.392 0.161 0.255 0.140 Sens 2 81% 84% 80% 80% 81% 80% 80% 83% 80% Spec 2 42% 27% 41% 46% 26% 45% 20% 29% 15% Cutoff 3 0.142 0.0373 0.157 0.185 0.192 0.185 0.112 0.178 0.0808 Sens 3 91% 95% 90% 91% 92% 90% 91% 92% 91% Spec 3 17% 2% 18% 24% 22% 22% 12% 21% 7% Cutoff 4 0.867 0.971 0.916 0.867 0.971 0.916 0.867 0.971 0.916 Sens 4 53% 37% 51% 52% 38% 53% 23% 50% 17% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 1.35 1.56 1.35 1.35 1.56 1.35 1.35 1.56 1.35 111 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 5 41% 16% 43% 37% 23% 41% 16% 46% 13% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 2.41 2.85 2.34 2.41 2.85 2.34 2.41 2.85 2.34 Sens 6 27% 5% 30% 22% 23% 26% 5% 29% 7% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.5 2.0 1.4 1.7 2.5 1.5 1.8 2.0 2.6 p Value 0.27 0.33 0.44 0.19 0.12 0.31 0.17 0.33 0.051 95% CI of 0.72 0.50 0.63 0.78 0.79 0.67 0.79 0.50 1.00 OR Quart2 3.2 8.1 2.9 3.6 8.2 3.5 3.9 8.1 6.9 OR Quart 3 1.6 1.7 1.4 2.8 1.3 2.8 1.5 1.3 1.7 p Value 0.20 0.48 0.44 0.0044 0.74 0.0075 0.31 0.71 0.31 95% CI of 0.77 0.40 0.63 1.4 0.33 1.3 0.67 0.30 0.61 OR Quart3 3.4 7.1 2.9 5.8 4.7 5.9 3.5 6.0 4.8 OR Quart 4 3.6 1.7 3.5 4.0 1.8 4.4 1.4 3.7 2.6 p Value 1.7E-4 0.48 3.4E-4 9.4E-5 0.37 5.iE-5 0.40 0.044 0.051 95% CI of 1.9 0.40 1.8 2.0 0.51 2.2 0.62 1.0 1.00 OR Quart4 7.1 7.1 6.8 8.0 6.1 9.1 3.3 14 6.9 Keratin, type II cytoskeletal 1; type cytoskeletal 10 (Keratin-1,-10 mix) sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0174 0.0113 0.0174 0.0502 0.0174 0.0113 Average 3.30 1.41 3.30 5.02 3.30 0.810 Stdev 17.2 2.88 17.2 31.4 17.2 1.80 p(t-test) 0.31 0.39 0.28 Min 0.000410 0.000410 0.000410 0.000410 0.000410 0.000410 Max 367 16.3 367 309 367 10.3 n (Samp) 938 88 938 97 938 56 n (Patient) 414 88 414 97 414 56 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0174 0.0113 0.0174 0.0502 0.0174 0.00962 Average 3.12 1.66 3.12 2.52 3.12 1.14 Stdev 17.3 3.10 17.3 5.71 17.3 2.23 p(t-test) 0.71 0.86 0.58 Min 0.000410 0.000410 0.000410 0.000410 0.000410 0.000410 Max 367 10.9 367 28.5 367 10.3 n (Samp) 1263 19 1263 26 1263 24 n (Patient) 496 19 496 26 496 24 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0174 0.0113 0.0174 0.0474 0.0174 0.0120 Average 2.82 1.86 2.82 5.15 2.82 0.771 Stdev 12.5 5.28 12.5 32.5 12.5 1.43 p(t-test) 0.49 0.17 0.27 Min 0.000410 0.000410 0.000410 0.000410 0.000410 0.000410 Max 217 42.0 217 309 217 6.14 n (Samp) 899 81 899 90 899 46 112 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 n (Patient) 357 81 357 90 357 46 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.44 0.45 0.45 0.52 0.56 0.52 0.39 0.41 0.40 SE 0.033 0.069 0.034 0.031 0.059 0.032 0.041 0.062 0.045 p 0.069 0.44 0.12 0.54 0.34 0.47 0.0087 0.16 0.021 nCohort 1 938 1263 899 938 1263 899 938 1263 899 nCohort 2 88 19 81 97 26 90 56 24 46 Cutoff 1 0.00508 0.00474 0.00508 0.00694 0.00926 0.00787 0.00408 0.00408 0.00471 Sens 1 70% 74% 72% 71% 77% 70% 73% 71% 72% Spec 1 19% 15% 19% 27% 39% 31% 12% 12% 14% Cutoff 2 0.000693 0.00408 0.000693 0.00508 0.00686 0.00508 0.000693 0 0 Sens 2 85% 84% 84% 81% 85% 83% 80% 100% 100% Spec 2 5% 12% 5% 19% 28% 19% 5% 0% 0% Cutoff 3 0 0 0 0.000693 0.000693 0.000693 0 0 0 Sens 3 100% 100% 100% 94% 96% 93% 100% 100% 100% Spec 3 0% 0% 0% 5% 6% 5% 0% 0% 0% Cutoff 4 1.18 1.39 1.18 1.18 1.39 1.18 1.18 1.39 1.18 Sens 4 32% 26% 33% 35% 35% 36% 21% 29% 26% Spec 4 70% 72% 70% 70% 72% 70% 70% 72% 70% Cutoff 5 2.41 2.41 2.41 2.41 2.41 2.41 2.41 2.41 2.41 Sens 5 20% 21% 22% 21% 27% 21% 9% 8% 11% Spec 5 81% 81% 81% 81% 81% 81% 81% 81% 81% Cutoff 6 5.76 5.20 5.20 5.76 5.20 5.20 5.76 5.20 5.20 Sens 6 8% 11% 9% 9% 15% 10% 4% 4% 2% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 0.66 0.40 0.68 0.59 2.0 0.69 1.0 0.66 0.77 p Value 0.24 0.27 0.29 0.11 0.25 0.26 0.99 0.53 0.62 95% CI of 0.34 0.077 0.34 0.31 0.60 0.36 0.41 0.19 0.28 OR Quart2 1.3 2.1 1.4 1.1 6.8 1.3 2.5 2.4 2.1 OR Quart 3 0.85 1.2 0.79 1.0 1.5 0.95 1.2 0.66 1.1 p Value 0.63 0.76 0.49 0.90 0.53 0.88 0.66 0.53 0.81 95% CI of 0.45 0.36 0.40 0.59 0.42 0.52 0.51 0.19 0.45 OR Quart3 1.6 4.0 1.6 1.8 5.4 1.7 2.9 2.4 2.8 OR Quart 4 1.5 1.2 1.6 1.1 2.0 1.1 2.6 1.7 2.3 p Value 0.15 0.76 0.11 0.79 0.26 0.78 0.015 0.31 0.039 95% CI of 0.86 0.36 0.90 0.62 0.60 0.61 1.2 0.61 1.0 OR Quart4 2.7 4.0 2.9 1.9 6.8 2.0 5.5 4.7 5.3 NF-kappa-B inhibitor alpha sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 9.81E-5 0.000146 9.81E-5 0.000262 9.81E-5 2.56E-6 Average 0.00524 0.00595 0.00524 0.00158 0.00524 0.00414 Stdev 0.0265 0.0259 0.0265 0.00361 0.0265 0.0158 p(t-test) 0.85 0.26 0.82 Min 3.52E-7 3.52E-7 3.52E-7 3.52E-7 3.52E-7 3.52E-7 Max 0.268 0.178 0.268 0.0167 0.268 0.0782 n (Samp) 515 55 515 68 515 30 n (Patient) 222 55 222 68 222 30 113 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 9.81E-5 0.000264 9.81E-5 0.000251 9.81E-5 1.06E-6 Average 0.00548 0.00775 0.00548 0.000656 0.00548 0.000443 Stdev 0.0279 0.0197 0.0279 0.00109 0.0279 0.00103 p(t-test) 0.76 0.46 0.53 Min 3.52E-7 3.80E-7 3.52E-7 4.17E-7 3.52E-7 4.17E-7 Max 0.326 0.0725 0.326 0.00446 0.326 0.00353 n (Samp) 734 14 734 18 734 12 n (Patient) 280 14 280 18 280 12 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.000103 0.000127 0.000103 0.000213 0.000103 2.25E-5 Average 0.00512 0.00581 0.00512 0.00574 0.00512 0.00495 Stdev 0.0257 0.0268 0.0257 0.0324 0.0257 0.0172 p(t-test) 0.86 0.86 0.97 Min 3.52E-7 3.52E-7 3.52E-7 3.52E-7 3.52E-7 3.52E-7 Max 0.268 0.178 0.268 0.257 0.268 0.0782 n (Samp) 558 48 558 63 558 25 n (Patient) 225 48 225 63 225 25 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.47 0.57 0.46 0.56 0.57 0.57 0.38 0.37 0.44 SE 0.042 0.080 0.044 0.038 0.071 0.039 0.056 0.087 0.061 p 0.47 0.40 0.38 0.10 0.36 0.097 0.034 0.14 0.34 nCohort 1 515 734 558 515 734 558 515 734 558 nCohort 2 55 14 48 68 18 63 30 12 25 Cutoff 1 5.23E-7 0.000132 5.23E-7 2.25E-5 2.94E-5 2.25E-5 4.18E-7 5.05E-7 1.03E-6 Sens 1 71% 71% 71% 74% 72% 71% 77% 75% 72% Spec 1 20% 52% 21% 37% 42% 38% 15% 19% 26% Cutoff 2 4.17E-7 3.80E-7 4.17E-7 9.58E-7 2.18E-5 9.58E-7 4.17E-7 3.80E-7 5.05E-7 Sens 2 82% 86% 83% 82% 83% 81% 80% 100% 84% Spec 2 11% 8% 12% 23% 37% 24% 11% 8% 16% Cutoff 3 3.52E-7 3.65E-7 0 4.17E-7 5.05E-7 4.17E-7 3.80E-7 3.80E-7 3.52E-7 Sens 3 91% 100% 100% 96% 94% 95% 90% 100% 92% Spec 3 4% 6% 0% 11% 19% 12% 7% 8% 4% Cutoff 4 0.000532 0.000566 0.000532 0.000532 0.000566 0.000532 0.000532 0.000566 0.000532 Sens 4 27% 36% 25% 44% 33% 44% 20% 17% 24% Spec 4 71% 71% 71% 71% 71% 71% 71% 71% 71% Cutoff 5 0.00101 0.00113 0.00102 0.00101 0.00113 0.00102 0.00101 0.00113 0.00102 Sens 5 20% 29% 19% 28% 17% 30% 13% 8% 12% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 0.00351 0.00371 0.00351 0.00351 0.00371 0.00351 0.00351 0.00371 0.00351 Sens 6 11% 29% 8% 10% 6% 13% 7% 0% 8% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.5 0.33 1.7 0.85 2.5 1.2 1.8 1.0 2.8 p Value 0.33 0.34 0.22 0.68 0.27 0.69 0.36 1.00 0.14 95% CI of 0.68 0.034 0.74 0.39 0.49 0.54 0.52 0.14 0.72 OR Quart2 3.1 3.2 3.8 1.8 13 2.5 6.3 7.2 11 OR Quart 3 0.29 1.7 0.69 1.1 4.1 0.92 1.5 1.0 2.4 p Value 0.033 0.48 0.46 0.72 0.075 0.83 0.51 1.0 0.21 95% CI of 0.091 0.40 0.25 0.55 0.87 0.40 0.42 0.14 0.61 OR Quart3 0.91 7.2 1.9 2.4 20 2.1 5.6 7.2 9.5 114 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only OR Quart 4 1.6 1.7 1.6 1.6 1.5 1.9 3.5 3.1 2.4 p Value 0.19 0.48 0.29 0.17 0.65 0.083 0.032 0.17 0.21 95% CI of 0.78 0.40 0.68 0.81 0.25 0.92 1.1 0.61 0.61 OR Quart4 3.4 7.2 3.6 3.2 9.1 3.9 11 15 9.5 Beta-nerve growth factor sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.58 1.85 2.58 2.88 2.58 1.89 Average 3.97 3.46 3.97 5.10 3.97 2.69 Stdev 5.00 4.55 5.00 7.55 5.00 2.80 p(t-test) 0.47 0.10 0.16 Min 0.000201 0.000201 0.000201 0.000506 0.000201 0.000201 Max 44.0 22.1 44.0 46.1 44.0 11.7 n(Samp) 516 55 516 68 516 30 n (Patient) 224 55 224 68 224 30 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.52 1.29 2.52 2.16 2.52 1.33 Average 3.97 3.17 3.97 2.45 3.97 2.08 Stdev 5.18 5.73 5.18 2.04 5.18 2.41 p(t-test) 0.57 0.21 0.21 Min 0.000201 0.000201 0.000201 0.000244 0.000201 0.000506 Max 46.1 22.1 46.1 6.35 46.1 8.38 n(Samp) 736 14 736 18 736 12 n (Patient) 282 14 282 18 282 12 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.32 1.78 2.32 3.08 2.32 1.99 Average 3.66 3.19 3.66 5.38 3.66 2.94 Stdev 4.54 3.95 4.54 7.77 4.54 2.96 p(t-test) 0.49 0.0095 0.43 Min 0.000201 0.000506 0.000201 0.000506 0.000201 0.000201 Max 35.5 20.4 35.5 46.1 35.5 11.7 n (Samp) 559 48 559 63 559 25 n (Patient) 227 48 227 63 227 25 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.45 0.38 0.46 0.52 0.43 0.55 0.42 0.37 0.47 SE 0.042 0.081 0.044 0.038 0.071 0.039 0.056 0.087 0.060 p 0.20 0.13 0.33 0.58 0.35 0.17 0.18 0.13 0.62 nCohort 1 516 736 559 516 736 559 516 736 559 nCohort 2 55 14 48 68 18 63 30 12 25 Cutoff 1 0.886 0.292 0.825 1.22 1.24 1.21 1.04 0.825 1.40 Sens 1 71% 71% 71% 71% 72% 71% 70% 75% 72% Spec 1 22% 11% 21% 29% 31% 31% 25% 21% 36% Cutoff 2 0.462 0.223 0.261 0.717 0.135 0.781 0.494 0.135 0.495 Sens 2 80% 86% 83% 82% 83% 81% 80% 83% 80% 115 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Spec 2 13% 10% 11% 17% 9% 21% 14% 9% 15% Cutoff 3 0.000506 0.111 0.000506 0.397 0.000499 0.462 0.161 0.000605 0.161 Sens 3 93% 93% 94% 91% 94% 90% 90% 92% 92% Spec 3 4% 9% 4% 11% 2% 14% 9% 6% 10% Cutoff 4 4.17 4.06 3.86 4.17 4.06 3.86 4.17 4.06 3.86 Sens 4 25% 21% 25% 32% 22% 37% 20% 17% 28% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 5.67 5.66 5.25 5.67 5.66 5.25 5.67 5.66 5.25 Sens 5 16% 14% 17% 25% 11% 29% 17% 8% 20% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 9.07 9.25 8.31 9.07 9.25 8.31 9.07 9.25 8.31 Sens 6 13% 7% 12% 15% 0% 19% 3% 0% 8% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 0.75 1.5 0.90 0.75 3.6 0.66 1.0 2.0 1.0 p Value 0.52 0.65 0.82 0.45 0.11 0.31 0.99 0.57 1.0 95% CI of 0.32 0.25 0.37 0.36 0.74 0.30 0.28 0.18 0.28 OR Quart2 1.8 9.2 2.2 1.6 18 1.5 3.6 22 3.5 OR Quart 3 1.2 1.5 1.1 0.88 2.0 1.0 2.5 5.1 1.9 p Value 0.69 0.65 0.83 0.72 0.42 1.0 0.089 0.14 0.28 95% CI of 0.54 0.25 0.47 0.43 0.37 0.48 0.87 0.59 0.61 OR Quart3 2.6 9.1 2.6 1.8 11 2.1 7.4 44 5.7 OR Quart 4 1.4 3.1 1.4 1.1 2.6 1.3 1.6 4.1 1.2 p Value 0.43 0.17 0.40 0.73 0.27 0.49 0.39 0.21 0.76 95% CI of 0.63 0.61 0.63 0.57 0.49 0.64 0.53 0.45 0.36 OR Quart4 2.9 15 3.2 2.2 13 2.6 5.2 37 4.1 Pancreatic prohormone sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 5.69 15.7 5.69 6.89 5.69 0.491 Average 89.0 96.7 89.0 83.4 89.0 27.0 Stdev 183 224 183 164 183 58.1 p(t-test) 0.85 0.87 0.18 Min 0.117 0.117 0.117 0.117 0.117 0.117 Max 1220 1020 1220 690 1220 225 n (Samp) 248 22 248 32 248 16 n (Patient) 160 22 160 32 160 16 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 4.35 98.1 4.35 33.7 Average nd nd 85.1 249 85.1 82.5 Stdev nd nd 181 316 181 105 p(t-test) nd nd 0.032 0.97 Min nd nd 0.117 0.134 0.117 0.122 Max nd nd 1220 728 1220 234 n (Samp) nd nd 314 6 314 7 n (Patient) nd nd 187 6 187 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 11.7 15.7 11.7 9.57 11.7 0.293 116 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Average 91.2 96.6 91.2 68.8 91.2 54.0 Stdev 185 224 185 145 185 145 p(t-test) 0.90 0.53 0.45 Min 0.117 0.117 0.117 0.117 0.117 0.117 Max 1220 1020 1220 690 1220 567 n (Samp) 216 22 216 29 216 15 n (Patient) 133 22 133 29 133 15 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.49 nd 0.48 0.49 0.68 0.47 0.35 0.54 0.35 SE 0.065 nd 0.065 0.055 0.12 0.058 0.077 0.11 0.079 p 0.92 nd 0.73 0.87 0.14 0.56 0.048 0.73 0.059 nCohort 1 248 nd 216 248 314 216 248 314 216 nCohort 2 22 nd 22 32 6 29 16 7 15 Cutoff 1 0.117 nd 0.117 0.134 0.635 0.134 0.117 0.635 0.117 Sens 1 82% nd 82% 75% 83% 76% 75% 71% 73% Spec 1 5% nd 5% 21% 32% 18% 5% 32% 5% Cutoff 2 0.117 nd 0.117 0.122 0.635 0.122 0 0.117 0 Sens 2 82% nd 82% 84% 83% 83% 100% 100% 100% Spec 2 5% nd 5% 11% 32% 8% 0% 8% 0% Cutoff 3 0 nd 0 0.117 0.122 0.117 0 0.117 0 Sens 3 100% nd 100% 94% 100% 93% 100% 100% 100% Spec 3 0% nd 0% 5% 15% 5% 0% 8% 0% Cutoff 4 40.9 nd 46.0 40.9 40.4 46.0 40.9 40.4 46.0 Sens 4 45% nd 41% 34% 67% 28% 12% 43% 20% Spec 4 70% nd 70% 70% 70% 70% 70% 70% 70% Cutoff 5 118 nd 118 118 96.3 118 118 96.3 118 Sens 5 14% nd 14% 22% 50% 17% 6% 29% 7% Spec 5 80% nd 80% 80% 80% 80% 80% 80% 80% Cutoff 6 338 nd 347 338 310 347 338 310 347 Sens 6 9% nd 9% 6% 33% 3% 0% 0% 7% Spec 6 90% nd 90% 90% 90% 90% 90% 90% 90% OR Quart 2 0.60 nd 0.47 0.56 1.0 1.0 2.6 0.49 1.4 p Value 0.40 nd 0.24 0.29 1.0 0.97 0.26 0.57 0.70 95% CI of 0.19 nd 0.13 0.19 0.061 0.33 0.49 0.044 0.29 OR Quart2 2.0 nd 1.7 1.6 16 3.1 14 5.6 6.4 OR Quart 3 0.23 nd 0.34 0.67 0 0.70 1.0 0.49 0 p Value 0.068 nd 0.13 0.44 na 0.56 1.0 0.57 na 95% CI of 0.046 nd 0.086 0.24 na 0.21 0.14 0.044 na OR Quart3 1.1 nd 1.4 1.9 na 2.3 7.3 5.6 na OR Quart 4 0.88 nd 0.88 0.89 4.2 1.5 3.8 1.5 3.0 p Value 0.81 nd 0.81 0.81 0.21 0.41 0.10 0.66 0.12 95% CI of 0.30 nd 0.30 0.34 0.45 0.55 0.76 0.24 0.75 OR Quart4 2.6 nd 2.6 2.3 38 .4 19 9.2 12 Transthyretin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 23.4 33.6 23.4 39.7 23.4 17.6 Average 45.4 62.2 45.4 86.7 45.4 36.6 Stdev 68.4 125 68.4 234 68.4 48.2 117 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) 0.082 7.8E-4 0.42 Min 0.000148 3.93 0.000148 2.10 0.000148 0.773 Max 668 997 668 2000 668 241 n (Samp) 599 70 599 79 599 40 n (Patient) 281 70 281 79 281 40 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 24.8 53.3 24.8 33.0 24.8 42.5 Average 52.0 84.7 52.0 102 52.0 89.4 Stdev 120 76.1 120 229 120 104 p(t-test) 0.39 0.089 0.22 Min 0.000148 17.5 0.000148 3.17 0.000148 0.773 Max 2000 229 2000 997 2000 380 n (Samp) 829 10 829 18 829 16 n (Patient) 353 10 353 18 353 16 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 24.1 33.0 24.1 43.0 24.1 17.7 Average 46.9 59.1 46.9 90.0 46.9 35.8 Stdev 69.3 126 69.3 241 69.3 39.8 p(t-test) 0.22 6.9E-4 0.35 Min 0.000148 3.93 0.000148 2.10 0.000148 1.67 Max 668 997 668 2000 668 182 n (Samp) 608 66 608 74 608 35 n (Patient) 266 66 266 74 266 35 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.58 0.73 0.55 0.60 0.57 0.60 0.46 0.63 0.47 SE 0.037 0.091 0.038 0.035 0.071 0.036 0.048 0.076 0.051 p 0.039 0.011 0.17 0.0046 0.31 0.0059 0.47 0.083 0.57 nCohort 1 599 829 608 599 829 608 599 829 608 nCohort 2 70 10 66 79 18 74 40 16 35 Cutoff 1 20.3 46.1 16.1 18.9 18.9 20.8 13.7 26.8 13.9 Sens 1 70% 70% 71% 71% 72% 70% 70% 75% 71% Spec 1 45% 69% 35% 42% 41% 44% 31% 53% 30% Cutoff 2 12.3 34.6 11.0 12.1 8.67 13.9 9.49 15.4 9.58 Sens 2 80% 80% 80% 81% 83% 81% 80% 81% 80% Spec 2 29% 62% 24% 28% 19% 30% 22% 33% 21% Cutoff 3 7.87 26.9 7.20 8.67 4.98 9.87 5.71 4.36 8.58 Sens 3 90% 90% 91% 91% 94% 91% 90% 94% 91% Spec 3 20% 53% 16% 21% 9% 22% 14% 8% 20% Cutoff 4 46.2 46.7 47.0 46.2 46.7 47.0 46.2 46.7 47.0 Sens 4 33% 60% 32% 43% 39% 43% 18% 50% 17% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 63.1 64.9 63.8 63.1 64.9 63.8 63.1 64.9 63.8 Sens 5 26% 40% 24% 28% 22% 30% 15% 44% 17% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff6 100 105 106 100 105 106 100 105 106 Sens 6 13% 30% 11% 15% 22% 15% 8% 31% 6% 118 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 0.75 >1.0 0.77 0.92 0.49 1.4 2.1 0.33 1.7 p Value 0.52 <1.0 0.52 0.83 0.42 0.42 0.15 0.34 0.31 95% CI of 0.32 >0.062 0.34 0.42 0.089 0.62 0.76 0.034 0.61 OR Quart2 1.8 na 1.7 2.0 2.7 3.1 5.7 3.2 4.8 OR Quart 3 2.3 >5.1 1.8 2.2 2.0 2.5 1.9 1.7 1.7 p Value 0.021 <0.14 0.088 0.023 0.25 0.016 0.22 0.48 0.31 95% CI of 1.1 >0.59 0.91 1.1 0.60 1.2 0.68 0.40 0.61 OR Quart3 4.6 na 3.7 4.3 6.8 5.2 5.3 7.1 4.8 OR Quart 4 1.6 >4.1 1.2 1.8 1.00 2.2 1.9 2.4 1.5 p Value 0.21 <0.21 0.58 0.092 0.99 0.035 0.21 0.22 0.42 95% CI of 0.77 >0.45 0.59 0.91 0.25 1.1 0.69 0.60 0.54 OR Quart4 3.3 na 2.6 3.7 4.0 4.8 5.3 9.3 4.4 C-peptide Urine sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 22500 22700 22500 19900 22500 21000 Average 33600 31100 33600 27000 33600 26600 Stdev 30100 30400 30100 25900 30100 24800 p(t-test) 0.51 0.062 0.14 Min 0.00978 55.3 0.00978 133 0.00978 53.8 Max 104000 114000 104000 100000 104000 100000 n (Samp) 599 70 599 79 599 41 n (Patient) 281 70 281 79 281 41 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 22000 7840 22000 24900 22000 7680 Average 32100 20400 32100 35200 32100 19700 Stdev 29300 26000 29300 32500 29300 27300 p(t-test) 0.21 0.66 0.093 Min 0.00978 240 0.00978 558 0.00978 180 Max 114000 83800 114000 100000 114000 100000 n (Samp) 829 10 829 18 829 16 n (Patient) 353 10 353 18 353 16 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 22900 22300 22900 19300 22900 19200 Average 33700 31800 33700 24900 33700 24400 Stdev 29800 31100 29800 24900 29800 22700 p(t-test) 0.62 0.015 0.067 Min 0.00978 55.3 0.00978 133 0.00978 53.8 Max 104000 114000 104000 100000 104000 81500 n (Samp) 608 66 608 74 608 36 n (Patient) 266 66 266 74 266 36 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO IsCr only UO only sCr or UO sCr only lUO only sCr or UO sCr only lUO only AUC 0.47 0.35 0.47 0.44 0.52 0.41 0.43 0.32 0.41 119 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only SE 0.037 0.095 0.038 0.035 0.070 0.036 0.048 0.075 0.051 p 0.35 0.11 0.39 0.073 0.74 0.011 0.16 0.017 0.080 nCohort 1 599 829 608 599 829 608 599 829 608 nCohort 2 70 10 66 79 18 74 41 16 36 Cutoff 1 8450 6690 8710 9680 12500 7110 7980 2440 6130 Sens 1 70% 70% 71% 71% 72% 70% 71% 75% 72% Spec 1 23% 18% 23% 25% 34% 17% 22% 6% 14% Cutoff 2 4980 1340 4690 5480 8820 5070 5200 2160 5200 Sens 2 80% 80% 80% 81% 83% 81% 80% 81% 81% Spec 2 12% 3% 11% 13% 25% 12% 13% 6% 12% Cutoff 3 1340 512 1240 1340 1540 1340 2370 800 1970 Sens 3 90% 90% 91% 91% 94% 91% 90% 94% 92% Spec 3 2% 2% 2% 2% 3% 2% 5% 2% 5% Cutoff 4 43100 39300 43400 43100 39300 43400 43100 39300 43400 Sens 4 23% 10% 24% 20% 33% 18% 22% 25% 19% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 60800 58100 59800 60800 58100 59800 60800 58100 59800 Sens 5 17% 10% 18% 10% 28% 11% 15% 6% 14% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 87200 83400 87100 87200 83400 87100 87200 83400 87100 Sens 6 7% 10% 9% 5% 17% 4% 2% 6% 0% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.5 3.0 1.1 1.2 1.2 1.4 1.3 1.0 1.2 p Value 0.28 0.34 0.84 0.58 0.74 0.44 0.63 1.00 0.79 95% CI of 0.73 0.31 0.52 0.60 0.33 0.63 0.49 0.14 0.41 OR Quart2 3.0 29 2.3 2.5 4.7 2.9 3.3 7.2 3.3 OR Quart 3 0.72 0 1.0 1.4 1.00 1.6 1.3 1.5 1.2 p Value 0.42 na 1.0 0.39 0.99 0.20 0.63 0.65 0.79 95% CI of 0.32 na 0.47 0.68 0.25 0.77 0.49 0.25 0.41 OR Quart3 1.6 na 2.1 2.7 4.0 3.4 3.3 9.2 3.3 OR Quart 4 1.6 6.2 1.4 1.5 1.2 2.0 1.7 4.7 1.9 p Value 0.17 0.093 0.36 0.23 0.74 0.057 0.26 0.050 0.17 95% CI of 0.82 0.74 0.68 0.77 0.33 0.98 0.68 1.00 0.75 OR Quart4 3.2 52 2.8 3.0 4.7 4.1 4.2 22 5.0 Gastric inhibitory polypeptide Urine sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.369 0.426 0.369 0.386 0.369 0.464 Average 29.4 10.6 29.4 21.2 29.4 1.72 Stdev 252 62.6 252 119 252 3.31 p(t-test) 0.53 0.77 0.48 Min 9.60E-5 9.60E-5 9.60E-5 0.000104 9.60E-5 0.000104 Max 3840 513 3840 1040 3840 13.1 n (Samp) 600 70 600 79 600 41 n (Patient) 281 70 281 79 281 41 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.397 0.260 0.397 0.728 0.397 0.734 Average 25.1 1.84 25.1 44.6 25.1 11.3 Stdev 219 4.60 219 143 219 28.7 120 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) 0.74 0.71 0.80 Min 9.60E-5 9.60E-5 9.60E-5 0.000520 9.60E-5 0.0460 Max 3840 14.9 3840 606 3840 114 n (Samp) 830 10 830 18 830 16 n (Patient) 353 10 353 18 353 16 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.385 0.376 0.385 0.334 0.385 0.446 Average 30.7 11.0 30.7 21.7 30.7 1.43 Stdev 251 64.4 251 123 251 2.57 p(t-test) 0.53 0.76 0.48 Min 9.60E-5 0.000104 9.60E-5 0.000104 9.60E-5 0.000104 Max 3840 513 3840 1040 3840 13.1 n (Samp) 609 66 609 74 609 36 n (Patient) 266 66 266 74 266 36 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.50 0.45 0.48 0.50 0.64 0.48 0.52 0.63 0.50 SE 0.037 0.094 0.038 0.035 0.071 0.036 0.047 0.076 0.050 p 0.94 0.61 0.56 0.90 0.050 0.60 0.67 0.074 0.92 nCohort 1 600 830 609 600 830 609 600 830 609 nCohort 2 70 10 66 79 18 74 41 16 36 Cutoff 1 0.221 0.186 0.221 0.143 0.348 0.143 0.142 0.254 0.142 Sens 1 70% 70% 71% 72% 72% 70% 71% 75% 72% Spec 1 37% 34% 36% 31% 47% 30% 31% 40% 30% Cutoff 2 0.0766 0.0381 0.0507 0.0484 0.259 0.0484 0.108 0.227 0.108 Sens 2 80% 80% 80% 81% 83% 81% 83% 81% 83% Spec 2 26% 21% 22% 23% 41% 22% 28% 38% 27% Cutoff 3 0.000161 0.000273 0.000104 0.000273 0.0269 0.000273 0.00116 0.0589 0.00104 Sens 3 90% 90% 92% 91% 94% 91% 90% 94% 92% Spec 3 7% 10% 4% 9% 20% 10% 16% 23% 15% Cutoff 4 0.908 0.835 0.956 0.908 0.835 0.956 0.908 0.835 0.956 Sens 4 21% 30% 20% 27% 39% 24% 29% 50% 31% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 1.73 1.58 2.00 1.73 1.58 2.00 1.73 1.58 2.00 Sens 5 14% 10% 14% 19% 33% 16% 24% 31% 25% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 6.24 5.24 7.60 6.24 5.24 7.60 6.24 5.24 7.60 Sens 6 9% 10% 8% 13% 33% 11% 7% 25% 3% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 2.2 3.0 2.1 1.2 2.5 1.5 1.8 1.5 1.9 p Value 0.036 0.34 0.048 0.62 0.27 0.29 0.24 0.66 0.22 95% CI of 1.1 0.31 1.0 0.61 0.49 0.72 0.68 0.25 0.68 OR Quart2 4.5 29 4.6 2.3 13 2.9 4.6 9.1 5.3 OR Quart 3 1.8 3.0 1.5 1.2 2.0 1.5 1.5 2.5 1.5 p Value 0.14 0.34 0.32 0.51 0.42 0.29 0.46 0.27 0.43 95% CI of 0.83 0.31 0.68 0.64 0.37 0.72 0.54 0.49 0.53 OR Quart3 3.7 29 3.3 2.4 11 2.9 3.9 13 4.4 OR Quart 4 1.2 3.0 1.6 0.99 3.6 1.2 1.8 3.0 1.7 p Value 0.67 0.34 0.23 0.99 0.11 0.70 0.25 0.18 0.32 95% CT of 0.53 0.31 0.73 0.50 0.74 0.56 0.67 0.61 0.60 121 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO IsCr only UO only sCr or UO sCr only lUO only sCr or UO sCr only lUO only OR Quart4 2.7 29 3.6 2.0 17 2.4 4.6 15 4.8 Peptide YY Urine sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 5.17 1.51 5.17 10.6 5.17 6.51 Average 46.8 31.6 46.8 43.9 46.8 21.8 Stdev 128 70.2 128 83.5 128 47.7 p(t-test) 0.33 0.85 0.21 Min 0.00976 0.00976 0.00976 0.00976 0.00976 0.00976 Max 1200 353 1200 478 1200 290 n (Samp) 598 70 598 79 598 41 n (Patient) 281 70 281 79 281 41 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 4.33 4.16 4.33 48.6 4.33 21.8 Average 44.3 17.6 44.3 98.9 44.3 57.6 Stdev 117 29.9 117 138 117 89.4 p(t-test) 0.47 0.052 0.65 Min 0.00976 0.00976 0.00976 0.00976 0.00976 0.0188 Max 1200 82.2 1200 554 1200 353 n (Samp) 828 10 828 18 828 16 n (Patient) 353 10 353 18 353 16 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 7.35 1.51 7.35 11.0 7.35 7.18 Average 47.0 31.8 47.0 40.8 47.0 23.8 Stdev 126 71.7 126 80.7 126 52.5 p(t-test) 0.34 0.68 0.27 Min 0.00976 0.00976 0.00976 0.00976 0.00976 0.00976 Max 1200 353 1200 478 1200 290 n (Samp) 607 66 607 74 607 36 n (Patient) 266 66 266 74 266 36 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.45 0.41 0.45 0.51 0.70 0.51 0.47 0.65 0.48 SE 0.037 0.095 0.038 0.035 0.070 0.036 0.047 0.075 0.050 p 0.21 0.34 0.21 0.71 0.0053 0.84 0.55 0.053 0.63 nCohort 1 598 828 607 598 828 607 598 828 607 nCohort 2 70 10 66 79 18 74 41 16 36 Cutoff 1 0.0196 0.0151 0.0196 0.0196 16.0 0.0196 0.0196 6.01 0.0196 Sens 1 71% 70% 71% 72% 72% 72% 78% 75% 81% Spec 1 23% 17% 25% 23% 61% 25% 23% 51% 25% Cutoff 2 0.0131 0.0128 0.0131 0.0151 0.677 0.0151 0.0188 0.817 0.0196 Sens 2 81% 90% 80% 82% 83% 82% 80% 81% 81% Spec 2 13% 11% 14% 15% 35% 16% 18% 39% 25% Cutoff 3 0.00976 0.0128 0.00976 0.0101 0.0151 0.0101 0.0131 0.0151 0.0131 Sens 3 96% 90% 97% 91% 94% 92% 93% 100% 92% 122 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Spec 3 3% 11% 3% 6% 17% 7% 13% 17% 14% Cutoff 4 25.8 27.7 27.9 25.8 27.7 27.9 25.8 27.7 27.9 Sens 4 27% 20% 26% 41% 61% 35% 27% 44% 28% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 44.2 44.4 48.2 44.2 44.4 48.2 44.2 44.4 48.2 Sens 5 20% 20% 15% 25% 56% 20% 12% 38% 11% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff6 103 104 106 103 104 106 103 104 106 Sens 6 9% 0% 9% 11% 33% 8% 2% 12% 6% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.2 1.5 1.4 0.62 1.00 0.69 1.8 1.0 1.9 p Value 0.58 0.65 0.44 0.17 1.00 0.29 0.19 1.0 0.22 95% CI of 0.59 0.25 0.63 0.31 0.14 0.34 0.74 0.14 0.68 OR Quart2 2.5 9.2 2.9 1.2 7.1 1.4 4.5 7.2 5.3 OR Quart 3 1.1 0.50 1.4 0.80 2.0 0.95 1.0 2.5 2.1 p Value 0.71 0.57 0.44 0.51 0.42 0.87 1.0 0.27 0.15 95% CI of 0.55 0.045 0.63 0.42 0.37 0.49 0.37 0.49 0.76 OR Quart3 2.4 5.5 2.9 1.5 11 1.8 2.7 13 5.7 OR Quart 4 1.4 2.0 1.5 0.94 5.2 0.83 1.4 3.6 1.2 p Value 0.37 0.42 0.26 0.86 0.035 0.60 0.47 0.11 0.77 95% CI of 0.68 0.37 0.73 0.50 1.1 0.43 0.55 0.74 0.39 OR Quart4 2.8 11 3.2 1.8 24 1.6 3.6 17 3.6 [0170] Table 3: Comparison of marker levels in urine samples collected within 12 hours of reaching stage R from Cohort 1 (patients that reached, but did not progress beyond, RIFLE stage R) and from Cohort 2 (patients that reached RIFLE stage I or F). Osteocalcin sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 7300 6390 6330 10500 7370 6390 Average 8940 9590 9850 11400 8960 8600 Stdev 7960 9540 10200 8940 7390 8200 p(t-test) 0.57 0.56 0.75 Min 475 473 475 714 1210 473 Max 67900 48000 52600 29500 67900 42300 n (Samp) 160 85 57 20 138 67 n (Patient) 160 85 57 20 138 67 At Enrollment sCr or UO sCr only UO only AUC 0.48 0.55 0.45 SE 0.039 0.076 0.043 p 0.55 0.49 0.25 nCohort 1 160 57 138 nCohort 2 85 20 67 Cutoff 1 4390 6000 4540 Sens 1 71% 70% 70% Spec 1 29% 46% 29% Cutoff 2 3220 1810 3320 Sens 2 80% 80% 81% 123 At Enrollment sCr or UO sCr only UO only Spec 2 17% 5% 18% Cutoff 3 1810 1120 2380 Sens 3 91% 90% 91% Spec 3 7% 4% 10% Cutoff 4 10400 12300 10500 Sens 4 26% 40% 18% Spec 4 70% 70% 70% Cutoff 5 12600 14500 13500 Sens 5 20% 25% 13% Spec 5 80% 81% 80% Cutoff 6 15900 20500 17400 Sens 6 15% 25% 9% Spec 6 90% 91% 91% OR Quart 2 1.2 0.33 1.8 p Value 0.65 0.22 0.17 95% CI of 0.56 0.055 0.77 OR Quart2 2.5 2.0 4.3 OR Quart 3 1.1 2.0 2.0 p Value 0.80 0.31 0.12 95% CI of 0.52 0.52 0.84 OR Quart3 2.4 8.0 4.7 OR Quart 4 1.6 0.93 1.8 p Value 0.23 0.93 0.17 95% CI of 0.75 0.22 0.77 OR Quart4 3.3 3.9 4.3 Follistatin sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 7.30 9.61 8.08 11.5 8.01 8.94 Average 17.3 18.6 24.9 21.5 15.1 18.9 Stdev 42.6 20.8 52.4 21.2 32.3 22.0 p(t-test) 0.81 0.80 0.41 Min 0.0425 0.0615 0.0425 2.82 0.0432 0.0615 Max 321 104 321 66.2 310 104 n (Samp) 137 77 54 17 114 61 n (Patient) 137 77 54 17 114 61 At Enrollment sCr or UO sCr only UO only AUC 0.59 0.58 0.58 SE 0.041 0.082 0.046 p 0.038 0.30 0.085 nCohort 1 137 54 114 nCohort 2 77 17 61 Cutoff 1 4.89 9.06 4.89 Sens 1 70% 71% 70% Spec 1 35% 56% 36% Cutoff 2 3.82 3.97 3.64 Sens 2 81% 82% 80% Spec 2 29% 28% 30% Cutoff 3 1.81 3.30 1.68 124 At Enrollment sCr or UO sCr only UO only Sens 3 91% 94% 90% Spec 3 19% 20% 18% Cutoff 4 11.6 21.0 11.6 Sens 4 45% 29% 43% Spec 4 70% 70% 70% Cutoff 5 19.6 31.4 18.7 Sens 5 30% 29% 33% Spec 5 80% 81% 81% Cutoff 6 33.2 47.8 40.3 Sens 6 21% 18% 16% Spec 6 91% 91% 90% OR Quart 2 1.5 0.58 2.0 p Value 0.34 0.58 0.13 95% CI of 0.66 0.085 0.81 OR Quart2 3.4 4.0 5.0 OR Quart 3 1.3 3.0 0.97 p Value 0.53 0.17 0.95 95% CI of 0.57 0.62 0.37 OR Quart3 3.0 14 2.6 OR Quart 4 2.0 1.8 2.7 p Value 0.085 0.48 0.034 95% CI of 0.91 0.36 1.1 OR Quart4 4.5 9.1 6.6 Islet amyloid polypeptide sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.228 0.359 0.545 1.19 0.424 0.00758 Average 3.62 1.44 5.21 5.04 2.98 0.231 Stdev 14.7 4.78 19.3 8.99 11.0 0.330 p(t-test) 0.49 0.98 0.32 Min 0.00151 0.00151 0.00151 0.359 0.00151 0.00151 Max 84.9 23.2 84.9 23.2 68.1 0.880 n(Samp) 53 23 19 6 43 16 n (Patient) 53 23 19 6 43 16 At Enrollment sCr or UO sCr only UO only AUC 0.45 0.69 0.32 SE 0.073 0.13 0.083 p 0.53 0.15 0.035 nCohort 1 53 19 43 nCohort 2 23 6 16 Cutoff 1 0.00353 0.359 0.00187 Sens 1 78% 83% 81% Spec 1 13% 47% 9% Cutoff 2 0.00187 0.359 0.00187 Sens 2 91% 83% 81% Spec 2 9% 47% 9% Cutoff 3 0.00187 0.0802 0.00151 Sens 3 91% 100% 94% Spec 3 9% 47% 5% 125 At Enrollment sCr or UO sCr only UO only Cutoff 4 1.16 1.52 1.16 Sens 4 13% 50% 0% Spec 4 75% 74% 77% Cutoff 5 1.50 2.03 1.50 Sens 5 13% 33% 0% Spec 5 81% 84% 81% Cutoff 6 2.31 2.49 3.12 Sens 6 9% 33% 0% Spec 6 91% 95% 91% OR Quart 2 4.8 >3.0 7.0 p Value 0.044 <0.43 0.097 95% CI of 1.0 >0.20 0.71 OR Quart2 22 na 69 OR Quart 3 1.4 >3.0 5.1 p Value 0.68 <0.43 0.17 95% CI of 0.27 >0.20 0.50 OR Quart3 7.4 na 52 OR Quart 4 3.1 >2.4 10 p Value 0.15 <0.52 0.044 95% CI of 0.66 >0.16 1.1 OR Quart4 15 na 100 Involucrin sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.602 0.686 0.619 0.696 0.639 0.743 Average 1.36 1.70 1.40 2.17 1.34 1.63 Stdev 2.69 2.71 2.75 3.82 2.36 2.23 p(t-test) 0.37 0.33 0.41 Min 0.0226 0.0181 0.0226 0.0244 0.0326 0.0181 Max 19.2 17.0 19.2 17.0 15.5 15.1 n (Samp) 144 80 55 21 123 62 n (Patient) 144 80 55 21 123 62 At Enrollment sCr or UO sCr only UO only AUC 0.58 0.54 0.58 SE 0.040 0.075 0.045 p 0.044 0.64 0.066 nCohort 1 144 55 123 nCohort 2 80 21 62 Cutoff 1 0.438 0.353 0.438 Sens 1 70% 71% 71% Spec 1 42% 33% 38% Cutoff 2 0.297 0.228 0.360 Sens 2 80% 81% 81% Spec 2 33% 20% 32% Cutoff 3 0.189 0.156 0.191 Sens 3 90% 90% 90% Spec 3 19% 15% 18% Cutoff 4 0.945 1.17 1.11 Sens 4 44% 33% 44% 126 At Enrollment sCr or UO sCr only UO only Spec 4 70% 71% 71% Cutoff 5 1.55 1.81 1.56 Sens 5 35% 29% 39% Spec 5 81% 80% 80% Cutoff 6 2.58 3.64 2.48 Sens 6 20% 19% 23% Spec 6 90% 91% 90% OR Quart 2 1.5 0.58 3.2 p Value 0.32 0.46 0.016 95% CI of 0.68 0.13 1.2 OR Quart2 3.3 2.5 8.0 OR Quart 3 0.91 0.77 1.1 p Value 0.83 0.72 0.80 95% CI of 0.40 0.19 0.42 OR Quart3 2.1 3.2 3.1 OR Quart 4 2.5 1.0 3.9 p Value 0.022 1.0 0.0037 95% CI of 1.1 0.25 1.6 OR Quart4 5.5 3.9 9.9 Collagenase 3 sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 3.82 1.55 3.33 0.202 4.58 6.79 Average 12.5 9.78 8.05 4.46 14.3 10.9 Stdev 24.4 15.6 12.8 13.1 27.1 13.1 p(t-test) 0.46 0.42 0.43 Min 0.00479 0.00479 0.00479 0.00479 0.00479 0.00479 Max 182 80.1 48.1 45.8 182 52.2 n (Samp) 86 57 32 12 73 44 n (Patient) 86 57 32 12 73 44 At Enrollment sCr or UO sCr only UO only AUC 0.45 0.31 0.50 SE 0.050 0.095 0.055 p 0.31 0.042 0.99 nCohort 1 86 32 73 nCohort 2 57 12 44 Cutoff 1 0.0466 0.00623 0.202 Sens 1 74% 75% 73% Spec 1 19% 3% 26% Cutoff 2 0.00623 0.00588 0.0198 Sens 2 86% 83% 84% Spec 2 8% 3% 14% Cutoff 3 0.00519 0.00479 0.00519 Sens 3 93% 92% 95% Spec 3 5% 3% 7% Cutoff 4 14.2 6.71 17.4 Sens 4 23% 8% 25% Spec 4 71% 72% 71% Cutoff 5 20.3 15.2 21.9 127 At Enrollment sCr or UO sCr only UO only Sens 5 18% 8% 20% Spec 5 80% 81% 81% Cutoff 6 30.4 21.2 30.4 Sens 6 9% 8% 9% Spec 6 91% 91% 90% OR Quart 2 1.1 2.2 0.54 p Value 0.81 0.54 0.27 95% CI of 0.43 0.17 0.18 OR Quart2 2.9 29 1.6 OR Quart 3 0.78 8.3 1.2 p Value 0.62 0.080 0.79 95% CI of 0.29 0.78 0.41 OR Quart3 2.1 89 3.3 OR Quart 4 2.1 5.7 0.82 p Value 0.13 0.15 0.71 95% CI of 0.81 0.52 0.29 OR Quart4 5.4 63 2.3 Pancreatic prohormone sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 8.76 1.15 1.15 132 8.76 7.38 Average 110 61.8 71.3 182 115 45.8 Stdev 227 132 132 207 241 81.2 p(t-test) 0.34 0.13 0.27 Min 0.122 0.117 0.122 1.15 0.122 0.117 Max 1220 567 396 567 1220 310 n(Samp) 53 23 19 6 43 16 n (Patient) 53 23 19 6 43 16 At Enrollment sCr or UO sCr only UO only AUC 0.44 0.76 0.45 SE 0.073 0.12 0.086 p 0.42 0.034 0.54 nCohort 1 53 19 43 nCohort 2 23 6 16 Cutoff 1 0.134 6.59 0.134 Sens 1 78% 83% 75% Spec 1 25% 63% 21% Cutoff 2 0.122 6.59 0.122 Sens 2 87% 83% 81% Spec 2 6% 63% 5% Cutoff 3 0.117 0.293 0 Sens 3 91% 100% 100% Spec 3 0% 47% 0% Cutoff 4 40.4 36.4 40.4 Sens 4 30% 67% 38% Spec 4 72% 74% 72% Cutoff 5 200 200 183 Sens 5 9% 33% 6% Spec 5 81% 84% 81% 128 At Enrollment sCr or UO sCr only UO only Cutoff 6 396 338 434 Sens 6 4% 17% 0% Spec 6 91% 95% 91% OR Quart 2 0.58 >1.2 1.0 p Value 0.46 <0.91 1.0 95% CI of 0.13 >0.059 0.20 OR Quart2 2.5 na 5.0 OR Quart 3 1.3 >3.0 0.69 p Value 0.73 <0.43 0.67 95% CI of 0.33 >0.20 0.12 OR Quart3 4.8 na 3.8 OR Quart 4 1.0 >4.5 1.5 p Value 1.0 <0.26 0.60 95% CI of 0.25 >0.34 0.31 OR Quart4 3.9 na 7.4 Transthyretin sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 23.4 42.0 26.4 40.0 26.0 52.7 Average 54.7 80.7 49.5 129 53.1 94.8 Stdev 86.1 120 65.3 266 86.0 132 p(t-test) 0.094 0.078 0.021 Min 0.430 2.55 1.04 5.86 0.430 2.55 Max 648 677 355 997 648 677 n (Samp) 113 67 42 13 96 53 n (Patient) 113 67 42 13 96 53 At Enrollment sCr or UO sCr only UO only AUC 0.61 0.59 0.66 SE 0.044 0.093 0.048 p 0.010 0.33 6.OE-4 nCohort 1 113 42 96 nCohort 2 67 13 53 Cutoff 1 26.3 26.9 27.3 Sens 1 70% 77% 72% Spec 1 52% 52% 52% Cutoff 2 16.7 16.1 22.6 Sens 2 81% 85% 81% Spec 2 36% 31% 48% Cutoff 3 8.43 6.53 11.7 Sens 3 91% 92% 91% Spec 3 23% 14% 27% Cutoff 4 52.9 51.2 52.2 Sens 4 39% 31% 51% Spec 4 71% 71% 71% Cutoff 5 75.4 64.2 64.8 Sens 5 27% 31% 36% Spec 5 81% 81% 80% Cutoff 6 119 98.6 131 Sens 6 16% 31% 15% 129 At Enrollment sCr or UO sCr only UO only Spec 6 90% 90% 91% OR Quart 2 1.5 1.5 1.4 p Value 0.35 0.69 0.57 95% CI of 0.62 0.21 0.45 OR Quart2 3.9 11 4.2 OR Quart 3 3.0 2.2 4.1 p Value 0.018 0.42 0.0086 95% CI of 1.2 0.33 1.4 OR Quart3 7.2 15 12 OR Quart 4 2.3 2.2 4.3 p Value 0.076 0.42 0.0061 95% CI of 0.92 0.33 1.5 OR Quart4 5.6 15 12 C-peptide Urine sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 19300 17200 14900 6130 24100 17200 Average 29000 24100 25200 17000 32400 23800 Stdev 26300 23400 25500 27800 26800 23900 p(t-test) 0.21 0.33 0.052 Min 0.0955 180 0.0614 558 0.0955 180 Max 100000 100000 100000 94700 100000 100000 n (Samp) 113 68 42 13 96 54 n (Patient) 113 68 42 13 96 54 At Enrollment sCr or UO sCr only UO only AUC 0.45 0.32 0.40 SE 0.045 0.090 0.049 p 0.22 0.042 0.032 nCohort 1 113 42 96 nCohort 2 68 13 54 Cutoff 1 8450 940 8070 Sens 1 71% 77% 70% Spec 1 26% 2% 18% Cutoff 2 6130 936 5600 Sens 2 81% 85% 81% Spec 2 14% 2% 11% Cutoff 3 1110 558 1340 Sens 3 91% 92% 91% Spec 3 2% 2% 3% Cutoff 4 38000 27100 42400 Sens 4 19% 15% 13% Spec 4 71% 71% 71% Cutoff 5 48200 43100 55400 Sens 5 16% 15% 11% Spec 5 81% 81% 80% Cutoff 6 70200 62400 71300 Sens 6 4% 8% 6% Spec 6 90% 90% 91% OR Quart 2 2.0 1.0 2.9 130 At Enrollment sCr or UO sCr only UO only p Value 0.11 1.0 0.043 95% CI of 0.85 0.12 1.0 OR Quart2 4.8 8.3 7.9 OR Quart 3 1.5 1.6 1.7 p Value 0.34 0.62 0.30 95% CI of 0.64 0.23 0.61 OR Quart3 3.7 12 4.9 OR Quart 4 1.7 5.1 3.6 p Value 0.24 0.083 0.014 95% CI of 0.70 0.81 1.3 OR Quart4 4.1 33 9.8 Peptide YY Urine sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 10.7 3.92 22.6 49.5 8.01 0.837 Average 50.6 29.4 56.2 78.0 49.4 17.3 Stdev 126 66.7 111 83.2 130 27.7 p(t-test) 0.20 0.52 0.076 Min 0.00976 0.00976 0.0101 0.0196 0.00976 0.00976 Max 762 478 502 278 762 113 n (Samp) 113 68 42 13 96 54 n (Patient) 113 68 42 13 96 54 At Enrollment sCr or UO sCr only UO only AUC 0.44 0.66 0.42 SE 0.044 0.091 0.049 p 0.16 0.078 0.11 nCohort 1 113 42 96 nCohort 2 68 13 54 Cutoff 1 0.0188 16.6 0.0188 Sens 1 72% 77% 72% Spec 1 17% 45% 18% Cutoff 2 0.0131 10.3 0.0131 Sens 2 85% 85% 83% Spec 2 9% 45% 10% Cutoff 3 0.0101 2.77 0.0101 Sens 3 93% 92% 91% Spec 3 4% 40% 5% Cutoff 4 28.2 36.9 26.8 Sens 4 31% 62% 26% Spec 4 71% 71% 71% Cutoff 5 50.0 60.1 35.6 Sens 5 16% 38% 19% Spec 5 81% 81% 80% Cutoff 6 110 157 95.4 Sens 6 6% 15% 2% Spec 6 90% 90% 91% OR Quart 2 0.85 4.8 1.0 p Value 0.71 0.19 0.94 95% CI of 0.35 0.46 0.39 131 At Enrollment sCr or UO sCr only UO only OR Quart2 2.0 50 2.7 OR Quart 3 0.76 3.3 1.1 p Value 0.55 0.33 0.81 95% CI of 0.31 0.29 0.43 OR Quart3 1.8 36 2.9 OR Quart 4 2.3 6.7 1.8 p Value 0.048 0.11 0.20 95% CI of 1.0 0.66 0.72 OR Quart4 5.5 67 4.7 [0171] Table 4: Comparison of the maximum marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0) and the maximum values in urine samples collected from subjects between enrollment and 0, 24 hours, and 48 hours prior to reaching stage F in Cohort 2. Agouti-related protein sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 1.34 1.80 1.34 1.78 1.34 1.63 Average 1.94 2.28 1.94 2.28 1.94 2.06 Stdev 2.71 1.77 2.71 1.77 2.71 1.45 p(t-test) 0.54 0.55 0.87 Min 0.0195 0.213 0.0195 0.213 0.0195 0.496 Max 20.0 6.53 20.0 6.53 20.0 5.30 n (Samp) 109 26 109 25 109 14 n (Patient) 109 26 109 25 109 14 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 1.39 2.35 1.39 2.35 1.39 2.35 Average 2.36 2.52 2.36 2.48 2.36 2.38 Stdev 3.00 1.96 3.00 1.92 3.00 1.55 p(t-test) 0.84 0.89 0.99 Min 0.0195 0.213 0.0195 0.213 0.0195 0.496 Max 20.0 6.53 20.0 6.53 20.0 5.30 n (Samp) 229 14 229 14 229 10 n (Patient) 229 14 229 14 229 10 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 1.28 1.30 1.28 1.44 1.28 0.962 Average 1.80 1.86 1.80 1.88 1.80 1.37 Stdev 2.52 1.47 2.52 1.51 2.52 1.05 p(t-test) 0.92 0.90 0.64 Min 0.0195 0.496 0.0195 0.496 0.0195 0.496 Max 20.0 6.12 20.0 6.12 20.0 3.44 n (Samp) 124 16 124 15 124 8 n (Patient) 124 16 124 15 124 8 132 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.60 0.56 0.56 0.60 0.56 0.56 0.58 0.58 0.45 SE 0.064 0.082 0.079 0.065 0.082 0.081 0.084 0.096 0.11 p 0.13 0.45 0.43 0.14 0.47 0.45 0.34 0.40 0.66 nCohort 1 109 229 124 109 229 124 109 229 124 nCohort 2 26 14 16 25 14 15 14 10 8 Cutoff 1 0.965 0.935 0.965 0.965 0.935 0.965 0.888 1.08 0.755 Sens 1 73% 71% 75% 72% 71% 73% 71% 70% 75% Spec 1 35% 29% 37% 35% 29% 37% 32% 36% 28% Cutoff 2 0.855 0.600 0.880 0.855 0.600 0.880 0.755 0.935 0.672 Sens 2 81% 86% 81% 80% 86% 80% 86% 80% 88% Spec 2 32% 19% 34% 32% 19% 34% 27% 29% 27% Cutoff 3 0.587 0.478 0.672 0.587 0.478 0.672 0.678 0.885 0.478 Sens 3 92% 93% 94% 92% 93% 93% 93% 90% 100% Spec 3 24% 15% 27% 24% 15% 27% 26% 28% 22% Cutoff 4 1.93 2.58 1.82 1.93 2.58 1.82 1.93 2.58 1.82 Sens 4 46% 43% 38% 44% 43% 33% 50% 40% 25% Spec 4 71% 70% 70% 71% 70% 70% 71% 70% 70% Cutoff 5 2.63 3.33 2.58 2.63 3.33 2.58 2.63 3.33 2.58 Sens 5 31% 36% 19% 32% 36% 20% 29% 30% 12% Spec 5 81% 80% 81% 81% 80% 81% 81% 80% 81% Cutoff 6 3.36 4.50 3.28 3.36 4.50 3.28 3.36 4.50 3.28 Sens 6 27% 14% 19% 28% 14% 20% 21% 10% 12% Spec 6 91% 90% 90% 91% 90% 90% 91% 90% 90% OR Quart 2 1.9 0.98 3.4 1.6 0.98 6.8 2.7 3.1 0 p Value 0.35 0.98 0.15 0.53 0.98 0.083 0.26 0.34 na 95% CI of 0.49 0.19 0.64 0.40 0.19 0.78 0.48 0.31 na OR Quart2 7.1 5.1 18 6.1 5.1 60 15 30 na OR Quart 3 1.2 0.64 1.5 1.3 0.64 4.3 0.47 2.0 2.8 p Value 0.76 0.64 0.64 0.72 0.64 0.21 0.54 0.58 0.25 95% CI of 0.30 0.10 0.24 0.31 0.10 0.45 0.040 0.18 0.50 OR Quart3 5.1 4.0 9.9 5.3 4.0 40 5.4 23 15 OR Quart 4 3.0 2.1 2.8 3.0 2.1 4.3 3.4 4.1 0.48 p Value 0.090 0.32 0.25 0.090 0.32 0.21 0.16 0.21 0.56 95% CI of 0.84 0.49 0.50 0.84 0.49 0.45 0.62 0.45 0.042 OR Quart4 11 8.7 15 11 8.7 40 18 38 5.6 Osteocalcin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 6840 8560 6840 8230 6840 8260 Average 7910 11600 7910 10100 7910 9960 Stdev 7360 9240 7360 8680 7360 6940 p(t-test) 0.0054 0.097 0.20 Min 146 1080 146 1080 146 2630 Max 83000 49400 83000 49400 83000 29500 n(Samp) 191 42 191 40 191 24 n (Patient) 191 42 191 40 191 24 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 7620 10400 7620 9740 7620 9960 Average 9420 12000 9420 10400 9420 12100 133 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Stdev 8790 8520 8790 7100 8790 7940 p(t-test) 0.20 0.63 0.28 Min 146 1080 146 1080 146 4220 Max 83500 29500 83500 29500 83500 29500 n (Samp) 386 20 386 20 386 13 n (Patient) 386 20 386 20 386 13 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 7010 7530 7010 6640 7010 5340 Average 8660 10700 8660 9600 8660 7990 Stdev 8580 9770 8580 9820 8580 6660 p(t-test) 0.25 0.60 0.74 Min 146 2240 146 2240 146 2630 Max 83000 49400 83000 49400 83000 29500 n (Samp) 202 29 202 27 202 18 n (Patient) 202 29 202 27 202 18 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.64 0.60 0.57 0.60 0.57 0.52 0.61 0.63 0.47 SE 0.050 0.068 0.059 0.051 0.068 0.060 0.064 0.084 0.072 p 0.0051 0.16 0.25 0.060 0.34 0.77 0.094 0.13 0.70 nCohort 1 191 386 202 191 386 202 191 386 202 nCohort 2 42 20 29 40 20 27 24 13 18 Cutoff 1 5800 5920 5040 5500 5920 4620 5500 5920 4440 Sens 1 71% 70% 72% 70% 70% 70% 71% 77% 72% Spec 1 40% 33% 35% 39% 33% 33% 39% 33% 30% Cutoff 2 4620 5130 4440 4540 5130 4190 4440 5500 3390 Sens 2 81% 80% 83% 80% 80% 81% 83% 85% 83% Spec 2 35% 28% 30% 34% 28% 27% 32% 30% 19% Cutoff 3 4210 4210 2760 3800 4210 2760 3390 4990 2760 Sens 3 90% 90% 93% 90% 90% 93% 92% 92% 94% Spec 3 29% 21% 13% 25% 21% 13% 21% 27% 13% Cutoff 4 8850 10400 9010 8850 10400 9010 8850 10400 9010 Sens 4 48% 50% 38% 45% 45% 33% 46% 46% 28% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 10400 12300 11200 10400 12300 11200 10400 12300 11200 Sens 5 40% 35% 28% 32% 25% 19% 33% 38% 17% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 14100 17200 15900 14100 17200 15900 14100 17200 15900 Sens 6 31% 20% 21% 18% 10% 11% 21% 15% 11% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 4.8 1.7 3.8 2.4 1.7 2.0 2.1 3.0 1.0 p Value 0.021 0.48 0.055 0.12 0.48 0.26 0.32 0.34 1.0 95% CI of 1.3 0.39 0.97 0.79 0.39 0.61 0.49 0.31 0.24 OR Quart2 18 7.2 14 7.5 7.2 6.2 8.8 30 4.2 OR Quart 3 3.4 1.3 2.5 2.2 2.1 1.2 2.1 3.0 1.6 p Value 0.081 0.70 0.21 0.18 0.32 0.75 0.32 0.34 0.51 95% CI of 0.86 0.29 0.61 0.69 0.50 0.35 0.49 0.31 0.42 OR Quart3 13 6.2 10 6.8 8.5 4.3 8.8 30 5.9 OR Quart 4 8.0 2.8 3.3 3.3 2.0 1.4 3.3 6.3 1.0 p Value 0.0015 0.14 0.085 0.033 0.32 0.56 0.084 0.092 1.0 134 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only 95% CI of 2.2 0.72 0.85 1.1 0.50 0.43 0.85 0.74 0.24 OR Quart4 29 11 13 9.9 8.4 4.8 13 53 4.2 Complement factor H sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 12.3 10.4 12.3 11.0 12.3 18.5 Average 23.3 26.3 23.3 26.9 23.3 25.5 Stdev 34.1 35.4 34.1 36.0 34.1 25.2 p(t-test) 0.67 0.62 0.80 Min 0.132 2.76 0.132 2.52 0.132 2.83 Max 282 142 282 142 282 99.4 n (Samp) 151 28 151 27 151 16 n (Patient) 151 28 151 27 151 16 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 13.7 9.74 13.7 9.74 13.7 20.2 Average 25.3 29.2 25.3 29.0 25.3 29.2 Stdev 35.7 39.9 35.7 40.1 35.7 29.7 p(t-test) 0.68 0.70 0.72 Min 0.0956 2.76 0.0956 2.76 0.0956 2.52 Max 282 142 282 142 282 99.4 n (Samp) 290 15 290 15 290 11 n (Patient) 290 15 290 15 290 11 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 14.1 9.35 14.1 9.74 14.1 10.4 Average 29.3 19.5 29.3 20.3 29.3 13.9 Stdev 68.9 27.0 68.9 27.6 68.9 9.50 p(t-test) 0.55 0.60 0.48 Min 0.132 2.76 0.132 2.52 0.132 2.83 Max 772 118 772 118 772 29.8 n (Samp) 155 18 155 17 155 10 n (Patient) 155 18 155 17 155 10 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.51 0.49 0.43 0.52 0.48 0.44 0.57 0.56 0.42 SE 0.060 0.077 0.074 0.061 0.077 0.076 0.078 0.091 0.097 p 0.86 0.95 0.33 0.80 0.84 0.43 0.35 0.54 0.43 nCohort 1 151 290 155 151 290 155 151 290 155 nCohort 2 28 15 18 27 15 17 16 11 10 Cutoff 1 7.66 7.96 6.43 7.66 7.34 7.34 9.47 9.47 8.52 Sens 1 71% 73% 72% 70% 73% 71% 75% 73% 70% Spec 1 30% 29% 21% 30% 27% 25% 39% 38% 30% Cutoff 2 6.14 7.34 6.00 6.03 6.03 6.00 8.52 7.34 7.34 Sens 2 82% 80% 83% 81% 80% 82% 81% 82% 80% Spec 2 25% 27% 19% 25% 20% 19% 36% 27% 25% Cutoff 3 3.56 3.56 2.81 3.56 3.56 2.81 3.56 3.56 3.56 135 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 3 93% 93% 94% 93% 93% 94% 94% 91% 90% Spec 3 13% 10% 8% 13% 10% 8% 13% 10% 10% Cutoff 4 23.9 24.3 24.8 23.9 24.3 24.8 23.9 24.3 24.8 Sens 4 32% 33% 28% 33% 33% 29% 38% 45% 20% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 29.8 34.9 31.5 29.8 34.9 31.5 29.8 34.9 31.5 Sens 5 29% 20% 17% 30% 20% 18% 31% 27% 0% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 52.5 51.2 60.5 52.5 51.2 60.5 52.5 51.2 60.5 Sens 6 11% 13% 6% 11% 13% 6% 12% 18% 0% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.6 0.19 0.75 1.4 0.19 0.73 2.6 1.5 3.2 p Value 0.43 0.14 0.72 0.59 0.14 0.69 0.26 0.65 0.32 95% CI of 0.51 0.022 0.16 0.43 0.022 0.15 0.48 0.25 0.32 OR Quart2 4.9 1.7 3.6 4.3 1.7 3.5 14 9.4 32 OR Quart 3 0.79 1.2 1.3 0.81 1.0 1.3 2.1 0.49 4.4 p Value 0.72 0.74 0.70 0.75 0.98 0.73 0.42 0.57 0.19 95% CI of 0.22 0.36 0.33 0.23 0.28 0.32 0.35 0.044 0.47 OR Quart3 2.8 4.2 5.3 2.9 3.7 5.1 12 5.6 41 OR Quart 4 1.4 0.59 1.6 1.4 0.80 1.3 2.6 2.6 2.1 p Value 0.59 0.48 0.48 0.59 0.75 0.73 0.26 0.27 0.55 95% CI of 0.43 0.14 0.42 0.43 0.21 0.32 0.48 0.48 0.18 OR Quart4 4.3 2.6 6.2 4.3 3.1 5.1 14 14 24 Follistatin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 9.97 27.7 9.97 23.1 9.97 27.7 Average 70.8 60.1 70.8 58.6 70.8 34.0 Stdev 543 137 543 139 543 24.7 p(t-test) 0.91 0.90 0.76 Min 0.0191 3.84 0.0191 3.84 0.0191 1.87 Max 8290 840 8290 840 8290 98.2 n (Samp) 242 36 242 35 242 20 n (Patient) 242 36 242 35 242 20 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 11.8 28.3 11.8 23.1 11.8 25.1 Average 55.5 37.6 55.5 33.2 55.5 31.7 Stdev 413 32.3 413 27.0 413 27.7 p(t-test) 0.85 0.81 0.83 Min 0.0191 3.84 0.0191 3.84 0.0191 1.87 Max 8290 125 8290 98.2 8290 98.2 n (Samp) 423 19 423 19 423 14 n (Patient) 423 19 423 19 423 14 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 11.0 37.5 11.0 26.9 11.0 27.1 Average 79.5 152 79.5 125 79.5 35.6 Stdev 589 420 589 300 589 21.5 136 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) 0.55 0.71 0.79 Min 0.0191 4.96 0.0191 4.96 0.0191 4.79 Max 8290 2010 8290 1300 8290 69.9 n (Samp) 205 25 205 24 205 13 n (Patient) 205 25 205 24 205 13 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.72 0.68 0.75 0.71 0.66 0.74 0.69 0.62 0.72 SE 0.050 0.069 0.059 0.052 0.070 0.060 0.068 0.081 0.082 p 8.8E-6 0.010 2.3E-5 5.6E-5 0.025 9.6E-5 0.0048 0.14 0.0066 nCohort 1 242 423 205 242 423 205 242 423 205 nCohort 2 36 19 25 35 19 24 20 14 13 Cutoff 1 18.6 18.6 19.9 15.0 15.2 19.9 20.4 16.8 21.4 Sens 1 72% 74% 72% 71% 74% 71% 70% 71% 77% Spec 1 67% 63% 67% 64% 59% 67% 70% 61% 69% Cutoff 2 14.5 12.0 14.4 14.5 12.0 12.1 18.6 4.69 19.9 Sens 2 81% 84% 80% 80% 84% 83% 80% 86% 85% Spec 2 63% 51% 59% 63% 51% 53% 67% 21% 67% Cutoff 3 9.57 4.09 9.34 9.57 3.96 9.34 4.53 3.79 8.95 Sens 3 92% 95% 92% 91% 95% 92% 90% 93% 92% Spec 3 49% 18% 45% 49% 17% 45% 25% 16% 43% Cutoff 4 21.8 23.9 23.7 21.8 23.9 23.7 21.8 23.9 23.7 Sens 4 61% 53% 60% 54% 47% 54% 65% 50% 62% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 33.9 39.0 34.9 33.9 39.0 34.9 33.9 39.0 34.9 Sens 5 42% 32% 52% 34% 32% 46% 30% 29% 38% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 68.2 71.8 64.8 68.2 71.8 64.8 68.2 71.8 64.8 Sens 6 22% 11% 32% 20% 11% 29% 10% 7% 15% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 0.65 0.99 4.1 0.66 0.99 4.2 0 0 0.98 p Value 0.64 0.99 0.21 0.65 0.99 0.20 na na 0.99 95% CI of 0.10 0.14 0.45 0.11 0.14 0.46 na na 0.060 OR Quart2 4.0 7.2 38 4.1 7.2 39 na na 16 OR Quart 3 6.6 4.2 7.8 7.2 4.8 9.1 3.3 2.4 5.4 p Value 0.0039 0.072 0.058 0.0025 0.048 0.040 0.083 0.21 0.13 95% CI of 1.8 0.88 0.93 2.0 1.0 1.1 0.86 0.61 0.61 OR Quart3 24 20 66 26 23 76 13 9.6 48 OR Quart 4 6.0 3.6 16 5.0 3.1 13 2.9 1.3 6.5 p Value 0.0065 0.11 0.0084 0.015 0.17 0.015 0.14 0.71 0.089 95% CI of 1.7 0.74 2.0 1.4 0.61 1.6 0.72 0.29 0.75 OR Quart4 22 18 130 18 16 110 11 6.1 56 Vitamin D-binding protein sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 218 4340 218 1900 218 5870 Average 9990 55000 9990 46300 9990 80600 Stdev 46300 113000 46300 110000 46300 147000 p(t-test) 0.0029 0.015 5.OE-4 Min 1.61 138 1.61 95.4 1.61 1.09 137 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max 352000 401000 352000 401000 352000 401000 n (Samp) 97 24 97 23 97 12 n (Patient) 97 24 97 23 97 12 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 344 11700 344 10400 344 11700 Average 12800 80800 12800 78200 12800 107000 Stdev 46000 139000 46000 141000 46000 162000 p(t-test) 2.5E-5 5.1E-5 8.9E-7 Min 1.61 223 1.61 95.4 1.61 1.09 Max 365000 401000 365000 401000 365000 401000 n (Samp) 210 13 210 13 210 9 n (Patient) 210 13 210 13 210 9 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 245 2710 245 1640 245 1270 Average 12400 45500 12400 32900 12400 59300 Stdev 47400 113000 47400 106000 47400 151000 p(t-test) 0.043 0.20 0.039 Min 6.72 138 6.72 138 6.72 190 Max 352000 401000 352000 401000 352000 401000 n (Samp) 109 15 109 14 109 7 n (Patient) 109 15 109 14 109 7 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.80 0.80 0.72 0.76 0.74 0.71 0.74 0.73 0.70 SE 0.057 0.075 0.078 0.062 0.080 0.081 0.085 0.097 0.11 p 1.3E-7 4.8E-5 0.0039 2.4E-5 0.0023 0.012 0.0040 0.016 0.076 nCohort 1 97 210 109 97 210 109 97 210 109 nCohort 2 24 13 15 23 13 14 12 9 7 Cutoff 1 1080 1150 967 954 968 967 464 1150 464 Sens 1 71% 77% 73% 74% 77% 71% 75% 78% 71% Spec 1 76% 70% 72% 74% 68% 72% 68% 70% 62% Cutoff 2 528 968 464 464 528 190 274 218 274 Sens 2 83% 85% 80% 83% 85% 86% 83% 89% 86% Spec 2 69% 68% 62% 68% 61% 39% 57% 37% 54% Cutoff 3 218 528 186 186 218 186 218 0 186 Sens 3 92% 92% 93% 91% 92% 93% 92% 100% 100% Spec 3 51% 61% 39% 44% 37% 39% 51% 0% 39% Cutoff 4 715 1500 954 715 1500 954 715 1500 954 Sens 4 79% 62% 73% 74% 54% 71% 67% 67% 57% Spec 4 70% 70% 71% 70% 70% 71% 70% 70% 71% Cutoff 5 3200 5060 4570 3200 5060 4570 3200 5060 4570 Sens 5 50% 62% 40% 43% 54% 36% 50% 67% 29% Spec 5 80% 80% 81% 80% 80% 81% 80% 80% 81% Cutoff 6 13000 29700 29300 13000 29700 29300 13000 29700 29300 Sens 6 29% 38% 13% 22% 31% 7% 25% 33% 14% Spec 6 91% 90% 91% 91% 90% 91% 91% 90% 91% OR Quart 2 >3.3 >1.0 >3.3 3.2 0.98 >3.2 1.0 0.98 >1.0 138 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only p Value <0.31 <1.0 <0.31 0.32 0.99 <0.32 1.0 0.99 <0.98 95% CI of >0.33 >0.061 >0.33 0.32 0.060 >0.32 0.059 0.060 >0.062 OR Quart2 na na na 33 16 na 17 16 na OR Quart 3 >13 >4.2 >6.0 12 4.2 >5.8 4.5 0.98 >4.6 p Value <0.019 <0.20 <0.11 0.021 0.21 <0.12 0.19 0.99 <0.18 95% CI of >1.5 >0.46 >0.65 1.5 0.45 >0.63 0.47 0.060 >0.49 OR Quart3 na na na 110 38 na 43 16 na OR Quart 4 >19 >9.2 >9.0 14 7.7 >7.2 7.1 6.5 >2.1 p Value <0.0065 <0.040 <0.046 0.014 0.060 <0.076 0.080 0.089 <0.54 95% CI of >2.3 >1.1 >1.0 1.7 0.92 >0.81 0.79 0.75 >0.18 OR Quart4 na na na 120 65 na 63 56 na Glucagon sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 238 9330 238 9330 238 9330 Average 1810 5710 1810 5510 1810 6750 Stdev 3130 4510 3130 4720 3130 4410 p(t-test) 1.8E-4 4.1E-4 1.5E-4 Min 2.40 45.3 2.40 31.5 2.40 238 Max 9330 9330 9330 9330 9330 9330 n(Samp) 98 12 98 12 98 7 n (Patient) 98 12 98 12 98 7 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 347 9330 347 9330 nd nd Average 2050 6650 2050 6260 nd nd Stdev 3360 4210 3360 4770 nd nd p(t-test) 0.0013 0.0034 nd nd Min 1.98 174 1.98 31.5 nd nd Max 9330 9330 9330 9330 nd nd n(Samp) 159 6 159 6 nd nd n (Patient) 159 6 159 6 nd nd UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 238 9330 238 9330 238 9330 Average 1570 5910 1570 5910 1570 6320 Stdev 2760 4720 2760 4720 2760 4670 p(t-test) 1.5E-4 1.5E-4 2.1E-4 Min 2.40 45.3 2.40 45.3 2.40 238 Max 9330 9330 9330 9330 9330 9330 n(Samp) 84 8 84 8 84 6 n (Patient) 84 8 84 8 84 6 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.76 0.79 0.77 0.72 0.70 0.77 0.82 nd 0.81 SE 0.084 0.11 0.10 0.087 0.12 0.10 0.099 nd 0.11 p 0.0020 0.011 0.0082 0.011 0.100 0.0082 0.0011 nd 0.0044 139 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only nCohort 1 98 159 84 98 159 84 98 nd 84 nCohort 2 12 6 8 12 6 8 7 nd 6 Cutoff 1 275 677 238 174 98.8 238 4790 nd 238 Sens 1 75% 83% 75% 75% 83% 75% 71% nd 83% Spec 1 56% 69% 55% 37% 28% 55% 87% nd 55% Cutoff 2 174 677 98.8 98.8 98.8 98.8 275 nd 238 Sens 2 83% 83% 88% 83% 83% 88% 86% nd 83% Spec 2 37% 69% 33% 37% 28% 33% 56% nd 55% Cutoff 3 98.8 98.8 41.7 41.7 16.2 41.7 98.8 nd 98.8 Sens 3 92% 100% 100% 92% 100% 100% 100% nd 100% Spec 3 37% 28% 32% 35% 25% 32% 37% nd 33% Cutoff 4 2420 2420 2420 2420 2420 2420 2420 nd 2420 Sens 4 58% 67% 62% 58% 67% 62% 71% nd 67% Spec 4 85% 82% 88% 85% 82% 88% 85% nd 88% Cutoff 5 2420 2420 2420 2420 2420 2420 2420 nd 2420 Sens 5 58% 67% 62% 58% 67% 62% 71% nd 67% Spec 5 85% 82% 88% 85% 82% 88% 85% nd 88% Cutoff 6 9330 9330 4790 9330 9330 4790 9330 nd 4790 Sens 6 0% 0% 62% 0% 0% 62% 0% nd 67% Spec 6 100% 100% 90% 100% 100% 90% 100% nd 90% OR Quart 2 >3.2 >1.0 >2.2 >4.5 1.0 >2.2 >1.0 nd >1.0 p Value <0.32 <0.99 <0.53 <0.19 1.0 <0.53 <0.98 nd <1.0 95% CI of >0.32 >0.062 >0.18 >0.47 0.060 >0.18 >0.062 nd >0.059 OR Quart2 na na na na 17 na na nd na OR Quart 3 >1.0 >1.0 >1.0 >1.0 0 >1.0 >1.0 nd >1.0 p Value <0.98 <0.99 <0.98 <0.98 na <0.98 <0.98 nd <0.97 95% CI of >0.062 >0.062 >0.062 >0.062 na >0.062 >0.062 nd >0.061 OR Quart3 na na na na na na na nd na OR Quart 4 >11 >4.3 >6.4 >9.0 4.2 >6.4 >5.9 nd >4.6 p Value <0.031 <0.20 <0.10 <0.047 0.21 <0.10 <0.12 nd <0.19 95% CI of >1.2 >0.46 >0.68 >1.0 0.45 >0.68 >0.64 nd >0.48 OR Quart4 na na na na 39 na na nd na Glucagon-like peptide 1 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 5.53 7.46 5.53 7.46 5.53 9.60 Average 10.3 16.1 10.3 16.1 10.3 10.2 Stdev 48.3 29.4 48.3 29.4 48.3 7.43 p(t-test) 0.68 0.68 1.00 Min 0.407 0.685 0.407 0.685 0.407 0.685 Max 482 107 482 107 482 24.9 n(Samp) 98 12 98 12 98 7 n (Patient) 98 12 98 12 98 7 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 5.53 4.31 5.53 4.31 nd nd Average 13.8 4.83 13.8 4.83 nd nd Stdev 57.7 4.04 57.7 4.04 nd nd p(t-test) 0.71 0.71 nd nd Min 0.407 0.685 0.407 0.685 nd nd 140 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max 519 9.60 519 9.60 nd nd n (Samp) 159 6 159 6 nd nd n (Patient) 159 6 159 6 nd nd UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 5.53 9.50 5.53 9.50 5.53 9.50 Average 11.2 21.8 11.2 21.8 11.2 10.3 Stdev 52.2 35.2 52.2 35.2 52.2 8.14 p(t-test) 0.57 0.57 0.97 Min 0.407 0.685 0.407 0.685 0.407 0.685 Max 482 107 482 107 482 24.9 n (Samp) 84 8 84 8 84 6 n (Patient) 84 8 84 8 84 6 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.63 0.43 0.70 0.63 0.43 0.70 0.72 nd 0.68 SE 0.091 0.12 0.11 0.091 0.12 0.11 0.11 nd 0.12 p 0.15 0.57 0.061 0.15 0.57 0.061 0.054 nd 0.15 nCohort 1 98 159 84 98 159 84 98 nd 84 nCohort 2 12 6 8 12 6 8 7 nd 6 Cutoff 1 5.14 0.407 5.14 5.14 0.407 5.14 8.07 nd 5.14 Sens 1 75% 100% 88% 75% 100% 88% 71% nd 83% Spec 1 44% 8% 46% 44% 8% 46% 72% nd 46% Cutoff 2 2.30 0.407 5.14 2.30 0.407 5.14 5.14 nd 5.14 Sens 2 83% 100% 88% 83% 100% 88% 86% nd 83% Spec 2 28% 8% 46% 28% 8% 46% 44% nd 46% Cutoff 3 0.407 0.407 0.407 0.407 0.407 0.407 0.407 nd 0.407 Sens 3 100% 100% 100% 100% 100% 100% 100% nd 100% Spec 3 9% 8% 8% 9% 8% 8% 9% nd 8% Cutoff 4 6.54 9.39 9.60 6.54 9.39 9.60 6.54 nd 9.60 Sens 4 50% 17% 38% 50% 17% 38% 71% nd 33% Spec 4 71% 70% 90% 71% 70% 90% 71% nd 90% Cutoff 5 9.60 9.60 9.60 9.60 9.60 9.60 9.60 nd 9.60 Sens 5 25% 0% 38% 25% 0% 38% 29% nd 33% Spec 5 93% 91% 90% 93% 91% 90% 93% nd 90% Cutoff 6 9.60 9.60 9.60 9.60 9.60 9.60 9.60 nd 9.60 Sens 6 25% 0% 38% 25% 0% 38% 29% nd 33% Spec 6 93% 91% 90% 93% 91% 90% 93% nd 90% OR Quart 2 0.46 >3.3 0 0.46 >3.3 0 1.0 nd 0.95 p Value 0.54 <0.31 na 0.54 <0.31 na 1.0 nd 0.97 95% CI of 0.039 >0.33 na 0.039 >0.33 na 0.059 nd 0.056 OR Quart2 5.4 na na 5.4 na na 17 nd 16 OR Quart 3 2.8 >1.0 4.6 2.8 >1.0 4.6 2.1 nd 2.1 p Value 0.24 <0.97 0.19 0.24 <0.97 0.19 0.56 nd 0.56 95% CI of 0.50 >0.064 0.48 0.50 >0.064 0.48 0.18 nd 0.18 OR Quart3 16 na 45 16 na 45 25 nd 25 OR Quart 4 2.1 >2.2 3.3 2.1 >2.2 3.3 3.1 nd 2.0 p Value 0.42 <0.54 0.32 0.42 <0.54 0.32 0.34 nd 0.58 95% CI of 0.35 >0.19 0.32 0.35 >0.19 0.32 0.30 nd 0.17 OR Quart4 12 na 34 12 na 34 32 nd 24 141 Appetite-regulating hormone sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.560 0.560 0.560 0.560 0.560 0.108 Average 1.04 6.38 1.04 6.25 1.04 1.09 Stdev 1.42 18.7 1.42 18.7 1.42 1.81 p(t-test) 0.0052 0.0064 0.93 Min 0.0793 0.0793 0.0793 0.0793 0.0793 0.0793 Max 8.07 65.5 8.07 65.5 8.07 4.96 n(Samp) 98 12 98 12 98 7 n (Patient) 98 12 98 12 98 7 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.560 0.560 0.560 0.396 nd nd Average 1.55 0.597 1.55 0.345 nd nd Stdev 5.30 0.610 5.30 0.242 nd nd p(t-test) 0.66 0.58 nd nd Min 0.0793 0.0793 0.0793 0.0793 nd nd Max 65.5 1.75 65.5 0.560 nd nd n(Samp) 159 6 159 6 nd nd n (Patient) 159 6 159 6 nd nd UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.560 0.560 0.560 0.560 0.560 0.334 Average 1.15 9.20 1.15 9.20 1.15 1.25 Stdev 1.51 22.8 1.51 22.8 1.51 1.92 p(t-test) 0.0012 0.0012 0.87 Min 0.0793 0.0793 0.0793 0.0793 0.0793 0.0793 Max 8.07 65.5 8.07 65.5 8.07 4.96 n(Samp) 84 8 84 8 84 6 n (Patient) 84 8 84 8 84 6 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.52 0.40 0.51 0.48 0.35 0.51 0.41 nd 0.42 SE 0.089 0.12 0.11 0.089 0.12 0.11 0.12 nd 0.13 p 0.86 0.44 0.89 0.85 0.21 0.89 0.45 nd 0.54 nCohort 1 98 159 84 98 159 84 98 nd 84 nCohort 2 12 6 8 12 6 8 7 nd 6 Cutoff 1 0.0995 0 0.0995 0.0995 0 0.0995 0.0995 nd 0 Sens 1 75% 100% 75% 75% 100% 75% 71% nd 100% Spec 1 16% 0% 13% 16% 0% 13% 16% nd 0% Cutoff 2 0 0 0 0 0 0 0 nd 0 Sens 2 100% 100% 100% 100% 100% 100% 100% nd 100% Spec 2 0% 0% 0% 0% 0% 0% 0% nd 0% Cutoff 3 0 0 0 0 0 0 0 nd 0 Sens 3 100% 100% 100% 100% 100% 100% 100% nd 100% Spec 3 0% 0% 0% 0% 0% 0% 0% nd 0% Cutoff 4 0.560 1.75 1.75 0.560 1.75 1.75 0.560 nd 1.75 Sens 4 33% 0% 25% 25% 0% 25% 29% nd 17% Spec 4 70% 76% 74% 70% 76% 74% 70% nd 74% Cutoff 5 2.40 2.40 2.67 2.40 2.40 2.67 2.40 nd 2.67 142 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 5 17% 0% 25% 17% 0% 25% 14% nd 17% Spec 5 83% 82% 89% 83% 82% 89% 83% nd 89% Cutoff 6 2.67 2.92 2.92 2.67 2.92 2.92 2.67 nd 2.92 Sens 6 17% 0% 25% 17% 0% 25% 14% nd 17% Spec 6 91% 91% 90% 91% 91% 90% 91% nd 90% OR Quart 2 0.96 >1.0 0 0 >3.3 0 0 nd 2.2 p Value 0.96 <0.97 na na <0.31 na na nd 0.53 95% CI of 0.21 >0.064 na na >0.33 na na nd 0.19 OR Quart2 4.3 na na na na na na nd 26 OR Quart 3 0.22 >3.3 1.0 1.8 >1.0 1.0 1.0 nd 1.0 p Value 0.19 <0.31 1.0 0.45 <0.97 1.0 0.97 nd 1.0 95% CI of 0.023 >0.33 0.18 0.39 >0.064 0.18 0.14 nd 0.059 OR Quart3 2.1 na 5.6 8.4 na 5.6 8.0 nd 17 OR Quart 4 0.69 >2.2 0.63 1.4 >2.2 0.63 1.6 nd 2.2 p Value 0.65 <0.54 0.64 0.65 <0.54 0.64 0.61 nd 0.53 95% CI of 0.14 >0.19 0.096 0.29 >0.19 0.096 0.25 nd 0.19 OR Quart4 3.4 na 4.2 7.2 na 4.2 11 nd 26 Islet amyloid polypeptide sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.444 1.14 0.444 1.14 0.444 0.618 Average 2.51 3.59 2.51 3.59 2.51 1.16 Stdev 10.9 6.46 10.9 6.46 10.9 1.53 p(t-test) 0.74 0.74 0.74 Min 0.00151 0.00151 0.00151 0.00151 0.00151 0.00151 Max 102 23.2 102 23.2 102 4.11 n(Samp) 98 12 98 12 98 7 n (Patient) 98 12 98 12 98 7 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.467 3.48 0.467 3.48 nd nd Average 2.89 5.71 2.89 5.71 nd nd Stdev 11.2 8.76 11.2 8.76 nd nd p(t-test) 0.54 0.54 nd nd Min 0.00151 0.00151 0.00151 0.00151 nd nd Max 102 23.2 102 23.2 nd nd n(Samp) 159 6 159 6 nd nd n (Patient) 159 6 159 6 nd nd UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.506 0.802 0.506 0.802 0.506 0.413 Average 1.66 1.62 1.66 1.62 1.66 0.955 Stdev 4.19 2.08 4.19 2.08 4.19 1.57 p(t-test) 0.98 0.98 0.68 Min 0.00151 0.00151 0.00151 0.00151 0.00151 0.00151 Max 30.4 5.59 30.4 5.59 30.4 4.11 n(Samp) 84 8 84 8 84 6 n (Patient) 84 8 84 8 84 6 143 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.63 0.62 0.56 0.63 0.62 0.56 0.55 nd 0.45 SE 0.091 0.12 0.11 0.091 0.12 0.11 0.12 nd 0.13 p 0.17 0.32 0.61 0.17 0.32 0.61 0.67 nd 0.71 nCohort 1 98 159 84 98 159 84 98 nd 84 nCohort 2 12 6 8 12 6 8 7 nd 6 Cutoff 1 0.156 0 0.156 0.156 0 0.156 0.156 nd 0.0802 Sens 1 75% 100% 75% 75% 100% 75% 71% nd 83% Spec 1 40% 0% 35% 40% 0% 35% 40% nd 30% Cutoff 2 0.0802 0 0.0802 0.0802 0 0.0802 0.0802 nd 0.0802 Sens 2 83% 100% 88% 83% 100% 88% 86% nd 83% Spec 2 37% 0% 30% 37% 0% 30% 37% nd 30% Cutoff 3 0 0 0 0 0 0 0 nd 0 Sens 3 100% 100% 100% 100% 100% 100% 100% nd 100% Spec 3 0% 0% 0% 0% 0% 0% 0% nd 0% Cutoff 4 1.06 1.16 1.16 1.06 1.16 1.16 1.06 nd 1.16 Sens 4 50% 67% 38% 50% 67% 38% 29% nd 17% Spec 4 70% 72% 71% 70% 72% 71% 70% nd 71% Cutoff 5 1.61 1.65 1.64 1.61 1.65 1.64 1.61 nd 1.64 Sens 5 42% 67% 25% 42% 67% 25% 29% nd 17% Spec 5 81% 81% 81% 81% 81% 81% 81% nd 81% Cutoff 6 3.74 3.39 2.66 3.74 3.39 2.66 3.74 nd 2.66 Sens 6 33% 50% 25% 33% 50% 25% 14% nd 17% Spec 6 91% 91% 90% 91% 91% 90% 91% nd 90% OR Quart 2 0.96 0 2.1 0.96 0 2.1 2.1 nd 2.2 p Value 0.97 na 0.56 0.97 na 0.56 0.56 nd 0.53 95% CI of 0.13 na 0.18 0.13 na 0.18 0.18 nd 0.19 OR Quart2 7.4 na 25 7.4 na 25 25 nd 26 OR Quart 3 1.6 0 3.3 1.6 0 3.3 2.1 nd 2.1 p Value 0.64 na 0.32 0.64 na 0.32 0.56 nd 0.56 95% CI of 0.24 na 0.32 0.24 na 0.32 0.18 nd 0.18 OR Quart3 10 na 34 10 na 34 25 nd 25 OR Quart 4 2.7 2.1 2.1 2.7 2.1 2.1 2.0 nd 1.0 p Value 0.26 0.42 0.56 0.26 0.42 0.56 0.58 nd 0.97 95% CI of 0.48 0.35 0.18 0.48 0.35 0.18 0.17 nd 0.061 OR Quart4 15 12 25 15 12 25 23 nd 18 Interleukin-17A sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.00492 0.00492 0.00492 0.00492 0.00492 0.00847 Average 1.98 1.41 1.98 1.29 1.98 1.34 Stdev 12.2 3.55 12.2 3.12 12.2 2.93 p(t-test) 0.74 0.70 0.79 Min 0.000344 0.000380 0.000344 0.000380 0.000344 0.000603 Max 133 17.7 133 13.0 133 13.0 n (Samp) 282 48 282 47 282 27 n (Patient) 282 48 282 47 282 27 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.00847 0.00492 0.00847 0.00492 0.00847 0.00483 Average 2.11 2.19 2.11 0.575 2.11 0.818 144 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Stdev 11.9 8.00 11.9 1.11 11.9 1.30 p(t-test) 0.98 0.53 0.66 Min 0.000344 0.000410 0.000344 0.000381 0.000344 0.000603 Max 157 39.4 157 4.03 157 4.03 n (Samp) 514 24 514 24 514 16 n (Patient) 514 24 514 24 514 16 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.00827 0.00740 0.00827 0.00492 0.00827 0.00847 Average 1.86 2.69 1.86 2.13 1.86 1.39 Stdev 12.2 6.77 12.2 4.69 12.2 3.32 p(t-test) 0.70 0.90 0.86 Min 0.000344 0.000380 0.000344 0.000380 0.000344 0.000747 Max 133 33.1 133 18.8 133 13.0 n (Samp) 251 34 251 33 251 20 n (Patient) 251 34 251 33 251 20 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.55 0.50 0.59 0.53 0.48 0.55 0.57 0.49 0.60 SE 0.046 0.060 0.054 0.046 0.061 0.055 0.060 0.074 0.069 p 0.25 0.98 0.11 0.57 0.76 0.32 0.27 0.94 0.16 nCohort1 282 514 251 282 514 251 282 514 251 nCohort 2 48 24 34 47 24 33 27 16 20 Cutoff 1 0.00361 0.00336 0.00392 0.00337 0.00336 0.00361 0.00336 0.00206 0.00392 Sens 1 71% 75% 71% 70% 71% 73% 74% 75% 70% Spec 1 46% 33% 44% 40% 33% 42% 40% 20% 44% Cutoff 2 0.00206 0.000662 0.00303 0.000747 0.000662 0.00263 0.00206 0.000662 0.00336 Sens 2 81% 83% 82% 81% 83% 82% 81% 81% 85% Spec 2 21% 9% 35% 10% 9% 31% 21% 9% 39% Cutoff 3 0.000521 0.000521 0.000662 0.000597 0.000521 0.000654 0.000603 0.000521 0.00303 Sens 3 94% 96% 91% 91% 96% 91% 93% 100% 90% Spec 3 2% 3% 11% 2% 3% 9% 4% 3% 35% Cutoff 4 0.113 0.214 0.121 0.113 0.214 0.121 0.113 0.214 0.121 Sens 4 42% 29% 44% 38% 29% 39% 44% 38% 40% Spec 4 70% 70% 71% 70% 70% 71% 70% 70% 71% Cutoff 5 0.418 0.665 0.464 0.418 0.665 0.464 0.418 0.665 0.464 Sens 5 31% 25% 32% 30% 25% 30% 33% 38% 30% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 1.30 1.90 1.30 1.30 1.90 1.30 1.30 1.90 1.30 Sens 6 21% 17% 24% 19% 12% 21% 26% 19% 20% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.3 0.56 2.7 1.2 0.42 2.2 1.2 0.16 3.7 p Value 0.52 0.37 0.079 0.66 0.21 0.14 0.77 0.094 0.11 95% CI of 0.55 0.16 0.89 0.51 0.11 0.78 0.38 0.019 0.75 OR Quart2 3.2 2.0 8.1 2.9 1.7 6.2 3.7 1.4 19 OR Quart 3 0.89 1.0 0.79 0.80 1.2 0.65 0.82 0.66 2.6 p Value 0.81 1.0 0.73 0.63 0.79 0.51 0.75 0.52 0.27 95% CI of 0.34 0.34 0.20 0.31 0.41 0.17 0.24 0.18 0.48 OR Quart3 2.3 2.9 3.1 2.0 3.3 2.4 2.8 2.4 14 OR Quart 4 1.7 0.86 2.9 1.3 0.86 2.0 1.5 0.83 3.1 p Value 0.22 0.79 0.055 0.54 0.79 0.20 0.43 0.77 0.17 145 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only 95% CI of 0.73 0.28 0.98 0.56 0.28 0.69 0.52 0.25 0.61 OR Quart4 4.1 2.6 8.6 3.1 2.6 5.7 4.6 2.8 16 Insulin receptor substrate 1 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.00227 0.00243 0.00227 0.00243 0.00227 0.00257 Average 0.00318 0.0143 0.00318 0.0145 0.00318 0.00330 Stdev 0.00880 0.0546 0.00880 0.0558 0.00880 0.00268 p(t-test) 0.045 0.044 0.96 Min 1.25E-9 7.25E-7 1.25E-9 7.25E-7 1.25E-9 4.51E-6 Max 0.0712 0.282 0.0712 0.282 0.0712 0.00914 n (Samp) 108 26 108 25 108 14 n (Patient) 108 26 108 25 108 14 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.00163 0.00243 0.00163 0.00243 0.00163 0.00257 Average 0.00828 0.00303 0.00828 0.00283 0.00828 0.00296 Stdev 0.0530 0.00242 0.0530 0.00253 0.0530 0.00294 p(t-test) 0.71 0.70 0.75 Min 1.25E-9 4.51E-6 1.25E-9 4.51E-6 1.25E-9 4.51E-6 Max 0.735 0.00914 0.735 0.00914 0.735 0.00914 n (Samp) 229 14 229 14 229 10 n (Patient) 229 14 229 14 229 10 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.00224 0.00243 0.00224 0.00243 0.00224 0.00243 Average 0.00335 0.0208 0.00335 0.0218 0.00335 0.00256 Stdev 0.00844 0.0697 0.00844 0.0720 0.00844 0.00225 p(t-test) 0.0081 0.0065 0.79 Min 1.25E-9 7.25E-7 1.25E-9 7.25E-7 1.25E-9 4.51E-6 Max 0.0712 0.282 0.0712 0.282 0.0712 0.00601 n (Samp) 123 16 123 15 123 8 n (Patient) 123 16 123 15 123 8 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.68 0.65 0.62 0.65 0.61 0.60 0.68 0.60 0.59 SE 0.062 0.082 0.079 0.065 0.082 0.081 0.083 0.097 0.11 p 0.0031 0.061 0.14 0.021 0.17 0.21 0.032 0.29 0.40 nCohort 1 108 229 123 108 229 123 108 229 123 nCohort 2 26 14 16 25 14 15 14 10 8 Cutoff 1 0.00224 0.00224 0.00110 0.00110 0.00110 0.00110 0.00229 0.00110 0.00110 Sens 1 73% 71% 75% 76% 71% 73% 71% 70% 75% Spec 1 50% 55% 45% 43% 47% 45% 58% 47% 45% Cutoff 2 0.00110 0.000646 2.78E-5 0.000646 0.000610 2.78E-5 2.32E-6 2.32E-6 2.78E-5 Sens 2 81% 86% 88% 80% 86% 87% 100% 100% 88% Spec 2 43% 34% 28% 29% 31% 28% 15% 13% 28% Cutoff 3 2.32E-6 2.32E-6 2.32E-6 2.32E-6 2.32E-6 2.32E-6 2.32E-6 2.32E-6 2.32E-6 146 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 3 96% 100% 94% 96% 100% 93% 100% 100% 100% Spec 3 15% 13% 15% 15% 13% 15% 15% 13% 15% Cutoff 4 0.00243 0.00243 0.00243 0.00243 0.00243 0.00243 0.00243 0.00243 0.00243 Sens 4 46% 43% 38% 40% 36% 33% 50% 50% 25% Spec 4 81% 77% 73% 81% 77% 73% 81% 77% 73% Cutoff 5 0.00243 0.00271 0.00281 0.00243 0.00271 0.00281 0.00243 0.00271 0.00281 Sens 5 46% 36% 38% 40% 36% 33% 50% 40% 25% Spec 5 81% 81% 82% 81% 81% 82% 81% 81% 82% Cutoff 6 0.00334 0.00576 0.00563 0.00334 0.00576 0.00563 0.00334 0.00576 0.00563 Sens 6 38% 7% 19% 36% 7% 20% 36% 10% 12% Spec 6 92% 91% 90% 92% 91% 90% 92% 91% 90% OR Quart 2 0.70 0.98 2.1 2.2 2.0 2.1 0.30 0.32 2.0 p Value 0.66 0.99 0.42 0.29 0.42 0.42 0.31 0.33 0.58 95% CI of 0.14 0.13 0.35 0.51 0.36 0.35 0.029 0.032 0.17 OR Quart2 3.4 7.2 12 9.8 12 12 3.1 3.1 23 OR Quart 3 2.0 2.0 2.1 2.2 1.5 2.1 1.0 0.32 3.1 p Value 0.33 0.42 0.42 0.29 0.66 0.40 1.0 0.33 0.34 95% CI of 0.51 0.36 0.35 0.51 0.24 0.36 0.19 0.032 0.31 OR Quart3 7.4 12 12 9.8 9.3 13 5.4 3.1 31 OR Quart 4 4.0 3.2 3.3 4.2 2.6 2.7 2.6 1.7 2.0 p Value 0.032 0.17 0.16 0.045 0.27 0.26 0.20 0.48 0.58 95% CI of 1.1 0.61 0.62 1.0 0.48 0.48 0.61 0.39 0.17 OR Quart4 14 16 18 17 14 15 11 7.4 23 Involucrin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.582 1.50 0.582 1.36 0.582 1.05 Average 1.43 3.41 1.43 3.06 1.43 2.26 Stdev 3.66 4.66 3.66 4.61 3.66 3.57 p(t-test) 0.0032 0.016 0.31 Min 0.0119 0.0767 0.0119 0.0767 0.0119 0.309 Max 47.1 19.7 47.1 19.7 47.1 17.0 n (Samp) 253 37 253 36 253 22 n (Patient) 253 37 253 36 253 22 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.763 1.15 0.763 1.10 0.763 1.15 Average 2.14 2.60 2.14 2.40 2.14 2.64 Stdev 6.06 3.29 6.06 3.36 6.06 3.61 p(t-test) 0.74 0.85 0.75 Min 0.0119 0.0767 0.0119 0.0767 0.0119 0.226 Max 102 14.5 102 14.5 102 14.5 n (Samp) 424 19 424 19 424 15 n (Patient) 424 19 424 19 424 15 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.622 2.24 0.622 2.18 0.622 1.02 Average 1.62 4.36 1.62 4.00 1.62 2.81 Stdev 4.08 5.31 4.08 5.31 4.08 4.40 147 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) 0.0020 0.0083 0.29 Min 0.0224 0.226 0.0224 0.226 0.0224 0.309 Max 47.1 19.7 47.1 19.7 47.1 17.0 n (Samp) 216 26 216 25 216 14 n (Patient) 216 26 216 25 216 14 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.73 0.65 0.75 0.69 0.58 0.73 0.70 0.65 0.66 SE 0.049 0.070 0.058 0.051 0.070 0.059 0.064 0.078 0.082 p 5.OE-6 0.037 2.OE-5 1.6E-4 0.23 1.1E-4 0.0022 0.053 0.051 nCohort 1 253 424 216 253 424 216 253 424 216 nCohort 2 37 19 26 36 19 25 22 15 14 Cutoff 1 0.794 0.750 0.941 0.720 0.697 0.941 0.720 0.906 0.688 Sens 1 70% 74% 73% 72% 74% 72% 73% 73% 71% Spec 1 62% 50% 62% 60% 47% 62% 60% 55% 53% Cutoff 2 0.697 0.697 0.731 0.605 0.357 0.731 0.697 0.750 0.522 Sens 2 81% 84% 81% 81% 84% 80% 82% 80% 86% Spec 2 58% 47% 55% 54% 25% 55% 58% 50% 41% Cutoff 3 0.356 0.357 0.418 0.298 0.188 0.378 0.522 0.697 0.418 Sens 3 92% 95% 92% 92% 95% 92% 91% 93% 93% Spec 3 32% 25% 32% 26% 13% 30% 46% 47% 32% Cutoff 4 1.13 1.60 1.23 1.13 1.60 1.23 1.13 1.60 1.23 Sens 4 59% 47% 65% 56% 42% 64% 45% 47% 43% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 1.68 2.42 1.73 1.68 2.42 1.73 1.68 2.42 1.73 Sens 5 43% 37% 54% 39% 32% 52% 27% 27% 36% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 2.59 3.90 2.68 2.59 3.90 2.68 2.59 3.90 2.68 Sens 6 38% 16% 42% 33% 16% 40% 23% 13% 29% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.3 2.0 1.5 0.74 0.99 1.5 2.0 3.0 2.0 p Value 0.71 0.42 0.66 0.70 0.99 0.65 0.58 0.34 0.58 95% CI of 0.29 0.36 0.24 0.16 0.24 0.25 0.18 0.31 0.18 OR Quart2 6.2 11 9.3 3.4 4.1 9.5 23 30 23 OR Quart 3 4.6 3.1 3.8 3.7 1.2 3.8 13 6.2 6.6 p Value 0.023 0.17 0.10 0.027 0.74 0.10 0.016 0.093 0.086 95% CI of 1.2 0.61 0.76 1.2 0.33 0.76 1.6 0.74 0.77 OR Quart3 17 16 19 12 4.8 19 100 53 57 OR Quart 4 7.5 3.6 8.6 4.8 1.5 7.9 8.8 5.1 5.3 p Value 0.0019 0.11 0.0058 0.0078 0.53 0.0086 0.043 0.14 0.13 95% CI of 2.1 0.74 1.9 1.5 0.42 1.7 1.1 0.59 0.60 OR Quart4 27 18 40 15 5.5 37 72 45 47 Collagenase 3 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 6.74 5.62 6.74 7.51 6.74 16.2 Average 20.4 16.2 20.4 16.7 20.4 27.9 Stdev 41.3 24.0 41.3 24.3 41.3 29.1 p(t-test) 0.64 0.68 0.55 Min 0.00479 0.00479 0.00479 0.00479 0.00479 0.202 148 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max 340 80.1 340 80.1 340 80.1 n (Samp) 98 24 98 23 98 12 n (Patient) 98 24 98 23 98 12 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 11.1 13.5 11.1 13.5 11.1 18.3 Average 21.4 24.2 21.4 24.2 21.4 34.9 Stdev 37.5 29.7 37.5 29.7 37.5 30.1 p(t-test) 0.79 0.79 0.29 Min 0.00479 0.00588 0.00479 0.00479 0.00479 0.202 Max 340 80.1 340 80.1 340 80.1 n (Samp) 210 13 210 13 210 9 n (Patient) 210 13 210 13 210 9 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 7.62 3.73 7.62 6.42 7.62 13.5 Average 21.7 9.64 21.7 9.88 21.7 12.8 Stdev 40.3 12.3 40.3 12.2 40.3 15.1 p(t-test) 0.25 0.28 0.56 Min 0.00479 0.00479 0.00479 0.00479 0.00479 0.202 Max 340 41.9 340 41.9 340 41.9 n (Samp) 111 15 111 14 111 7 n (Patient) 111 15 111 14 111 7 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.45 0.51 0.38 0.46 0.51 0.40 0.61 0.67 0.44 SE 0.067 0.083 0.081 0.068 0.083 0.084 0.091 0.10 0.12 p 0.43 0.87 0.13 0.57 0.88 0.22 0.24 0.085 0.60 nCohort1 98 210 111 98 210 111 98 210 111 nCohort 2 24 13 15 23 13 14 12 9 7 Cutoff 1 0.0425 0.0425 0.0466 0.0425 0.0425 0.0466 5.86 13.0 0.0466 Sens 1 88% 92% 87% 91% 92% 93% 75% 78% 100% Spec 1 4% 7% 6% 4% 7% 6% 50% 55% 6% Cutoff 2 0.0425 0.0425 0.0466 0.0425 0.0425 0.0466 0.0425 5.86 0.0466 Sens 2 88% 92% 87% 91% 92% 93% 100% 89% 100% Spec 2 4% 7% 6% 4% 7% 6% 4% 41% 6% Cutoff 3 0.00479 0.0425 0 0.0425 0.0425 0.0466 0.0425 0.0425 0.0466 Sens 3 92% 92% 100% 91% 92% 93% 100% 100% 100% Spec 3 1% 7% 0% 4% 7% 6% 4% 7% 6% Cutoff 4 20.0 24.1 20.4 20.0 24.1 20.4 20.0 24.1 20.4 Sens 4 21% 31% 13% 22% 31% 14% 33% 44% 14% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 34.6 33.2 36.7 34.6 33.2 36.7 34.6 33.2 36.7 Sens 5 17% 31% 7% 17% 31% 7% 33% 44% 14% Spec 5 81% 80% 80% 81% 80% 80% 81% 80% 80% Cutoff 6 52.0 51.3 57.0 52.0 51.3 57.0 52.0 51.3 57.0 Sens 6 12% 31% 0% 13% 31% 0% 25% 44% 0% Spec 6 91% 90% 90% 91% 90% 90% 91% 90% 90% OR Quart 2 2.5 0.47 7.4 2.5 0.47 7.4 0.30 0.98 3.3 149 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only p Value 0.18 0.40 0.071 0.18 0.40 0.071 0.31 0.99 0.31 95% CI of 0.65 0.083 0.84 0.65 0.083 0.84 0.029 0.060 0.33 OR Quart2 9.2 2.7 66 9.2 2.7 66 3.0 16 34 OR Quart 3 0.72 0.72 1.0 0.75 0.72 1.0 1.4 3.1 0 p Value 0.69 0.68 1.0 0.72 0.68 0.98 0.69 0.34 na 95% CI of 0.15 0.15 0.060 0.15 0.15 0.062 0.28 0.31 na OR Quart3 3.5 3.4 17 3.7 3.4 17 6.9 30 na OR Quart 4 2.9 0.98 9.0 2.5 0.98 7.4 1.3 4.2 3.3 p Value 0.11 0.98 0.046 0.18 0.98 0.071 0.72 0.21 0.31 95% CI of 0.78 0.23 1.0 0.65 0.23 0.84 0.27 0.45 0.33 OR Quart4 11 4.1 79 9.2 4.1 66 6.6 38 34 NF-kappa-B inhibitor alpha sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.000527 0.000580 0.000527 0.000523 0.000527 0.000330 Average 0.00895 0.0153 0.00895 0.0159 0.00895 0.0205 Stdev 0.0334 0.0514 0.0334 0.0523 0.0334 0.0684 p(t-test) 0.44 0.41 0.29 Min 4.17E-7 3.65E-7 4.17E-7 3.65E-7 4.17E-7 1.17E-6 Max 0.211 0.257 0.211 0.257 0.211 0.257 n (Samp) 108 26 108 25 108 14 n (Patient) 108 26 108 25 108 14 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.000493 0.000330 0.000493 0.000330 0.000493 0.000330 Average 0.00927 0.00714 0.00927 0.00714 0.00927 0.00291 Stdev 0.0338 0.0191 0.0338 0.0191 0.0338 0.00758 p(t-test) 0.82 0.82 0.55 Min 4.17E-7 1.17E-6 4.17E-7 1.17E-6 4.17E-7 1.17E-6 Max 0.245 0.0695 0.245 0.0695 0.245 0.0244 n (Samp) 229 14 229 14 229 10 n (Patient) 229 14 229 14 229 10 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.000566 0.000602 0.000566 0.000566 0.000566 0.000426 Average 0.00908 0.0187 0.00908 0.0199 0.00908 0.0325 Stdev 0.0319 0.0638 0.0319 0.0658 0.0319 0.0908 p(t-test) 0.32 0.28 0.090 Min 4.17E-7 3.65E-7 4.17E-7 3.65E-7 4.17E-7 2.62E-5 Max 0.211 0.257 0.211 0.257 0.211 0.257 n (Samp) 123 16 123 15 123 8 n (Patient) 123 16 123 15 123 8 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.54 0.48 0.54 0.53 0.48 0.54 0.48 0.45 0.46 SE 0.064 0.081 0.078 0.065 0.081 0.080 0.083 0.096 0.11 p 0.55 0.76 0.61 0.59 0.76 0.65 0.80 0.58 0.70 150 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only nCohort 1 108 229 123 108 229 123 108 229 123 nCohort 2 26 14 16 25 14 15 14 10 8 Cutoff 1 3.20E-5 3.20E-5 0.000219 3.20E-5 3.20E-5 0.000219 0.000193 0.000243 0.000193 Sens 1 77% 71% 75% 76% 71% 73% 71% 70% 75% Spec 1 31% 31% 36% 31% 31% 36% 39% 43% 35% Cutoff 2 2.62E-5 2.25E-5 3.20E-5 2.62E-5 2.25E-5 3.20E-5 2.62E-5 2.62E-5 3.20E-5 Sens 2 81% 93% 81% 80% 93% 80% 86% 80% 88% Spec 2 18% 11% 28% 18% 11% 28% 18% 15% 28% Cutoff 3 2.25E-5 2.25E-5 2.25E-5 2.25E-5 2.25E-5 2.25E-5 2.25E-5 2.25E-5 2.25E-5 Sens 3 92% 93% 94% 92% 93% 93% 93% 90% 100% Spec 3 11% 11% 11% 11% 11% 11% 11% 11% 11% Cutoff 4 0.00128 0.00130 0.00140 0.00128 0.00130 0.00140 0.00128 0.00130 0.00140 Sens 4 35% 21% 31% 32% 21% 33% 21% 20% 12% Spec 4 70% 70% 72% 70% 70% 72% 70% 70% 72% Cutoff 5 0.00274 0.00274 0.00274 0.00274 0.00274 0.00274 0.00274 0.00274 0.00274 Sens 5 27% 14% 31% 28% 14% 33% 14% 10% 12% Spec 5 81% 80% 80% 81% 80% 80% 81% 80% 80% Cutoff 6 0.00704 0.0142 0.0127 0.00704 0.0142 0.0127 0.00704 0.0142 0.0127 Sens 6 23% 14% 12% 24% 14% 13% 14% 10% 12% Spec 6 91% 90% 90% 91% 90% 90% 91% 90% 90% OR Quart 2 1.2 1.0 1.3 1.2 1.0 1.3 1.0 1.0 2.1 p Value 0.80 1.0 0.72 0.76 1.0 0.72 0.97 1.0 0.56 95% CI of 0.35 0.19 0.28 0.36 0.19 0.28 0.19 0.14 0.18 OR Quart2 3.9 5.2 6.5 4.1 5.2 6.5 5.6 7.3 24 OR Quart 3 0.80 1.7 1.3 0.62 1.7 1.0 1.8 1.5 4.4 p Value 0.74 0.47 0.72 0.49 0.47 1.0 0.45 0.65 0.20 95% CI of 0.22 0.39 0.28 0.16 0.39 0.19 0.39 0.25 0.47 OR Quart3 2.9 7.6 6.5 2.4 7.6 5.3 8.3 9.5 42 OR Quart 4 1.4 1.0 1.7 1.4 1.0 1.7 1.0 1.6 1.0 p Value 0.59 0.98 0.48 0.59 0.98 0.48 0.97 0.64 0.98 95% CI of 0.42 0.20 0.38 0.42 0.20 0.38 0.19 0.25 0.062 OR Quart4 4.5 5.3 7.8 4.5 5.3 7.8 5.6 9.7 17 Beta-nerve growth factor sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 4.27 4.34 4.27 4.42 4.27 4.53 Average 6.24 6.70 6.24 6.66 6.24 8.34 Stdev 6.49 6.86 6.49 7.04 6.49 8.77 p(t-test) 0.75 0.77 0.28 Min 0.00207 0.000506 0.00207 0.000506 0.00207 0.902 Max 44.0 25.2 44.0 25.2 44.0 25.2 n (Samp) 111 26 111 25 111 14 n (Patient) 111 26 111 25 111 14 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 3.81 5.50 3.81 5.50 3.81 5.76 Average 6.06 7.65 6.06 7.43 6.06 8.71 Stdev 6.74 7.09 6.74 7.25 6.74 8.21 p(t-test) 0.39 0.46 0.23 Min 0.000499 1.34 0.000499 0.943 0.000499 1.04 151 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max 46.1 25.2 46.1 25.2 46.1 25.2 n(Samp) 231 14 231 14 231 10 n(Patient) 231 14 231 14 231 10 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 3.81 3.38 3.81 3.79 3.81 2.51 Average 5.80 6.34 5.80 6.46 5.80 8.00 Stdev 5.90 7.72 5.90 7.95 5.90 10.4 p(t-test) 0.74 0.69 0.33 Min 0.000506 0.000506 0.000506 0.000506 0.000506 0.902 Max 32.2 25.2 32.2 25.2 32.2 25.2 n(Samp) 126 16 126 15 126 8 n (Patient) 126 16 126 15 126 8 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.52 0.61 0.47 0.51 0.58 0.48 0.55 0.63 0.46 SE 0.064 0.082 0.078 0.064 0.082 0.080 0.084 0.097 0.11 p 0.79 0.17 0.72 0.90 0.31 0.78 0.57 0.18 0.69 nCohort1 111 231 126 111 231 126 111 231 126 nCohort 2 26 14 16 25 14 15 14 10 8 Cutoff 1 2.63 4.24 1.92 2.63 4.07 2.29 2.61 4.36 1.89 Sens 1 73% 71% 75% 72% 71% 73% 71% 70% 75% Spec 1 30% 54% 22% 30% 53% 28% 29% 56% 22% Cutoff 2 2.29 2.63 1.77 2.29 2.61 1.77 1.77 4.07 1.77 Sens 2 81% 86% 81% 80% 86% 80% 86% 80% 88% Spec 2 25% 32% 22% 25% 31% 22% 20% 53% 22% Cutoff 3 0.950 2.61 0.771 0.771 1.49 0.223 1.04 2.61 0.771 Sens 3 92% 93% 94% 92% 93% 93% 93% 90% 100% Spec 3 9% 31% 9% 8% 16% 3% 10% 31% 9% Cutoff 4 7.11 6.46 6.50 7.11 6.46 6.50 7.11 6.46 6.50 Sens 4 27% 36% 31% 28% 36% 27% 36% 50% 25% Spec 4 71% 71% 71% 71% 71% 71% 71% 71% 71% Cutoff 5 8.14 8.14 7.78 8.14 8.14 7.78 8.14 8.14 7.78 Sens 5 19% 21% 25% 20% 21% 27% 29% 30% 25% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 13.7 13.7 13.5 13.7 13.7 13.5 13.7 13.7 13.5 Sens 6 12% 14% 12% 12% 14% 13% 21% 20% 25% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.2 2.0 0.75 1.0 1.0 0.75 1.0 1.0 0.50 p Value 0.76 0.57 0.72 1.0 1.0 0.72 1.0 1.0 0.58 95% CI of 0.36 0.18 0.16 0.29 0.14 0.16 0.19 0.061 0.043 OR Quart2 4.1 23 3.6 3.5 7.3 3.6 5.4 16 5.8 OR Quart 3 1.0 7.8 1.0 1.2 3.2 1.0 1.4 4.2 1.0 p Value 1.0 0.059 1.0 0.76 0.16 0.97 0.69 0.20 1.0 95% CI of 0.29 0.93 0.23 0.36 0.62 0.24 0.28 0.46 0.13 OR Quart3 3.5 65 4.3 4.1 17 4.5 6.8 39 7.5 OR Quart 4 1.2 4.1 1.3 1.0 2.0 1.0 1.3 4.1 1.6 p Value 0.80 0.21 0.69 1.0 0.42 0.97 0.72 0.21 0.62 95% CI of 0.35 0.45 0.33 0.29 0.36 0.24 0.27 0.45 0.25 OR Quart4 3.9 38 5.4 3.5 12 4.5 6.5 38 10 152 Pancreatic prohormone sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.98 57.1 2.98 57.1 2.98 29.5 Average 98.8 236 98.8 236 98.8 207 Stdev 201 317 201 317 201 320 p(t-test) 0.040 0.040 0.19 Min 0.117 0.122 0.117 0.122 0.117 0.122 Max 950 832 950 832 950 832 n(Samp) 98 12 98 12 98 7 n (Patient) 98 12 98 12 98 7 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 13.4 508 13.4 508 nd nd Average 111 429 111 429 nd nd Stdev 220 357 220 357 nd nd p(t-test) 8.5E-4 8.5E-4 nd nd Min 0.117 0.122 0.117 0.122 nd nd Max 1220 832 1220 832 nd nd n(Samp) 159 6 159 6 nd nd n (Patient) 159 6 159 6 nd nd UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 9.39 14.9 9.39 14.9 9.39 14.9 Average 98.0 87.7 98.0 87.7 98.0 103 Stdev 194 154 194 154 194 178 p(t-test) 0.88 0.88 0.95 Min 0.117 0.122 0.117 0.122 0.117 0.122 Max 950 448 950 448 950 448 n(Samp) 84 8 84 8 84 6 n (Patient) 84 8 84 8 84 6 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.56 0.66 0.44 0.56 0.66 0.44 0.54 nd 0.44 SE 0.091 0.12 0.11 0.091 0.12 0.11 0.12 nd 0.13 p 0.48 0.21 0.62 0.48 0.21 0.62 0.73 nd 0.63 nCohort 1 98 159 84 98 159 84 98 nd 84 nCohort 2 12 6 8 12 6 8 7 nd 6 Cutoff 1 0.134 0.117 0.134 0.134 0.117 0.134 0.134 nd 0.117 Sens 1 75% 100% 75% 75% 100% 75% 71% nd 100% Spec 1 18% 4% 15% 18% 4% 15% 18% nd 4% Cutoff 2 0.117 0.117 0.117 0.117 0.117 0.117 0.117 nd 0.117 Sens 2 100% 100% 100% 100% 100% 100% 100% nd 100% Spec 2 5% 4% 4% 5% 4% 4% 5% nd 4% Cutoff 3 0.117 0.117 0.117 0.117 0.117 0.117 0.117 nd 0.117 Sens 3 100% 100% 100% 100% 100% 100% 100% nd 100% Spec 3 5% 4% 4% 5% 4% 4% 5% nd 4% Cutoff 4 53.6 67.5 67.5 53.6 67.5 67.5 53.6 nd 67.5 Sens 4 50% 67% 38% 50% 67% 38% 43% nd 33% Spec 4 70% 70% 70% 70% 70% 70% 70% nd 70% Cutoff 5 137 142 142 137 142 142 137 nd 142 153 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 5 42% 67% 12% 42% 67% 12% 43% nd 17% Spec 5 81% 81% 81% 81% 81% 81% 81% nd 81% Cutoff 6 415 440 347 415 440 347 415 nd 347 Sens 6 33% 67% 12% 33% 67% 12% 29% nd 17% Spec 6 91% 91% 90% 91% 91% 90% 91% nd 90% OR Quart 2 0.21 0 1.0 0.21 0 1.0 0 nd 0.50 p Value 0.18 na 1.0 0.18 na 1.0 na nd 0.58 95% CI of 0.022 na 0.13 0.022 na 0.13 na nd 0.042 OR Quart2 2.0 na 7.8 2.0 na 7.8 na nd 5.9 OR Quart 3 0.46 0 0 0.46 0 0 0.31 nd 0 p Value 0.40 na na 0.40 na na 0.32 nd na 95% CI of 0.077 na na 0.077 na na 0.030 nd na OR Quart3 2.8 na na 2.8 na na 3.2 nd na OR Quart 4 1.2 2.1 2.2 1.2 2.1 2.2 0.96 nd 1.7 p Value 0.76 0.42 0.39 0.76 0.42 0.39 0.96 nd 0.60 95% CI of 0.30 0.35 0.36 0.30 0.35 0.36 0.18 nd 0.25 OR Quart4 5.3 12 13 5.3 12 13 5.2 nd 11 Transthyretin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 24.8 90.5 24.8 74.2 24.8 70.4 Average 56.1 126 56.1 99.3 56.1 107 Stdev 86.2 112 86.2 86.9 86.2 109 p(t-test) 2.4E-4 0.018 0.031 Min 0.164 3.29 0.164 3.29 0.164 11.6 Max 668 461 668 396 668 396 n (Samp) 151 28 151 27 151 16 n (Patient) 151 28 151 27 151 16 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 35.2 123 35.2 76.8 35.2 76.8 Average 72.2 133 72.2 119 72.2 117 Stdev 145 111 145 112 145 122 p(t-test) 0.11 0.22 0.31 Min 0.164 3.29 0.164 3.29 0.164 11.6 Max 2000 396 2000 396 2000 396 n (Samp) 290 15 290 15 290 11 n (Patient) 290 15 290 15 290 11 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 32.6 90.5 32.6 74.2 32.6 70.4 Average 66.2 133 66.2 103 66.2 109 Stdev 95.3 123 95.3 89.7 95.3 117 p(t-test) 0.0075 0.13 0.18 Min 0.411 13.8 0.411 13.8 0.411 13.8 Max 668 461 668 396 668 396 n (Samp) 155 18 155 17 155 10 n (Patient) 155 18 155 17 155 10 154 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.77 0.72 0.75 0.73 0.68 0.72 0.70 0.66 0.68 SE 0.055 0.076 0.069 0.058 0.078 0.072 0.076 0.091 0.096 p 9.2E-7 0.0035 2.2E-4 5.1E-5 0.021 0.0020 0.0073 0.086 0.064 nCohort 1 151 290 155 151 290 155 151 290 155 nCohort 2 28 15 18 27 15 17 16 11 10 Cutoff 1 50.3 48.3 66.2 48.3 46.2 56.7 29.3 32.6 48.3 Sens 1 71% 73% 72% 70% 73% 71% 75% 73% 70% Spec 1 69% 58% 71% 68% 58% 65% 54% 48% 61% Cutoff 2 41.3 46.2 48.3 31.2 31.2 48.3 25.6 26.5 29.3 Sens 2 82% 80% 83% 81% 80% 82% 81% 82% 80% Spec 2 64% 58% 61% 56% 47% 61% 52% 41% 49% Cutoff 3 25.6 26.5 29.3 18.2 18.6 29.3 13.2 18.6 18.2 Sens 3 93% 93% 94% 93% 93% 94% 94% 91% 90% Spec 3 52% 41% 49% 44% 32% 49% 32% 32% 37% Cutoff 4 51.9 67.7 64.9 51.9 67.7 64.9 51.9 67.7 64.9 Sens 4 68% 60% 72% 63% 53% 65% 56% 55% 60% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 77.7 93.5 91.5 77.7 93.5 91.5 77.7 93.5 91.5 Sens 5 50% 53% 50% 44% 47% 41% 38% 36% 40% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 123 145 187 123 145 187 123 145 187 Sens 6 39% 33% 22% 30% 27% 12% 31% 27% 20% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 3.1 2.0 1.0 4.2 3.1 1.0 >4.3 3.1 >3.2 p Value 0.34 0.57 1.0 0.21 0.33 1.0 <0.20 0.33 <0.32 95% CI of 0.31 0.18 0.061 0.45 0.31 0.061 >0.46 0.31 >0.32 OR Quart2 31 23 17 39 30 17 na 30 na OR Quart 3 12 4.2 8.2 13 4.2 8.2 >4.3 2.0 >3.2 p Value 0.019 0.21 0.055 0.018 0.21 0.055 <0.20 0.57 <0.32 95% CI of 1.5 0.45 0.96 1.5 0.45 0.96 >0.46 0.18 >0.32 OR Quart3 100 38 70 100 38 70 na 23 na OR Quart 4 19 8.7 11 16 7.5 9.6 >9.6 5.2 >4.3 p Value 0.0052 0.044 0.027 0.0099 0.063 0.037 <0.037 0.14 <0.20 95% CI of 2.4 1.1 1.3 1.9 0.90 1.1 >1.1 0.59 >0.46 OR Quart4 160 71 89 130 63 81 na 46 na C-peptide Urine sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 37100 14300 37100 10800 37100 21600 Average 45400 26400 45400 26300 45400 37100 Stdev 31300 29400 31300 29900 31300 34400 p(t-test) 0.0032 0.0037 0.32 Min 0.0119 940 0.0119 940 0.0119 1470 Max 102000 100000 102000 100000 102000 100000 n (Samp) 151 28 151 27 151 16 n (Patient) 151 28 151 27 151 16 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 35500 21000 35500 21000 35500 52900 Average 43700 36300 43700 35700 43700 45600 155 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Stdev 31500 34000 31500 34500 31500 35500 p(t-test) 0.38 0.34 0.85 Min 0.0119 3420 0.0119 3420 0.0119 4640 Max 114000 100000 114000 100000 114000 100000 n (Samp) 290 15 290 15 290 11 n (Patient) 290 15 290 15 290 11 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 38100 7740 38100 8290 38100 13700 Average 44900 23200 44900 23300 44900 31600 Stdev 30700 31500 30700 32200 30700 39600 p(t-test) 0.0053 0.0070 0.19 Min 0.0119 940 0.0119 940 0.0119 1470 Max 102000 122000 102000 122000 102000 122000 n (Samp) 155 18 155 17 155 10 n (Patient) 155 18 155 17 155 10 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.30 0.41 0.26 0.29 0.41 0.25 0.40 0.51 0.33 SE 0.058 0.079 0.069 0.059 0.079 0.071 0.078 0.089 0.096 p 5.3E-4 0.28 4.OE-4 5.2E-4 0.24 5.5E-4 0.22 0.94 0.078 nCohort 1 151 290 155 151 290 155 151 290 155 nCohort 2 28 15 18 27 15 17 16 11 10 Cutoff 1 4980 10500 4270 5980 8240 4980 7180 20600 7180 Sens 1 71% 73% 72% 70% 73% 71% 75% 73% 70% Spec 1 6% 17% 5% 6% 12% 5% 9% 32% 8% Cutoff 2 3420 8240 2020 4270 7180 2950 4980 8240 4980 Sens 2 82% 80% 83% 81% 80% 82% 81% 82% 80% Spec 2 4% 12% 2% 5% 10% 3% 6% 12% 5% Cutoff 3 1930 4360 1630 1930 4360 1630 1630 5550 1630 Sens 3 93% 93% 94% 93% 93% 94% 94% 91% 90% Spec 3 2% 6% 2% 2% 6% 2% 2% 7% 2% Cutoff 4 62300 60500 61000 62300 60500 61000 62300 60500 61000 Sens 4 11% 27% 17% 11% 27% 18% 19% 36% 30% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 76500 74400 75900 76500 74400 75900 76500 74400 75900 Sens 5 7% 13% 6% 7% 13% 6% 12% 18% 10% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 98500 100000 97900 98500 100000 97900 98500 100000 97900 Sens 6 7% 0% 6% 7% 0% 6% 12% 0% 10% Spec 6 90% 99% 90% 90% 99% 90% 90% 99% 90% OR Quart 2 3.3 2.1 0.50 3.4 2.1 0.49 2.7 0.66 2.1 p Value 0.16 0.41 0.58 0.15 0.41 0.56 0.25 0.65 0.55 95% CI of 0.63 0.37 0.044 0.65 0.37 0.043 0.49 0.11 0.18 OR Quart2 17 12 5.7 18 12 5.6 15 4.1 24 OR Quart 3 3.3 1.0 2.8 2.1 1.0 2.1 1.5 1.4 2.1 p Value 0.16 0.99 0.24 0.41 0.99 0.41 0.65 0.70 0.55 95% CI of 0.63 0.14 0.51 0.36 0.14 0.36 0.24 0.29 0.18 OR Quart3 17 7.4 15 12 7.4 12 9.7 6.3 24 OR Quart 4 10 3.8 6.4 11 3.8 6.2 3.4 0.65 5.7 p Value 0.0036 0.10 0.022 0.0023 0.10 0.024 0.15 0.64 0.12 156 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only 95% CI of 2.1 0.76 1.3 2.4 0.76 1.3 0.65 0.11 0.64 OR Quart4 47 19 31 52 19 130 18 4.0 51 Gastric inhibitory polypeptide Urine sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.599 1.40 0.599 1.39 0.599 1.24 Average 33.3 77.7 33.3 80.3 33.3 19.3 Stdev 315 225 315 229 315 62.2 p(t-test) 0.48 0.46 0.86 Min 0.000104 0.000165 0.000104 0.00873 0.000104 0.228 Max 3840 1040 3840 1040 3840 252 n (Samp) 151 28 151 27 151 16 n (Patient) 151 28 151 27 151 16 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.649 2.75 0.649 2.19 0.649 2.19 Average 41.1 64.5 41.1 64.1 41.1 27.5 Stdev 306 163 306 163 306 74.6 p(t-test) 0.77 0.77 0.88 Min 0.000104 0.00873 0.000104 0.00873 0.000104 0.375 Max 3840 606 3840 606 3840 252 n (Samp) 290 15 290 15 290 11 n (Patient) 290 15 290 15 290 11 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.711 0.963 0.711 0.990 0.711 0.773 Average 52.3 81.3 52.3 86.1 52.3 26.2 Stdev 373 248 373 255 373 79.3 p(t-test) 0.75 0.72 0.83 Min 0.000104 0.000165 0.000104 0.0429 0.000104 0.228 Max 3840 1040 3840 1040 3840 252 n (Samp) 155 18 155 17 155 10 n (Patient) 155 18 155 17 155 10 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.66 0.72 0.56 0.67 0.71 0.59 0.67 0.73 0.54 SE 0.060 0.076 0.074 0.060 0.077 0.076 0.077 0.088 0.096 p 0.0077 0.0031 0.45 0.0042 0.0076 0.25 0.026 0.010 0.69 nCohort 1 151 290 155 151 290 155 151 290 155 nCohort 2 28 15 18 27 15 17 16 11 10 Cutoff 1 0.629 1.09 0.372 0.835 0.935 0.529 0.629 1.09 0.372 Sens 1 71% 73% 72% 70% 73% 71% 75% 73% 70% Spec 1 52% 63% 35% 61% 60% 44% 52% 63% 35% Cutoff 2 0.372 0.935 0.292 0.529 0.897 0.320 0.599 0.935 0.320 Sens 2 82% 80% 83% 81% 80% 82% 81% 82% 80% Spec 2 40% 60% 30% 47% 59% 32% 50% 60% 32% Cutoff 3 0.0384 0.372 0.0384 0.227 0.372 0.227 0.292 0.629 0.292 157 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 3 93% 93% 94% 93% 93% 94% 94% 91% 90% Spec 3 16% 36% 12% 29% 36% 25% 35% 50% 30% Cutoff 4 1.38 1.65 2.13 1.38 1.65 2.13 1.38 1.65 2.13 Sens 4 54% 60% 33% 52% 53% 35% 50% 55% 30% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 3.75 3.58 5.24 3.75 3.58 5.24 3.75 3.58 5.24 Sens 5 36% 47% 17% 33% 40% 18% 31% 36% 10% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 10.3 10.3 15.3 10.3 10.3 15.3 10.3 10.3 15.3 Sens 6 25% 33% 17% 26% 33% 18% 25% 36% 10% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 2.1 2.0 1.8 3.2 2.0 2.7 >5.5 >2.1 4.3 p Value 0.32 0.57 0.46 0.17 0.57 0.25 <0.13 <0.56 0.20 95% CI of 0.49 0.18 0.39 0.62 0.18 0.49 >0.62 >0.18 0.46 OR Quart2 9.0 23 7.9 17 23 15 na na 40 OR Quart 3 2.5 4.2 1.4 4.7 5.3 2.7 >5.5 >4.2 2.1 p Value 0.20 0.21 0.69 0.061 0.13 0.25 <0.13 <0.20 0.56 95% CI of 0.61 0.45 0.29 0.93 0.60 0.49 >0.62 >0.46 0.18 OR Quart3 10 38 6.5 23 46 15 na na 24 OR Quart 4 5.0 8.7 2.1 6.8 7.5 2.7 >6.8 >5.3 3.1 p Value 0.020 0.044 0.32 0.017 0.063 0.25 <0.082 <0.13 0.34 95% CI of 1.3 1.1 0.49 1.4 0.90 0.49 >0.79 >0.60 0.31 OR Quart4 19 71 9.0 33 63 15 na na 31 Peptide YY Urine sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 14.8 58.9 14.8 54.0 14.8 41.8 Average 49.6 98.3 49.6 97.9 49.6 72.1 Stdev 107 98.2 107 101 107 82.1 p(t-test) 0.026 0.030 0.41 Min 0.00976 0.0188 0.00976 0.0188 0.00976 0.0188 Max 936 317 936 317 936 290 n (Samp) 151 28 151 27 151 16 n (Patient) 151 28 151 27 151 16 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 18.5 81.5 18.5 81.5 18.5 46.1 Average 63.5 97.5 63.5 93.1 63.5 59.1 Stdev 147 75.6 147 79.1 147 48.9 p(t-test) 0.37 0.44 0.92 Min 0.00976 0.957 0.00976 0.0188 0.00976 0.0188 Max 1200 278 1200 278 1200 139 n (Samp) 290 15 290 15 290 11 n (Patient) 290 15 290 15 290 11 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 20.2 35.0 20.2 31.4 20.2 18.4 Average 51.3 85.5 51.3 88.0 51.3 69.9 Stdev 104 109 104 112 104 102 158 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) 0.19 0.17 0.58 Min 0.00976 0.0188 0.00976 0.0188 0.00976 0.0188 Max 936 317 936 317 936 290 n (Samp) 155 18 155 17 155 10 n (Patient) 155 18 155 17 155 10 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.72 0.76 0.60 0.69 0.71 0.60 0.63 0.63 0.51 SE 0.058 0.073 0.074 0.060 0.076 0.076 0.078 0.092 0.095 p 1.9E-4 3.6E-4 0.17 0.0019 0.0051 0.20 0.094 0.17 0.92 nCohort 1 151 290 155 151 290 155 151 290 155 nCohort 2 28 15 18 27 15 17 16 11 10 Cutoff 1 25.9 46.1 10.5 25.5 36.6 10.5 10.6 25.9 0.817 Sens 1 71% 73% 72% 70% 73% 71% 75% 73% 80% Spec 1 64% 72% 39% 63% 68% 39% 45% 60% 25% Cutoff 2 10.6 36.6 1.71 2.87 25.9 1.71 0.817 18.6 0.817 Sens 2 82% 80% 83% 81% 80% 82% 88% 82% 80% Spec 2 45% 68% 32% 38% 60% 32% 26% 51% 25% Cutoff 3 0.817 18.6 0.0188 0.817 0.817 0.0188 0.0131 0.0151 0.0188 Sens 3 96% 93% 100% 93% 93% 100% 100% 100% 90% Spec 3 26% 51% 6% 26% 27% 6% 5% 6% 6% Cutoff 4 35.7 40.7 45.8 35.7 40.7 45.8 35.7 40.7 45.8 Sens 4 64% 73% 39% 59% 67% 41% 56% 55% 30% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 59.4 67.7 63.6 59.4 67.7 63.6 59.4 67.7 63.6 Sens 5 50% 53% 33% 48% 53% 35% 44% 45% 30% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff6 138 150 138 138 150 138 138 150 138 Sens 6 29% 20% 28% 30% 20% 29% 19% 0% 30% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 5.4 >2.1 2.7 1.3 2.0 1.4 1.5 0.49 1.5 p Value 0.13 <0.56 0.25 0.72 0.57 0.69 0.67 0.57 0.65 95% CI of 0.60 >0.18 0.49 0.28 0.18 0.29 0.24 0.044 0.24 OR Quart2 48 na 15 6.3 23 6.5 9.5 5.6 9.7 OR Quart 3 9.3 >4.2 2.7 2.6 4.2 1.4 2.1 1.5 1.0 p Value 0.040 <0.20 0.25 0.19 0.21 0.69 0.42 0.65 1.0 95% CI of 1.1 >0.46 0.49 0.62 0.45 0.29 0.35 0.25 0.13 OR Quart3 78 na 15 11 38 6.5 12 9.4 7.5 OR Quart 4 19 >10 3.2 5.6 8.7 2.2 3.9 2.6 1.5 p Value 0.0052 <0.031 0.17 0.012 0.044 0.30 0.10 0.27 0.67 95% CI of 2.4 >1.2 0.62 1.5 1.1 0.50 0.76 0.48 0.24 OR Quart4 160 na 17 21 71 9.3 20 14 9.5 [0172] Table 5: Comparison of marker levels in EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0) and in EDTA samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage R, I or F in Cohort 2. Agouti-related protein 159 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0547 0.0751 0.0547 0.0705 0.0547 0.0647 Average 0.0769 0.101 0.0769 0.0853 0.0769 0.0761 Stdev 0.0545 0.0797 0.0545 0.0725 0.0545 0.0539 p(t-test) 0.014 0.41 0.96 Min 0.0115 0.00624 0.0115 0.00798 0.0115 0.0283 Max 0.285 0.527 0.285 0.485 0.285 0.221 n (Samp) 133 67 133 47 133 12 n (Patient) 65 67 65 47 65 12 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0613 0.0902 0.0613 0.0878 0.0613 0.138 Average 0.0813 0.119 0.0813 0.124 0.0813 0.146 Stdev 0.0619 0.122 0.0619 0.112 0.0619 0.101 p(t-test) 0.019 0.023 0.0074 Min 0.00924 0.00624 0.00924 0.00798 0.00924 0.0415 Max 0.485 0.527 0.485 0.411 0.485 0.285 n (Samp) 326 18 326 12 326 7 n (Patient) 141 18 141 12 141 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0613 0.0818 0.0613 0.0707 0.0613 0.0622 Average 0.0802 0.109 0.0802 0.0896 0.0802 0.0788 Stdev 0.0531 0.0846 0.0531 0.0716 0.0531 0.0529 p(t-test) 0.0030 0.31 0.92 Min 0.00624 0.0215 0.00624 0.0215 0.00624 0.0283 Max 0.285 0.527 0.285 0.485 0.285 0.221 n(Samp) 162 58 162 51 162 14 n (Patient) 72 58 72 51 72 14 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.61 0.60 0.61 0.55 0.64 0.54 0.51 0.69 0.50 SE 0.043 0.072 0.044 0.050 0.088 0.047 0.088 0.11 0.081 p 0.012 0.18 0.012 0.27 0.12 0.37 0.91 0.10 0.97 nCohort 1 133 326 162 133 326 162 133 326 162 nCohort 2 67 18 58 47 12 51 12 7 14 Cutoff 1 0.0574 0.0596 0.0634 0.0497 0.0704 0.0498 0.0422 0.0616 0.0479 Sens 1 70% 72% 71% 70% 75% 71% 75% 71% 71% Spec 1 52% 48% 53% 41% 57% 36% 30% 51% 31% Cutoff 2 0.0445 0.0399 0.0469 0.0434 0.0497 0.0442 0.0359 0.0422 0.0359 Sens 2 81% 83% 81% 81% 83% 80% 83% 86% 86% Spec 2 33% 25% 29% 31% 36% 28% 18% 26% 17% Cutoff 3 0.0313 0.0300 0.0350 0.0305 0.0473 0.0369 0.0283 0.0413 0.0283 Sens 3 91% 94% 91% 91% 92% 90% 92% 100% 93% Spec 3 14% 13% 15% 14% 31% 18% 13% 25% 12% Cutoff 4 0.0886 0.0886 0.100 0.0886 0.0886 0.100 0.0886 0.0886 0.100 Sens 4 43% 50% 40% 32% 50% 31% 25% 57% 21% Spec 4 71% 70% 70% 71% 70% 70% 71% 70% 70% Cutoff 5 0.118 0.116 0.121 0.118 0.116 0.121 0.118 0.116 0.121 Sens 5 28% 28% 33% 19% 25% 25% 17% 57% 14% 160 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 0.157 0.166 0.152 0.157 0.166 0.152 0.157 0.166 0.152 Sens 6 18% 11% 22% 4% 25% 12% 8% 43% 7% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 0.89 0.49 1.6 2.2 2.0 1.3 0.65 >2.0 1.4 p Value 0.81 0.41 0.34 0.13 0.57 0.63 0.65 <0.56 0.69 95% CI of 0.35 0.087 0.61 0.79 0.18 0.49 0.10 >0.18 0.29 OR Quart2 2.3 2.7 4.1 6.2 22 3.2 4.1 na 6.5 OR Quart 3 2.7 1.0 2.1 2.5 5.3 1.5 1.8 >1.0 1.4 p Value 0.023 1.0 0.12 0.086 0.13 0.36 0.46 <0.99 0.69 95% CI of 1.1 0.24 0.83 0.88 0.60 0.62 0.39 >0.062 0.29 OR Quart3 6.3 4.1 5.3 6.8 46 3.9 8.1 na 6.5 OR Quart 4 2.3 2.1 2.9 2.2 4.1 1.7 0.63 >4.2 1.0 p Value 0.058 0.24 0.020 0.13 0.21 0.28 0.62 <0.21 1.0 95% CI of 0.97 0.61 1.2 0.79 0.45 0.67 0.099 >0.45 0.19 OR Quart4 5.4 7.3 7.2 6.2 37 4.1 4.0 na 5.2 Osteocalcin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 1940 2060 1940 1710 1940 1520 Average 2410 2760 2410 2440 2410 1920 Stdev 2110 2520 2110 2350 2110 1740 p(t-test) 0.22 0.90 0.23 Min 91.1 63.3 91.1 129 91.1 248 Max 14000 12800 14000 10900 14000 7760 n (Samp) 183 95 183 69 183 29 n (Patient) 107 95 107 69 107 29 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 1960 1750 1960 1770 1960 2250 Average 2570 2820 2570 3150 2570 3180 Stdev 2350 3120 2350 2990 2350 2410 p(t-test) 0.59 0.29 0.35 Min 0.729 129 0.729 129 0.729 263 Max 17700 12800 17700 10500 17700 7760 n(Samp) 451 27 451 19 451 13 n (Patient) 209 27 209 19 209 13 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2100 1980 2100 1430 2100 1440 Average 2710 2570 2710 2260 2710 1950 Stdev 2500 2190 2500 2210 2500 1680 p(t-test) 0.64 0.17 0.13 Min 91.1 63.3 91.1 197 91.1 248 Max 14000 8900 14000 10900 14000 6730 n(Samp) 206 81 206 74 206 26 n (Patient) 104 81 104 74 104 26 161 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.52 0.47 0.49 0.46 0.54 0.42 0.41 0.58 0.40 SE 0.037 0.058 0.038 0.041 0.069 0.040 0.059 0.084 0.062 p 0.61 0.61 0.73 0.38 0.60 0.045 0.12 0.33 0.10 nCohort 1 183 451 206 183 451 206 183 451 206 nCohort 2 95 27 81 69 19 74 29 13 26 Cutoff 1 1120 895 1120 1060 1180 951 684 1660 684 Sens 1 71% 70% 70% 71% 74% 70% 72% 77% 73% Spec 1 27% 20% 27% 26% 30% 21% 13% 42% 13% Cutoff 2 878 813 883 865 1100 724 583 1020 622 Sens 2 80% 81% 80% 81% 84% 81% 83% 85% 81% Spec 2 19% 16% 18% 18% 27% 13% 11% 24% 11% Cutoff 3 628 638 583 353 353 447 353 323 394 Sens 3 91% 93% 90% 91% 95% 91% 93% 92% 92% Spec 3 11% 11% 11% 9% 6% 10% 9% 5% 9% Cutoff 4 2790 2810 2810 2790 2810 2810 2790 2810 2810 Sens 4 33% 22% 33% 25% 32% 23% 24% 38% 27% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 3340 3720 3740 3340 3720 3740 3340 3720 3740 Sens 5 24% 22% 22% 22% 26% 19% 17% 38% 12% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 4570 5090 6390 4570 5090 6390 4570 5090 6390 Sens 6 16% 19% 10% 19% 21% 8% 10% 15% 4% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 0.75 1.2 0.81 0.69 2.4 0.84 0.68 0.33 0.47 p Value 0.43 0.76 0.57 0.39 0.21 0.67 0.54 0.34 0.31 95% CI of 0.37 0.39 0.39 0.30 0.60 0.36 0.20 0.034 0.11 OR Quart2 1.5 3.6 1.7 1.6 9.5 1.9 2.3 3.2 2.0 OR Quart 3 0.94 0.66 0.93 1.6 1.0 1.8 0.68 1.3 1.0 p Value 0.86 0.52 0.85 0.25 1.0 0.13 0.54 0.70 1.0 95% CI of 0.46 0.18 0.45 0.73 0.20 0.84 0.20 0.29 0.30 OR Quart3 1.9 2.4 1.9 3.4 5.1 3.8 2.3 6.1 3.3 OR Quart 4 1.2 1.7 1.1 1.3 2.0 1.8 1.9 1.7 2.0 p Value 0.53 0.30 0.81 0.55 0.32 0.13 0.21 0.48 0.20 95% CI of 0.63 0.61 0.53 0.58 0.50 0.84 0.69 0.40 0.70 OR Quart4 2.5 5.0 2.2 2.8 8.3 3.8 5.3 7.3 5.9 Complement factor H sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 182000 195000 182000 184000 182000 176000 Average 189000 187000 189000 193000 189000 193000 Stdev 66500 67800 66500 63800 66500 59000 p(t-test) 0.86 0.69 0.83 Min 57700 14900 57700 101000 57700 75300 Max 486000 339000 486000 427000 486000 297000 n (Samp) 157 77 157 57 157 15 n (Patient) 89 77 89 57 89 15 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 183000 176000 183000 192000 183000 200000 Average 192000 169000 192000 187000 192000 221000 162 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Stdev 79700 66300 79700 58400 79700 74200 p(t-test) 0.18 0.84 0.34 Min 14900 53600 14900 48200 14900 112000 Max 1070000 339000 1070000 285000 1070000 325000 n (Samp) 376 22 376 13 376 7 n (Patient) 178 22 178 13 178 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 184000 193000 184000 178000 184000 169000 Average 192000 188000 192000 189000 192000 184000 Stdev 67000 69200 67000 68000 67000 60400 p(t-test) 0.68 0.81 0.64 Min 29300 14900 29300 53600 29300 75300 Max 486000 320000 486000 427000 486000 297000 n (Samp) 183 66 183 60 183 17 n (Patient) 91 66 91 60 91 17 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.53 0.42 0.51 0.52 0.53 0.48 0.54 0.63 0.47 SE 0.040 0.065 0.042 0.045 0.083 0.043 0.080 0.11 0.074 p 0.52 0.25 0.83 0.69 0.73 0.72 0.63 0.27 0.71 nCohort 1 157 376 183 157 376 183 157 376 183 nCohort 2 77 22 66 57 13 60 15 7 17 Cutoff 1 154000 135000 143000 148000 178000 147000 162000 183000 159000 Sens 1 70% 73% 71% 70% 77% 70% 73% 71% 71% Spec 1 36% 19% 24% 32% 45% 29% 39% 50% 36% Cutoff 2 133000 114000 128000 141000 149000 138000 159000 177000 154000 Sens 2 81% 82% 80% 81% 85% 80% 80% 86% 82% Spec 2 17% 10% 15% 23% 29% 21% 37% 44% 34% Cutoff 3 89900 80000 93000 127000 141000 122000 154000 112000 115000 Sens 3 91% 91% 91% 91% 92% 90% 93% 100% 94% Spec 3 3% 2% 2% 12% 22% 11% 36% 9% 11% Cutoff 4 208000 213000 214000 208000 213000 214000 208000 213000 214000 Sens 4 39% 27% 35% 32% 15% 27% 27% 43% 24% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 236000 237000 241000 236000 237000 241000 236000 237000 241000 Sens 5 21% 5% 26% 23% 15% 17% 20% 43% 18% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 281000 272000 281000 281000 272000 281000 281000 272000 281000 Sens 6 8% 5% 9% 9% 15% 10% 13% 29% 12% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 0.45 1.3 0.49 0.98 1.5 1.0 8.2 0.99 0.48 p Value 0.059 0.72 0.097 0.95 0.65 1.0 0.055 0.99 0.41 95% CI of 0.20 0.33 0.21 0.41 0.25 0.43 0.96 0.061 0.084 OR Quart2 1.0 4.9 1.1 2.3 9.3 2.3 70 16 2.7 OR Quart 3 1.1 1.3 0.85 1.1 3.1 1.2 3.1 2.0 2.2 p Value 0.85 0.73 0.69 0.83 0.17 0.67 0.33 0.57 0.23 95% CI of 0.51 0.33 0.39 0.47 0.62 0.52 0.31 0.18 0.61 OR Quart3 2.3 4.8 1.9 2.6 16 2.7 32 22 7.8 OR Quart 4 1.0 2.1 0.98 0.98 0.99 1.2 4.3 3.0 0.73 p Value 0.90 0.24 0.95 0.95 0.99 0.64 0.20 0.34 0.70 163 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only 95% CI of 0.49 0.61 0.46 0.41 0.14 0.53 0.46 0.31 0.16 OR Quart4 2.2 7.2 2.1 2.3 7.2 12.8 40 30 3.5 Ciliary neurotrophic factor sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0767 0.00367 0.0767 0.0651 0.0767 0.0709 Average 0.404 0.151 0.404 0.177 0.404 0.186 Stdev 0.943 0.339 0.943 0.388 0.943 0.355 p(t-test) 0.035 0.11 0.43 Min 8.69E-5 8.69E-5 8.69E-5 8.69E-5 8.69E-5 0.000186 Max 5.36 2.02 5.36 2.52 5.36 1.29 n (Samp) 133 67 133 47 133 12 n (Patient) 65 67 65 47 65 12 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0129 0.0342 0.0129 0.165 0.0129 0.171 Average 0.228 0.370 0.228 0.308 0.228 0.199 Stdev 0.655 0.620 0.655 0.563 0.655 0.150 p(t-test) 0.37 0.68 0.90 Min 8.69E-5 8.69E-5 8.69E-5 0.000173 8.69E-5 0.0129 Max 5.36 2.22 5.36 2.02 5.36 0.397 n (Samp) 326 18 326 12 326 7 n (Patient) 141 18 141 12 141 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0651 0.00826 0.0651 0.0415 0.0651 0.136 Average 0.417 0.135 0.417 0.196 0.417 0.238 Stdev 1.02 0.315 1.02 0.458 1.02 0.335 p(t-test) 0.040 0.14 0.51 Min 8.69E-5 8.69E-5 8.69E-5 8.69E-5 8.69E-5 0.000186 Max 6.40 2.02 6.40 2.52 6.40 1.29 n(Samp) 162 58 162 51 162 14 n (Patient) 72 58 72 51 72 14 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.42 0.52 0.44 0.48 0.64 0.47 0.54 0.73 0.61 SE 0.043 0.071 0.045 0.049 0.088 0.047 0.089 0.11 0.083 p 0.066 0.74 0.18 0.68 0.11 0.58 0.63 0.035 0.17 nCohort 1 133 326 162 133 326 162 133 326 162 nCohort 2 67 18 58 47 12 51 12 7 14 Cutoff 1 0.000179 0.000179 0.000179 0.00238 0.0233 0.00191 0.00367 0.128 0.0647 Sens 1 76% 78% 76% 74% 75% 73% 83% 71% 71% Spec 1 22% 23% 27% 30% 52% 32% 41% 72% 48% Cutoff 2 0.000173 0 0.000173 0.000186 0.00238 0.000179 0.00367 0.0647 0.00367 Sens 2 84% 100% 84% 81% 83% 80% 83% 86% 86% Spec 2 14% 0% 17% 26% 35% 27% 41% 54% 44% Cutoff 3 8.69E-5 0 8.69E-5 8.69E-5 0.00191 8.69E-5 0.00268 0.00367 0.00268 164 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 3 91% 100% 93% 94% 92% 92% 92% 100% 93% Spec 3 5% 0% 9% 5% 34% 9% 34% 49% 36% Cutoff 4 0.206 0.117 0.200 0.206 0.117 0.200 0.206 0.117 0.200 Sens 4 16% 44% 16% 17% 58% 18% 25% 71% 43% Spec 4 73% 71% 70% 73% 71% 70% 73% 71% 70% Cutoff 5 0.397 0.206 0.361 0.397 0.206 0.361 0.397 0.206 0.361 Sens 5 9% 33% 9% 13% 25% 14% 8% 29% 21% Spec 5 80% 82% 80% 80% 82% 80% 80% 82% 80% Cutoff 6 0.896 0.410 0.896 0.896 0.410 0.896 0.896 0.410 0.896 Sens 6 4% 28% 3% 2% 17% 4% 8% 0% 7% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 2.0 0.27 2.3 2.3 2.0 1.8 5.6 >1.0 >6.9 p Value 0.13 0.11 0.076 0.095 0.57 0.22 0.12 <0.99 <0.079 95% CI of 0.82 0.054 0.92 0.86 0.18 0.70 0.62 >0.062 >0.80 OR Quart2 4.8 1.3 5.7 6.2 22 4.6 51 na na OR Quart 3 2.4 0.27 2.5 2.1 3.1 2.6 4.4 >3.1 >4.4 p Value 0.054 0.11 0.050 0.15 0.34 0.043 0.20 <0.33 <0.19 95% CI of 0.98 0.054 1.0 0.78 0.31 1.0 0.46 >0.32 >0.47 OR Quart3 5.7 1.3 6.2 5.6 30 6.4 41 na na OR Quart 4 2.0 1.0 1.7 1.3 6.3 1.2 2.0 >3.1 >4.4 p Value 0.13 1.0 0.24 0.60 0.092 0.77 0.58 <0.34 <0.19 95% CI of 0.82 0.34 0.68 0.47 0.74 0.43 0.17 >0.31 >0.47 OR Quart4 4.8 3.0 4.5 3.7 54 3.1 23 na na Follitropin subunit beta sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 7.83 4.95 7.83 5.51 7.83 5.05 Average 15.9 10.3 15.9 12.7 15.9 9.59 Stdev 20.2 11.0 20.2 16.2 20.2 10.9 p(t-test) 0.037 0.33 0.29 Min 0.138 0.316 0.138 0.0879 0.138 0.0600 Max 141 53.6 141 78.2 141 34.9 n (Samp) 133 67 133 47 133 12 n (Patient) 65 67 65 47 65 12 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 6.38 7.46 6.38 11.9 6.38 5.03 Average 12.8 12.7 12.8 18.1 12.8 7.09 Stdev 16.4 14.1 16.4 19.9 16.4 5.61 p(t-test) 0.97 0.28 0.35 Min 0.0600 1.34 0.0600 1.30 0.0600 0.913 Max 141 53.6 141 61.8 141 16.6 n (Samp) 326 18 326 12 326 7 n (Patient) 141 18 141 12 141 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 7.19 4.90 7.19 5.55 7.19 7.16 Average 17.0 9.92 17.0 12.4 17.0 10.3 Stdev 23.8 10.5 23.8 15.1 23.8 10.2 165 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) 0.029 0.19 0.29 Min 0.131 0.316 0.131 0.0879 0.131 0.0600 Max 141 48.5 141 78.2 141 34.9 n(Samp) 162 58 162 51 162 14 n (Patient) 72 58 72 51 72 14 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.42 0.53 0.43 0.44 0.58 0.47 0.40 0.45 0.45 SE 0.043 0.071 0.045 0.050 0.088 0.047 0.090 0.11 0.082 p 0.063 0.63 0.11 0.24 0.35 0.47 0.26 0.64 0.57 nCohort 1 133 326 162 133 326 162 133 326 162 nCohort 2 67 18 58 47 12 51 12 7 14 Cutoff 1 3.22 3.48 3.18 2.95 3.44 3.65 2.83 4.13 4.13 Sens 1 70% 72% 71% 70% 75% 71% 75% 71% 71% Spec 1 23% 33% 25% 22% 32% 29% 20% 37% 33% Cutoff 2 2.19 3.22 1.68 2.07 2.66 2.92 2.75 2.86 2.75 Sens 2 81% 83% 81% 81% 83% 80% 83% 86% 86% Spec 2 17% 30% 14% 17% 25% 25% 20% 28% 22% Cutoff 3 1.39 2.34 1.39 1.02 2.07 1.06 0.138 0.905 0.141 Sens 3 91% 94% 91% 91% 92% 90% 92% 100% 93% Spec 3 10% 23% 12% 7% 21% 7% 1% 8% 2% Cutoff 4 16.9 13.8 14.9 16.9 13.8 14.9 16.9 13.8 14.9 Sens 4 22% 28% 26% 28% 50% 31% 17% 14% 21% Spec 4 71% 70% 70% 71% 70% 70% 71% 70% 70% Cutoff 5 25.7 21.1 25.9 25.7 21.1 25.9 25.7 21.1 25.9 Sens 5 10% 22% 10% 15% 33% 14% 17% 0% 14% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 41.1 34.6 42.6 41.1 34.6 42.6 41.1 34.6 42.6 Sens 6 1% 11% 2% 6% 17% 6% 0% 0% 0% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.0 3.7 1.0 1.3 0.65 1.3 1.6 >3.1 2.7 p Value 1.0 0.11 1.0 0.62 0.64 0.61 0.62 <0.32 0.25 95% CI of 0.42 0.75 0.40 0.49 0.11 0.51 0.25 >0.32 0.49 OR Quart2 2.4 18 2.5 3.3 4.0 3.2 10 na 15 OR Quart 3 1.6 2.6 1.7 1.0 1.0 1.4 1.0 >3.1 1.5 p Value 0.29 0.26 0.20 1.0 1.0 0.46 0.98 <0.32 0.65 95% CI of 0.68 0.49 0.74 0.37 0.20 0.57 0.14 >0.32 0.24 OR Quart3 3.7 14 4.1 2.7 5.1 3.5 7.7 na 9.7 OR Quart 4 1.7 2.0 1.5 1.8 1.3 1.3 2.8 >1.0 2.1 p Value 0.21 0.41 0.38 0.24 0.71 0.61 0.23 <0.99 0.41 95% CI of 0.74 0.37 0.62 0.69 0.29 0.51 0.51 >0.063 0.36 OR Quart4 4.0 11 3.5 .5 6.1 3.2 16 na 12 Follistatin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 810 772 810 778 810 1120 Average 2870 2730 2870 1970 2870 1960 Stdev 4740 4060 4740 3210 4740 2630 p(t-test) 0.81 0.15 0.33 Min 0.0206 0.221 0.0206 0.0206 0.0206 5.88 166 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max 19900 15300 19900 12100 19900 10900 n (Samp) 184 94 184 69 184 28 n (Patient) 107 94 107 69 107 28 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 816 689 816 808 816 962 Average 2990 2620 2990 2110 2990 842 Stdev 4680 4000 4680 3370 4680 538 p(t-test) 0.69 0.42 0.11 Min 0.0206 13.2 0.0206 189 0.0206 1.35 Max 28900 11800 28900 11600 28900 1600 n(Samp) 451 28 451 19 451 12 n (Patient) 209 28 209 19 209 12 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 764 774 764 786 764 1110 Average 2910 2800 2910 1970 2910 1900 Stdev 4710 4250 4710 3170 4710 2720 p(t-test) 0.86 0.11 0.28 Min 0.0206 0.000554 0.0206 0.0206 0.0206 5.88 Max 19900 15900 19900 12100 19900 10900 n(Samp) 209 80 209 74 209 27 n (Patient) 107 80 107 74 107 27 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.48 0.48 0.48 0.48 0.52 0.49 0.61 0.46 0.57 SE 0.037 0.057 0.038 0.041 0.068 0.039 0.060 0.086 0.061 p 0.52 0.72 0.66 0.64 0.76 0.81 0.060 0.64 0.23 nCohort 1 184 451 209 184 451 209 184 451 209 nCohort 2 94 28 80 69 19 74 28 12 27 Cutoff 1 497 493 456 601 583 594 855 600 778 Sens 1 70% 71% 70% 71% 74% 70% 71% 75% 70% Spec 1 26% 28% 26% 33% 33% 37% 54% 35% 51% Cutoff 2 359 443 355 486 518 465 764 321 624 Sens 2 81% 82% 80% 81% 84% 81% 82% 83% 81% Spec 2 18% 24% 20% 24% 29% 27% 48% 16% 39% Cutoff 3 10.8 352 6.62 247 247 195 609 1.29 195 Sens 3 90% 93% 90% 91% 95% 91% 93% 100% 93% Spec 3 9% 18% 9% 14% 14% 14% 33% 2% 14% Cutoff 4 1230 1320 1330 1230 1320 1330 1230 1320 1330 Sens 4 32% 25% 30% 25% 32% 23% 36% 25% 33% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 2320 6970 4140 2320 6970 4140 2320 6970 4140 Sens 5 22% 18% 22% 16% 11% 14% 11% 0% 11% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 11500 10900 11600 11500 10900 11600 11500 10900 11600 Sens 6 6% 11% 5% 1% 11% 1% 0% 0% 0% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 0.68 0.83 0.95 1.5 4.2 1.8 2.7 6.3 2.1 167 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only p Value 0.30 0.76 0.89 0.29 0.074 0.13 0.26 0.092 0.31 95% CI of 0.33 0.25 0.46 0.69 0.87 0.84 0.49 0.74 0.50 OR Quart2 1.4 2.8 2.0 3.4 20 3.8 14 53 8.9 OR Quart 3 0.94 1.9 0.77 1.8 1.5 1.7 9.2 2.0 4.8 p Value 0.86 0.21 0.48 0.15 0.65 0.18 0.0048 0.57 0.021 95% CI of 0.47 0.69 0.36 0.81 0.25 0.78 2.0 0.18 1.3 OR Quart3 1.9 5.4 1.6 3.9 9.2 3.6 43 23 18 OR Quart 4 1.1 1.0 1.1 1.1 3.1 0.93 3.9 3.1 2.1 p Value 0.81 0.99 0.81 0.80 0.17 0.87 0.10 0.33 0.31 95% CI of 0.55 0.32 0.53 0.49 0.61 0.41 0.77 0.32 0.50 OR Quart4 2.2 3.2 2.2 2.6 16 2.1 20 30 8.9 Vitamin D-binding protein sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 179000 181000 179000 150000 179000 170000 Average 201000 205000 201000 175000 201000 181000 Stdev 92200 109000 92200 90000 92200 65400 p(t-test) 0.80 0.060 0.42 Min 41500 24700 41500 54200 41500 48700 Max 563000 630000 563000 497000 563000 314000 n (Samp) 158 76 158 57 158 15 n (Patient) 88 76 88 57 88 15 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 172000 149000 172000 152000 172000 180000 Average 193000 200000 193000 159000 193000 218000 Stdev 89600 138000 89600 82100 89600 120000 p(t-test) 0.74 0.22 0.47 Min 41500 42000 41500 24700 41500 101000 Max 630000 507000 630000 354000 630000 442000 n (Samp) 378 21 378 11 378 7 n (Patient) 176 21 176 11 176 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 181000 185000 181000 151000 181000 170000 Average 201000 206000 201000 169000 201000 178000 Stdev 94200 108000 94200 86000 94200 62600 p(t-test) 0.70 0.020 0.32 Min 41500 24700 41500 50900 41500 48700 Max 563000 630000 563000 497000 563000 314000 n (Samp) 185 66 185 61 185 17 n (Patient) 90 66 90 61 90 17 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.50 0.45 0.51 0.39 0.38 0.38 0.47 0.55 0.46 SE 0.040 0.066 0.042 0.045 0.092 0.043 0.079 0.11 0.075 p 0.96 0.43 0.86 0.013 0.19 0.0072 0.68 0.68 0.55 168 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only nCohort 1 158 378 185 158 378 185 158 378 185 nCohort 2 76 21 66 57 11 61 15 7 17 Cutoff 1 149000 133000 155000 128000 126000 128000 153000 154000 152000 Sens 1 71% 71% 71% 70% 73% 70% 73% 71% 71% Spec 1 30% 24% 36% 17% 20% 22% 30% 37% 32% Cutoff 2 130000 88700 132000 107000 108000 101000 146000 107000 133000 Sens 2 80% 81% 80% 81% 82% 80% 80% 86% 82% Spec 2 19% 5% 25% 7% 11% 9% 30% 11% 26% Cutoff 3 89100 72700 98100 92600 107000 89100 125000 101000 125000 Sens 3 91% 90% 91% 91% 91% 90% 93% 100% 94% Spec 3 3% 2% 9% 4% 11% 6% 16% 10% 19% Cutoff 4 224000 212000 230000 224000 212000 230000 224000 212000 230000 Sens 4 30% 33% 27% 16% 18% 15% 20% 43% 18% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 249000 242000 251000 249000 242000 251000 249000 242000 251000 Sens 5 25% 29% 18% 14% 9% 11% 20% 43% 18% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 312000 300000 312000 312000 300000 312000 312000 300000 312000 Sens 6 12% 19% 11% 9% 9% 7% 7% 14% 6% Spec 6 91% 90% 90% 91% 90% 90% 91% 90% 90% OR Quart 2 0.81 0.27 1.4 1.6 3.1 1.8 1.0 0.49 1.0 p Value 0.60 0.11 0.44 0.34 0.33 0.23 0.98 0.57 0.98 95% CI of 0.38 0.055 0.61 0.61 0.32 0.70 0.20 0.044 0.20 OR Quart2 1.8 1.3 3.1 4.1 30 4.4 5.4 5.5 5.3 OR Quart 3 0.73 0.70 1.4 1.8 2.0 2.6 2.2 0.49 3.0 p Value 0.43 0.55 0.44 0.24 0.56 0.035 0.28 0.57 0.12 95% CI of 0.34 0.21 0.61 0.68 0.18 1.1 0.52 0.044 0.74 OR Quart3 1.6 2.3 3.1 4.5 23 6.3 9.5 5.5 12 OR Quart 4 0.95 1.0 1.2 3.3 5.3 2.7 1.0 1.5 1.0 p Value 0.90 0.98 0.71 0.0099 0.13 0.031 0.98 0.66 0.98 95% CI of 0.45 0.34 0.51 1.3 0.60 1.1 0.20 0.25 0.20 OR Quart4 2.0 3.0 2.7 8.1 46 6.5 5.4 9.2 5.3 Glucagon sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 52.8 63.9 52.8 79.1 52.8 20200 Average 4350 10100 4350 8700 4350 20100 Stdev 12500 17600 12500 16600 12500 20400 p(t-test) 0.045 0.10 5.7E-6 Min 4.03 20.4 4.03 20.9 4.03 14.6 Max 40100 40100 40100 40100 40100 40100 n (Samp) 84 36 84 42 84 26 n (Patient) 75 36 75 42 75 26 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 70.1 43.2 70.1 61.2 70.1 77.3 Average 9040 12100 9040 11000 9040 17800 Stdev 16700 19300 16700 18700 16700 21100 p(t-test) 0.58 0.71 0.13 Min 1.01 21.2 1.01 11.1 1.01 14.6 169 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max 40100 40100 40100 40100 40100 40100 n(Samp) 201 10 201 11 201 9 n(Patient) 132 10 132 11 132 9 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 60.1 70.7 60.1 77.3 60.1 216 Average 6020 10700 6020 9430 6020 18100 Stdev 14300 18000 14300 17100 14300 20400 p(t-test) 0.16 0.25 0.0031 Min 4.03 20.4 4.03 20.9 4.03 14.6 Max 40100 40100 40100 40100 40100 40100 n(Samp) 74 30 74 43 74 20 n (Patient) 61 30 61 43 61 20 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.59 0.48 0.56 0.63 0.46 0.59 0.73 0.52 0.70 SE 0.058 0.095 0.063 0.054 0.091 0.055 0.061 0.100 0.071 p 0.11 0.86 0.32 0.018 0.67 0.11 1.3E-4 0.83 0.0058 nCohort 1 84 201 74 84 201 74 84 201 74 nCohort 2 36 10 30 42 11 43 26 9 20 Cutoff 1 24.4 37.0 41.4 28.7 20.9 29.9 86.8 20.9 89.9 Sens 1 72% 70% 70% 71% 91% 72% 73% 89% 70% Spec 1 37% 33% 36% 38% 5% 32% 75% 5% 69% Cutoff 2 20.4 20.9 20.4 24.4 20.9 23.7 28.4 20.9 71.5 Sens 2 97% 100% 97% 81% 91% 81% 81% 89% 80% Spec 2 10% 5% 7% 37% 5% 30% 38% 5% 59% Cutoff 3 20.4 20.9 20.4 20.9 20.9 20.9 18.6 12.9 18.6 Sens 3 97% 100% 97% 98% 91% 98% 96% 100% 95% Spec 3 10% 5% 7% 10% 5% 7% 10% 2% 7% Cutoff 4 79.0 167 98.8 79.0 167 98.8 79.0 167 98.8 Sens 4 44% 40% 43% 50% 36% 44% 73% 44% 65% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 143 40100 154 143 40100 154 143 40100 154 Sens 5 36% 0% 37% 36% 0% 37% 54% 0% 50% Spec 5 81% 100% 81% 81% 100% 81% 81% 100% 81% Cutoff 6 40100 40100 40100 40100 40100 40100 40100 40100 40100 Sens 6 0% 0% 0% 0% 0% 0% 0% 0% 0% Spec 6 100% 100% 100% 100% 100% 100% 100% 100% 100% OR Quart 2 0.85 0.32 1.0 3.1 0.65 1.4 0.44 0.31 0 p Value 0.77 0.33 1.0 0.062 0.65 0.57 0.37 0.32 na 95% CI of 0.28 0.032 0.29 0.94 0.10 0.45 0.074 0.032 na OR Quart2 2.6 3.2 3.4 10 4.1 4.2 2.6 3.1 na OR Quart 3 0.58 1.0 0.65 2.5 0.32 1.2 1.6 0.32 1.7 p Value 0.37 1.0 0.51 0.14 0.33 0.77 0.49 0.33 0.48 95% CI of 0.18 0.19 0.18 0.73 0.032 0.38 0.41 0.032 0.40 OR Quart3 1.9 5.2 2.4 8.4 3.2 3.7 6.6 3.2 7.0 OR Quart 4 1.8 1.0 2.0 4.6 1.7 3.0 5.8 1.3 3.4 p Value 0.29 0.98 0.25 0.012 0.47 0.047 0.0081 0.72 0.076 95% CI of 0.62 0.20 0.62 1.4 0.39 1.0 1.6 0.28 0.88 OR Quart4 5.2 5.3 6.4 15 7.7 8.9 21 6.3 13 170 Glucagon-like peptide 1 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 57.2 55.4 57.2 66.8 57.2 77.6 Average 60.4 65.6 60.4 78.5 60.4 89.1 Stdev 39.7 46.1 39.7 58.6 39.7 59.0 p(t-test) 0.53 0.042 0.0052 Min 2.37 3.01 2.37 3.01 2.37 2.37 Max 185 208 185 197 185 205 n (Samp) 84 36 84 42 84 26 n (Patient) 75 36 75 42 75 26 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 57.8 70.1 57.8 103 57.8 90.6 Average 67.2 71.7 67.2 89.6 67.2 90.9 Stdev 48.4 35.4 48.4 57.2 48.4 62.1 p(t-test) 0.77 0.14 0.16 Min 2.37 18.7 2.37 13.1 2.37 9.67 Max 240 134 240 171 240 186 n(Samp) 201 10 201 11 201 9 n (Patient) 132 10 132 11 132 9 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 50.6 50.8 50.6 66.3 50.6 74.1 Average 58.2 64.5 58.2 76.8 58.2 85.7 Stdev 41.1 50.1 41.1 58.1 41.1 63.5 p(t-test) 0.51 0.046 0.021 Min 2.37 3.01 2.37 3.01 2.37 2.37 Max 185 208 185 202 185 205 n(Samp) 74 30 74 43 74 20 n (Patient) 61 30 61 43 61 20 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.53 0.57 0.52 0.56 0.61 0.57 0.65 0.61 0.63 SE 0.058 0.096 0.063 0.055 0.093 0.056 0.065 0.10 0.074 p 0.66 0.46 0.78 0.29 0.23 0.20 0.019 0.27 0.084 nCohort 1 84 201 74 84 201 74 84 201 74 nCohort 2 36 10 30 42 11 43 26 9 20 Cutoff 1 35.0 60.4 34.8 33.1 47.5 33.1 45.2 32.0 44.0 Sens 1 72% 70% 70% 71% 73% 72% 73% 78% 70% Spec 1 27% 53% 31% 24% 44% 28% 45% 23% 49% Cutoff 2 31.2 44.0 27.0 22.9 32.0 22.9 31.2 17.7 27.0 Sens 2 81% 80% 80% 81% 82% 81% 81% 89% 80% Spec 2 23% 39% 22% 14% 23% 16% 23% 11% 22% Cutoff 3 14.6 32.4 14.6 17.7 24.0 17.7 9.67 6.97 9.67 Sens 3 92% 90% 90% 90% 91% 91% 92% 100% 90% Spec 3 10% 24% 11% 10% 17% 11% 8% 8% 9% Cutoff 4 71.7 78.1 68.3 71.7 78.1 68.3 71.7 78.1 68.3 Sens 4 33% 40% 33% 43% 55% 47% 65% 56% 60% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 81.8 96.7 79.8 81.8 96.7 79.8 81.8 96.7 79.8 171 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 5 33% 20% 33% 38% 55% 37% 42% 44% 40% Spec 5 81% 80% 81% 81% 80% 81% 81% 80% 81% Cutoff 6 119 138 119 119 138 119 119 138 119 Sens 6 8% 0% 10% 29% 18% 26% 35% 33% 30% Spec 6 90% 90% 91% 90% 90% 91% 90% 90% 91% OR Quart 2 1.2 0.48 0.83 0.61 0.65 1.0 0.42 0 0.51 p Value 0.78 0.55 0.76 0.37 0.65 1.0 0.26 na 0.40 95% CI of 0.39 0.042 0.25 0.20 0.10 0.34 0.093 na 0.11 OR Quart2 3.5 5.5 2.8 1.8 4.1 3.0 1.9 na 2.5 OR Quart 3 0.47 2.6 0.54 0.53 0 0.60 1.0 0.65 0.54 p Value 0.23 0.27 0.34 0.27 na 0.39 1.0 0.65 0.44 95% CI of 0.14 0.48 0.15 0.17 na 0.19 0.28 0.10 0.11 OR Quart3 1.6 14 1.9 1.6 na 1.9 3.6 4.1 2.6 OR Quart 4 1.6 0.98 1.4 1.8 2.1 2.2 2.3 1.3 2.2 p Value 0.42 0.98 0.56 0.25 0.30 0.15 0.18 0.72 0.24 95% CI of 0.53 0.13 0.45 0.66 0.50 0.76 0.69 0.28 0.59 OR Quart4 4.5 7.2 4.4 5.0 9.0 6.2 7.4 6.3 7.8 Appetite-regulating hormone sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 23.4 21.8 23.4 24.3 23.4 26.1 Average 28.8 28.8 28.8 31.6 28.8 33.2 Stdev 26.4 21.3 26.4 22.8 26.4 22.3 p(t-test) 1.00 0.56 0.45 Min 0.251 3.18 0.251 1.29 0.251 0.251 Max 195 86.6 195 92.2 195 81.4 n (Samp) 84 36 84 42 84 26 n (Patient) 75 36 75 42 75 26 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 24.1 28.4 24.1 33.7 24.1 21.3 Average 30.4 30.4 30.4 33.7 30.4 33.2 Stdev 24.2 20.0 24.2 27.0 24.2 28.2 p(t-test) 1.00 0.66 0.74 Min 0.251 6.94 0.251 6.30 0.251 1.29 Max 195 65.5 195 92.2 195 91.4 n(Samp) 201 10 201 11 201 9 n (Patient) 132 10 132 11 132 9 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 22.9 19.9 22.9 24.8 22.9 26.1 Average 26.4 30.2 26.4 30.4 26.4 33.3 Stdev 21.6 25.1 21.6 21.5 21.6 24.2 p(t-test) 0.44 0.33 0.22 Min 0.251 3.18 0.251 1.29 0.251 0.251 Max 119 90.4 119 91.4 119 81.4 n(Samp) 74 30 74 43 74 20 n (Patient) 61 30 61 43 61 20 172 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.50 0.53 0.52 0.54 0.51 0.56 0.58 0.51 0.60 SE 0.058 0.095 0.063 0.055 0.090 0.056 0.066 0.099 0.074 p 0.97 0.79 0.78 0.49 0.88 0.31 0.22 0.92 0.20 nCohort 1 84 201 74 84 201 74 84 201 74 nCohort 2 36 10 30 42 11 43 26 9 20 Cutoff 1 14.6 22.1 14.6 12.6 11.0 13.2 20.1 17.9 20.1 Sens 1 72% 70% 70% 71% 73% 72% 73% 78% 70% Spec 1 26% 43% 30% 23% 16% 30% 39% 34% 45% Cutoff 2 9.67 9.67 9.67 11.0 9.67 11.1 17.9 8.24 16.8 Sens 2 83% 80% 80% 81% 82% 81% 81% 89% 80% Spec 2 17% 15% 20% 18% 15% 26% 33% 13% 35% Cutoff 3 6.30 8.02 6.30 7.35 8.65 7.35 3.18 0.251 3.18 Sens 3 92% 90% 90% 90% 91% 91% 92% 100% 90% Spec 3 8% 12% 11% 11% 14% 14% 5% 2% 7% Cutoff 4 30.7 38.0 28.8 30.7 38.0 28.8 30.7 38.0 28.8 Sens 4 42% 30% 40% 45% 45% 40% 38% 33% 35% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 41.0 47.5 37.2 41.0 47.5 37.2 41.0 47.5 37.2 Sens 5 25% 20% 30% 38% 27% 35% 27% 22% 35% Spec 5 81% 80% 81% 81% 80% 81% 81% 80% 81% Cutoff 6 51.9 55.1 51.9 51.9 55.1 51.9 51.9 55.1 51.9 Sens 6 17% 20% 20% 19% 18% 19% 27% 22% 30% Spec 6 90% 90% 91% 90% 90% 91% 90% 90% 91% OR Quart 2 1.2 0.31 1.7 0.53 0 1.2 1.9 1.5 0.68 p Value 0.78 0.32 0.38 0.25 na 0.78 0.35 0.66 0.64 95% CI of 0.39 0.032 0.53 0.18 na 0.39 0.49 0.24 0.13 OR Quart2 3.5 3.1 5.5 1.6 na 3.5 7.5 9.4 3.4 OR Quart 3 0.71 1.3 0.35 0.38 0.38 1.0 1.6 1.0 1.7 p Value 0.56 0.72 0.17 0.098 0.26 1.0 0.49 1.0 0.48 95% CI of 0.22 0.28 0.080 0.12 0.070 0.33 0.41 0.14 0.40 OR Quart3 2.2 6.3 1.6 1.2 2.0 3.0 6.6 7.4 7.0 OR Quart 4 1.2 0.64 1.7 1.6 0.78 2.2 2.7 0.98 2.0 p Value 0.78 0.63 0.38 0.37 0.73 0.14 0.14 0.98 0.34 95% CI of 0.39 0.10 0.53 0.58 0.20 0.77 0.72 0.13 0.49 OR Quart4 3.5 .0 5.5 4.3 3.1 6.4 10 7.2 7.9 Islet amyloid polypeptide sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 9.07 8.98 9.07 7.32 9.07 10.1 Average 14.5 14.3 14.5 11.0 14.5 11.0 Stdev 19.8 16.4 19.8 11.2 19.8 7.80 p(t-test) 0.96 0.29 0.38 Min 0.0141 0.0166 0.0141 0.0141 0.0141 0.0141 Max 121 81.1 121 39.6 121 23.7 n (Samp) 84 36 84 42 84 26 n (Patient) 75 36 75 42 75 26 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 8.70 18.1 8.70 6.92 8.70 10.5 Average 13.0 24.3 13.0 13.5 13.0 11.5 173 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Stdev 15.3 24.4 15.3 15.0 15.3 7.40 p(t-test) 0.028 0.91 0.77 Min 0.0141 0.175 0.0141 0.0141 0.0141 0.0141 Max 121 81.1 121 39.6 121 23.5 n(Samp) 201 10 201 11 201 9 n (Patient) 132 10 132 11 132 9 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 9.44 7.87 9.44 7.67 9.44 6.33 Average 12.2 11.2 12.2 9.98 12.2 9.89 Stdev 13.3 11.4 13.3 9.45 13.3 8.09 p(t-test) 0.72 0.34 0.46 Min 0.0141 0.0166 0.0141 0.0141 0.0141 0.0141 Max 70.6 49.8 70.6 36.4 70.6 23.7 n(Samp) 74 30 74 43 74 20 n (Patient) 61 30 61 43 61 20 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.51 0.65 0.48 0.43 0.46 0.44 0.50 0.55 0.47 SE 0.058 0.096 0.063 0.055 0.091 0.056 0.065 0.10 0.074 p 0.92 0.12 0.73 0.22 0.70 0.27 0.99 0.65 0.64 nCohort 1 84 201 74 84 201 74 84 201 74 nCohort 2 36 10 30 42 11 43 26 9 20 Cutoff 1 6.02 8.70 5.53 3.02 2.53 3.73 4.92 9.79 4.41 Sens 1 72% 70% 70% 71% 73% 72% 73% 78% 70% Spec 1 32% 50% 32% 13% 14% 20% 24% 56% 26% Cutoff 2 3.53 8.19 3.53 2.01 0.466 2.01 3.63 2.88 2.81 Sens 2 81% 80% 80% 81% 82% 81% 81% 89% 80% Spec 2 14% 48% 18% 5% 6% 5% 15% 16% 14% Cutoff 3 0.897 2.81 0.897 1.11 0 1.11 2.19 0 2.19 Sens 3 92% 90% 90% 90% 100% 91% 92% 100% 90% Spec 3 5% 15% 5% 5% 0% 5% 8% 0% 9% Cutoff 4 12.7 13.1 12.6 12.7 13.1 12.6 12.7 13.1 12.6 Sens 4 39% 50% 37% 26% 36% 21% 38% 33% 35% Spec 4 70% 71% 70% 70% 71% 70% 70% 71% 70% Cutoff 5 17.9 17.9 15.9 17.9 17.9 15.9 17.9 17.9 15.9 Sens 5 19% 50% 20% 19% 27% 21% 23% 22% 30% Spec 5 81% 80% 81% 81% 80% 81% 81% 80% 81% Cutoff 6 25.9 27.9 23.1 25.9 27.9 23.1 25.9 27.9 23.1 Sens 6 14% 40% 10% 14% 18% 9% 0% 0% 10% Spec 6 90% 90% 91% 90% 90% 91% 90% 90% 91% OR Quart 2 1.0 0.98 0.45 0.90 0.65 1.2 0.48 0 0.23 p Value 1.0 0.98 0.22 0.85 0.65 0.71 0.29 na 0.091 95% CI of 0.33 0.13 0.13 0.31 0.10 0.41 0.12 na 0.042 OR Quart2 3.0 7.2 1.6 2.6 4.1 3.7 1.9 na 1.3 OR Quart 3 1.0 0.48 1.0 0.86 0.65 1.4 1.0 2.7 0.64 p Value 1.0 0.55 1.0 0.78 0.65 0.52 1.0 0.26 0.51 95% CI of 0.33 0.042 0.32 0.29 0.10 0.48 0.30 0.49 0.17 OR Quart3 3.0 5.5 3.1 2.5 4.1 4.2 3.4 14 2.4 OR Quart 4 1.0 2.6 0.70 1.8 1.4 1.9 1.1 0.98 0.86 p Value 1.0 0.27 0.55 0.26 0.70 0.24 0.83 0.98 0.81 174 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only 95% CI of 0.33 0.48 0.21 0.65 0.29 0.65 0.35 0.13 0.24 OR Quart4 3.0 14 2.3 5.1 6.4 5.5 3.8 7.2 3.1 Interleukin-17A sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 1.58 1.37 1.58 1.79 1.58 2.86 Average 3.40 2.81 3.40 3.36 3.40 3.89 Stdev 5.09 4.30 5.09 4.95 5.09 3.89 p(t-test) 0.36 0.96 0.66 Min 0.000362 0.000362 0.000362 0.000469 0.000362 0.000469 Max 33.6 29.6 33.6 33.0 33.6 18.0 n (Samp) 159 88 159 62 159 22 n (Patient) 87 88 87 62 87 22 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 1.51 1.90 1.51 2.19 1.51 2.54 Average 3.31 3.71 3.31 4.47 3.31 3.17 Stdev 5.49 5.99 5.49 6.78 5.49 2.20 p(t-test) 0.72 0.33 0.93 Min 0.000362 0.000532 0.000362 0.00408 0.000362 0.690 Max 53.4 29.6 53.4 33.0 53.4 8.69 n (Samp) 399 26 399 23 399 11 n (Patient) 184 26 184 23 184 11 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 1.72 1.22 1.72 1.56 1.72 3.30 Average 3.20 2.69 3.20 2.90 3.20 3.83 Stdev 4.75 4.48 4.75 3.65 4.75 4.05 p(t-test) 0.42 0.65 0.56 Min 0.000362 0.000362 0.000362 0.000362 0.000362 0.000469 Max 33.6 29.6 33.6 19.4 33.6 18.0 n (Samp) 189 76 189 65 189 21 n (Patient) 93 76 93 65 93 21 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.47 0.55 0.45 0.53 0.61 0.52 0.62 0.64 0.61 SE 0.039 0.060 0.040 0.044 0.064 0.042 0.067 0.091 0.068 p 0.44 0.44 0.17 0.45 0.089 0.70 0.069 0.13 0.096 nCohort 1 159 399 189 159 399 189 159 399 189 nCohort 2 88 26 76 62 23 65 22 11 21 Cutoff 1 0.176 0.348 0.150 0.634 1.06 0.608 2.17 2.05 2.04 Sens 1 73% 73% 71% 71% 74% 71% 73% 73% 71% Spec 1 26% 29% 25% 34% 44% 34% 57% 58% 56% Cutoff 2 0.00219 0.234 0.000532 0.373 0.608 0.348 2.04 2.04 0.790 Sens 2 83% 81% 80% 81% 83% 80% 82% 82% 81% Spec 2 14% 27% 13% 31% 35% 29% 55% 58% 37% Cutoff 3 0.000469 0.00436 0.000362 0.00219 0.490 0.00219 0.780 1.47 0.690 175 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 3 92% 96% 93% 94% 91% 92% 91% 91% 90% Spec 3 8% 19% 4% 14% 31% 14% 36% 50% 34% Cutoff 4 3.75 3.33 3.47 3.75 3.33 3.47 3.75 3.33 3.47 Sens 4 27% 35% 25% 27% 43% 29% 27% 27% 38% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 5.11 4.95 5.11 5.11 4.95 5.11 5.11 4.95 5.11 Sens 5 17% 23% 16% 21% 26% 18% 14% 18% 14% Spec 5 81% 80% 81% 81% 80% 81% 81% 80% 81% Cutoff 6 9.31 8.85 8.35 9.31 8.85 8.35 9.31 8.85 8.35 Sens 6 5% 8% 8% 8% 9% 6% 9% 0% 14% Spec 6 91% 90% 90% 91% 90% 90% 91% 90% 90% OR Quart 2 1.2 1.4 0.94 1.9 3.1 1.9 3.1 >2.0 5.3 p Value 0.70 0.55 0.88 0.13 0.17 0.12 0.33 <0.57 0.13 95% CI of 0.55 0.44 0.43 0.82 0.61 0.84 0.31 >0.18 0.60 OR Quart2 2.4 4.7 2.1 4.6 16 4.2 31 na 47 OR Quart 3 1.3 1.2 1.5 1.9 3.7 1.2 20 >7.5 14 p Value 0.45 0.76 0.31 0.13 0.11 0.67 0.0049 <0.061 0.014 95% CI of 0.63 0.36 0.69 0.82 0.75 0.52 2.5 >0.91 1.7 OR Quart3 2.8 4.1 3.1 4.6 18 2.8 160 na 110 OR Quart 4 1.2 1.6 1.4 1.5 4.2 1.3 4.2 >2.0 4.2 p Value 0.66 0.40 0.41 0.40 0.074 0.56 0.21 <0.57 0.21 95% CI of 0.56 0.52 0.64 0.60 0.87 0.56 0.45 >0.18 0.45 OR Quart4 2.5 5.2 2.9 3.6 20 2.9 39 na 39 Insulin receptor substrate 1 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0314 0.0263 0.0314 0.0316 0.0314 0.0106 Average 0.871 0.448 0.871 0.332 0.871 0.502 Stdev 5.30 1.54 5.30 0.912 5.30 1.37 p(t-test) 0.49 0.45 0.78 Min 3.03E-6 0.000111 3.03E-6 0.000645 3.03E-6 0.000172 Max 49.5 10.5 49.5 4.76 49.5 5.12 n (Samp) 158 78 158 56 158 16 n (Patient) 89 78 89 56 89 16 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0288 0.0461 0.0288 0.0437 0.0288 0.00737 Average 0.562 0.643 0.562 0.174 0.562 0.0163 Stdev 3.53 1.76 3.53 0.233 3.53 0.0196 p(t-test) 0.92 0.72 0.68 Min 3.03E-6 0.00276 3.03E-6 0.000645 3.03E-6 0.000645 Max 49.5 7.74 49.5 0.722 49.5 0.0477 n (Samp) 378 22 378 11 378 7 n (Patient) 177 22 177 11 177 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0345 0.0238 0.0345 0.0301 0.0345 0.0233 Average 0.793 0.484 0.793 0.379 0.793 0.487 Stdev 4.91 1.64 4.91 0.982 4.91 1.29 176 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) 0.61 0.52 0.79 Min 3.03E-6 0.000111 3.03E-6 0.000645 3.03E-6 0.000172 Max 49.5 10.5 49.5 4.76 49.5 5.12 n (Samp) 185 67 185 60 185 18 n (Patient) 91 67 91 60 91 18 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.51 0.57 0.50 0.51 0.55 0.50 0.36 0.28 0.44 SE 0.040 0.065 0.041 0.045 0.091 0.043 0.078 0.11 0.073 p 0.86 0.26 0.98 0.89 0.55 0.96 0.081 0.048 0.41 nCohort 1 158 378 185 158 378 185 158 378 185 nCohort 2 78 22 67 56 11 60 16 7 18 Cutoff 1 0.0143 0.0179 0.0143 0.0103 0.0154 0.0143 0.000172 0.000172 0.000645 Sens 1 72% 73% 70% 73% 73% 70% 88% 100% 72% Spec 1 32% 38% 33% 25% 36% 33% 4% 3% 10% Cutoff 2 0.00925 0.00831 0.0103 0.00605 0.00689 0.00831 0.000172 0.000172 0.000172 Sens 2 81% 82% 82% 82% 82% 80% 88% 100% 89% Spec 2 25% 22% 25% 18% 20% 23% 4% 3% 3% Cutoff 3 0.00323 0.00372 0.00323 0.00323 0.00372 0.00323 3.96E-5 0.000172 3.96E-5 Sens 3 92% 91% 93% 91% 91% 92% 100% 100% 100% Spec 3 17% 16% 17% 17% 16% 17% 3% 3% 3% Cutoff 4 0.0973 0.0777 0.106 0.0973 0.0777 0.106 0.0973 0.0777 0.106 Sens 4 29% 36% 28% 32% 45% 28% 25% 0% 28% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 0.148 0.147 0.175 0.148 0.147 0.175 0.148 0.147 0.175 Sens 5 22% 27% 21% 27% 36% 23% 19% 0% 22% Spec 5 80% 81% 80% 80% 81% 80% 80% 81% 80% Cutoff 6 0.764 0.503 0.527 0.764 0.503 0.527 0.764 0.503 0.527 Sens 6 10% 18% 12% 9% 9% 13% 12% 0% 11% Spec 6 91% 90% 90% 91% 90% 90% 91% 90% 90% OR Quart 2 1.4 0.59 1.0 0.98 0.66 0.77 0.67 >2.1 0.57 p Value 0.44 0.48 1.0 0.95 0.65 0.55 0.67 <0.56 0.47 95% CI of 0.63 0.14 0.45 0.41 0.11 0.33 0.11 >0.18 0.13 OR Quart2 2.9 2.5 2.2 2.3 4.0 1.8 4.2 na 2.5 OR Quart 3 0.92 1.4 1.5 0.91 0.33 1.4 1.4 >1.0 0.78 p Value 0.84 0.55 0.33 0.82 0.34 0.39 0.69 <0.99 0.73 95% CI of 0.42 0.44 0.68 0.38 0.033 0.64 0.29 >0.063 0.20 OR Quart3 2.0 4.7 3.2 2.2 3.2 3.1 6.5 na 3.1 OR Quart 4 1.3 1.4 0.84 1.1 1.7 0.93 2.7 >4.2 1.3 p Value 0.56 0.55 0.68 0.87 0.48 0.87 0.18 <0.20 0.72 95% CI of 0.58 0.44 0.37 0.46 0.39 0.41 0.64 >0.46 0.36 OR Quart4 2.7 4.7 1.9 2.5 7.3 2.1 11 na .4 Involucrin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.750 0.649 0.750 0.751 0.750 0.593 Average 0.946 0.949 0.946 1.20 0.946 0.789 Stdev 0.702 0.806 0.702 1.21 0.702 0.593 p(t-test) 0.97 0.063 0.39 Min 0.0472 0.148 0.0472 0.159 0.0472 0.258 177 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max 3.56 4.58 3.56 7.42 3.56 2.33 n (Samp) 158 78 158 56 158 16 n (Patient) 89 78 89 56 89 16 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.689 0.832 0.689 0.975 0.689 1.56 Average 0.966 1.05 0.966 1.25 0.966 1.44 Stdev 0.954 0.731 0.954 0.815 0.954 0.650 p(t-test) 0.69 0.32 0.19 Min 0.0472 0.148 0.0472 0.291 0.0472 0.591 Max 12.7 3.11 12.7 3.01 12.7 2.33 n (Samp) 378 22 378 11 378 7 n (Patient) 177 22 177 11 177 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.770 0.697 0.770 0.682 0.770 0.648 Average 0.983 0.926 0.983 1.19 0.983 0.796 Stdev 0.703 0.788 0.703 1.22 0.703 0.557 p(t-test) 0.58 0.10 0.28 Min 0.0472 0.185 0.0472 0.159 0.0472 0.258 Max 3.67 4.58 3.67 7.42 3.67 2.33 n (Samp) 185 67 185 60 185 18 n (Patient) 91 67 91 60 91 18 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.47 0.55 0.45 0.54 0.64 0.51 0.42 0.75 0.41 SE 0.040 0.065 0.042 0.045 0.091 0.043 0.078 0.11 0.073 p 0.50 0.44 0.21 0.41 0.14 0.86 0.28 0.019 0.22 nCohort 1 158 378 185 158 378 185 158 378 185 nCohort 2 78 22 67 56 11 60 16 7 18 Cutoff 1 0.490 0.511 0.501 0.560 0.910 0.560 0.439 0.997 0.461 Sens 1 71% 73% 70% 71% 73% 70% 75% 71% 72% Spec 1 27% 30% 24% 34% 67% 30% 21% 72% 20% Cutoff 2 0.401 0.419 0.446 0.428 0.571 0.446 0.428 0.824 0.428 Sens 2 81% 82% 81% 80% 82% 80% 81% 86% 83% Spec 2 18% 19% 18% 20% 35% 18% 20% 62% 17% Cutoff 3 0.317 0.317 0.330 0.290 0.368 0.312 0.267 0.584 0.291 Sens 3 91% 91% 91% 91% 91% 90% 94% 100% 94% Spec 3 10% 10% 10% 8% 14% 8% 8% 38% 5% Cutoff 4 0.994 0.976 1.05 0.994 0.976 1.05 0.994 0.976 1.05 Sens 4 28% 45% 25% 39% 45% 35% 19% 71% 17% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 1.30 1.31 1.36 1.30 1.31 1.36 1.30 1.31 1.36 Sens 5 24% 36% 19% 30% 36% 28% 19% 57% 11% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 2.03 1.98 2.03 2.03 1.98 2.03 2.03 1.98 2.03 Sens 6 9% 5% 9% 11% 9% 13% 6% 29% 6% Spec 6 91% 90% 90% 91% 90% 90% 91% 90% 90% OR Quart 2 0.61 1.0 0.83 1.4 0.49 1.2 0.67 >1.0 1.4 178 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only p Value 0.22 1.0 0.67 0.41 0.57 0.68 0.67 <0.99 0.70 95% CI of 0.27 0.28 0.36 0.60 0.044 0.53 0.11 >0.062 0.29 OR Quart2 1.4 3.6 1.9 3.4 5.5 2.7 4.2 na 6.4 OR Quart 3 1.3 0.79 1.4 0.70 2.0 0.53 1.8 >2.0 1.7 p Value 0.45 0.73 0.42 0.47 0.42 0.18 0.46 <0.56 0.47 95% CI of 0.63 0.21 0.63 0.27 0.37 0.21 0.39 >0.18 0.39 OR Quart3 2.8 3.0 3.0 1.8 11 1.3 7.8 na 7.7 OR Quart 4 1.0 1.7 1.5 1.9 2.0 1.4 2.2 >4.1 2.2 p Value 1.0 0.39 0.32 0.16 0.42 0.45 0.28 <0.21 0.29 95% CI of 0.47 0.52 0.68 0.79 0.36 0.61 0.52 >0.45 0.51 OR Quart4 2.1 5.2 3.3 4.3 11 3.0 9.5 na 9.3 Keratin, type II cytoskeletal 6 (6A, -6B, -6C mix) sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 5.13E-5 5.13E-5 5.13E-5 5.13E-5 5.13E-5 0.000220 Average 1.74 2.74 1.74 0.000120 1.74 13.5 Stdev 11.3 13.5 11.3 8.36E-5 11.3 53.9 p(t-test) 0.55 0.25 0.021 Min 5.13E-5 5.13E-5 5.13E-5 5.13E-5 5.13E-5 5.13E-5 Max 119 88.7 119 0.000220 119 216 n (Samp) 158 78 158 56 158 16 n (Patient) 89 78 89 56 89 16 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 5.13E-5 5.13E-5 5.13E-5 5.13E-5 5.13E-5 5.13E-5 Average 2.44 4.03 2.44 8.19E-5 2.44 0.000123 Stdev 18.0 18.9 18.0 6.81E-5 18.0 9.00E-5 p(t-test) 0.69 0.65 0.72 Min 5.13E-5 5.13E-5 5.13E-5 5.13E-5 5.13E-5 5.13E-5 Max 216 88.7 216 0.000220 216 0.000220 n (Samp) 378 22 378 11 378 7 n (Patient) 177 22 177 11 177 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 5.13E-5 5.13E-5 5.13E-5 5.13E-5 5.13E-5 0.000135 Average 1.34 5.09 1.34 1.70 1.34 12.0 Stdev 9.11 28.0 9.11 13.1 9.11 50.9 p(t-test) 0.11 0.81 0.013 Min 5.13E-5 5.13E-5 5.13E-5 5.13E-5 5.13E-5 5.13E-5 Max 94.9 216 94.9 102 94.9 216 n (Samp) 185 67 185 60 185 18 n (Patient) 91 67 91 60 91 18 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.43 0.44 0.47 0.51 0.43 0.54 0.63 0.55 0.61 SE 0.040 0.065 0.042 0.045 0.091 0.043 0.078 0.11 0.073 p 0.094 0.36 0.45 0.78 0.46 0.30 0.10 0.66 0.14 179 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only nCohort 1 158 378 185 158 378 185 158 378 185 nCohort 2 78 22 67 56 11 60 16 7 18 Cutoff 1 0 0 0 0 0 0 0 0 0 Sens 1 100% 100% 100% 100% 100% 100% 100% 100% 100% Spec 1 0% 0% 0% 0% 0% 0% 0% 0% 0% Cutoff 2 0 0 0 0 0 0 0 0 0 Sens 2 100% 100% 100% 100% 100% 100% 100% 100% 100% Spec 2 0% 0% 0% 0% 0% 0% 0% 0% 0% Cutoff 3 0 0 0 0 0 0 0 0 0 Sens 3 100% 100% 100% 100% 100% 100% 100% 100% 100% Spec 3 0% 0% 0% 0% 0% 0% 0% 0% 0% Cutoff 4 0.000220 0.000220 5.13E-5 0.000220 0.000220 5.13E-5 0.000220 0.000220 5.13E-5 Sens 4 6% 5% 21% 0% 0% 38% 6% 0% 50% Spec 4 95% 96% 71% 95% 96% 71% 95% 96% 71% Cutoff 5 0.000220 0.000220 0.000220 0.000220 0.000220 0.000220 0.000220 0.000220 0.000220 Sens 5 6% 5% 7% 0% 0% 2% 6% 0% 6% Spec 5 95% 96% 96% 95% 96% 96% 95% 96% 96% Cutoff 6 0.000220 0.000220 0.000220 0.000220 0.000220 0.000220 0.000220 0.000220 0.000220 Sens 6 6% 5% 7% 0% 0% 2% 6% 0% 6% Spec 6 95% 96% 96% 95% 96% 96% 95% 96% 96% OR Quart 2 0 0 0 6.1 0 7.5 5.4 3.1 9.1 p Value na na na 2.1E-4 na 2.4E-5 0.13 0.34 0.041 95% CI of na na na 2.3 na 2.9 0.60 0.31 1.1 OR Quart2 na na na 16 na 19 48 30 76 OR Quart 3 11 4.9 11 1.7 4.3 0.40 4.3 0 0 p Value 6.9E-8 0.0057 1.2E-8 0.30 0.069 0.20 0.20 na na 95% CI of 4.5 1.6 4.9 0.61 0.89 0.098 0.46 na na OR Quart3 26 15 26 4.8 21 1.6 40 na na OR Quart 4 0.70 0.24 0.30 1.9 0.50 3.7 6.6 3.0 10 p Value 0.40 0.21 0.031 0.23 0.57 0.0073 0.086 0.34 0.029 95% CI of 0.30 0.027 0.10 0.68 0.045 1.4 0.76 0.31 1.3 OR Quart4 1.6 2.2 0.90 5.2 5.6 9.5 58 30 86 Collagenase 3 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0305 0.0305 0.0305 0.0699 0.0305 0.102 Average 4.25 1.81 4.25 2.16 4.25 1.31 Stdev 29.8 9.45 29.8 15.4 29.8 4.47 p(t-test) 0.44 0.57 0.59 Min 0.00117 0.00117 0.00117 0.00117 0.00117 0.00117 Max 313 80.9 313 130 313 17.8 n (Samp) 186 95 186 72 186 30 n (Patient) 109 95 109 72 109 30 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0305 0.0288 0.0305 0.0699 0.0305 0.102 Average 3.17 3.35 3.17 5.75 3.17 5.18 Stdev 21.7 15.3 21.7 18.8 21.7 13.0 p(t-test) 0.96 0.60 0.75 Min 0.00117 0.00117 0.00117 0.00117 0.00117 0.00726 180 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max 313 80.9 313 78.6 313 43.1 n (Samp) 460 28 460 20 460 12 n (Patient) 213 28 213 20 213 12 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0297 0.0305 0.0297 0.0699 0.0297 0.102 Average 3.74 1.68 3.74 2.76 3.74 0.742 Stdev 28.0 7.14 28.0 16.2 28.0 3.27 p(t-test) 0.52 0.77 0.57 Min 0.00117 0.00117 0.00117 0.00117 0.00117 0.00117 Max 313 46.3 313 130 313 17.8 n(Samp) 211 81 211 77 211 29 n (Patient) 109 81 109 77 109 29 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.45 0.45 0.50 0.53 0.56 0.57 0.62 0.66 0.62 SE 0.037 0.058 0.038 0.040 0.068 0.039 0.058 0.087 0.059 p 0.15 0.39 0.97 0.47 0.40 0.076 0.041 0.060 0.033 nCohort 1 186 460 211 186 460 211 186 460 211 nCohort 2 95 28 81 72 20 77 30 12 29 Cutoff 1 0.00455 0.00374 0.00455 0.00726 0.0297 0.00726 0.0699 0.0297 0.0297 Sens 1 71% 75% 73% 72% 75% 71% 70% 83% 72% Spec 1 21% 15% 27% 32% 44% 39% 62% 44% 50% Cutoff 2 0.00374 0.00117 0.00374 0.00374 0.00117 0.00374 0.0297 0.0297 0.00455 Sens 2 82% 96% 83% 85% 90% 87% 83% 83% 86% Spec 2 13% 9% 20% 13% 9% 20% 42% 44% 27% Cutoff 3 0.00117 0.00117 0.00117 0.00117 0.00117 0.00117 0.00455 0.00726 0.00117 Sens 3 93% 96% 91% 94% 90% 96% 90% 92% 93% Spec 3 9% 9% 9% 9% 9% 9% 21% 34% 9% Cutoff 4 0.204 0.102 0.102 0.204 0.102 0.102 0.204 0.102 0.102 Sens 4 13% 21% 22% 19% 30% 32% 20% 33% 34% Spec 4 82% 72% 73% 82% 72% 73% 82% 72% 73% Cutoff 5 0.204 0.204 0.204 0.204 0.204 0.204 0.204 0.204 0.204 Sens 5 13% 14% 12% 19% 25% 19% 20% 33% 21% Spec 5 82% 83% 85% 82% 83% 85% 82% 83% 85% Cutoff 6 0.383 0.383 0.383 0.383 0.383 0.383 0.383 0.383 0.383 Sens 6 5% 7% 6% 4% 10% 5% 7% 17% 3% Spec 6 96% 95% 97% 96% 95% 97% 96% 95% 97% OR Quart 2 1.1 0.83 1.5 1.1 0.39 1.0 1.0 >4.1 1.7 p Value 0.81 0.76 0.27 0.88 0.27 1.0 1.0 <0.21 0.47 95% CI of 0.53 0.25 0.73 0.48 0.074 0.46 0.24 >0.46 0.39 OR Quart2 2.2 2.8 3.1 2.3 2.0 2.2 4.2 na 7.6 OR Quart 3 1.2 1.2 1.2 1.5 1.4 1.8 4.4 >4.1 5.8 p Value 0.67 0.78 0.71 0.33 0.56 0.14 0.015 <0.21 0.0085 95% CI of 0.57 0.38 0.55 0.68 0.44 0.83 1.3 >0.46 1.6 OR Quart3 2.4 3.6 2.4 3.2 4.6 3.7 14 na 21 OR Quart 4 1.7 1.7 1.1 1.1 1.2 1.4 2.2 >4.1 2.5 p Value 0.14 0.31 0.85 0.73 0.76 0.34 0.23 <0.21 0.20 95% CI of 0.84 0.61 0.51 0.52 0.36 0.68 0.61 >0.46 0.62 OR Quart4 3.4 4.9 2.3 2.5 4.1 3.1 7.7 na 10 181 NF-kappa-B inhibitor alpha sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.000560 0.00169 0.000560 0.00105 0.000560 3.67E-5 Average 0.0684 0.0159 0.0684 0.0248 0.0684 0.0211 Stdev 0.403 0.0440 0.403 0.0661 0.403 0.0689 p(t-test) 0.25 0.42 0.64 Min 1.84E-7 1.84E-7 1.84E-7 1.84E-7 1.84E-7 1.84E-7 Max 3.62 0.270 3.62 0.384 3.62 0.276 n (Samp) 158 78 158 56 158 16 n (Patient) 89 78 89 56 89 16 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.00127 0.00146 0.00127 0.00122 0.00127 3.67E-5 Average 0.0409 0.0159 0.0409 0.0256 0.0409 0.00465 Stdev 0.266 0.0377 0.266 0.0535 0.266 0.0114 p(t-test) 0.66 0.85 0.72 Min 1.84E-7 2.41E-5 1.84E-7 1.84E-7 1.84E-7 3.20E-6 Max 3.62 0.166 3.62 0.150 3.62 0.0306 n (Samp) 378 22 378 11 378 7 n (Patient) 177 22 177 11 177 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.00104 0.00166 0.00104 0.000976 0.00104 0.00203 Average 0.0657 0.0146 0.0657 0.0195 0.0657 0.0210 Stdev 0.376 0.0428 0.376 0.0606 0.376 0.0647 p(t-test) 0.27 0.34 0.62 Min 1.84E-7 1.84E-7 1.84E-7 1.84E-7 1.84E-7 1.84E-7 Max 3.62 0.270 3.62 0.384 3.62 0.276 n (Samp) 185 67 185 60 185 18 n (Patient) 91 67 91 60 91 18 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.54 0.56 0.51 0.50 0.51 0.48 0.42 0.38 0.47 SE 0.040 0.065 0.041 0.045 0.089 0.043 0.078 0.11 0.073 p 0.31 0.34 0.83 0.99 0.89 0.63 0.30 0.29 0.63 nCohort 1 158 378 185 158 378 185 158 378 185 nCohort 2 78 22 67 56 11 60 16 7 18 Cutoff 1 0.000425 0.000295 0.000425 3.31E-5 0.000156 3.31E-5 3.31E-5 3.31E-5 3.31E-5 Sens 1 71% 73% 72% 77% 73% 78% 75% 86% 78% Spec 1 44% 37% 39% 20% 33% 18% 20% 21% 18% Cutoff 2 3.31E-5 0.000228 3.31E-5 3.20E-6 3.31E-5 2.41E-5 3.20E-6 3.31E-5 3.20E-6 Sens 2 83% 82% 82% 93% 91% 80% 94% 86% 94% Spec 2 20% 35% 18% 3% 21% 15% 3% 21% 4% Cutoff 3 3.20E-6 3.31E-5 3.20E-6 3.20E-6 3.31E-5 3.20E-6 3.20E-6 9.39E-7 3.20E-6 Sens 3 95% 91% 94% 93% 91% 93% 94% 100% 94% Spec 3 3% 21% 4% 3% 21% 4% 3% 6% 4% Cutoff 4 0.00495 0.00402 0.00597 0.00495 0.00402 0.00597 0.00495 0.00402 0.00597 Sens 4 26% 45% 25% 32% 36% 32% 19% 14% 22% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 0.0147 0.0115 0.0150 0.0147 0.0115 0.0150 0.0147 0.0115 0.0150 182 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 5 18% 23% 16% 20% 18% 18% 12% 14% 22% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 0.0421 0.0421 0.0521 0.0421 0.0421 0.0521 0.0421 0.0421 0.0521 Sens 6 9% 9% 7% 16% 18% 7% 12% 0% 6% Spec 6 91% 90% 90% 91% 90% 90% 91% 90% 90% OR Quart 2 1.2 4.8 1.1 1.0 6.3 1.2 2.8 0 1.6 p Value 0.68 0.047 0.84 0.95 0.090 0.64 0.24 na 0.51 95% CI of 0.53 1.0 0.48 0.45 0.75 0.53 0.51 na 0.41 OR Quart2 2.6 23 2.5 2.3 54 2.8 15 na 5.9 OR Quart 3 2.0 2.0 1.5 0.19 1.0 1.0 0.49 4.2 0 p Value 0.084 0.42 0.32 0.0056 1.0 0.96 0.56 0.21 na 95% CI of 0.91 0.37 0.68 0.059 0.062 0.44 0.043 0.46 na OR Quart3 4.3 11 3.3 0.61 16 2.4 5.6 38 na OR Quart 4 1.3 3.7 1.1 1.4 3.0 1.2 4.8 2.0 2.2 p Value 0.55 0.11 0.84 0.38 0.34 0.64 0.057 0.56 0.21 95% CI of 0.58 0.75 0.48 0.64 0.31 0.53 0.96 0.18 0.63 OR Quart4 2.8 18 2.5 3.2 30 2.8 24 23 8.0 Beta-nerve growth factor sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 1.48 1.85 1.48 1.82 1.48 1.42 Average 2.42 2.30 2.42 2.35 2.42 1.84 Stdev 5.59 1.70 5.59 1.79 5.59 1.34 p(t-test) 0.87 0.93 0.69 Min 0.259 0.482 0.259 0.453 0.259 0.995 Max 70.0 8.57 70.0 9.39 70.0 6.48 n (Samp) 158 74 158 56 158 15 n (Patient) 88 74 88 56 88 15 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 1.61 2.21 1.61 2.67 1.61 1.79 Average 2.16 2.94 2.16 3.12 2.16 1.97 Stdev 3.75 2.05 3.75 2.29 3.75 0.828 p(t-test) 0.36 0.40 0.89 Min 0.221 0.951 0.221 1.28 0.221 0.983 Max 70.0 8.57 70.0 9.39 70.0 3.50 n (Samp) 378 20 378 11 378 7 n (Patient) 175 20 175 11 175 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 1.87 1.81 1.87 1.88 1.87 1.45 Average 2.67 2.25 2.67 2.37 2.67 1.97 Stdev 5.25 1.58 5.25 1.63 5.25 1.35 p(t-test) 0.53 0.65 0.57 Min 0.259 0.482 0.259 0.453 0.259 0.995 Max 70.0 8.47 70.0 7.22 70.0 6.48 n (Samp) 184 65 184 62 184 18 n (Patient) 89 65 89 62 89 18 183 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.55 0.66 0.49 0.57 0.72 0.52 0.50 0.57 0.45 SE 0.041 0.068 0.042 0.045 0.088 0.043 0.078 0.11 0.073 p 0.20 0.015 0.83 0.13 0.014 0.72 0.98 0.56 0.52 nCohort 1 158 378 184 158 378 184 158 378 184 nCohort 2 74 20 65 56 11 62 15 7 18 Cutoff 1 1.12 1.87 1.36 1.35 1.66 1.41 1.29 1.48 1.29 Sens 1 72% 70% 71% 71% 73% 71% 80% 86% 78% Spec 1 29% 61% 37% 45% 53% 38% 37% 43% 29% Cutoff 2 1.07 1.54 1.07 1.24 1.61 1.22 1.29 1.48 1.28 Sens 2 84% 80% 83% 80% 82% 81% 80% 86% 83% Spec 2 23% 48% 18% 35% 51% 26% 37% 43% 28% Cutoff 3 0.848 1.10 0.848 0.848 1.56 0.951 1.22 0.977 1.09 Sens 3 92% 90% 91% 91% 91% 90% 93% 100% 94% Spec 3 12% 22% 9% 12% 48% 13% 33% 16% 21% Cutoff 4 2.36 2.09 2.64 2.36 2.09 2.64 2.36 2.09 2.64 Sens 4 26% 55% 26% 30% 64% 26% 13% 29% 17% Spec 4 70% 70% 71% 70% 70% 71% 70% 70% 71% Cutoff 5 2.89 2.64 3.35 2.89 2.64 3.35 2.89 2.64 3.35 Sens 5 23% 30% 17% 23% 55% 18% 7% 14% 11% Spec 5 80% 81% 80% 80% 81% 80% 80% 81% 80% Cutoff 6 3.87 3.66 4.41 3.87 3.66 4.41 3.87 3.66 4.41 Sens 6 15% 30% 8% 12% 27% 11% 7% 0% 6% Spec 6 91% 90% 90% 91% 90% 90% 91% 90% 90% OR Quart 2 0.76 0.24 0.94 0.98 >2.0 1.5 7.0 2.0 2.1 p Value 0.52 0.21 0.88 0.96 <0.56 0.33 0.078 0.57 0.40 95% CI of 0.33 0.026 0.42 0.37 >0.18 0.66 0.80 0.18 0.37 OR Quart2 1.8 2.2 2.1 2.6 na 3.4 61 23 12 OR Quart 3 2.3 2.1 0.94 2.8 >3.1 1.4 8.4 2.0 6.0 p Value 0.036 0.24 0.88 0.021 <0.33 0.40 0.052 0.57 0.026 95% CI of 1.1 0.61 0.42 1.2 >0.32 0.62 0.98 0.18 1.2 OR Quart3 5.0 7.2 2.1 6.8 na 3.3 71 23 29 OR Quart 4 1.2 1.8 1.3 1.7 >6.3 1.1 1.0 2.0 1.0 p Value 0.68 0.37 0.51 0.28 <0.091 0.87 0.99 0.57 0.98 95% CI of 0.53 0.51 0.59 0.67 >0.75 0.46 0.062 0.18 0.14 OR Quart4 2.6 6.3 2.8 4.1 na 2.5 17 22 7.5 Pancreatic prohormone sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 51.1 59.9 51.1 61.9 51.1 63.0 Average 159 94.6 159 129 159 93.5 Stdev 247 107 247 182 247 77.2 p(t-test) 0.13 0.48 0.18 Min 0.731 0.683 0.731 0.770 0.731 8.51 Max 1300 498 1300 877 1300 300 n (Samp) 84 36 84 42 84 26 n (Patient) 75 36 75 42 75 26 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 62.8 59.2 62.8 48.2 62.8 77.9 Average 170 77.8 170 90.9 170 82.8 184 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Stdev 276 73.6 276 126 276 43.0 p(t-test) 0.30 0.35 0.35 Min 0.683 0.770 0.683 4.47 0.683 35.0 Max 1920 243 1920 443 1920 165 n(Samp) 201 10 201 11 201 9 n (Patient) 132 10 132 11 132 9 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 45.9 62.8 45.9 77.2 45.9 72.1 Average 128 125 128 162 128 100 Stdev 217 168 217 230 217 83.7 p(t-test) 0.93 0.43 0.57 Min 0.731 0.683 0.731 0.770 0.731 8.51 Max 1300 784 1300 1080 1300 300 n(Samp) 74 30 74 43 74 20 n (Patient) 61 30 61 43 61 20 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.48 0.44 0.55 0.52 0.43 0.58 0.54 0.52 0.58 SE 0.058 0.096 0.063 0.055 0.092 0.055 0.066 0.100 0.074 p 0.73 0.52 0.47 0.72 0.42 0.15 0.58 0.80 0.28 nCohort 1 84 201 74 84 201 74 84 201 74 nCohort 2 36 10 30 42 11 43 26 9 20 Cutoff 1 30.1 31.4 31.4 37.9 33.4 35.9 35.9 47.7 38.4 Sens 1 72% 70% 70% 71% 73% 72% 73% 78% 70% Spec 1 33% 27% 36% 39% 28% 39% 38% 43% 43% Cutoff 2 23.5 30.1 25.5 21.3 24.8 21.3 34.8 35.9 31.4 Sens 2 81% 80% 80% 81% 82% 81% 81% 89% 80% Spec 2 30% 26% 32% 27% 22% 30% 36% 30% 36% Cutoff 3 0.731 13.7 0.731 14.9 18.9 14.9 21.3 34.8 21.3 Sens 3 92% 90% 90% 90% 91% 91% 92% 100% 90% Spec 3 2% 10% 3% 20% 16% 22% 27% 29% 30% Cutoff 4 122 132 109 122 132 109 122 132 109 Sens 4 28% 20% 37% 29% 18% 37% 27% 11% 35% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 218 211 151 218 211 151 218 211 151 Sens 5 8% 10% 27% 12% 9% 26% 8% 0% 25% Spec 5 81% 80% 81% 81% 80% 81% 81% 80% 81% Cutoff 6 472 468 434 472 468 434 472 468 434 Sens 6 3% 0% 7% 7% 0% 12% 0% 0% 0% Spec 6 90% 90% 91% 90% 90% 91% 90% 90% 91% OR Quart 2 1.6 4.2 1.9 1.7 1.0 1.6 3.8 >3.1 3.5 p Value 0.41 0.20 0.34 0.32 1.0 0.40 0.070 <0.33 0.15 95% CI of 0.53 0.46 0.52 0.59 0.14 0.53 0.90 >0.31 0.63 OR Quart2 4.8 39 6.7 5.1 7.4 4.9 16 na 20 OR Quart 3 1.4 3.1 1.9 2.1 2.1 1.4 3.4 >6.8 3.7 p Value 0.57 0.33 0.34 0.18 0.41 0.57 0.10 <0.082 0.14 95% CI of 0.45 0.31 0.52 0.71 0.36 0.45 0.78 >0.79 0.66 OR Quart3 4.2 31 6.7 6.1 12 4.2 14 na 21 OR Quart 4 0.84 2.1 2.2 1.1 1.5 2.3 2.2 >0 3.5 p Value 0.77 0.55 0.22 0.84 0.65 0.13 0.31 <na 0.15 185 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only 95% CI of 0.26 0.18 0.63 0.37 0.25 0.78 0.49 >na 0.63 OR Quart4 2.7 24 7.9 3.4 9.5 16.8 9.8 na 20 Transthyretin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 61700 52800 61700 52200 61700 54000 Average 64900 60600 64900 57000 64900 59000 Stdev 33300 42300 33300 36200 33300 42300 p(t-test) 0.39 0.14 0.52 Min 12800 6500 12800 8510 12800 14200 Max 242000 248000 242000 215000 242000 167000 n (Samp) 157 77 157 57 157 15 n (Patient) 89 77 89 57 89 15 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 56500 49800 56500 43500 56500 57500 Average 63200 64400 63200 60000 63200 54900 Stdev 38000 53400 38000 53300 38000 27700 p(t-test) 0.90 0.77 0.56 Min 6500 15700 6500 8510 6500 17700 Max 293000 248000 293000 215000 293000 102000 n (Samp) 376 22 376 13 376 7 n (Patient) 178 22 178 13 178 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 57800 49900 57800 52500 57800 54000 Average 65300 56700 65300 55500 65300 57700 Stdev 37700 35300 37700 28000 37700 38500 p(t-test) 0.11 0.066 0.43 Min 8940 6500 8940 9150 8940 14200 Max 248000 170000 248000 171000 248000 167000 n (Samp) 183 66 183 60 183 17 n (Patient) 91 66 91 60 91 17 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.43 0.45 0.42 0.41 0.42 0.43 0.41 0.45 0.42 SE 0.040 0.065 0.042 0.045 0.084 0.044 0.080 0.11 0.075 p 0.067 0.48 0.065 0.053 0.36 0.12 0.27 0.64 0.31 nCohort 1 157 376 183 157 376 183 157 376 183 nCohort 2 77 22 66 57 13 60 15 7 17 Cutoff 1 34400 37200 32000 34200 27300 40100 28400 53000 34000 Sens 1 70% 73% 71% 70% 77% 70% 73% 71% 71% Spec 1 18% 29% 17% 18% 12% 27% 10% 46% 19% Cutoff 2 29400 34400 28000 27000 26200 32800 22800 26200 20900 Sens 2 81% 82% 80% 81% 85% 80% 80% 86% 82% Spec 2 11% 24% 10% 7% 11% 17% 3% 11% 4% Cutoff 3 20500 31700 19600 20900 16000 23200 14200 17400 16500 186 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 3 91% 91% 91% 91% 92% 90% 93% 100% 94% Spec 3 3% 20% 3% 3% 3% 4% 1% 4% 2% Cutoff 4 75500 73600 75200 75500 73600 75200 75500 73600 75200 Sens 4 25% 14% 26% 23% 31% 22% 27% 14% 24% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 89900 85300 88500 89900 85300 88500 89900 85300 88500 Sens 5 18% 14% 17% 9% 23% 7% 20% 14% 12% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 108000 114000 108000 108000 114000 108000 108000 114000 108000 Sens 6 12% 14% 9% 7% 8% 5% 13% 0% 12% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 0.87 2.1 0.78 0.83 0.24 1.3 0.48 3.1 1.0 p Value 0.73 0.31 0.56 0.68 0.21 0.51 0.41 0.34 1.0 95% CI of 0.39 0.51 0.34 0.33 0.027 0.56 0.082 0.31 0.24 OR Quart2 1.9 8.6 1.8 2.1 2.2 3.1 2.7 30 4.2 OR Quart 3 0.85 2.8 0.63 1.2 0.75 1.5 0.73 1.0 0.73 p Value 0.68 0.14 0.30 0.66 0.71 0.39 0.69 1.0 0.70 95% CI of 0.38 0.72 0.27 0.51 0.16 0.62 0.15 0.062 0.16 OR Quart3 1.9 11 1.5 2.9 3.4 3.4 3.5 16 3.5 OR Quart 4 2.0 1.7 2.1 1.6 1.3 1.6 1.6 2.0 1.6 p Value 0.076 0.47 0.052 0.26 0.72 0.27 0.50 0.56 0.51 95% CI of 0.93 0.40 0.99 0.70 0.33 0.69 0.41 0.18 0.41 OR Quart4 4.2 7.4 4.5 3.8 4.9 3.8 6.1 23 5.9 C-peptide EDTA sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2380 2820 2380 2170 2380 2020 Average 2850 3530 2850 2970 2850 2460 Stdev 2170 3160 2170 2610 2170 1860 p(t-test) 0.035 0.71 0.34 Min 53.0 21.7 53.0 51.9 53.0 179 Max 13900 19500 13900 11800 13900 7060 n (Samp) 185 96 185 73 185 31 n (Patient) 109 96 109 73 109 31 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2400 3320 2400 2720 2400 3330 Average 3060 4060 3060 3630 3060 3330 Stdev 2480 4270 2480 3260 2480 2310 p(t-test) 0.048 0.32 0.69 Min 7.96 157 7.96 114 7.96 88.8 Max 15400 19500 15400 11800 15400 7530 n (Samp) 461 28 461 20 461 13 n (Patient) 213 28 213 20 213 13 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2450 2590 2450 2090 2450 1490 Average 3130 3240 3130 2910 3130 2270 Stdev 2730 2530 2730 2470 2730 1810 187 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) 0.76 0.53 0.11 Min 53.0 21.7 53.0 51.9 53.0 179 Max 21700 11300 21700 11100 21700 6630 n (Samp) 208 82 208 78 208 28 n (Patient) 106 82 106 78 106 28 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.55 0.54 0.52 0.49 0.53 0.47 0.44 0.55 0.40 SE 0.037 0.057 0.038 0.040 0.067 0.039 0.057 0.083 0.060 p 0.20 0.49 0.62 0.77 0.70 0.49 0.33 0.51 0.082 nCohort 1 185 461 208 185 461 208 185 461 208 nCohort 2 96 28 82 73 20 78 31 13 28 Cutoff 1 1520 1290 1520 1140 1470 1210 929 1500 894 Sens 1 71% 71% 71% 71% 70% 71% 71% 77% 71% Spec 1 36% 28% 35% 21% 34% 24% 16% 34% 14% Cutoff 2 1140 1030 1280 929 753 974 805 1310 786 Sens 2 80% 82% 80% 81% 80% 81% 81% 85% 82% Spec 2 21% 18% 25% 16% 10% 15% 14% 28% 13% Cutoff 3 786 564 865 564 631 421 568 568 564 Sens 3 91% 93% 90% 90% 90% 91% 90% 92% 93% Spec 3 14% 8% 13% 11% 9% 6% 11% 8% 8% Cutoff 4 3600 3770 4080 3600 3770 4080 3600 3770 4080 Sens 4 36% 36% 27% 32% 40% 29% 26% 38% 14% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 4640 4720 4770 4640 4720 4770 4640 4720 4770 Sens 5 23% 25% 20% 22% 35% 19% 13% 23% 7% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 5460 6090 6100 5460 6090 6100 5460 6090 6100 Sens 6 19% 14% 15% 11% 20% 6% 6% 15% 7% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.2 0.61 1.5 0.53 0.49 0.48 1.4 1.5 1.9 p Value 0.59 0.40 0.29 0.12 0.32 0.063 0.57 0.66 0.35 95% CI of 0.60 0.19 0.71 0.24 0.12 0.22 0.45 0.25 0.51 OR Quart2 2.5 1.9 3.1 1.2 2.0 1.0 4.3 9.1 6.7 OR Quart 3 1.5 0.87 1.6 0.74 0.66 0.76 1.0 2.0 1.6 p Value 0.29 0.79 0.20 0.44 0.52 0.46 1.0 0.42 0.51 95% CI of 0.73 0.30 0.78 0.35 0.18 0.37 0.30 0.37 0.42 OR Quart3 3.0 2.5 3.4 1.6 2.4 1.6 3.3 11 5.8 OR Quart 4 1.2 0.99 1.1 1.1 1.2 1.0 2.0 2.0 3.2 p Value 0.63 0.99 0.88 0.80 0.79 0.95 0.19 0.42 0.063 95% CI of 0.59 0.36 0.49 0.53 0.38 0.51 0.70 0.36 0.94 OR Quart4 2.4 2.7 2.3 2.3 3.6 2.1 6.0 11 11 Gastric inhibitory polypeptide EDTA sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 28.0 27.2 28.0 22.8 28.0 17.2 Average 57.6 51.4 57.6 55.8 57.6 35.7 Stdev 101 62.1 101 72.2 101 41.2 p(t-test) 0.59 0.89 0.24 Min 0.888 2.35 0.888 2.33 0.888 2.35 188 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max 820 391 820 330 820 160 n (Samp) 185 96 185 73 185 31 n (Patient) 109 96 109 73 109 31 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 25.0 28.9 25.0 17.6 25.0 32.7 Average 55.3 61.7 55.3 59.8 55.3 57.0 Stdev 84.0 81.0 84.0 80.7 84.0 69.5 p(t-test) 0.70 0.81 0.94 Min 0.888 4.43 0.888 7.47 0.888 16.6 Max 820 391 820 289 820 251 n (Samp) 461 28 461 20 461 13 n (Patient) 213 28 213 20 213 13 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 25.6 27.2 25.6 23.6 25.6 14.6 Average 59.7 48.0 59.7 46.2 59.7 30.3 Stdev 102 53.5 102 60.8 102 36.1 p(t-test) 0.33 0.27 0.13 Min 0.888 2.35 0.888 2.33 0.888 2.35 Max 820 248 820 330 820 146 n (Samp) 208 82 208 78 208 28 n (Patient) 106 82 106 78 106 28 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.52 0.55 0.51 0.50 0.50 0.48 0.43 0.59 0.39 SE 0.036 0.058 0.038 0.040 0.066 0.039 0.057 0.084 0.060 p 0.62 0.38 0.80 0.94 0.95 0.64 0.19 0.28 0.058 nCohort 1 185 461 208 185 461 208 185 461 208 nCohort 2 96 28 82 73 20 78 31 13 28 Cutoff 1 15.0 17.1 14.2 13.5 16.1 13.5 13.0 19.4 9.80 Sens 1 71% 71% 71% 71% 70% 71% 71% 77% 71% Spec 1 34% 38% 32% 29% 36% 30% 28% 42% 21% Cutoff 2 11.1 14.2 9.32 11.1 12.8 10.6 8.09 17.1 7.52 Sens 2 80% 82% 80% 81% 80% 81% 81% 85% 82% Spec 2 22% 31% 20% 22% 26% 23% 14% 38% 13% Cutoff 3 7.92 10.2 7.37 7.74 9.89 7.37 6.56 16.8 5.69 Sens 3 91% 93% 90% 90% 90% 91% 90% 92% 93% Spec 3 13% 19% 13% 12% 19% 13% 11% 38% 9% Cutoff 4 42.7 48.7 43.5 42.7 48.7 43.5 42.7 48.7 43.5 Sens 4 38% 36% 38% 33% 30% 29% 26% 23% 21% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 68.1 80.9 72.2 68.1 80.9 72.2 68.1 80.9 72.2 Sens 5 24% 25% 18% 25% 25% 17% 19% 15% 18% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 132 132 165 132 132 165 132 132 165 Sens 6 10% 14% 5% 14% 15% 6% 6% 15% 0% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.5 2.1 0.74 1.4 2.1 1.3 0.54 >6.3 0.15 189 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only p Value 0.29 0.25 0.43 0.37 0.25 0.53 0.35 <0.092 0.086 95% CI of 0.73 0.61 0.36 0.66 0.61 0.60 0.15 >0.74 0.018 OR Quart2 3.0 7.1 1.5 3.0 7.1 2.7 2.0 na 1.3 OR Quart 3 0.87 2.1 0.76 0.70 0.74 1.4 1.9 >5.2 2.3 p Value 0.71 0.25 0.46 0.41 0.70 0.35 0.21 <0.13 0.13 95% CI of 0.42 0.61 0.36 0.31 0.16 0.68 0.69 >0.60 0.78 OR Quart3 1.8 7.1 1.6 1.6 3.4 3.0 5.3 na 6.5 OR Quart 4 1.6 2.1 1.1 1.3 1.2 1.2 1.2 >2.0 1.6 p Value 0.18 0.25 0.76 0.47 0.74 0.66 0.78 <0.57 0.41 95% CI of 0.80 0.60 0.55 0.62 0.33 0.55 0.39 >0.18 0.53 OR Quart4 3.2 7.0 2.2 2.8 4.8 2.5 3.5 na .8 Peptide YY EDTA sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 38.2 39.6 38.2 44.3 38.2 50.0 Average 56.6 55.6 56.6 64.1 56.6 82.9 Stdev 85.0 53.0 85.0 62.2 85.0 80.0 p(t-test) 0.92 0.49 0.11 Min 0.0108 0.00999 0.0108 0.00999 0.0108 0.0108 Max 789 284 789 299 789 406 n (Samp) 185 96 185 73 185 31 n (Patient) 109 96 109 73 109 31 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 39.3 42.8 39.3 65.6 39.3 47.9 Average 59.1 51.1 59.1 75.6 59.1 64.5 Stdev 78.3 42.7 78.3 64.4 78.3 35.5 p(t-test) 0.59 0.36 0.80 Min 0.00999 0.153 0.00999 1.06 0.00999 34.8 Max 789 158 789 299 789 146 n (Samp) 461 28 461 20 461 13 n (Patient) 213 28 213 20 213 13 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 40.4 38.1 40.4 40.6 40.4 41.6 Average 57.0 54.7 57.0 56.2 57.0 73.3 Stdev 79.0 55.5 79.0 56.5 79.0 86.6 p(t-test) 0.80 0.93 0.31 Min 0.0108 0.00999 0.0108 0.00999 0.0108 0.00999 Max 789 284 789 270 789 406 n (Samp) 208 82 208 78 208 28 n (Patient) 106 82 106 78 106 28 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.54 0.51 0.50 0.57 0.65 0.50 0.64 0.65 0.53 SE 0.037 0.057 0.038 0.040 0.068 0.038 0.057 0.084 0.059 p 0.32 0.87 0.96 0.071 0.033 0.96 0.014 0.079 0.67 190 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only nCohort 1 185 461 208 185 461 208 185 461 208 nCohort 2 96 28 82 73 20 78 31 13 28 Cutoff 1 25.2 20.4 24.3 32.7 43.7 25.5 34.7 37.8 28.9 Sens 1 71% 71% 71% 71% 70% 71% 71% 77% 71% Spec 1 35% 26% 31% 43% 56% 33% 45% 47% 35% Cutoff 2 18.0 12.6 14.1 21.5 33.6 16.8 32.1 36.5 0.0512 Sens 2 80% 82% 80% 81% 80% 81% 81% 85% 82% Spec 2 25% 18% 19% 29% 41% 21% 43% 46% 5% Cutoff 3 9.90 6.44 6.60 4.70 24.9 2.37 2.80 35.9 0.00999 Sens 3 91% 93% 90% 90% 90% 91% 90% 92% 96% Spec 3 17% 13% 13% 13% 31% 10% 11% 45% 0% Cutoff 4 54.8 57.4 57.9 54.8 57.4 57.9 54.8 57.4 57.9 Sens 4 36% 36% 32% 40% 60% 31% 48% 38% 39% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 70.6 82.5 78.8 70.6 82.5 78.8 70.6 82.5 78.8 Sens 5 21% 21% 18% 29% 30% 21% 48% 31% 39% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 110 116 112 110 116 112 110 116 112 Sens 6 10% 7% 10% 15% 15% 14% 29% 15% 25% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.3 0.74 0.83 1.4 2.0 1.2 1.6 >5.2 1.0 p Value 0.47 0.58 0.61 0.43 0.42 0.61 0.51 <0.14 1.0 95% CI of 0.64 0.25 0.40 0.61 0.37 0.58 0.42 >0.60 0.33 OR Quart2 2.6 2.2 1.7 3.2 11 2.5 5.9 na 3.1 OR Quart 3 1.1 0.74 1.1 1.8 2.6 1.1 1.6 >3.1 0.40 p Value 0.72 0.58 0.86 0.16 0.27 0.85 0.51 <0.33 0.20 95% CI of 0.56 0.25 0.52 0.80 0.49 0.51 0.42 >0.32 0.098 OR Quart3 2.3 2.2 2.2 4.0 13 2.3 5.9 na 1.6 OR Quart 4 1.4 0.99 1.0 2.1 4.7 1.1 4.8 >5.2 1.7 p Value 0.32 0.99 0.96 0.059 0.050 0.74 0.0091 <0.14 0.31 95% CI of 0.71 0.36 0.50 0.97 1.0 0.54 1.5 >0.60 0.61 OR Quart4 2.9 2.7 2.1 4.7 22 2.4 16 na 4.7 [0173] Table 6: Comparison of marker levels in EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0 or R) and in EDTA samples collected from subjects at 0, 24 hours, and 48 hours prior to reaching stage I or F in Cohort 2. Agouti-related protein sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0638 0.0818 0.0638 0.0707 0.0638 0.0710 Average 0.0814 0.154 0.0814 0.0898 0.0814 0.0865 Stdev 0.0564 0.248 0.0564 0.0667 0.0564 0.0555 p(t-test) 4.4E-5 0.45 0.70 Min 0.00624 0.0215 0.00624 0.00924 0.00624 0.0253 Max 0.485 1.34 0.485 0.258 0.485 0.235 n (Samp) 306 28 306 29 306 19 n (Patient) 143 28 143 29 143 19 191 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0674 0.0818 0.0674 0.0768 0.0674 0.0710 Average 0.0837 0.157 0.0837 0.0949 0.0837 0.0805 Stdev 0.0573 0.248 0.0573 0.0712 0.0573 0.0439 p(t-test) 4.8E-5 0.32 0.82 Min 0.00624 0.0215 0.00624 0.00924 0.00624 0.0253 Max 0.485 1.34 0.485 0.258 0.485 0.160 n (Samp) 305 28 305 30 305 17 n (Patient) 138 28 138 30 138 17 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.59 nd 0.59 0.53 nd 0.53 0.54 nd 0.51 SE 0.059 nd 0.059 0.057 nd 0.056 0.070 nd 0.073 p 0.11 nd 0.14 0.63 nd 0.58 0.61 nd 0.87 nCohort 1 306 nd 305 306 nd 305 306 nd 305 nCohort 2 28 nd 28 29 nd 30 19 nd 17 Cutoff 1 0.0574 nd 0.0574 0.0489 nd 0.0526 0.0500 nd 0.0531 Sens 1 71% nd 71% 72% nd 70% 74% nd 71% Spec 1 43% nd 41% 33% nd 37% 35% nd 37% Cutoff 2 0.0357 nd 0.0357 0.0350 nd 0.0434 0.0387 nd 0.0387 Sens 2 82% nd 82% 83% nd 80% 84% nd 82% Spec 2 17% nd 15% 16% nd 24% 22% nd 20% Cutoff 3 0.0262 nd 0.0262 0.0212 nd 0.0272 0.0271 nd 0.0271 Sens 3 93% nd 93% 93% nd 90% 95% nd 94% Spec 3 8% nd 8% 5% nd 9% 9% nd 9% Cutoff 4 0.0951 nd 0.100 0.0951 nd 0.100 0.0951 nd 0.100 Sens 4 43% nd 39% 34% nd 37% 32% nd 29% Spec 4 70% nd 70% 70% nd 70% 70% nd 70% Cutoff 5 0.123 nd 0.126 0.123 nd 0.126 0.123 nd 0.126 Sens 5 36% nd 36% 21% nd 23% 21% nd 18% Spec 5 80% nd 80% 80% nd 80% 80% nd 80% Cutoff 6 0.154 nd 0.161 0.154 nd 0.161 0.154 nd 0.161 Sens 6 29% nd 29% 14% nd 17% 16% nd 0% Spec 6 90% nd 90% 90% nd 90% 90% nd 90% OR Quart 2 0.40 nd 0.41 1.2 nd 0.59 0.58 nd 0.99 p Value 0.20 nd 0.20 0.79 nd 0.38 0.47 nd 0.99 95% CI of 0.10 nd 0.10 0.37 nd 0.19 0.13 nd 0.24 OR Quart2 1.6 nd 1.6 3.6 nd 1.9 2.5 nd 4.1 OR Quart 3 1.2 nd 1.2 1.2 nd 0.85 1.0 nd 1.0 p Value 0.79 nd 0.79 0.79 nd 0.77 1.0 nd 1.0 95% CI of 0.40 nd 0.40 0.37 nd 0.29 0.28 nd 0.24 OR Quart3 3.4 nd 3.4 3.6 nd 2.5 3.6 nd 4.1 OR Quart 4 1.5 nd 1.5 1.5 nd 1.3 1.2 nd 1.2 p Value 0.46 nd 0.46 0.43 nd 0.64 0.77 nd 0.75 95% CI of 0.53 nd 0.53 0.52 nd 0.47 0.35 nd 0.32 OR Quart4 4.1 nd 4.1 4.5 nd 3.4 4.1 nd 4.8 Osteocalcin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2030 1980 2030 1260 2030 1480 Average 2700 2480 2700 2430 2700 1970 192 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Stdev 2620 1960 2620 3000 2620 1770 p(t-test) 0.63 0.53 0.13 Min 0.729 213 0.729 59.3 0.729 221 Max 21800 8950 21800 17700 21800 6930 n (Samp) 426 35 426 42 426 31 n (Patient) 209 35 209 42 209 31 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd nd nd 1960 1350 Average nd nd nd nd 2650 1740 Stdev nd nd nd nd 2560 1400 p(t-test) nd nd nd nd 0.32 Min nd nd nd nd 0.729 336 Max nd nd nd nd 21800 4840 n (Samp) nd nd nd nd 571 8 n (Patient) nd nd nd nd 256 8 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2050 2160 2050 1650 2050 1240 Average 2750 2530 2750 2560 2750 1910 Stdev 2680 1970 2680 3020 2680 1800 p(t-test) 0.65 0.66 0.11 Min 0.729 213 0.729 59.3 0.729 221 Max 21800 8950 21800 17700 21800 6930 n (Samp) 407 32 407 42 407 27 n (Patient) 189 32 189 42 189 27 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.50 nd 0.50 0.43 nd 0.45 0.40 0.39 0.38 SE 0.051 nd 0.053 0.048 nd 0.048 0.055 0.11 0.059 p 0.98 nd 0.95 0.12 nd 0.27 0.079 0.30 0.052 nCohort 1 426 nd 407 426 nd 407 426 571 407 nCohort 2 35 nd 32 42 nd 42 31 8 27 Cutoff 1 1220 nd 1220 1020 nd 1020 865 1020 813 Sens 1 71% nd 72% 71% nd 71% 71% 75% 70% Spec 1 30% nd 30% 23% nd 23% 18% 25% 17% Cutoff 2 909 nd 909 686 nd 686 686 865 660 Sens 2 80% nd 81% 81% nd 81% 81% 88% 81% Spec 2 20% nd 20% 12% nd 13% 12% 19% 12% Cutoff 3 555 nd 555 553 nd 553 443 323 443 Sens 3 91% nd 91% 90% nd 90% 90% 100% 93% Spec 3 10% nd 10% 9% nd 10% 8% 5% 8% Cutoff 4 2890 nd 2930 2890 nd 2930 2890 2810 2930 Sens 4 29% nd 31% 21% nd 24% 19% 12% 19% Spec 4 70% nd 70% 70% nd 70% 70% 70% 70% Cutoff 5 3800 nd 3980 3800 nd 3980 3800 3780 3980 Sens 5 17% nd 16% 19% nd 21% 13% 12% 11% Spec 5 80% nd 80% 80% nd 80% 80% 80% 80% Cutoff 6 5550 nd 6010 5550 nd 6010 5550 5550 6010 193 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 6 6% nd 6% 12% nd 7% 6% 0% 7% Spec 6 90% nd 90% 90% nd 90% 90% 90% 90% OR Quart 2 0.69 nd 0.99 0.65 nd 0.69 1.4 1.0 2.4 p Value 0.46 nd 0.98 0.43 nd 0.46 0.54 1.0 0.20 95% CI of 0.25 nd 0.36 0.22 nd 0.25 0.44 0.062 0.62 OR Quart2 1.9 nd 2.7 1.9 nd 1.9 4.7 16 9.7 OR Quart 3 0.90 nd 0.73 1.6 nd 1.2 1.4 3.0 2.1 p Value 0.83 nd 0.57 0.28 nd 0.64 0.54 0.34 0.32 95% CI of 0.35 nd 0.24 0.68 nd 0.51 0.44 0.31 0.50 OR Quart3 2.3 nd 2.2 3.9 nd 3.0 4.7 30 8.4 OR Quart 4 0.90 nd 1.3 1.5 nd 1.4 2.6 3.1 4.0 p Value 0.83 nd 0.64 0.37 nd 0.50 0.084 0.33 0.037 95% CI of 0.35 nd 0.48 0.62 nd 0.57 0.88 0.31 1.1 OR Quart4 2.3 nd 3.3 3.7 nd 3.2 7.6 30 15 Complement factor H sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 185000 179000 185000 182000 185000 185000 Average 193000 186000 193000 187000 193000 198000 Stdev 82900 67500 82900 51400 82900 64100 p(t-test) 0.67 0.70 0.77 Min 14900 48200 14900 92800 14900 75300 Max 1070000 394000 1070000 331000 1070000 347000 n (Samp) 356 28 356 35 356 20 n (Patient) 178 28 178 35 178 20 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 184000 179000 184000 179000 184000 181000 Average 192000 184000 192000 185000 192000 191000 Stdev 83400 69200 83400 52500 83400 60000 p(t-test) 0.61 0.60 0.93 Min 14900 48200 14900 92800 14900 75300 Max 1070000 394000 1070000 331000 1070000 347000 n (Samp) 347 28 347 35 347 18 n (Patient) 165 28 165 35 165 18 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.49 nd 0.48 0.50 nd 0.49 0.53 nd 0.51 SE 0.057 nd 0.057 0.051 nd 0.052 0.068 nd 0.070 p 0.82 nd 0.79 0.99 nd 0.85 0.63 nd 0.92 nCohort 1 356 nd 347 356 nd 347 356 nd 347 nCohort 2 28 nd 28 35 nd 35 20 nd 18 Cutoff 1 156000 nd 156000 150000 nd 147000 165000 nd 163000 Sens 1 71% nd 71% 71% nd 71% 70% nd 72% Spec 1 34% nd 34% 31% nd 29% 38% nd 37% Cutoff 2 126000 nd 126000 143000 nd 143000 159000 nd 154000 Sens 2 82% nd 82% 80% nd 80% 80% nd 83% Spec 2 15% nd 15% 26% nd 25% 35% nd 34% Cutoff 3 95800 nd 89900 128000 nd 123000 146000 nd 135000 194 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 3 93% nd 93% 91% nd 91% 90% nd 94% Spec 3 5% nd 4% 17% nd 15% 28% nd 20% Cutoff 4 214000 nd 214000 214000 nd 214000 214000 nd 214000 Sens 4 36% nd 36% 29% nd 31% 25% nd 22% Spec 4 70% nd 70% 70% nd 70% 70% nd 70% Cutoff 5 241000 nd 242000 241000 nd 242000 241000 nd 242000 Sens 5 14% nd 14% 14% nd 14% 20% nd 17% Spec 5 80% nd 80% 80% nd 80% 80% nd 80% Cutoff 6 286000 nd 291000 286000 nd 291000 286000 nd 291000 Sens 6 4% nd 4% 3% nd 3% 10% nd 6% Spec 6 90% nd 90% 90% nd 90% 90% nd 90% OR Quart 2 0.70 nd 0.70 2.1 nd 1.0 4.3 nd 3.7 p Value 0.55 nd 0.55 0.15 nd 0.98 0.071 nd 0.11 95% CI of 0.21 nd 0.21 0.76 nd 0.36 0.88 nd 0.75 OR Quart2 2.3 nd 2.3 5.9 nd 2.8 21 nd 18 OR Quart 3 1.3 nd 1.3 1.5 nd 1.6 2.6 nd 2.6 p Value 0.60 nd 0.60 0.43 nd 0.35 0.26 nd 0.26 95% CI of 0.47 nd 0.47 0.52 nd 0.61 0.49 nd 0.49 OR Quart3 3.7 nd 3.7 4.5 nd 4.0 14 nd 14 OR Quart 4 1.0 nd 1.0 1.3 nd 0.88 2.6 nd 2.0 p Value 1.0 nd 0.98 0.59 nd 0.80 0.26 nd 0.42 95% CI of 0.34 nd 0.34 0.45 nd 0.30 0.49 nd 0.36 OR Quart4 3.0 nd 3.0 4.0 nd 2.5 14 nd 11 Ciliary neurotrophic factor sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0129 0.00367 0.0129 0.0129 0.0129 0.0767 Average 0.282 0.224 0.282 0.104 0.282 0.181 Stdev 0.785 0.470 0.785 0.152 0.785 0.301 p(t-test) 0.70 0.22 0.58 Min 8.69E-5 8.69E-5 8.69E-5 8.69E-5 8.69E-5 8.69E-5 Max 6.40 2.02 6.40 0.548 6.40 1.29 n (Samp) 306 28 306 29 306 19 n (Patient) 143 28 143 29 143 19 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0129 0.00367 0.0129 0.0448 0.0129 0.0651 Average 0.283 0.210 0.283 0.123 0.283 0.167 Stdev 0.786 0.449 0.786 0.183 0.786 0.314 p(t-test) 0.63 0.27 0.55 Min 8.69E-5 8.69E-5 8.69E-5 8.69E-5 8.69E-5 8.69E-5 Max 6.40 2.02 6.40 0.686 6.40 1.29 n (Samp) 305 28 305 30 305 17 n (Patient) 138 28 138 30 138 17 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.46 nd 0.46 0.47 nd 0.49 0.54 nd 0.50 SE 0.058 nd 0.058 0.057 nd 0.056 0.070 nd 0.072 p 0.53 nd 0.53 0.65 nd 0.84 0.59 nd 0.95 195 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only nCohort 1 306 nd 305 306 nd 305 306 nd 305 nCohort 2 28 nd 28 29 nd 30 19 nd 17 Cutoff 1 0.000179 nd 0.000179 0.000173 nd 0.000179 0.000179 nd 0.000179 Sens 1 71% nd 71% 76% nd 70% 79% nd 76% Spec 1 24% nd 25% 16% nd 25% 24% nd 25% Cutoff 2 8.69E-5 nd 8.69E-5 8.69E-5 nd 8.69E-5 0.000173 nd 0.000173 Sens 2 89% nd 89% 90% nd 90% 89% nd 88% Spec 2 8% nd 9% 8% nd 9% 16% nd 17% Cutoff 3 0 nd 0 0 nd 8.69E-5 0 nd 0 Sens 3 100% nd 100% 100% nd 90% 100% nd 100% Spec 3 0% nd 0% 0% nd 9% 0% nd 0% Cutoff 4 0.151 nd 0.151 0.151 nd 0.151 0.151 nd 0.151 Sens 4 29% nd 29% 21% nd 23% 37% nd 29% Spec 4 72% nd 71% 72% nd 71% 72% nd 71% Cutoff 5 0.226 nd 0.226 0.226 nd 0.226 0.226 nd 0.226 Sens 5 21% nd 21% 14% nd 17% 21% nd 18% Spec 5 80% nd 80% 80% nd 80% 80% nd 80% Cutoff 6 0.560 nd 0.548 0.560 nd 0.548 0.560 nd 0.548 Sens 6 11% nd 11% 0% nd 3% 5% nd 6% Spec 6 90% nd 90% 90% nd 90% 90% nd 90% OR Quart 2 0.36 nd 0.36 1.6 nd 2.0 0.74 nd 0.73 p Value 0.14 nd 0.14 0.42 nd 0.21 0.70 nd 0.69 95% CI of 0.091 nd 0.091 0.53 nd 0.69 0.16 nd 0.16 OR Quart2 1.4 nd 1.4 4.6 nd 5.6 3.4 nd 3.4 OR Quart 3 1.1 nd 1.2 0.82 nd 0.65 1.5 nd 1.5 p Value 0.80 nd 0.78 0.76 nd 0.52 0.52 nd 0.52 95% CI of 0.42 nd 0.42 0.24 nd 0.18 0.42 nd 0.42 OR Quart3 3.1 nd 3.2 2.8 nd 2.4 5.7 nd 5.7 OR Quart 4 1.0 nd 1.0 1.6 nd 1.6 1.5 nd 0.99 p Value 0.98 nd 0.98 0.41 nd 0.41 0.53 nd 0.99 95% CI of 0.36 nd 0.36 0.54 nd 0.54 0.41 nd 0.24 OR Quart4 2.8 nd 2.8 4.7 nd 4.7 5.6 nd 4.1 Follitropin subunit beta sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 6.19 6.77 6.19 6.50 6.19 11.5 Average 14.6 9.26 14.6 9.35 14.6 12.2 Stdev 20.6 7.59 20.6 8.24 20.6 8.69 p(t-test) 0.18 0.18 0.61 Min 0.0600 0.733 0.0600 0.0879 0.0600 0.913 Max 141 27.3 141 32.6 141 26.4 n (Samp) 306 28 306 29 306 19 n (Patient) 143 28 143 29 143 19 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 5.97 6.77 5.97 6.09 5.97 12.5 Average 14.1 9.25 14.1 9.21 14.1 13.1 Stdev 20.3 7.59 20.3 8.13 20.3 8.64 p(t-test) 0.21 0.19 0.84 Min 0.0600 0.733 0.0600 0.0879 0.0600 2.55 196 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max 141 27.3 141 32.6 141 26.4 n (Samp) 305 28 305 30 305 17 n (Patient) 138 28 138 30 138 17 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.49 nd 0.50 0.50 nd 0.50 0.58 nd 0.61 SE 0.057 nd 0.057 0.056 nd 0.055 0.070 nd 0.074 p 0.91 nd 0.95 0.93 nd 0.95 0.29 nd 0.12 nCohort 1 306 nd 305 306 nd 305 306 nd 305 nCohort 2 28 nd 28 29 nd 30 19 nd 17 Cutoff 1 3.44 nd 3.44 4.20 nd 4.25 5.41 nd 5.68 Sens 1 71% nd 71% 72% nd 70% 74% nd 71% Spec 1 33% nd 34% 39% nd 40% 46% nd 48% Cutoff 2 2.12 nd 2.12 2.75 nd 3.22 3.65 nd 4.48 Sens 2 82% nd 82% 83% nd 80% 84% nd 82% Spec 2 20% nd 22% 26% nd 32% 34% nd 43% Cutoff 3 1.21 nd 1.21 1.21 nd 2.12 2.50 nd 2.83 Sens 3 93% nd 93% 93% nd 90% 95% nd 94% Spec 3 12% nd 12% 12% nd 22% 24% nd 28% Cutoff 4 13.2 nd 12.9 13.2 nd 12.9 13.2 nd 12.9 Sens 4 29% nd 29% 21% nd 20% 42% nd 47% Spec 4 70% nd 70% 70% nd 70% 70% nd 70% Cutoff 5 22.8 nd 22.0 22.8 nd 22.0 22.8 nd 22.0 Sens 5 7% nd 7% 7% nd 7% 21% nd 24% Spec 5 80% nd 80% 80% nd 80% 80% nd 80% Cutoff 6 39.2 nd 38.4 39.2 nd 38.4 39.2 nd 38.4 Sens 6 0% nd 0% 0% nd 0% 0% nd 0% Spec 6 90% nd 90% 90% nd 90% 90% nd 90% OR Quart 2 2.2 nd 1.2 1.6 nd 2.1 3.2 nd 6.3 p Value 0.18 nd 0.77 0.42 nd 0.19 0.17 nd 0.091 95% CI of 0.71 nd 0.38 0.53 nd 0.69 0.62 nd 0.74 OR Quart2 6.6 nd 3.7 4.6 nd 6.5 16 nd 54 OR Quart 3 1.4 nd 1.4 1.6 nd 1.9 3.2 nd 5.3 p Value 0.55 nd 0.58 0.42 nd 0.28 0.17 nd 0.13 95% CI of 0.44 nd 0.45 0.53 nd 0.60 0.62 nd 0.60 OR Quart3 4.7 nd 4.1 4.6 nd 5.8 16 nd 46 OR Quart 4 1.2 nd 1.2 0.83 nd 1.2 2.6 nd 5.2 p Value 0.74 nd 0.79 0.77 nd 0.77 0.27 nd 0.14 95% CI of 0.36 nd 0.37 0.24 nd 0.35 0.48 nd 0.59 OR Quart4 4.2 nd 3.6 2.8 nd 4.1 14 nd 46 Follistatin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 808 678 808 813 808 832 Average 2700 3740 2700 2670 2700 2050 Stdev 4450 4750 4450 3940 4450 3320 p(t-test) 0.19 0.96 0.43 Min 0.0206 1.69 0.0206 0.000554 0.0206 1.35 Max 28900 15900 28900 15600 28900 11700 n (Samp) 426 35 426 44 426 30 197 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 n (Patient) 210 35 210 44 210 30 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 807 608 807 601 Average nd nd 2940 926 2940 640 Stdev nd nd 4570 983 4570 407 p(t-test) nd nd 0.25 0.13 Min nd nd 0.000554 13.2 0.000554 1.35 Max nd nd 28900 3050 28900 1280 n (Samp) nd nd 570 7 570 9 n (Patient) nd nd 256 7 256 9 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 795 874 795 846 795 973 Average 2830 4220 2830 2800 2830 2360 Stdev 4570 5080 4570 4030 4570 3510 p(t-test) 0.10 0.96 0.60 Min 0.0206 1.69 0.0206 0.000554 0.0206 2.41 Max 28900 15900 28900 15600 28900 11700 n (Samp) 409 32 409 43 409 26 n (Patient) 193 32 193 43 193 26 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.50 nd 0.52 0.53 0.42 0.52 0.48 0.37 0.51 SE 0.051 nd 0.054 0.046 0.11 0.047 0.055 0.10 0.059 p 0.92 nd 0.67 0.56 0.47 0.60 0.70 0.21 0.89 nCohort 1 426 nd 409 426 570 409 426 570 409 nCohort 2 35 nd 32 44 7 43 30 9 26 Cutoff 1 441 nd 394 594 594 518 442 518 394 Sens 1 71% nd 72% 70% 71% 72% 70% 78% 73% Spec 1 22% nd 20% 34% 36% 30% 22% 31% 20% Cutoff 2 312 nd 257 472 460 461 257 180 257 Sens 2 80% nd 81% 82% 86% 81% 80% 89% 81% Spec 2 14% nd 14% 24% 26% 25% 13% 11% 14% Cutoff 3 29.3 nd 29.3 312 13.0 312 13.0 1.29 13.0 Sens 3 91% nd 91% 91% 100% 91% 90% 100% 92% Spec 3 10% nd 11% 14% 9% 15% 8% 2% 9% Cutoff 4 1210 nd 1230 1210 1340 1230 1210 1340 1230 Sens 4 40% nd 44% 41% 14% 40% 33% 0% 42% Spec 4 70% nd 70% 70% 70% 70% 70% 70% 70% Cutoff 5 2310 nd 4140 2310 6480 4140 2310 6480 4140 Sens 5 34% nd 38% 23% 0% 23% 13% 0% 15% Spec 5 80% nd 80% 80% 80% 80% 80% 80% 80% Cutoff 6 10500 nd 10700 10500 10900 10700 10500 10900 10700 Sens 6 14% nd 16% 7% 0% 7% 7% 0% 8% Spec 6 90% nd 90% 90% 90% 90% 90% 90% 90% OR Quart 2 0.20 nd 0.48 1.2 1.0 1.4 0.48 >3.1 0.31 p Value 0.012 nd 0.19 0.67 1.00 0.49 0.19 <0.33 0.087 95% CI of 0.055 nd 0.16 0.50 0.062 0.55 0.16 >0.31 0.082 198 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only OR Quart2 0.70 nd 1.4 2.9 16 3.4 1.4 na 1.2 OR Quart 3 0.26 nd 0.28 0.89 4.1 1.0 0.48 >4.1 0.31 p Value 0.022 nd 0.059 0.81 0.21 1.0 0.19 <0.21 0.087 95% CI of 0.084 nd 0.075 0.35 0.45 0.38 0.16 >0.45 0.082 OR Quart3 0.82 nd 1.0 2.3 37 2.6 1.4 na 1.2 OR Quart 4 1.0 nd 1.4 1.3 1.0 1.5 1.0 >2.0 1.2 p Value 0.98 nd 0.40 0.53 1.00 0.37 1.0 <0.56 0.65 95% CI of 0.46 nd 0.61 0.56 0.062 0.61 0.40 >0.18 0.49 OR Quart4 2.2 nd 3.4 3.2 16 3.7 2.5 na 3.1 Vitamin D-binding protein sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 174000 178000 174000 164000 174000 161000 Average 197000 182000 197000 181000 197000 158000 Stdev 94500 82200 94500 99400 94500 67700 p(t-test) 0.41 0.34 0.071 Min 41500 24700 41500 54200 41500 48700 Max 630000 422000 630000 556000 630000 278000 n (Samp) 358 28 358 34 358 20 n (Patient) 175 28 175 34 175 20 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 174000 178000 174000 163000 174000 161000 Average 197000 179000 197000 177000 197000 154000 Stdev 93600 84900 93600 99700 93600 64200 p(t-test) 0.33 0.25 0.056 Min 41500 24700 41500 54200 41500 48700 Max 630000 422000 630000 556000 630000 273000 n (Samp) 350 28 350 35 350 18 n (Patient) 163 28 163 35 163 18 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.48 nd 0.46 0.43 nd 0.42 0.39 nd 0.38 SE 0.057 nd 0.058 0.053 nd 0.053 0.069 nd 0.072 p 0.68 nd 0.54 0.18 nd 0.11 0.11 nd 0.088 nCohort 1 358 nd 350 358 nd 350 358 nd 350 nCohort 2 28 nd 28 34 nd 35 20 nd 18 Cutoff 1 148000 nd 148000 139000 nd 128000 108000 nd 107000 Sens 1 71% nd 71% 71% nd 71% 70% nd 72% Spec 1 32% nd 33% 27% nd 22% 12% nd 12% Cutoff 2 120000 nd 103000 121000 nd 121000 102000 nd 77400 Sens 2 82% nd 82% 82% nd 80% 80% nd 83% Spec 2 18% nd 11% 18% nd 18% 10% nd 3% Cutoff 3 76300 nd 68600 98100 nd 89100 76700 nd 76300 Sens 3 93% nd 93% 91% nd 91% 90% nd 94% Spec 3 3% nd 2% 9% nd 6% 3% nd 3% Cutoff 4 220000 nd 222000 220000 nd 222000 220000 nd 222000 Sens 4 29% nd 29% 18% nd 17% 20% nd 17% Spec 4 70% nd 70% 70% nd 70% 70% nd 70% 199 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Cutoff 5 250000 nd 252000 250000 nd 252000 250000 nd 252000 Sens 5 14% nd 14% 12% nd 11% 10% nd 6% Spec 5 80% nd 80% 80% nd 80% 80% nd 80% Cutoff 6 310000 nd 307000 310000 nd 307000 310000 nd 307000 Sens 6 4% nd 7% 6% nd 6% 0% nd 0% Spec 6 90% nd 90% 90% nd 90% 90% nd 90% OR Quart 2 2.1 nd 2.1 1.0 nd 1.0 1.7 nd 2.6 p Value 0.18 nd 0.18 1.0 nd 0.99 0.47 nd 0.26 95% CI of 0.70 nd 0.70 0.31 nd 0.31 0.40 nd 0.49 OR Quart2 6.5 nd 6.5 3.2 nd 3.3 7.4 nd 14 OR Quart 3 1.2 nd 1.0 2.1 nd 2.2 1.3 nd 2.0 p Value 0.76 nd 1.0 0.15 nd 0.14 0.70 nd 0.42 95% CI of 0.36 nd 0.28 0.77 nd 0.78 0.29 nd 0.37 OR Quart3 4.1 nd 3.6 6.0 nd 6.0 6.2 nd 11 OR Quart 4 1.4 nd 1.7 1.7 nd 2.0 2.9 nd 3.7 p Value 0.54 nd 0.38 0.30 nd 0.20 0.13 nd 0.11 95% CI of 0.44 nd 0.53 0.61 nd 0.70 0.73 nd 0.75 OR Quart4 4.7 nd 5.3 5.0 nd 5.5 11 nd 18 Glucagon sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 61.3 21.2 61.3 113 61.3 297 Average 8600 5800 8600 6900 8600 16600 Stdev 16400 15100 16400 15300 16400 20300 p(t-test) 0.66 0.67 0.061 Min 1.01 21.2 1.01 21.2 1.01 21.2 Max 40100 40100 40100 40100 40100 40100 n (Samp) 197 7 197 18 197 17 n (Patient) 131 7 131 18 131 17 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 68.7 212 68.7 20200 Average nd nd 9190 9660 9190 20100 Stdev nd nd 16800 17400 16800 20700 p(t-test) nd nd 0.91 0.023 Min nd nd 1.01 21.2 1.01 21.2 Max nd nd 40100 40100 40100 40100 n (Samp) nd nd 171 17 171 14 n (Patient) nd nd 108 17 108 14 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.39 nd nd 0.59 nd 0.61 0.63 nd 0.65 SE 0.12 nd nd 0.073 nd 0.076 0.075 nd 0.082 p 0.35 nd nd 0.23 nd 0.14 0.092 nd 0.061 nCohort 1 197 nd nd 197 nd 171 197 nd 171 nCohort 2 7 nd nd 18 nd 17 17 nd 14 Cutoff 1 20.9 nd nd 50.4 nd 104 65.0 nd 104 Sens 1 100% nd nd 72% nd 71% 71% nd 71% Spec 1 7% nd nd 44% nd 64% 52% nd 64% 200 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Cutoff 2 20.9 nd nd 20.9 nd 36.0 24.7 nd 24.7 Sens 2 100% nd nd 100% nd 82% 82% nd 86% Spec 2 7% nd nd 7% nd 32% 29% nd 26% Cutoff 3 20.9 nd nd 20.9 nd 20.9 20.9 nd 20.9 Sens 3 100% nd nd 100% nd 100% 100% nd 100% Spec 3 7% nd nd 7% nd 6% 7% nd 6% Cutoff 4 140 nd nd 140 nd 148 140 nd 148 Sens 4 29% nd nd 44% nd 53% 53% nd 64% Spec 4 70% nd nd 70% nd 70% 70% nd 70% Cutoff 5 40100 nd nd 40100 nd 40100 40100 nd 40100 Sens 5 0% nd nd 0% nd 0% 0% nd 0% Spec 5 100% nd nd 100% nd 100% 100% nd 100% Cutoff 6 40100 nd nd 40100 nd 40100 40100 nd 40100 Sens 6 0% nd nd 0% nd 0% 0% nd 0% Spec 6 100% nd nd 100% nd 100% 100% nd 100% OR Quart 2 0 nd nd 0.47 nd 0.65 0.64 nd 1.0 p Value na nd nd 0.40 nd 0.65 0.63 nd 1.0 95% CI of na nd nd 0.083 nd 0.10 0.10 nd 0.13 OR Quart2 na nd nd 2.7 nd 4.1 4.0 nd 7.4 OR Quart 3 0.49 nd nd 1.2 nd 1.7 1.0 nd 1.5 p Value 0.57 nd nd 0.75 nd 0.46 1.0 nd 0.65 95% CI of 0.043 nd nd 0.32 nd 0.39 0.19 nd 0.24 OR Quart3 5.6 nd nd 4.9 nd 7.8 5.2 nd 9.6 OR Quart 4 2.1 nd nd 1.8 nd 2.6 3.3 nd 3.8 p Value 0.41 nd nd 0.36 nd 0.19 0.084 nd 0.10 95% CI of 0.36 nd nd 0.50 nd 0.62 0.85 nd 0.76 OR Quart4 12 nd nd 6.6 nd 11 13 nd 20 Glucagon-like peptide 1 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 57.2 58.6 57.2 78.5 57.2 90.6 Average 64.8 49.1 64.8 87.8 64.8 95.1 Stdev 43.9 32.5 43.9 59.1 43.9 68.1 p(t-test) 0.35 0.040 0.010 Min 2.37 2.52 2.37 13.1 2.37 2.81 Max 208 87.1 208 197 208 205 n (Samp) 197 7 197 18 197 17 n (Patient) 131 7 131 18 131 17 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 52.4 67.1 52.4 70.8 Average nd nd 62.5 85.3 62.5 89.1 Stdev nd nd 43.9 65.5 43.9 70.6 p(t-test) nd nd 0.053 0.040 Min nd nd 2.37 13.1 2.37 2.81 Max nd nd 208 202 208 205 n (Samp) nd nd 171 17 171 14 n (Patient) nd nd 108 17 108 14 Ohr prior to AKT stage 24hr prior to AKT stage 48hr prior to AKT stage 201 sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.42 nd nd 0.61 nd 0.58 0.61 nd 0.58 SE 0.11 nd nd 0.073 nd 0.076 0.075 nd 0.083 p 0.47 nd nd 0.14 nd 0.30 0.13 nd 0.34 nCohort 1 197 nd nd 197 nd 171 197 nd 171 nCohort 2 7 nd nd 18 nd 17 17 nd 14 Cutoff 1 27.3 nd nd 50.7 nd 35.0 40.5 nd 34.8 Sens 1 71% nd nd 72% nd 71% 71% nd 71% Spec 1 19% nd nd 47% nd 32% 34% nd 31% Cutoff 2 17.7 nd nd 28.3 nd 27.0 27.3 nd 18.7 Sens 2 86% nd nd 83% nd 82% 82% nd 86% Spec 2 11% nd nd 20% nd 22% 19% nd 13% Cutoff 3 2.37 nd nd 14.6 nd 14.6 17.7 nd 17.7 Sens 3 100% nd nd 94% nd 94% 94% nd 93% Spec 3 1% nd nd 10% nd 12% 11% nd 12% Cutoff 4 77.2 nd nd 77.2 nd 75.4 77.2 nd 75.4 Sens 4 29% nd nd 50% nd 41% 53% nd 50% Spec 4 70% nd nd 70% nd 71% 70% nd 71% Cutoff 5 96.4 nd nd 96.4 nd 92.8 96.4 nd 92.8 Sens 5 0% nd nd 39% nd 35% 47% nd 43% Spec 5 80% nd nd 80% nd 80% 80% nd 80% Cutoff 6 132 nd nd 132 nd 124 132 nd 124 Sens 6 0% nd nd 28% nd 29% 35% nd 36% Spec 6 90% nd nd 90% nd 90% 90% nd 90% OR Quart 2 >4.3 nd nd 0.72 nd 0.57 0.72 nd 0.48 p Value <0.20 nd nd 0.68 nd 0.46 0.68 nd 0.41 95% CI of >0.47 nd nd 0.15 nd 0.13 0.15 nd 0.083 OR Quart2 na nd nd 3.4 nd 2.5 3.4 nd 2.7 OR Quart 3 >0 nd nd 0.98 nd 0.57 0.48 nd 0.48 p Value <na nd nd 0.98 nd 0.46 0.41 nd 0.41 95% CI of >na nd nd 0.23 nd 0.13 0.084 nd 0.083 OR Quart3 na nd nd 4.1 nd 2.5 2.7 nd 2.7 OR Quart 4 >3.2 nd nd 1.8 nd 1.2 2.1 nd 1.5 p Value <0.32 nd nd 0.36 nd 0.75 0.24 nd 0.53 95% CI of >0.32 nd nd 0.50 nd 0.35 0.60 nd 0.40 ORQuart4 na nd nd 6.6 nd .3 7.6 nd 5.8 Appetite-regulating hormone sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 24.8 14.3 24.8 23.6 24.8 36.6 Average 30.5 15.2 30.5 31.7 30.5 39.3 Stdev 24.9 9.22 24.9 21.8 24.9 24.3 p(t-test) 0.11 0.84 0.16 Min 0.251 6.30 0.251 6.30 0.251 3.18 Max 195 31.3 195 92.2 195 91.4 n (Samp) 197 7 197 18 197 17 n (Patient) 131 7 131 18 131 17 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 23.7 23.4 23.7 29.6 Average nd nd 28.9 29.1 28.9 35.7 Stdev nd nd 22.7 19.5 22.7 22.0 202 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) nd nd 0.97 0.28 Min nd nd 0.251 6.30 0.251 3.18 Max nd nd 119 67.7 119 72.6 n (Samp) nd nd 171 17 171 14 n (Patient) nd nd 108 17 108 14 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.28 nd nd 0.53 nd 0.52 0.62 nd 0.61 SE 0.11 nd nd 0.072 nd 0.074 0.075 nd 0.083 p 0.052 nd nd 0.67 nd 0.82 0.11 nd 0.20 nCohort 1 197 nd nd 197 nd 171 197 nd 171 nCohort 2 7 nd nd 18 nd 17 17 nd 14 Cutoff 1 8.02 nd nd 17.3 nd 16.1 21.5 nd 21.5 Sens 1 71% nd nd 72% nd 71% 71% nd 71% Spec 1 13% nd nd 34% nd 34% 43% nd 46% Cutoff 2 6.64 nd nd 15.4 nd 13.6 20.0 nd 15.2 Sens 2 86% nd nd 83% nd 82% 82% nd 86% Spec 2 11% nd nd 30% nd 29% 39% nd 32% Cutoff 3 5.26 nd nd 11.1 nd 8.02 8.24 nd 8.24 Sens 3 100% nd nd 94% nd 94% 94% nd 93% Spec 3 9% nd nd 20% nd 15% 14% nd 16% Cutoff 4 38.6 nd nd 38.6 nd 35.7 38.6 nd 35.7 Sens 4 0% nd nd 28% nd 29% 47% nd 43% Spec 4 71% nd nd 71% nd 70% 71% nd 70% Cutoff 5 47.1 nd nd 47.1 nd 46.7 47.1 nd 46.7 Sens 5 0% nd nd 22% nd 24% 47% nd 43% Spec 5 80% nd nd 80% nd 80% 80% nd 80% Cutoff 6 55.1 nd nd 55.1 nd 55.1 55.1 nd 55.1 Sens 6 0% nd nd 11% nd 12% 29% nd 29% Spec 6 90% nd nd 90% nd 90% 90% nd 90% OR Quart 2 >1.0 nd nd 4.4 nd 2.1 2.6 nd 2.1 p Value <0.99 nd nd 0.068 nd 0.30 0.27 nd 0.41 95% CI of >0.062 nd nd 0.90 nd 0.50 0.48 nd 0.36 OR Quart2 na nd nd 22 nd 9.1 14 nd 12 OR Quart 3 >3.2 nd nd 1.5 nd 1.0 1.0 nd 1.0 p Value <0.32 nd nd 0.66 nd 1.0 1.0 nd 1.0 95% CI of >0.32 nd nd 0.24 nd 0.19 0.14 nd 0.13 OR Quart3 na nd nd 9.4 nd 5.2 7.4 nd 7.4 OR Quart 4 >3.2 nd nd 2.6 nd 1.7 4.4 nd 3.2 p Value <0.32 nd nd 0.27 nd 0.46 0.068 nd 0.17 95% CI of >0.32 nd nd 0.48 nd 0.39 0.90 nd 0.61 OR Quart4 na nd nd 14 nd 7.8 22 nd 17 Islet amyloid polypeptide sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 9.19 6.23 9.19 7.51 9.19 10.4 Average 13.7 9.06 13.7 11.3 13.7 11.1 Stdev 16.5 10.4 16.5 11.0 16.5 8.26 p(t-test) 0.46 0.53 0.52 Min 0.0141 0.175 0.0141 0.338 0.0141 0.0166 203 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max 121 31.4 121 38.0 121 30.2 n (Samp) 197 7 197 18 197 17 n (Patient) 131 7 131 18 131 17 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 8.70 6.02 8.70 8.16 Average nd nd 11.5 9.90 11.5 10.4 Stdev nd nd 11.9 9.56 11.9 9.01 p(t-test) nd nd 0.58 0.73 Min nd nd 0.0141 0.338 0.0141 0.0166 Max nd nd 70.6 29.5 70.6 30.2 n (Samp) nd nd 171 17 171 14 n (Patient) nd nd 108 17 108 14 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.39 nd nd 0.46 nd 0.45 0.51 nd 0.49 SE 0.12 nd nd 0.073 nd 0.075 0.073 nd 0.081 p 0.35 nd nd 0.55 nd 0.47 0.92 nd 0.91 nCohort 1 197 nd nd 197 nd 171 197 nd 171 nCohort 2 7 nd nd 18 nd 17 17 nd 14 Cutoff 1 4.48 nd nd 3.53 nd 3.53 6.99 nd 5.96 Sens 1 71% nd nd 72% nd 71% 71% nd 71% Spec 1 24% nd nd 20% nd 22% 40% nd 36% Cutoff 2 2.88 nd nd 1.42 nd 1.42 2.88 nd 2.01 Sens 2 86% nd nd 83% nd 82% 82% nd 86% Spec 2 16% nd nd 8% nd 9% 16% nd 11% Cutoff 3 0.133 nd nd 0.338 nd 0.338 0.0166 nd 0.0166 Sens 3 100% nd nd 94% nd 94% 94% nd 93% Spec 3 6% nd nd 6% nd 7% 6% nd 6% Cutoff 4 13.9 nd nd 13.9 nd 12.6 13.9 nd 12.6 Sens 4 14% nd nd 33% nd 29% 35% nd 29% Spec 4 70% nd nd 70% nd 70% 70% nd 70% Cutoff 5 19.0 nd nd 19.0 nd 16.5 19.0 nd 16.5 Sens 5 14% nd nd 28% nd 29% 18% nd 21% Spec 5 80% nd nd 80% nd 80% 80% nd 80% Cutoff 6 27.9 nd nd 27.9 nd 23.7 27.9 nd 23.7 Sens 6 14% nd nd 11% nd 12% 6% nd 7% Spec 6 90% nd nd 90% nd 90% 90% nd 90% OR Quart 2 1.0 nd nd 0.38 nd 0.18 0.72 nd 0.75 p Value 1.0 nd nd 0.26 nd 0.13 0.68 nd 0.72 95% CI of 0.061 nd nd 0.070 nd 0.020 0.15 nd 0.16 OR Quart2 16 nd nd 2.0 nd 1.6 3.4 nd 3.6 OR Quart 3 2.0 nd nd 1.0 nd 1.0 1.9 nd 0.75 p Value 0.57 nd nd 1.0 nd 1.0 0.35 nd 0.72 95% CI of 0.18 nd nd 0.27 nd 0.27 0.51 nd 0.16 OR Quart3 23 nd nd 3.7 nd 3.7 6.8 nd 3.6 OR Quart 4 3.1 nd nd 1.3 nd 1.2 0.72 nd 1.0 p Value 0.33 nd nd 0.73 nd 0.75 0.68 nd 0.97 95% CI of 0.31 nd nd 0.36 nd 0.35 0.15 nd 0.24 OR Quart4 31 nd nd .4 nd 4.3 3.4 nd 4.4 204 Interleukin-17A sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 1.86 0.787 1.86 1.97 1.86 2.41 Average 3.39 4.47 3.39 4.11 3.39 4.04 Stdev 5.30 11.7 5.30 6.26 5.30 6.10 p(t-test) 0.32 0.40 0.54 Min 0.000362 0.000362 0.000362 0.000362 0.000362 0.000362 Max 53.4 61.7 53.4 28.8 53.4 28.6 n (Samp) 370 35 370 45 370 28 n (Patient) 185 35 185 45 185 28 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 1.53 4.40 1.53 2.82 Average nd nd 3.47 4.59 3.47 3.50 Stdev nd nd 6.02 2.84 6.02 1.77 p(t-test) nd nd 0.62 0.99 Min nd nd 0.000362 0.901 0.000362 1.18 Max nd nd 61.7 9.53 61.7 6.18 n (Samp) nd nd 516 7 516 7 n (Patient) nd nd 231 7 231 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 1.74 0.655 1.74 1.97 1.74 1.60 Average 3.24 4.67 3.24 4.09 3.24 4.03 Stdev 5.09 12.3 5.09 6.15 5.09 6.48 p(t-test) 0.20 0.30 0.46 Min 0.000362 0.000362 0.000362 0.000362 0.000362 0.000362 Max 53.4 61.7 53.4 28.8 53.4 28.6 n (Samp) 359 32 359 47 359 25 n (Patient) 173 32 173 47 173 25 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.40 nd 0.40 0.53 0.72 0.53 0.55 0.68 0.53 SE 0.053 nd 0.055 0.046 0.11 0.045 0.058 0.11 0.061 p 0.065 nd 0.060 0.58 0.049 0.45 0.44 0.12 0.63 nCohort 1 370 nd 359 370 516 359 370 516 359 nCohort 2 35 nd 32 45 7 47 28 7 25 Cutoff 1 0.0873 nd 0.0705 0.857 3.19 0.790 1.17 2.51 1.03 Sens 1 71% nd 72% 71% 71% 70% 71% 71% 72% Spec 1 21% nd 21% 36% 68% 36% 42% 62% 41% Cutoff 2 0.00219 nd 0.000482 0.570 2.54 0.537 0.690 2.39 0.690 Sens 2 80% nd 81% 80% 86% 81% 82% 86% 80% Spec 2 12% nd 10% 30% 63% 31% 32% 61% 33% Cutoff 3 0.000469 nd 0.000469 0.00219 0.857 0.000482 0.00436 1.17 0.00436 Sens 3 94% nd 94% 91% 100% 91% 93% 100% 92% Spec 3 6% nd 7% 12% 39% 10% 16% 44% 17% Cutoff 4 3.68 nd 3.55 3.68 3.33 3.55 3.68 3.33 3.55 Sens 4 17% nd 19% 27% 57% 30% 32% 43% 32% Spec 4 70% nd 70% 70% 70% 70% 70% 70% 70% Cutoff 5 5.11 nd 5.11 5.11 5.04 5.11 5.11 5.04 5.11 205 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 5 11% nd 12% 22% 29% 23% 18% 29% 16% Spec 5 80% nd 80% 80% 80% 80% 80% 80% 80% Cutoff 6 8.31 nd 8.22 8.31 8.85 8.22 8.31 8.85 8.22 Sens 6 11% nd 12% 13% 14% 13% 14% 0% 16% Spec 6 90% nd 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.0 nd 0.59 2.1 >1.0 1.7 2.3 >1.0 2.7 p Value 0.99 nd 0.47 0.12 <1.0 0.26 0.17 <1.0 0.11 95% CI of 0.28 nd 0.14 0.82 >0.062 0.67 0.70 >0.062 0.81 OR Quart2 3.6 nd 2.5 5.5 na 4.3 7.9 na 8.8 OR Quart 3 2.9 nd 2.6 2.1 >2.0 1.9 2.7 >4.1 1.8 p Value 0.054 nd 0.085 0.12 <0.57 0.18 0.11 <0.21 0.36 95% CI of 0.98 nd 0.88 0.82 >0.18 0.75 0.81 >0.45 0.51 OR Quart3 8.4 nd 7.7 5.5 na 4.7 8.8 na 6.4 OR Quart 4 2.6 nd 2.6 1.5 >4.1 1.6 1.2 >2.0 1.0 p Value 0.082 nd 0.081 0.46 <0.21 0.36 0.75 <0.57 1.0 95% CI of 0.89 nd 0.89 0.53 >0.45 0.61 0.33 >0.18 0.24 OR Quart4 7.7 nd 7.8 4.0 na .0 4.8 na 4.1 Insulin receptor substrate 1 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0314 0.0336 0.0314 0.0499 0.0314 0.0389 Average 0.564 0.425 0.564 0.234 0.564 0.297 Stdev 3.59 1.49 3.59 0.641 3.59 0.796 p(t-test) 0.84 0.59 0.74 Min 3.03E-6 0.000111 3.03E-6 0.000645 3.03E-6 0.000645 Max 49.5 7.74 49.5 3.67 49.5 3.51 n (Samp) 358 28 358 34 358 20 n (Patient) 177 28 177 34 177 20 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0305 0.0336 0.0305 0.0506 0.0305 0.0435 Average 0.579 0.153 0.579 0.242 0.579 0.328 Stdev 3.64 0.402 3.64 0.633 3.64 0.836 p(t-test) 0.54 0.59 0.77 Min 3.03E-6 0.000111 3.03E-6 0.000645 3.03E-6 0.000645 Max 49.5 2.10 49.5 3.67 49.5 3.51 n (Samp) 349 28 349 35 349 18 n (Patient) 164 28 164 35 164 18 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.52 nd 0.52 0.54 nd 0.55 0.51 nd 0.54 SE 0.057 nd 0.057 0.053 nd 0.052 0.067 nd 0.071 p 0.71 nd 0.77 0.45 nd 0.32 0.82 nd 0.57 nCohort 1 358 nd 349 358 nd 349 358 nd 349 nCohort 2 28 nd 28 34 nd 35 20 nd 18 Cutoff 1 0.0191 nd 0.0191 0.0154 nd 0.0154 0.0144 nd 0.0144 Sens 1 71% nd 71% 71% nd 71% 70% nd 72% Spec 1 38% nd 39% 34% nd 34% 32% nd 33% Cutoff 2 0.0106 nd 0.0106 0.0106 nd 0.0106 0.0106 nd 0.0106 206 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 2 82% nd 82% 82% nd 80% 80% nd 83% Spec 2 27% nd 26% 25% nd 26% 25% nd 25% Cutoff 3 0.00323 nd 0.00323 0.00276 nd 0.00276 0.000645 nd 0.000645 Sens 3 93% nd 93% 91% nd 91% 90% nd 94% Spec 3 14% nd 13% 11% nd 11% 9% nd 9% Cutoff 4 0.0883 nd 0.0827 0.0883 nd 0.0827 0.0883 nd 0.0827 Sens 4 29% nd 29% 38% nd 40% 30% nd 33% Spec 4 70% nd 70% 70% nd 70% 70% nd 70% Cutoff 5 0.170 nd 0.170 0.170 nd 0.170 0.170 nd 0.170 Sens 5 18% nd 14% 26% nd 29% 25% nd 28% Spec 5 80% nd 80% 80% nd 80% 80% nd 80% Cutoff 6 0.527 nd 0.614 0.527 nd 0.614 0.527 nd 0.614 Sens 6 11% nd 4% 9% nd 9% 10% nd 11% Spec 6 90% nd 90% 90% nd 90% 90% nd 90% OR Quart 2 2.4 nd 2.4 1.6 nd 1.6 1.2 nd 0.99 p Value 0.17 nd 0.16 0.42 nd 0.42 0.75 nd 0.99 95% CI of 0.70 nd 0.71 0.53 nd 0.53 0.33 nd 0.24 OR Quart2 7.9 nd 8.0 4.5 nd 4.5 4.8 nd 4.1 OR Quart 3 1.8 nd 1.8 1.7 nd 1.7 1.3 nd 0.99 p Value 0.36 nd 0.36 0.30 nd 0.30 0.73 nd 0.99 95% CI of 0.51 nd 0.51 0.61 nd 0.61 0.33 nd 0.24 OR Quart3 6.4 nd 6.4 5.0 nd 5.0 4.9 nd 4.1 OR Quart 4 2.1 nd 2.1 1.6 nd 1.7 1.5 nd 1.5 p Value 0.25 nd 0.25 0.42 nd 0.30 0.53 nd 0.53 95% CI of 0.60 nd 0.60 0.53 nd 0.61 0.41 nd 0.41 OR Quart4 7.1 nd 7.1 4.5 nd 5.0 5.6 nd 5.6 Keratin, type II cytoskeletal 6 (6A, -6B, -6C mix) sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 5.13E-5 5.13E-5 5.13E-5 5.13E-5 5.13E-5 5.13E-5 Average 3.42 5.13E-5 3.42 6.35 3.42 9.34E-5 Stdev 20.3 0 20.3 37.0 20.3 7.48E-5 p(t-test) 0.37 0.46 0.45 Min 5.13E-5 5.13E-5 5.13E-5 5.13E-5 5.13E-5 5.13E-5 Max 216 5.13E-5 216 216 216 0.000220 n (Samp) 358 28 358 34 358 20 n (Patient) 177 28 177 34 177 20 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 5.13E-5 5.13E-5 5.13E-5 5.13E-5 5.13E-5 5.13E-5 Average 2.85 5.13E-5 2.85 6.16 2.85 8.87E-5 Stdev 19.1 0 19.1 36.5 19.1 7.21E-5 p(t-test) 0.43 0.38 0.53 Min 5.13E-5 5.13E-5 5.13E-5 5.13E-5 5.13E-5 5.13E-5 Max 216 5.13E-5 216 216 216 0.000220 n (Samp) 349 28 349 35 349 18 n (Patient) 164 28 164 35 164 18 lOhr prior to AKI stage 124hr prior to AKI stage 48hr prior to AKI stage sCr or JO sCr only IJO only sCr or JO sCr only IJO only sCr or JO sCr only IJO only 207 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.33 nd 0.35 0.46 nd 0.48 0.45 nd 0.46 SE 0.058 nd 0.058 0.053 nd 0.052 0.068 nd 0.071 p 0.0040 nd 0.0096 0.50 nd 0.66 0.48 nd 0.53 nCohort 1 358 nd 349 358 nd 349 358 nd 349 nCohort 2 28 nd 28 34 nd 35 20 nd 18 Cutoff 1 0 nd 0 0 nd 0 0 nd 0 Sens 1 100% nd 100% 100% nd 100% 100% nd 100% Spec 1 0% nd 0% 0% nd 0% 0% nd 0% Cutoff 2 0 nd 0 0 nd 0 0 nd 0 Sens 2 100% nd 100% 100% nd 100% 100% nd 100% Spec 2 0% nd 0% 0% nd 0% 0% nd 0% Cutoff 3 0 nd 0 0 nd 0 0 nd 0 Sens 3 100% nd 100% 100% nd 100% 100% nd 100% Spec 3 0% nd 0% 0% nd 0% 0% nd 0% Cutoff 4 0.000220 nd 0.000135 0.000220 nd 0.000135 0.000220 nd 0.000135 Sens 4 0% nd 0% 3% nd 26% 0% nd 22% Spec 4 94% nd 70% 94% nd 70% 94% nd 70% Cutoff 5 0.000220 nd 0.000220 0.000220 nd 0.000220 0.000220 nd 0.000220 Sens 5 0% nd 0% 3% nd 3% 0% nd 0% Spec 5 94% nd 95% 94% nd 95% 94% nd 95% Cutoff 6 0.000220 nd 0.000220 0.000220 nd 0.000220 0.000220 nd 0.000220 Sens 6 0% nd 0% 3% nd 3% 0% nd 0% Spec 6 94% nd 95% 94% nd 95% 94% nd 95% OR Quart 2 >0 nd >0 0 nd 0.12 0.24 nd 0 p Value <na nd <na na nd 0.044 0.21 nd na 95% CI of >na nd >na na nd 0.014 0.027 nd na OR Quart2 na nd na na nd 0.94 2.2 nd na OR Quart 3 >37 nd >38 3.2 nd 3.9 3.9 nd 3.6 p Value <4.4E-4 nd <4.1E-4 0.0057 nd 0.0019 0.020 nd 0.030 95% CI of >5.0 nd >5.1 1.4 nd 1.6 1.2 nd 1.1 OR Quart3 na nd na 7.3 nd 9.1 12 nd 12 OR Quart 4 >1.0 nd >1.0 0.10 nd 0.12 0.24 nd 0.24 p Value <0.99 nd <0.99 0.032 nd 0.044 0.21 nd 0.21 95% CI of >0.063 nd >0.063 0.013 nd 0.014 0.027 nd 0.027 OR Quart4 na nd na 0.82 nd 0.94 2.2 nd 2.2 Collagenase 3 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0305 0.0288 0.0305 0.0699 0.0305 0.0305 Average 2.63 6.31 2.63 5.18 2.63 3.31 Stdev 20.9 20.9 20.9 21.0 20.9 12.6 p(t-test) 0.32 0.44 0.86 Min 0.00117 0.00117 0.00117 0.00117 0.00117 0.00117 Max 313 84.7 313 130 313 57.0 n (Samp) 433 35 433 45 433 31 n (Patient) 212 35 212 45 212 31 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 0.0305 0.0305 0.0305 0.0699 Average nd nd 3.09 0.109 3.09 4.91 208 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Stdev nd nd 20.1 0.140 20.1 14.3 p(t-test) nd nd 0.70 0.79 Min nd nd 0.00117 0.00374 0.00117 0.00374 Max nd nd 313 0.383 313 43.1 n(Samp) nd nd 581 7 581 9 n (Patient) nd nd 261 7 261 9 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0305 0.0180 0.0305 0.0502 0.0305 0.0305 Average 2.95 4.37 2.95 5.29 2.95 2.18 Stdev 21.5 17.2 21.5 21.2 21.5 10.9 p(t-test) 0.72 0.49 0.85 Min 0.00117 0.00117 0.00117 0.00117 0.00117 0.00117 Max 313 84.7 313 130 313 57.0 n(Samp) 416 32 416 44 416 27 n (Patient) 195 32 195 44 195 27 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.40 nd 0.38 0.53 0.53 0.52 0.51 0.59 0.49 SE 0.052 nd 0.055 0.046 0.11 0.046 0.054 0.10 0.058 p 0.054 nd 0.035 0.49 0.76 0.66 0.91 0.36 0.82 nCohort 1 433 nd 416 433 581 416 433 581 416 nCohort 2 35 nd 32 45 7 44 31 9 27 Cutoff 1 0.00374 nd 0.00374 0.00455 0.00726 0.00455 0.00726 0.0297 0.00455 Sens 1 80% nd 81% 73% 71% 70% 71% 78% 74% Spec 1 16% nd 17% 24% 36% 26% 33% 46% 26% Cutoff 2 0.00374 nd 0.00374 0.00374 0.00455 0.00117 0.00374 0.00117 0.00374 Sens 2 80% nd 81% 82% 86% 91% 84% 100% 81% Spec 2 16% nd 17% 16% 27% 9% 16% 9% 17% Cutoff 3 0.00117 nd 0.00117 0.00117 0.00117 0.00117 0.00117 0.00117 0.00117 Sens 3 91% nd 91% 91% 100% 91% 94% 100% 93% Spec 3 9% nd 9% 9% 9% 9% 9% 9% 9% Cutoff 4 0.102 nd 0.102 0.102 0.102 0.102 0.102 0.102 0.102 Sens 4 11% nd 9% 36% 29% 32% 19% 33% 15% Spec 4 72% nd 73% 72% 74% 73% 72% 74% 73% Cutoff 5 0.204 nd 0.204 0.204 0.204 0.204 0.204 0.204 0.204 Sens 5 11% nd 9% 24% 14% 23% 16% 33% 11% Spec 5 84% nd 84% 84% 84% 84% 84% 84% 84% Cutoff 6 0.383 nd 0.383 0.383 0.383 0.383 0.383 0.383 0.383 Sens 6 11% nd 9% 11% 0% 11% 6% 11% 4% Spec 6 97% nd 96% 97% 95% 96% 97% 95% 96% OR Quart 2 1.5 nd 2.8 0.81 2.0 0.43 1.5 0.49 2.1 p Value 0.52 nd 0.14 0.64 0.57 0.10 0.45 0.57 0.24 95% CI of 0.42 nd 0.72 0.34 0.18 0.16 0.54 0.044 0.61 OR Quart2 5.6 nd 11 2.0 22 1.2 4.0 5.5 7.1 OR Quart 3 3.5 nd 4.8 0.56 2.0 1.1 1.2 1.5 2.1 p Value 0.032 nd 0.017 0.24 0.57 0.84 0.79 0.65 0.24 95% CI of 1.1 nd 1.3 0.21 0.18 0.49 0.40 0.25 0.61 OR Quart3 11 nd 17 1.5 22 2.4 3.3 9.2 7.1 OR Quart 4 3.2 nd 2.8 1.4 2.0 0.83 0.85 1.5 1.8 p Value 0.048 nd 0.14 0.44 0.57 0.67 0.78 0.66 0.35 209 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only 95% CI of 1.0 nd 0.72 0.62 0.18 0.36 0.28 0.25 0.52 OR Quart4 10 nd 11 3.0 22 11.9 2.6 9.1 6.4 NF-kappa-B inhibitor alpha sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.000953 0.00173 0.000953 0.00163 0.000953 0.00194 Average 0.0425 0.0194 0.0425 0.0116 0.0425 0.0148 Stdev 0.274 0.0431 0.274 0.0206 0.274 0.0346 p(t-test) 0.66 0.51 0.65 Min 1.84E-7 1.84E-7 1.84E-7 1.84E-7 1.84E-7 1.84E-7 Max 3.62 0.208 3.62 0.0836 3.62 0.152 n (Samp) 358 28 358 34 358 20 n (Patient) 177 28 177 34 177 20 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.00106 0.00173 0.00106 0.00166 0.00106 0.00194 Average 0.0434 0.0190 0.0434 0.0114 0.0434 0.0148 Stdev 0.278 0.0430 0.278 0.0203 0.278 0.0362 p(t-test) 0.64 0.50 0.66 Min 1.84E-7 1.84E-7 1.84E-7 1.84E-7 1.84E-7 1.84E-7 Max 3.62 0.208 3.62 0.0836 3.62 0.152 n (Samp) 349 28 349 35 349 18 n (Patient) 164 28 164 35 164 18 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.58 nd 0.57 0.55 nd 0.55 0.57 nd 0.56 SE 0.058 nd 0.058 0.053 nd 0.052 0.068 nd 0.072 p 0.18 nd 0.24 0.33 nd 0.38 0.33 nd 0.43 nCohort 1 358 nd 349 358 nd 349 358 nd 349 nCohort 2 28 nd 28 34 nd 35 20 nd 18 Cutoff 1 0.000936 nd 0.000936 0.000480 nd 0.000480 0.000543 nd 0.000543 Sens 1 71% nd 71% 71% nd 71% 70% nd 72% Spec 1 50% nd 49% 43% nd 42% 44% nd 42% Cutoff 2 0.000309 nd 0.000309 3.31E-5 nd 3.31E-5 3.31E-5 nd 3.31E-5 Sens 2 82% nd 82% 82% nd 83% 90% nd 89% Spec 2 40% nd 38% 21% nd 19% 21% nd 19% Cutoff 3 0 nd 0 3.20E-6 nd 3.20E-6 3.31E-5 nd 9.39E-7 Sens 3 100% nd 100% 94% nd 94% 90% nd 94% Spec 3 0% nd 0% 6% nd 6% 21% nd 5% Cutoff 4 0.00418 nd 0.00423 0.00418 nd 0.00423 0.00418 nd 0.00423 Sens 4 36% nd 36% 38% nd 37% 35% nd 33% Spec 4 70% nd 70% 70% nd 70% 70% nd 70% Cutoff 5 0.00930 nd 0.0115 0.00930 nd 0.0115 0.00930 nd 0.0115 Sens 5 32% nd 32% 26% nd 26% 30% nd 22% Spec 5 80% nd 80% 80% nd 80% 80% nd 80% Cutoff 6 0.0387 nd 0.0381 0.0387 nd 0.0381 0.0387 nd 0.0381 Sens 6 18% nd 14% 12% nd 11% 10% nd 11% Spec 6 90% nd 90% 90% nd 90% 90% nd 90% OR Quart 2 1.5 nd 1.8 1.0 nd 1.4 2.6 nd 0.99 210 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only p Value 0.53 nd 0.36 1.0 nd 0.58 0.27 nd 0.99 95% CI of 0.41 nd 0.51 0.34 nd 0.45 0.48 nd 0.19 OR Quart2 5.6 nd 6.4 3.0 nd 4.1 14 nd 5.0 OR Quart 3 2.1 nd 2.1 1.3 nd 1.7 3.1 nd 2.0 p Value 0.24 nd 0.24 0.60 nd 0.30 0.17 nd 0.32 95% CI of 0.61 nd 0.61 0.47 nd 0.61 0.62 nd 0.50 OR Quart3 7.2 nd 7.2 3.7 nd 5.0 16 nd 8.4 OR Quart 4 2.6 nd 2.4 1.6 nd 1.9 3.7 nd 2.0 p Value 0.11 nd 0.17 0.33 nd 0.21 0.11 nd 0.32 95% CI of 0.80 nd 0.70 0.61 nd 0.69 0.74 nd 0.50 OR Quart4 8.7 nd 7.9 .4 nd 5.5 18 nd 8.4 Beta-nerve growth factor sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 1.62 1.82 1.62 1.89 1.62 2.06 Average 2.32 2.29 2.32 2.23 2.32 2.53 Stdev 3.91 1.71 3.91 1.42 3.91 1.39 p(t-test) 0.97 0.89 0.80 Min 0.221 0.681 0.221 0.453 0.221 1.23 Max 70.0 8.70 70.0 6.73 70.0 6.48 n (Samp) 358 28 358 34 358 22 n (Patient) 175 28 175 34 175 22 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 1.70 1.70 1.70 1.87 1.70 2.06 Average 2.36 2.28 2.36 2.22 2.36 2.56 Stdev 3.95 1.72 3.95 1.40 3.95 1.46 p(t-test) 0.91 0.83 0.83 Min 0.221 0.681 0.221 0.453 0.221 1.23 Max 70.0 8.70 70.0 6.73 70.0 6.48 n (Samp) 349 28 349 35 349 20 n (Patient) 161 28 161 35 161 20 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.54 nd 0.52 0.54 nd 0.53 0.64 nd 0.63 SE 0.058 nd 0.057 0.053 nd 0.052 0.065 nd 0.069 p 0.53 nd 0.75 0.45 nd 0.58 0.027 nd 0.066 nCohort 1 358 nd 349 358 nd 349 358 nd 349 nCohort 2 28 nd 28 34 nd 35 22 nd 20 Cutoff 1 1.36 nd 1.36 1.30 nd 1.30 1.82 nd 1.82 Sens 1 71% nd 71% 74% nd 74% 73% nd 70% Spec 1 39% nd 37% 35% nd 33% 56% nd 54% Cutoff 2 1.12 nd 1.12 1.07 nd 1.16 1.49 nd 1.49 Sens 2 86% nd 86% 82% nd 80% 82% nd 80% Spec 2 26% nd 25% 20% nd 25% 45% nd 43% Cutoff 3 0.865 nd 0.865 0.786 nd 0.786 1.42 nd 1.42 Sens 3 93% nd 93% 94% nd 94% 91% nd 90% Spec 3 9% nd 9% 8% nd 7% 40% nd 38% Cutoff 4 2.25 nd 2.31 2.25 nd 2.31 2.25 nd 2.31 211 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 4 29% nd 29% 38% nd 34% 41% nd 35% Spec 4 70% nd 70% 70% nd 70% 70% nd 70% Cutoff 5 2.92 nd 3.05 2.92 nd 3.05 2.92 nd 3.05 Sens 5 18% nd 18% 24% nd 20% 27% nd 25% Spec 5 80% nd 80% 80% nd 80% 80% nd 80% Cutoff 6 4.06 nd 4.07 4.06 nd 4.07 4.06 nd 4.07 Sens 6 18% nd 18% 9% nd 9% 14% nd 15% Spec 6 90% nd 90% 90% nd 90% 90% nd 90% OR Quart 2 2.4 nd 1.4 1.0 nd 0.87 >6.4 nd >6.4 p Value 0.17 nd 0.58 1.0 nd 0.79 <0.088 nd <0.088 95% CI of 0.70 nd 0.45 0.34 nd 0.30 >0.76 nd >0.76 OR Quart2 7.9 nd 4.1 3.0 nd 2.5 na nd na OR Quart 3 1.8 nd 1.4 1.6 nd 1.4 >11 nd >8.8 p Value 0.36 nd 0.58 0.33 nd 0.47 <0.023 nd <0.043 95% CI of 0.51 nd 0.45 0.61 nd 0.55 >1.4 nd >1.1 OR Quart3 6.4 nd 4.1 4.4 nd 3.7 na nd na OR Quart 4 2.1 nd 0.99 1.3 nd 1.1 >6.4 nd >6.3 p Value 0.25 nd 0.98 0.60 nd 0.80 <0.088 nd <0.090 95% CI of 0.60 nd 0.31 0.47 nd 0.42 >0.76 nd >0.75 OR Quart4 7.1 nd 3.2 3.7 nd 3.1 na nd na Pancreatic prohormone sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 60.9 152 60.9 112 60.9 104 Average 162 243 162 166 162 125 Stdev 270 343 270 211 270 140 p(t-test) 0.44 0.94 0.58 Min 0.683 32.3 0.683 3.78 0.683 0.731 Max 1920 1000 1920 869 1920 455 n (Samp) 197 7 197 18 197 17 n (Patient) 131 7 131 18 131 17 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 58.4 126 58.4 119 Average nd nd 157 225 157 151 Stdev nd nd 272 308 272 149 p(t-test) nd nd 0.33 0.93 Min nd nd 0.683 3.78 0.683 0.731 Max nd nd 1920 1080 1920 455 n (Samp) nd nd 171 17 171 14 n (Patient) nd nd 108 17 108 14 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.65 nd nd 0.56 nd 0.58 0.52 nd 0.57 SE 0.11 nd nd 0.073 nd 0.076 0.074 nd 0.083 p 0.18 nd nd 0.40 nd 0.28 0.82 nd 0.41 nCohort 1 197 nd nd 197 nd 171 197 nd 171 nCohort 2 7 nd nd 18 nd 17 17 nd 14 Cutoff 1 63.8 nd nd 33.4 nd 33.4 42.5 nd 45.3 212 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 1 71% nd nd 72% nd 71% 71% nd 71% Spec 1 53% nd nd 30% nd 29% 38% nd 42% Cutoff 2 51.2 nd nd 27.7 nd 27.7 21.4 nd 18.5 Sens 2 86% nd nd 83% nd 82% 82% nd 86% Spec 2 45% nd nd 25% nd 24% 20% nd 16% Cutoff 3 31.4 nd nd 8.51 nd 8.51 0.731 nd 0.731 Sens 3 100% nd nd 94% nd 94% 94% nd 93% Spec 3 29% nd nd 8% nd 8% 3% nd 2% Cutoff 4 116 nd nd 116 nd 112 116 nd 112 Sens 4 57% nd nd 50% nd 53% 35% nd 57% Spec 4 70% nd nd 70% nd 70% 70% nd 70% Cutoff 5 207 nd nd 207 nd 176 207 nd 176 Sens 5 29% nd nd 22% nd 29% 18% nd 29% Spec 5 80% nd nd 80% nd 80% 80% nd 80% Cutoff 6 468 nd nd 468 nd 443 468 nd 443 Sens 6 14% nd nd 6% nd 12% 0% nd 14% Spec 6 90% nd nd 90% nd 90% 90% nd 90% OR Quart 2 >2.1 nd nd 0.72 nd 0.18 0.98 nd 0.23 p Value <0.55 nd nd 0.68 nd 0.13 0.98 nd 0.20 95% CI of >0.18 nd nd 0.15 nd 0.020 0.23 nd 0.025 OR Quart2 na nd nd 3.4 nd 1.6 4.1 nd 2.2 OR Quart 3 >2.1 nd nd 1.5 nd 1.0 1.3 nd 1.0 p Value <0.55 nd nd 0.53 nd 1.0 0.73 nd 1.0 95% CI of >0.18 nd nd 0.41 nd 0.27 0.32 nd 0.23 OR Quart3 na nd nd 5.8 nd 3.7 5.0 nd 4.3 OR Quart 4 >3.2 nd nd 1.2 nd 1.2 0.98 nd 1.2 p Value <0.32 nd nd 0.75 nd 0.75 0.98 nd 0.75 95% CI of >0.32 nd nd 0.32 nd 0.35 0.23 nd 0.31 OR Quart4 na nd nd 4.9 nd 4.3 4.1 nd 5.0 Transthyretin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 57600 56100 57600 56500 57600 50800 Average 64500 65800 64500 65800 64500 54000 Stdev 40500 35600 40500 37900 40500 31600 p(t-test) 0.87 0.86 0.26 Min 6500 25500 6500 8510 6500 14200 Max 293000 165000 293000 168000 293000 147000 n (Samp) 356 28 356 35 356 20 n (Patient) 178 28 178 35 178 20 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 56600 54200 56600 56600 56600 50800 Average 62900 65300 62900 67200 62900 55300 Stdev 38100 35900 38100 36700 38100 32700 p(t-test) 0.75 0.53 0.41 Min 6500 25500 6500 20000 6500 14200 Max 293000 165000 293000 168000 293000 147000 n (Samp) 347 28 347 35 347 18 n (Patient) 165 28 165 35 165 18 213 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.52 nd 0.52 0.51 nd 0.54 0.42 nd 0.44 SE 0.057 nd 0.057 0.052 nd 0.052 0.068 nd 0.072 p 0.73 nd 0.71 0.77 nd 0.47 0.22 nd 0.37 nCohort 1 356 nd 347 356 nd 347 356 nd 347 nCohort 2 28 nd 28 35 nd 35 20 nd 18 Cutoff 1 44100 nd 42600 43300 nd 44900 36600 nd 36800 Sens 1 71% nd 71% 71% nd 71% 70% nd 72% Spec 1 35% nd 34% 34% nd 37% 26% nd 25% Cutoff 2 31000 nd 31000 36200 nd 36800 29000 nd 29000 Sens 2 82% nd 82% 80% nd 80% 80% nd 83% Spec 2 18% nd 18% 25% nd 25% 16% nd 16% Cutoff 3 29400 nd 29400 21600 nd 29900 24600 nd 16500 Sens 3 93% nd 93% 91% nd 91% 90% nd 94% Spec 3 17% nd 17% 6% nd 17% 9% nd 3% Cutoff 4 73800 nd 73400 73800 nd 73400 73800 nd 73400 Sens 4 32% nd 32% 37% nd 37% 15% nd 17% Spec 4 70% nd 70% 70% nd 70% 70% nd 70% Cutoff 5 85300 nd 83800 85300 nd 83800 85300 nd 83800 Sens 5 29% nd 29% 26% nd 29% 10% nd 17% Spec 5 80% nd 80% 80% nd 80% 80% nd 80% Cutoff 6 111000 nd 108000 111000 nd 108000 111000 nd 108000 Sens 6 11% nd 11% 14% nd 14% 5% nd 11% Spec 6 90% nd 90% 90% nd 90% 90% nd 90% OR Quart 2 1.2 nd 1.1 1.4 nd 1.5 1.7 nd 1.7 p Value 0.79 nd 0.80 0.48 nd 0.46 0.47 nd 0.46 95% CI of 0.40 nd 0.40 0.54 nd 0.53 0.40 nd 0.40 OR Quart2 3.3 nd 3.3 3.7 nd 4.0 7.3 nd 7.4 OR Quart 3 0.70 nd 0.69 0.60 nd 0.70 2.1 nd 1.7 p Value 0.55 nd 0.54 0.38 nd 0.55 0.31 nd 0.46 95% CI of 0.21 nd 0.21 0.19 nd 0.21 0.50 nd 0.40 OR Quart3 2.3 nd 2.3 1.9 nd 2.3 8.5 nd 7.4 OR Quart 4 1.2 nd 1.1 1.4 nd 2.0 2.1 nd 1.7 p Value 0.79 nd 0.80 0.48 nd 0.17 0.31 nd 0.46 95% CI of 0.40 nd 0.40 0.54 nd 0.75 0.50 nd 0.40 OR Quart4 3.3 nd 3.3 3.7 nd 5.2 8.5 nd 7.4 C-peptide EDTA sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2540 3170 2540 2120 2540 2430 Average 3180 4620 3180 2850 3180 2900 Stdev 2730 4410 2730 2110 2730 1960 p(t-test) 0.0049 0.43 0.56 Min 39.8 21.7 39.8 51.9 39.8 88.8 Max 21700 19500 21700 8450 21700 7570 n (Samp) 434 35 434 43 434 32 n (Patient) 212 35 212 43 212 32 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 2660 2210 2660 1800 214 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Average nd nd 3270 2640 3270 2620 Stdev nd nd 2700 1950 2700 2610 p(t-test) nd nd 0.57 0.50 Min nd nd 7.96 878 7.96 137 Max nd nd 21700 5360 21700 7530 n (Samp) nd nd 583 6 583 8 n (Patient) nd nd 262 6 262 8 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2540 3070 2540 2110 2540 2430 Average 3230 4270 3230 2740 3230 2720 Stdev 2780 3710 2780 2110 2780 1820 p(t-test) 0.050 0.26 0.34 Min 39.8 21.7 39.8 51.9 39.8 88.8 Max 21700 17300 21700 8450 21700 7570 n (Samp) 415 32 415 43 415 28 n (Patient) 192 32 192 43 192 28 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.60 nd 0.59 0.48 0.44 0.46 0.50 0.41 0.48 SE 0.052 nd 0.055 0.047 0.12 0.047 0.053 0.11 0.057 p 0.064 nd 0.12 0.66 0.60 0.38 0.98 0.40 0.71 nCohort 1 434 nd 415 434 583 415 434 583 415 nCohort 2 35 nd 32 43 6 43 32 8 28 Cutoff 1 1920 nd 1920 1330 894 1290 1650 959 1630 Sens 1 71% nd 72% 72% 83% 72% 72% 75% 71% Spec 1 42% nd 42% 30% 13% 27% 38% 15% 37% Cutoff 2 1500 nd 1400 998 894 934 1270 159 974 Sens 2 80% nd 81% 81% 83% 81% 81% 88% 82% Spec 2 35% nd 31% 17% 13% 16% 27% 3% 17% Cutoff 3 904 nd 904 754 875 708 564 114 163 Sens 3 91% nd 91% 91% 100% 91% 91% 100% 93% Spec 3 15% nd 15% 11% 13% 10% 8% 2% 3% Cutoff 4 4080 nd 4110 4080 4110 4110 4080 4110 4110 Sens 4 37% nd 38% 23% 33% 21% 28% 25% 25% Spec 4 70% nd 70% 70% 70% 70% 70% 70% 70% Cutoff 5 4920 nd 4930 4920 4920 4930 4920 4920 4930 Sens 5 31% nd 31% 14% 17% 14% 12% 25% 7% Spec 5 80% nd 80% 80% 80% 80% 80% 80% 80% Cutoff 6 6170 nd 6430 6170 6360 6430 6170 6360 6430 Sens 6 26% nd 25% 9% 0% 9% 6% 12% 4% Spec 6 90% nd 90% 90% 90% 90% 90% 90% 90% OR Quart 2 2.6 nd 2.3 1.3 2.0 1.1 1.9 0.50 1.2 p Value 0.11 nd 0.17 0.63 0.57 0.80 0.22 0.57 0.78 95% CI of 0.80 nd 0.70 0.50 0.18 0.44 0.68 0.045 0.38 OR Quart2 8.7 nd 7.8 3.2 23 2.9 5.3 5.5 3.6 OR Quart 3 2.4 nd 2.1 1.4 0 1.4 1.2 1.0 1.5 p Value 0.16 nd 0.25 0.48 na 0.49 0.78 1.0 0.43 95% CI of 0.70 nd 0.60 0.56 na 0.55 0.38 0.14 0.53 OR Quart3 7.9 nd 7.0 3.4 na 3.4 3.6 7.2 4.5 OR Quart 4 3.2 nd 2.9 1.3 3.1 1.4 1.3 1.5 1.0 215 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only p Value 0.050 nd 0.075 0.63 0.33 0.48 0.59 0.65 0.99 95% CI of 1.0 nd 0.90 0.50 0.31 0.56 0.45 0.25 0.32 OR Quart4 10 nd 9.4 3.2 30 3.4 4.0 9.2 3.2 Gastric inhibitory polypeptide EDTA sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 25.6 41.6 25.6 16.9 25.6 19.7 Average 54.7 70.9 54.7 35.9 54.7 44.1 Stdev 82.4 80.8 82.4 59.3 82.4 59.3 p(t-test) 0.26 0.15 0.48 Min 0.888 3.61 0.888 2.33 0.888 4.13 Max 820 405 820 287 820 251 n (Samp) 434 35 434 43 434 32 n (Patient) 212 35 212 43 212 32 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 26.2 19.1 26.2 28.1 Average nd nd 55.2 39.6 55.2 55.8 Stdev nd nd 81.0 40.3 81.0 80.2 p(t-test) nd nd 0.64 0.98 Min nd nd 0.888 7.99 0.888 8.68 Max nd nd 820 92.9 820 251 n (Samp) nd nd 583 6 583 8 n (Patient) nd nd 262 6 262 8 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 24.5 47.3 24.5 17.2 24.5 15.8 Average 55.9 71.2 55.9 37.1 55.9 37.8 Stdev 85.0 82.4 85.0 60.4 85.0 49.2 p(t-test) 0.33 0.16 0.27 Min 0.888 3.61 0.888 2.33 0.888 4.13 Max 820 405 820 287 820 192 n (Samp) 415 32 415 43 415 28 n (Patient) 192 32 192 43 192 28 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.59 nd 0.59 0.39 0.45 0.40 0.46 0.53 0.43 SE 0.052 nd 0.055 0.047 0.12 0.048 0.054 0.10 0.058 p 0.091 nd 0.084 0.021 0.71 0.038 0.43 0.75 0.20 nCohort 1 434 nd 415 434 583 415 434 583 415 nCohort 2 35 nd 32 43 6 43 32 8 28 Cutoff 1 17.3 nd 17.3 9.01 9.01 9.01 14.2 19.5 13.0 Sens 1 71% nd 72% 72% 83% 72% 72% 75% 71% Spec 1 37% nd 38% 16% 15% 17% 30% 41% 28% Cutoff 2 14.2 nd 14.2 7.47 9.01 7.37 12.6 17.6 8.52 Sens 2 80% nd 81% 81% 83% 81% 81% 88% 82% Spec 2 29% nd 31% 11% 15% 11% 26% 38% 15% 216 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Cutoff 3 7.95 nd 9.29 6.25 7.95 6.25 6.93 8.52 5.69 Sens 3 91% nd 91% 91% 100% 91% 91% 100% 93% Spec 3 13% nd 19% 9% 13% 9% 10% 13% 7% Cutoff 4 47.6 nd 48.4 47.6 48.7 48.4 47.6 48.7 48.4 Sens 4 49% nd 50% 16% 33% 16% 25% 25% 25% Spec 4 70% nd 70% 70% 70% 70% 70% 70% 70% Cutoff 5 75.0 nd 80.9 75.0 77.2 80.9 75.0 77.2 80.9 Sens 5 34% nd 28% 9% 33% 9% 16% 12% 14% Spec 5 80% nd 80% 80% 80% 80% 80% 80% 80% Cutoff 6 145 nd 146 145 145 146 145 145 146 Sens 6 17% nd 16% 5% 0% 5% 9% 12% 7% Spec 6 90% nd 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.0 nd 0.99 1.3 0 1.5 0.49 3.0 0.41 p Value 1.0 nd 0.99 0.59 na 0.44 0.25 0.34 0.21 95% CI of 0.34 nd 0.31 0.48 na 0.54 0.14 0.31 0.10 OR Quart2 2.9 nd 3.2 3.7 na 4.0 1.7 29 1.6 OR Quart 3 0.85 nd 0.99 1.6 1.0 1.5 1.9 2.0 1.8 p Value 0.78 nd 0.99 0.32 0.99 0.45 0.18 0.57 0.24 95% CI of 0.28 nd 0.31 0.61 0.14 0.54 0.75 0.18 0.68 OR Quart3 2.6 nd 3.2 4.4 7.2 4.0 4.6 22 4.8 OR Quart 4 2.3 nd 2.5 2.5 1.0 2.5 0.74 2.0 0.86 p Value 0.083 nd 0.071 0.052 0.99 0.051 0.59 0.57 0.79 95% CI of 0.90 nd 0.92 0.99 0.14 0.99 0.25 0.18 0.28 OR Quart4 5.8 nd 6.8 6.3 7.2 6.4 2.2 22 2.6 Peptide YY EDTA sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 39.6 41.0 39.6 42.8 39.6 46.2 Average 56.6 56.9 56.6 63.2 56.6 79.8 Stdev 73.1 63.2 73.1 65.3 73.1 87.2 p(t-test) 0.98 0.57 0.089 Min 0.00999 0.0108 0.00999 0.00999 0.00999 0.0108 Max 789 284 789 270 789 406 n (Samp) 434 35 434 43 434 32 n (Patient) 212 35 212 43 212 32 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 40.2 56.3 40.2 57.6 Average nd nd 59.4 51.0 59.4 81.8 Stdev nd nd 74.6 24.5 74.6 65.7 p(t-test) nd nd 0.78 0.40 Min nd nd 0.00999 21.6 0.00999 13.4 Max nd nd 789 78.3 789 211 n (Samp) nd nd 583 6 583 8 n (Patient) nd nd 262 6 262 8 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 40.2 40.1 40.2 42.5 40.2 45.0 Average 56.6 57.7 56.6 64.0 56.6 75.0 217 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Stdev 72.7 65.7 72.7 67.8 72.7 88.3 p(t-test) 0.93 0.52 0.20 Min 0.00999 0.0108 0.00999 0.00999 0.00999 0.0108 Max 789 284 789 270 789 406 n (Samp) 415 32 415 43 415 28 n (Patient) 192 32 192 43 192 28 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.49 nd 0.48 0.53 0.57 0.52 0.56 0.65 0.53 SE 0.051 nd 0.053 0.047 0.12 0.047 0.054 0.11 0.057 p 0.90 nd 0.78 0.57 0.58 0.73 0.25 0.15 0.57 nCohort 1 434 nd 415 434 583 415 434 583 415 nCohort 2 35 nd 32 43 6 43 32 8 28 Cutoff 1 18.0 nd 18.0 21.6 22.6 21.6 26.7 43.7 23.7 Sens 1 71% nd 72% 72% 83% 72% 72% 75% 71% Spec 1 22% nd 22% 26% 28% 27% 32% 54% 30% Cutoff 2 14.0 nd 14.0 10.5 22.6 10.5 13.4 36.5 13.4 Sens 2 80% nd 81% 81% 83% 81% 84% 88% 82% Spec 2 18% nd 18% 15% 28% 15% 18% 45% 18% Cutoff 3 10.5 nd 10.5 0.0512 21.6 0.0512 7.32 13.4 0.0108 Sens 3 91% nd 91% 91% 100% 91% 91% 100% 93% Spec 3 15% nd 15% 6% 27% 6% 14% 19% 2% Cutoff 4 58.7 nd 60.4 58.7 60.4 60.4 58.7 60.4 60.4 Sens 4 29% nd 25% 40% 50% 33% 41% 50% 39% Spec 4 70% nd 70% 70% 70% 70% 70% 70% 70% Cutoff 5 79.5 nd 79.5 79.5 85.3 79.5 79.5 85.3 79.5 Sens 5 20% nd 22% 26% 0% 28% 34% 38% 29% Spec 5 80% nd 80% 80% 80% 80% 80% 80% 80% Cutoff6 111 nd 110 111 123 110 111 123 110 Sens 6 11% nd 12% 16% 0% 19% 28% 25% 25% Spec 6 90% nd 90% 90% 90% 90% 90% 90% 90% OR Quart 2 1.0 nd 1.0 0.71 >2.0 0.89 0.99 0.99 0.84 p Value 0.99 nd 1.0 0.47 <0.57 0.80 0.99 1.00 0.76 95% CI of 0.39 nd 0.36 0.27 >0.18 0.36 0.34 0.062 0.27 OR Quart2 2.6 nd 2.8 1.8 na 2.2 2.9 16 2.6 OR Quart 3 0.65 nd 0.74 0.90 >2.0 0.80 0.85 3.0 0.69 p Value 0.44 nd 0.58 0.82 <0.57 0.64 0.78 0.34 0.54 95% CI of 0.23 nd 0.25 0.37 >0.18 0.32 0.28 0.31 0.21 OR Quart3 1.9 nd 2.2 2.2 na 2.0 2.6 29 2.3 OR Quart 4 1.3 nd 1.3 1.3 >2.0 1.2 1.8 3.0 1.5 p Value 0.63 nd 0.61 0.54 <0.57 0.68 0.24 0.34 0.46 95% CI of 0.50 nd 0.49 0.56 >0.18 0.51 0.67 0.31 0.53 OR Quart4 3.2 nd 3.4 3.0 na 2.8 4.7 29 4.0 [0174] Table 7: Comparison of marker levels in EDTA samples collected within 12 hours of reaching stage R from Cohort 1 (patients that reached, but did not progress beyond, RIFLE stage R) and from Cohort 2 (patients that reached RIFLE stage I or F). Osteocalcin sCr or UO sCr only UO only 218 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2080 1220 1590 827 2080 1240 Average 3060 2150 3400 953 2640 2350 Stdev 3400 1990 4600 410 2320 2140 p(t-test) 0.13 0.21 0.56 Min 0.729 59.3 129 648 0.729 59.3 Max 21800 8560 21800 1750 10500 8560 n(Samp) 83 36 31 6 65 31 n (Patient) 83 36 31 6 65 31 At Enrollment sCr or UO sCr only UO only AUC 0.41 0.24 0.45 SE 0.058 0.12 0.064 p 0.13 0.029 0.39 nCohort 1 83 31 65 nCohort 2 36 6 31 Cutoff 1 860 654 888 Sens 1 72% 83% 71% Spec 1 20% 10% 20% Cutoff 2 785 654 790 Sens 2 81% 83% 81% Spec 2 17% 10% 18% Cutoff 3 628 586 628 Sens 3 94% 100% 90% Spec 3 11% 6% 15% Cutoff 4 2980 2400 2980 Sens 4 25% 0% 29% Spec 4 71% 71% 71% Cutoff 5 3980 4150 3320 Sens 5 14% 0% 29% Spec 5 81% 81% 80% Cutoff 6 8250 8370 5110 Sens 6 3% 0% 13% Spec 6 90% 90% 91% OR Quart 2 0.47 >1.2 0.33 p Value 0.23 <0.88 0.11 95% CI of 0.14 >0.067 0.086 OR Quart2 1.6 na 1.3 OR Quart 3 1.2 >2.9 0.69 p Value 0.78 <0.43 0.54 95% CI of 0.39 >0.21 0.21 OR Quart3 3.5 na 2.3 OR Quart 4 1.6 >5.0 1.4 p Value 0.36 <0.20 0.56 95% CI of 0.56 >0.42 0.45 OR Quart4 4.8 na 4.5 Follistatin sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 766 840 748 519 806 886 Average 2150 3450 2410 839 2250 3770 Stdev 3480 4980 3790 1000 3750 5250 219 sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) 0.11 0.29 0.11 Min 0.221 2.51 2.00 13.2 0.221 0.000554 Max 11800 15600 11800 3050 15900 15600 n(Samp) 83 36 32 7 64 31 n (Patient) 83 36 32 7 64 31 At Enrollment sCr or UO sCr only UO only AUC 0.53 0.37 0.52 SE 0.058 0.12 0.064 p 0.57 0.28 0.70 nCohort 1 83 32 64 nCohort 2 36 7 31 Cutoff 1 502 502 371 Sens 1 72% 71% 71% Spec 1 30% 31% 20% Cutoff 2 314 460 310 Sens 2 81% 86% 81% Spec 2 14% 22% 16% Cutoff 3 9.59 9.59 3.75 Sens 3 92% 100% 90% Spec 3 8% 6% 5% Cutoff 4 1190 1170 1180 Sens 4 39% 14% 42% Spec 4 71% 72% 70% Cutoff 5 1430 1430 1450 Sens 5 36% 14% 39% Spec 5 81% 81% 81% Cutoff 6 9880 10300 9880 Sens 6 17% 0% 19% Spec 6 90% 91% 91% OR Quart 2 0.58 1.0 0.34 p Value 0.35 1.0 0.10 95% CI of 0.18 0.054 0.095 OR Quart2 1.8 19 1.2 OR Quart 3 0.48 3.9 0.26 p Value 0.22 0.28 0.051 95% CI of 0.15 0.33 0.067 OR Quart3 1.5 46 1.0 OR Quart 4 1.5 2.6 1.3 p Value 0.49 0.48 0.65 95% CI of 0.51 0.19 0.41 OR Quart4 4.2 34 4.1 Islet amyloid polypeptide sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 8.57 8.76 nd nd 8.57 10.4 Average 13.3 10.7 nd nd 11.7 10.9 Stdev 15.5 8.47 nd nd 11.4 9.82 p(t-test) 0.57 nd nd 0.85 Min 0.0141 0.338 nd nd 0.0141 0.338 220 sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max 81.1 29.5 nd nd 49.8 29.5 n(Samp) 42 13 nd nd 34 9 n (Patient) 42 13 nd nd 34 9 At Enrollment sCr or UO sCr only UO only AUC 0.51 nd 0.50 SE 0.093 nd 0.11 p 0.95 nd 0.98 nCohort 1 42 nd 34 nCohort 2 13 nd 9 Cutoff 1 3.61 nd 3.21 Sens 1 77% nd 78% Spec 1 26% nd 26% Cutoff 2 3.21 nd 0.338 Sens 2 85% nd 89% Spec 2 26% nd 12% Cutoff 3 0.338 nd 0.0166 Sens 3 92% nd 100% Spec 3 10% nd 12% Cutoff 4 14.1 nd 14.1 Sens 4 31% nd 33% Spec 4 71% nd 71% Cutoff 5 17.5 nd 17.5 Sens 5 23% nd 22% Spec 5 81% nd 82% Cutoff 6 29.3 nd 24.8 Sens 6 8% nd 11% Spec 6 90% nd 91% OR Quart 2 2.2 nd 0.89 p Value 0.42 nd 0.92 95% CI of 0.33 nd 0.10 OR Quart2 15 nd 7.9 OR Quart 3 1.5 nd 0.89 p Value 0.69 nd 0.92 95% CI of 0.21 nd 0.10 OR Quart3 11 nd 7.9 OR Quart 4 2.2 nd 1.5 p Value 0.42 nd 0.70 95% CI of 0.33 nd 0.20 OR Quart4 15 nd 12 Pancreatic prohormone sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 68.6 126 nd nd 80.8 126 Average 166 199 nd nd 193 246 Stdev 316 247 nd nd 360 286 p(t-test) 0.73 nd nd 0.69 Min 0.683 0.731 nd nd 0.683 0.731 Max 1920 869 nd nd 1920 869 n(Samp) 42 13 nd nd 34 9 221 sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 n (Patient) 42 13 nd nd 34 9 At Enrollment sCr or UO sCr only UO only AUC 0.58 nd 0.58 SE 0.094 nd 0.11 p 0.41 nd 0.49 nCohort 1 42 nd 34 nCohort 2 13 nd 9 Cutoff 1 31.4 nd 31.4 Sens 1 77% nd 78% Spec 1 31% nd 26% Cutoff 2 20.4 nd 4.47 Sens 2 85% nd 89% Spec 2 19% nd 15% Cutoff 3 13.7 nd 0.683 Sens 3 92% nd 100% Spec 3 19% nd 3% Cutoff 4 137 nd 137 Sens 4 31% nd 44% Spec 4 71% nd 71% Cutoff 5 211 nd 211 Sens 5 31% nd 44% Spec 5 81% nd 82% Cutoff 6 361 nd 498 Sens 6 23% nd 11% Spec 6 90% nd 91% OR Quart 2 0.56 nd 0.89 p Value 0.56 nd 0.92 95% CI of 0.077 nd 0.10 OR Quart2 4.0 nd 7.9 OR Quart 3 1.3 nd 0.40 p Value 0.75 nd 0.49 95% CI of 0.24 nd 0.030 OR Quart3 7.6 nd 5.2 OR Quart 4 1.3 nd 2.3 p Value 0.75 nd 0.41 95% CI of 0.24 nd 0.32 OR Quart4 7.6 nd 17 Transthyretin sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 56300 52800 nd nd 51000 57400 Average 61900 66500 nd nd 56700 68900 Stdev 44300 41000 nd nd 35900 43300 p(t-test) 0.63 nd nd 0.20 Min 6500 22300 nd nd 6500 22300 Max 248000 170000 nd nd 165000 170000 n (Samp) 67 29 nd nd 52 25 n (Patient) 67 29 nd nd 52 25 222 At Enrollment sCr or UO sCr only UO only AUC 0.54 nd 0.57 SE 0.065 nd 0.071 p 0.49 nd 0.32 nCohort 1 67 nd 52 nCohort 2 29 nd 25 Cutoff 1 35600 nd 34900 Sens 1 72% nd 72% Spec 1 33% nd 35% Cutoff 2 32000 nd 31400 Sens 2 83% nd 80% Spec 2 28% nd 29% Cutoff 3 25400 nd 25400 Sens 3 93% nd 92% Spec 3 16% nd 19% Cutoff 4 68600 nd 69000 Sens 4 38% nd 40% Spec 4 70% nd 71% Cutoff 5 85900 nd 84200 Sens 5 24% nd 28% Spec 5 81% nd 81% Cutoff 6 120000 nd 107000 Sens 6 14% nd 20% Spec 6 91% nd 90% OR Quart 2 2.7 nd 1.6 p Value 0.13 nd 0.49 95% CI of 0.76 nd 0.41 OR Quart2 9.7 nd 6.5 OR Quart 3 1.0 nd 0.75 p Value 1.0 nd 0.70 95% CI of 0.25 nd 0.17 OR Quart3 4.0 nd 3.4 OR Quart 4 2.3 nd 2.3 p Value 0.21 nd 0.23 95% CI of 0.63 nd 0.59 OR Quart4 8.2 nd 8.8 C-peptide EDTA sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2770 2630 3500 1160 2480 2490 Average 3320 3300 3930 2700 3150 2980 Stdev 2700 2540 2990 3770 2450 2140 p(t-test) 0.96 0.35 0.74 Min 39.8 137 157 163 39.8 137 Max 11400 11000 11400 11000 10200 10600 n(Samp) 84 37 32 7 66 31 n (Patient) 84 37 32 7 66 31 At Enrollment sCr or UO sCr only UO only AUC 0.51 0.30 0.51 SE 0.057 0.12 0.063 223 At Enrollment sCr or UO sCr only UO only p 0.80 0.10 0.91 nCohort 1 84 32 66 nCohort 2 37 7 31 Cutoff 1 2050 1050 2050 Sens 1 70% 71% 71% Spec 1 43% 16% 44% Cutoff 2 1520 865 1710 Sens 2 81% 86% 81% Spec 2 33% 12% 39% Cutoff 3 1050 157 1030 Sens 3 92% 100% 90% Spec 3 21% 3% 20% Cutoff 4 4030 4370 3890 Sens 4 24% 14% 16% Spec 4 70% 72% 71% Cutoff 5 5230 6070 4660 Sens 5 16% 14% 10% Spec 5 81% 81% 80% Cutoff 6 6840 8360 6470 Sens 6 8% 14% 6% Spec 6 90% 91% 91% OR Quart 2 2.2 1.0 2.7 p Value 0.17 1.0 0.13 95% CI of 0.72 0.054 0.76 OR Quart2 6.7 19 9.7 OR Quart 3 1.6 2.2 3.2 p Value 0.39 0.54 0.072 95% CI of 0.53 0.17 0.90 OR Quart3 5.1 30 11 OR Quart 4 1.1 4.5 0.95 p Value 0.82 0.24 0.94 95% CI of 0.36 0.37 0.24 OR Quart4 3.7 54 3.8 Peptide YY EDTA sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 40.5 48.2 42.8 48.0 39.6 37.8 Average 52.5 60.5 57.3 47.6 52.5 53.7 Stdev 42.2 57.0 53.8 28.8 42.8 53.1 p(t-test) 0.39 0.65 0.91 Min 0.00999 0.00999 0.00999 13.4 0.00999 0.0108 Max 189 234 234 79.9 189 229 n(Samp) 84 37 32 7 66 31 n (Patient) 84 37 32 7 66 31 At Enrollment sCr or UO sCr only UO only AUC 0.52 0.50 0.47 SE 0.057 0.12 0.063 p 0.75 0.97 0.62 nCohort 1 84 32 66 224 At Enrollment sCr or UO sCr only UO only nCohort 2 37 7 31 Cutoff 1 24.6 21.0 19.3 Sens 1 70% 71% 71% Spec 1 23% 28% 21% Cutoff 2 14.6 18.0 11.4 Sens 2 81% 86% 81% Spec 2 18% 28% 12% Cutoff 3 6.60 12.1 6.66 Sens 3 92% 100% 90% Spec 3 11% 22% 11% Cutoff 4 63.3 65.8 64.6 Sens 4 38% 43% 29% Spec 4 70% 72% 71% Cutoff 5 79.8 97.1 74.9 Sens 5 22% 0% 19% Spec 5 81% 81% 80% Cutoff 6 104 129 98.8 Sens 6 14% 0% 16% Spec 6 90% 91% 91% OR Quart 2 0.43 2.0 0.88 p Value 0.16 0.60 0.83 95% CI of 0.14 0.15 0.26 OR Quart2 1.4 27 3.0 OR Quart 3 0.63 2.0 0.71 p Value 0.41 0.60 0.59 95% CI of 0.21 0.15 0.20 OR Quart3 1.9 27 2.5 OR Quart 4 1.1 2.0 1.5 p Value 0.87 0.60 0.48 95% CI of 0.39 0.15 0.47 OR Quart4 3.1 27 4.9 [0175] Table 8: Comparison of the maximum marker levels in EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0) and the maximum values in EDTA samples collected from subjects between enrollment and 0, 24 hours, and 48 hours prior to reaching stage F in Cohort 2. Agouti-related protein sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0554 0.235 0.0554 0.235 0.0554 0.238 Average 0.0814 0.338 0.0814 0.243 0.0814 0.242 Stdev 0.0613 0.391 0.0613 0.152 0.0613 0.102 p(t-test) 3.2E-6 1.OE-7 1.9E-7 Min 0.0164 0.0923 0.0164 0.0670 0.0164 0.0923 Max 0.285 1.34 0.285 0.527 0.285 0.411 n(Samp) 65 9 65 9 65 6 n (Patient) 65 9 65 9 65 6 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage 225 sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.90 nd nd 0.89 nd nd 0.94 nd nd SE 0.069 nd nd 0.074 nd nd 0.070 nd nd p .4E-9 nd nd 2.2E-7 nd nd 6.OE-10 nd nd nCohort 1 65 nd nd 65 nd nd 65 nd nd nCohort 2 9 nd nd 9 nd nd 6 nd nd Cutoff 1 0.100 nd nd 0.0923 nd nd 0.220 nd nd Sens 1 78% nd nd 78% nd nd 83% nd nd Spec 1 75% nd nd 75% nd nd 95% nd nd Cutoff 2 0.0923 nd nd 0.0904 nd nd 0.220 nd nd Sens 2 89% nd nd 89% nd nd 83% nd nd Spec 2 75% nd nd 75% nd nd 95% nd nd Cutoff 3 0.0904 nd nd 0.0634 nd nd 0.0904 nd nd Sens 3 100% nd nd 100% nd nd 100% nd nd Spec 3 75% nd nd 58% nd nd 75% nd nd Cutoff 4 0.0837 nd nd 0.0837 nd nd 0.0837 nd nd Sens 4 100% nd nd 89% nd nd 100% nd nd Spec 4 71% nd nd 71% nd nd 71% nd nd Cutoff 5 0.118 nd nd 0.118 nd nd 0.118 nd nd Sens 5 67% nd nd 67% nd nd 83% nd nd Spec 5 80% nd nd 80% nd nd 80% nd nd Cutoff 6 0.184 nd nd 0.184 nd nd 0.184 nd nd Sens 6 67% nd nd 67% nd nd 83% nd nd Spec 6 91% nd nd 91% nd nd 91% nd nd OR Quart 2 >0 nd nd >0 nd nd >0 nd nd p Value <na nd nd <na nd nd <na nd nd 95% CIof >na nd nd >na nd nd >na nd nd OR Quart2 na nd nd na nd nd na nd nd OR Quart 3 >3.6 nd nd >3.6 nd nd >1.0 nd nd p Value <0.29 nd nd <0.29 nd nd <1.0 nd nd 95% CI of >0.34 nd nd >0.34 nd nd >0.058 nd nd OR Quart3 na nd nd na nd nd na nd nd OR Quart 4 >8.3 nd nd >8.3 nd nd >6.5 nd nd p Value <0.063 nd nd <0.063 nd nd <0.10 nd nd 95% CI of >0.89 nd nd >0.89 nd nd >0.68 nd nd OR Quart4 na nd nd na nd nd na nd nd Osteocalcin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2120 2030 2120 2030 2120 2250 Average 2640 2830 2640 2800 2640 3280 Stdev 2410 2040 2410 2060 2410 2440 p(t-test) 0.78 0.81 0.44 Min 91.1 674 91.1 674 91.1 691 Max 14000 7230 14000 7230 14000 7230 n (Samp) 107 14 107 14 107 9 n (Patient) 107 14 107 14 107 9 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2140 1820 2140 1820 2140 2030 Average 2850 3010 2850 3010 2850 3400 Stdev 2770 2680 2770 2680 2770 2710 226 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) 0.88 0.88 0.63 Min 0.729 674 0.729 674 0.729 1100 Max 17700 7230 17700 7230 17700 7230 n (Samp) 209 7 209 7 209 6 n (Patient) 209 7 209 7 209 6 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2270 2550 2270 2550 nd nd Average 3050 3060 3050 3030 nd nd Stdev 2890 1960 2890 2010 nd nd p(t-test) 0.99 0.98 nd nd Min 91.1 1230 91.1 900 nd nd Max 14000 7230 14000 7230 nd nd n (Samp) 104 9 104 9 nd nd n (Patient) 104 9 104 9 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.54 0.49 0.56 0.53 0.49 0.55 0.58 0.56 nd SE 0.084 0.11 0.10 0.084 0.11 0.10 0.10 0.12 nd p 0.62 0.94 0.55 0.68 0.94 0.62 0.46 0.64 nd nCohort 1 107 209 104 107 209 104 107 209 nd nCohort 2 14 7 9 14 7 9 9 6 nd Cutoff 1 1770 1530 1790 1770 1530 1780 1510 1530 nd Sens 1 71% 71% 78% 71% 71% 78% 78% 83% nd Spec 1 42% 34% 38% 42% 34% 38% 36% 34% nd Cutoff 2 1210 1100 1770 1020 1100 1770 1020 1530 nd Sens 2 86% 86% 89% 86% 86% 89% 89% 83% nd Spec 2 28% 22% 38% 23% 22% 38% 23% 34% nd Cutoff 3 1020 622 1210 855 622 874 622 1100 nd Sens 3 93% 100% 100% 93% 100% 100% 100% 100% nd Spec 3 23% 10% 27% 19% 10% 17% 12% 22% nd Cutoff 4 2880 3210 3290 2880 3210 3290 2880 3210 nd Sens 4 29% 29% 22% 29% 29% 22% 44% 33% nd Spec 4 70% 70% 70% 70% 70% 70% 70% 70% nd Cutoff 5 3780 4020 4200 3780 4020 4200 3780 4020 nd Sens 5 21% 29% 22% 21% 29% 22% 33% 33% nd Spec 5 80% 80% 81% 80% 80% 81% 80% 80% nd Cutoff 6 4720 5140 7160 4720 5140 7160 4720 5140 nd Sens 6 21% 29% 11% 21% 29% 11% 33% 33% nd Spec 6 91% 90% 90% 91% 90% 90% 91% 90% nd OR Quart 2 2.8 0.49 >4.7 1.4 0.49 3.2 1.0 2.0 nd p Value 0.24 0.57 <0.18 0.69 0.57 0.32 1.0 0.58 nd 95% CI of 0.50 0.043 >0.49 0.28 0.043 0.32 0.13 0.18 nd OR Quart2 16 5.6 na 6.8 5.6 33 7.6 23 nd OR Quart 3 2.2 1.0 >3.4 1.4 1.0 3.2 1.0 0.98 nd p Value 0.40 1.0 <0.31 0.69 1.0 0.32 1.0 0.99 nd 95% CI of 0.36 0.14 >0.33 0.28 0.14 0.32 0.13 0.060 nd OR Quart3 13 7.4 na 6.8 7.4 33 7.6 16 nd OR Quart 4 1.5 1.0 >2.1 0.96 1.0 2.0 1.6 2.0 nd p Value 0.67 1.0 <0.56 0.97 1.0 0.58 0.64 0.58 nd 95% CT of 0.23 0.14 >0.18 0.18 0.14 0.17 0.24 0.18 nd 227 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO IsCr only UO only sCr or UO sCr only lUO only sCr or UO sCr only lUO only OR Quart4 9.7 7.4 na 5.2 7.4 23 10 23 nd Complement factor H sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 191000 187000 191000 187000 191000 268000 Average 203000 206000 203000 206000 203000 259000 Stdev 69100 92100 69100 92100 69100 79900 p(t-test) 0.90 0.90 0.060 Min 57700 92800 57700 92800 57700 125000 Max 486000 347000 486000 347000 486000 347000 n (Samp) 89 10 89 10 89 6 n (Patient) 89 10 89 10 89 6 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 191000 138000 191000 138000 nd nd Average 206000 152000 206000 152000 nd nd Stdev 70900 66700 70900 66700 nd nd p(t-test) 0.072 0.072 nd nd Min 29300 92800 29300 92800 nd nd Max 486000 281000 486000 281000 nd nd n (Samp) 91 6 91 6 nd nd n (Patient) 91 6 91 6 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.49 nd 0.24 0.49 nd 0.24 0.73 nd nd SE 0.097 nd 0.12 0.097 nd 0.12 0.12 nd nd p 0.91 nd 0.025 0.91 nd 0.025 0.052 nd nd nCohort 1 89 nd 91 89 nd 91 89 nd nd nCohort 2 10 nd 6 10 nd 6 6 nd nd Cutoff 1 147000 nd 110000 147000 nd 110000 223000 nd nd Sens 1 70% nd 83% 70% nd 83% 83% nd nd Spec 1 19% nd 5% 19% nd 5% 72% nd nd Cutoff 2 115000 nd 110000 115000 nd 110000 223000 nd nd Sens 2 80% nd 83% 80% nd 83% 83% nd nd Spec 2 7% nd 5% 7% nd 5% 72% nd nd Cutoff 3 110000 nd 29300 110000 nd 29300 115000 nd nd Sens 3 90% nd 100% 90% nd 100% 100% nd nd Spec 3 6% nd 1% 6% nd 1% 7% nd nd Cutoff 4 223000 nd 228000 223000 nd 228000 223000 nd nd Sens 4 50% nd 17% 50% nd 17% 83% nd nd Spec 4 71% nd 70% 71% nd 70% 71% nd nd Cutoff 5 251000 nd 254000 251000 nd 254000 251000 nd nd Sens 5 40% nd 17% 40% nd 17% 67% nd nd Spec 5 81% nd 80% 81% nd 80% 81% nd nd Cutoff 6 306000 nd 299000 306000 nd 299000 306000 nd nd Sens 6 20% nd 0% 20% nd 0% 33% nd nd Spec 6 91% nd 90% 91% nd 90% 91% nd nd OR Quart 2 0.22 nd 0 0.22 nd 0 0 nd nd p Value 0.19 nd na 0.19 nd na na nd nd 228 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only 95% CI of 0.023 nd na 0.023 nd na na nd nd OR Quart2 2.1 nd na 2.1 nd na na nd nd OR Quart 3 0.22 nd 1.0 0.22 nd 1.0 0.96 nd nd p Value 0.19 nd 0.98 0.19 nd 0.98 0.98 nd nd 95% CI of 0.023 nd 0.062 0.023 nd 0.062 0.056 nd nd OR Quart3 2.1 nd 18 2.1 nd 18 16 nd nd OR Quart 4 1.0 nd 4.8 1.0 nd 4.8 4.4 nd nd p Value 0.95 nd 0.18 0.95 nd 0.18 0.20 nd nd 95% CI of 0.23 nd 0.50 0.23 nd 0.50 0.45 nd nd OR Quart4 4.8 nd 46 .8 nd 46 43 nd nd Follistatin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 896 1280 896 1280 896 942 Average 2500 4650 2500 4380 2500 3010 Stdev 4480 4920 4480 4890 4480 4210 p(t-test) 0.088 0.13 0.75 Min 8.52 328 8.52 328 8.52 328 Max 19900 12900 19900 12900 19900 11100 n (Samp) 107 15 107 15 107 9 n (Patient) 107 15 107 15 107 9 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 1010 1160 1010 1160 1010 1050 Average 3020 3990 3020 3490 3020 3550 Stdev 4950 4500 4950 4330 4950 4670 p(t-test) 0.58 0.79 0.78 Min 8.52 328 8.52 328 8.52 328 Max 28900 11100 28900 11100 28900 11100 n (Samp) 209 8 209 8 209 7 n (Patient) 209 8 209 8 209 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 921 1160 921 1160 nd nd Average 2870 4080 2870 4080 nd nd Stdev 4720 5070 4720 5070 nd nd p(t-test) 0.44 0.44 nd nd Min 8.52 570 8.52 570 nd nd Max 19900 12900 19900 12900 nd nd n (Samp) 107 10 107 10 nd nd n (Patient) 107 10 107 10 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.63 0.55 0.60 0.63 0.55 0.60 0.49 0.51 nd SE 0.082 0.11 0.099 0.082 0.11 0.099 0.10 0.11 nd p 0.12 0.61 0.32 0.12 0.62 0.32 0.93 0.90 nd nCohort 1 107 209 107 107 209 107 107 209 nd 229 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only nCohort 2 15 8 10 15 8 10 9 7 nd Cutoff 1 834 921 834 834 921 834 541 921 nd Sens 1 73% 75% 70% 73% 75% 70% 78% 71% nd Spec 1 46% 48% 45% 46% 48% 45% 15% 48% nd Cutoff 2 764 554 764 764 554 764 429 554 nd Sens 2 80% 88% 80% 80% 88% 80% 89% 86% nd Spec 2 36% 15% 36% 36% 15% 36% 9% 15% nd Cutoff 3 541 254 690 541 254 690 195 254 nd Sens 3 93% 100% 90% 93% 100% 90% 100% 100% nd Spec 3 15% 5% 29% 15% 5% 29% 5% 5% nd Cutoff 4 1210 1380 1360 1210 1380 1360 1210 1380 nd Sens 4 53% 38% 40% 53% 38% 40% 33% 29% nd Spec 4 70% 70% 70% 70% 70% 70% 70% 70% nd Cutoff 5 1470 1890 2050 1470 1890 2050 1470 1890 nd Sens 5 47% 38% 40% 47% 38% 40% 33% 29% nd Spec 5 80% 80% 80% 80% 80% 80% 80% 80% nd Cutoff 6 10300 12400 11900 10300 12400 11900 10300 12400 nd Sens 6 20% 0% 20% 20% 0% 20% 11% 0% nd Spec 6 91% 90% 91% 91% 90% 91% 91% 90% nd OR Quart 2 1.5 0.49 3.2 1.5 0.49 3.2 0.64 0.49 nd p Value 0.67 0.57 0.32 0.67 0.57 0.32 0.64 0.57 nd 95% CI of 0.23 0.043 0.32 0.23 0.043 0.32 0.099 0.043 nd OR Quart2 9.7 5.6 33 9.7 5.6 33 4.2 5.6 nd OR Quart 3 1.6 1.0 2.1 1.6 1.0 2.1 0.31 1.0 nd p Value 0.64 1.0 0.56 0.64 1.0 0.56 0.32 1.0 nd 95% CI of 0.24 0.14 0.18 0.24 0.14 0.18 0.030 0.14 nd OR Quart3 10 7.4 24 10 7.4 24 3.2 7.4 nd OR Quart 4 4.1 1.5 4.3 4.1 1.5 4.3 1.0 1.0 nd p Value 0.097 0.66 0.20 0.097 0.66 0.20 1.0 1.0 nd 95% CI of 0.77 0.24 0.45 0.77 0.24 0.45 0.18 0.14 nd OR Quart4 22 9.4 41 22 9.4 41 5.4 7.4 nd Vitamin D-binding protein sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 197000 136000 197000 136000 197000 191000 Average 226000 189000 226000 188000 226000 246000 Stdev 102000 124000 102000 125000 102000 122000 p(t-test) 0.28 0.26 0.62 Min 72400 54200 72400 54200 72400 125000 Max 563000 442000 563000 442000 563000 442000 n(Samp) 88 11 88 11 88 7 n (Patient) 88 11 88 11 88 7 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 196000 234000 196000 234000 196000 234000 Average 222000 264000 222000 264000 222000 264000 Stdev 105000 122000 105000 122000 105000 122000 p(t-test) 0.34 0.34 0.34 Min 54200 125000 54200 125000 54200 125000 Max 630000 442000 630000 442000 630000 442000 230 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 n (Samp) 176 6 176 6 176 6 n (Patient) 176 6 176 6 176 6 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 214000 112000 214000 106000 nd nd Average 234000 144000 234000 142000 nd nd Stdev 105000 114000 105000 115000 nd nd p(t-test) 0.046 0.041 nd nd Min 68000 54200 68000 54200 nd nd Max 563000 370000 563000 370000 nd nd n (Samp) 90 6 90 6 nd nd n (Patient) 90 6 90 6 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.35 0.60 0.20 0.34 0.60 0.19 0.53 0.60 nd SE 0.094 0.12 0.11 0.094 0.12 0.11 0.12 0.12 nd p 0.10 0.41 0.0067 0.089 0.41 0.0042 0.81 0.41 nd nCohort 1 88 176 90 88 176 90 88 176 nd nCohort 2 11 6 6 11 6 6 7 6 nd Cutoff 1 125000 180000 72400 98900 180000 72400 179000 180000 nd Sens 1 73% 83% 83% 73% 83% 83% 71% 83% nd Spec 1 10% 41% 2% 2% 41% 2% 38% 41% nd Cutoff 2 81500 180000 72400 78700 180000 72400 134000 180000 nd Sens 2 82% 83% 83% 82% 83% 83% 86% 83% nd Spec 2 1% 41% 2% 1% 41% 2% 15% 41% nd Cutoff 3 72400 125000 0 72400 125000 0 125000 125000 nd Sens 3 91% 100% 100% 91% 100% 100% 100% 100% nd Spec 3 1% 12% 0% 1% 12% 0% 10% 12% nd Cutoff 4 247000 249000 251000 247000 249000 251000 247000 249000 nd Sens 4 27% 50% 17% 27% 50% 17% 43% 50% nd Spec 4 70% 70% 70% 70% 70% 70% 70% 70% nd Cutoff 5 296000 278000 302000 296000 278000 302000 296000 278000 nd Sens 5 18% 33% 17% 18% 33% 17% 29% 33% nd Spec 5 81% 80% 80% 81% 80% 80% 81% 80% nd Cutoff 6 388000 388000 388000 388000 388000 388000 388000 388000 nd Sens 6 9% 17% 0% 9% 17% 0% 14% 17% nd Spec 6 91% 90% 90% 91% 90% 90% 91% 90% nd OR Quart 2 0 2.0 0 0 2.0 0 0.95 2.0 nd p Value na 0.58 na na 0.58 na 0.96 0.58 nd 95% CI of na 0.17 na na 0.17 na 0.12 0.17 nd OR Quart2 na 23 na na 23 na 7.4 23 nd OR Quart 3 0.64 0 0 0.64 0 0 0 0 nd p Value 0.64 na na 0.64 na na na na nd 95% CI of 0.097 na na 0.097 na na na na nd OR Quart3 4.2 na na 4.2 na na na na nd OR Quart 4 2.4 3.1 6.1 2.4 3.1 6.1 1.5 3.1 nd p Value 0.25 0.34 0.11 0.25 0.34 0.11 0.67 0.34 nd 95% CI of 0.53 0.31 0.65 0.53 0.31 0.65 0.23 0.31 nd OR Quart4 11 31 56 11 31 56 9.9 31 nd 231 Glucagon sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 61.3 40100 61.3 40100 nd nd Average 4870 27000 4870 27000 nd nd Stdev 13100 20200 13100 20200 nd nd p(t-test) 2.6E-4 2.6E-4 nd nd Min 10.8 66.0 10.8 66.0 nd nd Max 40100 40100 40100 40100 nd nd n (Samp) 75 6 75 6 nd nd n (Patient) 75 6 75 6 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.86 nd nd 0.86 nd nd nd nd nd SE 0.097 nd nd 0.097 nd nd nd nd nd p 2.OE-4 nd nd 2.OE-4 nd nd nd nd nd nCohort 1 75 nd nd 75 nd nd nd nd nd nCohort 2 6 nd nd 6 nd nd nd nd nd Cutoff 1 562 nd nd 562 nd nd nd nd nd Sens 1 83% nd nd 83% nd nd nd nd nd Spec 1 88% nd nd 88% nd nd nd nd nd Cutoff 2 562 nd nd 562 nd nd nd nd nd Sens 2 83% nd nd 83% nd nd nd nd nd Spec 2 88% nd nd 88% nd nd nd nd nd Cutoff 3 64.3 nd nd 64.3 nd nd nd nd nd Sens 3 100% nd nd 100% nd nd nd nd nd Spec 3 53% nd nd 53% nd nd nd nd nd Cutoff 4 83.0 nd nd 83.0 nd nd nd nd nd Sens 4 83% nd nd 83% nd nd nd nd nd Spec 4 71% nd nd 71% nd nd nd nd nd Cutoff 5 148 nd nd 148 nd nd nd nd nd Sens 5 83% nd nd 83% nd nd nd nd nd Spec 5 80% nd nd 80% nd nd nd nd nd Cutoff 6 40100 nd nd 40100 nd nd nd nd nd Sens 6 0% nd nd 0% nd nd nd nd nd Spec 6 100% nd nd 100% nd nd nd nd nd OR Quart 2 >0 nd nd >0 nd nd nd nd nd p Value <na nd nd <na nd nd nd nd nd 95% CIof >na nd nd >na nd nd nd nd nd OR Quart2 na nd nd na nd nd nd nd nd OR Quart 3 >1.1 nd nd >1.1 nd nd nd nd nd p Value <0.97 nd nd <0.97 nd nd nd nd nd 95% CI of >0.061 nd nd >0.061 nd nd nd nd nd OR Quart3 na nd nd na nd nd nd nd nd OR Quart 4 >6.2 nd nd >6.2 nd nd nd nd nd p Value <0.11 nd nd <0.11 nd nd nd nd nd 95% CI of >0.66 nd nd >0.66 nd nd nd nd nd OR Quart4 na nd nd na nd nd nd nd nd Glucagon-like peptide 1 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 52.4 177 52.4 177 nd nd 232 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Average 59.2 169 59.2 169 nd nd Stdev 39.7 55.0 39.7 55.0 nd nd p(t-test) 1.3E-8 1.3E-8 nd nd Min 2.37 87.4 2.37 87.4 nd nd Max 185 240 185 240 nd nd n (Samp) 75 6 75 6 nd nd n (Patient) 75 6 75 6 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.95 nd nd 0.95 nd nd nd nd nd SE 0.062 nd nd 0.062 nd nd nd nd nd p 3.7E-13 nd nd 3.7E-13 nd nd nd nd nd nCohort 1 75 nd nd 75 nd nd nd nd nd nCohort 2 6 nd nd 6 nd nd nd nd nd Cutoff 1 129 nd nd 129 nd nd nd nd nd Sens 1 83% nd nd 83% nd nd nd nd nd Spec 1 93% nd nd 93% nd nd nd nd nd Cutoff 2 129 nd nd 129 nd nd nd nd nd Sens 2 83% nd nd 83% nd nd nd nd nd Spec 2 93% nd nd 93% nd nd nd nd nd Cutoff 3 81.8 nd nd 81.8 nd nd nd nd nd Sens 3 100% nd nd 100% nd nd nd nd nd Spec 3 80% nd nd 80% nd nd nd nd nd Cutoff 4 69.7 nd nd 69.7 nd nd nd nd nd Sens 4 100% nd nd 100% nd nd nd nd nd Spec 4 71% nd nd 71% nd nd nd nd nd Cutoff 5 81.8 nd nd 81.8 nd nd nd nd nd Sens 5 100% nd nd 100% nd nd nd nd nd Spec 5 80% nd nd 80% nd nd nd nd nd Cutoff 6 119 nd nd 119 nd nd nd nd nd Sens 6 83% nd nd 83% nd nd nd nd nd Spec 6 91% nd nd 91% nd nd nd nd nd OR Quart 2 >0 nd nd >0 nd nd nd nd nd p Value <na nd nd <na nd nd nd nd nd 95% CIof >na nd nd >na nd nd nd nd nd OR Quart2 na nd nd na nd nd nd nd nd OR Quart 3 >0 nd nd >0 nd nd nd nd nd p Value <na nd nd <na nd nd nd nd nd 95% CIof >na nd nd >na nd nd nd nd nd OR Quart3 na nd nd na nd nd nd nd nd OR Quart 4 >8.0 nd nd >8.0 nd nd nd nd nd p Value <0.066 nd nd <0.066 nd nd nd nd nd 95% CI of >0.87 nd nd >0.87 nd nd nd nd nd OR Quart4 na nd nd na nd nd nd nd nd Appetite-regulating hormone sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 24.1 57.7 24.1 57.7 nd nd Average 29.0 54.3 29.0 54.3 nd nd Stdev 27.4 26.6 27.4 26.6 nd nd 233 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) 0.032 0.032 nd nd Min 0.251 22.3 0.251 22.3 nd nd Max 195 88.8 195 88.8 nd nd n (Samp) 75 6 75 6 nd nd n (Patient) 75 6 75 6 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.79 nd nd 0.79 nd nd nd nd nd SE 0.11 nd nd 0.11 nd nd nd nd nd p 0.0090 nd nd 0.0090 nd nd nd nd nd nCohort 1 75 nd nd 75 nd nd nd nd nd nCohort 2 6 nd nd 6 nd nd nd nd nd Cutoff 1 26.2 nd nd 26.2 nd nd nd nd nd Sens 1 83% nd nd 83% nd nd nd nd nd Spec 1 61% nd nd 61% nd nd nd nd nd Cutoff 2 26.2 nd nd 26.2 nd nd nd nd nd Sens 2 83% nd nd 83% nd nd nd nd nd Spec 2 61% nd nd 61% nd nd nd nd nd Cutoff 3 21.3 nd nd 21.3 nd nd nd nd nd Sens 3 100% nd nd 100% nd nd nd nd nd Spec 3 41% nd nd 41% nd nd nd nd nd Cutoff 4 31.1 nd nd 31.1 nd nd nd nd nd Sens 4 67% nd nd 67% nd nd nd nd nd Spec 4 71% nd nd 71% nd nd nd nd nd Cutoff 5 40.8 nd nd 40.8 nd nd nd nd nd Sens 5 67% nd nd 67% nd nd nd nd nd Spec 5 80% nd nd 80% nd nd nd nd nd Cutoff 6 51.9 nd nd 51.9 nd nd nd nd nd Sens 6 50% nd nd 50% nd nd nd nd nd Spec 6 91% nd nd 91% nd nd nd nd nd OR Quart 2 >1.1 nd nd >1.1 nd nd nd nd nd p Value <0.97 nd nd <0.97 nd nd nd nd nd 95% CI of >0.061 nd nd >0.061 nd nd nd nd nd OR Quart2 na nd nd na nd nd nd nd nd OR Quart 3 >1.1 nd nd >1.1 nd nd nd nd nd p Value <0.97 nd nd <0.97 nd nd nd nd nd 95% CI of >0.061 nd nd >0.061 nd nd nd nd nd OR Quart3 na nd nd na nd nd nd nd nd OR Quart 4 >4.7 nd nd >4.7 nd nd nd nd nd p Value <0.18 nd nd <0.18 nd nd nd nd nd 95% CI of >0.48 nd nd >0.48 nd nd nd nd nd OR Quart4 na nd nd na nd nd nd nd nd Islet amyloid polypeptide sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 9.67 19.0 9.67 19.0 nd nd Average 15.3 18.7 15.3 18.7 nd nd Stdev 20.8 8.44 20.8 8.44 nd nd p(t-test) 0.69 0.69 nd nd Min 0.0141 8.76 0.0141 8.76 nd nd 234 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max 121 31.6 121 31.6 nd nd n (Samp) 75 6 75 6 nd nd n (Patient) 75 6 75 6 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.74 nd nd 0.74 nd nd nd nd nd SE 0.12 nd nd 0.12 nd nd nd nd nd p 0.047 nd nd 0.047 nd nd nd nd nd nCohort 1 75 nd nd 75 nd nd nd nd nd nCohort 2 6 nd nd 6 nd nd nd nd nd Cutoff 1 11.0 nd nd 11.0 nd nd nd nd nd Sens 1 83% nd nd 83% nd nd nd nd nd Spec 1 59% nd nd 59% nd nd nd nd nd Cutoff 2 11.0 nd nd 11.0 nd nd nd nd nd Sens 2 83% nd nd 83% nd nd nd nd nd Spec 2 59% nd nd 59% nd nd nd nd nd Cutoff 3 8.38 nd nd 8.38 nd nd nd nd nd Sens 3 100% nd nd 100% nd nd nd nd nd Spec 3 47% nd nd 47% nd nd nd nd nd Cutoff 4 13.1 nd nd 13.1 nd nd nd nd nd Sens 4 67% nd nd 67% nd nd nd nd nd Spec 4 71% nd nd 71% nd nd nd nd nd Cutoff 5 18.4 nd nd 18.4 nd nd nd nd nd Sens 5 50% nd nd 50% nd nd nd nd nd Spec 5 80% nd nd 80% nd nd nd nd nd Cutoff 6 26.6 nd nd 26.6 nd nd nd nd nd Sens 6 17% nd nd 17% nd nd nd nd nd Spec 6 91% nd nd 91% nd nd nd nd nd OR Quart 2 >1.1 nd nd >1.1 nd nd nd nd nd p Value <0.97 nd nd <0.97 nd nd nd nd nd 95% CI of >0.061 nd nd >0.061 nd nd nd nd nd OR Quart2 na nd nd na nd nd nd nd nd OR Quart 3 >2.2 nd nd >2.2 nd nd nd nd nd p Value <0.53 nd nd <0.53 nd nd nd nd nd 95% CI of >0.19 nd nd >0.19 nd nd nd nd nd OR Quart3 na nd nd na nd nd nd nd nd OR Quart 4 >3.3 nd nd >3.3 nd nd nd nd nd p Value <0.32 nd nd <0.32 nd nd nd nd nd 95% CI of >0.32 nd nd >0.32 nd nd nd nd nd OR Quart4 na nd nd na nd nd nd nd nd Interleukin-17A sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.90 4.49 2.90 4.49 2.90 5.24 Average 4.63 10.1 4.63 8.46 4.63 9.12 Stdev 5.51 14.5 5.51 9.05 5.51 8.67 p(t-test) 0.0066 0.018 0.016 Min 0.000362 0.000482 0.000362 0.000469 0.000362 0.000532 Max 33.6 61.7 33.6 29.6 33.6 28.6 n(Samp) 87 19 87 19 87 12 235 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 n (Patient) 87 19 87 19 87 12 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.91 4.18 2.91 4.18 2.91 4.49 Average 4.94 6.98 4.94 6.98 4.94 8.43 Stdev 6.61 8.09 6.61 8.09 6.61 9.34 p(t-test) 0.35 0.35 0.18 Min 0.000362 0.901 0.000362 0.901 0.000362 2.56 Max 53.4 28.6 53.4 28.6 53.4 28.6 n (Samp) 184 10 184 10 184 7 n (Patient) 184 10 184 10 184 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.51 4.73 2.51 4.73 2.51 5.24 Average 4.37 11.3 4.37 8.67 4.37 7.96 Stdev 5.33 17.1 5.33 9.14 5.33 7.19 p(t-test) 0.0031 0.018 0.079 Min 0.000362 0.000482 0.000362 0.000469 0.000362 0.000532 Max 33.6 61.7 33.6 29.6 33.6 19.4 n(Samp) 93 12 93 12 93 8 n (Patient) 93 12 93 12 93 8 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.64 0.63 0.65 0.64 0.63 0.65 0.69 0.69 0.68 SE 0.074 0.097 0.090 0.074 0.097 0.090 0.089 0.11 0.11 p 0.056 0.18 0.088 0.059 0.18 0.093 0.034 0.10 0.098 nCohort 1 87 184 93 87 184 93 87 184 93 nCohort 2 19 10 12 19 10 12 12 7 8 Cutoff 1 3.27 3.27 3.33 3.27 3.27 3.33 3.33 3.84 3.33 Sens 1 74% 70% 75% 74% 70% 75% 75% 71% 75% Spec 1 54% 53% 58% 54% 53% 58% 55% 60% 58% Cutoff 2 2.51 2.66 2.59 2.51 2.66 2.59 2.59 2.66 2.59 Sens 2 84% 80% 83% 84% 80% 83% 83% 86% 88% Spec 2 48% 49% 52% 48% 49% 52% 49% 49% 52% Cutoff 3 0.000482 2.51 0.000482 0.000482 2.51 0.000482 2.51 2.51 0.000482 Sens 3 95% 90% 92% 95% 90% 92% 92% 100% 100% Spec 3 5% 46% 4% 5% 46% 4% 48% 46% 4% Cutoff 4 5.11 5.19 5.04 5.11 5.19 5.04 5.11 5.19 5.04 Sens 4 42% 40% 42% 42% 40% 42% 50% 43% 50% Spec 4 70% 70% 71% 70% 70% 71% 70% 70% 71% Cutoff 5 7.72 7.64 7.66 7.72 7.64 7.66 7.72 7.64 7.66 Sens 5 32% 20% 33% 32% 20% 33% 42% 29% 38% Spec 5 80% 80% 81% 80% 80% 81% 80% 80% 81% Cutoff 6 11.0 11.2 10.4 11.0 11.2 10.4 11.0 11.2 10.4 Sens 6 26% 10% 33% 26% 10% 33% 25% 14% 25% Spec 6 91% 90% 90% 91% 90% 90% 91% 90% 90% OR Quart 2 0.96 2.0 0.48 0.96 2.0 0.48 2.0 >2.0 1.0 p Value 0.96 0.58 0.56 0.96 0.58 0.56 0.58 <0.57 1.0 95% CI of 0.18 0.18 0.041 0.18 0.18 0.041 0.17 >0.18 0.059 236 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only OR Quart2 5.2 23 5.6 5.2 23 5.6 24 na 17 OR Quart 3 2.8 4.3 2.2 2.8 4.3 2.2 4.4 >3.1 2.1 p Value 0.17 0.20 0.39 0.17 0.20 0.39 0.20 <0.33 0.56 95% CI of 0.64 0.46 0.36 0.64 0.46 0.36 0.45 >0.31 0.18 OR Quart3 12 40 13 12 40 13 42 na 25 OR Quart 4 2.2 3.1 2.7 2.2 3.1 2.7 5.8 >2.0 4.4 p Value 0.31 0.34 0.26 0.31 0.34 0.26 0.12 <0.57 0.20 95% CI of 0.49 0.31 0.48 0.49 0.31 0.48 0.62 >0.18 0.45 OR Quart4 9.9 31 16 9.9 31 16 53 na 42 Insulin receptor substrate 1 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0512 1.17 0.0512 1.17 0.0512 1.54 Average 0.912 1.72 0.912 1.72 0.912 2.78 Stdev 5.31 2.37 5.31 2.37 5.31 2.59 p(t-test) 0.64 0.64 0.40 Min 0.000172 0.0342 0.000172 0.0289 0.000172 1.09 Max 49.5 7.74 49.5 7.74 49.5 7.74 n (Samp) 89 10 89 10 89 6 n (Patient) 89 10 89 10 89 6 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0512 0.196 0.0512 0.196 nd nd Average 0.949 1.59 0.949 1.59 nd nd Stdev 5.27 3.05 5.27 3.05 nd nd p(t-test) 0.77 0.77 nd nd Min 0.000172 0.0342 0.000172 0.0289 nd nd Max 49.5 7.74 49.5 7.74 nd nd n (Samp) 91 6 91 6 nd nd n (Patient) 91 6 91 6 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.83 nd 0.76 0.82 nd 0.75 0.93 nd nd SE 0.082 nd 0.12 0.083 nd 0.12 0.073 nd nd p 5.9E-5 nd 0.025 1.1E-4 nd 0.033 3.1E-9 nd nd nCohort 1 89 nd 91 89 nd 91 89 nd nd nCohort 2 10 nd 6 10 nd 6 6 nd nd Cutoff 1 0.212 nd 0.114 0.212 nd 0.114 1.09 nd nd Sens 1 70% nd 83% 70% nd 83% 83% nd nd Spec 1 82% nd 70% 82% nd 70% 90% nd nd Cutoff 2 0.170 nd 0.114 0.170 nd 0.114 1.09 nd nd Sens 2 80% nd 83% 80% nd 83% 83% nd nd Spec 2 79% nd 70% 79% nd 70% 90% nd nd Cutoff 3 0.114 nd 0.0332 0.114 nd 0.0271 0.929 nd nd Sens 3 90% nd 100% 90% nd 100% 100% nd nd Spec 3 69% nd 41% 69% nd 34% 90% nd nd Cutoff 4 0.134 nd 0.114 0.134 nd 0.114 0.134 nd nd Sens 4 80% nd 83% 80% nd 83% 100% nd nd Spec 4 71% nd 70% 71% nd 70% 71% nd nd 237 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Cutoff 5 0.186 nd 0.186 0.186 nd 0.186 0.186 nd nd Sens 5 70% nd 50% 70% nd 50% 100% nd nd Spec 5 81% nd 80% 81% nd 80% 81% nd nd Cutoff 6 1.27 nd 1.19 1.27 nd 1.19 1.27 nd nd Sens 6 30% nd 33% 30% nd 33% 50% nd nd Spec 6 91% nd 90% 91% nd 90% 91% nd nd OR Quart 2 >1.0 nd >1.0 >1.0 nd >1.0 >0 nd nd p Value <1.0 nd <0.98 <1.0 nd <0.98 <na nd nd 95% CI of >0.059 nd >0.062 >0.059 nd >0.062 >na nd nd OR Quart2 na nd na na nd na na nd nd OR Quart 3 >2.1 nd >1.0 >2.1 nd >1.0 >0 nd nd p Value <0.56 nd <0.98 <0.56 nd <0.98 <na nd nd 95% CI of >0.18 nd >0.062 >0.18 nd >0.062 >na nd nd OR Quart3 na nd na na nd na na nd nd OR Quart 4 >9.3 nd >4.6 >9.3 nd >4.6 >7.7 nd nd p Value <0.045 nd <0.19 <0.045 nd <0.19 <0.070 nd nd 95% CI of >1.1 nd >0.47 >1.1 nd >0.47 >0.85 nd nd OR Quart4 na nd na na nd na na nd nd Involucrin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.751 3.27 0.751 2.93 0.751 3.39 Average 0.949 3.05 0.949 2.98 0.949 3.31 Stdev 0.724 2.13 0.724 2.13 0.724 2.55 p(t-test) 1.7E-9 4.4E-9 2.5E-8 Min 0.0472 0.278 0.0472 0.278 0.0472 0.278 Max 3.56 7.42 3.56 7.42 3.56 7.42 n (Samp) 89 10 89 10 89 6 n (Patient) 89 10 89 10 89 6 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.800 3.56 0.800 3.23 nd nd Average 1.04 3.62 1.04 3.51 nd nd Stdev 0.779 2.25 0.779 2.28 nd nd p(t-test) 1.6E-9 6.7E-9 nd nd Min 0.0472 1.26 0.0472 1.26 nd nd Max 3.67 7.42 3.67 7.42 nd nd n (Samp) 91 6 91 6 nd nd n (Patient) 91 6 91 6 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.84 nd 0.92 0.84 nd 0.92 0.80 nd nd SE 0.080 nd 0.077 0.081 nd 0.079 0.11 nd nd p 2.3E-5 nd 4.3E-8 3.2E-5 nd 1.5E-7 0.0074 nd nd nCohort 1 89 nd 91 89 nd 91 89 nd nd nCohort 2 10 nd 6 10 nd 6 6 nd nd Cutoff 1 1.33 nd 1.33 1.33 nd 1.33 1.02 nd nd Sens 1 70% nd 83% 70% nd 83% 83% nd nd Spec 1 83% nd 80% 83% nd 80% 73% nd nd 238 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Cutoff 2 1.25 nd 1.33 1.25 nd 1.33 1.02 nd nd Sens 2 80% nd 83% 80% nd 83% 83% nd nd Spec 2 79% nd 80% 79% nd 80% 73% nd nd Cutoff 3 1.02 nd 1.25 1.02 nd 1.25 0.240 nd nd Sens 3 90% nd 100% 90% nd 100% 100% nd nd Spec 3 73% nd 75% 73% nd 75% 9% nd nd Cutoff 4 0.983 nd 1.16 0.983 nd 1.16 0.983 nd nd Sens 4 90% nd 100% 90% nd 100% 83% nd nd Spec 4 71% nd 70% 71% nd 70% 71% nd nd Cutoff 5 1.30 nd 1.33 1.30 nd 1.33 1.30 nd nd Sens 5 70% nd 83% 70% nd 83% 67% nd nd Spec 5 81% nd 80% 81% nd 80% 81% nd nd Cutoff 6 1.73 nd 2.12 1.73 nd 2.12 1.73 nd nd Sens 6 60% nd 67% 60% nd 67% 67% nd nd Spec 6 91% nd 90% 91% nd 90% 91% nd nd OR Quart 2 0 nd >0 0 nd >0 0 nd nd p Value na nd <na na nd <na na nd nd 95% CIof na nd >na na nd >na na nd nd OR Quart2 na nd na na nd na na nd nd OR Quart 3 2.0 nd >1.0 2.0 nd >1.0 0.96 nd nd p Value 0.58 nd <0.98 0.58 nd <0.98 0.98 nd nd 95% CI of 0.17 nd >0.062 0.17 nd >0.062 0.056 nd nd OR Quart3 24 nd na 24 nd na 16 nd nd OR Quart 4 8.9 nd >6.0 8.9 nd >6.0 4.4 nd nd p Value 0.049 nd <0.11 0.049 nd <0.11 0.20 nd nd 95% CI of 1.0 nd >0.65 1.0 nd >0.65 0.45 nd nd OR Quart4 79 nd na 79 nd na 43 nd nd Keratin, type II cytoskeletal 6 (6A, -6B, -6C mix) sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.000220 5.13E-5 0.000220 5.13E-5 0.000220 5.13E-5 Average 2.60 8.50E-5 2.60 8.50E-5 2.60 5.13E-5 Stdev 14.8 7.1OE-5 14.8 7.1OE-5 14.8 0 p(t-test) 0.58 0.58 0.67 Min 5.13E-5 5.13E-5 5.13E-5 5.13E-5 5.13E-5 5.13E-5 Max 119 0.000220 119 0.000220 119 5.13E-5 n (Samp) 89 10 89 10 89 6 n (Patient) 89 10 89 10 89 6 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.000220 5.13E-5 0.000220 5.13E-5 nd nd Average 2.24 0.000107 2.24 0.000107 nd nd Stdev 12.7 8.70E-5 12.7 8.70E-5 nd nd p(t-test) 0.67 0.67 nd nd Min 5.13E-5 5.13E-5 5.13E-5 5.13E-5 nd nd Max 94.9 0.000220 94.9 0.000220 nd nd n (Samp) 91 6 91 6 nd nd n (Patient) 91 6 91 6 nd nd Ohr prior to AKT stage 24hr prior to AKT stage 48hr prior to AKT stage 239 sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.29 nd 0.40 0.29 nd 0.40 0.19 nd nd SE 0.095 nd 0.13 0.095 nd 0.13 0.11 nd nd p 0.025 nd 0.44 0.025 nd 0.44 0.0046 nd nd nCohort 1 89 nd 91 89 nd 91 89 nd nd nCohort 2 10 nd 6 10 nd 6 6 nd nd Cutoff 1 0 nd 0 0 nd 0 0 nd nd Sens 1 100% nd 100% 100% nd 100% 100% nd nd Spec 1 0% nd 0% 0% nd 0% 0% nd nd Cutoff 2 0 nd 0 0 nd 0 0 nd nd Sens 2 100% nd 100% 100% nd 100% 100% nd nd Spec 2 0% nd 0% 0% nd 0% 0% nd nd Cutoff3 0 nd 0 0 nd 0 0 nd nd Sens 3 100% nd 100% 100% nd 100% 100% nd nd Spec 3 0% nd 0% 0% nd 0% 0% nd nd Cutoff 4 0.000220 nd 0.000220 0.000220 nd 0.000220 0.000220 nd nd Sens 4 0% nd 0% 0% nd 0% 0% nd nd Spec 4 94% nd 96% 94% nd 96% 94% nd nd Cutoff 5 0.000220 nd 0.000220 0.000220 nd 0.000220 0.000220 nd nd Sens 5 0% nd 0% 0% nd 0% 0% nd nd Spec 5 94% nd 96% 94% nd 96% 94% nd nd Cutoff 6 0.000220 nd 0.000220 0.000220 nd 0.000220 0.000220 nd nd Sens 6 0% nd 0% 0% nd 0% 0% nd nd Spec 6 94% nd 96% 94% nd 96% 94% nd nd OR Quart 2 >0 nd >2.3 >0 nd >2.3 >0 nd nd p Value <na nd <0.51 <na nd <0.51 <na nd nd 95% CI of >na nd >0.19 >na nd >0.19 >na nd nd OR Quart2 na nd na na nd na na nd nd OR Quart 3 >14 nd >3.6 >14 nd >3.6 >6.3 nd nd p Value <0.016 nd <0.29 <0.016 nd <0.29 <0.11 nd nd 95% CI of >1.6 nd >0.35 >1.6 nd >0.35 >0.68 nd nd OR Quart3 na nd na na nd na na nd nd OR Quart 4 >1.1 nd >1.1 >1.1 nd >1.1 >1.1 nd nd p Value <0.95 nd <0.95 <0.95 nd <0.95 <0.95 nd nd 95% CI of >0.064 nd >0.064 >0.064 nd >0.064 >0.064 nd nd OR Quart4 na nd na na nd na na nd nd Lipopolysaccharide (serotypes -K,-O) sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0185 0.0572 0.0185 0.0488 0.0185 0.0323 Average 0.0813 0.103 0.0813 0.0893 0.0813 0.0326 Stdev 0.303 0.129 0.303 0.128 0.303 0.0231 p(t-test) 0.82 0.93 0.70 Min 6.10E-6 6.10E-6 6.10E-6 6.10E-6 6.10E-6 6.10E-6 Max 2.81 0.436 2.81 0.436 2.81 0.0575 n (Samp) 89 10 89 10 89 6 n (Patient) 89 10 89 10 89 6 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0185 0.112 0.0185 0.0716 nd nd Average 0.0827 0.149 0.0827 0.126 nd nd Stdev 0.304 0.153 0.304 0.159 nd nd 240 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) 0.60 0.73 nd nd Min 6.10E-6 6.10E-6 6.10E-6 6.10E-6 nd nd Max 2.81 0.436 2.81 0.436 nd nd n (Samp) 91 6 91 6 nd nd n (Patient) 91 6 91 6 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.68 nd 0.75 0.66 nd 0.70 0.54 nd nd SE 0.097 nd 0.12 0.098 nd 0.12 0.12 nd nd p 0.060 nd 0.038 0.11 nd 0.095 0.74 nd nd nCohort 1 89 nd 91 89 nd 91 89 nd nd nCohort 2 10 nd 6 10 nd 6 6 nd nd Cutoff 1 0.0401 nd 0.0542 0.0354 nd 0.0354 0.0159 nd nd Sens 1 70% nd 83% 70% nd 83% 83% nd nd Spec 1 66% nd 76% 64% nd 65% 47% nd nd Cutoff 2 0.0205 nd 0.0542 0.0205 nd 0.0354 0.0159 nd nd Sens 2 80% nd 83% 80% nd 83% 83% nd nd Spec 2 53% nd 76% 53% nd 65% 47% nd nd Cutoff 3 0.0159 nd 0 0.0159 nd 0 0 nd nd Sens 3 90% nd 100% 90% nd 100% 100% nd nd Spec 3 47% nd 0% 47% nd 0% 0% nd nd Cutoff 4 0.0506 nd 0.0469 0.0506 nd 0.0469 0.0506 nd nd Sens 4 60% nd 83% 50% nd 67% 33% nd nd Spec 4 71% nd 70% 71% nd 70% 71% nd nd Cutoff 5 0.0951 nd 0.0829 0.0951 nd 0.0829 0.0951 nd nd Sens 5 30% nd 67% 20% nd 50% 0% nd nd Spec 5 81% nd 80% 81% nd 80% 81% nd nd Cutoff 6 0.121 nd 0.121 0.121 nd 0.121 0.121 nd nd Sens 6 30% nd 50% 20% nd 33% 0% nd nd Spec 6 91% nd 90% 91% nd 90% 91% nd nd OR Quart 2 0.96 nd 0 0.96 nd 0 0.96 nd nd p Value 0.98 nd na 0.98 nd na 0.98 nd nd 95% CI of 0.057 nd na 0.057 nd na 0.056 nd nd OR Quart2 16 nd na 16 nd na 16 nd nd OR Quart 3 4.4 nd 1.0 5.8 nd 2.1 4.4 nd nd p Value 0.20 nd 1.0 0.12 nd 0.56 0.20 nd nd 95% CI of 0.45 nd 0.059 0.62 nd 0.18 0.45 nd nd OR Quart3 42 nd 17 53 nd 25 43 nd nd OR Quart 4 4.4 nd 4.4 3.1 nd 3.1 0 nd nd p Value 0.20 nd 0.20 0.34 nd 0.34 na nd nd 95% CI of 0.45 nd 0.45 0.30 nd 0.30 na nd nd OR Quart4 42 nd 42 32 nd 32 na nd nd Collagenase 3 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.204 0.102 0.204 0.102 0.204 0.0305 Average 4.13 17.3 4.13 12.4 4.13 4.83 Stdev 30.7 39.2 30.7 34.5 30.7 14.4 p(t-test) 0.14 0.34 0.95 Min 0.00117 0.00455 0.00117 0.00117 0.00117 0.00374 241 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max 313 130 313 130 313 43.1 n (Samp) 109 15 109 15 109 9 n (Patient) 109 15 109 15 109 9 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.102 0.0502 0.102 0.0502 0.102 0.0305 Average 4.35 5.47 4.35 5.47 4.35 6.24 Stdev 26.0 15.2 26.0 15.2 26.0 16.3 p(t-test) 0.90 0.90 0.85 Min 0.00117 0.00726 0.00117 0.00726 0.00117 0.00726 Max 313 43.1 313 43.1 313 43.1 n (Samp) 213 8 213 8 213 7 n (Patient) 213 8 213 8 213 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.102 0.102 0.102 0.102 nd nd Average 4.11 21.6 4.11 14.2 nd nd Stdev 30.7 46.5 30.7 40.9 nd nd p(t-test) 0.10 0.33 nd nd Min 0.00117 0.00455 0.00117 0.00117 nd nd Max 313 130 313 130 nd nd n (Samp) 109 10 109 10 nd nd n (Patient) 109 10 109 10 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.48 0.43 0.54 0.47 0.43 0.53 0.32 0.43 nd SE 0.081 0.11 0.098 0.081 0.11 0.097 0.10 0.11 nd p 0.79 0.53 0.67 0.74 0.53 0.75 0.079 0.51 nd nCohort 1 109 213 109 109 213 109 109 213 nd nCohort 2 15 8 10 15 8 10 9 7 nd Cutoff 1 0.00455 0.00455 0.00726 0.00455 0.00455 0.00726 0.00455 0.00455 nd Sens 1 93% 100% 70% 93% 100% 70% 89% 100% nd Spec 1 9% 13% 25% 9% 13% 25% 9% 13% nd Cutoff 2 0.00455 0.00455 0.00455 0.00455 0.00455 0.00455 0.00455 0.00455 nd Sens 2 93% 100% 90% 93% 100% 90% 89% 100% nd Spec 2 9% 13% 14% 9% 13% 14% 9% 13% nd Cutoff 3 0.00455 0.00455 0.00455 0.00455 0.00455 0.00455 0.00117 0.00455 nd Sens 3 93% 100% 90% 93% 100% 90% 100% 100% nd Spec 3 9% 13% 14% 9% 13% 14% 2% 13% nd Cutoff 4 0.204 0.204 0.204 0.204 0.204 0.204 0.204 0.204 nd Sens 4 33% 25% 40% 33% 25% 40% 11% 29% nd Spec 4 72% 70% 74% 72% 70% 74% 72% 70% nd Cutoff 5 0.383 0.383 0.383 0.383 0.383 0.383 0.383 0.383 nd Sens 5 20% 12% 20% 20% 12% 20% 11% 14% nd Spec 5 96% 94% 96% 96% 94% 96% 96% 94% nd Cutoff 6 0.383 0.383 0.383 0.383 0.383 0.383 0.383 0.383 nd Sens 6 20% 12% 20% 20% 12% 20% 11% 14% nd Spec 6 96% 94% 96% 96% 94% 96% 96% 94% nd OR Quart 2 0.64 1.0 0.96 0.64 1.0 0.96 0 0 nd 242 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only p Value 0.64 0.99 0.97 0.64 0.99 0.97 na na nd 95% CI of 0.100 0.062 0.18 0.100 0.062 0.18 na na nd OR Quart2 4.1 17 5.2 4.1 17 5.2 na na nd OR Quart 3 1.8 3.2 0 1.8 3.2 0 3.2 0.49 nd p Value 0.45 0.32 na 0.45 0.32 na 0.32 0.57 nd 95% CI of 0.39 0.32 na 0.39 0.32 na 0.32 0.043 nd OR Quart3 8.3 31 na 8.3 31 na 33 5.6 nd OR Quart 4 1.8 3.2 1.3 1.8 3.2 1.3 6.0 2.1 nd p Value 0.45 0.32 0.72 0.45 0.32 0.72 0.11 0.41 nd 95% CI of 0.39 0.32 0.27 0.39 0.32 0.27 0.66 0.36 nd OR Quart4 8.3 31 6.6 8.3 31 6.6 55 12 nd NF-kappa-B inhibitor alpha sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.000295 0.0117 0.000295 0.0107 0.000295 0.0145 Average 0.0562 0.0848 0.0562 0.0846 0.0562 0.0184 Stdev 0.384 0.156 0.384 0.156 0.384 0.0169 p(t-test) 0.82 0.82 0.81 Min 2.41E-5 3.67E-5 2.41E-5 3.67E-5 2.41E-5 0.00131 Max 3.62 0.400 3.62 0.400 3.62 0.0395 n (Samp) 89 10 89 10 89 6 n (Patient) 89 10 89 10 89 6 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.000560 0.00902 0.000560 0.00801 nd nd Average 0.0635 0.130 0.0635 0.130 nd nd Stdev 0.387 0.194 0.387 0.194 nd nd p(t-test) 0.68 0.68 nd nd Min 1.84E-7 3.67E-5 1.84E-7 3.67E-5 nd nd Max 3.62 0.400 3.62 0.400 nd nd n (Samp) 91 6 91 6 nd nd n (Patient) 91 6 91 6 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.77 nd 0.73 0.76 nd 0.73 0.78 nd nd SE 0.091 nd 0.12 0.091 nd 0.12 0.11 nd nd p 0.0034 nd 0.050 0.0036 nd 0.055 0.014 nd nd nCohort 1 89 nd 91 89 nd 91 89 nd nd nCohort 2 10 nd 6 10 nd 6 6 nd nd Cutoff 1 0.00457 nd 0.00266 0.00457 nd 0.00266 0.00266 nd nd Sens 1 70% nd 83% 70% nd 83% 83% nd nd Spec 1 72% nd 66% 72% nd 66% 70% nd nd Cutoff 2 0.00266 nd 0.00266 0.00266 nd 0.00266 0.00266 nd nd Sens 2 80% nd 83% 80% nd 83% 83% nd nd Spec 2 70% nd 66% 70% nd 66% 70% nd nd Cutoff 3 0.00126 nd 2.41E-5 0.00126 nd 2.41E-5 0.00126 nd nd Sens 3 90% nd 100% 90% nd 100% 100% nd nd Spec 3 60% nd 19% 60% nd 19% 60% nd nd Cutoff 4 0.00423 nd 0.00465 0.00423 nd 0.00465 0.00423 nd nd 243 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 4 70% nd 67% 70% nd 67% 67% nd nd Spec 4 71% nd 70% 71% nd 70% 71% nd nd Cutoff 5 0.0115 nd 0.0138 0.0115 nd 0.0138 0.0115 nd nd Sens 5 50% nd 33% 40% nd 33% 50% nd nd Spec 5 81% nd 80% 81% nd 80% 81% nd nd Cutoff 6 0.0521 nd 0.0479 0.0521 nd 0.0479 0.0521 nd nd Sens 6 20% nd 33% 20% nd 33% 0% nd nd Spec 6 91% nd 90% 91% nd 90% 91% nd nd OR Quart 2 0 nd >1.0 0 nd >1.0 >0 nd nd p Value na nd <0.98 na nd <0.98 <na nd nd 95% CI of na nd >0.062 na nd >0.062 >na nd nd OR Quart2 na nd na na nd na na nd nd OR Quart 3 3.1 nd >2.2 3.1 nd >2.2 >2.1 nd nd p Value 0.34 nd <0.54 0.34 nd <0.54 <0.56 nd nd 95% CI of 0.30 nd >0.18 0.30 nd >0.18 >0.18 nd nd OR Quart3 32 nd na 32 nd na na nd nd OR Quart 4 7.3 nd >3.3 7.3 nd >3.3 >4.6 nd nd p Value 0.078 nd <0.32 0.078 nd <0.32 <0.19 nd nd 95% CI of 0.80 nd >0.32 0.80 nd >0.32 >0.47 nd nd OR Quart4 66 nd na 66 nd na na nd nd Beta-nerve growth factor sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 1.71 3.44 1.71 3.44 1.71 3.44 Average 3.00 4.15 3.00 3.86 3.00 3.59 Stdev 7.39 2.13 7.39 1.60 7.39 1.32 p(t-test) 0.61 0.70 0.83 Min 0.717 1.92 0.717 1.92 0.717 1.81 Max 70.0 8.70 70.0 6.73 70.0 5.85 n(Samp) 88 11 88 11 88 7 n (Patient) 88 11 88 11 88 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.00 3.44 2.00 3.44 nd nd Average 3.36 4.52 3.36 4.07 nd nd Stdev 7.36 2.60 7.36 1.95 nd nd p(t-test) 0.68 0.80 nd nd Min 0.774 1.92 0.774 1.92 nd nd Max 70.0 8.70 70.0 6.73 nd nd n(Samp) 89 7 89 7 nd nd n (Patient) 89 7 89 7 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.82 nd 0.76 0.82 nd 0.75 0.82 nd nd SE 0.079 nd 0.11 0.080 nd 0.11 0.100 nd nd p 4.5E-5 nd 0.019 5.9E-5 nd 0.023 0.0015 nd nd nCohort 1 88 nd 89 88 nd 89 88 nd nd nCohort 2 11 nd 7 11 nd 7 7 nd nd Cutoff 1 2.79 nd 2.79 2.79 nd 2.79 3.05 nd nd 244 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 1 73% nd 71% 73% nd 71% 71% nd nd Spec 1 76% nd 69% 76% nd 69% 83% nd nd Cutoff 2 2.64 nd 2.09 2.64 nd 2.09 2.64 nd nd Sens 2 82% nd 86% 82% nd 86% 86% nd nd Spec 2 75% nd 53% 75% nd 53% 75% nd nd Cutoff 3 2.06 nd 1.90 2.06 nd 1.90 1.78 nd nd Sens 3 91% nd 100% 91% nd 100% 100% nd nd Spec 3 62% nd 44% 62% nd 44% 52% nd nd Cutoff 4 2.57 nd 2.91 2.57 nd 2.91 2.57 nd nd Sens 4 82% nd 57% 82% nd 57% 86% nd nd Spec 4 70% nd 72% 70% nd 72% 70% nd nd Cutoff 5 2.92 nd 3.63 2.92 nd 3.63 2.92 nd nd Sens 5 64% nd 43% 64% nd 43% 71% nd nd Spec 5 81% nd 81% 81% nd 81% 81% nd nd Cutoff 6 4.01 nd 4.99 4.01 nd 4.99 4.01 nd nd Sens 6 36% nd 43% 36% nd 43% 29% nd nd Spec 6 91% nd 91% 91% nd 91% 91% nd nd OR Quart 2 >1.0 nd >1.0 >1.0 nd >1.0 >1.0 nd nd p Value <1.0 nd <0.98 <1.0 nd <0.98 <1.0 nd nd 95% CI of >0.059 nd >0.062 >0.059 nd >0.062 >0.059 nd nd OR Quart2 na nd na na nd na na nd nd OR Quart 3 >3.3 nd >2.2 >3.3 nd >2.2 >1.0 nd nd p Value <0.32 nd <0.54 <0.32 nd <0.54 <1.0 nd nd 95% CI of >0.32 nd >0.18 >0.32 nd >0.18 >0.059 nd nd OR Quart3 na nd na na nd na na nd nd OR Quart 4 >9.3 nd >4.8 >9.3 nd >4.8 >6.1 nd nd p Value <0.045 nd <0.18 <0.045 nd <0.18 <0.11 nd nd 95% CI of >1.1 nd >0.50 >1.1 nd >0.50 >0.65 nd nd OR Quart4 na nd na na nd na na nd nd Pancreatic prohormone sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 59.6 182 59.6 182 nd nd Average 171 313 171 313 nd nd Stdev 256 379 256 379 nd nd p(t-test) 0.21 0.21 nd nd Min 0.731 55.6 0.731 55.6 nd nd Max 1300 1080 1300 1080 nd nd n (Samp) 75 6 75 6 nd nd n (Patient) 75 6 75 6 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.74 nd nd 0.74 nd nd nd nd nd SE 0.12 nd nd 0.12 nd nd nd nd nd p 0.043 nd nd 0.043 nd nd nd nd nd nCohort 1 75 nd nd 75 nd nd nd nd nd nCohort 2 6 nd nd 6 nd nd nd nd nd Cutoff 1 132 nd nd 132 nd nd nd nd nd Sens 1 83% nd nd 83% nd nd nd nd nd Spec 1 71% nd nd 71% nd nd nd nd nd 245 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Cutoff 2 132 nd nd 132 nd nd nd nd nd Sens 2 83% nd nd 83% nd nd nd nd nd Spec 2 71% nd nd 71% nd nd nd nd nd Cutoff 3 55.2 nd nd 55.2 nd nd nd nd nd Sens 3 100% nd nd 100% nd nd nd nd nd Spec 3 48% nd nd 48% nd nd nd nd nd Cutoff 4 132 nd nd 132 nd nd nd nd nd Sens 4 83% nd nd 83% nd nd nd nd nd Spec 4 71% nd nd 71% nd nd nd nd nd Cutoff 5 218 nd nd 218 nd nd nd nd nd Sens 5 33% nd nd 33% nd nd nd nd nd Spec 5 80% nd nd 80% nd nd nd nd nd Cutoff 6 504 nd nd 504 nd nd nd nd nd Sens 6 17% nd nd 17% nd nd nd nd nd Spec 6 91% nd nd 91% nd nd nd nd nd OR Quart 2 >1.1 nd nd >1.1 nd nd nd nd nd p Value <0.97 nd nd <0.97 nd nd nd nd nd 95% CI of >0.061 nd nd >0.061 nd nd nd nd nd OR Quart2 na nd nd na nd nd nd nd nd OR Quart 3 >2.2 nd nd >2.2 nd nd nd nd nd p Value <0.53 nd nd <0.53 nd nd nd nd nd 95% CI of >0.19 nd nd >0.19 nd nd nd nd nd OR Quart3 na nd nd na nd nd nd nd nd OR Quart 4 >3.3 nd nd >3.3 nd nd nd nd nd p Value <0.32 nd nd <0.32 nd nd nd nd nd 95% CI of >0.32 nd nd >0.32 nd nd nd nd nd OR Quart4 na nd nd na nd nd nd nd nd Transthyretin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 70200 61300 70200 61300 70200 74200 Average 73000 63100 73000 63100 73000 73900 Stdev 37700 20700 37700 20700 37700 15600 p(t-test) 0.42 0.42 0.95 Min 12800 30100 12800 30100 12800 57400 Max 242000 91800 242000 91800 242000 91800 n (Samp) 89 10 89 10 89 6 n (Patient) 89 10 89 10 89 6 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 72000 55400 72000 55400 nd nd Average 74900 56100 74900 56100 nd nd Stdev 41800 22300 41800 22300 nd nd p(t-test) 0.28 0.28 nd nd Min 8940 30100 8940 30100 nd nd Max 248000 91800 248000 91800 nd nd n (Samp) 91 6 91 6 nd nd n (Patient) 91 6 91 6 nd nd Ohr prior to AKT stage 24hr prior to AKT stage 48hr prior to AKT stage 246 sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.42 nd 0.35 0.42 nd 0.35 0.53 nd nd SE 0.099 nd 0.13 0.099 nd 0.13 0.12 nd nd p 0.45 nd 0.23 0.45 nd 0.23 0.79 nd nd nCohort 1 89 nd 91 89 nd 91 89 nd nd nCohort 2 10 nd 6 10 nd 6 6 nd nd Cutoff 1 55600 nd 34000 55600 nd 34000 57800 nd nd Sens 1 70% nd 83% 70% nd 83% 83% nd nd Spec 1 34% nd 14% 34% nd 14% 37% nd nd Cutoff 2 53300 nd 34000 53300 nd 34000 57800 nd nd Sens 2 80% nd 83% 80% nd 83% 83% nd nd Spec 2 33% nd 14% 33% nd 14% 37% nd nd Cutoff 3 36200 nd 29300 36200 nd 29300 55600 nd nd Sens 3 90% nd 100% 90% nd 100% 100% nd nd Spec 3 17% nd 11% 17% nd 11% 34% nd nd Cutoff 4 89900 nd 88500 89900 nd 88500 89900 nd nd Sens 4 10% nd 17% 10% nd 17% 17% nd nd Spec 4 71% nd 70% 71% nd 70% 71% nd nd Cutoff 5 98900 nd 97800 98900 nd 97800 98900 nd nd Sens 5 0% nd 0% 0% nd 0% 0% nd nd Spec 5 81% nd 80% 81% nd 80% 81% nd nd Cutoff 6 120000 nd 123000 120000 nd 123000 120000 nd nd Sens 6 0% nd 0% 0% nd 0% 0% nd nd Spec 6 91% nd 90% 91% nd 90% 91% nd nd OR Quart 2 >3.4 nd 0 >3.4 nd 0 >3.3 nd nd p Value <0.30 nd na <0.30 nd na <0.32 nd nd 95% CI of >0.33 nd na >0.33 nd na >0.32 nd nd OR Quart2 na nd na na nd na na nd nd OR Quart 3 >6.2 nd 3.4 >6.2 nd 3.4 >3.3 nd nd p Value <0.11 nd 0.30 <0.11 nd 0.30 <0.32 nd nd 95% CI of >0.67 nd 0.33 >0.67 nd 0.33 >0.32 nd nd OR Quart3 na nd 36 na nd 36 na nd nd OR Quart 4 >2.3 nd 2.2 >2.3 nd 2.2 >0 nd nd p Value <0.51 nd 0.54 <0.51 nd 0.54 <na nd nd 95% CI of >0.19 nd 0.18 >0.19 nd 0.18 >na nd nd OR Quart4 na nd 26 na nd 26 na nd nd C-peptide EDTA sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2640 3360 2640 3360 2640 2520 Average 3140 4210 3140 4080 3140 3740 Stdev 2280 2920 2280 2780 2280 3320 p(t-test) 0.11 0.16 0.46 Min 65.0 878 65.0 878 65.0 878 Max 13900 11000 13900 11000 13900 11000 n (Samp) 109 14 109 14 109 9 n (Patient) 109 14 109 14 109 9 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2940 2880 2940 2880 2940 2450 Average 3530 4170 3530 4170 3530 4320 Stdev 2810 3700 2810 3700 2810 4030 247 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) 0.56 0.56 0.50 Min 51.9 878 51.9 878 51.9 878 Max 15400 11000 15400 11000 15400 11000 n (Samp) 213 7 213 7 213 6 n (Patient) 213 7 213 7 213 6 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 3080 3420 3080 3420 nd nd Average 3620 3840 3620 3640 nd nd Stdev 3160 2070 3160 1670 nd nd p(t-test) 0.84 0.99 nd nd Min 65.0 999 65.0 999 nd nd Max 21700 7900 21700 6070 nd nd n (Samp) 106 9 106 9 nd nd n (Patient) 106 9 106 9 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.60 0.53 0.58 0.60 0.53 0.57 0.52 0.52 nd SE 0.084 0.11 0.10 0.084 0.11 0.10 0.10 0.12 nd p 0.21 0.81 0.45 0.23 0.81 0.49 0.81 0.87 nd nCohort 1 109 213 106 109 213 106 109 213 nd nCohort 2 14 7 9 14 7 9 9 6 nd Cutoff 1 2570 2010 2570 2570 2010 2570 1730 1620 nd Sens 1 71% 71% 78% 71% 71% 78% 78% 83% nd Spec 1 50% 36% 46% 50% 36% 46% 33% 29% nd Cutoff 2 1460 1620 1970 1460 1620 1970 1460 1620 nd Sens 2 86% 86% 89% 86% 86% 89% 89% 83% nd Spec 2 28% 29% 37% 28% 29% 37% 28% 29% nd Cutoff 3 894 875 894 894 875 894 776 875 nd Sens 3 93% 100% 100% 93% 100% 100% 100% 100% nd Spec 3 13% 10% 11% 13% 10% 11% 12% 10% nd Cutoff 4 4260 4400 4360 4260 4400 4360 4260 4400 nd Sens 4 43% 29% 44% 43% 29% 44% 22% 33% nd Spec 4 71% 70% 71% 71% 70% 71% 71% 70% nd Cutoff 5 5000 5250 5370 5000 5250 5370 5000 5250 nd Sens 5 29% 29% 11% 29% 29% 11% 22% 33% nd Spec 5 81% 80% 80% 81% 80% 80% 81% 80% nd Cutoff 6 5940 6840 6420 5940 6840 6420 5940 6840 nd Sens 6 21% 29% 11% 21% 29% 0% 22% 33% nd Spec 6 91% 90% 91% 91% 90% 91% 91% 90% nd OR Quart 2 1.5 3.1 3.1 1.5 3.1 3.1 4.3 3.1 nd p Value 0.67 0.33 0.34 0.67 0.33 0.34 0.20 0.34 nd 95% CI of 0.23 0.31 0.30 0.23 0.31 0.30 0.45 0.31 nd OR Quart2 9.7 31 32 9.7 31 32 41 30 nd OR Quart 3 2.1 1.0 2.0 2.1 1.0 2.0 2.1 0 nd p Value 0.42 1.0 0.58 0.42 1.0 0.58 0.56 na nd 95% CI of 0.35 0.061 0.17 0.35 0.061 0.17 0.18 na nd OR Quart3 12 16 23 12 16 23 24 na nd OR Quart 4 2.7 2.0 3.1 2.7 2.0 3.1 2.0 2.0 nd p Value 0.26 0.57 0.34 0.26 0.57 0.34 0.58 0.58 nd 95% CT of 0.48 0.18 0.30 0.48 0.18 0.30 0.17 0.18 nd 248 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO IsCr only UO only sCr or UO sCr only lUO only sCr or UO sCr only lUO only OR Quart4 15 23 32 15 23 32 23 23 nd Gastric inhibitory polypeptide EDTA sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 39.5 52.3 39.5 47.0 39.5 95.8 Average 74.0 74.7 74.0 73.9 74.0 103 Stdev 110 70.8 110 71.0 110 73.0 p(t-test) 0.98 1.00 0.43 Min 0.888 7.04 0.888 7.04 0.888 18.2 Max 820 251 820 251 820 251 n (Samp) 109 14 109 14 109 9 n (Patient) 109 14 109 14 109 9 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 41.6 95.8 41.6 95.8 41.6 116 Average 77.3 96.1 77.3 96.1 77.3 111 Stdev 99.3 88.6 99.3 88.6 99.3 87.2 p(t-test) 0.62 0.62 0.41 Min 0.888 7.99 0.888 7.99 0.888 18.2 Max 820 251 820 251 820 251 n (Samp) 213 7 213 7 213 6 n (Patient) 213 7 213 7 213 6 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 40.8 45.1 40.8 45.1 nd nd Average 82.5 58.7 82.5 57.5 nd nd Stdev 117 49.5 117 49.6 nd nd p(t-test) 0.55 0.53 nd nd Min 0.888 7.04 0.888 7.04 nd nd Max 820 137 820 137 nd nd n (Samp) 106 9 106 9 nd nd n (Patient) 106 9 106 9 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.55 0.58 0.51 0.54 0.58 0.50 0.69 0.66 nd SE 0.084 0.11 0.10 0.084 0.11 0.10 0.10 0.12 nd p 0.55 0.49 0.93 0.59 0.49 0.98 0.057 0.20 nd nCohort 1 109 213 106 109 213 106 109 213 nd nCohort 2 14 7 9 14 7 9 9 6 nd Cutoff 1 20.5 20.5 18.1 20.5 20.5 18.1 43.5 20.5 nd Sens 1 71% 71% 78% 71% 71% 78% 78% 83% nd Spec 1 29% 30% 28% 29% 30% 28% 60% 30% nd Cutoff 2 15.0 18.2 15.0 15.0 18.2 15.0 20.5 20.5 nd Sens 2 86% 86% 89% 86% 86% 89% 89% 83% nd Spec 2 24% 29% 25% 24% 29% 25% 29% 30% nd Cutoff 3 7.37 7.95 6.56 7.37 7.95 6.56 18.1 18.2 nd Sens 3 93% 100% 100% 93% 100% 100% 100% 100% nd 249 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Spec 3 10% 11% 10% 10% 11% 10% 28% 29% nd Cutoff 4 61.5 89.4 80.9 61.5 89.4 80.9 61.5 89.4 nd Sens 4 43% 57% 33% 43% 57% 33% 67% 67% nd Spec 4 71% 70% 71% 71% 70% 71% 71% 70% nd Cutoff 5 106 118 116 106 118 116 106 118 nd Sens 5 29% 43% 22% 29% 43% 22% 44% 50% nd Spec 5 81% 80% 80% 81% 80% 80% 81% 80% nd Cutoff 6 204 195 215 204 195 215 204 195 nd Sens 6 7% 14% 0% 7% 14% 0% 11% 17% nd Spec 6 91% 90% 91% 91% 90% 91% 91% 90% nd OR Quart 2 0.96 2.0 3.1 0.96 2.0 3.1 >2.1 >2.0 nd p Value 0.97 0.57 0.34 0.97 0.57 0.34 <0.56 <0.57 nd 95% CI of 0.18 0.18 0.30 0.18 0.18 0.30 >0.18 >0.18 nd OR Quart2 5.2 23 32 5.2 23 32 na na nd OR Quart 3 0.96 1.0 3.1 0.96 1.0 3.1 >2.1 >1.0 nd p Value 0.97 1.0 0.34 0.97 1.0 0.34 <0.54 <1.0 nd 95% CI of 0.18 0.061 0.30 0.18 0.061 0.30 >0.18 >0.061 nd OR Quart3 5.2 16 32 5.2 16 32 na na nd OR Quart 4 1.7 3.1 2.0 1.7 3.1 2.0 >5.8 >3.1 nd p Value 0.48 0.33 0.58 0.48 0.33 0.58 <0.12 <0.33 nd 95% CI of 0.38 0.31 0.17 0.38 0.31 0.17 >0.63 >0.31 nd OR Quart4 8.0 31 23 8.0 31 23 na na nd Peptide YY EDTA sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 44.5 98.1 44.5 98.1 44.5 89.2 Average 67.9 139 67.9 135 67.9 125 Stdev 97.9 113 97.9 108 97.9 132 p(t-test) 0.013 0.018 0.10 Min 0.0512 21.6 0.0512 21.6 0.0512 21.6 Max 789 427 789 427 789 427 n (Samp) 109 14 109 14 109 9 n (Patient) 109 14 109 14 109 9 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 48.2 78.3 48.2 78.3 48.2 68.6 Average 72.8 83.4 72.8 83.4 72.8 84.3 Stdev 87.4 65.3 87.4 65.3 87.4 71.5 p(t-test) 0.75 0.75 0.75 Min 0.0143 21.6 0.0143 21.6 0.0143 21.6 Max 789 216 789 216 789 216 n (Samp) 213 7 213 7 213 6 n (Patient) 213 7 213 7 213 6 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 48.3 172 48.3 172 nd nd Average 69.8 187 69.8 181 nd nd Stdev 95.4 114 95.4 110 nd nd p(t-test) 6.9E-4 0.0012 nd nd 250 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Min 0.0512 44.4 0.0512 44.4 nd nd Max 789 427 789 427 nd nd n (Samp) 106 9 106 9 nd nd n (Patient) 106 9 106 9 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.75 0.59 0.88 0.75 0.59 0.87 0.65 0.57 nd SE 0.078 0.11 0.076 0.078 0.11 0.077 0.10 0.12 nd p 0.0013 0.43 8.8E-7 0.0013 0.43 1.OE-6 0.16 0.56 nd nCohort 1 109 213 106 109 213 106 109 213 nd nCohort 2 14 7 9 14 7 9 9 6 nd Cutoff 1 76.2 48.0 98.5 76.2 48.0 98.5 29.6 30.9 nd Sens 1 71% 71% 78% 71% 71% 78% 78% 83% nd Spec 1 75% 49% 83% 75% 49% 83% 29% 25% nd Cutoff 2 44.1 30.9 93.7 44.1 30.9 93.7 22.5 30.9 nd Sens 2 86% 86% 89% 86% 86% 89% 89% 83% nd Spec 2 50% 25% 82% 50% 25% 82% 23% 25% nd Cutoff 3 29.6 21.5 41.0 29.6 21.5 41.0 21.5 21.5 nd Sens 3 93% 100% 100% 93% 100% 100% 100% 100% nd Spec 3 29% 15% 45% 29% 15% 45% 20% 15% nd Cutoff 4 65.8 78.8 70.6 65.8 78.8 70.6 65.8 78.8 nd Sens 4 71% 43% 89% 71% 43% 89% 56% 50% nd Spec 4 71% 70% 71% 71% 70% 71% 71% 70% nd Cutoff 5 88.7 98.5 90.2 88.7 98.5 90.2 88.7 98.5 nd Sens 5 64% 29% 89% 64% 29% 89% 56% 33% nd Spec 5 81% 80% 80% 81% 80% 80% 81% 80% nd Cutoff6 113 128 114 113 128 114 113 128 nd Sens 6 43% 14% 67% 43% 14% 67% 33% 17% nd Spec 6 91% 90% 91% 91% 90% 91% 91% 90% nd OR Quart 2 2.0 2.0 >1.0 2.0 2.0 >1.0 0.47 2.0 nd p Value 0.58 0.57 <1.0 0.58 0.57 <1.0 0.54 0.58 nd 95% CI of 0.17 0.18 >0.060 0.17 0.18 >0.060 0.040 0.18 nd OR Quart2 23 23 na 23 23 na 5.4 23 nd OR Quart 3 2.0 1.0 >0 2.0 1.0 >0 0.48 0 nd p Value 0.58 1.0 <na 0.58 1.0 <na 0.56 na nd 95% CI of 0.17 0.061 >na 0.17 0.061 >na 0.041 na nd OR Quart3 23 16 na 23 16 na 5.6 na nd OR Quart 4 12 3.1 >11 12 3.1 >11 2.7 3.1 nd p Value 0.023 0.33 <0.031 0.023 0.33 <0.031 0.26 0.34 nd 95% CI of 1.4 0.31 >1.2 1.4 0.31 >1.2 0.48 0.31 nd OR Quart4 100 31 na 100 31 na 15 30 nd [0176] Table 9: Comparison of marker levels in urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0, R, or I) and in urine samples collected from Cohort 2 (subjects who progress to RIFLE stage F) at 0, 24 hours, and 48 hours prior to the subject reaching RIFLE stage I. Agouti-related protein sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage 251 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.839 1.61 0.839 1.48 0.839 0.686 Average 1.38 2.09 1.38 1.67 1.38 0.831 Stdev 1.92 1.69 1.92 1.46 1.92 0.802 p(t-test) 0.18 0.53 0.42 Min 0.00198 0.183 0.00198 0.213 0.00198 0.00498 Max 20.0 6.53 20.0 6.12 20.0 2.33 n (Samp) 807 13 807 18 807 8 n (Patient) 298 13 298 18 298 8 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 0.847 0.978 nd nd Average nd nd 1.38 1.70 nd nd Stdev nd nd 1.90 1.91 nd nd p(t-test) nd nd 0.61 nd nd Min nd nd 0.00198 0.213 nd nd Max nd nd 20.0 6.53 nd nd n (Samp) nd nd 833 9 nd nd n (Patient) nd nd 309 9 nd nd UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.871 0.867 0.871 1.44 nd nd Average 1.39 1.29 1.39 1.65 nd nd Stdev 1.89 1.12 1.89 1.62 nd nd p(t-test) 0.89 0.62 nd nd Min 0.00198 0.183 0.00198 0.126 nd nd Max 20.0 3.44 20.0 6.12 nd nd n (Samp) 833 7 833 13 nd nd n (Patient) 292 7 292 13 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.68 nd 0.54 0.61 0.59 0.58 0.40 nd nd SE 0.083 nd 0.11 0.071 0.10 0.084 0.11 nd nd p 0.025 nd 0.75 0.12 0.39 0.33 0.33 nd nd nCohort 1 807 nd 833 807 833 833 807 nd nd nCohort 2 13 nd 7 18 9 13 8 nd nd Cutoff 1 0.867 nd 0.767 0.761 0.770 0.701 0.218 nd nd Sens 1 77% nd 71% 72% 78% 77% 75% nd nd Spec 1 51% nd 45% 46% 46% 41% 15% nd nd Cutoff 2 0.786 nd 0.638 0.600 0.600 0.488 0.140 nd nd Sens 2 85% nd 86% 83% 89% 85% 88% nd nd Spec 2 47% nd 39% 38% 37% 31% 9% nd nd Cutoff 3 0.767 nd 0.182 0.366 0.211 0.366 0.00318 nd nd Sens 3 92% nd 100% 94% 100% 92% 100% nd nd Spec 3 46% nd 12% 25% 15% 24% 0% nd nd Cutoff 4 1.48 nd 1.54 1.48 1.50 1.54 1.48 nd nd Sens 4 54% nd 29% 50% 44% 38% 25% nd nd Spec 4 70% nd 70% 70% 70% 70% 70% nd nd Cutoff 5 2.05 nd 2.10 2.05 2.05 2.10 2.05 nd nd Sens 5 46% nd 29% 22% 22% 15% 12% nd nd Spec 5 80% nd 80% 80% 80% 80% 80% nd nd 252 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Cutoff 6 2.99 nd 2.99 2.99 2.95 2.99 2.99 nd nd Sens 6 23% nd 14% 17% 11% 15% 0% nd nd Spec 6 90% nd 90% 90% 90% 90% 90% nd nd OR Quart 2 2.0 nd 3.0 3.1 3.0 2.0 3.0 nd nd p Value 0.57 nd 0.34 0.17 0.34 0.42 0.34 nd nd 95% CI of 0.18 nd 0.31 0.61 0.31 0.36 0.31 nd nd OR Quart2 22 nd 29 15 29 11 29 nd nd OR Quart 3 4.1 nd 1.0 1.5 3.0 1.0 1.0 nd nd p Value 0.21 nd 1.0 0.65 0.34 1.0 1.0 nd nd 95% CI of 0.45 nd 0.062 0.25 0.31 0.14 0.062 nd nd OR Quart3 37 nd 16 9.1 29 7.2 16 nd nd OR Quart 4 6.2 nd 2.0 3.6 2.0 2.5 3.0 nd nd p Value 0.094 nd 0.57 0.12 0.57 0.27 0.34 nd nd 95% CI of 0.73 nd 0.18 0.73 0.18 0.48 0.31 nd nd OR Quart4 52 nd 22 17 22 13 30 nd nd Complement factor H sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 9.38 6.86 9.38 5.31 9.38 8.96 Average 18.5 11.7 18.5 19.3 18.5 15.4 Stdev 37.6 15.9 37.6 35.9 37.6 18.0 p(t-test) 0.46 0.92 0.78 Min 0.0620 2.25 0.0620 1.61 0.0620 0.121 Max 772 70.6 772 142 772 59.2 n (Samp) 892 17 892 20 892 11 n (Patient) 370 17 370 20 370 11 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 9.32 20.2 9.32 13.3 Average nd nd 18.3 38.3 18.3 20.0 Stdev nd nd 37.2 48.1 37.2 19.2 p(t-test) nd nd 0.11 0.90 Min nd nd 0.0620 4.62 0.0620 2.52 Max nd nd 772 142 772 59.2 n (Samp) nd nd 922 9 922 8 n (Patient) nd nd 382 9 382 8 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 9.32 6.55 9.32 6.01 nd nd Average 18.1 15.4 18.1 9.37 nd nd Stdev 36.6 29.4 36.6 10.0 nd nd p(t-test) 0.81 0.36 nd nd Min 0.0620 2.25 0.0620 1.61 nd nd Max 772 98.7 772 35.1 nd nd n (Samp) 886 10 886 15 nd nd n (Patient) 345 10 345 15 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage 253 sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.42 nd 0.38 0.40 0.68 0.37 0.46 0.58 nd SE 0.073 nd 0.095 0.068 0.099 0.078 0.090 0.11 nd p 0.29 nd 0.21 0.15 0.077 0.084 0.63 0.48 nd nCohort 1 892 nd 886 892 922 886 892 922 nd nCohort 2 17 nd 10 20 9 15 11 8 nd Cutoff 1 6.04 nd 5.90 3.91 8.99 3.89 3.30 6.01 nd Sens 1 71% nd 70% 70% 78% 73% 73% 75% nd Spec 1 31% nd 30% 18% 49% 18% 14% 31% nd Cutoff 2 4.88 nd 4.76 3.28 6.57 3.28 2.83 5.33 nd Sens 2 82% nd 80% 80% 89% 80% 82% 88% nd Spec 2 24% nd 23% 14% 36% 14% 11% 27% nd Cutoff 3 2.60 nd 2.60 2.41 4.58 2.41 2.72 2.41 nd Sens 3 94% nd 90% 90% 100% 93% 91% 100% nd Spec 3 10% nd 10% 10% 23% 9% 11% 10% nd Cutoff 4 15.6 nd 15.4 15.6 15.4 15.4 15.6 15.4 nd Sens 4 12% nd 10% 25% 56% 20% 36% 50% nd Spec 4 70% nd 70% 70% 70% 70% 70% 70% nd Cutoff 5 22.2 nd 22.0 22.2 22.2 22.0 22.2 22.2 nd Sens 5 12% nd 10% 15% 33% 13% 27% 38% nd Spec 5 80% nd 80% 80% 80% 80% 80% 80% nd Cutoff 6 38.7 nd 37.8 38.7 37.8 37.8 38.7 37.8 nd Sens 6 6% nd 10% 10% 22% 0% 9% 12% nd Spec 6 90% nd 90% 90% 90% 90% 90% 90% nd OR Quart 2 1.0 nd 1.0 0.50 2.0 1.0 0.66 2.0 nd p Value 1.00 nd 1.0 0.42 0.57 1.00 0.66 0.57 nd 95% CI of 0.14 nd 0.062 0.090 0.18 0.14 0.11 0.18 nd OR Quart2 7.2 nd 16 2.7 22 7.2 4.0 22 nd OR Quart 3 4.7 nd 5.1 1.0 1.00 2.0 0.66 2.0 nd p Value 0.050 nd 0.14 1.0 1.00 0.42 0.66 0.57 nd 95% CI of 1.00 nd 0.59 0.25 0.062 0.37 0.11 0.18 nd OR Quart3 22 nd 44 4.0 16 11 4.0 22 nd OR Quart 4 2.0 nd 3.0 2.6 5.1 3.6 1.3 3.0 nd p Value 0.42 nd 0.34 0.12 0.14 0.11 0.70 0.34 nd 95% CI of 0.37 nd 0.31 0.79 0.59 0.74 0.30 0.31 nd OR Quart4 11 nd 29 8.3 44 18 6.1 29 nd Ciliary neurotrophic factor sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0325 0.000166 0.0325 0.267 0.0325 0.102 Average 0.216 0.156 0.216 0.233 0.216 0.143 Stdev 0.679 0.215 0.679 0.218 0.679 0.158 p(t-test) 0.75 0.92 0.76 Min 0.000103 0.000103 0.000103 0.000119 0.000103 0.000119 Max 14.0 0.657 14.0 0.778 14.0 0.397 n (Samp) 807 13 807 18 807 8 n (Patient) 298 13 298 18 298 8 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 0.0325 0.0194 nd nd Average nd nd 0.218 0.152 nd nd Stdev nd nd 0.674 0.195 nd nd 254 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) nd nd 0.77 nd nd Min nd nd 0.000103 0.000123 nd nd Max nd nd 14.0 0.521 nd nd n (Samp) nd nd 833 9 nd nd n (Patient) nd nd 309 9 nd nd UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0325 0.0175 0.0325 0.290 nd nd Average 0.209 0.176 0.209 0.250 nd nd Stdev 0.671 0.264 0.671 0.226 nd nd p(t-test) 0.90 0.83 nd nd Min 0.000103 0.000103 0.000103 0.000119 nd nd Max 14.0 0.657 14.0 0.778 nd nd n (Samp) 833 7 833 13 nd nd n (Patient) 292 7 292 13 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.50 nd 0.51 0.63 0.55 0.66 0.52 nd nd SE 0.081 nd 0.11 0.071 0.099 0.083 0.10 nd nd p 1.00 nd 0.92 0.065 0.63 0.056 0.82 nd nd nCohort 1 807 nd 833 807 833 833 807 nd nd nCohort 2 13 nd 7 18 9 13 8 nd nd Cutoff 1 0.000123 nd 0.000161 0.0175 0.000166 0.0175 0.000121 nd nd Sens 1 85% nd 71% 78% 78% 85% 88% nd nd Spec 1 27% nd 31% 44% 36% 45% 22% nd nd Cutoff 2 0.000123 nd 0.000123 0.000123 0.000123 0.0175 0.000121 nd nd Sens 2 85% nd 86% 83% 89% 85% 88% nd nd Spec 2 27% nd 27% 27% 27% 45% 22% nd nd Cutoff 3 0.000121 nd 0 0.000121 0.000121 0.000119 0.000118 nd nd Sens 3 92% nd 100% 94% 100% 92% 100% nd nd Spec 3 22% nd 0% 22% 22% 18% 11% nd nd Cutoff 4 0.229 nd 0.191 0.229 0.229 0.191 0.229 nd nd Sens 4 31% nd 29% 56% 33% 62% 25% nd nd Spec 4 72% nd 72% 72% 72% 72% 72% nd nd Cutoff 5 0.327 nd 0.290 0.327 0.327 0.290 0.327 nd nd Sens 5 23% nd 29% 28% 22% 46% 25% nd nd Spec 5 81% nd 80% 81% 81% 80% 81% nd nd Cutoff 6 0.459 nd 0.434 0.459 0.459 0.434 0.459 nd nd Sens 6 8% nd 14% 11% 11% 8% 0% nd nd Spec 6 91% nd 90% 91% 91% 90% 91% nd nd OR Quart 2 2.5 nd 3.0 1.0 >5.1 1.00 0.50 nd nd p Value 0.27 nd 0.34 1.0 <0.14 1.00 0.57 nd nd 95% CI of 0.49 nd 0.31 0.20 >0.59 0.14 0.045 nd nd OR Quart2 13 nd 29 5.0 na 7.1 5.5 nd nd OR Quart 3 1.0 nd 1.0 1.0 >1.0 0.50 1.5 nd nd p Value 1.0 nd 1.0 1.0 <1.00 0.57 0.66 nd nd 95% CI of 0.14 nd 0.062 0.20 >0.062 0.045 0.25 nd nd OR Quart3 7.2 nd 16 5.0 na 5.5 9.1 nd nd OR Quart 4 2.0 nd 2.0 3.1 >3.0 4.1 1.00 nd nd p Value 0.42 nd 0.57 0.096 <0.34 0.077 1.00 nd nd 95% CT of 0.37 nd 0.18 0.82 >0.31 0.86 0.14 nd nd 255 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO IsCr only UO only sCr or UO sCr only lUO only sCr or UO sCr only lUO only OR Quart4 11 nd 22 12 na 20 7.1 nd nd Follistatin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 7.39 15.8 7.39 14.8 7.39 12.0 Average 26.7 23.8 26.7 56.9 26.7 21.2 Stdev 225 20.6 225 169 225 28.8 p(t-test) 0.95 0.51 0.93 Min 0.000347 2.82 0.000347 0.0412 0.000347 0.0767 Max 8290 63.0 8290 840 8290 98.2 n (Samp) 1487 23 1487 24 1487 14 n (Patient) 518 23 518 24 518 14 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 7.79 15.8 7.79 11.1 7.79 26.6 Average 27.9 32.4 27.9 12.7 27.9 30.0 Stdev 223 39.1 223 8.34 223 30.9 p(t-test) 0.95 0.83 0.98 Min 0.000347 4.14 0.000347 0.299 0.000347 1.26 Max 8290 125 8290 28.6 8290 98.2 n (Samp) 1540 9 1540 10 1540 9 n (Patient) 534 9 534 10 534 9 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 7.38 18.9 7.38 21.8 7.38 20.9 Average 27.0 166 27.0 129 27.0 22.0 Stdev 232 532 232 322 232 24.0 p(t-test) 0.029 0.048 0.96 Min 0.000347 2.66 0.000347 0.0412 0.000347 0.0767 Max 8290 2010 8290 1300 8290 66.2 n (Samp) 1391 14 1391 21 1391 6 n (Patient) 444 14 444 21 444 6 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.68 0.70 0.69 0.64 0.58 0.75 0.50 0.65 0.58 SE 0.062 0.098 0.079 0.062 0.095 0.062 0.078 0.10 0.12 p 0.0044 0.042 0.017 0.019 0.39 4.2E-5 0.97 0.14 0.53 nCohort 1 1487 1540 1391 1487 1540 1391 1487 1540 1391 nCohort 2 23 9 14 24 10 21 14 9 6 Cutoff 1 6.24 12.0 9.70 9.60 9.60 12.2 1.26 3.83 1.02 Sens 1 74% 78% 71% 71% 70% 71% 71% 78% 83% Spec 1 44% 66% 60% 59% 58% 67% 11% 29% 9% Cutoff 2 5.79 5.45 5.79 4.95 9.36 9.60 0.820 3.36 1.02 Sens 2 83% 89% 86% 83% 80% 81% 86% 89% 83% Spec 2 42% 39% 42% 37% 57% 59% 9% 26% 9% Cutoff 3 .75 4.11 2.82 1.70 3.98 8.92 0.301 1.26 0.0615 Sens 3 91% 100% 93% 92% 90% 90% 93% 100% 100% 256 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Spec 3 36% 31% 23% 14% 30% 57% 6% 10% 4% Cutoff 4 13.6 14.4 13.7 13.6 14.4 13.7 13.6 14.4 13.7 Sens 4 57% 67% 57% 54% 40% 67% 50% 67% 67% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 21.8 23.1 21.7 21.8 23.1 21.7 21.8 23.1 21.7 Sens 5 43% 33% 50% 38% 10% 52% 36% 56% 33% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 42.7 45.0 42.3 42.7 45.0 42.3 42.7 45.0 42.3 Sens 6 22% 22% 29% 25% 0% 38% 14% 22% 17% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 6.1 >2.0 1.0 1.00 1.00 1.0 0 2.0 0 p Value 0.096 <0.57 1.0 1.00 1.00 1.0 na 0.57 na 95% CI of 0.73 >0.18 0.14 0.20 0.062 0.062 na 0.18 na OR Quart2 51 na 7.1 5.0 16 16 na 22 na OR Quart 3 6.1 >4.0 1.5 3.0 6.1 8.2 0.28 0 0 p Value 0.095 <0.21 0.66 0.097 0.095 0.048 0.12 na na 95% CI of 0.73 >0.45 0.25 0.82 0.73 1.0 0.058 na na OR Quart3 51 na 9.1 11 51 66 1.4 na na OR Quart 4 10 >3.0 3.5 3.0 2.0 11 0.71 6.1 2.0 p Value 0.027 <0.34 0.12 0.097 0.57 0.020 0.57 0.096 0.42 95% CI of 1.3 >0.31 0.73 0.82 0.18 1.5 0.22 0.73 0.36 OR Quart4 80 na 17 11 22 88 2.3 51 11 Vitamin D-binding protein sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 220 2710 220 968 220 10.2 Average 7580 54300 7580 2190 7580 49500 Stdev 34700 99900 34700 3120 34700 131000 p(t-test) 2.8E-5 0.52 0.0027 Min 0.259 5.93 0.259 52.6 0.259 0.337 Max 379000 283000 379000 11500 379000 347000 n (Samp) 684 11 684 17 684 7 n (Patient) 274 11 274 17 274 7 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 224 567 nd nd Average nd nd 7740 2250 nd nd Stdev nd nd 35100 3790 nd nd p(t-test) nd nd 0.64 nd nd Min nd nd 0.259 79.9 nd nd Max nd nd 379000 11000 nd nd n (Samp) nd nd 705 9 nd nd n (Patient) nd nd 284 9 nd nd UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 218 1530 218 1330 nd nd Average 8340 84500 8340 2940 nd nd Stdev 37200 131000 37200 3470 nd nd p(t-test) 1.9E-6 0.62 nd nd 257 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Min 0.200 5.93 0.200 31.9 nd nd M(ax 379000 283000 379000 11500 nd nd n (S amp) 703 6 703 12 nd nd n (Patient) 267 6 267 12 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.75 nd 0.64 0.64 0.59 0.69 0.21 nd nd SE 0.086 nd 0.12 0.073 0.10 0.086 0.10 nd nd p 0.0036 nd 0.24 0.056 0.38 0.031 0.0040 nd nd nCohort 1 684 nd 703 684 705 703 684 nd nd nCohort 2 11 nd 6 17 9 12 7 nd nd Cutoff 1 575 nd 143 190 112 467 0.892 nd nd Sens 1 73% nd 83% 71% 78% 75% 71% nd nd Spec 1 72% nd 39% 47% 33% 69% 1% nd nd Cutoff 2 284 nd 143 112 94.9 190 0.611 nd nd Sens 2 82% nd 83% 82% 89% 83% 86% nd nd Spec 2 58% nd 39% 33% 29% 47% 1% nd nd Cutoff 3 222 nd 5.82 79.5 79.5 80.8 0.333 nd nd Sens 3 91% nd 100% 94% 100% 92% 100% nd nd Spec 3 50% nd 4% 26% 26% 26% 0% nd nd Cutoff 4 477 nd 510 477 498 510 477 nd nd Sens 4 73% nd 50% 59% 56% 67% 14% nd nd Spec 4 70% nd 70% 70% 70% 70% 70% nd nd Cutoff 5 1310 nd 1500 1310 1490 1500 1310 nd nd Sens 5 55% nd 50% 35% 22% 42% 14% nd nd Spec 5 80% nd 80% 80% 80% 80% 80% nd nd Cutoff 6 10300 nd 12300 10300 10400 12300 10300 nd nd Sens 6 36% nd 33% 6% 11% 0% 14% nd nd Spec 6 90% nd 90% 90% 90% 90% 90% nd nd OR Quart 2 0.99 nd 1.0 5.1 >4.1 2.0 0 nd nd p Value 1.00 nd 1.0 0.14 <0.21 0.57 na nd nd 95% CI of 0.062 nd 0.062 0.59 >0.45 0.18 na nd nd OR Quart2 16 nd 16 44 na 22 na nd nd OR Quart 3 2.0 nd 1.0 2.0 >1.0 0.99 1.0 nd nd p Value 0.57 nd 1.0 0.57 <1.00 1.00 1.0 nd nd 95% CI of 0.18 nd 0.062 0.18 >0.062 0.062 0.062 nd nd OR Quart3 22 nd 16 22 na 16 16 nd nd OR Quart 4 7.2 nd 3.0 9.4 >4.1 8.3 5.1 nd nd p Value 0.066 nd 0.34 0.035 <0.21 0.047 0.14 nd nd 95% CI of 0.88 nd 0.31 1.2 >0.45 1.0 0.60 nd nd OR Quart4 59 nd 29 75 na 67 45 nd nd Glucagon sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 238 9330 238 20.5 nd nd Average 1840 5460 1840 1900 nd nd Stdev 3210 4830 3210 3920 nd nd p(t-test) 0.0037 0.95 nd nd Min 0.0247 174 0.0247 4.85 nd nd Max 9330 9330 9330 9330 nd nd 258 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 n (Samp) 331 7 331 10 nd nd n (Patient) 191 7 191 10 nd nd UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 238 27.4 nd nd Average nd nd 1660 2370 nd nd Stdev nd nd 3020 4300 nd nd p(t-test) nd nd 0.51 nd nd Min nd nd 0.0247 4.85 nd nd Max nd nd 9330 9330 nd nd n (Samp) nd nd 289 8 nd nd n (Patient) nd nd 160 8 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.75 nd nd 0.36 nd 0.39 nd nd nd SE 0.11 nd nd 0.096 nd 0.11 nd nd nd p 0.018 nd nd 0.15 nd 0.32 nd nd nd nCohort 1 331 nd nd 331 nd 289 nd nd nd nCohort 2 7 nd nd 10 nd 8 nd nd nd Cutoff 1 275 nd nd 8.98 nd 8.64 nd nd nd Sens 1 86% nd nd 70% nd 75% nd nd nd Spec 1 53% nd nd 21% nd 20% nd nd nd Cutoff 2 275 nd nd 8.64 nd 5.82 nd nd nd Sens 2 86% nd nd 80% nd 88% nd nd nd Spec 2 53% nd nd 20% nd 9% nd nd nd Cutoff 3 174 nd nd 5.82 nd 4.46 nd nd nd Sens 3 100% nd nd 90% nd 100% nd nd nd Spec 3 34% nd nd 9% nd 6% nd nd nd Cutoff 4 347 nd nd 347 nd 347 nd nd nd Sens 4 57% nd nd 20% nd 25% nd nd nd Spec 4 70% nd nd 70% nd 72% nd nd nd Cutoff 5 2420 nd nd 2420 nd 2420 nd nd nd Sens 5 57% nd nd 20% nd 25% nd nd nd Spec 5 85% nd nd 85% nd 87% nd nd nd Cutoff 6 9330 nd nd 9330 nd 9330 nd nd nd Sens 6 0% nd nd 0% nd 0% nd nd nd Spec 6 100% nd nd 100% nd 100% nd nd nd OR Quart 2 >1.0 nd nd 0 nd 0 nd nd nd p Value <1.0 nd nd na nd na nd nd nd 95% CI of >0.062 nd nd na nd na nd nd nd OR Quart2 na nd nd na nd na nd nd nd OR Quart 3 >2.0 nd nd 1.5 nd 1.0 nd nd nd p Value <0.56 nd nd 0.64 nd 0.99 nd nd nd 95% CI of >0.18 nd nd 0.25 nd 0.14 nd nd nd OR Quart3 na nd nd 9.4 nd 7.4 nd nd nd OR Quart 4 >4.1 nd nd 2.6 nd 2.1 nd nd nd p Value <0.21 nd nd 0.26 nd 0.40 nd nd nd 95% CI of >0.45 nd nd 0.50 nd 0.37 nd nd nd OR Quart4 na nd nd 14 nd 12 nd nd nd 259 Glucagon-like peptide 1 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 3.10 5.53 3.10 5.53 nd nd Average 8.40 4.22 8.40 17.9 nd nd Stdev 40.0 3.67 40.0 32.1 nd nd p(t-test) 0.78 0.46 nd nd Min 0.407 0.407 0.407 0.685 nd nd Max 519 9.39 519 107 nd nd n (Samp) 331 7 331 10 nd nd n (Patient) 191 7 191 10 nd nd UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 3.10 7.57 nd nd Average nd nd 8.83 21.3 nd nd Stdev nd nd 42.7 35.5 nd nd p(t-test) nd nd 0.41 nd nd Min nd nd 0.407 0.685 nd nd Max nd nd 519 107 nd nd n (Samp) nd nd 289 8 nd nd n (Patient) nd nd 160 8 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.45 nd nd 0.70 nd 0.74 nd nd nd SE 0.11 nd nd 0.094 nd 0.10 nd nd nd p 0.67 nd nd 0.038 nd 0.018 nd nd nd nCohort 1 331 nd nd 331 nd 289 nd nd nd nCohort 2 7 nd nd 10 nd 8 nd nd nd Cutoff 1 0.407 nd nd 5.14 nd 5.14 nd nd nd Sens 1 71% nd nd 80% nd 88% nd nd nd Spec 1 14% nd nd 56% nd 58% nd nd nd Cutoff 2 0 nd nd 5.14 nd 5.14 nd nd nd Sens 2 100% nd nd 80% nd 88% nd nd nd Spec 2 0% nd nd 56% nd 58% nd nd nd Cutoff 3 0 nd nd 2.30 nd 0.407 nd nd nd Sens 3 100% nd nd 90% nd 100% nd nd nd Spec 3 0% nd nd 36% nd 16% nd nd nd Cutoff 4 5.53 nd nd 5.53 nd 5.53 nd nd nd Sens 4 43% nd nd 40% nd 50% nd nd nd Spec 4 71% nd nd 71% nd 72% nd nd nd Cutoff 5 9.60 nd nd 9.60 nd 9.60 nd nd nd Sens 5 0% nd nd 30% nd 38% nd nd nd Spec 5 94% nd nd 94% nd 94% nd nd nd Cutoff 6 9.60 nd nd 9.60 nd 9.60 nd nd nd Sens 6 0% nd nd 30% nd 38% nd nd nd Spec 6 94% nd nd 94% nd 94% nd nd nd OR Quart 2 3.1 nd nd 1.0 nd 0 nd nd nd p Value 0.33 nd nd 1.0 nd na nd nd nd 95% CI of 0.32 nd nd 0.062 nd na nd nd nd OR Quart2 31 nd nd 16 nd na nd nd nd OR Quart 3 0 nd nd 4.1 nd 3.1 nd nd nd p Value na nd nd 0.21 nd 0.33 nd nd nd 260 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only 95% CI of na nd nd 0.45 nd 0.31 nd nd nd OR Quart3 na nd nd 38 nd 30 nd nd nd OR Quart 4 3.1 nd nd 4.1 nd 4.1 nd nd nd p Value 0.33 nd nd 0.21 nd 0.21 nd nd nd 95% CI of 0.32 nd nd 0.45 nd 0.45 nd nd nd OR Quart4 31 nd nd 37 nd 38 nd nd nd Interleukin-17A sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.00337 0.00492 0.00337 0.00409 0.00337 0.00348 Average 0.945 1.06 0.945 0.859 0.945 0.332 Stdev 7.23 3.01 7.23 2.96 7.23 0.952 p(t-test) 0.93 0.95 0.72 Min 0.000344 0.000381 0.000344 0.000381 0.000344 0.000521 Max 157 12.5 157 13.0 157 4.03 n (Samp) 1925 33 1925 29 1925 18 n (Patient) 639 33 639 29 639 18 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.00360 0.00337 0.00360 0.00492 0.00360 0.00190 Average 0.963 0.0491 0.963 0.162 0.963 0.145 Stdev 7.10 0.104 7.10 0.278 7.10 0.284 p(t-test) 0.64 0.71 0.70 Min 0.000344 0.000344 0.000344 0.000381 0.000344 0.000521 Max 157 0.363 157 0.710 157 0.814 n (Samp) 2013 13 2013 11 2013 11 n (Patient) 660 13 660 11 660 11 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.00337 0.00847 0.00337 0.00427 0.00337 0.00360 Average 0.926 3.25 0.926 2.45 0.926 0.0596 Stdev 7.22 8.12 7.22 5.23 7.22 0.111 p(t-test) 0.14 0.28 0.72 Min 0.000344 0.000603 0.000344 0.000380 0.000344 0.000763 Max 157 33.1 157 18.8 157 0.292 n (Samp) 1825 21 1825 26 1825 9 n (Patient) 561 21 561 26 561 9 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.57 0.46 0.62 0.51 0.45 0.57 0.50 0.41 0.57 SE 0.052 0.082 0.066 0.054 0.089 0.059 0.069 0.091 0.100 p 0.17 0.63 0.064 0.83 0.61 0.21 0.95 0.32 0.47 nCohort 1 1925 2013 1825 1925 2013 1825 1925 2013 1825 nCohort 2 33 13 21 29 11 26 18 11 9 Cutoff 1 0.00190 0.000662 0.00190 0.00221 0.000597 0.00263 0.00190 0.000603 0.00322 Sens 1 73% 77% 76% 72% 73% 73% 72% 73% 78% Spec 1 32% 18% 34% 36% 11% 0% 32% 14% 7% 261 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Cutoff 2 0.000662 0.000380 0.00182 0.000410 0.000410 0.000747 0.000603 0.000597 0.00221 Sens 2 85% 92% 81% 86% 82% 81% 83% 82% 89% Spec 2 18% 4% 32% 7% 7% 25% 14% 11% 38% Cutoff 3 0.000597 0.000380 0.000662 0.000380 0.000380 0.000380 0.000410 0.000410 0.000747 Sens 3 91% 92% 90% 100% 100% 96% 100% 100% 100% Spec 3 12% 4% 20% 4% 4% 4% 7% 7% 25% Cutoff 4 0.00875 0.00988 0.00875 0.00875 0.00988 0.00875 0.00875 0.00988 0.00875 Sens 4 45% 31% 48% 28% 27% 35% 28% 27% 22% Spec 4 70% 71% 70% 70% 71% 70% 70% 71% 70% Cutoff 5 0.152 0.160 0.155 0.152 0.160 0.155 0.152 0.160 0.155 Sens 5 27% 8% 38% 21% 27% 31% 28% 27% 22% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 0.830 0.950 0.855 0.830 0.950 0.855 0.830 0.950 0.855 Sens 6 15% 0% 24% 7% 0% 19% 6% 0% 0% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 0.71 0.50 0.75 0.49 1.0 1.00 0.80 0 >3.0 p Value 0.56 0.42 0.70 0.25 1.0 1.00 0.74 na <0.34 95% CI of 0.22 0.091 0.17 0.15 0.20 0.29 0.21 na >0.31 OR Quart2 2.3 2.7 3.4 1.7 5.0 3.5 3.0 na na OR Quart 3 1.1 0.75 1.3 1.3 0 1.4 0.80 1.3 >4.0 p Value 0.79 0.71 0.74 0.63 na 0.57 0.74 0.71 <0.21 95% CI of 0.41 0.17 0.33 0.49 na 0.44 0.21 0.30 >0.45 OR Quart3 3.2 3.4 4.7 3.2 na 4.5 3.0 6.0 na OR Quart 4 1.9 1.0 2.3 0.87 1.7 1.8 1.00 1.3 >2.0 p Value 0.18 1.00 0.18 0.79 0.48 0.29 1.00 0.71 <0.57 95% CI of 0.74 0.25 0.69 0.31 0.40 0.60 0.29 0.30 >0.18 OR Quart4 4.7 .0 7.4 2.4 7.0 5.4 3.5 6.0 na Insulin receptor substrate 1 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.78E-5 0.00148 2.78E-5 0.00243 2.78E-5 0.000546 Average 0.00276 0.00234 0.00276 0.0183 0.00276 0.000975 Stdev 0.0271 0.00292 0.0271 0.0658 0.0271 0.00130 p(t-test) 0.96 0.022 0.85 Min 1.25E-9 1.25E-9 1.25E-9 7.25E-7 1.25E-9 2.32E-6 Max 0.735 0.00914 0.735 0.282 0.735 0.00334 n (Samp) 805 13 805 18 805 8 n (Patient) 298 13 298 18 298 8 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 2.78E-5 0.00224 nd nd Average nd nd 0.00308 0.00172 nd nd Stdev nd nd 0.0283 0.00156 nd nd p(t-test) nd nd 0.89 nd nd Min nd nd 1.25E-9 7.25E-7 nd nd Max nd nd 0.735 0.00456 nd nd n (Samp) nd nd 831 9 nd nd n (Patient) nd nd 309 9 nd nd IJO only Ohr prior to AKT stage 24hr prior to AKT stage 48hr prior to AKT stage 262 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.78E-5 1.50E-6 2.78E-5 0.00243 nd nd Average 0.00271 0.000980 0.00271 0.0245 nd nd Stdev 0.0266 0.00180 0.0266 0.0774 nd nd p(t-test) 0.86 0.0055 nd nd Min 1.25E-9 1.25E-9 1.25E-9 7.25E-7 nd nd Max 0.735 0.00456 0.735 0.282 nd nd n (Samp) 831 7 831 13 nd nd n (Patient) 292 7 292 13 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.55 nd 0.33 0.72 0.63 0.69 0.57 nd nd SE 0.083 nd 0.11 0.069 0.10 0.082 0.11 nd nd p 0.54 nd 0.14 0.0012 0.19 0.021 0.49 nd nd nCohort 1 805 nd 831 805 831 831 805 nd nd nCohort 2 13 nd 7 18 9 13 8 nd nd Cutoff 1 1.25E-9 nd 0 0.00101 3.73E-6 2.78E-5 3.73E-6 nd nd Sens 1 85% nd 100% 72% 78% 77% 88% nd nd Spec 1 7% nd 0% 64% 34% 52% 34% nd nd Cutoff 2 1.25E-9 nd 0 3.73E-6 1.78E-6 3.73E-6 3.73E-6 nd nd Sens 2 85% nd 100% 89% 89% 85% 88% nd nd Spec 2 7% nd 0% 34% 27% 34% 34% nd nd Cutoff 3 0 nd 0 1.25E-9 1.25E-9 1.25E-9 1.78E-6 nd nd Sens 3 100% nd 100% 100% 100% 100% 100% nd nd Spec 3 0% nd 0% 7% 7% 7% 27% nd nd Cutoff 4 0.00110 nd 0.00110 0.00110 0.00110 0.00110 0.00110 nd nd Sens 4 54% nd 29% 67% 56% 62% 25% nd nd Spec 4 71% nd 71% 71% 70% 71% 71% nd nd Cutoff 5 0.00229 nd 0.00229 0.00229 0.00229 0.00229 0.00229 nd nd Sens 5 38% nd 14% 67% 44% 62% 25% nd nd Spec 5 82% nd 82% 82% 81% 82% 82% nd nd Cutoff 6 0.00281 nd 0.00281 0.00281 0.00281 0.00281 0.00281 nd nd Sens 6 31% nd 14% 22% 11% 31% 12% nd nd Spec 6 92% nd 91% 92% 91% 91% 92% nd nd OR Quart 2 0.49 nd 0 1.00 2.0 0.50 >3.0 nd nd p Value 0.42 nd na 1.00 0.57 0.57 <0.34 nd nd 95% CI of 0.089 nd na 0.14 0.18 0.045 >0.31 nd nd OR Quart2 2.7 nd na 7.1 22 5.5 na nd nd OR Quart 3 0.25 nd 0.50 1.00 2.0 1.0 >3.0 nd nd p Value 0.21 nd 0.57 1.00 0.57 1.0 <0.34 nd nd 95% CI of 0.027 nd 0.045 0.14 0.18 0.14 >0.31 nd nd OR Quart3 2.2 nd 5.5 7.1 22 7.2 na nd nd OR Quart 4 1.5 nd 2.0 6.3 4.1 4.1 >2.0 nd nd p Value 0.53 nd 0.42 0.017 0.21 0.076 <0.57 nd nd 95% CI of 0.42 nd 0.37 1.4 0.45 0.86 >0.18 nd nd OR Quart4 5.4 nd 11 28 37 20 na nd nd Involucrin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.499 0.604 0.499 1.15 0.499 0.420 Average 1.33 2.11 1.33 2.58 1.33 0.526 Stdev 3.76 2.84 3.76 4.14 3.76 0.521 263 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) 0.32 0.099 0.41 Min 0.00244 0.0767 0.00244 0.151 0.00244 0.0268 Max 102 9.05 102 17.0 102 2.13 n (Samp) 1363 23 1363 25 1363 15 n (Patient) 521 23 521 25 521 15 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.508 0.380 0.508 0.473 0.508 0.696 Average 1.38 0.646 1.38 1.18 1.38 2.51 Stdev 3.78 0.786 3.78 1.46 3.78 4.63 p(t-test) 0.61 0.87 0.37 Min 0.00244 0.0767 0.00244 0.193 0.00244 0.119 Max 102 2.34 102 4.04 102 14.5 n (Samp) 1407 7 1407 10 1407 9 n (Patient) 536 7 536 10 536 9 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.507 1.43 0.507 1.36 0.507 0.528 Average 1.35 2.91 1.35 3.09 1.35 0.481 Stdev 3.85 3.15 3.85 4.51 3.85 0.296 p(t-test) 0.12 0.036 0.55 Min 0.00244 0.144 0.00244 0.124 0.00244 0.0268 Max 102 9.05 102 17.0 102 0.811 n (Samp) 1287 15 1287 22 1287 7 n (Patient) 448 15 448 22 448 7 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.59 0.42 0.68 0.69 0.53 0.68 0.41 0.55 0.42 SE 0.063 0.11 0.077 0.059 0.093 0.063 0.078 0.099 0.11 p 0.14 0.46 0.020 0.0014 0.71 0.0036 0.25 0.58 0.50 nCohort 1 1363 1407 1287 1363 1407 1287 1363 1407 1287 nCohort 2 23 7 15 25 10 22 15 9 7 Cutoff 1 0.380 0.234 0.502 0.683 0.357 0.591 0.178 0.255 0.419 Sens 1 74% 71% 73% 72% 70% 73% 73% 78% 71% Spec 1 41% 26% 49% 60% 38% 55% 21% 29% 43% Cutoff 2 0.357 0.142 0.398 0.485 0.230 0.457 0.162 0.178 0.162 Sens 2 83% 86% 80% 80% 80% 82% 80% 89% 86% Spec 2 39% 15% 42% 49% 26% 46% 18% 20% 17% Cutoff 3 0.234 0.0763 0.273 0.225 0.225 0.225 0.0270 0.118 0.0265 Sens 3 91% 100% 93% 92% 90% 91% 93% 100% 100% Spec 3 27% 6% 30% 26% 26% 25% 1% 12% 1% Cutoff 4 0.979 1.00 1.00 0.979 1.00 1.00 0.979 1.00 1.00 Sens 4 35% 14% 53% 60% 30% 55% 7% 33% 0% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 1.56 1.59 1.57 1.56 1.59 1.57 1.56 1.59 1.57 Sens 5 30% 14% 47% 36% 20% 41% 7% 33% 0% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 2.88 2.99 2.90 2.88 2.99 2.90 2.88 2.99 2.90 Sens 6 22% 0% 33% 20% 20% 27% 0% 22% 0% 264 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 3.5 2.0 4.0 2.0 5.1 1.0 6.1 1.0 >4.1 p Value 0.12 0.57 0.21 0.42 0.14 1.0 0.095 1.0 <0.21 95% CI of 0.73 0.18 0.45 0.37 0.59 0.20 0.73 0.14 >0.45 OR Quart2 17 22 36 11 44 5.0 51 7.1 na OR Quart 3 3.0 2.0 2.0 3.6 2.0 1.3 3.0 1.0 >1.0 p Value 0.18 0.57 0.57 0.12 0.57 0.70 0.34 1.0 <1.00 95% CI of 0.61 0.18 0.18 0.73 0.18 0.30 0.31 0.14 >0.062 OR Quart3 15 22 22 17 22 6.0 29 7.1 na OR Quart 4 4.1 2.0 8.2 6.2 2.0 4.1 5.1 1.5 >2.0 p Value 0.078 0.57 0.049 0.018 0.57 0.030 0.14 0.66 <0.57 95% CI of 0.86 0.18 1.0 1.4 0.18 1.1 0.59 0.25 >0.18 OR Quart4 19 22 66 28 22 15 44 9.1 na Keratin, type II cytoskeletal 1; type cytoskeletal 10 (Keratin-1,-10 mix) sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0174 0.00790 0.0174 0.0502 0.0174 0.0174 Average 2.77 0.269 2.77 13.3 2.77 0.839 Stdev 14.5 0.884 14.5 61.6 14.5 1.30 p(t-test) 0.41 0.0016 0.61 Min 0.000410 0.000410 0.000410 0.000410 0.000410 0.000410 Max 367 3.62 367 309 367 4.35 n (Samp) 1363 23 1363 25 1363 15 n (Patient) 521 23 521 25 521 15 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0174 0.00432 0.0174 0.0502 0.0174 0.0174 Average 2.95 0.00582 2.95 1.77 2.95 0.749 Stdev 16.4 0.00474 16.4 2.44 16.4 1.02 p(t-test) 0.64 0.82 0.69 Min 0.000410 0.000410 0.000410 0.00694 0.000410 0.000410 Max 367 0.0113 367 6.14 367 2.40 n (Samp) 1407 7 1407 10 1407 9 n (Patient) 536 7 536 10 536 9 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0174 0.00694 0.0174 0.0174 0.0174 0.0153 Average 2.43 3.15 2.43 15.2 2.43 0.825 Stdev 10.7 10.8 10.7 65.6 10.7 1.64 p(t-test) 0.79 liE-5 0.69 Min 0.000410 0.000410 0.000410 0.000410 0.000410 0.000410 Max 217 42.0 217 309 217 4.35 n (Samp) 1287 15 1287 22 1287 7 n (Patient) 448 15 448 22 448 7 IOhr prior to AKI stage 124hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO IsCr only UO only sCr or UO sCr only UO only 265 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.30 0.21 0.33 0.54 0.62 0.51 0.47 0.43 0.38 SE 0.062 0.10 0.077 0.059 0.095 0.062 0.076 0.100 0.11 p 9.5E-4 0.0056 0.023 0.52 0.21 0.90 0.74 0.49 0.31 nCohort 1 1363 1407 1287 1363 1407 1287 1363 1407 1287 nCohort 2 23 7 15 25 10 22 15 9 7 Cutoff 1 0.00380 0.00380 0.00408 0.00926 0.0128 0.00892 0.00787 0 0.00303 Sens 1 74% 71% 73% 76% 70% 73% 73% 100% 71% Spec 1 11% 11% 12% 40% 45% 36% 33% 0% 10% Cutoff 2 0 0 0 0.00694 0.00926 0.00562 0.00380 0 0 Sens 2 100% 100% 100% 80% 90% 82% 80% 100% 100% Spec 2 0% 0% 0% 30% 40% 26% 11% 0% 0% Cutoff 3 0 0 0 0.000693 0.00926 0.000693 0 0 0 Sens 3 100% 100% 100% 92% 90% 91% 100% 100% 100% Spec 3 0% 0% 0% 6% 40% 6% 0% 0% 0% Cutoff 4 1.21 1.21 1.39 1.21 1.21 1.39 1.21 1.21 1.39 Sens 4 9% 0% 13% 28% 40% 23% 27% 22% 14% Spec 4 70% 70% 72% 70% 70% 72% 70% 70% 72% Cutoff 5 2.40 2.40 2.40 2.40 2.40 2.40 2.40 2.40 2.40 Sens 5 4% 0% 13% 16% 30% 18% 7% 0% 14% Spec 5 80% 80% 80% 80% 80% 80% 80% 80% 80% Cutoff 6 5.19 5.20 4.71 5.19 5.20 4.71 5.19 5.20 4.71 Sens 6 0% 0% 13% 4% 10% 14% 0% 0% 0% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 0.50 >0 0 2.0 >4.0 1.8 1.7 1.0 1.0 p Value 0.57 <na na 0.25 <0.21 0.37 0.48 1.0 1.00 95% CI of 0.045 >na na 0.60 >0.45 0.51 0.40 0.14 0.062 OR Quart2 5.5 na na 6.8 na 6.1 7.1 7.1 16 OR Quart 3 5.6 >3.0 4.1 1.5 >2.0 1.5 1.0 1.0 2.0 p Value 0.025 <0.34 0.077 0.53 <0.57 0.53 1.0 1.0 0.57 95% CI of 1.2 >0.31 0.86 0.42 >0.18 0.42 0.20 0.14 0.18 OR Quart3 26 na 19 5.4 na 5.4 5.0 7.1 22 OR Quart 4 4.6 >4.1 2.5 1.8 >4.0 1.2 1.3 1.5 3.0 p Value 0.052 <0.21 0.27 0.37 <0.21 0.74 0.70 0.66 0.34 95% CI of 0.99 >0.45 0.49 0.51 >0.45 0.33 0.30 0.25 0.31 OR Quart4 21 na 13 6.1 na .7 6.0 9.1 29 Lipopolysaccharide (serotypes -K,-O) sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.53E-5 9.72E-5 2.53E-5 9.77E-5 2.53E-5 9.77E-5 Average 0.115 0.0760 0.115 0.0268 0.115 0.00189 Stdev 0.634 0.241 0.634 0.116 0.634 0.00425 p(t-test) 0.77 0.49 0.49 Min 1.40E-8 1.14E-5 1.40E-8 4.54E-6 1.40E-8 6.10E-6 Max 6.42 1.04 6.42 0.579 6.42 0.0162 n (Samp) 1363 23 1363 25 1363 15 n (Patient) 521 23 521 25 521 15 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.53E-5 1.85E-5 2.53E-5 9.74E-5 2.53E-5 9.72E-5 Average 0.119 0.152 0.119 0.00587 0.119 0.00144 266 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Stdev 0.641 0.394 0.641 0.0149 0.641 0.00346 p(t-test) 0.89 0.58 0.58 Min 1.40E-8 1.18E-5 1.40E-8 1.18E-5 1.40E-8 6.10E-6 Max 6.42 1.04 6.42 0.0478 6.42 0.0105 n (Samp) 1407 7 1407 10 1407 9 n (Patient) 536 7 536 10 536 9 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.53E-5 0.00215 2.53E-5 0.000150 2.53E-5 0.00160 Average 0.0998 0.318 0.0998 0.278 0.0998 0.00367 Stdev 0.584 0.830 0.584 0.815 0.584 0.00588 p(t-test) 0.15 0.16 0.66 Min 1.40E-8 1.14E-5 1.40E-8 4.54E-6 1.40E-8 6.10E-6 Max 6.40 2.77 6.40 3.10 6.40 0.0162 n (Samp) 1287 15 1287 22 1287 7 n (Patient) 448 15 448 22 448 7 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.58 0.57 0.64 0.51 0.55 0.57 0.51 0.45 0.54 SE 0.063 0.11 0.078 0.059 0.094 0.064 0.075 0.099 0.11 p 0.18 0.55 0.077 0.81 0.61 0.31 0.92 0.64 0.70 nCohort 1 1363 1407 1287 1363 1407 1287 1363 1407 1287 nCohort 2 23 7 15 25 10 22 15 9 7 Cutoff 1 1.57E-5 1.57E-5 1.80E-5 1.48E-5 1.65E-5 1.49E-5 1.49E-5 1.14E-5 1.65E-5 Sens 1 74% 71% 73% 76% 70% 77% 73% 89% 71% Spec 1 38% 37% 44% 32% 40% 36% 34% 19% 42% Cutoff 2 1.48E-5 1.48E-5 1.57E-5 1.14E-5 1.48E-5 1.48E-5 1.14E-5 1.14E-5 1.14E-5 Sens 2 87% 86% 80% 88% 90% 82% 93% 89% 86% Spec 2 32% 31% 38% 20% 31% 32% 20% 19% 19% Cutoff 3 1.38E-5 1.14E-5 1.38E-5 5.32E-6 1.48E-5 5.32E-6 1.14E-5 5.32E-6 5.32E-6 Sens 3 91% 100% 93% 96% 90% 95% 93% 100% 100% Spec 3 28% 19% 29% 4% 31% 4% 20% 4% 4% Cutoff 4 0.00160 0.00196 0.00159 0.00160 0.00196 0.00159 0.00160 0.00196 0.00159 Sens 4 43% 43% 53% 32% 40% 36% 27% 22% 57% Spec 4 70% 70% 70% 70% 70% 70% 70% 70% 70% Cutoff 5 0.00755 0.00766 0.00671 0.00755 0.00766 0.00671 0.00755 0.00766 0.00671 Sens 5 22% 29% 33% 16% 10% 23% 7% 11% 14% Spec 5 80% 81% 80% 80% 81% 80% 80% 81% 80% Cutoff 6 0.0331 0.0381 0.0289 0.0331 0.0381 0.0289 0.0331 0.0381 0.0289 Sens 6 13% 14% 20% 8% 10% 14% 0% 0% 0% Spec 6 90% 90% 90% 90% 90% 90% 90% 90% 90% OR Quart 2 4.6 3.0 5.0 0.83 3.0 1.3 0.50 4.0 0.50 p Value 0.053 0.34 0.14 0.76 0.34 0.74 0.42 0.21 0.57 95% CI of 0.98 0.31 0.59 0.25 0.31 0.33 0.090 0.45 0.045 OR Quart2 21 29 43 2.7 29 4.7 2.7 36 5.5 OR Quart 3 2.0 0 2.0 1.3 4.0 1.5 1.8 1.0 1.0 p Value 0.42 na 0.57 0.59 0.21 0.53 0.37 1.0 1.0 95% CI of 0.37 na 0.18 0.46 0.45 0.42 0.51 0.062 0.14 OR Quart3 11 na 22 3.9 36 5.4 6.1 16 7.1 OR Quart 4 4.1 3.0 7.1 1.0 2.0 1.8 0.50 3.0 1.00 p Value 0.078 0.34 0.067 1.0 0.57 0.37 0.42 0.34 1.00 267 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only 95% CI of 0.86 0.31 0.87 0.32 0.18 0.51 0.090 0.31 0.14 OR Quart4 19 29 58 3.1 22 16.1 2.7 29 7.1 Collagenase 3 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 3.12 0.202 3.12 0.230 3.12 1.55 Average 12.7 14.8 12.7 9.77 12.7 7.58 Stdev 25.8 24.4 25.8 16.5 25.8 12.3 p(t-test) 0.79 0.64 0.60 Min 0.00479 0.00479 0.00479 0.00479 0.00479 0.00588 Max 340 70.5 340 55.0 340 32.7 n (Samp) 687 11 687 17 687 7 n (Patient) 275 11 275 17 275 7 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 3.10 7.51 nd nd Average nd nd 12.5 20.3 nd nd Stdev nd nd 25.5 25.2 nd nd p(t-test) nd nd 0.36 nd nd Min nd nd 0.00479 0.202 nd nd Max nd nd 340 58.5 nd nd n (Samp) nd nd 708 9 nd nd n (Patient) nd nd 285 9 nd nd UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 3.54 0.0149 3.54 0.718 nd nd Average 13.3 4.01 13.3 7.31 nd nd Stdev 26.0 7.38 26.0 12.9 nd nd p(t-test) 0.38 0.42 nd nd Min 0.00479 0.00479 0.00479 0.00479 nd nd Max 340 18.4 340 41.9 nd nd n (Samp) 706 6 706 12 nd nd n (Patient) 268 6 268 12 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.42 nd 0.29 0.49 0.63 0.46 0.48 nd nd SE 0.091 nd 0.12 0.071 0.10 0.086 0.11 nd nd p 0.35 nd 0.078 0.92 0.18 0.61 0.85 nd nd nCohort 1 687 nd 706 687 708 706 687 nd nd nCohort 2 11 nd 6 17 9 12 7 nd nd Cutoff 1 0.00479 nd 0.00479 0.0466 0.202 0.0466 1.39 nd nd Sens 1 73% nd 83% 88% 78% 92% 71% nd nd Spec 1 2% nd 3% 29% 37% 29% 46% nd nd Cutoff 2 0 nd 0.00479 0.0466 0.0466 0.0466 0.0425 nd nd Sens 2 100% nd 83% 88% 100% 92% 86% nd nd Spec 2 0% nd 3% 29% 29% 29% 27% nd nd Cutoff 3 0 nd 0 0.0200 0.0466 0.0466 0.00519 nd nd 268 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 3 100% nd 100% 94% 100% 92% 100% nd nd Spec 3 0% nd 0% 23% 29% 29% 5% nd nd Cutoff 4 13.0 nd 13.5 13.0 12.3 13.5 13.0 nd nd Sens 4 36% nd 17% 24% 44% 17% 29% nd nd Spec 4 71% nd 70% 71% 70% 70% 71% nd nd Cutoff 5 20.9 nd 22.4 20.9 20.4 22.4 20.9 nd nd Sens 5 18% nd 0% 18% 33% 17% 14% nd nd Spec 5 80% nd 80% 80% 80% 80% 80% nd nd Cutoff 6 35.5 nd 38.2 35.5 34.2 38.2 35.5 nd nd Sens 6 18% nd 0% 12% 33% 8% 0% nd nd Spec 6 90% nd 90% 90% 90% 90% 90% nd nd OR Quart 2 0 nd 1.0 1.3 >4.1 1.0 1.0 nd nd p Value na nd 1.0 0.70 <0.21 1.00 1.00 nd nd 95% CI of na nd 0.062 0.30 >0.45 0.14 0.062 nd nd OR Quart2 na nd 16 6.1 na 7.2 16 nd nd OR Quart 3 0.49 nd 0 3.1 >2.0 3.6 4.1 nd nd p Value 0.42 nd na 0.093 <0.57 0.11 0.21 nd nd 95% CI of 0.089 nd na 0.83 >0.18 0.74 0.45 nd nd OR Quart3 2.7 nd na 12 na 18 37 nd nd OR Quart 4 1.3 nd 4.1 0.33 >3.0 0.50 1.0 nd nd p Value 0.73 nd 0.21 0.34 <0.34 0.57 1.00 nd nd 95% CI of 0.33 nd 0.45 0.034 >0.31 0.045 0.062 nd nd OR Quart4 4.8 nd 37 3.2 na 5.6 16 nd nd NF-kappa-B inhibitor alpha sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.000108 0.000422 0.000108 0.000127 0.000108 1.06E-6 Average 0.00508 0.0131 0.00508 0.00193 0.00508 0.000344 Stdev 0.0267 0.0266 0.0267 0.00423 0.0267 0.000884 p(t-test) 0.28 0.62 0.62 Min 3.52E-7 3.52E-7 3.52E-7 9.58E-7 3.52E-7 5.23E-7 Max 0.326 0.0725 0.326 0.0159 0.326 0.00252 n (Samp) 805 13 805 18 805 8 n (Patient) 298 13 298 18 298 8 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 0.000108 3.20E-5 nd nd Average nd nd 0.00556 0.000260 nd nd Stdev nd nd 0.0281 0.000443 nd nd p(t-test) nd nd 0.57 nd nd Min nd nd 3.52E-7 5.23E-7 nd nd Max nd nd 0.326 0.00125 nd nd n (Samp) nd nd 831 9 nd nd n (Patient) nd nd 309 9 nd nd UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.000108 0.000422 0.000108 0.000566 nd nd Average 0.00503 0.00828 0.00503 0.0224 nd nd Stdev 0.0264 0.0208 0.0264 0.0707 nd nd 269 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) 0.75 0.025 nd nd Min 3.52E-7 3.52E-7 3.52E-7 2.25E-5 nd nd Max 0.326 0.0554 0.326 0.257 nd nd n (Samp) 831 7 831 13 nd nd n (Patient) 292 7 292 13 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.60 nd 0.55 0.58 0.47 0.70 0.37 nd nd SE 0.084 nd 0.11 0.071 0.098 0.082 0.11 nd nd p 0.23 nd 0.66 0.24 0.77 0.017 0.23 nd nd nCohort 1 805 nd 831 805 831 831 805 nd nd nCohort 2 13 nd 7 18 9 13 8 nd nd Cutoff 1 9.77E-5 nd 0.000219 2.25E-5 2.18E-5 2.25E-5 5.23E-7 nd nd Sens 1 77% nd 71% 83% 78% 92% 88% nd nd Spec 1 49% nd 60% 39% 36% 40% 23% nd nd Cutoff 2 9.58E-7 nd 0 2.25E-5 1.03E-6 2.25E-5 5.23E-7 nd nd Sens 2 85% nd 100% 83% 89% 92% 88% nd nd Spec 2 26% nd 0% 39% 27% 40% 23% nd nd Cutoff 3 0 nd 0 1.03E-6 5.05E-7 2.25E-5 5.05E-7 nd nd Sens 3 100% nd 100% 94% 100% 92% 100% nd nd Spec 3 0% nd 0% 27% 19% 40% 19% nd nd Cutoff 4 0.000566 nd 0.000532 0.000566 0.000566 0.000532 0.000566 nd nd Sens 4 46% nd 43% 33% 22% 54% 12% nd nd Spec 4 71% nd 70% 71% 71% 70% 71% nd nd Cutoff 5 0.00113 nd 0.00110 0.00113 0.00121 0.00110 0.00113 nd nd Sens 5 31% nd 29% 22% 11% 31% 12% nd nd Spec 5 80% nd 80% 80% 80% 80% 80% nd nd Cutoff 6 0.00351 nd 0.00343 0.00351 0.00381 0.00343 0.00351 nd nd Sens 6 23% nd 14% 17% 0% 31% 0% nd nd Spec 6 90% nd 90% 90% 90% 90% 90% nd nd OR Quart 2 1.00 nd 0 7.2 2.0 >4.1 1.0 nd nd p Value 1.00 nd na 0.066 0.57 <0.21 1.00 nd nd 95% CI of 0.14 nd na 0.87 0.18 >0.45 0.062 nd nd OR Quart2 7.1 nd na 59 22 na 16 nd nd OR Quart 3 2.5 nd 1.5 4.0 5.1 >3.0 2.0 nd nd p Value 0.27 nd 0.65 0.21 0.14 <0.34 0.57 nd nd 95% CI of 0.49 nd 0.25 0.45 0.59 >0.31 0.18 nd nd OR Quart3 13 nd 9.1 36 44 na 22 nd nd OR Quart 4 2.0 nd 1.00 6.1 1.0 >6.2 4.1 nd nd p Value 0.42 nd 1.00 0.095 1.0 <0.093 0.21 nd nd 95% CI of 0.36 nd 0.14 0.73 0.062 >0.74 0.45 nd nd OR Quart4 11 nd 7.1 51 16 na 37 nd nd Beta-nerve growth factor sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.36 1.85 2.36 4.01 2.36 1.75 Average 3.81 3.82 3.81 5.40 3.81 2.52 Stdev 5.01 5.92 5.01 5.87 5.01 2.76 p(t-test) 0.99 0.19 0.47 Min 0.000201 0.000201 0.000201 0.000605 0.000201 0.000201 270 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max 46.1 22.1 46.1 25.2 46.1 8.38 n (Samp) 807 13 807 18 807 8 n (Patient) 300 13 300 18 300 8 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 2.32 3.88 nd nd Average nd nd 3.79 3.76 nd nd Stdev nd nd 5.02 1.92 nd nd p(t-test) nd nd 0.99 nd nd Min nd nd 0.000201 0.731 nd nd Max nd nd 46.1 6.35 nd nd n (Samp) nd nd 833 9 nd nd n (Patient) nd nd 311 9 nd nd UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.31 1.68 2.31 3.79 nd nd Average 3.67 1.97 3.67 5.95 nd nd Stdev 4.74 2.28 4.74 6.74 nd nd p(t-test) 0.34 0.089 nd nd Min 0.000201 0.000605 0.000201 0.000605 nd nd Max 46.1 6.80 46.1 25.2 nd nd n (Samp) 833 7 833 13 nd nd n (Patient) 294 7 294 13 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.45 nd 0.37 0.62 0.63 0.63 0.42 nd nd SE 0.083 nd 0.11 0.071 0.10 0.084 0.11 nd nd p 0.57 nd 0.27 0.10 0.21 0.12 0.45 nd nd nCohort 1 807 nd 833 807 833 833 807 nd nd nCohort 2 13 nd 7 18 9 13 8 nd nd Cutoff 1 0.942 nd 1.02 2.39 2.75 1.91 1.04 nd nd Sens 1 77% nd 71% 72% 78% 77% 75% nd nd Spec 1 25% nd 27% 50% 55% 45% 27% nd nd Cutoff 2 0.886 nd 0.261 1.30 1.53 1.30 0.147 nd nd Sens 2 85% nd 86% 83% 89% 85% 88% nd nd Spec 2 24% nd 11% 33% 37% 33% 9% nd nd Cutoff 3 0.000506 nd 0.000506 0.397 0.717 0.798 0 nd nd Sens 3 92% nd 100% 94% 100% 92% 100% nd nd Spec 3 4% nd 4% 13% 20% 22% 0% nd nd Cutoff 4 3.85 nd 3.84 3.85 3.84 3.84 3.85 nd nd Sens 4 31% nd 14% 50% 56% 46% 25% nd nd Spec 4 70% nd 70% 70% 70% 70% 70% nd nd Cutoff 5 5.38 nd 5.18 5.38 5.37 5.18 5.38 nd nd Sens 5 23% nd 14% 33% 22% 31% 12% nd nd Spec 5 80% nd 80% 80% 80% 80% 80% nd nd Cutoff 6 8.82 nd 8.33 8.82 8.78 8.33 8.82 nd nd Sens 6 8% nd 0% 17% 0% 23% 0% nd nd Spec 6 90% nd 90% 90% 90% 90% 90% nd nd OR Quart 2 0.33 nd 0 1.0 1.00 1.00 2.0 nd nd 271 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only p Value 0.34 nd na 1.0 1.00 1.00 0.57 nd nd 95% CI of 0.034 nd na 0.20 0.062 0.14 0.18 nd nd OR Quart2 3.2 nd na 5.0 16 7.1 22 nd nd OR Quart 3 2.0 nd 4.1 1.7 4.1 2.0 3.0 nd nd p Value 0.32 nd 0.21 0.48 0.21 0.42 0.34 nd nd 95% CI of 0.50 nd 0.45 0.40 0.45 0.37 0.31 nd nd OR Quart3 8.2 nd 37 7.1 37 11 29 nd nd OR Quart 4 1.0 nd 2.0 2.4 3.0 2.5 2.0 nd nd p Value 1.0 nd 0.57 0.22 0.34 0.27 0.57 nd nd 95% CI of 0.20 nd 0.18 0.60 0.31 0.48 0.18 nd nd OR Quart4 5.0 nd 22 9.3 29 13 22 nd nd Transthyretin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 24.7 51.6 24.7 47.5 24.7 15.5 Average 53.7 101 53.7 60.5 53.7 44.6 Stdev 124 121 124 57.8 124 70.8 p(t-test) 0.12 0.81 0.81 Min 0.000148 3.29 0.000148 5.08 0.000148 1.67 Max 2000 461 2000 238 2000 241 n (Samp) 892 17 892 20 892 11 n (Patient) 370 17 370 20 370 11 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 25.7 31.4 25.7 31.1 Average nd nd 55.5 42.0 55.5 70.6 Stdev nd nd 124 35.5 124 79.0 p(t-test) nd nd 0.74 0.73 Min nd nd 0.000148 6.54 0.000148 9.84 Max nd nd 2000 127 2000 241 n (Samp) nd nd 922 9 922 8 n (Patient) nd nd 382 9 382 8 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 25.2 61.5 25.2 50.5 nd nd Average 54.9 114 54.9 63.2 nd nd Stdev 125 140 125 62.7 nd nd p(t-test) 0.14 0.80 nd nd Min 0.000148 9.87 0.000148 5.08 nd nd Max 2000 461 2000 238 nd nd n (Samp) 886 10 886 15 nd nd n (Patient) 345 10 345 15 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.67 nd 0.70 0.63 0.56 0.62 0.43 0.61 nd SE 0.073 nd 0.093 0.068 0.100 0.078 0.090 0.11 nd p 0.022 nd 0.031 0.059 0.54 0.12 0.46 0.29 nd 272 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only nCohort 1 892 nd 886 892 922 886 892 922 nd nCohort 2 17 nd 10 20 9 15 11 8 nd Cutoff 1 35.5 nd 39.8 31.1 18.9 22.0 9.69 26.8 nd Sens 1 71% nd 70% 70% 78% 73% 73% 75% nd Spec 1 63% nd 65% 58% 40% 45% 21% 51% nd Cutoff 2 12.9 nd 35.5 16.2 17.0 19.2 8.79 15.4 nd Sens 2 82% nd 80% 80% 89% 80% 82% 88% nd Spec 2 28% nd 62% 35% 35% 41% 19% 32% nd Cutoff 3 6.65 nd 12.9 12.4 6.53 10.7 5.71 9.69 nd Sens 3 94% nd 90% 90% 100% 93% 91% 100% nd Spec 3 15% nd 27% 27% 14% 23% 13% 21% nd Cutoff 4 46.1 nd 47.0 46.1 47.3 47.0 46.1 47.3 nd Sens 4 59% nd 60% 50% 33% 53% 18% 38% nd Spec 4 70% nd 70% 70% 70% 70% 70% 70% nd Cutoff 5 63.5 nd 65.0 63.5 66.5 65.0 63.5 66.5 nd Sens 5 47% nd 50% 30% 11% 33% 18% 38% nd Spec 5 80% nd 80% 80% 80% 80% 80% 80% nd Cutoff6 108 nd 109 108 111 109 108 111 nd Sens 6 29% nd 30% 15% 11% 13% 9% 25% nd Spec 6 90% nd 90% 90% 90% 90% 90% 90% nd OR Quart 2 0.33 nd 1.0 2.0 2.0 1.5 1.5 1.00 nd p Value 0.34 nd 1.0 0.42 0.57 0.66 0.66 1.00 nd 95% CI of 0.034 nd 0.062 0.37 0.18 0.25 0.25 0.062 nd OR Quart2 3.2 nd 16 11 22 9.1 9.1 16 nd OR Quart 3 1.7 nd 3.0 3.6 5.1 2.5 1.0 3.0 nd p Value 0.48 nd 0.34 0.11 0.14 0.27 1.0 0.34 nd 95% CI of 0.40 nd 0.31 0.74 0.59 0.49 0.14 0.31 nd OR Quart3 7.1 nd 29 17 44 13 7.2 29 nd OR Quart 4 2.7 nd 5.1 3.6 1.00 2.5 2.0 3.0 nd p Value 0.14 nd 0.14 0.11 1.00 0.27 0.42 0.34 nd 95% CI of 0.71 nd 0.59 0.74 0.062 0.48 0.37 0.31 nd OR Quart4 10 nd 44 17 16 13 11 29 nd C-peptide Urine sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 22200 6700 22200 14400 22200 22000 Average 32300 16200 32300 22300 32300 33900 Stdev 29300 24400 29300 25900 29300 31600 p(t-test) 0.024 0.13 0.86 Min 0.00978 734 0.00978 419 0.00978 936 Max 114000 100000 114000 100000 114000 100000 n (Samp) 893 17 893 20 893 11 n (Patient) 370 17 370 20 370 11 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 21700 18000 21700 14600 Average nd nd 31400 24100 31400 28200 Stdev nd nd 29200 17800 29200 33300 p(t-test) nd nd 0.45 0.75 Min nd nd 0.00978 4640 0.00978 936 273 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max nd nd 114000 59400 114000 100000 n (Samp) nd nd 923 9 923 8 n (Patient) nd nd 382 9 382 8 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 22000 3460 22000 5980 nd nd Average 31900 14600 31900 16800 nd nd Stdev 29100 26900 29100 25300 nd nd p(t-test) 0.062 0.046 nd nd Min 0.00978 734 0.00978 419 nd nd Max 114000 87500 114000 99100 nd nd n (Samp) 887 10 887 15 nd nd n (Patient) 345 10 345 15 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.29 nd 0.23 0.38 0.48 0.29 0.50 0.44 nd SE 0.071 nd 0.088 0.068 0.098 0.076 0.088 0.11 nd p 0.0025 nd 0.0026 0.066 0.82 0.0063 0.98 0.54 nd nCohort 1 893 nd 887 893 923 887 893 923 nd nCohort 2 17 nd 10 20 9 15 11 8 nd Cutoff 1 2160 nd 2000 5480 12500 1870 7980 5860 nd Sens 1 71% nd 70% 70% 78% 73% 73% 75% nd Spec 1 6% nd 6% 14% 36% 6% 22% 16% nd Cutoff 2 1580 nd 1580 2700 10800 1460 5980 4910 nd Sens 2 82% nd 80% 80% 89% 80% 82% 88% nd Spec 2 4% nd 5% 7% 31% 4% 15% 14% nd Cutoff 3 1240 nd 1240 1400 4620 936 4100 800 nd Sens 3 94% nd 90% 90% 100% 93% 91% 100% nd Spec 3 3% nd 4% 4% 13% 3% 10% 3% nd Cutoff 4 40700 nd 39400 40700 38600 39400 40700 38600 nd Sens 4 6% nd 10% 15% 22% 7% 36% 38% nd Spec 4 70% nd 70% 70% 70% 70% 70% 70% nd Cutoff 5 58100 nd 56700 58100 56900 56700 58100 56900 nd Sens 5 6% nd 10% 15% 11% 7% 27% 12% nd Spec 5 80% nd 80% 80% 80% 80% 80% 80% nd Cutoff 6 83300 nd 83300 83300 82300 83300 83300 82300 nd Sens 6 6% nd 10% 5% 0% 7% 9% 12% nd Spec 6 90% nd 90% 90% 90% 90% 90% 90% nd OR Quart 2 3.0 nd 1.0 1.0 2.0 3.0 0.50 2.0 nd p Value 0.34 nd 1.00 1.00 0.57 0.34 0.42 0.57 nd 95% CI of 0.31 nd 0.062 0.20 0.18 0.31 0.090 0.18 nd OR Quart2 29 nd 16 5.0 22 29 2.7 22 nd OR Quart 3 3.0 nd 1.0 2.0 5.1 3.0 0.50 1.0 nd p Value 0.34 nd 1.00 0.32 0.14 0.34 0.42 1.0 nd 95% CI of 0.31 nd 0.062 0.50 0.59 0.31 0.090 0.062 nd OR Quart3 29 nd 16 8.2 44 29 2.7 16 nd OR Quart 4 10 nd 7.2 2.7 1.0 8.3 0.75 4.1 nd p Value 0.026 nd 0.065 0.14 1.0 0.047 0.70 0.21 nd 95% CI of 1.3 nd 0.88 0.72 0.062 1.0 0.17 0.45 nd OR Quart4 82 nd 59 10 16 67 3.4 37 nd 274 Gastric inhibitory polypeptide Urine sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.376 0.262 0.376 0.626 0.376 1.39 Average 23.7 38.1 23.7 64.2 23.7 3.44 Stdev 209 147 209 232 209 4.64 p(t-test) 0.78 0.39 0.75 Min 9.60E-5 9.60E-5 9.60E-5 0.0273 9.60E-5 0.137 Max 3840 606 3840 1040 3840 12.7 n (Samp) 894 17 894 20 894 11 n (Patient) 370 17 370 20 370 11 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 0.372 0.815 0.372 2.07 Average nd nd 24.2 76.5 24.2 8.10 Stdev nd nd 209 199 209 11.7 p(t-test) nd nd 0.45 0.83 Min nd nd 9.60E-5 0.0273 9.60E-5 0.137 Max nd nd 3840 606 3840 34.1 n (Samp) nd nd 924 9 924 8 n (Patient) nd nd 382 9 382 8 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.397 0.228 0.397 0.990 nd nd Average 23.7 3.88 23.7 81.3 nd nd Stdev 210 11.7 210 268 nd nd p(t-test) 0.76 0.30 nd nd Min 9.60E-5 0.000104 9.60E-5 0.109 nd nd Max 3840 37.2 3840 1040 nd nd n (Samp) 888 10 888 15 nd nd n (Patient) 345 10 345 15 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.44 nd 0.35 0.63 0.68 0.66 0.68 0.76 nd SE 0.073 nd 0.095 0.068 0.099 0.077 0.090 0.100 nd p 0.39 nd 0.10 0.046 0.068 0.034 0.045 0.0098 nd nCohort 1 894 nd 888 894 924 888 894 924 nd nCohort 2 17 nd 10 20 9 15 11 8 nd Cutoff 1 0.0766 nd 0.0766 0.304 0.393 0.304 0.462 1.09 nd Sens 1 71% nd 70% 70% 78% 73% 73% 75% nd Spec 1 25% nd 24% 45% 51% 43% 55% 75% nd Cutoff 2 0.00847 nd 0.000161 0.206 0.108 0.261 0.246 0.462 nd Sens 2 82% nd 80% 80% 89% 80% 82% 88% nd Spec 2 18% nd 7% 36% 28% 41% 41% 55% nd Cutoff 3 9.60E-5 nd 9.60E-5 0.108 0.0269 0.119 0.222 0.136 nd Sens 3 94% nd 100% 90% 100% 93% 91% 100% nd Spec 3 0% nd 0% 27% 21% 28% 37% 31% nd Cutoff 4 0.828 nd 0.880 0.828 0.828 0.880 0.828 0.828 nd Sens 4 24% nd 10% 45% 44% 53% 55% 75% nd Spec 4 70% nd 70% 70% 70% 70% 70% 70% nd Cutoff 5 1.58 nd 1.58 1.58 1.58 1.58 1.58 1.58 nd 275 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only Sens 5 12% nd 10% 40% 44% 40% 45% 50% nd Spec 5 80% nd 80% 80% 80% 80% 80% 80% nd Cutoff 6 5.82 nd 5.85 5.82 5.66 5.85 5.82 5.66 nd Sens 6 12% nd 10% 25% 44% 20% 18% 38% nd Spec 6 90% nd 90% 90% 90% 90% 90% 90% nd OR Quart 2 2.0 nd 1.0 2.5 1.0 >5.1 >3.0 >1.0 nd p Value 0.42 nd 1.00 0.27 1.0 <0.14 <0.34 <1.00 nd 95% CI of 0.37 nd 0.062 0.48 0.062 >0.59 >0.31 >0.062 nd OR Quart2 11 nd 16 13 16 na na na nd OR Quart 3 3.1 nd 4.1 2.0 3.0 >3.0 >2.0 >2.0 nd p Value 0.17 nd 0.21 0.42 0.34 <0.34 <0.57 <0.57 nd 95% CI of 0.61 nd 0.45 0.37 0.31 >0.31 >0.18 >0.18 nd OR Quart3 15 nd 37 11 29 na na na nd OR Quart 4 2.5 nd 4.1 4.6 4.0 >7.2 >6.1 >5.1 nd p Value 0.27 nd 0.21 0.052 0.21 <0.066 <0.094 <0.14 nd 95% CI of 0.49 nd 0.45 0.99 0.45 >0.88 >0.73 >0.59 nd OR Quart4 13 nd 37 22 36 na na na nd Peptide YY Urine sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 5.26 14.6 5.26 22.7 5.26 0.957 Average 43.1 44.4 43.1 78.3 43.1 46.1 Stdev 115 61.7 115 105 115 86.4 p(t-test) 0.96 0.17 0.93 Min 0.00976 0.0188 0.00976 0.00976 0.00976 0.0188 Max 1200 196 1200 317 1200 290 n (Samp) 892 17 892 20 892 11 n (Patient) 370 17 370 20 370 11 sCr only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 5.61 98.0 5.61 37.7 Average nd nd 43.7 102 43.7 41.4 Stdev nd nd 114 93.9 114 35.4 p(t-test) nd nd 0.13 0.95 Min nd nd 0.00976 0.00976 0.00976 0.0188 Max nd nd 1200 278 1200 82.4 n (Samp) nd nd 922 9 922 8 n (Patient) nd nd 382 9 382 8 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 6.34 21.5 6.34 18.9 nd nd Average 43.5 30.3 43.5 72.2 nd nd Stdev 114 46.0 114 104 nd nd p(t-test) 0.71 0.33 nd nd Min 0.00976 0.0128 0.00976 0.0188 nd nd Max 1200 153 1200 317 nd nd n (Samp) 886 10 886 15 nd nd n (Patient) 345 10 345 15 nd nd 276 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.62 nd 0.54 0.65 0.71 0.65 0.52 0.64 nd SE 0.073 nd 0.094 0.067 0.098 0.078 0.089 0.11 nd p 0.10 nd 0.68 0.028 0.033 0.056 0.82 0.19 nd nCohort 1 892 nd 886 892 922 886 892 922 nd nCohort 2 17 nd 10 20 9 15 11 8 nd Cutoff 1 10.7 nd 0.817 3.26 25.9 3.26 0.0196 18.8 nd Sens 1 71% nd 70% 70% 78% 73% 73% 75% nd Spec 1 55% nd 40% 49% 69% 48% 26% 62% nd Cutoff 2 0.817 nd 0.0196 0.963 0.0151 2.77 0.0151 0.0151 nd Sens 2 82% nd 80% 80% 89% 80% 100% 100% nd Spec 2 40% nd 27% 43% 18% 47% 18% 18% nd Cutoff 3 0.0196 nd 0.0128 0.0188 0 0.0188 0.0151 0.0151 nd Sens 3 94% nd 90% 90% 100% 93% 100% 100% nd Spec 3 26% nd 12% 24% 0% 26% 18% 18% nd Cutoff 4 27.1 nd 28.3 27.1 27.9 28.3 27.1 27.9 nd Sens 4 47% nd 50% 45% 67% 40% 36% 50% nd Spec 4 70% nd 70% 70% 70% 70% 70% 70% nd Cutoff 5 44.2 nd 47.0 44.2 45.6 47.0 44.2 45.6 nd Sens 5 24% nd 10% 45% 67% 40% 27% 50% nd Spec 5 80% nd 80% 80% 80% 80% 80% 80% nd Cutoff 6 103 nd 104 103 104 104 103 104 nd Sens 6 18% nd 10% 25% 44% 20% 9% 0% nd Spec 6 90% nd 90% 90% 90% 90% 90% 90% nd OR Quart 2 4.1 nd 1.0 2.5 0 4.1 1.00 0 nd p Value 0.21 nd 1.0 0.27 na 0.21 1.00 na nd 95% CI of 0.45 nd 0.14 0.49 na 0.45 0.20 na nd OR Quart2 37 nd 7.2 13 na 37 5.0 na nd OR Quart 3 7.2 nd 2.0 2.0 0.50 4.1 0.33 1.0 nd p Value 0.066 nd 0.42 0.42 0.57 0.21 0.34 1.0 nd 95% CI of 0.88 nd 0.37 0.37 0.045 0.45 0.034 0.14 nd OR Quart3 59 nd 11 11 5.5 37 3.2 7.2 nd OR Quart 4 5.1 nd 1.0 4.6 3.0 6.1 1.3 2.0 nd p Value 0.14 nd 1.0 0.051 0.18 0.095 0.71 0.42 nd 95% CI of 0.59 nd 0.14 0.99 0.61 0.73 0.29 0.36 nd OR Quart4 44 nd 7.2 22 15 51 6.0 11 nd [0177] Table 10: Comparison of marker levels in EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0, R, or I) and in EDTA samples collected from Cohort 2 (subjects who progress to RIFLE stage F) at 0, 24 hours, and 48 hours prior to the subject reaching RIFLE stage I. Complement factor H sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 183000 169000 nd nd Average nd nd 191000 171000 nd nd Stdev nd nd 76200 64200 nd nd p(t-test) nd nd 0.52 nd nd Min nd nd 14900 92800 nd nd Max nd nd 1070000 255000 nd nd n (Samp) nd nd 488 6 nd nd 277 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 n (Patient) nd nd 222 6 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC nd nd nd 0.43 nd nd nd nd nd SE nd nd nd 0.12 nd nd nd nd nd p nd nd nd 0.57 nd nd nd nd nd nCohort 1 nd nd nd 488 nd nd nd nd nd nCohort 2 nd nd nd 6 nd nd nd nd nd Cutoff 1 nd nd nd 112000 nd nd nd nd nd Sens I nd nd nd 83% nd nd nd nd nd Spec1 nd nd nd 9% nd nd nd nd nd Cutoff 2 nd nd nd 112000 nd nd nd nd nd Sens2 nd nd nd 83% nd nd nd nd nd Spec2 nd nd nd 9% nd nd nd nd nd Cutoff 3 nd nd nd 92200 nd nd nd nd nd Sens 3 nd nd nd 100% nd nd nd nd nd Spec3 nd nd nd 5% nd nd nd nd nd Cutoff 4 nd nd nd 213000 nd nd nd nd nd Sens4 nd nd nd 33% nd nd nd nd nd Spec 4 nd nd nd 70% nd nd nd nd nd Cutoff 5 nd nd nd 236000 nd nd nd nd nd Sens5 nd nd nd 17% nd nd nd nd nd Spec 5 nd nd nd 80% nd nd nd nd nd Cutoff 6 nd nd nd 273000 nd nd nd nd nd Sens 6 nd nd nd 0% nd nd nd nd nd Spec 6 nd nd nd 90% nd nd nd nd nd OR Quart 2 nd nd nd 0.50 nd nd nd nd nd p Value nd nd nd 0.57 nd nd nd nd nd 95% CI of nd nd nd 0.045 nd nd nd nd nd OR Quart2 nd nd nd 5.6 nd nd nd nd nd OR Quart 3 nd nd nd 0.50 nd nd nd nd nd p Value nd nd nd 0.57 nd nd nd nd nd 95% CI of nd nd nd 0.044 nd nd nd nd nd OR Quart3 nd nd nd 5.5 nd nd nd nd nd OR Quart 4 nd nd nd 1.0 nd nd nd nd nd p Value nd nd nd 0.99 nd nd nd nd nd 95% CI of nd nd nd 0.14 nd nd nd nd nd OR Quart4 nd nd nd 7.3 nd nd nd nd nd Follistatin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 796 942 796 736 796 529 Average 2910 3920 2910 2380 2910 754 Stdev 4540 4600 4540 3980 4540 759 p(t-test) 0.56 0.73 0.21 Min 0.000554 2.75 0.000554 570 0.000554 1.35 Max 28900 12100 28900 12800 28900 2290 n (Samp) 588 7 588 9 588 7 n (Patient) 263 7 263 9 263 7 278 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 778 781 nd nd Average nd nd 3000 2280 nd nd Stdev nd nd 4620 4260 nd nd p(t-test) nd nd 0.66 nd nd Min nd nd 0.000554 366 nd nd Max nd nd 28900 12800 nd nd n (Samp) nd nd 571 8 nd nd n (Patient) nd nd 243 8 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.56 nd nd 0.56 nd 0.54 0.36 nd nd SE 0.11 nd nd 0.10 nd 0.10 0.11 nd nd p 0.59 nd nd 0.52 nd 0.74 0.23 nd nd nCohort 1 588 nd nd 588 nd 571 588 nd nd nCohort 2 7 nd nd 9 nd 8 7 nd nd Cutoff 1 839 nd nd 702 nd 702 394 nd nd Sens 1 71% nd nd 78% nd 75% 71% nd nd Spec 1 54% nd nd 45% nd 46% 21% nd nd Cutoff 2 441 nd nd 594 nd 563 240 nd nd Sens 2 86% nd nd 89% nd 88% 86% nd nd Spec 2 24% nd nd 36% nd 37% 13% nd nd Cutoff 3 2.51 nd nd 563 nd 360 1.29 nd nd Sens 3 100% nd nd 100% nd 100% 100% nd nd Spec 3 4% nd nd 34% nd 21% 2% nd nd Cutoff 4 1320 nd nd 1320 nd 1370 1320 nd nd Sens 4 43% nd nd 22% nd 12% 14% nd nd Spec 4 70% nd nd 70% nd 70% 70% nd nd Cutoff 5 6590 nd nd 6590 nd 7330 6590 nd nd Sens 5 29% nd nd 11% nd 12% 0% nd nd Spec 5 80% nd nd 80% nd 80% 80% nd nd Cutoff 6 10800 nd nd 10800 nd 10900 10800 nd nd Sens 6 14% nd nd 11% nd 12% 0% nd nd Spec 6 90% nd nd 90% nd 90% 90% nd nd OR Quart 2 0 nd nd >5.2 nd 3.0 1.0 nd nd p Value na nd nd <0.14 nd 0.34 1.0 nd nd 95% CI of na nd nd >0.60 nd 0.31 0.062 nd nd OR Quart2 na nd nd na nd 29 16 nd nd OR Quart 3 0.99 nd nd >2.0 nd 3.0 2.0 nd nd p Value 0.99 nd nd <0.57 nd 0.34 0.57 nd nd 95% CI of 0.14 nd nd >0.18 nd 0.31 0.18 nd nd OR Quart3 7.1 nd nd na nd 29 22 nd nd OR Quart 4 1.5 nd nd >2.0 nd 0.99 3.1 nd nd p Value 0.66 nd nd <0.57 nd 1.00 0.33 nd nd 95% CI of 0.25 nd nd >0.18 nd 0.062 0.31 nd nd OR Quart4 9.1 nd nd na nd 16 30 nd nd Vitamin D-binding protein sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 172000 102000 nd nd Average nd nd 193000 115000 nd nd 279 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Stdev nd nd 92800 54200 nd nd p(t-test) nd nd 0.042 nd nd Min nd nd 22500 54200 nd nd Max nd nd 630000 183000 nd nd n (Samp) nd nd 489 6 nd nd n (Patient) nd nd 218 6 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC nd nd nd 0.23 nd nd nd nd nd SE nd nd nd 0.11 nd nd nd nd nd p nd nd nd 0.016 nd nd nd nd nd nCohort 1 nd nd nd 489 nd nd nd nd nd nCohort 2 nd nd nd 6 nd nd nd nd nd Cutoff 1 nd nd nd 68600 nd nd nd nd nd Sens I nd nd nd 83% nd nd nd nd nd Spec 1 nd nd nd 2% nd nd nd nd nd Cutoff 2 nd nd nd 68600 nd nd nd nd nd Sens2 nd nd nd 83% nd nd nd nd nd Spec2 nd nd nd 2% nd nd nd nd nd Cutoff 3 nd nd nd 50900 nd nd nd nd nd Sens 3 nd nd nd 100% nd nd nd nd nd Spec3 nd nd nd 1% nd nd nd nd nd Cutoff 4 nd nd nd 215000 nd nd nd nd nd Sens4 nd nd nd 0% nd nd nd nd nd Spec 4 nd nd nd 70% nd nd nd nd nd Cutoff 5 nd nd nd 249000 nd nd nd nd nd Sens5 nd nd nd 0% nd nd nd nd nd Spec 5 nd nd nd 80% nd nd nd nd nd Cutoff 6 nd nd nd 304000 nd nd nd nd nd Sens 6 nd nd nd 0% nd nd nd nd nd Spec 6 nd nd nd 90% nd nd nd nd nd OR Quart 2 nd nd nd >2.0 nd nd nd nd nd p Value nd nd nd <0.56 nd nd nd nd nd 95% CI of nd nd nd >0.18 nd nd nd nd nd OR Quart2 nd nd nd na nd nd nd nd nd OR Quart 3 nd nd nd >0 nd nd nd nd nd p Value nd nd nd <na nd nd nd nd nd 95% CIof nd nd nd >na nd nd nd nd nd OR Quart3 nd nd nd na nd nd nd nd nd OR Quart 4 nd nd nd >4.2 nd nd nd nd nd p Value nd nd nd <0.20 nd nd nd nd nd 95% CI of nd nd nd >0.46 nd nd nd nd nd OR Quart4 nd nd nd na nd nd nd nd nd Interleukin-17A sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 1.59 3.29 1.59 2.67 1.59 5.39 Average 3.15 9.06 3.15 7.88 3.15 9.95 Stdev 5.05 19.9 5.05 8.58 5.05 9.99 p(t-test) 0.0017 0.0062 5.4E-4 280 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Min 0.000362 0.000482 0.000362 0.901 0.000362 1.18 Max 53.4 61.7 53.4 24.2 53.4 28.6 n (Samp) 532 9 532 9 532 7 n (Patient) 238 9 238 9 238 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 1.51 5.48 nd nd Average nd nd 3.10 8.82 nd nd Stdev nd nd 5.02 8.77 nd nd p(t-test) nd nd 0.0017 nd nd Min nd nd 0.000362 0.000532 nd nd Max nd nd 53.4 24.2 nd nd n (Samp) nd nd 525 8 nd nd n (Patient) nd nd 224 8 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.55 nd nd 0.73 nd 0.74 0.80 nd nd SE 0.100 nd nd 0.097 nd 0.10 0.10 nd nd p 0.61 nd nd 0.020 nd 0.017 0.0035 nd nd nCohort 1 532 nd nd 532 nd 525 532 nd nd nCohort 2 9 nd nd 9 nd 8 7 nd nd Cutoff 1 0.490 nd nd 2.07 nd 2.66 3.84 nd nd Sens 1 78% nd nd 78% nd 75% 71% nd nd Spec 1 29% nd nd 57% nd 66% 75% nd nd Cutoff 2 0.000482 nd nd 1.80 nd 2.07 2.82 nd nd Sens 2 89% nd nd 89% nd 88% 86% nd nd Spec 2 10% nd nd 53% nd 58% 66% nd nd Cutoff 3 0.000469 nd nd 0.857 nd 0.000482 1.17 nd nd Sens 3 100% nd nd 100% nd 100% 100% nd nd Spec 3 7% nd nd 38% nd 10% 43% nd nd Cutoff 4 3.30 nd nd 3.30 nd 3.29 3.30 nd nd Sens 4 44% nd nd 44% nd 62% 71% nd nd Spec 4 70% nd nd 70% nd 70% 70% nd nd Cutoff 5 4.67 nd nd 4.67 nd 4.86 4.67 nd nd Sens 5 33% nd nd 44% nd 62% 57% nd nd Spec 5 80% nd nd 80% nd 80% 80% nd nd Cutoff 6 7.86 nd nd 7.86 nd 7.86 7.86 nd nd Sens 6 11% nd nd 33% nd 38% 43% nd nd Spec 6 90% nd nd 90% nd 90% 90% nd nd OR Quart 2 1.0 nd nd >1.0 nd 0 >1.0 nd nd p Value 1.0 nd nd <1.00 nd na <1.0 nd nd 95% CI of 0.14 nd nd >0.062 nd na >0.062 nd nd OR Quart2 7.2 nd nd na nd na na nd nd OR Quart 3 1.0 nd nd >4.1 nd 2.0 >2.0 nd nd p Value 1.0 nd nd <0.21 nd 0.57 <0.57 nd nd 95% CI of 0.14 nd nd >0.45 nd 0.18 >0.18 nd nd OR Quart3 7.2 nd nd na nd 22 na nd nd OR Quart 4 1.5 nd nd >4.1 nd 5.1 >4.1 nd nd p Value 0.66 nd nd <0.21 nd 0.14 <0.21 nd nd 95% CI of 0.25 nd nd >0.45 nd 0.59 >0.45 nd nd OR Quart4 9.1 nd nd na nd 4 na nd nd 281 Insulin receptor substrate 1 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 0.0289 0.170 nd nd Average nd nd 0.476 0.352 nd nd Stdev nd nd 3.12 0.380 nd nd p(t-test) nd nd 0.92 nd nd Min nd nd 3.03E-6 0.0217 nd nd Max nd nd 49.5 0.934 nd nd n (Samp) nd nd 490 6 nd nd n (Patient) nd nd 220 6 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC nd nd nd 0.77 nd nd nd nd nd SE nd nd nd 0.11 nd nd nd nd nd p nd nd nd 0.020 nd nd nd nd nd nCohort 1 nd nd nd 490 nd nd nd nd nd nCohort 2 nd nd nd 6 nd nd nd nd nd Cutoff 1 nd nd nd 0.0883 nd nd nd nd nd Sens I nd nd nd 83% nd nd nd nd nd Spec 1 nd nd nd 72% nd nd nd nd nd Cutoff 2 nd nd nd 0.0883 nd nd nd nd nd Sens2 nd nd nd 83% nd nd nd nd nd Spec 2 nd nd nd 72% nd nd nd nd nd Cutoff 3 nd nd nd 0.0216 nd nd nd nd nd Sens 3 nd nd nd 100% nd nd nd nd nd Spec 3 nd nd nd 42% nd nd nd nd nd Cutoff 4 nd nd nd 0.0807 nd nd nd nd nd Sens4 nd nd nd 83% nd nd nd nd nd Spec 4 nd nd nd 70% nd nd nd nd nd Cutoff 5 nd nd nd 0.163 nd nd nd nd nd Sens5 nd nd nd 50% nd nd nd nd nd Spec 5 nd nd nd 80% nd nd nd nd nd Cutoff 6 nd nd nd 0.395 nd nd nd nd nd Sens 6 nd nd nd 33% nd nd nd nd nd Spec 6 nd nd nd 90% nd nd nd nd nd OR Quart 2 nd nd nd >1.0 nd nd nd nd nd p Value nd nd nd <1.00 nd nd nd nd nd 95% CI of nd nd nd >0.062 nd nd nd nd nd OR Quart2 nd nd nd na nd nd nd nd nd OR Quart 3 nd nd nd >1.0 nd nd nd nd nd p Value nd nd nd <1.00 nd nd nd nd nd 95% CI of nd nd nd >0.062 nd nd nd nd nd OR Quart3 nd nd nd na nd nd nd nd nd OR Quart 4 nd nd nd >4.1 nd nd nd nd nd p Value nd nd nd <0.21 nd nd nd nd nd 95% CI of nd nd nd >0.46 nd nd nd nd nd OR Quart4 nd nd nd na nd nd nd nd nd Involucrin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage 282 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 0.696 2.03 nd nd Average nd nd 0.932 2.46 nd nd Stdev nd nd 0.855 1.85 nd nd p(t-test) nd nd 2.3E-5 nd nd Min nd nd 0.0472 0.185 nd nd Max nd nd 12.7 4.83 nd nd n (Samp) nd nd 490 6 nd nd n (Patient) nd nd 220 6 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC nd nd nd 0.77 nd nd nd nd nd SE nd nd nd 0.11 nd nd nd nd nd p nd nd nd 0.018 nd nd nd nd nd nCohort 1 nd nd nd 490 nd nd nd nd nd nCohort 2 nd nd nd 6 nd nd nd nd nd Cutoff 1 nd nd nd 1.25 nd nd nd nd nd Sens I nd nd nd 83% nd nd nd nd nd Spec 1 nd nd nd 80% nd nd nd nd nd Cutoff 2 nd nd nd 1.25 nd nd nd nd nd Sens2 nd nd nd 83% nd nd nd nd nd Spec 2 nd nd nd 80% nd nd nd nd nd Cutoff 3 nd nd nd 0.173 nd nd nd nd nd Sens 3 nd nd nd 100% nd nd nd nd nd Spec3 nd nd nd 2% nd nd nd nd nd Cutoff 4 nd nd nd 0.959 nd nd nd nd nd Sens4 nd nd nd 83% nd nd nd nd nd Spec 4 nd nd nd 70% nd nd nd nd nd Cutoff 5 nd nd nd 1.26 nd nd nd nd nd Sens5 nd nd nd 67% nd nd nd nd nd Spec 5 nd nd nd 80% nd nd nd nd nd Cutoff 6 nd nd nd 1.82 nd nd nd nd nd Sens 6 nd nd nd 50% nd nd nd nd nd Spec 6 nd nd nd 90% nd nd nd nd nd OR Quart 2 nd nd nd 0 nd nd nd nd nd p Value nd nd nd na nd nd nd nd nd 95% CI of nd nd nd na nd nd nd nd nd OR Quart2 nd nd nd na nd nd nd nd nd OR Quart 3 nd nd nd 0 nd nd nd nd nd p Value nd nd nd na nd nd nd nd nd 95% CI of nd nd nd na nd nd nd nd nd OR Quart3 nd nd nd na nd nd nd nd nd OR Quart 4 nd nd nd 5.2 nd nd nd nd nd p Value nd nd nd 0.14 nd nd nd nd nd 95% CI of nd nd nd 0.59 nd nd nd nd nd OR Quart4 nd nd nd 45 nd nd nd nd nd NF-kappa-B inhibitor alpha sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 0.00106 0.00387 nd nd Average nd nd 0.0344 0.00393 nd nd Stdev nd nd 0.235 0.00297 nd nd 283 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) nd nd 0.75 nd nd Min nd nd 1.84E-7 3.67E-5 nd nd Max nd nd 3.62 0.00890 nd nd n (Samp) nd nd 490 6 nd nd n (Patient) nd nd 220 6 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC nd nd nd 0.63 nd nd nd nd nd SE nd nd nd 0.12 nd nd nd nd nd p nd nd nd 0.30 nd nd nd nd nd nCohort 1 nd nd nd 490 nd nd nd nd nd nCohort 2 nd nd nd 6 nd nd nd nd nd Cutoff 1 nd nd nd 0.00217 nd nd nd nd nd Sens I nd nd nd 83% nd nd nd nd nd Spec 1 nd nd nd 62% nd nd nd nd nd Cutoff 2 nd nd nd 0.00217 nd nd nd nd nd Sens2 nd nd nd 83% nd nd nd nd nd Spec 2 nd nd nd 62% nd nd nd nd nd Cutoff 3 nd nd nd 3.31E-5 nd nd nd nd nd Sens 3 nd nd nd 100% nd nd nd nd nd Spec 3 nd nd nd 20% nd nd nd nd nd Cutoff 4 nd nd nd 0.00413 nd nd nd nd nd Sens4 nd nd nd 50% nd nd nd nd nd Spec 4 nd nd nd 70% nd nd nd nd nd Cutoff 5 nd nd nd 0.0122 nd nd nd nd nd Sens5 nd nd nd 0% nd nd nd nd nd Spec 5 nd nd nd 80% nd nd nd nd nd Cutoff 6 nd nd nd 0.0421 nd nd nd nd nd Sens 6 nd nd nd 0% nd nd nd nd nd Spec 6 nd nd nd 90% nd nd nd nd nd OR Quart 2 nd nd nd 0 nd nd nd nd nd p Value nd nd nd na nd nd nd nd nd 95% CI of nd nd nd na nd nd nd nd nd OR Quart2 nd nd nd na nd nd nd nd nd OR Quart 3 nd nd nd 4.1 nd nd nd nd nd p Value nd nd nd 0.21 nd nd nd nd nd 95% CI of nd nd nd 0.45 nd nd nd nd nd OR Quart3 nd nd nd 37 nd nd nd nd nd OR Quart 4 nd nd nd 1.0 nd nd nd nd nd p Value nd nd nd 1.0 nd nd nd nd nd 95% CI of nd nd nd 0.062 nd nd nd nd nd OR Quart4 nd nd nd 16 nd nd nd nd nd Beta-nerve growth factor sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 1.71 2.96 nd nd Average nd nd 2.28 3.76 nd nd Stdev nd nd 3.40 1.74 nd nd p(t-test) nd nd 0.29 nd nd Min nd nd 0.221 2.36 nd nd 284 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max nd nd 70.0 6.73 nd nd n (Samp) nd nd 489 6 nd nd n (Patient) nd nd 218 6 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC nd nd nd 0.83 nd nd nd nd nd SE nd nd nd 0.10 nd nd nd nd nd p nd nd nd 0.0014 nd nd nd nd nd nCohort 1 nd nd nd 489 nd nd nd nd nd nCohort 2 nd nd nd 6 nd nd nd nd nd Cutoff 1 nd nd nd 2.53 nd nd nd nd nd Sens 1 nd nd nd 83% nd nd nd nd nd Spec 1 nd nd nd 74% nd nd nd nd nd Cutoff 2 nd nd nd 2.53 nd nd nd nd nd Sens2 nd nd nd 83% nd nd nd nd nd Spec 2 nd nd nd 74% nd nd nd nd nd Cutoff 3 nd nd nd 2.35 nd nd nd nd nd Sens 3 nd nd nd 100% nd nd nd nd nd Spec 3 nd nd nd 71% nd nd nd nd nd Cutoff 4 nd nd nd 2.30 nd nd nd nd nd Sens4 nd nd nd 100% nd nd nd nd nd Spec 4 nd nd nd 70% nd nd nd nd nd Cutoff 5 nd nd nd 2.91 nd nd nd nd nd Sens5 nd nd nd 50% nd nd nd nd nd Spec 5 nd nd nd 80% nd nd nd nd nd Cutoff 6 nd nd nd 4.06 nd nd nd nd nd Sens 6 nd nd nd 33% nd nd nd nd nd Spec 6 nd nd nd 90% nd nd nd nd nd OR Quart 2 nd nd nd >0 nd nd nd nd nd p Value nd nd nd <na nd nd nd nd nd 95% CIof nd nd nd >na nd nd nd nd nd OR Quart2 nd nd nd na nd nd nd nd nd OR Quart 3 nd nd nd >2.0 nd nd nd nd nd p Value nd nd nd <0.57 nd nd nd nd nd 95% CI of nd nd nd >0.18 nd nd nd nd nd OR Quart3 nd nd nd na nd nd nd nd nd OR Quart 4 nd nd nd >4.1 nd nd nd nd nd p Value nd nd nd <0.21 nd nd nd nd nd 95% CI of nd nd nd >0.45 nd nd nd nd nd OR Quart4 nd nd nd na nd nd nd nd nd Transthyretin sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 55200 45500 nd nd Average nd nd 63200 55200 nd nd Stdev nd nd 39800 25800 nd nd p(t-test) nd nd 0.62 nd nd Min nd nd 6500 30100 nd nd Max nd nd 293000 89900 nd nd n (Samp) nd nd 488 6 nd nd 285 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 n (Patient) nd nd 222 6 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC nd nd nd 0.47 nd nd nd nd nd SE nd nd nd 0.12 nd nd nd nd nd p nd nd nd 0.83 nd nd nd nd nd nCohort 1 nd nd nd 488 nd nd nd nd nd nCohort 2 nd nd nd 6 nd nd nd nd nd Cutoff 1 nd nd nd 36200 nd nd nd nd nd Sens I nd nd nd 83% nd nd nd nd nd Spec 1 nd nd nd 27% nd nd nd nd nd Cutoff 2 nd nd nd 36200 nd nd nd nd nd Sens2 nd nd nd 83% nd nd nd nd nd Spec 2 nd nd nd 27% nd nd nd nd nd Cutoff 3 nd nd nd 29900 nd nd nd nd nd Sens 3 nd nd nd 100% nd nd nd nd nd Spec 3 nd nd nd 18% nd nd nd nd nd Cutoff 4 nd nd nd 73300 nd nd nd nd nd Sens4 nd nd nd 33% nd nd nd nd nd Spec 4 nd nd nd 70% nd nd nd nd nd Cutoff 5 nd nd nd 85300 nd nd nd nd nd Sens5 nd nd nd 17% nd nd nd nd nd Spec 5 nd nd nd 80% nd nd nd nd nd Cutoff 6 nd nd nd 118000 nd nd nd nd nd Sens 6 nd nd nd 0% nd nd nd nd nd Spec 6 nd nd nd 90% nd nd nd nd nd OR Quart 2 nd nd nd 0 nd nd nd nd nd p Value nd nd nd na nd nd nd nd nd 95% CI of nd nd nd na nd nd nd nd nd OR Quart2 nd nd nd na nd nd nd nd nd OR Quart 3 nd nd nd 1.5 nd nd nd nd nd p Value nd nd nd 0.65 nd nd nd nd nd 95% CI of nd nd nd 0.25 nd nd nd nd nd OR Quart3 nd nd nd 9.2 nd nd nd nd nd OR Quart 4 nd nd nd 0.50 nd nd nd nd nd p Value nd nd nd 0.57 nd nd nd nd nd 95% CI of nd nd nd 0.045 nd nd nd nd nd OR Quart4 nd nd nd 5.6 nd nd nd nd nd C-peptide EDTA sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2660 3260 2660 2410 2660 2360 Average 3310 4600 3310 3140 3310 3480 Stdev 2840 3170 2840 2630 2840 2950 p(t-test) 0.23 0.87 0.88 Min 7.96 1740 7.96 726 7.96 163 Max 21700 9770 21700 8140 21700 7570 n(Samp) 601 7 601 8 601 7 n (Patient) 269 7 269 8 269 7 286 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 2600 1520 nd nd Average nd nd 3300 2670 nd nd Stdev nd nd 2850 2130 nd nd p(t-test) nd nd 0.56 nd nd Min nd nd 7.96 674 nd nd Max nd nd 21700 5230 nd nd n (Samp) nd nd 582 7 nd nd n (Patient) nd nd 246 7 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.64 nd nd 0.48 nd 0.44 0.52 nd nd SE 0.11 nd nd 0.10 nd 0.11 0.11 nd nd p 0.20 nd nd 0.81 nd 0.60 0.85 nd nd nCohort 1 601 nd nd 601 nd 582 601 nd nd nCohort 2 7 nd nd 8 nd 7 7 nd nd Cutoff 1 2450 nd nd 998 nd 998 1650 nd nd Sens 1 71% nd nd 75% nd 71% 71% nd nd Spec 1 47% nd nd 16% nd 17% 34% nd nd Cutoff 2 1790 nd nd 875 nd 708 1630 nd nd Sens 2 86% nd nd 88% nd 86% 86% nd nd Spec 2 36% nd nd 13% nd 10% 34% nd nd Cutoff 3 1730 nd nd 708 nd 656 159 nd nd Sens 3 100% nd nd 100% nd 100% 100% nd nd Spec 3 36% nd nd 10% nd 10% 3% nd nd Cutoff 4 4100 nd nd 4100 nd 4090 4100 nd nd Sens 4 43% nd nd 38% nd 43% 29% nd nd Spec 4 70% nd nd 70% nd 70% 70% nd nd Cutoff 5 4920 nd nd 4920 nd 4940 4920 nd nd Sens 5 43% nd nd 12% nd 14% 29% nd nd Spec 5 80% nd nd 80% nd 80% 80% nd nd Cutoff 6 6430 nd nd 6430 nd 6630 6430 nd nd Sens 6 29% nd nd 12% nd 0% 29% nd nd Spec 6 90% nd nd 90% nd 90% 90% nd nd OR Quart 2 >3.1 nd nd 0.33 nd 0 3.0 nd nd p Value <0.34 nd nd 0.34 nd na 0.34 nd nd 95% CI of >0.31 nd nd 0.034 nd na 0.31 nd nd OR Quart2 na nd nd 3.2 nd na 30 nd nd OR Quart 3 >1.0 nd nd 0.33 nd 0.33 1.0 nd nd p Value <1.00 nd nd 0.34 nd 0.34 1.0 nd nd 95% CI of >0.062 nd nd 0.034 nd 0.034 0.062 nd nd OR Quart3 na nd nd 3.2 nd 3.2 16 nd nd OR Quart 4 >3.1 nd nd 1.0 nd 1.0 2.0 nd nd p Value <0.34 nd nd 0.99 nd 0.99 0.57 nd nd 95% CI of >0.31 nd nd 0.20 nd 0.20 0.18 nd nd OR Quart4 na nd nd 5.1 nd 5.1 22 nd nd Gastric inhibitory polypeptide EDTA sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 26.8 14.2 26.8 8.52 26.8 19.4 Average 56.3 22.6 56.3 23.4 56.3 59.1 287 sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Stdev 81.4 19.5 81.4 24.2 81.4 89.2 p(t-test) 0.27 0.25 0.93 Min 0.888 7.46 0.888 6.35 0.888 7.18 Max 820 59.5 820 72.4 820 251 n(Samp) 601 7 601 8 601 7 n (Patient) 269 7 269 8 269 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 24.8 37.0 nd nd Average nd nd 55.8 45.7 nd nd Stdev nd nd 82.5 43.3 nd nd p(t-test) nd nd 0.75 nd nd Min nd nd 0.888 7.04 nd nd Max nd nd 820 130 nd nd n(Samp) nd nd 582 7 nd nd n (Patient) nd nd 246 7 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.35 nd nd 0.32 nd 0.52 0.45 nd nd SE 0.11 nd nd 0.11 nd 0.11 0.11 nd nd p 0.19 nd nd 0.094 nd 0.84 0.68 nd nd nCohort 1 601 nd nd 601 nd 582 601 nd nd nCohort 2 7 nd nd 8 nd 7 7 nd nd Cutoff 1 7.95 nd nd 7.83 nd 25.8 14.3 nd nd Sens 1 71% nd nd 75% nd 71% 71% nd nd Spec 1 12% nd nd 12% nd 51% 29% nd nd Cutoff 2 7.56 nd nd 6.99 nd 7.83 8.52 nd nd Sens 2 86% nd nd 88% nd 86% 86% nd nd Spec 2 11% nd nd 10% nd 13% 13% nd nd Cutoff 3 7.37 nd nd 6.25 nd 6.99 6.99 nd nd Sens 3 100% nd nd 100% nd 100% 100% nd nd Spec 3 10% nd nd 8% nd 10% 10% nd nd Cutoff 4 49.7 nd nd 49.7 nd 49.1 49.7 nd nd Sens 4 14% nd nd 12% nd 29% 29% nd nd Spec 4 70% nd nd 70% nd 70% 70% nd nd Cutoff 5 81.4 nd nd 81.4 nd 80.9 81.4 nd nd Sens 5 0% nd nd 0% nd 14% 29% nd nd Spec 5 80% nd nd 80% nd 80% 80% nd nd Cutoff 6 147 nd nd 147 nd 147 147 nd nd Sens 6 0% nd nd 0% nd 0% 14% nd nd Spec 6 90% nd nd 90% nd 90% 90% nd nd OR Quart 2 >2.0 nd nd 2.0 nd 0 0 nd nd p Value <0.57 nd nd 0.57 nd na na nd nd 95% CI of >0.18 nd nd 0.18 nd na na nd nd OR Quart2 na nd nd 23 nd na na nd nd OR Quart 3 >2.0 nd nd 0 nd 1.5 1.5 nd nd p Value <0.57 nd nd na nd 0.65 0.65 nd nd 95% CI of >0.18 nd nd na nd 0.25 0.25 nd nd OR Quart3 na nd nd na nd 9.2 9.2 nd nd OR Quart 4 >3.1 nd nd 5.2 nd 0.99 1.0 nd nd p Value <0.34 nd nd 0.14 nd 0.99 1.0 nd nd 288 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only 95% CI of >0.31 nd nd 0.60 nd 0.14 0.14 nd nd OR Quart4 na nd nd 45 nd 17.1 7.2 nd nd Peptide YY EDTA sCr or UO Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 40.2 95.2 40.2 87.1 40.2 89.2 Average 56.3 111 56.3 102 56.3 135 Stdev 68.1 96.7 68.1 85.9 68.1 143 p(t-test) 0.037 0.063 0.0029 Min 0.00999 12.7 0.00999 12.0 0.00999 8.31 Max 789 284 789 270 789 406 n(Samp) 601 7 601 8 601 7 n (Patient) 269 7 269 8 269 7 UO only Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median nd nd 39.4 118 nd nd Average nd nd 54.6 128 nd nd Stdev nd nd 67.4 84.8 nd nd p(t-test) nd nd 0.0044 nd nd Min nd nd 0.00999 22.6 nd nd Max nd nd 789 270 nd nd n(Samp) nd nd 582 7 nd nd n (Patient) nd nd 246 7 nd nd Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only AUC 0.69 nd nd 0.69 nd 0.79 0.66 nd nd SE 0.11 nd nd 0.11 nd 0.10 0.11 nd nd p 0.098 nd nd 0.076 nd 0.0039 0.16 nd nd nCohort 1 601 nd nd 601 nd 582 601 nd nd nCohort 2 7 nd nd 8 nd 7 7 nd nd Cutoff 1 55.3 nd nd 45.0 nd 95.9 44.1 nd nd Sens 1 71% nd nd 75% nd 71% 71% nd nd Spec 1 67% nd nd 56% nd 86% 55% nd nd Cutoff 2 18.0 nd nd 21.6 nd 45.0 13.4 nd nd Sens 2 86% nd nd 88% nd 86% 86% nd nd Spec 2 23% nd nd 27% nd 58% 19% nd nd Cutoff 3 12.6 nd nd 11.7 nd 22.6 7.32 nd nd Sens 3 100% nd nd 100% nd 100% 100% nd nd Spec 3 18% nd nd 17% nd 30% 14% nd nd Cutoff 4 60.3 nd nd 60.3 nd 58.5 60.3 nd nd Sens 4 57% nd nd 62% nd 71% 57% nd nd Spec 4 70% nd nd 70% nd 70% 70% nd nd Cutoff 5 81.2 nd nd 81.2 nd 79.0 81.2 nd nd Sens 5 57% nd nd 50% nd 71% 57% nd nd Spec 5 80% nd nd 80% nd 80% 80% nd nd Cutoff 6 113 nd nd 113 nd 110 113 nd nd Sens 6 43% nd nd 38% nd 57% 43% nd nd Spec 6 90% nd nd 90% nd 90% 90% nd nd OR Quart 2 0 nd nd 1.0 nd >1.0 0 nd nd 289 Ohr prior to AKI stage 24hr prior to AKI stage 48hr prior to AKI stage sCr or UO sCr only UO only sCr or UO sCr only UO only sCr or UO sCr only UO only p Value na nd nd 1.0 nd <1.00 na nd nd 95% CI of na nd nd 0.062 nd >0.062 na nd nd OR Quart2 na nd nd 16 nd na na nd nd OR Quart 3 0.50 nd nd 1.0 nd >1.0 0.50 nd nd p Value 0.57 nd nd 1.0 nd <1.00 0.57 nd nd 95% CI of 0.045 nd nd 0.062 nd >0.062 0.045 nd nd OR Quart3 5.5 nd nd 16 nd na 5.5 nd nd OR Quart 4 2.0 nd nd 5.1 nd >5.1 2.0 nd nd p Value 0.42 nd nd 0.14 nd <0.14 0.42 nd nd 95% CI of 0.37 nd nd 0.59 nd >0.59 0.37 nd nd OR Quart4 11 nd nd 4 nd na 11 nd nd [0178] Table 11: Comparison of marker levels in enroll urine samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0 or R within 48hrs) and in enroll urine samples collected from Cohort 2 (subjects reaching RIFLE stage I or F within 48hrs). Enroll samples from patients already at RIFLE stage I or F were included in Cohort 2. Agouti-related protein sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.698 0.922 0.729 0.982 0.698 0.949 Average 1.25 1.43 1.25 1.91 1.24 1.43 Stdev 2.34 1.46 2.20 1.93 2.32 1.49 p(t-test) 0.59 0.33 0.57 Min 0.00198 0.00498 0.00198 0.126 0.00198 0.00498 Max 20.0 6.53 20.0 6.53 20.0 6.53 n (Samp) 210 57 250 11 208 50 n (Patient) 210 57 250 11 208 50 At Enrollment sCr or UO sCr only UO only AUC 0.60 0.63 0.60 SE 0.044 0.092 0.046 p 0.030 0.14 0.037 nCohort 1 210 250 208 nCohort 2 57 11 50 Cutoff 1 0.579 0.720 0.549 Sens 1 70% 73% 70% Spec 1 45% 50% 44% Cutoff 2 0.301 0.579 0.301 Sens 2 81% 82% 80% Spec 2 29% 43% 28% Cutoff 3 0.156 0.129 0.202 Sens 3 91% 91% 90% Spec 3 16% 12% 19% Cutoff 4 1.16 1.24 1.16 Sens 4 42% 45% 44% Spec 4 70% 70% 70% Cutoff 5 1.51 1.60 1.51 290 At Enrollment sCr or UO sCr only UO only Sens 5 37% 45% 38% Spec 5 80% 80% 80% Cutoff 6 2.33 2.33 2.34 Sens 6 18% 36% 16% Spec 6 90% 90% 90% OR Quart 2 1.5 1.0 1.4 p Value 0.37 1.0 0.48 95% CI of 0.60 0.14 0.53 OR Quart2 3.9 7.3 3.8 OR Quart 3 1.5 1.0 1.5 p Value 0.37 1.0 0.46 95% CI of 0.60 0.14 0.54 OR Quart3 3.9 7.3 3.9 OR Quart 4 3.1 2.6 3.1 p Value 0.011 0.27 0.014 95% CI of 1.3 0.48 1.3 OR Quart4 7.4 14 7.7 Osteocalcin sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 6300 8150 6550 9180 6450 7750 Average 8120 10500 8500 12300 8410 9760 Stdev 7530 9290 7980 9120 7880 9070 p(t-test) 0.0090 0.033 0.17 Min 73.4 123 73.4 699 73.4 123 Max 83000 49400 83000 33400 83000 49400 n(Samp) 341 101 413 21 324 86 n (Patient) 341 101 413 21 324 86 At Enrollment sCr or UO sCr only UO only AUC 0.59 0.65 0.55 SE 0.033 0.066 0.036 p 0.0086 0.024 0.12 nCohort1 341 413 324 nCohort 2 101 21 86 Cutoff 1 5010 7030 4960 Sens 1 70% 71% 71% Spec 1 40% 54% 40% Cutoff 2 4190 5090 3570 Sens 2 80% 81% 80% Spec 2 33% 40% 26% Cutoff 3 2770 4190 2240 Sens 3 90% 90% 91% Spec 3 18% 31% 11% Cutoff 4 9160 9550 9550 Sens 4 41% 48% 31% Spec 4 70% 70% 70% Cutoff 5 11400 12000 12000 Sens 5 32% 38% 23% Spec 5 80% 80% 80% 291 At Enrollment sCr or UO sCr only UO only Cutoff 6 16700 17000 17300 Sens 6 15% 24% 10% Spec 6 90% 90% 90% OR Quart 2 0.99 1.5 1.1 p Value 0.98 0.66 0.88 95% CI of 0.49 0.25 0.51 OR Quart2 2.0 9.2 2.2 OR Quart 3 1.9 4.2 1.8 p Value 0.055 0.072 0.091 95% CI of 0.99 0.88 0.91 OR Quart3 3.6 20 3.6 OR Quart 4 1.9 4.2 1.5 p Value 0.043 0.074 0.24 95% CI of 1.0 0.87 0.76 OR Quart4 3.7 20 3.0 Follitropin subunit beta sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 15.5 15.4 15.9 8.19 15.9 16.6 Average 34.6 28.3 33.4 39.7 36.1 24.2 Stdev 44.9 43.7 42.6 87.2 48.5 25.0 p(t-test) 0.34 0.66 0.095 Min 0.342 0.716 0.342 1.46 0.342 0.716 Max 246 300 246 300 300 119 n (Samp) 210 57 250 11 208 50 n (Patient) 210 57 250 11 208 50 At Enrollment sCr or UO sCr only UO only AUC 0.49 0.43 0.48 SE 0.043 0.092 0.046 p 0.82 0.41 0.67 nCohort 1 210 250 208 nCohort 2 57 11 50 Cutoff 1 8.14 5.26 8.50 Sens 1 70% 73% 70% Spec 1 34% 23% 36% Cutoff 2 6.06 5.23 6.34 Sens 2 81% 82% 80% Spec 2 27% 23% 28% Cutoff 3 2.98 2.84 4.72 Sens 3 91% 91% 90% Spec 3 15% 13% 22% Cutoff 4 38.4 36.6 38.4 Sens 4 21% 9% 22% Spec 4 70% 70% 70% Cutoff 5 56.4 53.3 57.0 Sens 5 9% 9% 8% Spec 5 80% 80% 80% Cutoff 6 86.0 84.9 97.1 Sens 6 4% 9% 2% 292 At Enrollment sCr or UO sCr only UO only Spec 6 90% 90% 90% OR Quart 2 1.9 3.1 1.7 p Value 0.15 0.33 0.25 95% CI of 0.81 0.32 0.69 OR Quart2 4.3 31 4.1 OR Quart 3 1.7 3.1 1.8 p Value 0.21 0.33 0.19 95% CI of 0.74 0.32 0.75 OR Quart3 4.0 31 4.3 OR Quart 4 1.0 4.3 0.90 p Value 0.97 0.20 0.83 95% CI of 0.41 0.46 0.34 OR Quart4 2.5 39 2.4 Follistatin sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 6.79 10.6 7.20 19.0 6.69 9.59 Average 38.8 43.3 37.8 94.8 41.7 46.2 Stdev 402 150 371 279 441 159 p(t-test) 0.91 0.49 0.92 Min 0.000347 0.224 0.000347 4.40 0.000347 0.224 Max 8290 1300 8290 1300 8290 1300 n (Samp) 428 108 507 21 355 96 n (Patient) 428 108 507 21 355 96 At Enrollment sCr or UO sCr only UO only AUC 0.60 0.73 0.59 SE 0.032 0.064 0.034 p 0.0023 2.7E-4 0.0054 nCohort 1 428 507 355 nCohort 2 108 21 96 Cutoff 1 4.96 11.9 4.69 Sens 1 70% 71% 71% Spec 1 39% 66% 38% Cutoff 2 4.39 8.95 4.00 Sens 2 81% 81% 80% Spec 2 36% 57% 34% Cutoff 3 2.44 5.51 2.40 Sens 3 91% 90% 91% Spec 3 23% 42% 22% Cutoff 4 13.1 13.7 12.8 Sens 4 43% 67% 43% Spec 4 70% 70% 70% Cutoff 5 22.8 23.6 19.6 Sens 5 27% 33% 32% Spec 5 80% 80% 80% Cutoff 6 45.9 47.8 40.0 Sens 6 18% 29% 19% Spec 6 90% 90% 90% OR Quart 2 1.9 >4.1 1.5 293 At Enrollment sCr or UO sCr only UO only p Value 0.070 <0.21 0.23 95% CI of 0.95 >0.45 0.76 OR Quart2 3.6 na 3.1 OR Quart 3 1.9 >7.4 1.5 p Value 0.050 <0.063 0.23 95% CI of 1.00 >0.90 0.76 OR Quart3 3.8 na 3.1 OR Quart 4 2.8 >11 2.6 p Value 0.0017 <0.024 0.0051 95% CI of 1.5 >1.4 1.3 OR Quart4 5.4 na 5.0 Vitamin D-binding protein sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 139 425 162 567 152 383 Average 1730 8720 2980 12000 2400 7380 Stdev 7110 31500 16300 22200 9120 32200 p(t-test) 0.0051 0.078 0.064 Min 0.200 0.337 0.259 31.9 0.200 0.337 Max 63300 221000 221000 62500 63300 221000 n (Samp) 189 56 229 11 187 49 n (Patient) 189 56 229 11 187 49 At Enrollment sCr or UO sCr only UO only AUC 0.67 0.70 0.63 SE 0.043 0.090 0.047 p 1.4E-4 0.024 0.0057 nCohort 1 189 229 187 nCohort 2 56 11 49 Cutoff 1 160 301 121 Sens 1 71% 73% 71% Spec 1 54% 64% 45% Cutoff 2 80.3 229 78.7 Sens 2 80% 82% 82% Spec 2 35% 59% 34% Cutoff 3 41.5 80.3 32.2 Sens 3 91% 91% 92% Spec 3 16% 32% 11% Cutoff 4 325 435 350 Sens 4 57% 55% 53% Spec 4 70% 70% 70% Cutoff 5 662 876 683 Sens 5 41% 45% 41% Spec 5 80% 80% 80% Cutoff 6 1670 4210 3130 Sens 6 32% 36% 22% Spec 6 90% 90% 90% OR Quart 2 0.87 1.0 0.87 p Value 0.79 1.0 0.79 95% CI of 0.31 0.061 0.31 294 At Enrollment sCr or UO sCr only UO only OR Quart2 2.4 16 2.4 OR Quart 3 2.1 4.2 1.4 p Value 0.12 0.20 0.47 95% CI of 0.83 0.46 0.55 OR Quart3 5.1 39 3.7 OR Quart 4 3.4 5.4 2.8 p Value 0.0061 0.13 0.021 95% CI of 1.4 0.61 1.2 OR Quart4 8.2 7 6.9 Glucagon sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 238 347 nd nd 238 347 Average 1410 3470 nd nd 1260 3360 Stdev 2870 4300 nd nd 2630 4250 p(t-test) 0.0045 nd nd 0.0037 Min 1.98 5.61 nd nd 1.98 5.61 Max 9330 9330 nd nd 9330 9330 n (Samp) 111 24 nd nd 92 22 n (Patient) 111 24 nd nd 92 22 At Enrollment sCr or UO sCr only UO only AUC 0.63 nd 0.63 SE 0.066 nd 0.069 p 0.057 nd 0.060 nCohort 1 111 nd 92 nCohort 2 24 nd 22 Cutoff 1 41.7 nd 41.7 Sens 1 71% nd 73% Spec 1 39% nd 39% Cutoff 2 8.21 nd 8.21 Sens 2 83% nd 82% Spec 2 27% nd 28% Cutoff 3 6.53 nd 6.52 Sens3 92% nd 91% Spec 3 20% nd 21% Cutoff 4 347 nd 347 Sens4 46% nd 45% Spec 4 76% nd 76% Cutoff 5 2420 nd 2420 Sens 5 33% nd 32% Spec 5 89% nd 91% Cutoff 6 9330 nd 2420 Sens 6 0% nd 32% Spec 6 100% nd 91% OR Quart 2 1.2 nd 0.96 p Value 0.76 nd 0.96 95% CI of 0.30 nd 0.22 OR Quart2 5.1 nd 4.3 OR Quart 3 0.97 nd 1.0 295 At Enrollment sCr or UO sCr only UO only p Value 0.96 nd 1.0 95% CI of 0.22 nd 0.22 OR Quart3 4.2 nd 4.5 OR Quart 4 3.5 nd 3.2 p Value 0.055 nd 0.085 95% CI of 0.98 nd 0.86 OR Quart4 12 nd 12 Interleukin-17A sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.00360 0.00409 0.00360 0.00537 0.00360 0.00409 Average 0.858 1.17 0.906 1.50 0.743 1.35 Stdev 6.05 4.58 5.89 4.22 5.58 4.91 p(t-test) 0.57 0.59 0.28 Min 0.000344 0.000344 0.000344 0.000380 0.000344 0.000344 Max 105 39.1 105 18.8 105 39.1 n (Samp) 525 138 623 30 448 119 n (Patient) 525 138 623 30 448 119 At Enrollment sCr or UO sCr only UO only AUC 0.54 0.52 0.56 SE 0.028 0.055 0.030 p 0.19 0.66 0.045 nCohort 1 525 623 448 nCohort 2 138 30 119 Cutoff 1 0.00287 0.00172 0.00303 Sens 1 71% 70% 71% Spec 1 38% 22% 44% Cutoff 2 0.000734 0.000734 0.000734 Sens 2 82% 80% 82% Spec 2 14% 15% 18% Cutoff 3 0.000410 0.000380 0.000410 Sens 3 91% 97% 92% Spec 3 5% 3% 6% Cutoff 4 0.00988 0.0127 0.00988 Sens 4 33% 33% 35% Spec 4 70% 70% 70% Cutoff 5 0.121 0.150 0.129 Sens 5 28% 23% 30% Spec 5 80% 80% 80% Cutoff 6 0.682 0.766 0.668 Sens 6 17% 17% 19% Spec 6 90% 90% 90% OR Quart 2 0.55 0.085 1.1 p Value 0.042 0.019 0.78 95% CI of 0.31 0.011 0.59 OR Quart2 0.98 0.67 2.0 OR Quart 3 1.1 0.71 1.4 p Value 0.72 0.48 0.25 95% CI of 0.66 0.28 0.79 296 At Enrollment sCr or UO sCr only UO only OR Quart3 1.8 1.8 2.6 OR Quart 4 1.2 0.90 1.7 p Value 0.54 0.81 0.066 95% CI of 0.71 0.37 0.96 OR Quart4 2.0 2.2 3.1 Insulin receptor substrate 1 sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.000546 0.00110 0.000546 0.00148 0.000546 0.000578 Average 0.00521 0.00831 0.00618 0.00178 0.00522 0.00930 Stdev 0.0509 0.0384 0.0501 0.00164 0.0512 0.0409 p(t-test) 0.67 0.77 0.60 Min 1.25E-9 1.25E-9 1.25E-9 7.25E-7 1.25E-9 1.25E-9 Max 0.735 0.282 0.735 0.00563 0.735 0.282 n (Samp) 209 57 249 11 207 50 n (Patient) 209 57 249 11 207 50 At Enrollment sCr or UO sCr only UO only AUC 0.55 0.62 0.55 SE 0.044 0.092 0.046 p 0.26 0.19 0.25 nCohort 1 209 249 207 nCohort 2 57 11 50 Cutoff 1 2.32E-6 0.000646 2.32E-6 Sens 1 75% 73% 74% Spec 1 30% 55% 31% Cutoff 2 9.90E-7 2.78E-5 9.90E-7 Sens 2 84% 82% 84% Spec 2 13% 45% 14% Cutoff 3 1.25E-9 2.32E-6 1.25E-9 Sens 3 96% 91% 96% Spec 3 7% 30% 7% Cutoff 4 0.00229 0.00229 0.00148 Sens 4 35% 36% 42% Spec 4 75% 73% 71% Cutoff 5 0.00243 0.00243 0.00243 Sens 5 25% 18% 26% Spec 5 85% 83% 85% Cutoff 6 0.00303 0.00334 0.00303 Sens 6 18% 9% 20% Spec 6 90% 91% 90% OR Quart 2 1.1 2.0 1.0 p Value 0.86 0.57 1.0 95% CI of 0.46 0.18 0.41 OR Quart2 2.5 23 2.4 OR Quart 3 1.3 4.2 0.62 p Value 0.53 0.21 0.33 95% CI of 0.57 0.46 0.23 OR Quart3 3.0 39 1.6 OR Quart 4 1.1 4.2 1.7 297 At Enrollment sCr or UO sCr only UO only p Value 0.86 0.21 0.23 95% CI of 0.46 0.46 0.72 OR Quart4 2.5 39 3.8 Involucrin sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.462 0.811 0.507 0.612 0.487 1.05 Average 1.05 2.51 1.26 2.28 1.10 2.56 Stdev 2.17 4.01 2.61 3.12 2.35 4.10 p(t-test) 2.2E-6 0.11 3.3E-5 Min 0.0119 0.0294 0.0119 0.0767 0.0191 0.0294 Max 31.3 19.7 31.3 9.64 31.3 19.7 n (Samp) 433 84 491 17 362 74 n (Patient) 433 84 491 17 362 74 At Enrollment sCr or UO sCr only UO only AUC 0.66 0.56 0.67 SE 0.035 0.073 0.037 p 6.8E-6 0.44 5.9E-6 nCohort 1 433 491 362 nCohort 2 84 17 74 Cutoff 1 0.450 0.246 0.489 Sens 1 70% 71% 70% Spec 1 49% 29% 50% Cutoff 2 0.274 0.191 0.357 Sens 2 81% 82% 81% Spec 2 34% 22% 42% Cutoff 3 0.185 0.114 0.185 Sens 3 90% 94% 91% Spec 3 23% 13% 21% Cutoff 4 0.905 1.00 0.916 Sens 4 49% 35% 51% Spec 4 70% 70% 70% Cutoff 5 1.36 1.59 1.36 Sens 5 45% 35% 47% Spec 5 80% 80% 80% Cutoff 6 2.24 2.64 2.19 Sens 6 29% 29% 30% Spec 6 90% 90% 90% OR Quart 2 1.6 1.0 1.8 p Value 0.23 1.0 0.20 95% CI of 0.73 0.24 0.74 OR Quart2 3.6 4.1 4.2 OR Quart 3 1.7 0.74 1.8 p Value 0.17 0.70 0.20 95% CI of 0.79 0.16 0.74 OR Quart3 3.8 3.4 4.2 OR Quart 4 4.4 1.5 5.3 p Value 5.6E-5 0.52 4.OE-5 95% CI of 2.1 0.42 2.4 298 At Enrollment sCr or UO sCr only UO only OR Quart4 9.1 5.5 12 Lipopolysaccharide (serotypes -K,-O) sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.53E-5 9.99E-5 2.53E-5 0.00200 4.34E-5 9.88E-5 Average 0.136 0.107 0.124 0.420 0.118 0.0993 Stdev 0.690 0.444 0.650 0.920 0.603 0.459 p(t-test) 0.71 0.069 0.80 Min 1.40E-8 4.54E-6 1.40E-8 4.54E-6 2.09E-8 6.10E-6 Max 6.42 3.10 6.42 3.10 5.44 3.10 n (Samp) 433 84 491 17 362 74 n (Patient) 433 84 491 17 362 74 At Enrollment sCr or UO sCr only UO only AUC 0.54 0.63 0.52 SE 0.035 0.074 0.037 p 0.30 0.071 0.56 nCohort 1 433 491 362 nCohort 2 84 17 74 Cutoff 1 1.48E-5 1.80E-5 1.48E-5 Sens 1 70% 71% 70% Spec 1 30% 42% 31% Cutoff 2 1.14E-5 1.48E-5 1. 14E-5 Sens 2 81% 82% 81% Spec 2 18% 30% 18% Cutoff 3 4.54E-6 2.09E-8 4.54E-6 Sens 3 98% 100% 100% Spec 3 5% 1% 4% Cutoff 4 0.00110 0.00134 0.00159 Sens 4 37% 53% 34% Spec 4 70% 70% 70% Cutoff 5 0.00662 0.00713 0.00713 Sens 5 26% 41% 23% Spec 5 80% 80% 80% Cutoff 6 0.0358 0.0396 0.0396 Sens 6 17% 35% 14% Spec 6 90% 90% 90% OR Quart 2 0.53 1.0 0.66 p Value 0.082 1.0 0.26 95% CI of 0.26 0.20 0.31 OR Quart2 1.1 5.1 1.4 OR Quart 3 0.76 1.0 1.0 p Value 0.40 1.0 1.0 95% CI of 0.39 0.20 0.50 OR Quart3 1.5 5.1 2.0 OR Quart 4 1.1 2.8 1.0 p Value 0.66 0.14 1.0 95% CI of 0.62 0.72 0.50 OR Quart4 2.1 11 2.0 299 Collagenase 3 sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.230 3.88 1.29 0.202 1.23 6.71 Average 10.1 10.6 9.83 4.52 10.1 12.0 Stdev 22.3 16.2 20.7 12.5 22.4 16.8 p(t-test) 0.86 0.40 0.59 Min 0.00479 0.00479 0.00479 0.00479 0.00479 0.00479 Max 182 79.6 182 41.9 182 79.6 n (Samp) 189 56 229 11 187 49 n (Patient) 189 56 229 11 187 49 At Enrollment sCr or UO sCr only UO only AUC 0.54 0.35 0.58 SE 0.044 0.092 0.047 p 0.42 0.11 0.091 nCohort 1 189 229 187 nCohort 2 56 11 49 Cutoff 1 0.0466 0.00741 0.0466 Sens 1 75% 73% 80% Spec 1 29% 12% 32% Cutoff 2 0.0198 0 0.0425 Sens 2 84% 100% 82% Spec 2 19% 0% 29% Cutoff 3 0 0 0.00519 Sens 3 100% 100% 92% Spec 3 0% 0% 4% Cutoff 4 7.62 8.97 7.51 Sens 4 43% 9% 49% Spec 4 72% 70% 70% Cutoff 5 15.2 15.2 15.2 Sens 5 23% 9% 27% Spec 5 80% 80% 80% Cutoff 6 29.8 29.8 29.8 Sens 6 12% 9% 14% Spec 6 90% 90% 90% OR Quart 2 0.90 3.1 1.1 p Value 0.82 0.33 0.80 95% CI of 0.36 0.31 0.42 OR Quart2 2.2 31 3.0 OR Quart 3 1.6 3.1 1.9 p Value 0.29 0.33 0.17 95% CI of 0.68 0.31 0.75 OR Quart3 3.7 31 4.8 OR Quart 4 1.4 4.2 1.9 p Value 0.42 0.20 0.17 95% CI of 0.61 0.46 0.75 OR Quart4 3.3 39 4.8 NF-kappa-B inhibitor alpha sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 3.20E-5 0.000211 9.81E-5 0.000566 3.20E-5 0.000202 300 sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Average 0.00582 0.00754 0.00516 0.0325 0.00631 0.00660 Stdev 0.0293 0.0351 0.0269 0.0776 0.0298 0.0363 p(t-test) 0.71 0.0039 0.95 Min 3.52E-7 3.52E-7 3.52E-7 9.58E-7 3.52E-7 3.52E-7 Max 0.268 0.257 0.268 0.257 0.268 0.257 n (Samp) 209 57 249 11 207 50 n (Patient) 209 57 249 11 207 50 At Enrollment sCr or UO sCr only UO only AUC 0.58 0.63 0.56 SE 0.044 0.092 0.046 p 0.077 0.14 0.17 nCohort 1 209 249 207 nCohort 2 57 11 50 Cutoff 1 2.62E-5 2.94E-5 2.62E-5 Sens 1 70% 73% 70% Spec 1 37% 38% 37% Cutoff 2 1.03E-6 2.25E-5 1.03E-6 Sens 2 82% 82% 82% Spec 2 21% 33% 21% Cutoff 3 5.23E-7 6.66E-6 5.23E-7 Sens 3 93% 91% 92% Spec 3 17% 31% 17% Cutoff 4 0.000493 0.000532 0.000523 Sens 4 42% 55% 40% Spec 4 71% 71% 71% Cutoff 5 0.00113 0.00128 0.00113 Sens 5 25% 27% 24% Spec 5 81% 80% 81% Cutoff 6 0.00351 0.00427 0.00381 Sens 6 19% 27% 16% Spec 6 90% 90% 90% OR Quart 2 0.79 4.2 0.69 p Value 0.61 0.21 0.46 95% CI of 0.32 0.46 0.26 OR Quart2 2.0 39 1.8 OR Quart 3 1.7 1.0 1.9 p Value 0.22 1.0 0.14 95% CI of 0.74 0.061 0.81 OR Quart3 3.9 16 4.4 OR Quart 4 1.5 5.3 1.2 p Value 0.32 0.13 0.68 95% CI of 0.67 0.61 0.49 OR Quart4 3.5 7 2.9 Beta-nerve growth factor sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2.84 1.92 2.82 2.35 2.83 1.61 Average 4.22 3.48 4.21 2.38 4.19 3.65 Stdev 4.78 4.95 4.92 1.82 4.77 5.25 301 sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) 0.31 0.22 0.48 Min 0.000201 0.000506 0.000201 0.0483 0.000201 0.000506 Max 29.2 25.2 29.2 6.35 29.2 25.2 n (Samp) 210 57 250 11 209 50 n (Patient) 210 57 250 11 209 50 At Enrollment sCr or UO sCr only UO only AUC 0.41 0.41 0.42 SE 0.044 0.092 0.046 p 0.046 0.31 0.067 nCohort 1 210 250 209 nCohort 2 57 11 50 Cutoff 1 0.937 0.937 0.869 Sens 1 70% 73% 70% Spec 1 19% 20% 17% Cutoff 2 0.676 0.781 0.676 Sens 2 81% 82% 80% Spec 2 13% 16% 13% Cutoff 3 0.000506 0.771 0.000506 Sens 3 96% 91% 96% Spec 3 2% 16% 2% Cutoff 4 4.15 4.15 4.02 Sens 4 23% 9% 26% Spec 4 70% 70% 70% Cutoff 5 5.99 5.99 5.99 Sens 5 16% 9% 18% Spec 5 80% 80% 80% Cutoff 6 9.80 9.80 11.0 Sens 6 7% 0% 8% Spec 6 90% 90% 90% OR Quart 2 1.2 2.1 0.79 p Value 0.65 0.56 0.63 95% CI of 0.51 0.18 0.30 OR Quart2 3.0 23 2.1 OR Quart 3 0.89 4.3 0.89 p Value 0.81 0.20 0.81 95% CI of 0.35 0.46 0.35 OR Quart3 2.3 39 2.3 OR Quart 4 2.7 4.3 2.2 p Value 0.017 0.20 0.060 95% CI of 1.2 0.46 0.97 OR Quart4 6.2 39 5.2 Transthyretin sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 24.4 46.1 26.7 54.5 25.1 38.0 Average 47.5 112 60.1 120 50.7 115 Stdev 78.1 259 141 179 80.5 274 p(t-test) 7.5E-4 0.16 0.0021 Min 0.164 1.67 0.164 3.29 0.430 1.67 302 sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max 648 2000 2000 638 648 2000 n (Samp) 247 69 298 12 234 61 n (Patient) 247 69 298 12 234 61 At Enrollment sCr or UO sCr only UO only AUC 0.64 0.64 0.61 SE 0.039 0.088 0.042 p 4.7E-4 0.10 0.0067 nCohort 1 247 298 234 nCohort 2 69 12 61 Cutoff 1 19.2 21.7 19.2 Sens 1 71% 75% 70% Spec 1 41% 42% 39% Cutoff 2 14.2 19.2 14.6 Sens 2 81% 83% 80% Spec 2 32% 38% 31% Cutoff 3 8.67 10.0 11.0 Sens 3 91% 92% 90% Spec 3 20% 21% 24% Cutoff 4 43.4 48.3 46.2 Sens 4 51% 58% 46% Spec 4 70% 70% 70% Cutoff 5 60.7 73.6 67.7 Sens 5 41% 42% 39% Spec 5 80% 80% 80% Cutoff 6 108 120 116 Sens 6 25% 33% 20% Spec 6 90% 90% 90% OR Quart 2 1.8 0.99 1.8 p Value 0.20 0.99 0.20 95% CI of 0.74 0.14 0.74 OR Quart2 4.1 7.2 4.4 OR Quart 3 1.6 1.5 1.5 p Value 0.28 0.65 0.38 95% CI of 0.68 0.25 0.60 OR Quart3 3.9 9.4 3.8 OR Quart 4 3.8 2.6 3.4 p Value 0.0012 0.27 0.0047 95% CI of 1.7 0.48 1.5 OR Quart4 8.5 14 8.0 [0179] Table 12: Comparison of marker levels in enroll EDTA samples collected from Cohort 1 (patients that did not progress beyond RIFLE stage 0 or R within 48hrs) and in enroll EDTA samples collected from Cohort 2 (subjects reaching RIFLE stage I or F within 48hrs). Enroll samples from patients already at stage I or F were included in Cohort 2. Agouti-related protein sCr or UO sCr only UO only 303 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0557 0.0789 nd nd 0.0560 0.0855 Average 0.0721 0.108 nd nd 0.0730 0.111 Stdev 0.0486 0.0802 nd nd 0.0489 0.0811 p(t-test) 0.0036 nd nd 0.0031 Min 0.00892 0.0112 nd nd 0.00892 0.0112 Max 0.224 0.335 nd nd 0.224 0.335 n (Samp) 120 24 nd nd 117 23 n (Patient) 120 24 nd nd 117 23 At Enrollment sCr or UO sCr only UO only AUC 0.66 nd 0.66 SE 0.065 nd 0.066 p 0.014 nd 0.015 nCohort 1 120 nd 117 nCohort 2 24 nd 23 Cutoff 1 0.0560 nd 0.0560 Sens 1 71% nd 74% Spec 1 52% nd 50% Cutoff 2 0.0500 nd 0.0500 Sens 2 83% nd 83% Spec 2 44% nd 43% Cutoff 3 0.0434 nd 0.0434 Sens3 92% nd 91% Spec 3 35% nd 33% Cutoff 4 0.0845 nd 0.0846 Sens 4 50% nd 52% Spec 4 70% nd 70% Cutoff 5 0.104 nd 0.104 Sens 5 38% nd 39% Spec 5 80% nd 80% Cutoff 6 0.141 nd 0.141 Sens 6 25% nd 26% Spec 6 90% nd 91% OR Quart 2 8.4 nd 7.0 p Value 0.052 nd 0.079 95% CI of 0.98 nd 0.80 OR Quart2 73 nd 62 OR Quart 3 8.4 nd 8.5 p Value 0.052 nd 0.052 95% CI of 0.98 nd 0.99 OR Quart3 73 nd 73 OR Quart 4 12 nd 12 p Value 0.024 nd 0.023 95% CI of 1.4 nd 1.4 OR Quart4 98 nd 99 Osteocalcin sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 2150 1740 2080 1270 2110 1850 Average 3030 2770 3030 1970 3070 2990 Stdev 3240 3170 3290 1550 3320 3290 304 sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 p(t-test) 0.66 0.39 0.89 Min 0.729 59.3 0.729 674 0.729 59.3 Max 21800 17700 21800 5090 21800 17700 n (Samp) 160 38 187 7 150 34 n (Patient) 160 38 187 7 150 34 At Enrollment sCr or UO sCr only UO only AUC 0.46 0.41 0.49 SE 0.053 0.12 0.055 p 0.46 0.45 0.88 nCohort 1 160 187 150 nCohort 2 38 7 34 Cutoff 1 1100 991 1230 Sens 1 71% 71% 71% Spec 1 26% 24% 31% Cutoff 2 855 860 854 Sens 2 82% 86% 82% Spec 2 18% 19% 19% Cutoff 3 672 672 686 Sens 3 92% 100% 91% Spec 3 12% 12% 15% Cutoff 4 3280 3280 3290 Sens 4 24% 14% 26% Spec 4 70% 70% 70% Cutoff 5 4300 4420 4300 Sens 5 21% 14% 24% Spec 5 80% 80% 80% Cutoff 6 5740 6460 5810 Sens 6 13% 0% 12% Spec 6 90% 90% 90% OR Quart 2 1.0 2.1 1.0 p Value 0.96 0.55 1.0 95% CI of 0.35 0.18 0.34 OR Quart2 3.0 24 2.9 OR Quart 3 1.5 1.0 1.3 p Value 0.45 1.0 0.60 95% CI of 0.54 0.061 0.47 OR Quart3 4.1 16 3.7 OR Quart 4 1.5 3.2 1.0 p Value 0.42 0.32 1.0 95% CI of 0.55 0.32 0.34 OR Quart4 4.2 32 2.9 Follitropin subunit beta sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 7.89 4.24 nd nd 7.48 4.21 Average 18.7 8.87 nd nd 18.4 8.97 Stdev 25.7 11.5 nd nd 25.4 11.8 p(t-test) 0.068 nd nd 0.085 Min 0.0600 1.14 nd nd 0.0600 1.14 305 sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Max 141 47.7 nd nd 141 47.7 n (Samp) 120 24 nd nd 117 23 n (Patient) 120 24 nd nd 117 23 At Enrollment sCr or UO sCr only UO only AUC 0.38 nd 0.38 SE 0.066 nd 0.067 p 0.060 nd 0.065 nCohort 1 120 nd 117 nCohort 2 24 nd 23 Cutoff 1 3.33 nd 3.05 Sens 1 71% nd 74% Spec 1 28% nd 26% Cutoff 2 2.23 nd 2.23 Sens 2 83% nd 83% Spec 2 18% nd 18% Cutoff 3 1.29 nd 1.29 Sens3 92% nd 91% Spec 3 8% nd 8% Cutoff 4 16.5 nd 16.1 Sens 4 17% nd 17% Spec 4 70% nd 70% Cutoff 5 27.5 nd 27.5 Sens 5 8% nd 9% Spec 5 80% nd 80% Cutoff 6 51.5 nd 51.5 Sens 6 0% nd 0% Spec 6 90% nd 91% OR Quart 2 0.47 nd 0.47 p Value 0.40 nd 0.40 95% CI of 0.081 nd 0.080 OR Quart2 2.7 nd 2.7 OR Quart 3 4.0 nd 3.6 p Value 0.030 nd 0.049 95% CI of 1.1 nd 1.0 OR Quart3 14 nd 13 OR Quart 4 1.6 nd 1.6 p Value 0.50 nd 0.50 95% CI of 0.41 nd 0.41 OR Quart4 6.2 nd 6.3 Follistatin sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 912 864 912 846 962 864 Average 2970 2520 2870 1220 3120 2660 Stdev 4670 4030 4540 975 4790 4230 p(t-test) 0.58 0.34 0.61 Min 0.0206 8.66 0.0206 366 0.0206 8.66 Max 28900 15600 28900 3050 28900 15600 n (Samp) 163 38 190 7 153 34 306 sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 n (Patient) 163 38 190 7 153 34 At Enrollment sCr or UO sCr only UO only AUC 0.49 0.48 0.48 SE 0.052 0.11 0.055 p 0.78 0.87 0.76 nCohort 1 163 190 153 nCohort 2 38 7 34 Cutoff 1 486 609 486 Sens 1 71% 71% 71% Spec 1 23% 32% 24% Cutoff 2 466 466 398 Sens 2 82% 86% 82% Spec 2 21% 21% 17% Cutoff 3 314 360 314 Sens 3 92% 100% 91% Spec 3 12% 14% 12% Cutoff 4 1390 1380 1430 Sens 4 29% 29% 26% Spec 4 71% 70% 71% Cutoff 5 6420 2310 7700 Sens 5 16% 14% 15% Spec 5 80% 80% 80% Cutoff 6 10900 10900 10900 Sens 6 11% 0% 12% Spec 6 90% 90% 90% OR Quart 2 1.0 0.50 1.0 p Value 0.96 0.58 1.0 95% CI of 0.37 0.044 0.34 OR Quart2 2.8 5.7 2.9 OR Quart 3 0.89 1.0 1.0 p Value 0.82 0.98 1.0 95% CI of 0.31 0.14 0.34 OR Quart3 2.5 7.6 2.9 OR Quart 4 1.5 1.0 1.4 p Value 0.43 0.98 0.57 95% CI of 0.56 0.14 0.48 OR Quart4 3.9 7.6 3.8 Vitamin D-binding protein sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 154000 148000 nd nd 153000 145000 Average 166000 153000 nd nd 167000 149000 Stdev 75600 70500 nd nd 77200 68600 p(t-test) 0.39 nd nd 0.25 Min 54900 22500 nd nd 54900 22500 Max 531000 276000 nd nd 531000 276000 n (Samp) 138 29 nd nd 132 28 n (Patient) 138 29 nd nd 132 28 307 At Enrollment sCr or UO sCr only UO only AUC 0.46 nd 0.45 SE 0.060 nd 0.061 p 0.55 nd 0.38 nCohort 1 138 nd 132 nCohort 2 29 nd 28 Cutoff 1 102000 nd 102000 Sens 1 72% nd 71% Spec 1 14% nd 14% Cutoff 2 77400 nd 77400 Sens 2 83% nd 82% Spec 2 5% nd 5% Cutoff 3 69700 nd 69700 Sens 3 93% nd 93% Spec 3 4% nd 5% Cutoff 4 176000 nd 178000 Sens 4 31% nd 29% Spec 4 70% nd 70% Cutoff 5 215000 nd 217000 Sens5 24% nd 21% Spec 5 80% nd 80% Cutoff 6 250000 nd 250000 Sens 6 14% nd 11% Spec 6 91% nd 90% OR Quart 2 1.0 nd 1.2 p Value 1.0 nd 0.76 95% CI of 0.32 nd 0.37 OR Quart2 3.2 nd 4.0 OR Quart 3 0.68 nd 0.81 p Value 0.53 nd 0.75 95% CI of 0.20 nd 0.23 OR Quart3 2.3 nd 2.9 OR Quart 4 1.6 nd 1.9 p Value 0.39 nd 0.27 95% CI of 0.55 nd 0.61 OR Quart4 4.8 nd 5.8 Glucagon sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 74.3 206 nd nd 74.4 297 Average 9680 12200 nd nd 10100 12000 Stdev 17200 18700 nd nd 17500 18700 p(t-test) 0.57 nd nd 0.69 Min 11.1 21.2 nd nd 11.1 21.2 Max 40100 40100 nd nd 40100 40100 n (Samp) 75 20 nd nd 64 17 n (Patient) 75 20 nd nd 64 17 At Enrollment sCr or UO sCr only UO only AUC 0.56 nd 0.58 SE 0.074 nd 0.080 308 At Enrollment sCr or UO sCr only UO only p 0.44 nd 0.30 nCohort 1 75 nd 64 nCohort 2 20 nd 17 Cutoff 1 48.5 nd 104 Sens 1 70% nd 71% Spec 1 37% nd 59% Cutoff 2 14.6 nd 23.1 Sens 2 100% nd 82% Spec 2 3% nd 19% Cutoff 3 14.6 nd 14.6 Sens 3 100% nd 100% Spec 3 3% nd 3% Cutoff 4 219 nd 243 Sens4 50% nd 53% Spec 4 71% nd 70% Cutoff 5 40100 nd 40100 Sens 5 0% nd 0% Spec 5 100% nd 100% Cutoff 6 40100 nd 40100 Sens 6 0% nd 0% Spec 6 100% nd 100% OR Quart 2 0.12 nd 0.21 p Value 0.063 nd 0.18 95% CI of 0.014 nd 0.021 OR Quart2 1.1 nd 2.1 OR Quart 3 1.2 nd 2.2 p Value 0.81 nd 0.29 95% CI of 0.32 nd 0.52 OR Quart3 4.2 nd 9.0 OR Quart 4 0.94 nd 1.2 p Value 0.93 nd 0.77 95% CI of 0.25 nd 0.28 OR Quart4 3.5 nd 5.5 Interleukin-17A sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 1.88 2.41 1.89 2.45 1.85 2.51 Average 3.71 4.94 4.05 2.70 3.52 5.47 Stdev 6.39 7.60 6.84 2.50 6.06 8.03 p(t-test) 0.31 0.56 0.12 Min 0.000362 0.000469 0.000362 0.000532 0.000362 0.000469 Max 53.4 28.8 53.4 6.61 53.4 28.8 n (Samp) 149 38 175 9 142 33 n (Patient) 149 38 175 9 142 33 At Enrollment sCr or UO sCr only UO only AUC 0.53 0.50 0.56 SE 0.053 0.099 0.057 p 0.55 0.97 0.27 nCohort 1 149 175 142 309 At Enrollment sCr or UO sCr only UO only nCohort 2 38 9 33 Cutoff 1 0.787 0.520 0.787 Sens 1 71% 78% 73% Spec 1 30% 23% 32% Cutoff 2 0.520 0.0656 0.520 Sens 2 82% 89% 82% Spec 2 24% 18% 26% Cutoff 3 0.00436 0.000482 0.00436 Sens 3 92% 100% 91% Spec 3 15% 7% 16% Cutoff 4 4.00 3.87 3.77 Sens 4 29% 33% 36% Spec 4 71% 70% 70% Cutoff 5 5.11 5.11 5.11 Sens 5 26% 22% 30% Spec 5 81% 80% 81% Cutoff 6 8.85 9.07 8.84 Sens 6 13% 0% 15% Spec 6 91% 90% 90% OR Quart 2 0.84 0.65 1.4 p Value 0.75 0.65 0.59 95% CI of 0.29 0.10 0.43 OR Quart2 2.4 4.1 4.3 OR Quart 3 1.1 0.32 1.4 p Value 0.84 0.33 0.59 95% CI of 0.40 0.032 0.43 OR Quart3 3.0 3.2 4.3 OR Quart 4 1.3 1.0 2.1 p Value 0.65 1.0 0.20 95% CI of 0.47 0.19 0.68 OR Quart4 3.4 5.2 6.2 Insulin receptor substrate 1 sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.0314 0.0824 nd nd 0.0314 0.0816 Average 0.643 0.263 nd nd 0.662 0.267 Stdev 4.30 0.471 nd nd 4.39 0.479 p(t-test) 0.64 nd nd 0.64 Min 3.96E-5 0.000645 nd nd 3.96E-5 0.000645 Max 49.5 2.31 nd nd 49.5 2.31 n (Samp) 137 29 nd nd 131 28 n (Patient) 137 29 nd nd 131 28 At Enrollment sCr or UO sCr only UO only AUC 0.60 nd 0.60 SE 0.060 nd 0.061 p 0.091 nd 0.11 nCohort 1 137 nd 131 nCohort 2 29 nd 28 Cutoff 1 0.0238 nd 0.0238 310 At Enrollment sCr or UO sCr only UO only Sens 1 72% nd 71% Spec 1 42% nd 42% Cutoff 2 0.00696 nd 0.00696 Sens 2 83% nd 82% Spec 2 20% nd 19% Cutoff 3 0.00372 nd 0.00372 Sens 3 93% nd 93% Spec 3 15% nd 15% Cutoff 4 0.0827 nd 0.0810 Sens 4 48% nd 50% Spec 4 70% nd 70% Cutoff 5 0.165 nd 0.147 Sens 5 41% nd 43% Spec 5 80% nd 80% Cutoff 6 0.614 nd 0.503 Sens 6 10% nd 11% Spec 6 91% nd 90% OR Quart 2 0.79 nd 0.79 p Value 0.71 nd 0.71 95% CI of 0.22 nd 0.22 OR Quart2 2.8 nd 2.8 OR Quart 3 0.81 nd 0.79 p Value 0.75 nd 0.71 95% CI of 0.23 nd 0.22 OR Quart3 2.9 nd 2.8 OR Quart 4 2.6 nd 2.4 p Value 0.083 nd 0.13 95% CI of 0.88 nd 0.78 OR Quart4 7.7 nd 7.1 Involucrin sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.749 1.11 nd nd 0.732 1.18 Average 1.02 2.10 nd nd 1.02 2.15 Stdev 0.839 2.59 nd nd 0.847 2.62 p(t-test) 8.7E-5 nd nd 7.5E-5 Min 0.0472 0.339 nd nd 0.0472 0.339 Max 5.41 12.7 nd nd 5.41 12.7 n (Samp) 137 29 nd nd 131 28 n (Patient) 137 29 nd nd 131 28 At Enrollment sCr or UO sCr only UO only AUC 0.67 nd 0.68 SE 0.059 nd 0.060 p 0.0038 nd 0.0026 nCohort 1 137 nd 131 nCohort 2 29 nd 28 Cutoff 1 0.767 nd 0.805 Sens 1 72% nd 71% Spec 1 53% nd 56% 311 At Enrollment sCr or UO sCr only UO only Cutoff 2 0.658 nd 0.658 Sens 2 83% nd 82% Spec 2 41% nd 41% Cutoff 3 0.477 nd 0.477 Sens 3 93% nd 93% Spec 3 26% nd 25% Cutoff 4 1.07 nd 1.05 Sens 4 52% nd 54% Spec 4 70% nd 70% Cutoff 5 1.57 nd 1.44 Sens 5 31% nd 39% Spec 5 80% nd 80% Cutoff 6 2.29 nd 2.29 Sens 6 31% nd 32% Spec 6 91% nd 90% OR Quart 2 2.1 nd 1.7 p Value 0.32 nd 0.48 95% CI of 0.49 nd 0.38 OR Quart2 9.1 nd 7.7 OR Quart 3 2.6 nd 2.5 p Value 0.19 nd 0.20 95% CI of 0.62 nd 0.61 OR Quart3 11 nd 11 OR Quart 4 5.7 nd 5.8 p Value 0.011 nd 0.011 95% CI of 1.5 nd 1.5 OR Quart4 22 nd 22 NF-kappa-B inhibitor alpha sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 0.00122 0.00279 nd nd 0.00140 0.00374 Average 0.0448 0.0324 nd nd 0.0459 0.0335 Stdev 0.317 0.0783 nd nd 0.324 0.0795 p(t-test) 0.84 nd nd 0.84 Min 1.84E-7 1.84E-7 nd nd 1.84E-7 1.84E-7 Max 3.62 0.400 nd nd 3.62 0.400 n (Samp) 137 29 nd nd 131 28 n (Patient) 137 29 nd nd 131 28 At Enrollment sCr or UO sCr only UO only AUC 0.60 nd 0.60 SE 0.060 nd 0.061 p 0.098 nd 0.10 nCohort 1 137 nd 131 nCohort 2 29 nd 28 Cutoff 1 0.000457 nd 0.000457 Sens 1 72% nd 71% Spec 1 42% nd 39% Cutoff 2 3.31E-5 nd 3.31E-5 Sens 2 83% nd 82% 312 At Enrollment sCr or UO sCr only UO only Spec 2 18% nd 17% Cutoff 3 3.20E-6 nd 3.20E-6 Sens 3 93% nd 93% Spec 3 6% nd 6% Cutoff 4 0.00393 nd 0.00402 Sens 4 48% nd 50% Spec 4 70% nd 70% Cutoff 5 0.00743 nd 0.00743 Sens 5 38% nd 39% Spec 5 80% nd 80% Cutoff 6 0.0360 nd 0.0266 Sens 6 24% nd 29% Spec 6 91% nd 90% OR Quart 2 0.66 nd 0.51 p Value 0.51 nd 0.31 95% CI of 0.19 nd 0.14 OR Quart2 2.3 nd 1.9 OR Quart 3 0.53 nd 0.51 p Value 0.34 nd 0.31 95% CI of 0.14 nd 0.14 OR Quart3 2.0 nd 1.9 OR Quart 4 2.2 nd 2.2 p Value 0.14 nd 0.14 95% CI of 0.77 nd 0.77 OR Quart4 6.2 nd 6.3 Beta-nerve growth factor sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 1.53 2.07 nd nd 1.53 2.00 Average 2.43 2.39 nd nd 2.48 2.36 Stdev 5.88 1.37 nd nd 6.01 1.39 p(t-test) 0.97 nd nd 0.92 Min 0.221 0.983 nd nd 0.221 0.983 Max 70.0 6.73 nd nd 70.0 6.73 n (Samp) 141 30 nd nd 135 29 n (Patient) 141 30 nd nd 135 29 At Enrollment sCr or UO sCr only UO only AUC 0.63 nd 0.62 SE 0.059 nd 0.060 p 0.027 nd 0.055 nCohort1 141 nd 135 nCohort 2 30 nd 29 Cutoff 1 1.77 nd 1.63 Sens 1 70% nd 72% Spec 1 61% nd 55% Cutoff 2 1.30 nd 1.30 Sens 2 80% nd 83% Spec 2 38% nd 35% Cutoff 3 1.08 nd 1.07 313 At Enrollment sCr or UO sCr only UO only Sens 3 90% nd 93% Spec 3 22% nd 21% Cutoff 4 2.07 nd 2.22 Sens4 50% nd 38% Spec 4 70% nd 70% Cutoff 5 2.76 nd 2.89 Sens 5 30% nd 17% Spec 5 80% nd 80% Cutoff 6 3.97 nd 3.97 Sens 6 10% nd 10% Spec 6 91% nd 90% OR Quart 2 0.97 nd 1.0 p Value 0.97 nd 1.0 95% CI of 0.23 nd 0.23 OR Quart2 4.2 nd 4.3 OR Quart 3 4.1 nd 4.3 p Value 0.023 nd 0.020 95% CI of 1.2 nd 1.3 OR Quart3 14 nd 15 OR Quart 4 2.5 nd 2.2 p Value 0.15 nd 0.22 95% CI of 0.71 nd 0.62 OR Quart4 8.9 nd 8.1 Transthyretin sCr or UO sCr only UO only Cohort 1 Cohort 2 Cohort 1 Cohort 2 Cohort 1 Cohort 2 Median 62800 58200 nd nd 61700 61300 Average 64800 70100 nd nd 64700 70900 Stdev 33600 38500 nd nd 33000 39000 p(t-test) 0.45 nd nd 0.38 Min 12700 10600 nd nd 12700 10600 Max 165000 156000 nd nd 165000 156000 n (Samp) 137 29 nd nd 131 28 n (Patient) 137 29 nd nd 131 28 At Enrollment sCr or UO sCr only UO only AUC 0.53 nd 0.54 SE 0.060 nd 0.061 p 0.61 nd 0.56 nCohort 1 137 nd 131 nCohort 2 29 nd 28 Cutoff 1 48500 nd 48500 Sens 1 72% nd 71% Spec 1 39% nd 38% Cutoff 2 35400 nd 35400 Sens 2 83% nd 82% Spec 2 21% nd 20% Cutoff 3 25200 nd 24600 Sens 3 93% nd 93% Spec 3 8% nd 6% 314 At Enrollment sCr or UO sCr only UO only Cutoff 4 76200 nd 75900 Sens 4 34% nd 36% Spec 4 70% nd 70% Cutoff 5 84400 nd 83800 Sens5 24% nd 25% Spec 5 80% nd 80% Cutoff 6 109000 nd 106000 Sens6 17% nd 18% Spec 6 91% nd 90% OR Quart 2 1.6 nd 1.4 p Value 0.42 nd 0.59 95% CI of 0.51 nd 0.43 OR Quart2 5.0 nd 4.4 OR Quart 3 0.81 nd 0.79 p Value 0.75 nd 0.71 95% CI of 0.23 nd 0.22 OR Quart3 2.9 nd 2.8 OR Quart 4 1.6 nd 1.6 p Value 0.42 nd 0.42 95% CI of 0.51 nd 0.51 OR Quart4 5.0 nd 5.0 [0180] While the invention has been described and exemplified in sufficient detail for those skilled in this art to make and use it, various alternatives, modifications, and improvements should be apparent without departing from the spirit and scope of the invention. The examples provided herein are representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Modifications therein and other uses will occur to those skilled in the art. These modifications are encompassed within the spirit of the invention and are defined by the scope of the claims. [0181] It will be readily apparent to a person skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. [0182] All patents and publications mentioned in the specification are indicative of the levels of those of ordinary skill in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. [0183] The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically 315 disclosed herein. Thus, for example, in each instance herein any of the terms "comprising", "consisting essentially of" and "consisting of" may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims. [0184] Other embodiments are set forth within the following claims. 316

Claims (108)

1. A method for evaluating renal status in a subject, comprising: performing one or more assaysconfigured to detect one or more biomarkers selected from the group consisting of Beta-nerve growth factor, Interleukin-17A, Follitropin subunit beta, Collagenase 3, Follistatin, Vitamin D Binding Protein, Islet amyloid polypeptide, Insulin C-peptide, Complement Factor H, Gastric inhibitory polypeptide, Glucagon-like peptide 1, Glucagon, Involucrin, Type II cytoskeletal Keratin-1/Keratin-10, Type II cytoskeletal Keratin-6A/6B/6C, Osteocalcin, Lipopolysaccharide, Pancreatic prohormone, Peptide YY, Agouti-related protein, Ciliary neurotrophic factor, Appetite regulating hormone, Transthyretin, Insulin receptor substrate 1, and NF-kappa-B inhibitor alpha on a body fluid sample obtained from the subject to provide an assay result; and correlating the assay result(s) to the renal status of the subject.

2. A method according to claim 1, wherein said correlation step comprises correlating the assay result(s) to one or more of risk stratification, diagnosis, staging, prognosis, classifying and monitoring of the renal status of the subject.

3. A method according to claim 1, wherein said correlating step comprises assigning a likelihood of one or more future changes in renal status to the subject based on the assay result(s).

4. A method according to claim 3, wherein said one or more future changes in renal status comprise one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF).

5. A method according to one of claims 1-4, wherein said assay results comprise at least 2, 3, or 4 of: a measured urine or plasma concentration of Beta-nerve growth factor, a measured urine or plasma concentration of Interleukin- 17A, a measured urine or plasma concentration of Follitropin subunit beta, a measured urine or plasma concentration of Collagenase 3, a measured urine or plasma concentration of Follistatin, a measured urine or plasma concentration of Vitamin D Binding Protein, 317 a measured urine or plasma concentration of Islet amyloid polypeptide, a measured urine or plasma concentration of Insulin C-peptide, a measured urine or plasma concentration of Complement Factor H, a measured urine or plasma concentration of Gastric inhibitory polypeptide, a measured urine or plasma concentration of Glucagon-like peptide 1, a measured urine or plasma concentration of Glucagon, a measured urine or plasma concentration of Involucrin, a measured urine or plasma concentration of type II cytoskeletal Keratin-1/10, a measured urine or plasma concentration of type II cytoskeletal 6A/6B/6C, a measured urine or plasma concentration of Osteocalcin, a measured urine or plasma concentration of Lipopolysaccharide, a measured urine or plasma concentration of Pancreatic prohormone, a measured urine or plasma concentration of Peptide YY, a measured urine or plasma concentration of Agouti-related protein, a measured urine or plasma concentration of Ciliary neurotrophic factor, a measured urine or plasma concentration of Appetite-regulating hormone, a measured urine or plasma concentration of Transthyretin, a measured urine or plasma concentration of Insulin receptor substrate 1, and a measured urine or plasma concentration of and NF-kappa-B inhibitor alpha.

6. A method according to one of claims 1-5, wherein a plurality of assay results are combined using a function that converts the plurality of assay results into a single composite result.

7. A method according to claim 3, wherein said one or more future changes in renal status comprise a clinical outcome related to a renal injury suffered by the subject.

8. A method according to claim 3, wherein the likelihood of one or more future changes in renal status is that an event of interest is more or less likely to occur within 30 days of the time at which the body fluid sample is obtained from the subject. 318

9. A method according to claim 8, wherein the likelihood of one or more future changes in renal status is that an event of interest is more or less likely to occur within a period selected from the group consisting of 21 days, 14 days, 7 days, 5 days, 96 hours, 72 hours, 48 hours, 36 hours, 24 hours, and 12 hours.

10. A method according to one of claims 1-5, wherein the subject is selected for evaluation of renal status based on the pre-existence in the subject of one or more known risk factors for prerenal, intrinsic renal, or postrenal ARF.

11. A method according to one of claims 1-5, wherein the subject is selected for evaluation of renal status based on an existing diagnosis of one or more of congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, glomerular filtration below the normal range, cirrhosis, serum creatinine above the normal range, sepsis, injury to renal function, reduced renal function, or ARF, or based on undergoing or having undergone major vascular surgery, coronary artery bypass, or other cardiac surgery, or based on exposure to NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin.

12. A method according to one of claims 1-5, wherein said correlating step comprises assigning a diagnosis of the occurrence or nonoccurrence of one or more of an injury to renal function, reduced renal function, or ARF to the subject based on the assay result(s).

13. A method according to one of claims 1-5, wherein said correlating step comprises assessing whether or not renal function is improving or worsening in a subject who has suffered from an injury to renal function, reduced renal function, or ARF based on the assay result(s).

14. A method according to one of claims 1-5, wherein said method is a method of diagnosing the occurrence or nonoccurrence of an injury to renal function in said subject.

15. A method according to one of claims 1-5, wherein said method is a method of diagnosing the occurrence or nonoccurrence of reduced renal function in said subject.

16. A method according to one of claims 1-5, wherein said method is a method of diagnosing the occurrence or nonoccurrence of acute renal failure in said subject. 319

17. A method according to one of claims 1-5, wherein said method is a method of diagnosing the occurrence or nonoccurrence of a need for renal replacement therapy in said subject.

18. A method according to one of claims 1-5, wherein said method is a method of diagnosing the occurrence or nonoccurrence of a need for renal transplantation in said subject.

19. A method according to one of claims 1-5, wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of an injury to renal function in said subject.

20. A method according to one of claims 1-5, wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of reduced renal function in said subject.

21. A method according to one of claims 1-5, wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of acute renal failure in said subject.

22. A method according to one of claims 1-5, wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of a need for renal replacement therapy in said subject.

23. A method according to one of claims 1-5, wherein said method is a method of assigning a risk of the future occurrence or nonoccurrence of a need for renal transplantation in said subject.

24. A method according to one of claims 1-5, wherein said one or more future changes in renal status comprise one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF) within 72 hours of the time at which the body fluid sample is obtained.

25. A method according to one of claims 1-5, wherein said one or more future changes in renal status comprise one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF) within 48 hours of the time at which the body fluid sample is obtained.

26. A method according to one of claims 1-5, wherein said one or more future changes in renal status comprise one or more of a future injury to renal function, future 320 reduced renal function, future improvement in renal function, and future acute renal failure (ARF) within 24 hours of the time at which the body fluid sample is obtained.

27. A method according to one of claims 1-5, wherein the subject is in RIFLE stage 0 or R.

28. A method according to claim 27, wherein the subject is in RIFLE stage 0, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage R, I or F within 72 hours.

29. A method according to claim 28, wherein the subject is in RIFLE stage 0, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 72 hours.

30. A method according to claim 28, wherein the subject is in RIFLE stage 0, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours.

31. A method according to claim 27, wherein the subject is in RIFLE stage 0 or R, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 72 hours.

32. A method according to claim 31, wherein the subject is in RIFLE stage 0 or R, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours.

33. A method according to claim 27, wherein the subject is in RIFLE stage R, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 72 hours.

34. A method according to claim 33, wherein the subject is in RIFLE stage R, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours.

35. A method according to one of claims 1-5, wherein the subject is in RIFLE stage 0, R, or I, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours.

36. A method according to claim 35, wherein the subject is in RIFLE stage I, and said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 72 hours. 321

37. A method according to claim 28, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage R, I or F within 48 hours.

38. A method according to claim 29, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 48 hours.

39. A method according to claim 30, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 48 hours.

40. A method according to claim 31, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 48 hours.

41. A method according to claim 32, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 48 hours.

42. A method according to claim 33, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 48 hours.

43. A method according to claim 34, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 48 hours.

44. A method according to claim 35, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 48 hours.

45. A method according to claim 36, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 48 hours.

46. A method according to claim 28, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage R, I or F within 24 hours.

47. A method according to claim 29, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 24 hours.

48. A method according to claim 30, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 24 hours.

49. A method according to claim 31, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 24 hours.

50. A method according to claim 32, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 24 hours. 322

51. A method according to claim 33, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage I or F within 24 hours.

52. A method according to claim 34, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 24 hours.

53. A method according to claim 35, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 24 hours.

54. A method according to claim 36, wherein said correlating step comprises assigning a likelihood that the subject will reach RIFLE stage F within 24 hours.

55. A method according to one of claims 1-5, wherein the subject is not in acute renal failure.

56. A method according to one of claims 1-5, wherein the subject has not experienced a 1.5-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

57. A method according to one of claims 1-5, wherein the subject has a urine output of at least 0.5 ml/kg/hr over the 6 hours preceding the time at which the body fluid sample is obtained.

58. A method according to one of claims 1-5, wherein the subject has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

59. A method according to one of claims 1-5, wherein the subject (i) has not experienced a 1.5-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, (ii) has a urine output of at least 0.5 ml/kg/hr over the 6 hours preceding the time at which the body fluid sample is obtained, and (iii) has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

60. A method according to one of claims 1-5, wherein the subject has not experienced a 1.5-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained. 323

61. A method according to one of claims 1-5, wherein the subject has a urine output of at least 0.5 ml/kg/hr over the 6 hours preceding the time at which the body fluid sample is obtained.

62. A method according to one of claims 1-5, wherein the subject (i) has not experienced a 1.5-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, (ii) has a urine output of at least 0.5 ml/kg/hr over the 12 hours preceding the time at which the body fluid sample is obtained, and (iii) has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

63. A method according to one of claims 1-5, wherein said correlating step comprises assigning one or more of: a likelihood that within 72 hours the subject will (i) experience a 1.5-fold or greater increase in serum creatinine (ii) have a urine output of less than 0.5 ml/kg/hr over a 6 hour period, or (iii) experience an increase of 0.3 mg/dL or greater in serum creatinine.

64. A method according to claim 63, wherein said correlating step comprises assigning one or more of: a likelihood that within 48 hours the subject will (i) experience a 1.5-fold or greater increase in serum creatinine (ii) have a urine output of less than 0.5 ml/kg/hr over a 6 hour period, or (iii) experience an increase of 0.3 mg/dL or greater in serum creatinine.

65. A method according to claim 63, wherein said correlating step comprises assigning one or more of: a likelihood that within 24 hours the subject will (i) experience a 1.5-fold or greater increase in serum creatinine (ii) have a urine output of less than 0.5 ml/kg/hr over a 6 hour period, or (iii) experience an increase of 0.3 mg/dL or greater in serum creatinine.

66. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 72 hours the subject will experience a 1.5-fold or greater increase in serum creatinine.

67. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 72 hours the subject will have a urine output of less than 0.5 ml/kg/hr over a 6 hour period. 324

68. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 72 hours the subject will experience an increase of 0.3 mg/dL or greater in serum creatinine.

69. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 48 hours the subject will experience a 1.5-fold or greater increase in serum creatinine.

70. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 48 hours the subject will have a urine output of less than 0.5 ml/kg/hr over a 6 hour period.

71. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 48 hours the subject will experience an increase of 0.3 mg/dL or greater in serum creatinine.

72. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 24 hours the subject will experience a 1.5-fold or greater increase in serum creatinine.

73. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 24 hours the subject will have a urine output of less than 0.5 ml/kg/hr over a 6 hour period.

74. A method according to claim 63, wherein said correlating step comprises assigning a likelihood that within 24 hours the subject will experience an increase of 0.3 mg/dL or greater in serum creatinine.

75. A method according to one of claims 1-5, wherein the subject has not experienced a 2-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

76. A method according to one of claims 1-5, wherein the subject has a urine output of at least 0.5 ml/kg/hr over the 12 hours preceding the time at which the body fluid sample is obtained.

77. A method according to one of claims 1-5, wherein the subject (i) has not experienced a 2-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, (ii) has a urine output of at least 0.5 ml/kg/hr over the 2 hours preceding the time at which the body fluid 325 sample is obtained, and (iii) has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

78. A method according to one of claims 1-5, wherein the subject has not experienced a 3-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

79. A method according to one of claims 1-5, wherein the subject has a urine output of at least 0.3 ml/kg/hr over the 24 hours preceding the time at which the body fluid sample is obtained, or anuria over the 12 hours preceding the time at which the body fluid sample is obtained.

80. A method according to one of claims 1-5, wherein the subject (i) has not experienced a 3-fold or greater increase in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained, (ii) has a urine output of at least 0.3 ml/kg/hr over the 24 hours preceding the time at which the body fluid sample is obtained, or anuria over the 12 hours preceding the time at which the body fluid sample is obtained, and (iii) has not experienced an increase of 0.3 mg/dL or greater in serum creatinine over a baseline value determined prior to the time at which the body fluid sample is obtained.

81. A method according to one of claims 1-5, wherein said correlating step comprises assigning one or more of: a likelihood that within 72 hours the subject will (i) experience a 2-fold or greater increase in serum creatinine (ii) have a urine output of less than 0.5 ml/kg/hr over a 12 hour period, or (iii) experience an increase of 0.3 mg/dL or greater in serum creatinine.

82. A method according to claim 81, wherein said correlating step comprises assigning one or more of: a likelihood that within 48 hours the subject will (i) experience a 2-fold or greater increase in serum creatinine (ii) have a urine output of less than 0.5 ml/kg/hr over a 6 hour period, or (iii) experience an increase of 0.3 mg/dL or greater in serum creatinine.

83. A method according to claim 81, wherein said correlating step comprises assigning one or more of: a likelihood that within 24 hours the subject will (i) experience a 2-fold or greater increase in serum creatinine, or (ii) have a urine output of less than 0.5 ml/kg/hr over a 6 hour period. 326

84. A method according to claim 81, wherein said correlating step comprises assigning a likelihood that within 72 hours the subject will experience a 2-fold or greater increase in serum creatinine.

85. A method according to claim 81, wherein said correlating step comprises assigning a likelihood that within 72 hours the subject will have a urine output of less than 0.5 ml/kg/hr over a 6 hour period.

86. A method according to claim 81, wherein said correlating step comprises assigning a likelihood that within 48 hours the subject will experience a 2-fold or greater increase in serum creatinine.

87. A method according to claim 81, wherein said correlating step comprises assigning a likelihood that within 48 hours the subject will have a urine output of less than 0.5 ml/kg/hr over a 6 hour period.

88. A method according to claim 81, wherein said correlating step comprises assigning a likelihood that within 24 hours the subject will experience a 2-fold or greater increase in serum creatinine.

89. A method according to claim 81, wherein said correlating step comprises assigning a likelihood that within 24 hours the subject will have a urine output of less than 0.5 ml/kg/hr over a 6 hour period.

90. A method according to one of claims 1-5, wherein said correlating step comprises assigning one or more of: a likelihood that within 72 hours the subject will (i) experience a 3-fold or greater increase in serum creatinine, or (ii) have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period.

91. A method according to claim 90, wherein said correlating step comprises assigning one or more of: a likelihood that within 48 hours the subject will (i) experience a 3-fold or greater increase in serum creatinine, or (ii) have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period.

92. A method according to claim 90, wherein said correlating step comprises assigning one or more of: a likelihood that within 24 hours the subject will (i) experience a 3-fold or greater increase in serum creatinine, or (ii) have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period. 327

93. A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 72 hours the subject will experience a 3-fold or greater increase in serum creatinine.

94. A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 72 hours the subject will have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period.

95. A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 48 hours the subject will experience a 3-fold or greater increase in serum creatinine.

96. A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 48 hours the subject will have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period.

97. A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 24 hours the subject will experience a 3-fold or greater increase in serum creatinine.

98. A method according to claim 90, wherein said correlating step comprises assigning a likelihood that within 24 hours the subject will have a urine output of less than 0.3 ml/kg/hr over a 24 hour period or anuria over a 12 hour period.

99. A method according to one of claims 1-98, wherein the body fluid sample is a urine sample.

100. A method according to one of claims 1-99, wherein said method comprises performing assays that detect one, two or three, or more of Beta-nerve growth factor, Interleukin-17A, Follitropin subunit beta, Collagenase 3, Follistatin, Vitamin D Binding Protein, Islet amyloid polypeptide, Insulin C-peptide, Complement Factor H, Gastric inhibitory polypeptide, Glucagon-like peptide 1, Glucagon, Involucrin, Type II cytoskeletal Keratin-1/Keratin-10, Type II cytoskeletal Keratin-6A/6B/6C, Osteocalcin, Lipopolysaccharide, Pancreatic prohormone, Peptide YY, Agouti-related protein, Ciliary neurotrophic factor, Appetite-regulating hormone, Transthyretin, Insulin receptor substrate 1, and NF-kappa-B inhibitor alpha.

101. Measurement of one or more biomarkers selected from the group consisting of Beta-nerve growth factor, Interleukin- 17A, Follitropin subunit beta, Collagenase 3, 328 Follistatin, Vitamin D Binding Protein, Islet amyloid polypeptide, Insulin C-peptide, Complement Factor H, Gastric inhibitory polypeptide, Glucagon-like peptide 1, Glucagon, Involucrin, Type II cytoskeletal Keratin-1/Keratin-10, Type II cytoskeletal Keratin-6A/6B/6C, Osteocalcin, Lipopolysaccharide, Pancreatic prohormone, Peptide YY, Agouti-related protein, Ciliary neurotrophic factor, Appetite-regulating hormone, Transthyretin, Insulin receptor substrate 1, and NF-kappa-B inhibitor alpha for the evaluation of renal injury.

102. Measurement of one or more biomarkers selected from the group consisting of Beta-nerve growth factor, Interleukin- 17A, Follitropin subunit beta, Collagenase 3, Follistatin, Vitamin D Binding Protein, Islet amyloid polypeptide, Insulin C-peptide, Complement Factor H, Gastric inhibitory polypeptide, Glucagon-like peptide 1, Glucagon, Involucrin, Type II cytoskeletal Keratin-1/Keratin-10, Type II cytoskeletal Keratin-6A/6B/6C, Osteocalcin, Lipopolysaccharide, Pancreatic prohormone, Peptide YY, Agouti-related protein, Ciliary neurotrophic factor, Appetite-regulating hormone, Transthyretin, Insulin receptor substrate 1, and NF-kappa-B inhibitor alpha for the evaluation of acute renal injury.

103. A kit, comprising: reagents for performing one or more assays configured to detect one or more kidney injury markers selected from the group consisting of Beta-nerve growth factor, Interleukin-17A, Follitropin subunit beta, Collagenase 3, Follistatin, Vitamin D Binding Protein, Islet amyloid polypeptide, Insulin C-peptide, Complement Factor H, Gastric inhibitory polypeptide, Glucagon-like peptide 1, Glucagon, Involucrin, Type II cytoskeletal Keratin-1/Keratin-10, Type II cytoskeletal Keratin-6A/6B/6C, Osteocalcin, Lipopolysaccharide, Pancreatic prohormone, Peptide YY, Agouti-related protein, Ciliary neurotrophic factor, Appetite-regulating hormone, Transthyretin, Insulin receptor substrate 1, and NF-kappa-B inhibitor alpha.

104. A kit according to claim 103, wherein said reagents comprise one or more binding reagents, each of which specifically binds one of said of kidney injury markers.

105. A kit according to claim 104, wherein a plurality of binding reagents are contained in a single assay device.

106. A kit according to claim 103, wherein at least one of said assays is configured as a sandwich binding assay. 329

107. A kit according to claim 103, wherein at least one of said assays is configured as a competitive binding assay.

108. A kit according to one of claims 103-107, wherein said one or more assays comprise assays that detect one, two or three, or more of Beta-nerve growth factor, Interleukin-17A, Follitropin subunit beta, Collagenase 3, Follistatin, Vitamin D Binding Protein, Islet amyloid polypeptide, Insulin C-peptide, Complement Factor H, Gastric inhibitory polypeptide, Glucagon-like peptide 1, Glucagon, Involucrin, Type II cytoskeletal Keratin-1/Keratin-10, Type II cytoskeletal Keratin-6A/6B/6C, Osteocalcin, Lipopolysaccharide, Pancreatic prohormone, Peptide YY, Agouti-related protein, Ciliary neurotrophic factor, Appetite-regulating hormone, Transthyretin, Insulin receptor substrate 1, and NF-kappa-B inhibitor alpha. 330